Pocket Emergency Medicine

Fourth Edition

Erica Ashley Morse, MD
Graham Ingalsbe, MD
Denver Health Residency in Emergency Medicine

Amy Follmer Hildreth, MD
Naval Medical Center San Diego

David Silvestri, MD, MBA
National Clinician Scholars Program
Yale School of Medicine

Edited by
Richard D. Zane, MD, FAAEM
The George B. Boedecker Professor and Chair
Department of Emergency Medicine
University of Colorado School of Medicine
Executive Director, Emergency Services
University of Colorado Health
Aurora, Colorado

Joshua M. Kosowsky, MD, FACEP
Assistant Professor
Harvard Medical School
Department of Emergency Medicine
Brigham and Women’s Hospital
Boston, Massachusetts
range. To the maximum extent permitted under applicable law, no responsibility is assumed by the publisher for any injury and/or damage to persons or property, as a matter of products liability, negligence law or otherwise, or from any reference to or use by any person of this work.
CONTRIBUTORS

Amy Follmer Hildreth, MD*
Emergency Medicine Physician
Naval Medical Center San Diego
San Diego, California

Graham Ingalsbe, MD
Chief Resident, 2016–2017
Department of Emergency Medicine
University of Colorado School of Medicine
Denver Health Residency in Emergency Medicine
Denver, Colorado

Erica Ashley Morse, MD
Resident Physician
Department of Emergency Medicine
University of Colorado School of Medicine
Denver Health Residency in Emergency Medicine
Denver, Colorado

David Silvestri, MD, MBA
National Clinician Scholars Program
Department of Emergency Medicine
Yale School of Medicine
New Haven, Connecticut

*The views expressed in this publication are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the United States Government.
ACKNOWLEDGMENTS

Practicing medicine is like having a front row seat at the play of life. If that is true, and I believe it is, emergency medicine is like being back stage. This book is for the dedicated men and women who are often back stage making life and death decisions without a net knowing that the expectation is that they get it right the first time, every time, without blinking.

Siobhan, Jake, Gaby, Finn, for whom I exist, thank you for tolerating my passion of academic medicine.

RICHARD D. ZANE, MD

To all those from whom I continue to gain wisdom—my teachers, my colleagues, my students, and perhaps foremost, my patients. And to Devorah, Harry, Jake, and Judah, whose support means the world to me.

JOSHUA M. KOSOWSKY, MD
The practice of emergency medicine, like all disciplines, is changing and evolving. More than ever, the care of our patients depends upon having accurate, actionable, and accessible information in real time. Now in its fourth edition, *Pocket Emergency Medicine* remains the essential, go-to reference for busy clinicians on the front lines of emergency care. Unlike traditional texts, *Pocket Emergency Medicine* is designed to be used at the bedside, organized around presenting conditions and mirroring the thought process of clinicians: from history and physical exam to differential diagnosis testing; from testing and therapeutics to disposition. Clinical pearls and updates in medical practice are highlighted throughout the text.

This book was written by four dedicated emergency medicine residents from the University of Colorado and Harvard University and edited by senior faculty; the text has been updated and referenced in exacting detail, while retaining the fundamental ease of use so cherished by busy providers. We hope our readers find this edition of *Pocket Emergency Medicine* to be a valuable tool in their daily practice.

Richard D. Zane, MD
Joshua M. Kosowsky, MD
CONTENTS

Contributors
Acknowledgments
Preface

SECTION I: CARDIOVASCULAR
Chest Pain
Electrocardiography
Acute Coronary Syndrome
Risk Stratification Testing
Cardiac Catheterization
Post-MI Complications
Prinzmetal’s (Variant) Angina
Cocaine-induced Angina
DVT and Pulmonary Embolism
 Decompensated Heart Failure
Aortic Dissection
Thoracic Aortic Aneurysm
Acute Pericarditis
Cardiac Tamponade
Myocarditis
Syncope
Hypertension and Hypertensive Emergencies
Hypotension and Shock
Hypovolemic Shock
Cardiogenic Shock
Septic Shock
Neurogenic Shock
Dysrhythmia
Bradyarrhythmia
AV Node Block
Tachycardia/Palpitations
Pacemaker and AICD Malfunction

SECTION II: PULMONARY
Cough
Dyspnea (Shortness of Breath)
Hemoptysis

SECTION III: GASTROINTESTINAL
Abdominal Pain
Nausea and Vomiting
Gastrointestinal Bleed
Difficulty Swallowing
Diarrhea
Constipation
Jaundice
Rectal Pain (Proctalgia)

SECTION IV: INFECTIOUS DISEASE
Fever
Abscess
Soft Tissue Infections
Viral Infections
Syphilis
Tetanus
Scabies
Vector-borne Infections
Bioterrorism

SECTION V: NEUROLOGY
Altered Mental Status
Headache
CNS Infections
Seizure
Vertigo
Facial Droop
Intracranial Hemorrhage
Ischemic Stroke
Neuromuscular Syndromes

SECTION VI: RENAL & GENITOURINARY
Dysuria
Urinary Tract Infections
Flank Pain
Hematuria
Acute Kidney Injury
Testicular Torsion/Torsion of Testicular Appendix
Phimosis and Paraphimosis
Priapism
Emergencies in Dialysis Patients

SECTION VII: OBGYN
Vaginal Bleeding
Preeclampsia and Eclampsia
Hyperemesis Gravidarum
Emergency Delivery
Female Pelvic Pain
Vaginal Discharge (Sexually Transmitted Infection)
Pelvic Inflammatory Disease and Tubo-ovarian Abscess

SECTION VIII: DERMATOLOGY
Rash
Viral Exanthems
Bacterial Exanthems
Fungal Exanthems
High-Risk Exanthems
Other Exanthems

SECTION IX: ENDOCRINE & METABOLIC
Acid–Base Disorders
Abnormal Electrolytes
Hyperglycemic Emergencies (DKA/HHS)
Thyroid Emergencies
Adrenal Insufficiency

SECTION X: ENVIRONMENTAL
Dehydration
Bites and Stings
Occupational Exposure
Burns
Carbon Monoxide Poisoning
Dysbarism
Electrical Injury
High-Altitude Illness
Hypothermia
Hyperthermia
Lightning Injury
Drowning
Botulism

SECTION XI: HEMATOLOGY & ONCOLOGY
Anaphylaxis and Angioedema
Oncologic Emergencies
Sickle Cell Disease
Abnormal Bleeding
Emergencies in the Transplant Patient

SECTION XII: MUSCULOSKELETAL & RHEUMATOLOGICAL
Leg Pain and Swelling
Lower Back Pain
Joint Pain

SECTION XIII: OTOLARYNGOLOGY/DENTAL/OPHTHALMOLOGY
Ear Pain
Hearing Loss
Sore Throat
Sinusitis
Epistaxis
Eye Pain/Redness
Vision Change & Vision Loss
Toothache

SECTION XIV: PEDIATRICS
Resuscitation
Abdominal Pain
Cyanosis
Pediatric Fever
Jaundice
Limp
Pediatric Seizure
Nausea and Vomiting
Pediatric Meningitis (SEE 5D)
Neonatal Complaints
Congenital Heart Disease
Respiratory Complaints
Diabetic Ketoacidosis
Hypoglycemia
Fluid and Electrolyte Abnormalities
Pediatric Exanthems
Urinary Tract Infection

SECTION XV: PSYCHIATRIC PATIENT
Psychiatric Patient

SECTION XVI: TOXICOLOGY
General Approach to the Intoxicated Patient
Anticholinergic Ingestion
Psychopharmacologic Ingestion
Alcohols
Drugs of Abuse
Analgesic Overdose
Cardiac Medication Overdose
Caustic Ingestions
Cellular Asphyxiates

SECTION XVII: AIRWAY MANAGEMENT
Airway Management
Rapid Sequence Intubation
Cricothyrotomy

SECTION XVIII: TRAUMA
Primary Survey
Head Trauma
Maxillofacial Injury
Eye Injury
Neck Trauma
Cervical Spine Trauma
Thoracic/Lumbar/Sacral Spine Trauma
Thoracic Trauma
Abdominal Trauma
Genitourinary Trauma
Hip/Pelvic Trauma
Extremity Injury
Wound Management
Abuse

SECTION XIX: APPENDIX
Abbreviations
Pediatric Advanced Life Support (PALS)
Mechanical Ventilation
Analgesia & Conscious Sedation
ICU Medications
Equations
Procedures

INDEX
CHEST PAIN

Approach

- Immediate: All nontrivial CP get IV access, O₂, cardiac monitoring, ECG, CXR
- Compare all ECGs to prior, repeat q15–20min if high suspicion for ACS; consider R-sided +/- posterior ECG if high suspicion (see Electrocardiography section)
- History: Obtain thorough pain HPI (position, quality, radiation, severity, timing, associated sx, alleviating & exacerbating factors), cardiac risk factors (eg, for CAD, aortic dz, PE, etc.), prior cardiac testing (timing & results of last stress test, catheterization, echo) & prior cardiac events/procedures (eg, myocardial infarction [MI], CABG, valve repair, etc.)
- Empiric tx: ASA 325 mg (if considering ACS & low suspicion for AoD), NTG for pain (unless R-sided ischemia, hypotension, PDE-inh)
- Risk stratify for dxs being considered: ACS (TIMI, GRACE, or PURSUIT), PE (Well’s), AoD (Aortic Dissection Detection risk score)

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Etiologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac</td>
<td>ACS (UA/NSTEMI, STEMI), Prinzmetal’s/cocaine-induced angina, myocarditis, pericarditis, cardiac tamponade, constrictive pericarditis, CHF/acute pulmonary edema, post-MI cx</td>
</tr>
<tr>
<td>Vascular</td>
<td>PE, AoD, thoracic aortic aneurysm, pulmonary HTN</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>PNA, PTX, pleural effusion/empyema, pleuritis, pulmonary infarct</td>
</tr>
<tr>
<td>GI</td>
<td>GERD, esophageal spasm, Mallory–Weiss tear, Boerhaave syndrome, PUD, biliary dz, pancreatitis</td>
</tr>
</tbody>
</table>
ELECTROCARDIOGRAPHY

Approach
- Always check: correct pt, date, lead placement; calibration (mV, paper speed)
- Rate, rhythm, axis
- Waves (P, Q, R, T, U waves) & segments (PR, QRS, QT intervals, & ST segment)
- Conduction & bundle blocks
- Atrial enlargement, ventricular hypertrophy
- Ischemia/infarction
- Miscellaneous (stigmata of electrolyte abx, syncope, tox, PMs, PE, etc.)

Orientation: ECG Calibration and Standardization

<table>
<thead>
<tr>
<th>Voltage calibration</th>
<th>Standard ECG voltage is usually set w/ a calibration box encompassing 2 large vertical squares (10 mm tall) &amp; is equal to 1 mV (10 mm/mV): 1 small vertical box = 0.1 mV</th>
</tr>
</thead>
</table>
| Paper recording speed     | Standard ECG paper speed if usually set at 25 mm/s:  
  - Large horizontal box (5 mm wide) = 200 ms (0.2 s)  
  - Small horizontal box (1 mm wide) = 40 ms (0.04 s) |

Determining Heart Rate \( (nl = 60–100 \text{ bpm}) \)

<table>
<thead>
<tr>
<th>Quick approach</th>
<th>Count the number of bold vertical lines b/w adjacent R waves: 0 = 300 bpm, 1 = 150 bpm, 2 = 100 bpm, 3 = 75 bpm, 4 = 60 bpm, 5 = 50 bpm.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathematical approach</td>
<td>Multiply the number of QRS complexes on the ECG by 6 (at a standard paper speed of 25 mm/s), each ECG records 10 s of activity.</td>
</tr>
</tbody>
</table>

Determining Rhythm (see also section on \textit{Dysrhythmia})
Determining the heart’s rhythm is a complex process that requires synthesis of other features of ECG interpretation (esp rate, axis, intervals, & waves/segments). Key questions to help narrow the DDx of dysrhythmias include:

1. Is the rate slow (eg, bradydysrhythmia) or fast (eg, tachydysrhythmia)?
2. Is the QRS narrow (eg, SVT) or wide (eg, aberrancy, ventricular, electrolyte d/o)?
3. Is the rhythm regular (eg, AFL, SVT, VT) or irregular (eg, AF, AFL w/ variable block, MAT, polymorphic VT)?
4. Are P waves present? (If absent: AF vs. nodal/ventricular etiology)
5. Is every P wave followed by a QRS & every QRS preceded by a P wave?
6. For select tachydysrhythmias, is there response to vagal maneuvers or adenosine?

**Determining Axis** \( (\text{nl QRS axis } = -30^\circ \text{ to } +90^\circ) \)

<table>
<thead>
<tr>
<th>Type</th>
<th>Definition</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>L axis deviation</td>
<td>QRS b/w (-30^\circ \text{ &amp; } -90^\circ)</td>
<td>LVH, LBBB, inferior MI, LAFB, ventricular pre-excitation w/ posteroseptal accessory pathway (WPW)</td>
</tr>
<tr>
<td></td>
<td>• Lead I: Positive</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Lead II: Negative</td>
<td></td>
</tr>
<tr>
<td>R axis deviation</td>
<td>QRS b/w (+90^\circ \text{ &amp; } +180^\circ)</td>
<td>RVH, lateral MI, LPFB, ventricular pre-excitation w/ free wall accessory pathway (WPW), COPD, dextrocardia</td>
</tr>
<tr>
<td></td>
<td>• Lead I: Negative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• aVF: Positive</td>
<td></td>
</tr>
<tr>
<td>Extreme axis deviation</td>
<td>QRS b/w (+180^\circ \text{ &amp; } -90^\circ) (–QRS lead I, –QRS aVF)</td>
<td>Ventricular tachycardia, Hyperkalemia, apical MI, RVH</td>
</tr>
</tbody>
</table>

**ECG Waveforms and Segments**

<table>
<thead>
<tr>
<th>Type</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>P wave</td>
<td>• Represents atrial depolarization (1st half represents predominant R atrial depolarization &amp; 2nd half L atrial depolarization); best seen in leads II &amp; V1  (\text{NL: Duration }&lt;0.12\text{ s, Amplitude }\leq 0.2\text{ mV (frontal) or }\leq 0.1\text{ mV (transverse), axis upright in I, II, aVF, V2–V4 &amp; inverted in aVR})  (\text{Can be absent (AF, SVT), aberrant shape (AT, MAT, AFL)})</td>
</tr>
<tr>
<td>PR interval</td>
<td>• Represents time b/w onset of atrial depolarization (start of P) &amp; onset of ventricular depolarization (start of QRS); isoelectric region represents conduction w/i AV node, bundle of His, bundle branches, &amp; Purkinje fibers (\text{NL: duration normally }0.12–0.20\text{ s (120–200 ms)})</td>
</tr>
<tr>
<td>Q wave</td>
<td>• Defined as any initial negative deflection; represents onset of ventricular depolarization (specifically: L to R depolarization of septum)</td>
</tr>
</tbody>
</table>
- **Nl**: Small Qw can be nl in all leads EXCEPT V1, V2, V3; Large Q waves can be nl variant in Lead III & aVR
- **Pathologic Q waves**: Any Qw V1–V3, Qw >0.04 s (1 mm) & ≥0.2 mV (2 mm); or any Qw >25% of QRS complex

<table>
<thead>
<tr>
<th><strong>R wave</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Defined as any positive deflection w/i QRS; normally, Rw should become greater than Sw -V3–V4 (called R-wave progression [RWP])</td>
</tr>
<tr>
<td>Pathology suggested by poor RWP (LVH, LBBB, LAFB, ant-MI, WPW, COPD, infiltrative d/o, etc.), early RWP/dominant Rw in V1–V2 (RVH, RBBB, post-MI, WPW, HOCM, etc.), dominant Rw in aVR (TCA o/d)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>QRS complex</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Represents ventricular depolarization (1st half: septum &amp; RV; 2nd half: LV)</td>
</tr>
<tr>
<td>Nl duration 0.06–0.11 s (60–110 ms) measured in lead w/ widest QRS complex (see Causes of Abnl Interval Duration)</td>
</tr>
<tr>
<td>Pathology suggested by prolongation (see Causes of Prolonged QRS below) or low voltage (R + S &lt;0.5 mV in limb leads or &lt;0.1 mV precordial; suggests presence of fluid [pericardial/pleural effusion], air [COPD], or excess fat/tissue [obesity, infiltrative CMP, myxedema])</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ST segment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Represents plateau from end of ventricular depolarization (end of S) to start of repolarization (beginning of T); jxn of QRS &amp; ST called J point</td>
</tr>
<tr>
<td>Normally isoelectric w/ TP segment</td>
</tr>
<tr>
<td>Pathology suggested by ST elevation (≥0.2 mV contiguous precordial leads, ≥0.1 mV limb leads, &amp; ≥0.5 mV in R-sided &amp; posterior leads) or depression (horizontal or downsloping depression ≥0.05 mV in 2 contiguous leads) (see Causes of ST Elevation)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>T wave</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Represents ventricular repolarization</td>
</tr>
<tr>
<td>Normally smooth &amp; round morphology, positive in all leads except aVR; may be biphasic in V1/V2; amplitude generally 2/3 that of the R wave</td>
</tr>
<tr>
<td>Pathology suggested by Tw inversions in I, II, aVL, V2–V6 (BBBs, LVH w/ strain pattern, Wellens' sign, myocardial ischemia, myopericarditis, cardiac contusion, MVP, SAH, hypokalemia, digoxin effect) or peaked-Tw morphology (hyperkalemia, early myocardial ischemia)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>U wave</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Small wave following T wave; represents prolonged repolarization of mid-myocardial layer cells “M cells”</td>
</tr>
<tr>
<td>Nl amplitude &lt;1.5 mm tall or ~10% on T-wave amplitude</td>
</tr>
<tr>
<td>Pathology suggested by prominent Uw (hypokalemia/hypocalcemia, sinus bradycardia, LVH, MVP, hyperthyroid, etc.)</td>
</tr>
</tbody>
</table>
**QT interval**
- Measured from start of QRS complex to end of T wave; represents duration of electrical activation & recovery of ventricle
- NL duration 390–450 ms in men; 390–460 ms in women (see *Causes of Abnl Interval Duration*).

<table>
<thead>
<tr>
<th>Normal &amp; Causes of Abnormal Interval Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td>PR</td>
</tr>
<tr>
<td>QRS</td>
</tr>
<tr>
<td>QTc</td>
</tr>
</tbody>
</table>

*Several formulas can be used to calculate QTc manually: [1] QTc = QT/√RR; [2] QTc = QT/RR^{1/3}; [3] QTc = QT + 0.154 × (1 − RR)*

**Conduction Delays**

<table>
<thead>
<tr>
<th>Category</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>RBBB</td>
<td>1. QRS duration ≥120 ms (≥100–120 ms = “incomplete” RBBB) 2. Late intrinsicoid (R-wave peak time &gt;0.05 s) M-shaped QRS (rsr’, rSr’, rSR’) in V1–V2 (“rabbit ears”)</td>
</tr>
</tbody>
</table>
3. Early intrinsicoid, broad terminal slurred S wave in I, V5–V6

Causes: AMI, Right-heart strain (PE, pHTN), myopericarditis, CMP, endomyocardial fibrosis, Chagas dz, CHD (ASD, VSD, ToF)

**LBBB**

1. QRS ≥120 ms (≥100–120 ms = “incomplete” RBBB)
2. Wide, notched R wave & absent Q wave in V5–V6, I, aVL
3. Late intrinsicoid (R-wave peak time >0.06 s) in V5–V6
4. Wide S wave in V1 w/ rS or QS complex

Causes: Anterior AMI, LV, CMP, hyperkalemia, digoxin tox

**LAFB**

1. QRS duration ≤120 ms
2. LAD (usually ≥−60°)
3. QR pattern in I & aVL
4. rS pattern in II, III, & aVF
5. Late intrinsicoid (R-wave peak time >0.045 s) in aVL
6. Increased QRS voltage in limb leads

Causes: Acute or remote MI, AS, OSA, CMP, endomyocardial fibrosis, Chagas dz, CHD

**LPFB**

1. QRS duration ≤120 ms
2. RAD (usually ≥+120°) w/o e/o RVH
3. rS pattern in I & aVL
4. QR pattern in II, III, & aVF
5. Late intrinsicoid (R-wave peak time >0.045 s) in aVF

Causes: Acute cor pulmonale, CAD Lenègre’s dz, CMP, endomyocardial fibrosis, Chagas dz, hyperkalemia

**Bifascicular block**

2 of RBB, LAFB, & LPFB; can be complete or incomplete

**Trifascicular block**

All 3 of RBBB, LAFB, & LPFB; can be complete or incomplete (ie, incomplete trifascicular block can present w/ fixed block of both fascicles w/ e/o delayed conduction in remaining fascicle as in a 1° or 2° AVB)

**Intraventricular conduction delay**

1. QRS duration >110 ms
2. Typical waveforms of RBBB & LBBB not present

---

**Atrial Abnormality and Ventricular Hypertrophy**

<table>
<thead>
<tr>
<th>Type</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAE (P pulmonale)</td>
<td>P ≥0.15 mV in V1/V2</td>
</tr>
</tbody>
</table>
2. P ≥0.25 mV in II or aVF
3. P-wave duration <0.12 s
4. P-wave axis (>75°–90°)

Causes: TR, PS; pHTN (eg, ILD, COPD, CHF); ASD, VSD

LAE
1. Terminal negative P wave in V1 >0.04 s & >0.01 mV
2. Duration b/w peaks in P wave notches >0.04 s (in II)
3. P-wave duration >0.12 s

Causes: MS/MR, AS; CHF; HTN, HOCM

RVH
1. Right atrial enlargement
2. Right-axis deviation
3. S wave in I + Q wave in III
4. R in V1 >0.7 mV or S in V5 or V6 >0.7 mV
5. QR complex V1 or raR′ in V1 w/ R′ >1 mV (w/ QRS duration <120 ms)

LVH
Sokolow–Lyon criteria:
- S wave in V1 + R wave in V5 or V6 ≥3.50 mV (sens 22%, spec 100%)
- R wave in aVL >0.9 (F) or >1.1 mV (M) (sens 11%, spec 100%)
Cornell voltage criteria:
- R wave aVL + S wave V3 >2 mV (women), >2.8 mV (men) (sens 42%, spec 96%)

Causes & Morphologies of ST Elevation *(NEJM 2003;349;2128–2135)*

<table>
<thead>
<tr>
<th>Differential</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>STEMI</td>
<td>Upward convex; coronary distribution; large T waves</td>
</tr>
<tr>
<td>Prinzmetal’s angina</td>
<td>As above (STEMI), but transient due to coronary spasm etiology</td>
</tr>
<tr>
<td>Myo/pericarditis</td>
<td>Upward concave; diffuse (can be regional); +/- PR depression</td>
</tr>
<tr>
<td>Massive PE</td>
<td>Inferior &amp; anteroseptal leads</td>
</tr>
<tr>
<td>LV aneurysm</td>
<td>Concave or convex; precordium common; ±pathologic Q waves; smaller T waves compared to STEMI</td>
</tr>
<tr>
<td>LBBB</td>
<td>Concave, usually discordant w/ QRS</td>
</tr>
<tr>
<td>LVH</td>
<td>Concave, other features of LVH present</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>Seen w/ other features of hyperkalemia</td>
</tr>
</tbody>
</table>
Brugada
- Usually incomplete RBBB, RAD, rSR' & downsloping STE V1, V2

nl (esp young men)
- Concave, seen in healthy young men, most marked in V2

Early repolarization
- Most marked at V4, notching at J point; tall upright T waves present

Cardioversion
- Seen 1–2 min after DCCV; can be markedly elevated

---

**ACUTE CORONARY SYNDROME**

**Overview**
- Approach to patient w/ angina sx: See section on *Chest Pain*
- **Chronic Stable Angina**: Substernal chest discomfort (pain, tightness, pressure) of less than 10-min duration, provoked by exertion or stress & alleviated by rest or NTG, & nonprogressive (ie, stable) over long periods of time (see table; compare to unstable angina [UA])
- Chronic angina should be a dx of exclusion in ED (after reviewing recent stress or cath results), as pts often present to EDs b/c sx are worse in some capacity

**Canadian Cardiovascular Society (CCS) Grading of Angina Pectoris**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade I</td>
<td><em>Ordinary physical activity does not cause angina.</em> Angina w/ strenuous or rapid or prolonged exertion as work or recreation.</td>
</tr>
<tr>
<td>Grade II</td>
<td><em>Slight limitation of ordinary activity:</em> walking or climbing stairs rapidly; walking uphill; walking or stair climbing after meals; in cold, wind, or under emotional stress; or only during the few hours after awakening; walking &gt;2 blocks on level &amp; climbing &gt;1 flight of ordinary stairs at a nl pace &amp; in nl conditions.</td>
</tr>
<tr>
<td>Grade III</td>
<td><em>Marked limitation of ordinary physical activity.</em> Angina occurs on walking 1 or 2 blocks on the level &amp; climbing 1 flight of stairs in nl conditions &amp; at nl pace.</td>
</tr>
<tr>
<td>Grade IV</td>
<td><em>Inability to carry on any physical activity w/o discomfort.</em> At rest.</td>
</tr>
</tbody>
</table>

- **Acute Coronary Syndrome**: Clinical spectrum of conditions
ranging from UA through MI (NSTEMI & STEMI); due to vulnerable or high-risk plaque undergoing disruption of the fibrous cap causing thrombogenesis & ultimate imbalance b/w myocardial O₂ supply & demand (eg, tissue ischemia)

- **Myocardial Infarction** (see *Universal Definition*): death of myocardial cells due to myocardial tissue hypoxia, acutely causing release of intracellular cardiac biomarkers
- Once diagnosed, important to consider subtype & etiology (see tables below)
  - MI DDx is broad: not always 2/2 acute plaque rupture (see table below)
  - Elevated troponin not always MI: consider nonischemic etiologies (see table below)

<table>
<thead>
<tr>
<th>Universal Definition of Myocardial Infarction Classification System <em>(JACC 2012;60(16):1581)</em></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summary of Criteria for Acute MI</strong></td>
</tr>
<tr>
<td>Detection of a rise &amp;/or fall of cardiac biomarker values (preferably cTn) w/ at least one value above the 99th percentile upper reference limit w/ at least one of the following:</td>
</tr>
<tr>
<td>- <strong>Symptoms</strong>: Sxs of ischemia</td>
</tr>
<tr>
<td>- <strong>ECG</strong>: New or presumed new significant ST-T changes, LBBB, Qw</td>
</tr>
<tr>
<td>- <strong>Imaging</strong>: e/o new loss of viable myocardium or new regional wall motion abx</td>
</tr>
<tr>
<td>- <strong>Pathology</strong>: Identification of an intracoronary thrombus by angiography or autopsy</td>
</tr>
<tr>
<td><strong>Criteria for Prior MI</strong></td>
</tr>
<tr>
<td>- <strong>ECG</strong>: Pathologic Q waves w/ or w/o sxs in the absence of nonischemic causes</td>
</tr>
<tr>
<td>- <strong>Imaging</strong>: e/o loss of viable myocardium in the absence of nonischemic causes</td>
</tr>
<tr>
<td>- <strong>Pathology</strong>: Pathologic findings of a prior MI</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Universal Classification of MI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type 1</strong></td>
</tr>
<tr>
<td><strong>Type 2</strong></td>
</tr>
<tr>
<td><strong>Type 3</strong></td>
</tr>
<tr>
<td><strong>Type 4a</strong></td>
</tr>
<tr>
<td><strong>Type 4b</strong></td>
</tr>
</tbody>
</table>
### Differential for MI and Injury

<table>
<thead>
<tr>
<th>Causes</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ischemic injury</strong></td>
<td></td>
</tr>
<tr>
<td>Atherosclerotic plaque rupture</td>
<td>Most common cause of 1° ACS</td>
</tr>
<tr>
<td>Coronary artery dissection</td>
<td>1° (spontaneous, a/w pregnancy), or 2° (type A AoD w/ retrograde RCA dissection, post-PCI)</td>
</tr>
<tr>
<td>Coronary artery spasm</td>
<td>Prinzmetal’s variant, cocaine-induced</td>
</tr>
<tr>
<td>Coronary artery embolism</td>
<td>Thrombus, endocarditis, myxoma</td>
</tr>
<tr>
<td>Fixed atherosclerotic plaque w/ increased O\textsubscript{2} demand</td>
<td>↑ HR, ↑ BP, AoS (↑ O\textsubscript{2} demand) \quad ↓ BP, anemia, hypoxia (↓ O\textsubscript{2} supply)</td>
</tr>
<tr>
<td><strong>Nonischemic injury</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Myocarditis, myocardial contusion, infiltrative dz, drug-induced myocardial injury</td>
</tr>
</tbody>
</table>

### History

- **Typical symptoms of angina:** Substernal pressure, pain, or tightness; often radiating to neck, jaw, or arm(s); precipitated by exertion & relieved w/ rest or NTG
  - Associated sxs: dyspnea, diaphoresis, N/V, palpitations, LH
  - Up to 23% of AMIs lack typical anginal sxs (AJC 1973;32:1)
- **Concerning features:** new, at rest, or crescendo (frequency, severity, duration, ↓ threshold)

### Value of Specific Symptoms in Diagnosis of AMI (JAMA 2005;294:2623)

<table>
<thead>
<tr>
<th>Pain Descriptor</th>
<th>LR (95% CI)</th>
<th>Pain Descriptor</th>
<th>LR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Increased Likelihood of AMI</strong></td>
<td></td>
<td><strong>Decreased Likelihood of AMI</strong></td>
<td></td>
</tr>
<tr>
<td>Radiation: R arm/shoulder</td>
<td>4.7 (1.9–12)</td>
<td>Described as pleuritic</td>
<td>0.2 (0.1–0.3)</td>
</tr>
<tr>
<td>Radiation: B/L arms/shoulders</td>
<td>4.1 (2.5–6.5)</td>
<td>Described as positional</td>
<td>0.3 (0.2–0.5)</td>
</tr>
<tr>
<td>Exertional</td>
<td>2.4 (1.5–3.8)</td>
<td>Described as sharp</td>
<td>0.3 (0.2–0.5)</td>
</tr>
<tr>
<td>Radiation to L arm</td>
<td>2.3 (1.7–3.1)</td>
<td>Reproducible w/ palpation</td>
<td>0.3 (0.2–0.4)</td>
</tr>
<tr>
<td>A/w diaphoresis</td>
<td>2 (1.9–2.2)</td>
<td>Inframammary location</td>
<td>0.8 (0.7–0.9)</td>
</tr>
<tr>
<td>A/w N/V</td>
<td>1.9 (1.7–2.3)</td>
<td>Nonexertional</td>
<td>0.8 (0.6–0.9)</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Worse w/ previous angina or similar to previous MI</td>
<td>1.8 (1.6–2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Described as pressure</td>
<td>1.3 (1.2–1.5)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Physical Exam**
- Can be unremarkable unless c/b hypotension, heart block/arrhythmia, pulm edema
- Helpful for assessing for other causes of chest pain: bilateral UE BPs (AoD), lung exam (CHF, PTX, PNA), abdominal exam (biliary & pancreatic etiologies), chest wall ttp

**Evaluation**
- **ECG**: always check w/i 10 min, if sxs change, at 6–12 h; always compare w/ baseline; if pain persists or changes present, always repeat q15–20min; always consider posterior ECG (leads V7–V9) in pts w/ non-dx initial ECG to r/o L circumflex STEMI
  - Acute ischemia changes: ↑ or ↓ in ST or new TWI in anatomic distribution, new LBBB
  - Old ischemic changes: Qw or PRWP (indicates presence of CAD even if no known hx)
  - Sgarbossa criteria: Used to identify STEMI in the presence of old LBBB (see table)

<table>
<thead>
<tr>
<th>Anatomic Area</th>
<th>ECG Leads</th>
<th>Coronary Artery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Septal</td>
<td>V1–V2</td>
<td>Proximal LAD¹</td>
</tr>
<tr>
<td>Anterior</td>
<td>V3–V4</td>
<td>LAD</td>
</tr>
<tr>
<td>Apical</td>
<td>V5–V6</td>
<td>Distal LAD, LCx, or RCA</td>
</tr>
<tr>
<td>Lateral</td>
<td>I, aVL, V5–V6</td>
<td>LCx</td>
</tr>
<tr>
<td>Anterolateral</td>
<td>aVR</td>
<td>L main CA</td>
</tr>
<tr>
<td>Inferior²</td>
<td>II, III, aVF</td>
<td>RCA (~85%), LCx (~15%)</td>
</tr>
<tr>
<td>RV</td>
<td>V1–V2 &amp; V4R (most sens)</td>
<td>Proximal RCA</td>
</tr>
<tr>
<td>Posterior</td>
<td>ST depression V1–V2</td>
<td>RCA or LCx (obtain posterior leads)</td>
</tr>
</tbody>
</table>
Sgarbossa Criteria for Identifying AMI in Presence of Old LBBB

<table>
<thead>
<tr>
<th>Criteria &amp; Points</th>
<th>Sens (%)</th>
<th>Spec (%)</th>
<th>Pos LR</th>
<th>Neg LR</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 pts: ≥1 mm STE concordant w/ QRS</td>
<td>73</td>
<td>92</td>
<td>9.5</td>
<td>0.3</td>
</tr>
<tr>
<td>3 pts: ≥1 mm STD in V1–V3</td>
<td>25</td>
<td>96</td>
<td>6.6</td>
<td>0.8</td>
</tr>
<tr>
<td>2 pts: ≥5 mm discordant w/ QRS</td>
<td>31</td>
<td>92</td>
<td>3.6</td>
<td>0.8</td>
</tr>
</tbody>
</table>


- **Cardiac biomarkers:** Troponin (I or T) preferred over CK-MB
  - Troponin: longer duration (↑ Sens) & higher specificity
  - CK-MB: only useful in addition to Tn if c/f new event w/i 1 wk from prior event in which +Tn (eg, return visit after recent PCI, MI, CABG, etc.)
    - Cardiac index: CI = (CK − MB/CK) × 100. CI <3 suggests skeletal source, CI 3–5 → indeterminate, CI >5 suggests cardiac source
    - Serial biomarker testing if signs/sx ACS: Perform repeat troponin at 3–6 h after arrival, & at 6 h (+/− 12 h) if intermediate- or high-suspicion of ACS; if positive, continue measuring until levels peak & downtrend (J Am Coll Cardiol 2014;64(24):e139–228)
    - If initial Tn positive (eg, CKD), Δ Tn > +20% suggests new myocardial injury (if no AKI)
  - Non-MI causes of elevated biomarkers: myopericarditis; drug toxicity; acute neurologic diseases (eg, ICH); myocardial contusion; myocardial O₂ supply-demand mismatch 2/2 tachyarrhythmia, CHF, HTN, hypotension, PE, sepsis, burns, respiratory failure
  - **Special note on novel high-sensitivity troponin I assays:** HS TnI assays can detect TnI levels far earlier, but may also detect nonnecrosis processes (eg, nl apoptosis), & thus can even be positive even in some healthy individuals
  - Single- & serial-HS-Tn protocols under investigation: Prelim studies suggest very high Sens at 0 h (99.6–100%) & 3 h (Am Heart J 2016;181:16–25; Int J Cardiol 2013;168(4):3896–3901); potentially helpful for
ruling out AMI quickly

- Due to lower Spec, Δ in serial HS-Tn may have greater clinical significance than elevation itself for ACS (*J Am Coll Cardiol* 2014;64(24):e139–e228), though absolute elevations may have prognostic value (*J Am Heart Assoc* 2014;3(1):e000403)

<table>
<thead>
<tr>
<th>Cardiac Enzyme</th>
<th>Initial Elevation</th>
<th>Peak</th>
<th>Return to Baseline</th>
<th>Sens @ 8 h (%)</th>
<th>Sens @ 12 h (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CK-MB</td>
<td>4–6 h</td>
<td>18 h</td>
<td>2–3 d</td>
<td>91</td>
<td>93–95</td>
</tr>
<tr>
<td>Troponin I</td>
<td>3–12 h</td>
<td>24 h</td>
<td>1–2 wk</td>
<td>90</td>
<td>95–100</td>
</tr>
</tbody>
</table>

*A single set of cardiac enzymes cannot r/o MI (& multiple sets cannot r/o ischemia w/o infarction)*

- **Other labs:** Chem 7, CBC, coags, T/S (if intervention planned), tox (if cocaine suspected)
- **CXR:** Useful to r/o other causes of CP; check lungs, cardiac silhouette, mediastinum
- **Transthoracic echo:** If ECG is not interpretable (prior LBBB, paced) & suspicion for ACS is high, can obtain TTE to assess for regional wall motion abnormalities; +WMA in pt w/ ongoing CP may suggest benefit from earlier PCI (*J Am Coll Cardiol* 2014;64(24):e139–e228)
- **Risk-stratification testing:** See section on *Risk Stratification Testing*
- Coronary CTA, exercise stress testing, stress echocardiography, nuclear stress testing
Treatment

- Give ASA if considering ACS & no CIs (50–70% drop in D/MI for UA/NSTEMI (NEJM 1988;319(17):1105–1111); 23% drop in death in STEMI (Lancet 1988;2(8607):349–360)
- **Chronic stable angina:** ASA (NNT = 50 in pts w/ known or suspected CAD), BP control, moderate- to high-intensity statin supported by mx RCTs (NEJM 2016;374:1167–1176; Lancet 2009;373(9678):1849–1860)
- **ACS:** See *UA/NSTEMI & STEMI* for details

Disposition

- Admit all STEMI, NSTEMI, & UA (see *UA/NSTEMI & STEMI* for details)
- For patients w/ nondiagnostic hx, ECG, & biomarkers: Risk-stratify w/ HEART score
  - HEART (score ≤ 3) > TIMI & GRACE in predicting major adverse
cardiac events w/i 30 d (Sens 99%, NPV 98%) (Int J Cardiol 2016;221:759–764; Int J Cardiol 2017;227:65–661)

<table>
<thead>
<tr>
<th>HEART Score for Chest Pain Patients in the ED (Neth Heart J 2008;16(6):191–196)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History</strong></td>
</tr>
<tr>
<td>Highly suspicious</td>
</tr>
<tr>
<td>Moderately suspicious</td>
</tr>
<tr>
<td>Slightly/nonsuspicious</td>
</tr>
</tbody>
</table>

**ECG**

<table>
<thead>
<tr>
<th>Risk Factors***</th>
</tr>
</thead>
<tbody>
<tr>
<td>Significant ST depressions</td>
</tr>
<tr>
<td>Nonspecific repolarization</td>
</tr>
<tr>
<td>Nl</td>
</tr>
</tbody>
</table>

**Age**

<table>
<thead>
<tr>
<th>Risk factors include: Current DM, current or recent (&lt;1 mo) smoker, HTN, HLD, FHx CAD, obesity</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥65 y</td>
</tr>
<tr>
<td>&gt;45 to &lt;65 y</td>
</tr>
<tr>
<td>≤45 y</td>
</tr>
</tbody>
</table>

**Total Score, Prognostic Value, and Disposition**

<table>
<thead>
<tr>
<th>Score</th>
<th>MACE over next 6 wk</th>
<th>Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–3</td>
<td>2.5%</td>
<td>Discharge home w/ f/u</td>
</tr>
<tr>
<td>4–6</td>
<td>20.3%</td>
<td>Observation &amp; risk-stratification testing</td>
</tr>
<tr>
<td>7–10</td>
<td>72.7%</td>
<td>Admit for early catheterization</td>
</tr>
</tbody>
</table>

**STEMI: Overview & Treatment**

**Definition**

- Acute complete occlusion of coronary artery (usually proximal) due to unstable thrombus, causing transmural ischemia & myocardial necrosis; characterized by angina usually at rest usually >30 min, ECG e/o ST elevations (see below for criteria), & +troponin
ECG Criteria: ≥0.2 mV precordial leads, ≥0.1 mV limb leads, & ≥0.5 mV in R-sided & posterior leads in at least 2 contiguous leads

Treatment Approach
- Initiate early medical therapies (ASA, heparin, nitrates prn, O₂ prn, analgesia)
  - Antithrombotic/adjunctive therapy should not delay transfer for pPCI
- Reperfusion: Immediate decision regarding availability of 1° PCI (see below)
  - pPCI or transfer to PCI-capable hospital preferred for all pts except if time b/w 1st medical contact (FMC) & pPCI is expected >120 min
  - Fibrinolysis may be preferred if delay to pPCI expected >120 min: after 120 min, no benefit of tfx to PCI-capable facility (Circulation 2011;124:2512–2521)
    - Goal time from FMC to lysis: <30 min
  - If FMC-to-pPCI time expected >120 min, consider: (J Am Coll Cardiol 2009;54(23):2205–2241)
    - Known CI to lysis (see below): pPCI preferred
    - Delay from sx onset (>3 h): pPCI preferred (lytics have ↓ efficacy w/ ↑ delays)
    - High-risk patient (shock, Killip class ≥3): pPCI preferred
    - Dx of STEMI in doubt (eg, AoD w/ RCA dissection): pPCI preferred
  - If planning PCI, call cardiology/PCI lab as early as possible (potentially even before the pt arrives in the ED—if reliable pre-notification by EMS)
  - If transferring for PCI, call for tfx early & ensure their door-to-balloon time is <90 min
- Monitor & treat complications (eg, CHB, cardiogenic shock, pulm edema, arrhythmias)

Adjunctive Medical Therapies (Fibrinolytics or pPCI)
- Analgesia: Morphine formerly used widely but may carry increased risk of adverse outcomes; use opioids only if absolutely needed (Am Heart J 2005;149(6):1043–1049)
- O₂ supplementation: No e/o benefit & may cause harm, possibly
2/2 free radical formation; use only in hypoxic pts w/ O₂ saturation <90% (Cochrane 2013;8:CD007160)

- **Nitrates:** No proven long-term mortality benefit, but may ameliorate sxss; typical dose 0.4 mg SL q5min × 3; CI w/ ↓ BP, RV infarct, PD-inh w/i 24–48 h (Cochrane 2009;4:CD006743)

- **Anti-plt tx:** Always give ASA (162–325 mg PO/PR), 23% ↓ in death c/w placebo (Lancet 1988;2:349); additional benefit from other anti-plt agents (see table); all patients should be administered additional anti-plt agents either in the ED or cath lab

- **Antithrombotic tx:** See table for recommended regimens

- **Beta-blockers:** Early IV BB ↓ VT/VF & reinfarction acutely & ↑ LVEF in long term, but also ↑ acute cardiogenic shock (esp if >70 y/o, SBP <120 mmHg, HR >110 bpm); give oral BB w/i 24 h of STEMI; consider IV BB acutely if no CI or ongoing ischemia (Int J Cardiol 2013;168(2):915–921; 2017;228:295–302. COMMIT/CCS-2, Lancet 2005;366:1607)

- **Other:** Often started as inpatients include oral BBs, statins, ACE inh/ARBs

---

<table>
<thead>
<tr>
<th>Adjunctive Therapies for Fibrinolysis in STEMI (Circulation 2013;127(4):529–555)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P₂Y₁₂ receptor inh</strong> (loading dose)</td>
</tr>
<tr>
<td>Antithrombotic tx</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Adjunctive Therapies for PCI in STEMI (Circulation 2013;127(4):529–555)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P₂Y₁₂ receptor inh</strong></td>
</tr>
</tbody>
</table>
**loading dose**

- thrombosis, & ↓ 30-d MACE c/w 300 mg load *(J Am Coll Cardiol 2011;58(15):1592–1599. Lancet 2010;376(9748):1233–1243)* but ↑ bleeding & ICU LOS if need for urgent CABG *(Am Heart J 2011;161(2):404–410); discuss w/ cardiology if potential CABG w/i 5 d*

**Prasugrel:** 60 mg load; mild ↓ ischemic cx but ↑ bleeding c/w clopidogrel; best if young & no need for surgery w/i 1 y; avoid if hx of CVA/TIA *(NEJM 2007;357:2001; TRITON-TIMI, Lancet 2009;373:732)*

**Ticagrelor:** 180 mg load; mild ↓ mortality, MI, stroke c/w clopidogrel, but ↑ nonprocedural bleeding (eg, ICH) *(NEJM 2009;361:1045–1057)*

**Antithrombotic tx**

| **UFH:** | IV bolus 50–70 U/kg IV, then 12 U/kg/h (max 1,000 U), maintain aPTT ∼50–70 s; may need higher doses |
| **Bivalirudin:** | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h infusion w/ or w/o UFH; preferred over UFH w/ GP IIb/IIIa inh in pts at high risk of bleeding; useful if hx of HIT |

**NOTE:** ACCF/AHA Guideline for Mgmt of STEMI recommends GIIb/IIIa inh (Class IIa recommendation) in selected patients, though often performed in cath lab. Options include: Abciximab 0.25 mg/kg bolus, then 0.125 mcg/kg/min (max 10 mcg/min); Tirofiban (high-bolus dose): 25 mcg/kg IV bolus, then 0.15 mcg/kg/min, ↓ by 50% in CKD; Eptifibatide (double bolus): 180 mcg/kg IV bolus, then 2 mcg/kg/min; a 2nd 180 mcg/kg bolus given 10 min after 1st bolus, ↓ by 50% in CKD, avoid in dialysis pts.

**Fibrinolysis**

- **Indications:** STEMI AND sx onset <12 h prior AND time b/w 1st medical contact & pPCI >120 min; may consider up to 24 h after sx onset if persistent sx, ongoing STE, rising troponin, hemodynamic instability, & pPCI unavailable
- **Goal:** Door-to-needle time should be ≤30 min
- **Benefits:** ~20% ↓ mortality in anterior MI or new LBBB; 10% ↓ mortality in IMI
- **Risks:** ICH (<1%), high-risk groups include elderly (~2% if >75 y), women, low weight
- **Fibrin-specific lytic (front-loaded tPA)** 14% ↓ mortality c/w SK (1% abs Δ; GUSTO, NEJM 1993;329:673) although ↑ ICH (0.7% vs. 0.5%); 3rd-generation bolus lytics easier to administer, but no more safe or efficacious
### Contraindications to Fibrinolysis in STEMI (*Circulation* 2013;127(4):529–555)

<table>
<thead>
<tr>
<th>Absolute CIs</th>
<th>Relative CIs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intracranial neoplasm, aneurysm, AVM</td>
<td>Any known active intracranial path not listed w/i absolute contraindications</td>
</tr>
<tr>
<td>H/o intracranial hemorrhage</td>
<td>H/o iCVA &gt;3 mo prior</td>
</tr>
<tr>
<td>H/o intracranial/spinal surgery w/i 2 mo</td>
<td>Active PUD, pregnancy, or dementia</td>
</tr>
<tr>
<td>H/o i-CVA/closed head trauma w/i 3 mo</td>
<td>Current use of anticoagulants</td>
</tr>
<tr>
<td>Active internal bleeding or bleeding d/o</td>
<td>H/o trauma or major surgery w/i 3 wk</td>
</tr>
<tr>
<td>Suspected aortic dissection</td>
<td>H/o recent internal bleeding w/i 2–4 wk</td>
</tr>
<tr>
<td>Severe HTN (unresponsive to IV tx)</td>
<td>H/o severe poorly controlled HTN, or SBP &gt;180 or DBP &gt;110 on presentation</td>
</tr>
<tr>
<td>If considering using streptokinase: prior streptokinase use w/i 6 mo</td>
<td>Traumatic or prolonged CPR (&gt;10 min)</td>
</tr>
<tr>
<td></td>
<td>Noncompressible vascular punctures</td>
</tr>
</tbody>
</table>

### Fibrinolytic Agents for STEMI (*Circulation* 2013;127(4):529–555)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Dosing</th>
<th>Patency, 90 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenecteplase (TNK-tPA)</td>
<td>Single IV weight-based bolus: &lt;60 kg (30 mg), 60–69 kg (35 mg), 70–79 kg (40 mg), 80–89 kg (45 mg), ≥90 kg (50 mg)</td>
<td>85%</td>
</tr>
<tr>
<td>Reteplase (rPA)</td>
<td>10 U + 10 U IV bolus given 30 min apart</td>
<td>84%</td>
</tr>
<tr>
<td>Alteplase (tPA)</td>
<td>Bolus 15 mg, infusion 0.75 mg/kg for 30 min (max 50 mg), then 0.5 mg/kg (max 35 mg) over 60 min; total dose not to exceed 100 mg</td>
<td>73–84%</td>
</tr>
</tbody>
</table>

### Indications for Transfer for PCI After Fibrinolysis

- Cardiogenic shock or severe acute HF: Immediate tfx regardless of time from sx onset (can tfx even >48 h after MI); ↓ 6-mo mortality w/immediate tfx; (*NEJM* 1999;341:625–634)
- Any pt: As part of an invasive strategy in stable pts after successful fibrinolysis; ideally PCI performed >3 h & <24 h after fibrinolysis; greatest benefit in high-risk pts
  - Routine angio ± PCI w/i 24 h of successful lysis: ↓ D/MI/Revasc
Primary PCI *(NEJM 2007;356:47)*

- **Indications:** STEMI sx onset <12 h prior, STEMI sx onset >12 h if CI to fibrinolytics, or presence of severe acute HF, or cardiogenic shock; ongoing ischemia 12–24 h
- **Goal:** door-to-balloon <90 min by skilled operator at high-volume center
- **Benefits:** 27% ↓ death, 65% ↓ re-MI, 54% ↓ stroke, 95% ↓ ICH c/w lysis *(Lancet 2003;361:13)*
- PCI w/i 3 h of lytics in stable pts (w/o e/o failed re-perfusion) may cause harm *(Lancet 2006;367:569; Lancet 2006;367:579; FINESSE, NEJM 2008;358:2205)*

Disposition

- If no PCI available: transfer to PCI-capable center regardless of decision to use lytics
- If PCI available: admit to cath lab → CCU/cardiology

---

**Unstable Angina / NSTEMI: Overview & Treatment**

**Definition**

- Pathogenesis: Nonocclusive coronary thrombus on pre-existing plaque, causing dynamic & progressive obstruction, inflammation, & ischemia
  - Coronary lesion can be located proximally or distally for UA, usually distal for NSTEMI
- **Unstable Angina:** Any angina that is new-onset (if CCS III-IV severity), occurring at rest (if >20 min), or crescendo in nature (frequency, severity, duration, or more easily triggered), but *lacking* both ST elevations & positive troponin
- **NSTEMI:** Similar as UA, but characterized by positive troponin
- **ECG Criteria:** None; can have nl ECG, territorial STD, TWI, or NSSTTW changes

**Treatment Approach**

- Initiate early medical therapies (ASA, heparin, nitrates prn, O₂ prn,
- Determine risk using TIMI or GRACE risk scores to guide early vs. delayed timing of angiography (see section below) (*Eur Heart J* 2005;26(9):865–872)
- Monitor & treat complications (eg, CHB, cardiogenic shock, pulm edema, arrhythmias)

<table>
<thead>
<tr>
<th>GRACE Risk Score for UA/NSTEMI (<em>BMJ</em> 2006;333(7578):1091)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (y)</strong></td>
</tr>
<tr>
<td>≤30              0 pts</td>
</tr>
<tr>
<td>30–39            8 pts</td>
</tr>
<tr>
<td><strong>Heart Rate (bpm)</strong></td>
</tr>
<tr>
<td>≤50              0 pts</td>
</tr>
<tr>
<td>50–69            3 pts</td>
</tr>
<tr>
<td><strong>Systolic Blood Pressure (mmHg)</strong></td>
</tr>
<tr>
<td>≤80              58 pts</td>
</tr>
<tr>
<td>80–99            53 pts</td>
</tr>
<tr>
<td><strong>Killip Class</strong></td>
</tr>
<tr>
<td>I (No heart failure)</td>
</tr>
<tr>
<td>0 pts            0 pts</td>
</tr>
<tr>
<td>II (Crackles in lower lung fields)</td>
</tr>
<tr>
<td>20 pts           39 pts</td>
</tr>
<tr>
<td>III (Crackles in whole lung field)</td>
</tr>
<tr>
<td>0 pts            39 pts</td>
</tr>
<tr>
<td>IV (Cardiogenic shock)</td>
</tr>
<tr>
<td>59 pts           59 pts</td>
</tr>
<tr>
<td><strong>Serum Creatinine Level (mg/dL)</strong></td>
</tr>
<tr>
<td>0–0.38           1 pt</td>
</tr>
<tr>
<td>0.39–0.79        4 pts</td>
</tr>
<tr>
<td><strong>Cardiac Arrest at admx</strong></td>
</tr>
<tr>
<td>Yes              0 pts</td>
</tr>
<tr>
<td>No               39 pts</td>
</tr>
<tr>
<td><strong>ST-Segment Deviation</strong></td>
</tr>
<tr>
<td>Yes              0 pts</td>
</tr>
<tr>
<td>No               28 pts</td>
</tr>
<tr>
<td><strong>Troponin Elevation</strong></td>
</tr>
<tr>
<td>Yes              0 pts</td>
</tr>
<tr>
<td>No               14 pts</td>
</tr>
</tbody>
</table>

**Risk Classification and Prognosis**

| Total score ≤100            | Low risk | In-hospital death <1% |
| Total score 101–170         | Medium risk | In-hospital death 1–9% |
| Total score ≥171            | High risk  | In-hospital death >9%  |
TIMI Risk Score for UA/NSTEMI *(JAMA 2000;284:825)*

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Score</th>
<th>Description</th>
<th>14d Risk: D/MI/Urg Revasc (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥65 y</td>
<td>1 pt</td>
<td>Severe angina (≥2 episodes w/i 24 h)</td>
<td>1 pt</td>
</tr>
<tr>
<td>≥3 RFs for CAD</td>
<td>1 pt</td>
<td>ST deviation ≥0.5 mm</td>
<td>1 pt</td>
</tr>
<tr>
<td>Known CAD (stenosis ≥50%)</td>
<td>1 pt</td>
<td>+cardiac marker (Tn, CK-MB)</td>
<td>1 pt</td>
</tr>
<tr>
<td>ASA use in past 7 d</td>
<td>1 pt</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Risk Classification and Risk of Death/MI/Urgent Revascularization w/i 14 d**

<table>
<thead>
<tr>
<th>Total score</th>
<th>14d Risk: D/MI/Urg Revasc (%)</th>
<th>Total score</th>
<th>14d Risk: D/MI/Urg Revasc (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–1 pt</td>
<td>5</td>
<td>4 pts</td>
<td>20</td>
</tr>
<tr>
<td>2 pts</td>
<td>8</td>
<td>5 pts</td>
<td>26</td>
</tr>
<tr>
<td>3 pts</td>
<td>13</td>
<td>6–7 pts</td>
<td>41</td>
</tr>
</tbody>
</table>

**Adjunctive Medical Therapies**

- **Analgesia**: Morphine formerly used widely but may carry increased risk of adverse outcomes; use opioids only if absolutely needed *(Am Heart J 2005;149(6):1043–1049)*
- **O₂ supplementation**: No e/o benefit & may cause harm, possibly 2/2 free radical formation; use only in hypoxic pts w/ O₂ saturation <90% *(Cochrane 2013;8:CD007160)*
- **Nitrates**: No proven long-term mortality benefit, but may ameliorate sxds; typical dose 0.4 mg SL q5min × 3, continuous gtt if CP not improved w/SL (titrate until CP free; once CP free, titrate off); CI w/ ↓ BP, RV infarct, PD-inh w/i 24–48 h *(Cochrane 2009;4:CD006743)*
- **Anti-plt tx**: Always give ASA (162–325 mg PO/PR), 23% ↓ in death c/w placebo *(Lancet 1988;2:349)*; additional benefit from other anti-plt agents (see table)
  - If allergic to ASA: Clopidogrel 300–600 mg load (regardless of PCI approach)
  - If early invasive approach: Once decision made to proceed to PCI made, give Clopidogrel (600 mg), Ticagrelor (180 mg), or GP IIb/IIIa inh (eptifibatide IV, tirofiban IV) in addition to ASA; discuss w/ cardiology, may have greatest value if expected delay to PCI;
further agents (P2Y12 inh, GPI) may have benefit when given peri-PCI in cath lab \(\text{(J Am Coll Cardiol} 2013;61(23):e179–e347)\)

- **If conservative approach:** If PCI uncertain or not planned, give Clopidogrel (300 mg or 600 mg) or Ticagrelor (180 mg) in addition to ASA; reasonable to consider addition of GP IIb/IIIa inh (eptifibatide IV, tirofiban IV) unless low risk score &/or high bleeding risk \(\text{(J Am Coll Cardiol} 2013;61(23):e179–e347)\)

- Inconclusive benefit from ED administration (vs. cath lab/inpatient unit) of DAPT in either early invasive or conservative approach, though generally earlier tx is better if UA/NSTEMI dx certain & low bleeding risk

  - **Antithrombotic tx:** See table for recommended regimens; continue until angiography (early invasive approach) or 48 h (conservative approach, if stress results indicate no need for angiography); hold anticoagulation if on warfarin until INR <2.0; anticoagulants have short-term benefit (UFH ↓ mortality 33–56% at 2–12 wk), but long-term benefit unclear, as dz process resumes once anticoagulation discontinued

  - **Beta-blockers:** Early IV BB ↓ VT/VF & reinfarction acutely & ↑ LVEF in long term, but also ↑ acute cardiogenic shock (esp if >70 y/o, SBP <120 mmHg, HR >110 bpm); give oral BB w/i 24 h of UA/NSTEMI; IV not routinely indicated \(\text{(Int J Cardiol} 2013;168(2):915–921. \text{Int J Cardiol} 2017;228:295–302. \text{COMMIT/CCS-2, Lancet} 2005;366:1622)\)

  - Other: Often started as inpatients include oral BBs, statins, ACE inh/ARBs

### Antithrombotic Therapy in UA/NSTEMI

<table>
<thead>
<tr>
<th>Early invasive approach</th>
<th>UFH: IV bolus 60 U/kg (max 4,000 U) then gtt at 12 U/kg/h (max 1,000 U), maintain aPTT (\approx) 50–70 s x 48 h or until revasc</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Enoxaparin:</strong> If &lt;75 y/o, 30 mg IV bolus, then 15 min later, 1 mg/kg SC q12h; if &gt;75 y/o, no bolus, 0.75 mg/kg SC q12h; if CrCl &lt;30 mL/min, 1 mg/kg q24h; mild ↓ in nonfatal MI c/w UFH</td>
</tr>
<tr>
<td></td>
<td><strong>Bivalirudin:</strong> 0.75 mg/kg IV bolus, then 1.75 mg/kg/h infusion w/ or w/o UFH; preferred over UFH w/ GP IIb/IIIa inh in pts at high risk of bleeding</td>
</tr>
<tr>
<td>Conservative approach</td>
<td>UFH: IV bolus 60 U/kg (max 4,000 U) then gtt at 12 U/kg/h</td>
</tr>
</tbody>
</table>
(max 1,000 U), maintain aPTT -50–70 s x 48 h or until revasc

| **Enoxaparin:** | If <75 y/o, 30 mg IV bolus, then 15 min later, 1 mg/kg SC q12h; if >75 y/o, no bolus, 0.75 mg/kg SC q12h; if CrCl <30 mL/min, 1 mg/kg q24h |
| **Fondaparinux:** | Initial 2.5 mg IV, then 2.5 mg SC the following day; preferred if hx of HIT or ↑ bleeding risk |

**J Am Coll Cardiol** 2013;61(23):e179–e347; 64(24):e139–e228

**Early Invasive vs. Conservative Approach** *(J Am Coll Cardiol)*

- Ultimately, approach decided by interventional cardiology based on multiple factors: risk score, procedural risks, recent angiography results, clinical stability & sx, individual pt goals, etc.
- **Early invasive approach:** Routine angiography w/i 72 h, urgency based on presentation:
  - *Immediate-invasive (PCI <2 h):* Any HD instability, VT/VF, HF/MVR, refractory angina
  - *Routine-invasive (PCI w/i 12–48 h):* High-risk scores (TIMI ≥ 3, GRACE > 140), rising troponin, or new STD on ECG
  - *Delayed-invasive (PCI 25–72 h):* Medium-risk (TIMI ≥ 2, GRACE 109–140) or high-risk scores (w/o rising troponin or STD); +/- hx of PCI w/i 6 mo, prior CAbG, CKD, ↓ EF
- **Conservative (“selective invasive”) approach:** Best for initially stabilized pts w/o high-risk scores, ongoing symptoms, arrhythmias, heart failure; 2/2 marginal benefit but ↑ risks of early invasive approach *(Cochrane 2016;26(5):CD004815)*
  - Medical therapies (see above) for 48 h minimum, pre-discharge stress test
  - Angiography only if recurrent ischemia, arrhythmias, heart failure, positive stress test
- Early invasive approach: In meta-analysis, no ↓ all-cause mortality/nonfatal MI, may ↓ risk of MI, refractory angina, & rehosp at 6–12 mo c/w conservative approach; however, also ↑ bleeding risk & procedure-related MI *(Cochrane 2016;26(5):CD004815)*
- Higher-risk pts benefit most from earlier angiography *(J Am Coll Cardiol)*

* TIMACS, NEJM 2009;360:2165–2175* as reflected in
guidelines above

**Disposition**

- Admission to CCU/cardiology based on risk, clinical stability, arrhythmia risk
- If UA, low-risk score, –Tn, nondiagnostic ECG: consider admitting to a CP/observation unit for serial troponin testing & stress testing; admx if recurrent sx, Δ ECG, +Tn


| Angiography Selection & Timing in UA/NSTEMI (*J Am Coll Cardiol* 2014;64(24):e139–e228) |
|---------------------------------|-------------------------------------------------|
| **Immediate (<2 h) invasive**   | Hemodynamic instability                          |
|                                 | Sustained VT or VF                               |
|                                 | Signs or sx of HF or new or worsening mitral valve regurg |
|                                 | Refractory angina                                |
| **Selective (med tx, PCI prn) invasive** | Low-risk score (eg, TIMI 0–1, GRACE <109)       |
|                                 | Low-risk Troponin-negative female pts            |
|                                 | Patient or clinician preference in absence of high-risk features |
| **Early (<24 h) invasive**      | None of above, but high risk (TIMI ≥ 3, GRACE score > 140) |
|                                 | Temporal change in Troponin                      |
|                                 | New or presumably new STD on ECG                |
| **Delayed (25–72 h) invasive**  | None of above but DM                             |
|                                 | Renal insufficiency (GFR <60 mL/min)            |
|                                 | Reduced LV systolic function (EF <0.40)         |
|                                 | Early postinfarction angina                      |
|                                 | PCI w/i 6 mo                                     |
|                                 | Prior CABG                                       |
|                                 | Medium-risk score (TIMI 2, GRACE 109–140)        |

**RISK STRATIFICATION TESTING**

**Approach**

- **Definition:** Noninvasive eval for obstructive CAD in low-risk pts w/ acute CP/sx c/f ACS
  - Result usually qualitative (“positive” vs. “negative”) for ischemia
- **Indications:** dx obstructive CAD, assess Δ clinical status in pt w/ known obstructive CAD, localize ischemia in pts w/ known
symptomatic obstructive CAD

- **Contraindications:** severe acute illness, AMI w/i 48 h, high-risk UA, alternative critical dx (PE, AoD, myopericarditis, acute decompensated CHF, arrhythmias, severe AoS)
- Low-risk (HEART 0–3, TIMI 0–1, GRACE <109) pts may be safely discharged w/o stress testing if close f/u for outpatient stress testing can be arranged
- ED stress testing in low-risk pts is low yield & high-cost (*Am J Cardiol* 2015;116(2):204–207)
- 6-mo risk of MACE is low & may be unchanged regardless of whether pt receives stress in ED (*Int J Cardiol* 2017;227:656–661; *Crit Pathw Cardiol* 2016;15(4):145–151)

### Exercise Treadmill Testing

- Patient runs on treadmill; monitoring includes ECG, symptoms, Δ hemodynamics (HR, BP)
- “Diagnostic” test requires pt to achieve min of 85% of predicted HR (pHR = 220 – age)
- **Test characteristics:** 68% Sens, 77% Spec (*NEJM* 2011;344(24):1840–1845)
- **Benefits:** Lowest cost of risk stratification tests
- **Downsides:** requires nl resting ECG; ↓ Sens if low-risk pt; ↓ Sens & Spec in women; ↓ Sens if anti-ischemic drugs not d/c-ed (d/c BBs, digoxin, vasodilators, anti-HTN drugs ~2 d prior to testing if possible)
- Duke Treadmill Score: weighted index of treadmill time, ECG chgs, induced angina sx
  - DTS = Duration of exercise in min – (5 * max STD in mm) – (4 * angina index)
  - Angina index: No angina (AI = 0), nonlimiting angina (AI = 1), limiting angina (AI = 2)

<table>
<thead>
<tr>
<th>DTS Risk</th>
<th>1-y Mortality</th>
<th>No Stenosis ≥ 75%</th>
<th>1VD ≥ 75%</th>
<th>2VD ≥ 75%</th>
<th>3VD ≥ 75%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male: Low</td>
<td>0.9%</td>
<td>52.6%</td>
<td>22.4%</td>
<td>13.6%</td>
<td>11.4%</td>
</tr>
<tr>
<td>Male: Mod</td>
<td>2.9%</td>
<td>17.8%</td>
<td>15.6%</td>
<td>27.9%</td>
<td>38.7%</td>
</tr>
<tr>
<td>Male: High</td>
<td>8.3%</td>
<td>1.8%</td>
<td>9.1%</td>
<td>17.5%</td>
<td>71.5%</td>
</tr>
<tr>
<td>Fem: Low</td>
<td>0.5%</td>
<td>80.9%</td>
<td>9.4%</td>
<td>6.2%</td>
<td>3.5%</td>
</tr>
<tr>
<td>-------------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>Fem: Mod</td>
<td>1.1%</td>
<td>65.1%</td>
<td>14.2%</td>
<td>8.3%</td>
<td>12.4%</td>
</tr>
<tr>
<td>Fem: High</td>
<td>1.8%</td>
<td>10.8%</td>
<td>18.9%</td>
<td>24.3%</td>
<td>46.0%</td>
</tr>
</tbody>
</table>


**Pharmacologic Stress w/ Nuclear SPECT Imaging**
- Ischemia induced by pharmacologic agents (dobutamine, adenosine, dipyridamole); radio-labeled tracers (eg, sestamibi) enter myocardial cells & reflect regional perfusion; ↓ tracer uptake during stress that resolves w/ time suggests viable area of tissue ischemia; fixed defect suggest existing infarct
- Note: nuclear imaging can be performed after physical exercise as well

**Test characteristics:** Adenosine SPECT Sens 90%, Spec 75%; dipyridamole SPECT Sens 89%, Spec 65%; dobutamine SPECT Sens 82%, Spec 75% (*Am Heart J* 2001;142(6):934–944)

**Benefits:** Can use if abnl baseline ECG or unable to exercise; can localize ischemia

**Downsides:** More expensive than exercise stress; ↓ Sens & Spec in women; ↓ Sens if anti-ischemic drugs not d/c-ed (d/c BBs, digoxin, vasodilators, anti-HTN drugs ~2 dys prior to testing if possible)

**Pharmacologic/Exercise Stress w/ Echo Imaging**
- Ischemia induced by pharmacologic agents (dobutamine, adenosine, dipyridamole) or exercise; echocardiography performed to assess for regional WMAs compared to rest

**Test characteristics:** Adenosine Echo Sens 72%, Spec 91%; dipyridamole Echo Sens 70%, Spec 93%; dobutamine Echo Sens 80%, Spec 84% (*Am Heart J* 2001;142(6):934–944)

**Benefits:** Can use if abnl baseline ECG or unable to exercise; can localize ischemia; can provide information re LVEF & valvular fxn

**Downsides:** More expensive than exercise stress; ↓ Sens & Spec in women; ↓ Sens if anti-ischemic drugs not d/c-ed (d/c BBs, digoxin, vasodilators, anti-HTN drugs ~2 dys prior to testing if possible)

**Coronary Computed Tomographic Angiography**
CT angiography of coronary arteries; images timed in conjunction w/ HR; assesses CAD burden & severity based on CA calcification; does not assess myocardial perfusion

**Test characteristics:** Sens 85–99%, Spec 64–97%, NPV >95% ([Eur Heart J](https://doi.org/10.1093/eurheartj/ehw078) 2016;37(30):2397–2405)

**Benefits:** ↓ LOS & ↓ costs c/w conventional stress testing; especially useful for low-risk pts or intermediate-risk & nl serial ECGs/biomarkers, can evaluate global & regional LV fxn ([Circulation](https://doi.org/10.1161/CIRCULATIONAHA.106.650674) 2006;114:1761; [JACC](https://doi.org/10.1016/j.jacc.2006.01.016) 2006;48:1475; [NEJM](https://doi.org/10.1056/NEJMoA1201214) 2012;366(15):393; [NEJM](https://doi.org/10.1056/NEJMoA1201214) 2012;367(4):299)

**Downsides:** Increased risk of downstream testing (2/2 ↓ Spec & detection of incidental findings), radiation exposure, requires relative bradycardia (often requires βB)

- Radiation: 3× more radiation than ETT or stress echo, but equivalent to nuclear stress; more important to avoid in young pts & women; newer protocols are being designed to minimize radiation exposure ([Eur Heart J](https://doi.org/10.1093/eurheartj/ehw078) 2016;37(30):2397–2405)

Combination of single negative conventional troponin & negative coronary CTA has equivalent risk of 28 d MACE c/w conventional stress ([Eur Heart J](https://doi.org/10.1093/eurheartj/ehw078) 2016;37(30):2397–2405)

**Disposition**

- Inadequate quality study: discuss case w/ cardiology
- Adequate quality + Neg result + Low-risk: d/c w/ f/u
- Adequate quality + Neg result + Int-risk: discuss case w/ cardiology, likely d/c w/ f/u
- Adequate quality + Pos result: discuss w/ cardiology, admit
- For adequate study w/ high-risk test results, consider coronary angiography, ± admission depending on clinical presentation

**Pearls**

- False-positives: Positive risk-stratification testing in a pt who presented to ED w/ CP does not necessarily mean CP was 2/2 by CAD; esp if low pre-TP & other causes possible
- False-negatives: Negative risk-stratification testing in a pt who presented to ED w/ CP does not necessarily mean CP was not 2/2 by CAD; esp if high pre-TP
CARDIAC CATHETERIZATION

Overview

- **Indications:** ACS (see STEMI & UA/NSTEMI above for timing of PCI); high-risk stress test result OR indeterminate-risk stress test result & high PreTP for obstructive CAD; ongoing angina despite tx; r/o CAD in pts w/ CP suspected from nonatherosclerotic etiology (ie, spasm) or systolic dysfxn suspected of nonischemic etiology (ie, ni-CMP); after ROSC in pts w/ cardiac arrest (see below for criteria)
  - Postarrest PCI recommended if STEMI &/or absence of mx unfavorable features (unwitnessed arrest, no bystander CPR, initial non-VF rhythm, >30 min to ROSC, ongoing CPR, noncardiac / traumatic arrest, pH <7.2, lactate >7, age >85, ESRD); decision individualized for each case (J Am Coll Cardiol 2015;66(1):62–73)

- Types of percutaneous coronary interventions:
  - Balloon angioplasty: Effective but ↑ risk of CA dissection & restenosis 2/2 remodeling
  - Bare metal stent: ↓ restenosis, repeat revasc, & MACE c/w BA, but may ↑ MI (most periprocedural), no Δ D (Am Heart J 2006;151(3):682–689); requires DAPT × 4 wk & lifelong ASA thereafter
  - Drug-eluting stent: ↓ restenosis & repeat revasc c/w BMS, but no Δ D/MI over 6 y (NEJM 2016;375;1242–1252); requires DAPT × 1 y & lifelong ASA thereafter

Post-PCI Complications

- **Bleeding (femoral access site):** Apply pressure, reverse/stop anticoag
- **Bleeding (retroperitoneum):** May c/o back pain, ±Hct drop, ↓ BP, ↑ HR; obtain abd/pelvic CT (I–); reverse/stop anticoag, consult IR/surgery
- **Vascular damage (pseudoaneurysm):** Pain, expanding mass, systolic bruit; obtain US; tx w/ manual compression, ± thrombin injection/surgery
- **Vascular damage (AV fistula):** May p/w sx 2/2 ↓ perfusion to LE (2/2 emboli, dissection, thrombus), continuous bruit, ↓ distal pulses; obtain US ± angiogram; consult card &/or surgery for repair
Renal failure: Usually 2/2 contrast, occurs w/i 24 h, peaks 3–5 d

Stent thrombosis: P/w acute CP & STE; consult cards/cath lab, for urgent catheterization; may be more common in BMS than DES (JACC Cardiovasc Interv 2015;8(12):1552–1562); commonly 2/2 underexpanded stent, dissection, or d/c anti-plt Rx (JAMA 2005;293:2126)

Stent stenosis: P/w subacute or chronic return of prior anginal sx months after PCI (but 10% p/w ACS); occurs 2° postprocedure remodeling, not atherosclerosis; despite advances, occurs still >10% cases (BA > BMS > DES) (BMJ 2015;351:h5392)

POST-MI COMPLICATIONS

Immediate Complications

LV systolic dysfunction/cardiogenic shock: Common in L-sided (esp anterior) AMI; Dx w/ JVD, CXR or BSUS (B/L B-lines, ↓ EF); Tx w/ O₂ for hypoxia, ↓ preload (NTG SL → gtt), ↓ afterload (nitroprusside; IV ACE-I if Cl; avoid hydral 2/2 reflex ↑ HR), inotropy PRN (norepi > dopamine 2/2 fewer arrhythmias [NEJM 2010;362(9):779–789]; ± dobutamine esp if SVR high), diuretics, minimize PEEP (if intubated), emergent reperfusion (lytics/pPCI), may need IABP in cath lab (Lancet 2000;356(9231):749–756).

RV systolic dysfunction/cardiogenic shock: Common in RV AMI; Dx w/ R-sided leads, BSUS (few B-lines, ↑ RV:LV ratio, dilated IVC); Tx w/ O₂ for hypoxia, ↑ preload (IVF until e/o nonfluid responsive; ongoing IVF may aggravate), ↓ PVR (bronchodilators, inh NO or prostacyclins), inotropy PRN (milrinone > norepi), minimize PEEP/TV (if intubated), emergent reperfusion (lytics/pPCI) (J Am Coll Cardiol 2010;56(18):1435–1446)

Tachyarrhythmias (eg, VT/VF, AF): Ischemia causes re-entry circuits in myocardium; place defibrillation pads on pt immediately on arrival; If unstable, tx per ACLS; If stable VT, tx w/ IV BB / membrane stabilization (amiodarone, metoprolol), check & replete lytes; emergent reperfusion (lytics/pPCI)

Bradyarrhythmias (eg, Heart block): Heart block can be 2/2 strong
vagal tone (1° AVNB) &/or ischemia to AV node (1°–3° AVNB); place pacer pads on pt immediately on arrival; Tx w/ IVF (for BP), atropine, TC/TV pacing if unstable; emergent reperfusion (lytics/pPCI)

**Early Complications**

- **Infarct expansion, re-infarction, postinfarction ischemia:** Usually w/i 4 d of MI; can present similarly to initial MI but diagnostics subtler: Δ ECG (2/2 nl evolution from prior MI vs. new ischemia), +Tn (may be ↓ from prior MI; ↑ suggests new ischemia), +CK-MB (suggests new ischemia); tx as w/ ACS; discuss w/ cardiology; depending on prior mgmt (pPCI vs. lytics; BA vs. BMS/DES), may need pPCI
- **Ventricular wall rupture:** Usually w/i 2–7 d after MI; RFs include ↑ age, female, anterior infarct, ↑ wall strain (↑ HR, ↑ afterload); occur at jxn of nl tissue & infarct
  - Free wall rupture: Rapid bleeding into pericardium causing s/sx of tamponade; Tx w/ IVF/blood; emergent pericardiocentesis & cardiac surgery; mortality >90%
  - Pseudoaneurysm: Bleeding contained w/i myocardial wall; may p/w arrhythmias, heart failure, systemic embolization, or be asx & dx’ed only on imaging; once identified, c/s cardiology & cardiac surgery
  - Septal rupture: May be asx or p/w sx of L → R shunt & ↓ L-sided CO (angina, shock, pulm edema); new pansystolic murmur; dx by echo; tx w/ urgent surgical closure
- **Papillary muscle rupture:** Usually w/i 7 d of MI; frequency i-MI & p-MI > a-MI; p/w sx of acute pulmonary edema, pansystolic murmur; BSUS differentiate from post-MI VSD; tx w/ ↓ preload & afterload (nitroprusside), diuretics, O₂, IABP, emergent surgical repair
- **Pericarditis:** Usually w/i 7 d of MI; most common w/ a-MI; p/w low-grade fever, chest pain, friction rub; ECG w/ diffuse STE w/o reciprocal chgs; BSUS ± pericardial effusion; tx w/ NSAIDs; NOTE: early pericarditis is distinct from Dressler’s syndrome (below)

**Delayed Complications**

- **Left ventricular aneurysm:** Suspect if ECG w/ persistent STE post-
MI; can p/w HF, embolic sx, arrhythmias; dx w/ echo; c/s cardiology (reperfusion), cardiac surgery

- **Left ventricular thrombus**: Most common in a-MI; RFs include ↓ EF, severe MVR, LV aneurysm (eg, slow, nonlaminar flow); tx w/ anticoagulation
- **Dressler’s syndrome**: Usually 2–10 wk after MI; presumed autoimmune-mediated; p/w fever, chest pain, pleurisy; BSUS w/ pericardial & pleural effusions; self-limited w/ NSAIDs

---

**PRINZMETAL’S (VARIANT) ANGINA**

**Overview**

- **Definition**: Distinct syndrome of ischemic CP classically occurring at rest 2/2 focal coronary artery spasm, & a/w transient STE; exact etiology unknown
- Most vasospasm occurs in areas of pre-existing stenosis
- Can be a/w infarction, arrhythmia, & sudden cardiac death; consider in all pts w/ healthy SCD, particularly if arrest occurred in morning or cold settings

**History**

- Often young (35–50 y/o), F > M, tobacco use, EtOH use; PMH/FHx migraine, Raynaud’s, pericarditis, MV prolapse; may have no known cardiac hx but CAD not uncommon
- Sxs include substernal pressure radiating to jaw & arm; can respond to NTG; often occur midnight to early AM (↑ vagal tone), or after hyperventilation or cold
- May be a/w marked diurnal variation in exercise tolerance (↓ tolerance in AM, ↑ in PM)

**Evaluation**

- EKG reveals transient territorial STE & reciprocal ST Δs; may induce a variety of conduction disturbances or arrhythmias
- Stress testing may induce no ST Δs, STDs, or STEs, or STEs may be seen during recovery phase of stress testing
- Dx definitively w/ angiography & provocative intracoronary ACH &/or
ergot derivative (>90% Sens, >90% Spec; even better if combined); noninvasive approach w/ hyperventilation & exercise (65% Sens, >90% Spec) (J Am Coll Cardiol 2013;63(2):103–109)

Treatment
- High-dose CCB (nifedipine, verapamil, diltiazem), nitrates (SL prn); d/c smoking

Disposition
- Admit, given risk of MI & arrhythmia during acute episodes

COCaine-INDUCED ANGINA

Overview
- Definition: Anginal sx occurring after cocaine use, 2/2 ↑ myocardial O₂ demand (↑ HR, ↑ afterload, ↑ contractility & end-systolic wall stress) & ↓ O₂ supply (vasoconstriction); generally not 2/2 acute thrombosis, though cocaine a/w premature CAD/ACS
- Overall incidence of cocaine-associated MI is 0.7–6% of those presenting w/ CP after cocaine (Acad Emerg Med 2000;36:469; COCHPA, Acad Emerg Med 1994;1:330)
- Can be c/b arrhythmia & heart failure (~90% occur w/i 12 h of presentation)

History
- CP that may be a/w dyspnea, anxiety, palpitations, diaphoresis, dizziness, or nausea
- Sxs typically occur w/i 3 h of ingestion, but cocaine metabolites may persist up to 24 h to cause delayed or recurrent vasoconstriction
- RF for cocaine-induced MI: Male gender, current smoker, non-white

Evaluation
- Similar to ACS (see above)
- Maintain high index of suspicion for aortic dissection as well
- Urine toxicology: Usually detects cocaine metabolite benzoylecgonine (urine t₁/₂ of 6–8 h) up to 24–48 h (range 16–66 h); however, chronic cocaine users may have detectable levels for
weeks after last use

Treatment
- Given risk of MI, tx similarly to ACS (see ACS, “Adjunctive Medical Therapies”)
  - ASA, analgesia PRN, O₂ PRN, NTG PRN, antithrombotic tx all as per ACS guidelines
  - Avoid BB given risk of unopposed α-adrenergic effect (↑ CA vasospasm, ↑ BP)
- IV Benzodiazepines (↓ central stimulatory effects of cocaine)
- IV Anti-HTN (NTG, sodium nitroprusside, phentolamine; avoid BB)
- If STEMI: pPCI preferred over lytics 2/2 ↑ ICH risk after cocaine
- VT/VF immediately after cocaine is 2/2 local anesthetic (Na channel) effect & may respond to sodium bicarbonate tx in addition to standard therapies

Disposition
- Admit: If +Tn, ongoing CP, persistent unstable VS
- EDOU: If sx & VS controlled, -Tn, nonischemic ECG; no difference in 30-d outcomes if pts w/ & w/o stress-testing, consider if CAD RFs & poor f/u (Circulation 2008;117:1897–1907)
- Provide drug-abuse counseling to all pts prior to d/c

DVT AND PULMONARY EMBOLISM

Overview
- Definition: In situ thrombosis of LE/UE deep veins, often provoked by stasis/turbulence, hypercoagulability, endothelial injury (Virchow’s triad)
- RFs: Hypercoagulable state (cancer, pregnancy, OCPs, APLAS); recent surgery or trauma; prolonged immobilization; venous outlet obstruction; excess extremity use (eg, sports, occupation; for UE DVT); increased age; obesity; FHx of DVT/PE
Lower-extremity DVT: Comprise 90% of DVTs; but as many as ~50% may be isolated distal DVT of the calf (only require tx if severe sx or propagating; see below)

Upper-extremity DVT: Comprise the minority (10%) of DVTs; c/w LE DVT, ↓ risk of PE (6% vs. 15–32%), ↓ risk of recurrence (2–5% vs. 10%); can be 1° (20%) or 2° (80%) (NEJM 2011;364(9):861–869; Circulation 2012;126;768–773)

- Primary: thoracic outlet compression of SC vein (eg, ribs, clavicle), microtrauma to SC vein from repeat UE movements (often young, athletes or occupation), idiopathic
- Secondary: catheter-associated, cancer-associated (hypercoag, compression) surgery (immobilization, endothelial trauma), systemic hypercoag state (preg, etc.)
- Management based on location (proximal vs. distal), depth (deep vs. superficial)

History & Physical Exam

- HX: May have unilateral discomfort, swelling, paresthesia, weakness, erythema, warmth
- Always ask about RFs; obtain ROS to assess for s/sx of concurrent PE
- EX: Physical exam notoriously insensitive for DVT (JAMA 1998;279:1094–1099)

Evaluation

- Use Well’s score to determine pre-TP of DVT (see table)

<table>
<thead>
<tr>
<th>Well’s Criteria for DVT</th>
<th>1 pt</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active cancer (tx ongoing or w/i 6 mo or palliative)</td>
<td></td>
</tr>
<tr>
<td>Paralysis, paresis, or recent immobilization of LE</td>
<td></td>
</tr>
<tr>
<td>Recently bedridden &gt;3 d or major surgery w/i 4 wk</td>
<td></td>
</tr>
<tr>
<td>Localized tenderness along deep venous system</td>
<td></td>
</tr>
<tr>
<td>Entire leg swelling</td>
<td></td>
</tr>
<tr>
<td>Calf swelling by &gt;3 cm c/w asx (10 cm below tibial tuberosity)</td>
<td></td>
</tr>
<tr>
<td>Pitting edema (greater in symptomatic leg)</td>
<td></td>
</tr>
</tbody>
</table>
Collateral superficial veins (nonvaricose) | 1 pt
Previously documented DVT | 1 pt
Alternative dx as likely or greater than that of DVT | −2 pts

<table>
<thead>
<tr>
<th>Points</th>
<th>Pre-Test Prob</th>
<th>D-dimer Sensitivity (%)</th>
<th>Prevalence of DVT (%)</th>
<th>NPV of D-dimer (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>−2 to 0 pts</td>
<td>Low</td>
<td>86</td>
<td>5</td>
<td>99</td>
</tr>
<tr>
<td>1 to 2 pts</td>
<td>Moderate</td>
<td>85</td>
<td>17</td>
<td>95</td>
</tr>
<tr>
<td>≥3 pts</td>
<td>High</td>
<td>90</td>
<td>53</td>
<td>81</td>
</tr>
</tbody>
</table>

RFs not incorporated into score but a/w inc risk of DVT include FHx of DVT (>2 1st-degree relatives), hospitalization w/i 6 mo; erythema.

- UE DVT: Compression US (Sens 97%, Spec 96%); if negative US but high pre-TP, obtain serial US or D-dimer (Sens 100%, Spec 14%) (NEJM 2011;364(9):861–869)
- LE DVT (initial eval): lab & imaging directed based on pre-TP (see Algorithms below)
  - D-dimer: Assays include enzyme-linked immunofluorescence assays (Sens 96%, Spec 46%), microplate ELISA (Sens 94%, Spec 53%), immunoturbidimetric (Sens 93%, 53%), whole-blood assay (Sens 83%, Spec 71%), & quantitative latex agglutination assays (Sens 95%, 53%) (Chest 2012;141(2Suppl):e351S–418S)
  - Lower-extremity ultrasound (two types: Proximal compression, Whole-leg)
    - WL-US: Superior to PC-US alone in detection of DVT (mostly distal)
      - Increased chance of dx isolated distal DVT of unclear significance (see Tx)
    - PC-US: should be used w/ D-dimer to increase sensitivity (see Algorithm)
      - If PC-US neg & D-dimer pos, repeat PC-US in 1 wk
    - 3-mo rate of PE after negative WL-US: 0.3% (low pre-TP), 0.8% (mod pre-TP), 2.5% (high pre-TP) (Chest 2012;141(2Suppl):e351S–418S)
      - No difference c/w combined PC-US + D-dimer (& prn repeat PC-US): No difference in 3-mo risk of PE (0.6%) (Chest
CT venography: Highest sensitivity but risk of radiation & contrast; use selectively if mod or high pre-TP, positive PC-US & D-dimer but unable to obtain WL-US or repeat PC-US in 1 wk (Chest 2012;141(2Suppl):e351S–418S)

- LE DVT (recurrent): Risk of false-positives (2/2 scarring, postthrombotic syndrome) high
- Recommended approach: Combined D-dimer (usually nl w/i 3 mo of starting tx for DVT) & PC-US; if PC-US neg or undiagnostic, repeat in 1 wk (if unable: CTV, MRV)

Figure 1.2 Diagnosis and Treatment of DVT, Low Pre-Test Probability. (Chest 2012;141(2)(suppl):e351S)
Figure 1.3 Diagnosis and Treatment of DVT, Mod Pre-Test Probability. (A) Starting with D-dimer assessment, and (B) Starting with ultrasonography (Chest 2012;141(2) (suppl):e351S)
**Figure 1.4** Diagnosis and Treatment of DVT, High Pre-Test Probability (*Chest* 2012;141(2)(suppl):e351S)

**Treatment**

- UE DVT: Anticoagulation × 3–6 mo, though comparative data lacking on specific regimens
  - Cather-associated DVT: Catheter removal only indicated if catheter malfxn or infxn, no further need for catheter, or strong CIs to systemic A/C (*NEJM* 2011;364(9):861–869)
  - Isolated basilic/cephalic vein thrombosis: very low risk of PE, no A/C required
- LE DVT: Anticoagulation × 3–6 mo unless strong CIs (*Chest* 2012;141(2) (Suppl):e419S–e494S)
  - Anticoagulation regimen should be selected based on comorbidities, ability to take PO medications, patient preference (monitoring, etc.), risks of bleeding:
    - SC LMWH (1 mg/kg BID; renally dose): slight ↓ risk of death, recurrence, major bleeding c/w UFH; preferred w/ malignancy; relative CIs include CKD & obesity
    - SC Fondaparinux (5 mg QD [<50 kg], 7.5 mg QD [50–100 kg], 10
mg QD [>100 kg]; renally dose): Similar risk of death, recurrence, major bleeding c/w LMWH; preferred w/ hx of HIT
- IV UFH (80 U/kg bolus, 18 U/kg/h gtt): As above, may be preferred over LMWH if CKD/ESRD; risk of HIT higher than LMWH
- PO Warfarin (INR 2.0–3.0): Bridge w/ LMWH/Fondaparinux until INR therapeutic
- PO Rivaroxaban (15 mg BID x 3 wk, 20 mg QD thereafter)
- PO Apixaban (10 mg BID x 7 d, 5 mg BID thereafter)
- Duration of treatment generally depends if provoked (3 mo) or nonprovoked (6 mo if no bleeding risk, 3 mo if bleeding risk)
- If strong contraindications to A/C: SVC filter until bleeding risk resolves
- Isolated distal DVT: Tx as above if severe sx or e/o extension on repeat U/S (1–2 wk)

Complications
- **Phlegmasia alba dolens**: Emergent complication; P/w swollen white leg 2/2 extensive DVT obstructing collaterals (but not involving them), largely impeding arterial inflow; Tx w/ IV Heparin (in case need for surgery), +/- catheter-directed thrombolytic tx
- **Phlegmasia cerulea dolens**: Emergent complication; P/w severely swollen cyanotic leg 2/2 extensive DVT including thrombosis of collaterals & capillary beds, fully impeding arterial flow, causing massive fluid sequestration in affected limb (2/2 hydrostatic pressure), circulatory shock, death (20–40% cases); Tx w/ IV Heparin (in case need for surgery), catheter-directed thrombolytic tx, aspiration thrombectomy, or open surgical thrombectomy

---

**PULMONARY EMBOLISM**

**Overview**
- Definition: embolization of systemic venous thrombus into pulmonary arterial system
- Diff from amniotic fluid embolism (RF: peripartum) & fat embolism (RF: long bone fx)
- RFs: See section on DVT above; Major identifiable RFs include
recent surgery (OR 21.0), trauma (OR 12.7), immobility (hosp or nursing home) (OR 8.0), cancer (OR 4.1–6.5), paraplegia (OR 3.0), estrogen tx (OR 3.0) *(JAMA 2003;290(21):2849–2858)*

**Approach**
- IV access (if PE), ECG, O₂ prn, Monitor, CXR to r/o alternative dx
- If HD stable: diagnostic tests depending on pre-TP
- If unstable, consider empiric antithrombotic tx ± lysis if potential benefit > bleeding risk

**History & Physical Exam** *(Chest 1991;100:598; Am J Card 1991;68:1723)*
- HX: Dyspnea (73%), pleuritic CP (66%), cough (37%), syncope, ↓ BP, PEA
- Assess PreTP: May use PERC (to decide whether any testing is necessary) or Wells criteria (to decide whether D-dimer is sufficient w/u)
- EX: Unexplained ↑ HR, ↑ RR, ↓ SpO₂, fever, JVD

<table>
<thead>
<tr>
<th>PERC Criteria for Pts w/ Low Risk of PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 50</td>
</tr>
<tr>
<td>HR ≥ 100</td>
</tr>
<tr>
<td>O₂ Sat on room air &lt;95%</td>
</tr>
<tr>
<td>Prior hx of DVT/PE</td>
</tr>
<tr>
<td>Recent trauma or surgery or hosp w/i 4 wk</td>
</tr>
<tr>
<td>Hemoptysis</td>
</tr>
<tr>
<td>Exogenous estrogen</td>
</tr>
<tr>
<td>Unilateral leg swelling</td>
</tr>
</tbody>
</table>

**Using the PERC Criteria:** If any of above criteria present, PE cannot be r/o PE w/o additional dx tests. If all criteria negative, PE unlikely (Sens 97.4%, Spec 21.9%). *(Thromb Haemost 2006;6:772)*

<table>
<thead>
<tr>
<th>Wells Criteria for PE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Criteria</strong></td>
</tr>
<tr>
<td>Clinical signs &amp; sx of DVT (OR 5.8)</td>
</tr>
<tr>
<td>Tachycardia &gt;100 bpm (OR 3.0)</td>
</tr>
<tr>
<td>Immobilization or surgery w/i 4 wk (OR 2.5)</td>
</tr>
<tr>
<td>Previous DVT/PE (OR 2.5)</td>
</tr>
<tr>
<td>Hemoptysis (OR 2.4)</td>
</tr>
<tr>
<td>Malignancy (OR 2.30)</td>
</tr>
</tbody>
</table>
PE more likely than alternative dx (OR 4.6) | 3 pts | 2 pts | 1 pt
---|---|---|---
Cut-off for “PE unlikely” (sum of points) | ≤4 pts | ≤2 pts | ≤1 pt

<table>
<thead>
<tr>
<th>Rates of PE Based on Score</th>
<th>Original</th>
<th>Modified</th>
<th>Simplified</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤4 pts</td>
<td>12.6%*</td>
<td>≤2 pts</td>
<td>11.5%*</td>
</tr>
<tr>
<td>&gt;4 pts</td>
<td>38.5%**</td>
<td>&gt;2 pts</td>
<td>37.3%**</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;1 pt</td>
<td>35.8%**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rates of PE Based on “PE Unlikely” Score &amp; Negative D-dimer</th>
<th>Original</th>
<th>Modified</th>
<th>Simplified</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5%</td>
<td>0.3%</td>
<td>0.5%</td>
<td></td>
</tr>
</tbody>
</table>

*Order D-dimer to r/o out PE.

**Revised & Simplified Geneva Score for PE**

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Revised</th>
<th>Simplified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;65</td>
<td>1 pt</td>
<td>1 pt</td>
</tr>
<tr>
<td>Previous DVT/PE</td>
<td>3 pts</td>
<td>1 pt</td>
</tr>
<tr>
<td>Surgery (under GA) or fx (LE) w/i 1 mo</td>
<td>2 pts</td>
<td>1 pt</td>
</tr>
<tr>
<td>Active malignancy or cure &lt;1 y</td>
<td>2 pts</td>
<td>1 pt</td>
</tr>
<tr>
<td>Unilateral LE pain</td>
<td>3 pts</td>
<td>1 pt</td>
</tr>
<tr>
<td>Hemoptysis</td>
<td>2 pts</td>
<td>1 pt</td>
</tr>
<tr>
<td>HR 75–94</td>
<td>3 pts</td>
<td>1 pt</td>
</tr>
<tr>
<td>HR ≥ 95</td>
<td>5 pts</td>
<td>1 pt</td>
</tr>
<tr>
<td>Pain w/ LE deep vein palpation &amp; unilateral edema</td>
<td>4 pts</td>
<td>1 pt</td>
</tr>
</tbody>
</table>

Cut-off for “PE unlikely” (sum of points) | NA | ≤2 pts

<table>
<thead>
<tr>
<th>Rates of PE Using Simplified Geneva Score</th>
<th>≤1 pt (%)</th>
<th>2–4 pts (%)</th>
<th>5–7 pts (%)</th>
<th>0–2 pts (%)</th>
<th>3–7 pts (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate of PE</td>
<td>8</td>
<td>29</td>
<td>64</td>
<td>13</td>
<td>42</td>
</tr>
<tr>
<td>Rate of PE if D-dimer neg</td>
<td>1</td>
<td>3</td>
<td>12</td>
<td>1–3* **</td>
<td>5–14* ** ** ***</td>
</tr>
</tbody>
</table>

*Order D-dimer in “PE Unlikely” to r/o PE.
**Range of rates includes both high- & low-sensitivity D-dimer.
***Order imaging (eg, CTA, V/Q) in “PE Likely” to r/o PE. *Arch Intern Med* 2008;168(19):2131–
Evaluation

- ECG (Sinus tach, S1Q3T3 not sens/spec, diffuse TWI), CBC, PT/PTT, Cr
- CXR: R/o other dx; “classic” PE findings (Hampton’s hump, Westermark’s sign) not Sens/Spec
- Patients w/ low clinical gestalt for PE & negative PERC score may not need D-dimer
  - Combined low gestalt & PERC negative: Sens 97.4%, Spec 21.9%
  - If unable to r/o by PERC criteria, compute Well’s score (or modified Geneva)
  - Know your hospital’s D-dimer test characteristics; wide variation among assays
  - False-positive D-dimer: Pregnancy, trauma, infection, malignancy, inflammatory conditions, surgery, ↑ age, SCD, AF, ACS, CVA, acute UGIB, DIC
- If “PE likely” by Well’s score or D-dimer positive, obtain additional testing:
  - Bedside Ultrasound: Echo for RV dilatation (RV:LV >1) or dysfxn (hypokinesis, paradoxical septal wall motion, McConnell’s sign) can suggest dx but not r/o (Sens 50%, Spec 98%, PPV 88%, NPV 88%) (Ann Emerg Med 2014;63(1):16–24); combined thoracic & LE ultrasound can reduce need for CTA by dx’ing DVT or suggesting alternative dx (Chest 2014;145(4):818–823)
  - CT angiography (CTA Sens 83%, CTA/CTV Sens 90%, Spec 95%): (NEJM 2006;354:2317)
    - May miss small/subsegmental PEs (of uncertain clinical significance if asx & no further clot burden on LENIs); If negative for PE but suspicion is high, consider additional test (D-dimer, US, pulmonary angiogram); requires dye load (relative CI if CrCl <50 NEJM 2006;354:379)
  - V/Q scan (if CI to CTA): Requires nl baseline CXR; tx if results are high-probability; 2/3 of all cases may result in low/intermediate
probability

- MR angiography (MRA Sens 78%, Spec 99%; MRA/MRV Sens 92%, Spec 96%): Use in pts w/ Cl to CTA; high proportion of studies limited qual (Ann Intern Med 2010;152(7):434–443)
- Pulmonary angiogram: Gold standard, though rarely used
  - Risk stratify: ↑ HR, ↓ BP, ↓ SpO₂, CTA RV/LV dimension >0.9, ↑ Tn or BNP, echo e/o RV dysfxn, D-dimer >4,000 all predict bad outcomes

Treatment

- Supportive: O₂, IV fluids for ↓ BP (preload dep)
- Anticoagulation regimen should be selected based on comorbidities, ability to take PO medications, patient preference (monitoring, etc.), risks of bleeding:
  - SC LMWH (1 mg/kg BID; renally dose): slight ↓ risk of death, recurrence, major bleeding c/w UFH; preferred w/ malignancy; relative CIs include CKD & obesity
  - SC Fondaparinux (5 mg QD [<50kg], 7.5 mg QD [50–100 kg], 10 mg QD [>100 kg]; renally dose): Similar risk of death, recurrence, major bleeding c/w LMWH; preferred w/ hx of HIT
  - IV UFH (80 U/kg bolus, 18 U/kg/h gtt): As above, may be preferred over LMWH if CKD/ESRD; risk of HIT higher than LMWH
  - PO Warfarin (INR 2.0–3.0): Bridge w/ LMWH/Fondaparinux until INR therapeutic
  - PO Rivaroxaban (15 mg BID × 3 wk, 20 mg QD thereafter)
  - PO Apixaban (10 mg BID × 7 d, 5 mg BID thereafter)
- IV thrombolysis (tPA: 100 mg over 2 h): Indicated if massive PE / HD instability (SBP <90 mmHg), HD unstable & high suspicion of PE, or submassive PE w/ high risk of hypotension (e/o significant pHTN or RV dysfxn)
  - Submassive PE: tPA + UFH ↓ mortality & deterioration c/w UFH alone (NEJM 2002;347:1143–1150)
  - Consider lytics in unexplained PEA arrest if possibly 2/2 massive PE
- Catheter or surgical thrombectomy (PE): For pts w/ HD instability & massive PE if (1) CI to lysis, (2) failed lysis w/ tPA, or (3) experienced center & +RV dysfxn. Consult cardiac surgery;
improved outcomes c/w UFH alone (Circulation 2014;129:479–486)

- IVC filter: When a/c fails or CI; no long-term mortality benefit (NEJM 1998;338:409).

**Disposition**

- HD stable, few comorbidities, no e/o RV strain: Observation Unit for A/C, LENIs, echo
- HD stable, comorbidities, e/o RV strain: Admit, tele floor
- HD unstable, mx comorbidities, e/o RV strain: Admit, ICU

---

**DECOMPENSATED HEART FAILURE**

**Overview**

- Heart failure: Any chronic state in which the heart’s ability to pump blood w/ nl efficiency to meet the body’s metabolic demands is impaired; either 2/2 ↓ systolic fxn (reduced EF: HFrEF) or ↓ diastolic relaxation (preserved EF: HFpEF); can be primarily L-sided, R-sided, or biventricular; although a chronic illness, characterized by intermittent decompensation 2/2 volume disequilibrium

- Manifestations of decompensated L-sided HF: pulmonary edema (↑ PCWP 2/2 hydrostatic forces), pleural effusions (↑ PCWP 2/2 hydrostatic forces), atrial arrhythmias (↑ atrial size), systemic hypoperfusion (HFrEF: ↑ LV end-diastolic volume → ↓ contractility [once over Frank–Starling curve] → ↓ EF; HFpEF: ↓ LV end-diastolic volume 2/2 impaired relaxation → ↓ EF)

- Manifestations of decompensated R-sided HF: pleural effusions (↑ systemic venous pressure → ↑ thoracic duct / lymphatic pressure → ↓ absorption of nl pleural fluid), peripheral edema (↑ systemic venous pressure), liver dysfxn (congestion)

- Acute decompensations can occur 2/2 many causes (see table)

<table>
<thead>
<tr>
<th>Common Precipitants of Acute Decompensated Heart Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication change or nonadherence*</td>
</tr>
<tr>
<td>Dietary indiscretion (↑ Na)</td>
</tr>
<tr>
<td>Myocardial infarct/ischemia</td>
</tr>
<tr>
<td>-----------------------------</td>
</tr>
<tr>
<td>Tachyarrhythmia (eg, AF)</td>
</tr>
<tr>
<td>COPD/PE (↑ RH pressures)</td>
</tr>
<tr>
<td>Renal failure (↑ volume)</td>
</tr>
</tbody>
</table>

*Especially diuretics, anti-HTN, or rate-controlling agents; however, review any med changes, as may have pharmacokinetic properties that affect cardiac meds

**Approach**
- Initiate immediately: IV access, O₂ PRN, ECG, Monitor, CXR
- If e/o severe respiratory distress, early CPAP/BiPAP, NTG gtt (unless ↓ BP)
- Early use of bedside U/S (thoracic & echo) can reduce time to dx

**History & Physical Exam**
- HX: SOB/DOE, CP, cough (clear → pink sputum), orthopnea/PND, LE/abd swelling
  - Always ask: timing (acuity), severity (fxnal capacity), behavioral chgs (sleeping upright), chg in home O₂, frequency of wt monitoring & any change from dry wt
  - Always assess for possible precipitants (see table above)
- EX: ↑ BP, ↑ HR, ↑ RR, cardiac dysrhythmia; +S3 (HFrEF) +S4 (HFpEF); Rales or ↓ BS, wheeze (L-sided); Leg edema, JVD, ↑ liver size, +hepatojugular reflex (R-sided)

**Acute Decompensated HF: Value of Specific Hx Components** *(JAMA 2005;294:1944)*

<table>
<thead>
<tr>
<th>Historical Factor</th>
<th>Likelihood Ratio (95% CI)</th>
<th>Historical Factor</th>
<th>Likelihood Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H/o heart failure</td>
<td>5.8 (4.1–8)</td>
<td>No h/o HF</td>
<td>0.45 (0.38–0.53)</td>
</tr>
<tr>
<td>H/o MI</td>
<td>3.1 (2–4.9)</td>
<td>No DOE</td>
<td>0.48 (0.35–0.67)</td>
</tr>
<tr>
<td>PND</td>
<td>2.6 (1.5–4.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orthopnea</td>
<td>2.2 (1.2–3.9)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Historical Features w/ Minimal Diagnostic Utility**
- H/o CAD, HLD, DM, HTN, COPD, smoking. Sxs of edema, cough, fatigue, & weight gain.
### Acute Decompensated HF: Value of Specific PEx Components *(JAMA 2005;294:1944)*

<table>
<thead>
<tr>
<th>Exam Factor</th>
<th>Increase Likelihood of ADHF</th>
<th>Likelihood Ratio (95% CI)</th>
<th>Decrease Likelihood of ADHF</th>
<th>Exam Factor</th>
<th>Likelihood Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S3 on auscultation</td>
<td></td>
<td>11 (4.9–25)</td>
<td></td>
<td>No rales</td>
<td>0.51 (0.37–0.7)</td>
</tr>
<tr>
<td>JVD</td>
<td></td>
<td>5.1 (3.2–7.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rales</td>
<td></td>
<td>2.8 (1.9–4.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any murmur</td>
<td></td>
<td>2.6 (1.7–4.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LE edema</td>
<td></td>
<td>2.3 (1.5–3.7)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Exam Features w/ Minimal Diagnostic Utility**

- Abdominojugular reflex, SBP <100 mmHg or >150 mmHg, wheezing, ascites

### Evaluation

- Acute decompensated HF is primarily a clinical dx, aided by lab & imaging evaluations
- ECG: L-atrial enlargement, LVH, tachyarrhythmia, ischemia, e/o old infarction(s)
- Labs: CBC, lytes, Cr, troponin, LFTs, VBG, BNP/NT-proBNP (see below)
- Bedside thoracic U/S (Sens 94%, Spec 92%): >3 B-lines/field in 2+ fields bilaterally *(Acad Emerg Med 2014;21(8):843–852)*; operator-dependent (some studies w/ Sens as low as 60%), but w/ skilled operator may be superior to CXR in dx of L-sided HF *(Chest 2015;148(1):202–210)*; BSUS also used to eval for other dx:
  - Pleural effusions (2/2 CHF or other dx)
  - Focal B-lines (eg, 2/2 PNA, infarct > asymmetric pulm edema)
  - Reduced EF & pericardial effusion
  - IVC inspiratory collapsibility: <50% collapsibility w/ inspiration suggests volume overload; cannot be used if pt on PPV *(Am J Emerg Med 2015;33(5):653–657)*
- CXR (Sens 70%, Spec 82%): Pulm edema, pl effusion, ↑ heart size *(Chest 2015;148(1):202–210)*
- BNP (>100 ng/L), NT-proBNP (>300 ng/L): Imp to compare w/ dry weight BNP if hx of CHF; levels correlate w/ dz severity (NYHA) of underlying CHF *(NEJM 2002;347:161–167)*
- False-negatives: Obesity (Int J Cardiol 2014;176(3):611–617)
- False-positives: Large PE, cor pulmonale, ESRD, AMI
- NT-proBNP may also be elevated w/ ↑ age; higher cut-offs suggested (>900 ng/mL if over 50 y)

### Pooled Sensitivity & Specificity of BNP/NT-proBNP for Acute Decompensated HF

<table>
<thead>
<tr>
<th>BNP Level</th>
<th>Sens (%)</th>
<th>Spec (%)</th>
<th>NT-proBNP Level</th>
<th>Sens (%)</th>
<th>Spec (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤100 ng/L</td>
<td>95</td>
<td>63</td>
<td>≤300 ng/L</td>
<td>99</td>
<td>43</td>
</tr>
<tr>
<td>100–500 ng/L</td>
<td>85</td>
<td>86</td>
<td>300–1800 pg/ml</td>
<td>90</td>
<td>76</td>
</tr>
<tr>
<td>≥500 ng/L</td>
<td>35</td>
<td>78</td>
<td>≥1800 ng/L</td>
<td>67</td>
<td>72</td>
</tr>
</tbody>
</table>


### Treatment

- **Diuresis (↓ volume):** Patients w/ refractory edema have impaired PO absorption & may need IV diuresis; give 2× home dose in IV form (see conversions below); give home nonloop diuretics (eg, metolazone) for sequential nephron blockade (NEJM 2010;362(3):228–238)
- Conversions: Furosemide:Torsemide:Bumetanide 40:10:1; Furosemide (PO:IV) 2:1; Torsemide (PO:IV) 1:1; Bumetanide (PO:IV) 1:1
- If allergy to furosemide/torsemide/bumetanide, can use ethacrylic acid
- **Nitrates (↓ preload):** Nitrates (0.4 mg SL or 10–300 mcg/min IV): Caution in pts w/ AS → ↓ BP 2° preload dep; nitroprusside if NTG ineffective; nesiritide may ↑ Cr/mortality compared to noninotropic tx (JAMA 2005;293:1900)
- **Positive Pressure Ventilation:** CPAP/BiPAP for ↓ SaO₂ (if no CIs); ↓ mortality, ↓ need for intubation (JAMA 2005;294:3124; Lancet 2006;367:1155); Intubate profound AMS, resp failure
- **Inotropes:** Cardiogenic shock (see section on Shock)
- **Other:** Positioning (sit up > supine), Foley may be necessary to assess ins/outs, IABP/LVAD (severe cardiogenic shock)

### Disposition

- Mild exacerbation, benign etiology (ie, dietary indiscretion), & close
f/u: Discharge after discussion w/ cardiologist; may ↑ diuretic for a few days

- Selected HF pts can be managed by a rapid tx protocol in the Observation Unit w/ fewer bed days & similar readmission rates to admitted pts *(Acad Emerg Med 2013;20(6):554)*

- Most pts require admission/Δs to tx regimen before d/c home: Cardiology/Tele

- All pts on PPV or severe resp distress: ICU

<table>
<thead>
<tr>
<th>Structural Causes of Heart Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dilated CMP</strong></td>
</tr>
<tr>
<td><strong>Pathophys:</strong> Ventricular dilatation → ↓ contractility → ↑ EDV → ↓ EF</td>
</tr>
<tr>
<td><strong>Causes:</strong> Idiopathic, familial, ischemia, valvular, infxn (Chagas), EtOH, cocaine, autoimmune</td>
</tr>
<tr>
<td><strong>Presentation:</strong> L or R HF sx; embolic events; arrhythmia</td>
</tr>
<tr>
<td><strong>Evaluation:</strong> ECG (PRWP, Qw, BBB, AF), CXR (↑ heart size), Echo (LV dilatation, ↓ EF, LV ± RV HK)</td>
</tr>
<tr>
<td><strong>Treatment:</strong> See standard HF tx below</td>
</tr>
<tr>
<td><strong>Pearl:</strong> Always consider in chronic EtOH users w/ SOB</td>
</tr>
<tr>
<td><strong>Hypertrophic CMP</strong></td>
</tr>
<tr>
<td><strong>Pathophys:</strong> LV outflow tract obstruction, worse if ↓ EDV → ↓ EF</td>
</tr>
<tr>
<td><strong>Causes:</strong> 50% are familial; asymmetric septal hypertrophy (eg, 2/2 HTN) may result in HOCM physiology (not true HOCM)</td>
</tr>
<tr>
<td><strong>Presentation:</strong> SOB/angina; arrhythmias; sudden death</td>
</tr>
<tr>
<td><strong>Evaluation:</strong> Systolic crescendo/decrescendo murmur; ECG (LVH, septal Qw), CXR (↑ heart size), Echo (↑ septal thickness)</td>
</tr>
<tr>
<td><strong>Treatment:</strong> βB, CCB (verapamil)</td>
</tr>
<tr>
<td><strong>Pearl:</strong> Avoid diuretics/preload reduction (inc PPV), digoxin, exercise</td>
</tr>
<tr>
<td><strong>Restrictive CMP</strong></td>
</tr>
<tr>
<td><strong>Pathophys:</strong> ↓ compliance → ↓ EDV → ↓ EF</td>
</tr>
<tr>
<td><strong>Causes:</strong> Amyloidosis, sarcoidosis, hemochromatosis, XRT, cancer</td>
</tr>
<tr>
<td><strong>Presentation:</strong> R &gt; L HF; embolic events; poor response to diuretics</td>
</tr>
<tr>
<td><strong>Evaluation:</strong> ↑ JVP, S3, S4, ECG (low voltage), CXR (pulm edema w/o ↑ heart size), Echo (symmetric wall thickening, LAE/RAE)</td>
</tr>
<tr>
<td><strong>Treatment:</strong> Treat underlying cause, gentle diuresis</td>
</tr>
<tr>
<td><strong>Constrictive pericarditis</strong></td>
</tr>
<tr>
<td><strong>Pathophys:</strong> ↓ compliance → ↓ EDV → ↓ EF</td>
</tr>
<tr>
<td><strong>Causes:</strong> Postviral, XRT, TB, Postcardiac surgery, idiopathic</td>
</tr>
<tr>
<td><strong>Presentation:</strong> R &gt; L HF</td>
</tr>
</tbody>
</table>
**Evaluation:** ↑ JVP, pericardial knock; Echo (septal bounce)
**Treatment:** Diuresis, pericardiotomy

### Valvular Heart Disease

| Aortic Stenosis | **Causes:** Calcification (age >70 y), bicuspid valve, rheumatic heart dz
| **Presentation:** Angina, syncope, CHF
| **Exam:** Midsystolic, crescendo–decrescendo @ RUSB
| **Eval:** Echo (transvalvular velocity, EF, AVA)
| **Acute tx:** ↓ Afterload; minimize ↓ preload & negative inotropy; if severe acute HF decompensation 2/2 critical AS, c/s cardiac surg for consideration of urgent AVR
| **Pearl:** Indications for AVR (if sx) include: $V_{\text{max}}$ ≥4 m/s; $V_{\text{max}}$ <4 m/s + EF<50% + AVA ≤1.0 cm²; or $V_{\text{max}}$ <4 m/s + AVA ≤0.6 cm² (*NEJM* 2014;372:744–756) |

| Aortic Regurg | **Causes:** Rheumatic heart dz, bicuspid valve, endocarditis, HTN
| **Presentation:** Acute or chronic CHF
| **Exam:** Diastolic decrescendo murmur, wide pulse pressure
| **Eval:** Echo: Severity of AI → width of regurgitant jet
| **Acute tx:** ↓ Afterload (nifedipine, ACEi); vasodilators ± dobutamine; if severe & unstable, c/s cardiac surg for consideration of urgent AVR
| **Pearl:** Limited data on mortality benefit of AVR; indications for AVR mostly based on sx severity (NYHA III/IV) (*NEJM* 2004;351:1539–1546) |

| Mitral Stenosis | **Causes:** Rheumatic heart dz
| **Presentation:** Pulmonary edema, AF, Emboli
| **Exam:** Diastolic murmur, opening snap
| **Eval:** ECG (LAE), Echo (valve area, pressure gradients)
| **Acute tx:** Careful diuresis, βBs; however percutaneous balloon valvuloplasty (PBV) & MVR have best outcomes
| **Pearl:** Most have sx if MVA <1 cm²; MVR/PBV based on sx (NYHA III/IV sx [+/- NYHA II]); PBV favorable c/w MVR, but 10–40% may have delayed re-stenosis & require repeat (*Lancet* 2009;374:1271–1283) |

| Mitral Regurg | **Causes:** MVP, endocarditis, rheumatic heart dz, ruptured chordae, papillary muscle dysfxn
| **Presentation:** Pulmonary edema
| **Exam:** Blowing holosystolic murmur
| **Eval:** ECG (LAE), Echo (width of regurgitant jet)
| **Acute tx:** Vasodilators (ACEi), βB; however, MVR is only intervention w/ proven outcome benefit (*Lancet* 2009;373:1382–1394) |
AORTIC DISSECTION

Overview

- **Definition**: Any extent of tearing of the aortic *tunica intima* that enables blood to enter into & traverse the aortic wall b/w *tunica intima* & *tunica media* layers
- Intramural “false lumen” can obstruct nl flow in true aortic lumen, including critical vascular branches (esp carotid, celiac, sup/inf mesenteric, renal, & spinal arteries)
- Can also manifest w/ penetrating ulcer, pseudoaneurysm, & traumatic rupture
- Classification of dissection impacts management & prognosis (see table)

<table>
<thead>
<tr>
<th>Stanford Type</th>
<th>% of Cases</th>
<th>Anatomical Distribution</th>
<th>Organs at Risk</th>
<th>Prognosis w/ Medical Tx</th>
<th>Prognosis w/ Surgical Tx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type A</td>
<td>62%</td>
<td>Ascending aorta +/- descending</td>
<td>Brain, Coronary Art, Spinal cord Abd/kidneys Legs</td>
<td>58%</td>
<td>26%</td>
</tr>
<tr>
<td>Type B</td>
<td>38%</td>
<td>Descending aorta w/o ascending</td>
<td>Spinal cord Abd/kidneys Legs</td>
<td>10.7%</td>
<td>31%</td>
</tr>
</tbody>
</table>

Approach

- Immediate IV, ECG, pCXR, Analgesia, BP control (if HTN)
- Consult cardiothoracic surgery early, esp for type A dissection if clinically suspected
- Attention to extent of dissection, size of T/F lumens, involvement of branches, presence of periaortic/mediastinal hematoma or pleural effusion

Risk Factors for Aortic Dissection *(Circulation 2010;121:e266)*
### Mechanism

<table>
<thead>
<tr>
<th>Associated Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>↑ Aortic wall stress</td>
</tr>
<tr>
<td>Hypertension, cocaine/stimulant use, extreme valsala (eg, power lifting), blunt trauma/deceleration injury, aortic coarctation, pheochromocytoma</td>
</tr>
<tr>
<td>Vulnerability of Ao wall</td>
</tr>
<tr>
<td>Genetic disorders (Ehlers–Danlos, Marfan, Turner, Loeys–Dietz, Noonan syndromes, congenital bicuspid valve, familial dissection), inflammatory vasculitides (SLE, GCA, Behçet’s), infectious vasculitides (syphilis, TB)</td>
</tr>
<tr>
<td>Iatrogenic wall injury</td>
</tr>
<tr>
<td>Cardiac/valve surgery, IABP use, aortic cannulation, cath</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Male, &gt;50 y/o, pregnancy, PCKD, chronic steroids, immunosupp</td>
</tr>
</tbody>
</table>

### History & Physical Exam

- Individual elements of hx in isolation notoriously insensitive &/or nonspecific (see table)
- HX: Abrupt onset & often worst-ever CP (ascending), interscapular back pain (descending), or neck pain; often maximal at onset, ripping/tearing in quality, & can migrate; can be a/w syncope, neurologic deficits
  - Note that up to 10% of pts may not p/w pain
  - As for RFs & consider in all blunt trauma pts w/ CP or back pain
- EX: Check for murmur, B/L UE BP asymmetry >20 mmHg (↓ Sens, but ominous finding), pulse deficit (27% of pts), neurologic deficits including Horner syndrome, abd pain +/- guaiac exam (+ result can suggest bowel ischemia), flank pain

### Aortic Dissection: Frequency of History, Exam, & CXR Findings

<table>
<thead>
<tr>
<th>Component</th>
<th>Overall (%)</th>
<th>Type A (%)</th>
<th>Type B (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe/worst-ever pain</td>
<td>90</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>Abrupt onset of pain</td>
<td>90</td>
<td>91</td>
<td>89</td>
</tr>
<tr>
<td>Chest or back pain</td>
<td>85</td>
<td>85</td>
<td>86</td>
</tr>
<tr>
<td>Pain presenting w/i 6 h of sx</td>
<td>—</td>
<td>79</td>
<td>—</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>30</td>
<td>22</td>
<td>43</td>
</tr>
<tr>
<td>Hypertension at presentation</td>
<td>49</td>
<td>36</td>
<td>69</td>
</tr>
<tr>
<td>Hypotension, shock, or tamponade</td>
<td>18</td>
<td>27</td>
<td>3</td>
</tr>
</tbody>
</table>
### Exam

<table>
<thead>
<tr>
<th>Exam</th>
<th>Sens (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any focal neuro deficit</td>
<td>12</td>
</tr>
<tr>
<td>Any pulse deficit</td>
<td>27</td>
</tr>
<tr>
<td>Aortic regurgitation</td>
<td>32</td>
</tr>
</tbody>
</table>

### CXR

<table>
<thead>
<tr>
<th>CXR</th>
<th>Sens (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CXR w/ widened mediastinum</td>
<td>60</td>
</tr>
<tr>
<td>CXR w/ abnl aortic contour</td>
<td>48</td>
</tr>
<tr>
<td>CXR nl</td>
<td>16</td>
</tr>
</tbody>
</table>


### Aortic Dissection: Sensitivity of Components of History

<table>
<thead>
<tr>
<th>Sens (95% CI)</th>
<th>Sens (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hx of HTN</td>
<td>64% (54–72)</td>
</tr>
<tr>
<td>Any pain</td>
<td>90% (85–94)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>67% (56–77)</td>
</tr>
<tr>
<td>Anterior chest pain</td>
<td>57% (48–66)</td>
</tr>
<tr>
<td>Posterior chest pain</td>
<td>32% (24–40)</td>
</tr>
<tr>
<td>Severe pain</td>
<td>90% (88–92)</td>
</tr>
<tr>
<td>Sudden-onset pain</td>
<td>84% (80–89)</td>
</tr>
</tbody>
</table>

*IRAD, JAMA 2002;287(17):2262.*

### Evaluation

- ECG: Assess for inf-STEMI (Type A dissection can involve RCA; ~4–8% of thoracic dissections will present w/ signs of STEMI), LVH (e/o chronic HTN)
  - In pts w/ inferior STEMI, consider Type A dissection always
- Labs: Type & Cross, CBC, Lytes, Cr (↑ w/ renal ischemia), Troponin, Lactate (↑ w/ any ischemia, ↑↑ suggests abd viscera ischemia), PT/PTT
- CXR: may be nl in 20%; characteristic findings include wide mediastinum, abnl aortic knob, L apical cap, trachea shift → R, depressed L bronchus, L pl effusion
- Combined use of D-dimer & Aortic Detection (ADD) Risk Score: Early data support combined use of ADD & D-dimer; ADD <1 & neg D-dimer can r/o AoD (Sens 100%, NPV 100%); ADD 1 & neg D-
dimer also very high Sens (98.7%) & NPV (99.2%), & likely improved further if CXR nl (60% of pts w/ AoD have wide mediastinum) (see table)

- D-dimer not appropriate in pts w/ ADD 2–3, given ↓ Sens & ↓↓ Spec
- Bedside cardiac US: Limited data suggest high diagnostic utility (Sens 88%, Spec 94%), esp in conjunction w/ ADD 0 (Sens 96%, Spec 98%); positive study includes any of following findings: intimal flap, intramural hematoma, ascending Ao dilatation, AV insuff, pericardial effusion; operator-dependent (*Intern Emerg Med* 2014;9(6):665–670)
- May be most useful in low-risk pts w/ chronically elevated D-dimer (eg, cancer, age)
- Definitive diagnostic modalities: TEE (Sens 98%, Spec 95%), CTA (Sens 100%, Spec 98%), MRI (Sens 98%, Spec 98%) (*Arch Intern Med* 2006;166:1350–1356)

<table>
<thead>
<tr>
<th>Test Characteristics of ADD &amp; Combined Approach Using ADD + D-Dimer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No. ADD High Risk Categories Present</strong></td>
</tr>
<tr>
<td><strong>Sens (%)</strong></td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>0 (Low risk)</td>
</tr>
<tr>
<td>1 (Int risk)</td>
</tr>
<tr>
<td>2–3 (High risk)</td>
</tr>
</tbody>
</table>

*Note that half (48.6%) of low-risk pts w/ AoD in derivation data had widened mediastinum on CXR. *Circulation* 2011;123:2213–18.

**Int J Cardiol 2014;175:78–82.
### Diagnostic Characteristics of Advanced Imaging for AD *(Arch Intern Med 2006;166:1350)*

<table>
<thead>
<tr>
<th>Imaging Study</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>+LR</th>
<th>−LR</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEE</td>
<td>98% (95–99%)</td>
<td>95% (92–97%)</td>
<td>14.1 (6–33)</td>
<td>0.04 (0.02–0.08)</td>
</tr>
<tr>
<td>CTA</td>
<td>100% (96–100%)</td>
<td>98% (87–99%)</td>
<td>14 (4.2–46)</td>
<td>0.02 (0.01–0.11)</td>
</tr>
<tr>
<td>MRI</td>
<td>98% (95–99%)</td>
<td>98% (95–100)</td>
<td>24 (11–57)</td>
<td>0.05 (0.03–0.10)</td>
</tr>
</tbody>
</table>

### Treatment *(Lancet 2008;372:55–66)*

- In general, surgical tx preferred for Type A, medical tx for Type B
- Tx revolves around close BP & HR control; Goal HR 60–80, SBP 100–120
  - First-line: IV BB gtt preferred to bolus (esmolol, labetalol)
  - Second-line (CI to BB, need for further control): IV CCB gtt (eg, nicardipine, diltiazem)
  - If refractory HTN/tachy: Vasodilator (nitroprusside)
  - A-line for close monitoring (pref RUE or farthest from false lumen)
- Analgesia: Short-acting narcotics preferred in case of hemodynamic changes
- Urgent surgical consultation should be obtained (cardiac surgery for Type A, vascular surgery for Type B) for all pts diagnosed w/ thoracic aortic dissection regardless of the location as soon as the Dx is made or suspected
  - Type A: Evaluate for emergent surgical repair (1–2% mortality/h in 1st 24 h)
  - Type B: Manage medically w/ consideration for endovascular repair (esp if e/o malperfusion, enlarging aneurysm, inability to control BP/sx)

### Disposition

- All patients w/ acute aortic dissection are admitted to ICU (+/− via OR)

---

### THORACIC AORTIC ANEURYSM

#### Overview
- Normal aortic diameter ↑ w/ age, sex (M > F), body surface area, imaging modality
- **Thoracic Aortic Aneurysm:** Permanent localized of aortic wall dilatation involving all 3 layers (tunica intima, tunica media, tunica externa) & reaching 1.5 × nl aortic diameter; dilatation b/w >1 & <1.5 × nl dilatation referred to as ectatic.
- **Thoracic Aortic Pseudoaneurysm:** See TAA, but involves <3 aortic wall layers
- Can occur at the aortic root (annular aortic ectasia) &/or ascending aorta (50%), descending aorta (40%), aortic arch (10%), or thoracoabdominal aorta (10%)
  - Up to ~25% of pts w/ TAA may also have an AAA
- Most TAAs are caused by degenerative dz resulting in dilation of the aorta
- RFs: See section on *Aortic Dissection* (see above)
- Complications vary based on diameter; average rate of expansion 0.10–0.42 cm/y

### Yearly Complication Rates as a Function of Aortic Size *(Ann Thorac Surg 2002;74:S1877)*

<table>
<thead>
<tr>
<th>Aortic Size</th>
<th>&gt;3.5 cm (%)</th>
<th>&gt;4 cm (%)</th>
<th>&gt;5 cm (%)</th>
<th>&gt;6 cm (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rupture</td>
<td>0</td>
<td>0.3</td>
<td>1.7</td>
<td>3.6</td>
</tr>
<tr>
<td>Dissection</td>
<td>2.2</td>
<td>1.5</td>
<td>2.5</td>
<td>3.7</td>
</tr>
<tr>
<td>Death</td>
<td>5.9</td>
<td>4.6</td>
<td>4.8</td>
<td>10.8</td>
</tr>
<tr>
<td>Any of above</td>
<td>7.2</td>
<td>5.3</td>
<td>6.5</td>
<td>14.1</td>
</tr>
</tbody>
</table>

### History, Physical Exam, & Evaluation
- **HX:** Often discovered incidentally on imaging; sx can vary widely:
  - Compressive sx: Hoarseness (compression of recurrent laryngeal nerve), stridor (compression of trachea/bronchi), dyspnea (lung compression), dysphagia (esophageal compression), plethora/edema (SVC compression)
  - Heart failure sx: May occur 2/2 aortic regurgitation
  - Embolization of atherosclerotic debris w/ end-organ sxs may occur
  - May lead to dissection (see *Aortic Dissection* section) or rupture
- **EX:** May have nl exam; see Aortic Dissection section exam above
- Imaging: CTA (Good Sens, quick, noninvasive); MRI (best for Ao
Root); TTE (limited for eval of Ao Root or descending TA); TEE (Better than TTE for Ao Root & descending TA)

**Treatment**
- Risk factor modification: Lipid profile optimization, smoking cessation, BP control (BB, ACEi), avoid intense exercise or valsalva
- Urgent open vs. endovascular repair as indicated (see table)

<table>
<thead>
<tr>
<th>Indications for Urgent Cardiac Surgical Consultation <em>(Circulation 2010;121:e266)</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Asymptomatic pts w/ degenerative TAAs, chronic aortic dissection, intramural hematoma, penetrating atherosclerotic ulcer, mycotic aneurysm, or pseudoaneurysm for whom the ascending aorta or aortic sinus diameter is ≥5.5 cm</td>
</tr>
<tr>
<td>• Pts w/ Marfan syndrome or other genetically mediated disorders (see above) for whom the ascending aorta or aortic sinus diameter is 4–5 cm</td>
</tr>
<tr>
<td>• Pts who have a growth rate of more than 0.5 cm/y in an aorta that is &lt;5.5 cm</td>
</tr>
<tr>
<td>• Pts w/ sx suggestive of expansion of TAA</td>
</tr>
</tbody>
</table>

**Disposition**
- Admit: Patients meeting indications for urgent repair, symptomatic patients
- Discharge (w/ vascular/cardiac surgery f/u): Pts w/ large but asx (ie, incidental) TAA
- Discharge (w/ PCP f/u for surgery referral): Pts w/ small & asx (ie, incidental) TAA
- All discharged pts: DC w/ RF modification (eg, improved BP control) & serial monitoring

---

**ACUTE PERICARDITIS**

**Definition** *(NEJM 2014;371(25):2410–2416)*
- Acute inflammatory dz of the pericardium due to a variety of causes:
  - Idiopathic (80% in developed nations)—Presumed post-viral
  - Infectious (TB, fungal, less likely staph/strep)
  - Post-MI (Dressler’s)
  - Systemic dz (cancer, connective tissue d/o, myxedema, uremia)
  - Trauma or treatment (postsurgical, XRT, posttraumatic)
- Dx requires the absence of more likely cause of CP (eg, ACS, etc.)
& ≥2 of the following:
1. Characteristic CP (see below)
2. Pericardial friction rub (high pitched, scratch sound heard best at left sternal border)
3. Suggestive ECG findings (see below)
4. New or worsening pericardial effusion
   † Can be relapsing in 10–30%: Incessant (d/c of tx or attempts to wean cause relapse in <6 wk) or intermittent (symptom-free intervals >6 wk, but recurs)
   † Can be a/w pericardial effusion w/ or w/o tamponade, or can be constrictive

History & Physical Exam
† HX: Characteristic CP—Sudden onset, retrosternal, pleuritic, positional (better w/ leaning forward or upright); pain can radiate to neck, arms, shoulders similar to ACS
   • Ask about recent viral illness
   • May have low-grade fever, SOB, dysphagia
† EX: Friction rub (high pitched, scratch sound heard best at LLSB apex), ↑ HR, ↑ RR, nl BP

Evaluation
† ECG: findings occur in 4 stages (see table), generally characterized by diffuse STE & PR depressions, though subtle PR depressions may be only sign
   • Assess for electrical alternans (suggests pericardial tamponade, see next section)

<table>
<thead>
<tr>
<th>Stages of ECG Changes in Pericarditis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 1: Acute</td>
</tr>
<tr>
<td>ST ↑ I, V5, V6; reciprocal STD aVR &amp; V1 PR</td>
</tr>
<tr>
<td>Stage 2: Early resolution</td>
</tr>
<tr>
<td>Normalization of ST &amp; PR segments</td>
</tr>
<tr>
<td>Stage 3: Late resolution</td>
</tr>
<tr>
<td>TWI I, V5, V6 which can be widespread</td>
</tr>
<tr>
<td>Stage 4: Complete resolution</td>
</tr>
<tr>
<td>Normalization of ECG</td>
</tr>
</tbody>
</table>

† Labs: CBC, BUN/Cr (r/o uremia), LFTs, ESR/CRP (↑ CRP in 75%), cardiac enzymes (as much as 1/3 cases a/w myocarditis) (NEJM
Further testing unnecessary unless WBC >13 k, T >38.5 F, or comorbidities or hx suggests specific underlying cause; PRN TSH, serologies (infxn, inflam)

- CXR: r/o other dx; can see cardiomegaly if >250 cc pericardial effusion
- Bedside echo: Assess for (1) pericardial effusion, (2) tamponade physiology (late diastolic collapse of RA, persistence of RA collapse >1/3 cardiac cycle, early diastolic collapse of RV, collapse of LA, dilated IVC w/ <50% respiratory collapse)
- Although not routinely indicated, CT & MRI can help make dx (pericardial thickening)

**Treatment**

- Pharmacologic tx is mainstay:
  - NSAIDs: Ibuprofen (600–800 mg q6h–q8h), Indomethacin (25–50 mg q8h), aspirin (2–4 g qd in divided doses) x 1–2 wk; Give w/ PPI for gastric protection
  - ASA preferred among NSAIDs in early post-MI period
  - Colchicine (0.5 mg QD if ≤70 kg; 0.5 mg BID if >70 kg): Used in conjunction w/ NSAIDs; c/w placebo, ↓ risk of recurrence & persistent sx at 72 h by 50% (*NEJM* 2013;369:1522–1528)
  - Use cautiously w/ CKD, hepatobiliary dz, bleeding dyscrasias, GI motility d/o
  - In conjunction w/ NSAIDs, usually improves sx w/i 1–3 d
  - Steroids (prednisone 1 mg/kg/d w/ slow taper after 2–4 wk): First-line for autoimmune or uremic etiologies, or those who fail NSAID or colchicine therapy; may ↑ risk of recurrence (COPE, *Circulation* 2005;112:2012).
  - Optimal duration of tx unclear: 3 mo course recommended (*NEJM* 2013;369:1522–1528)
- Tx underlying condition PRN (abx, dialysis, chemo, etc.)
- Pericardiocentesis indicated for purulent (postsurgical, TB, etc.) or neoplastic pericarditis
- Cardiology consult: If tamponade/echo is being considered
- CT surgery consult: Recent cardiac surgery or if pericardial window needed
Disposition
- 85% of pts can be discharged home
- Admit anyone w/ HD abnlty, myocarditis, uremia, large effusion

CARDIAC TAMPONADE

Overview
- Definition: A life-threatening state in which intrapericardial pressure (2/2 fluid, blood, pus) > RVEDP → ↓ LV preload → ↓ LVEDP → equilibration of L & R heart pressures → ↓ CO
- Tamponade more related to rate of fluid accumulation than volume of fluid
- Can be caused by blood (Type A AoD, post-MI free wall rupture, postsurgical, trauma), pus (TB, postsurgical), or fluid (myxedema, uremia, malignancy, SLE, XRT)

History & Physical Exam
- HX: If atraumatic, can p/w progressive SOB/DOE, orthopnea, PND, CP, LH, AMS, weakness; Traumatic usually w/ gross penetrating wound or blunt aortic injury
- EX: ↑ HR, ↑ RR, Beck’s triad (↓ BP, distended neck veins, muffled heart sounds), narrow pulse pressure, pulsus paradoxus (see below)

Performing Pulsus Paradoxus Test: Assessing the Reversed Bernheim Effect
- Using a sphygmomanometer, inflate the cuff to 20 mmHg above systolic pressure, then deflate until the 1st Korotkoff sound is heard, which you should only hear during expiration. Record this number. Next, deflate the cuff until Korotkoff sounds are heard equally during both inspiration & expiration. Subtract this number from the 1st.
- If the difference b/w these 2 numbers is >10 mmHg, the pt has a pulsus paradoxus of a magnitude equal to that difference
- DDx: Cardiac tamponade, severe asthma/COPD, PE, constrictive pericarditis

Evaluation
- ECG: Low voltage, electrical alternans, ± signs of pericarditis
- CXR: Globular heart, but may be nl if rapid accumulation (eg, trauma)
- Bedside Echo: Can confirm dx; effusion (can be variable size) w/
septal shift, late diastolic collapse of RA, persistence of RA collapse >1/3 cardiac cycle, early diastolic collapse of RV, collapse of LA, dilated IVC w/ <50% respiratory collapse

- Pericardial fluid: If atraumatic, consider sending fluid culture & Gram stain, BUN, Cr, ANA, RF, malignancy screen/cytology

**Treatment**

- IVF Bolus: Preload dependent state; ↑ preload to RV causes ↑ RVEDP > intrapericardial pressure → ↑ LV preload → ↑ CO
  - Preload is purely temporizing to pericardiocentesis; ultimately, w/ excess preload pts will develop pulm edema & hypoxia; any need for PPV must be avoided at all costs given profound effect on ↓ preload
  - Pericardiocentesis: cardiac tamponade w/ HD compromise requires urgent drainage (bedside if unstable; preferred in OR if time)

**Disposition**

- Admit all patients w/ cardiac tamponade. If drained effectively & stable, can be admx to tele floor (ie, cardiology). If admitted while awaiting drainage, ICU.

---

**MYOCARDITIS**

**Overview**

- Definition: Acute lymphocytic inflammatory dz of the myocardium of varying severity ranging from subclinical dz to fulminant systolic failure & death
- Frequently a/w viral infections (coxsackie, enterovirus, adenovirus), Chagas dz, toxins/meds (cocaine, lithium, doxorubicin), SLE, scleroderma

**History & Physical Exam**

- HX: Dyspnea (72%), CP (32%), arrhythmias (18%); May have systemic sxs including fever, arthralgia, malaise; Can present similar to HFrEF
- EX: Ranges from subtle signs of systolic dysfxn (crackles, LE edema) to fulminant respiratory failure (JVD, tachypnea, dec BS, LE
edema), arrhythmia, or cardiac arrest

Evaluation
- ECG: Sinus tach, STE/STD/NSSTW Δs, VT/VF, heart block, Δs of pericarditis (see above)
- CXR: ↑ cardiac size
- Labs: Cardiac enzymes (Troponin > CKMB; 34% Sens, 89% Spec; ↑ Sens w/↑ extent of dz), BNP, CBC w/diff (can see eosinophilia), ↑ ESR/CRP (NEJM 2009;360:1526–1538)
- Cardiac MRI: Useful for establishing definitive dx &/or planning bx

Treatment
- Largely supportive; treat CHF, cardiogenic shock, or arrhythmias

---

**SYNCOPE**

Overview
- Definition (syncope): Loss of consciousness & postural tone arising from an abrupt drop in cerebral perfusion w/ spontaneous recovery.
- Definition (pre-syncope, near-syncope): As above, but sxs resolve before complete LOC or loss of tone; may experience AMS & weakness before return to nl
- Objective in ED is to distinguish from other causes of sudden LOC, & differentiate benign etiologies from those requiring further eval or tx (see table)

<table>
<thead>
<tr>
<th>Common or Concerning Causes of Syncope</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Cardiac Etiologies</strong></td>
</tr>
<tr>
<td>Tachydysrhythmia</td>
</tr>
<tr>
<td><strong>Mechanism:</strong> ↑ HR (eg, VT, AF, AT, SVT, WPW), ↓ LVEDV, ↓ CO; <strong>HX:</strong> May be unheralded or prodrome of LH, CP, palp, diaphoresis, nausea, SOB; <strong>DX:</strong> ECG, Tele, o/p cardiac monitor; <strong>TX:</strong> rhythm-specific; <strong>DISPO:</strong> Admx</td>
</tr>
<tr>
<td>Bradydysrhythmia</td>
</tr>
<tr>
<td><strong>Mechanism:</strong> ↓ HR (eg, SSS, BB, CCB, Heart block esp 3°), ↓ CO; <strong>HX:</strong> May be unheralded or prodrome of LH, CP, weakness, diaphoresis, nausea, SOB; <strong>DX:</strong> ECG, Tele, o/p cardiac monitor; <strong>TX:</strong> rhythm-specific; <strong>DISPO:</strong> Admx, may need PPM</td>
</tr>
<tr>
<td>Condition</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Valvular Heart dz (usually AoS)</td>
</tr>
<tr>
<td>HFrEF (eg, post-MI)</td>
</tr>
<tr>
<td>HOCM</td>
</tr>
<tr>
<td>Tamponade</td>
</tr>
<tr>
<td>Primary Vascular Etiologies</td>
</tr>
<tr>
<td>Pulm Embolism</td>
</tr>
<tr>
<td>Pulm HTN</td>
</tr>
<tr>
<td>AoD (Type A&gt;B)</td>
</tr>
<tr>
<td>TAA/AAA</td>
</tr>
<tr>
<td>Condition</td>
</tr>
<tr>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Subclavian (SCA) steal syndrome</td>
</tr>
<tr>
<td>Carotid stenosis</td>
</tr>
<tr>
<td>Vertebrobasilar insufficiency</td>
</tr>
<tr>
<td>Non-Cardiovascular Etiologies</td>
</tr>
<tr>
<td>Vasovagal</td>
</tr>
<tr>
<td>Carotid sinus hypersensitivity</td>
</tr>
<tr>
<td>Orthostatic hypotension</td>
</tr>
<tr>
<td>Autonomic dysfxn</td>
</tr>
</tbody>
</table>
DISPO: Admx; can d/c w/ close o/p f/u if low-risk pt & low-frequency events

<table>
<thead>
<tr>
<th>Medications</th>
<th>Common medications (new or ↑ dose) a/w syncope: vasodilators (α-blockers, nitrates, ACEI/ARB, CCB, hydralazine, phenothiazines, antidepressants), diuretics, negative chronotropes (BB, CCB), antiarrhythmics (class IA, IC, III), psychoactive meds (antipsych, TCAs, barbs, benzos), substances (EtOH)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Syncope mimics</td>
<td>Seizure,* TIA/stroke,* ICH,* migraine*</td>
</tr>
</tbody>
</table>

*Can mimic syncope, but not considered true syncopal events. (modified from: NEJM 2002;347:878; JACC 2006;47:473)

**History & Physical Exam**
- HPI: Always ask about preceding activity (inc. posture), precipitants, prodromal sx (weakness, LH, diaphoresis, visual chgs), duration (<5 s suggests cardiac; >5 s suggests vasovagal), assoc sx (CP, palp, focal neuro deficits, HA, abd pain, nausea)
  - Differentiate from seizure: C/w seizure, syncope typically more abrupt, shorter duration, quicker return to nl (seconds–minutes), no tongue biting or incontinence, lack of rigidity; note syncope commonly can occur w/ slow & irregular myoclonic jerking mistaken as seizure/convulsive activity.
  - ROS, PMH (cardiac dz), meds, & FHx (sudden cardiac death) are very important
    - High-risk hx: Older age, structural heart dz, h/o CAD
    - Lower-risk hx: Young, healthy, nonexertional, no hx or e/o cardiac dz, no FHx SCD
  - EX: Guided by hx; evaluate neuro exam (inc stability w/ standing/gait), murmurs, carotid bruits, abd exam +/- guaiac

**Evaluation**
- ECG in all pts: Evaluate for stigmata of malignant dysrhythmia (HOCM, ARVD, Brugada syndrome, prolonged QTc, pre-excitation syndrome, coronary artery abnormalities)

<table>
<thead>
<tr>
<th>Characteristic ECG Findings in Patients with Selected Cardiac Causes of Syncope</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiac Dz</strong></td>
</tr>
</tbody>
</table>

**Notes:**
- Syncope mimics: Seizure, TIA/stroke, ICH, migraine.
Brugada syndrome  
(Circulation 2005;111:659)
- **Type I**: Coved ST-segment elevation ≥2 mm followed by a negative T wave in >1 R precordial lead (V1–V3)
- **Type II**: STE w/ saddle-back appearance w/ a high takeoff STE ≥2 mm, a trough displaying STE ≥1 mm, & then either a + or biphasic T wave
- **Type III**: Either saddleback or coved appearance w/ STE <1 mm
- Other: Prolonged QT, P wave, PR interval, QRS

HOCM  
- Characteristic findings of LVH (see ECG section)
- Deep narrow Q waves in inferior (II, III, aVF) & lateral (I aVL, V5, V6) leads in pts w/ septal hypertrophy
- Deep inverted T waves in mid & lateral precordial leads in pts w/ isolated apical hypertrophy

Arrhythmogenic R ventricular dysplasia  
(Am J Med 2004;117:685)
- Epsilon waves (small amplitude deflections at transition of QRS & ST segment) in R precordial leads
- Prolonged QRS complex to >110 ms in V1–V3 w/o RBBB
- Inverted T waves n V1–V3 in absence of RBBB
- Reduced R-wave amplitude

Long QT syndrome  
(Circulation 1995;92:2929; Circulation 2000;102:2849)
- Prolongation of QT interval, usually >500 ms
- LQT1 has a broad T wave, LQT2 has small &/or notched T wave, LQT3 has unusually long onset T wave

Pre-excitation syndrome  
(WPW)  
(Am Heart J 1930;6:685)
- Short PR interval
- Slurred upstroke of QRS complex (delta wave)
- Increased QRS duration

- Labs & imaging: All guided by history/exam & specific dx’s being considered; consider CBC, electrolytes (+/- Hcg) in most pts; however, obvious vasovagal syncope in a young o/w healthy male may not require any labs at all
  - Consider cardiac markers, UA, stool guaiac, head CT in elderly
- Any pt w/ ICD who has syncope should have their ICD interrogated by an appropriate specialist given the high likelihood of malignant dysrhythmia in such pts, which was likely the initial indication for ICD placement prophylactically.

**Disposition**  
(Ann Emerg Med 1997;29:4)
- Home if low-risk cardiac features: (1) Age <45, (2) nl ECG, (3) nl exam. Consider outpatient f/u.
- Admit if high-risk cardiac features: (1) Age (unknown age threshold, but continuous variable), (2) h/o cardiac dz (esp e/o heart failure or structural heart dz), (3) one or more Criteria of San Francisco
Syncope rule
- Other if diagnosed or suspected life-threatening diseases (e.g., MI, aortic dissection, GI bleed), acute neurologic abnlty (e.g., stroke, sz), ± for congenital heart dz, FHx sudden death, exertional syncope in pt w/o obvious cause

**Decision Rules in Evaluation of Syncope**
- Note at present no single clinical decision rule should outweigh clinical judgment

<table>
<thead>
<tr>
<th>San Francisco Syncope Rule</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Features (“CHESS”)</strong></td>
</tr>
<tr>
<td>CHF (past or present)</td>
</tr>
<tr>
<td>Hct &lt;30%</td>
</tr>
<tr>
<td>ECG abnl (new change or nonsinus)</td>
</tr>
</tbody>
</table>

**Using SFSR to Guide Disposition Decisions**
- If any of above features present, admit patient.
- Predicts risk of serious outcome (mortality, MI, arrhythmia, PE, CVA, SAH, significant hemorrhage, return to ED) w/i 7 d; Sens 86% (CI 83–89%), spec 49% (CI 48–41%) *(Ann Emerg Med 2010;56(4):362)*
- If none of above features present, consider d/c. Note that at publication of this book, pooled studies on SFSR have revealed a considerable population of pts w/ serious outcomes that do not have any of the five SFSR clinical features; however, all of these patients were admitted for other reasons. Combination of clinical gestalt & SFSR may have higher Sens & NPV than SFSR alone.
- Note: most robust syncope rule in terms of external validation


<table>
<thead>
<tr>
<th>OESIL Score (Osservatorio Epidemiologico sulla Sincope nel Lazio)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Features</strong></td>
</tr>
<tr>
<td>Age &gt;65 y</td>
</tr>
<tr>
<td>Syncope w/o prodrome</td>
</tr>
<tr>
<td>H/o Cardiovascular dz: Clinical or lab dx of any form of structural heart dz (ischemic, valvular, 1° myocardial dz, CHF, PAD, TIA/CVA)</td>
</tr>
<tr>
<td>Abnl ECG: Abnl rhythm (AF/AFL, SVT, MAT, frequent or repetitive PATs/PVCs,</td>
</tr>
</tbody>
</table>
sustained or nonsustained VT, paced rhythms), AV or interventricular conduction d/o (CHB, Mobitz I or II AVB, BBB, IVCD), LVH, RVH, left-axis deviation, definitive or possible e/o prior MI

### Prognostication Based on OESIL Score

<table>
<thead>
<tr>
<th>Points</th>
<th>All-Cause Mortality w/i 12 mo of ED Visit (%)</th>
<th>Notes:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.8</td>
<td>Sens 95% (CI 88–98%), spec 31% (CI 29–34%) (Ann Emerg Med 2010;56(4):362)</td>
</tr>
<tr>
<td>2</td>
<td>19.6</td>
<td>Best at long-term outcomes, poor w/ short term</td>
</tr>
<tr>
<td>3</td>
<td>34.7</td>
<td>Not rigorously externally validated compared to other syncope scores; derived &amp; validated in Italian community ED settings.</td>
</tr>
<tr>
<td>4</td>
<td>57.1</td>
<td></td>
</tr>
</tbody>
</table>


### Boston Syncope Criteria for Predicting Adverse Event or Critical Interventions

#### Clinical Features

<table>
<thead>
<tr>
<th>Ischemic symptoms</th>
<th>CP of possible cardiac origin, Ischemic ECG chgs (STE or &gt;0.1 mV STD), Other ECG chgs (VT/VF, SVT, rapid AF, or new STTW changes), SOB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signs of conduction dz</td>
<td>Multiple syncopal episodes w/i last 6 mo, rapid HR by hx, syncope during exercise, QT &gt;500 ms, 2° or 3° AVB or intraventricular block</td>
</tr>
<tr>
<td>H/o underlying cardiac dz</td>
<td>H/o CAD (inc deep Q waves, hCMP, dCMP), CHF or LV dysfxn, VT/VF, PPM/AICD</td>
</tr>
<tr>
<td>Family Hx (1st degree)</td>
<td>Sudden death, HOCM, Brugada, or long QT synd</td>
</tr>
<tr>
<td>Persistent (&gt;15 min) abnl VS w/o need for intervention</td>
<td>RR &gt;24, O₂ &lt;90% RA, HR &lt;50 or 100 bpm, SBP &lt;90 mmHg</td>
</tr>
<tr>
<td>Volume depletion</td>
<td>GIB by hx or hemoccult, Hct &lt;30%, Dehydration not corrected in ED by treating EP discretion</td>
</tr>
<tr>
<td>1° CNS event</td>
<td>(eg, SAH, CVA/TIA)</td>
</tr>
</tbody>
</table>

- Predicts critical intervention (PM/ICD placement, PCI, surgery, blood transfusion, CPR, alteration in antidysrhythmic therapy, endoscopy w/ intervention, or correction of carotid artery stenosis) or an adverse outcome (death, PE, CVA, severe infection/sepsis, ventricular/atrial dysrhythmia, ICH, hemorrhage, AMI, cardiac arrest, or other life-threatening sequelae) w/i 30 d
- Authors recommend admission for any + finding
HYPERTENSION AND HYPERTENSIVE EMERGENCIES

Approach
- Must differentiate chronic elevations in BP from an acute elevation
- Must differentiate transient elevations (ie, from anxiety or pain) from other causes
- Search for life-threatening causes of elevations in BP, including e/o end-organ damage (see HTN emergency)

### Differential for Hypertension

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other</td>
<td>Anxiety, pain, medications (cocaine, steroids, NSAIDs), rebound HTN (clonidine, βBs), EtOH withdrawal, preeclampsia–eclampsia, ICH, CVA</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Essential HTN, ADHF, aortic dissection, coarctation of aorta, polycythemia vera</td>
</tr>
<tr>
<td>Renal</td>
<td>CRF, renal artery stenosis, glomerulonephritis, fibromuscular dysplasia</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Cushing, pheochromocytoma</td>
</tr>
</tbody>
</table>

### Definition

(JAMA 2003;289:2560)
- HTN: SBP ≥140 or DBP ≥90
- HTN urgency: SBP ≥180 or DBP ≥110 w/ no acute organ damage; this term is also referred to as “hypertensive crisis” & has largely fallen out of favor
- HTN emergency: Elevated BP w/ acute organ damage (cardiac, CNS, renal)

### History
- H/o CAD, CHF, TIA, stroke, peripheral a. dz, renal insufficiency,
meds (sympathomimetics, cocaine, amphetamines), med noncompliance

**Evaluation**
- Check BP in both arms, check cuff/cuff size
- In ED pts w/ asymptomatic markedly elevated BP, routine screening for acute target organ injury (ie, serum Cr, US, ECG) is not required
- In select pt populations (ie, those w/ poor f/u), screening for an elevated Cr level may identify kidney injury that affects disposition

**Treatment**
- Goal BP <140/90 mmHg; if DM or renal dz goal is <130/80 mmHg
- Tx HTN results in 50% ↓ CHF, 40% ↓ stroke, 20–25% ↓ MI *(Lancet 2000;356:1955)*
- In pts w/ asymptomatic markedly elevated BP (ie, ≥180/≥110), routine ED medical intervention is not required
- In selected pt populations (ie, those w/ poor f/u), EPs may treat markedly elevated BP in the ED &/or initiate therapy for long-term control
  - For initiation of long-term therapy, it may be reasonable to start a thiazide-type diuretic for most pts, but may consider ACEI, ARB, BB, CCB, or combination *(Hypertension 2003:42:1206)*
  - In this situation, consider HCTZ 12.5–50 mg QD or Chlorthalidone 12.5–25 mg QD. Chlorthalidone may be superior to HCTZ *(MRFIT, Circulation 1990;82(5):1616; SHEP, JAMA 1991;265;265(24):3255; ALLHAT, JAMA 2002;288(23):2981)*

<table>
<thead>
<tr>
<th>Dz</th>
<th>Drug Choice</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac ischemia</td>
<td>Metoprolol, NTG</td>
<td>2.5–10 mg IV, 10–200 mcg/min IV</td>
</tr>
<tr>
<td>CHF</td>
<td>NTG</td>
<td>10–200 mcg/min IV</td>
</tr>
<tr>
<td>ICH, HTN encephalopathy</td>
<td>Nitroprusside, Labetalol</td>
<td>0.3–10 mcg/kg/min IV, 10 mg IV, up to 300 mg</td>
</tr>
<tr>
<td>Aortic dissection</td>
<td>Esmolol + nitroprusside, or labetalol alone</td>
<td>Esmolol: Bolus 0.25–0.5 mg/kg over 1–2 min, then 10–200 mcg/kg/min gtt; see above for nitroprusside &amp; labetalol</td>
</tr>
<tr>
<td>Renal artery stenosis</td>
<td>ACEI or ARBs</td>
<td>Captopril 25 mg PO BID, Losartan 50 mg PO QD</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>Pheochromocytoma</td>
<td>Phenoxybenzamine Phentolamine</td>
<td>10 mg PO BID 5 mg IV during HTN crisis</td>
</tr>
<tr>
<td>Preeclampsia–eclampsia</td>
<td>Magnesium Hydralazine</td>
<td>1–4 g IV over 2–4 min 10 mg IV</td>
</tr>
</tbody>
</table>

**Disposition**
- Asymptomatic pts may be d/c home w/ PCP f/u

**Pearls**
- HTN in the ED is often a/w anxiety/pain. Always re\sqrt{} BP once pt is calm & pain free
- Tx of pts w/ asymptomatic HTN in the ED is *not* necessary if outpatient f/u is available
- In neonates, suspect renovascular dz, coarctation of the aorta, or kidney malformation

**Hypertensive Emergency**

**Approach**
- Look for e/o acute end-organ damage
- Neurologic: Encephalopathy, hemorrhagic or ischemic stroke, papilledema
- Cardiac: ACS, CHF, aortic dissection
- Renal: ARF
- Other: Preeclampsia–eclampsia

**History**
- Look for precipitants: Progression of essential HTN, medication noncompliance, rebound HTN (clonidine), worsening renal dz, pheochromocytoma, Cushing drug use (cocaine, amphetamines, MAOIs + tyramine), cerebral injury
- CP, dyspnea, HA, blurry vision, confusion, oliguria, hematuria

**Findings**
- Assess MS, e/o papilledema, visual acuity

**Evaluation**
- BUN/Cr, lytes, CBC, UA, ECG (e/o LVH), CXR, cardiac enzymes (if ischemia suspected), head CT (if ICH suspected)
Treatment

- ↓ MAP by 25% w/i 1–2 h using IV meds, then f/u w/ PO version
- Avoid tx HTN during acute stroke unless pt is getting lysed, has extreme HTN (>220/110), aortic dissection, active ischemia, or CHF (Stroke 2003;34:1056)
- Treat by underlying cause as noted above

Disposition

- True hypertensive emergencies require ICU admission for BP monitoring


HYPOTENSION AND SHOCK

Approach

- ABCs: Always address airway/breathing prior to circulation
- Differentiate hypotension from shock

Definition

- Hypotension: BP below pt’s baseline, often defined as SBP <90 mmHg
- Shock: Insufficient perfusion pressures for organs’ metabolic needs

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential for Hypotension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shock</td>
<td>↓ intravascular volume</td>
</tr>
<tr>
<td></td>
<td>Hypovolemic shock</td>
</tr>
<tr>
<td></td>
<td>↓ CO</td>
</tr>
<tr>
<td></td>
<td>Cardiogenic shock</td>
</tr>
<tr>
<td></td>
<td>Obstructive shock</td>
</tr>
<tr>
<td></td>
<td>PE</td>
</tr>
<tr>
<td></td>
<td>Cardiac tamponade</td>
</tr>
<tr>
<td>Peripheral</td>
<td>Septic shock, anaphylactic shock,</td>
</tr>
<tr>
<td></td>
<td>Tension PTX</td>
</tr>
</tbody>
</table>
vasodilation (ie, distributive)
neurogenic shock

Hypotension*
Adrenal insufficiency, medications (eg, nitrates, narcotics, antihypertensives), orthostatic hypotension, neurocardiogenic syncope, pregnancy, hypoglycemia, pseudohypotension (ie, inaccurate measurement, faulty BP cuff)

*Some causes of hypotension can lead to shock.

**History**
- AMS, CP, SOB

**Findings**
- ↓ BP, ↑ HR, hypoxia, ↑ RR, UOP <1 mL/kg/h

**Evaluation**
- CBC, Chem 7, PT/PTT, cardiac markers, LFTs, blood gas, lactate, T/S, stool guaiac, ECG e/o ischemia
- POC ultrasonography: RUSH (Rapid Ultrasound in Shock, *Emerg Med Clin N Am* 2010;28:29) protocol incorporates a 3-part bedside physiologic assessment simplified as:
  - **the pump** (POC cardiac US to assess for pericardial effusion, global LV contractility, relative size of LV to RV)
  - **the tank** (POC IVC US to assess respiratory dynamics of IVC & volume status, as well as lung, pl & abdominal US to assess for pathology that could alter vascular volume; ie, PTX, pl effusion, free intra-abdominal fluid)
  - **the pipes** (POC thoracic & abdominal aortic US to assess for AD/AAA & LE compression US to assess for DVT)

<table>
<thead>
<tr>
<th>RUSH Evaluation</th>
<th>Hypovolemic Shock</th>
<th>Cardiogenic Shock</th>
<th>Obstructive Shock</th>
<th>Distributive Shock</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pump</td>
<td>Hypercontractile heart Small chambers</td>
<td>Hypocontractile heart Dilated heart</td>
<td>Hypercontractile heart Pericardial eff Cardiac tampon RV strain Cardiac thromb</td>
<td>Hypercontractile heart (early) Hypocontractile heart (late)</td>
</tr>
</tbody>
</table>
Tank
- Flat IVC
- Flat IJ
- Peritoneal fluid
- PI fluid

Distended IVC
- Distended IJ
- Lung rockets
- PI fluid
- Peritoneal fluid

Distended IVC
- Distended IJ
- No lung sliding (PTX)

nl or small IVC
- Peritoneal fluid
- PI fluid

Pipes
- AAA
- AD
- nl

DVT
- nl

Treatment
- Priority should be to obtain adequate IV access. If peripheral large-bore IVs cannot be placed in timely manner, consider IO (humeral/tibial/sterenal) or stat central venous access w/ large internal diameter catheters (ie, cordis).
- Priority should be to restore hemodynamics before time-consuming diagnostic w/u:
  - 1–2 L of isotonic crystalloid infusion as rapid as possible (ie, on pressure bag if indicated)
  - Consider stat uncrossmatched blood in life-threatening hemorrhage; consider using rapid infuser device; consider permissive hypotension in hemorrhagic shock
  - Consider peripheral vasoactive agents if persistently hypotensive after IVF bolus as bridge to obtaining central venous access

<table>
<thead>
<tr>
<th>Vasoactive Agent</th>
<th>Primary Receptor Activity</th>
<th>Relative Effects</th>
<th>Typical IV Dosing</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenylephrine</td>
<td>α1 +++</td>
<td>↑ SVR ↓ HR</td>
<td>20–200 mcg/min</td>
<td>Reflex bradycardia</td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>α1 ++++, α2 ++, β1 ++++, β2 0(+)</td>
<td>↑ HR ↑ SV ↑ SVR</td>
<td>1–40 mcg/min</td>
<td>Tachydysrhythmia</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>α1 ++++, α2 ++(+), 1 +++, β2 0(+)</td>
<td>↑↑↑ HR ↑↑↑ SV ↑↑↑ SVR Brchodilate</td>
<td>1–20 mcg/min</td>
<td>Tachydysrhythmia Splanchnic ischemia Acute MI</td>
</tr>
<tr>
<td>Dopamine</td>
<td>α2+, β1+, β2+, D++</td>
<td>Natriuresis ↑↑ HR</td>
<td>Dose dependent:</td>
<td>Tachydysrhythmia</td>
</tr>
<tr>
<td>Drug</td>
<td>Receptor Activity</td>
<td>Effect on SV, HR, SVR</td>
<td>Dose Range</td>
<td>Symptoms</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------</td>
<td>-----------------------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>V1 receptor</td>
<td>↑ SVR ↓ HR</td>
<td>0.01–0.03 U/min</td>
<td>HypoTN, Bradycardia</td>
</tr>
<tr>
<td>Dobutamine</td>
<td>α1 0(+), α2 0(+)</td>
<td>↑↑ HR ↑↑↑ SV ↓ SVR</td>
<td>2–20 mcg/kg/min</td>
<td>HypoTN, Bradycardia, Tachydysrhythmia</td>
</tr>
<tr>
<td>Milrinone</td>
<td>PDE inhibition</td>
<td>↑ HR ↑↑↑ SV ↓ SVR</td>
<td>0.25–0.75 mcg/kg/min</td>
<td>HypoTN, Bradycardia, Tachydysrhythmia</td>
</tr>
</tbody>
</table>

- Use MS, UOP, & MAP as early e/o adequate end-organ perfusion

**Pearls**
- Not all hypotension is clinically significant. Use clinical context, pt’s baseline BP, & check the BP cuff.
- Pulses provide a marker of baseline SBP, but may overestimate the absolute value (*BMJ* 2000;321:673)

<table>
<thead>
<tr>
<th>Pulse Present</th>
<th>Minimum SBP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radial artery</td>
<td>80</td>
</tr>
<tr>
<td>Femoral artery</td>
<td>70</td>
</tr>
<tr>
<td>Carotid</td>
<td>60</td>
</tr>
</tbody>
</table>

**HYPOVOLEMIC SHOCK**

**Approach**
- Dehydration is a Dx of exclusion; consider other etiologies (hemorrhage, ectopic pregnancy, etc.)

**Definition**
Intravascular volume depletion → ↓ perfusion, most commonly 2° blood loss

<table>
<thead>
<tr>
<th>Differential for Hypovolemic Shock</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathophysiology</td>
</tr>
<tr>
<td>Hemorrhage</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

**History**
- Trauma, melena, hematochezia, hematemesis, ↓ PO intake

**Findings**
- E/o trauma, guaiac + stool, pelvic exam

**Evaluation**
- As above +UA/HCG, FAST (blood in abdomen or chest); consider CT chest/abd/pelvis, pelvic US, type/screen

**Treatment**
- **Identify/treat cause**, IV fluid bolus; consider PRBCs; consult immediately for life-threatening disorders requiring definitive tx (surgery, GI, OB/Gyn)

**Disposition**
- Admit vs. OR

**CARDIOGENIC SHOCK**

**Approach**
- Consider intubation early, look for & **treat underlying cause**

**Definition**
- ↓ CO + nl intravascular volume → ↓ systolic contractility + ↑ diastolic filling
ACS, myocarditis, dysrhythmia, valvular failure, severe CMP, cardiac contusion, pulmonary HTN

Findings
- ↑ HR, ↓ BP, ↑ RR, hypoxia, pulmonary rales, S3, S4

Evaluation
- CBC, Chem 7, Ca, Mg, PO4, ECG, CXR, stat echo (systolic/diastolic dysfxn, papillary muscle rupture, ventricular wall rupture, VSD, pericardial effusion, R heart strain)

Treatment
- Treat underlying dz, IV fluids (if ↓ intravascular volume)
- Dopamine: ↑ myocardial contractility & BP, but ↑ O2 demand
- Dobutamine: ↑ HR & inotropy, less O2 demand, but causes vasodilation (best if not tachycardic or severely hypotensive)
- Central venous catheter: Consider for CVP monitoring, administration of pressors
- Cardiology consult
- Other: Thrombolytics, IABP, ventricular assist device

Disposition
- Admit to ICU

SEPTIC SHOCK

Approach (NEJM 2006;355:1699)
- Identify & treat early → best outcomes when treated w/i 6 h
- Look for source of infection

Definition
- Sepsis = SIRS (severe inflammatory response syndrome) + source infection
- SIRS: ≥2 of the following: Temp ≥38°C or ≤36°C, HR ≥ 90, RR ≥ 20, WBC (≥12,000, ≤4,000, or >10% bands)
Severe sepsis: Sepsis + sepsis-induced hypoperfusion (hypotension persisting after initial fluid challenge or blood lactate >4 mmol/L) or organ dysfxn (see organ dysfxn variables below)

Septic shock: Severe sepsis + ↓ BP despite adequate fluid resuscitation

### Common Causes of Sepsis

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory</td>
<td>PNA, empyema</td>
</tr>
<tr>
<td>Abdominal</td>
<td>Peritonitis, abscess, cholangitis</td>
</tr>
<tr>
<td>Skin</td>
<td>Cellulitis, fasciitis</td>
</tr>
<tr>
<td>Renal</td>
<td>Pyelonephritis</td>
</tr>
<tr>
<td>CNS</td>
<td>Meningitis, brain abscess</td>
</tr>
</tbody>
</table>

### Evaluation

- CBC w/ diff, Chem 10, LFTs, lactate, blood (×2)/urine/sputum culture, PT/PTT, cardiac markers, VBG, CXR; consider CT brain/LP, CT chest &/or abdomen, RUQ US based on pt
- Consider 1,3 beta-D-glucan assay & galactomannan assay if available & invasive candidiasis is in the DDx as cause of infection

### Diagnostic Criteria for Sepsis

**Inflammatory variables:**
- Leukocytosis (WBC >12,000 μL⁻¹)
- Leukopenia (WBC <4,000 μL⁻¹)
- nl WBC w/ >10% immature cells (band forms)
- Plasma CRP >2 SD above nl
- Plasma procalcitonin >2 SD above nl

**Organ dysfxn variables:**
- Arterial hypoxemia (PaO₂/FiO₂ <300)
- Acute oliguria (UOP <0.5 mL/kg/h for at least 2 h despite fluid resuscitation)
- Cr increase >0.5 mg/dL
- Coagulation abx (INR >1.5 or aPTT >60 s)
- Ileus
- TTP (plt count <100,000 μL⁻¹)
- Hyperbilirubinemia (plasma Tbili >4 mg/dL)

**Tissue perfusion variables:**
- Hyperlactemia (>1 mmol/L)
**Decreased cap refill/mottling**

**Treatment**

- EGDT ([NEJM](https://www.nejm.org) 2001;345:1368); ↓ mortality/hospital stay in 1 study, though no prospective validation study
- Protocolized quantitative resuscitation of pts w/ sepsis-induced hypoperfusion. *Goals during the 1st 6 h:*
  - **CVP 8–12 mmHg** → crystalloid (NS or LR) is the initial fluid of choice; *initial fluid challenge* 30 cc/kg; consider albumin when pts require substantial IVFs
  - Central venous access should be obtained as soon as practical
  - **MAP ≥65 mmHg** → use of vasopressors, whereby:
    - Norepinephrine is 1st choice
    - Epinephrine (added to or substituting NE) when additional agent needed
    - Vasopressin 0.03 U/min can be added to NE to raise MAP or decrease NE dose
    - Dopamine as alternative to NE only in highly selected pts (low-risk arrhythmia)
    - Phenylephrine not recommended except special circumstances
    - Arterial catheter should be placed as soon as practical
  - **UOP ≥0.5 mL/kg/h**
    - Foley catheter should be placed as soon as practical for I/O monitoring
  - **ScvO₂ or mixed venous O₂ saturation 70% or 65%, respectively**
    - Trial of dobutamine up to 20 mcg/kg/min should be given or added to vasoactive agent in the presence of myocardial dysfxn (elevated filling pressure/low CO) or ongoing signs of hypoperfusion, despite CVP & MAP goals (ScvO₂ <70%)
- **Abx**: Broad spectrum, given prior to drawing cultures (cover gram+, gram−, anaerobes; consider double coverage for pseudomonas)
- Start abx w/i 1 h of recognition, regardless of whether source is known
- Source control
Hydrocortisone: Consider hydrocortisone use in pts w/ severe sepsis refractory to IV fluids & pressors; corticotropin test + routine steroid use → no benefit & possibly harm (NEJM 2008;358:111)

Blood products: PRBCs to target Hgb 7–9 g/dL; Plts if <10,000 μL⁻¹ w/o bleed, <20,000 μL⁻¹ w/ risk of bleeding, <50,000 μL⁻¹ for active bleeding, surgery, procedure

Oxygenation/ventilation: Supplemental O₂; consider need for intubation early; if intubated use VTs of 6 cc/kg predicted BW (NEJM 2000;342:1301) use of sedation/paralytics → ↓ O₂ consumption

Glucose control: q1–2h measurements; initiate protocolized blood glucose management when 2 consecutive measurements >180 mg/dL to a target <180 mg/dL

Renal replacement therapy: Use continuous therapies (ie, CVVH) to facilitate managing fluid balance in HD unstable pts

Activated protein C: Use is controversial; ↓ mortality in severe sepsis based on 1 phase 3 trial (NEJM 2001;344:699; Crit Care Med 2003;31:12), but ↑ bleeding, ↑ cost, & no benefit in less sick (APACHE II <25) populations (NEJM 2005;353:1332); recently taken off market

Disposition

Admit


NEUROGENIC SHOCK

Approach

Cervical spine injury → risk of apnea, may require intubation; evaluate according to ATLS

Definition

Transection of the spinal cord → disruption of sympathetic pathways → loss of vascular sympathetic tone → vasodilation (typically cervical or high thoracic lesions)
History
- Trauma w/ severe injury to the spinal cord

Findings
- ↓ HR, ↓ BP, anesthesia, paralysis below an spec dermatome; saddle anesthesia, ↓ rectal tone, areflexia, Horner syndrome, absent bulbocavernosus reflex, priapism (unopposed PNS stimulation)

Evaluation
- CT spine (esp cervical, thoracic); consider CT head, chest, abd/pelvis if h/o trauma

Treatment
- C-spine immobilization: Aspen or Philadelphia collar for prolonged immobilization
- Strict log-roll precautions
- IV fluids: Prior to starting pressors
- Vasopressors: Dopamine, norepinephrine, phenylephrine
- Consult neurosurgery immediately

Disposition
- Admit

Pearl
- Any trauma pt w/ hypotension should be suspected of having hemorrhagic shock until proven o/w, thus neurogenic shock should be treated if suspected but should not be the 1° DDx in the hypotensive trauma pt.

DYSRHYTHMIA

Approach
- Follow ACLS protocols for anyone unstable or symptomatic (CP, SOB, AMS, abnl VS)

<table>
<thead>
<tr>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Bradycardia</td>
<td>Sinus bradycardia, SA node block/escape rhythm, sick node dysfxn, AV blocks (2nd- &amp; 3rd-degree AV block)</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Tachycardia</td>
<td></td>
</tr>
<tr>
<td>Regular</td>
<td></td>
</tr>
<tr>
<td>Regular</td>
<td>Narrow-complex Sinus tachycardia, SVT (AVNRT, AVRT), AT, AFL</td>
</tr>
<tr>
<td>Wide-complex</td>
<td>Ventricular tachycardia, SVT w/ aberrancy, SVT w/ pre-excitation (eg, WPW), tachycardia w/ PM</td>
</tr>
<tr>
<td>Irregular</td>
<td></td>
</tr>
<tr>
<td>Irregular</td>
<td>Narrow-complex AF, AFL w/ variable AV block, multifocal atrial tachycardia</td>
</tr>
<tr>
<td>Wide-complex</td>
<td>AF w/ aberrancy, polymorphic VT</td>
</tr>
</tbody>
</table>

### BRADYCARDIA

#### Approach
- Follow ACLS protocols for anyone unstable or severely symptomatic (CP, SOB, AMS)
- Anticipate need for external/transvenous pacing & cardiology consult early
- Always obtain ECG & rhythm strip
- Medication hx is crucial
- In children, be highly suspicious of toxic ingestion
- In neonates, consider congenital cardiac dz

#### Definition
- HR <60 in an adult, <80 in a child <15 y/o, <100 in an infant <1 y/o. Caused by depressed function of the SA node or conduction system block/delay.

#### Sinus Bradycardia *(NEJM 2000;342:703)*

#### History
- Fatigue, syncope/presyncope, DOE, medication hx (esp βBs)

#### Differential
- Physiologic (athletic young adults), medications (nodal agents), hypothyroidism, ↑ vagal tone (including inferior MI), hypothermia, ↑ ICP
Evaluation
- ECG (HR <60 in adults, nl PR intervals, P wave preceding each QRS), rhythm strip

Treatment
- Asymptomatic bradycardia does not require tx. Tx only if symptomatic or life-threatening cause is suspected w/ atropine &/or pacing.

Disposition
- Admit anyone who is symptomatic

SA Node Block/Escape Rhythm

History
- Same as for sinus bradycardia

Differential
- Same as for sinus bradycardia. Also a/w ↑ K, ↑ vagal tone.

Evaluation
- ECG (absent atrial depolarization & missing P waves), rhythm strip, lytes, consider TSH, cardiac markers

Treatment
- Asymptomatic bradycardia does not require tx. Tx only if symptomatic or life-threatening cause is suspected.

Disposition
- Admit anyone who is symptomatic

Sinus Node Dysfunction (Sick Sinus Syndrome/Tachy–Brady Syndrome)

Definition
- Sinus node dysfxn includes a series of ECG abnormalities characterized by failure to generate appropriate cardiac potentials from the sinus node
- In sick sinus syndrome, there are frequent long sinus pauses that may degenerate to absent atrial depolarization for a period of time before the resumption of regular cardiac conduction (sinus arrest)
- In tachy–brady syndrome, episodes of sinus bradycardia or sinus arrest are interspersed w/ episodes of supraventricular tachycardia
History
- Syncope, presyncope, fatigue, weakness, DOE, palpitations
- Typically observed in 70–80 y/o, suggesting age-related degeneration

Differential
- Consider other life-threatening arrhythmias

Evaluation
- ECG (frequent sinus pauses, bradycardia/tachycardia rhythms); consider electrolytes, cardiac markers, CBC; Holter or event monitoring

Treatment
- Acute tx only for symptomatic or life-threatening arrhythmia; ultimately may require combination of rate control for tachycardia & PPM for bradycardia

Disposition
- Admit anyone who is symptomatic for permanent PM placement
- If minimal or no sx are present, d/c home w/ close f/u

AV NODE BLOCK

Definition
- These occur when conduction from the atria to the AV node & into the His bundle is disrupted
- These blocks can anatomically be located above, w/i, or below the His bundle
- Classified as 1st-degree, 2nd-degree Mobitz I (Wenckebach), 2nd-degree Mobitz II, & 3rd-degree blocks based on characteristic ECG patterns:

<table>
<thead>
<tr>
<th>Classification</th>
<th>ECG Findings</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>1° AV block</td>
<td>Prolonged PR interval &gt;0.2 s, nl</td>
<td>↑ vagal tone, MI, age-</td>
</tr>
<tr>
<td></td>
<td>QRS</td>
<td>related degeneration, drugs (BB, CCB, digoxin), infection, endocarditis</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 2° AV block Mobitz type I | • Progressive ↑ PR interval w/ RR interval shortening until QRS dropped  
• Appears as grouped beats  
• Block at level of AV node | ↑ vagal tone, inferior MI, age-related degeneration, drugs (BB, CCB, digoxin), infection, endocarditis, RF |
| 2° AV block Mobitz type II | • Stable PR & RR interval w/ occasional dropped QRS  
• Can be regular (2:1) or irregular  
• Block at level of His–Purkinje | Age-related degeneration, anteroseptal MI |
| 3° AV block | • Complete AV dissociation  
• P waves are not conducted & never produce a QRS  
• Escape rhythm is a regular narrow junctional or wide ventricular response | MI (IMI w/ AV node ischemia or anteroseptal MI w/ H-P ischemia), age-related degeneration, drugs (BB, CCB, digoxin), infection, endocarditis, myocarditis, RF, congenital |

**Approach**
- Differentiate 1st, 2nd Mobitz I (Wenckebach), 2nd Mobitz II, & 3rd-degree blocks
- 2° Mobitz II & 3° blocks are never nl → look for underlying cardiac dz
- In children, be highly suspicious of toxic ingestion
- In neonates, consider congenital cardiac dz
- Determine (1) rate, (2) wide or narrow QRS, (3) rhythm regular or irregular, (4) P waves present or absent, (5) every P wave followed by QRS & every QRS preceded by P

**History**
- 1°: Asymptomatic, incidental finding on ECG
- 2° Mobitz I (Wenckebach): Often asymptomatic; irregular heartbeat, fatigue
- 2° Mobitz II: May be asymptomatic; presyncope/syncope, fatigue, DOE
- 3°: Usually symptomatic; presyncope/syncope, fatigue, weakness,
DOE

Findings
- See above

Evaluation
- ECG & rhythm strip
- 2° Mobitz II & 3°: Labs in anticipation of PPM placement

Treatment
- 1° & 2° Mobitz I: No tx generally necessary
- 2° Mobitz II & 3°:
  - Continuous tele monitoring
  - Symptomatic pts require transcutaneous &/or transvenous pacing; if HD unstable, consider a beta-adrenergic agent (dopamine, epinephrine, or isoproterenol) as bridge to pacing. Dopamine has been demonstrated to have equivalent survival outcomes & adverse events to transcutaneous pacing (PrePACE, Resuscitation 2008;76(3):341)
  - Treat active cardiac ischemia
  - Consult cardiology

Disposition
- Pts w/ 1° & 2° Mobitz I: D/c home w/ f/u
- Pts w/ 2° Mobitz II & 3°: Admit all to Tele ward for cardiology consult & PPM

Pearls
- Avoid atropine for reversal of AV block as this can worsen conduction
- Have transcutaneous pacer attached & ready for use in high-risk pts
- Mobitz II is concerning b/c risk of progression to 3°

TACHYCARDIA/PALPITATIONS

Approach
- Follow ACLS protocols for anyone unstable or severely symptomatic
Anticipate need for intubation & defibrillator early
Always obtain ECG & rhythm strip
Determine (1) rate, (2) wide or narrow QRS, (3) rhythm regular or irregular

### Causes of Wide Complex Tachycardia

<table>
<thead>
<tr>
<th>Tx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventricular tachycardia</td>
</tr>
<tr>
<td>Amiodarone, lidocaine, DCCV</td>
</tr>
<tr>
<td>SVT w/ *aberrancy (ie, BBB)</td>
</tr>
<tr>
<td>Adenosine, vagal maneuvers, DCCV</td>
</tr>
<tr>
<td>SVT w/ pre-excitation</td>
</tr>
<tr>
<td>Procainamide, DCCV</td>
</tr>
<tr>
<td>Tachycardia + PM</td>
</tr>
<tr>
<td>Treat cause of tachycardia, apply magnet if PM-mediated</td>
</tr>
</tbody>
</table>

*Causes of aberrancy: Bundle branch blocks (fixed, rate-related, Ashman’s phenomenon), accessory pathways (ie, WPW), meds (ie, class Ia/Ic antiarrhythmics, TCAs), pseudo-STEMI, PM, hyperkalemia, hypothermia, cardiomyopathies, channelopathies.

### Supraventricular Tachycardia

**Approach**
- Differentiate type based on ECG, rhythm strip, & response to adenosine/vagal maneuvers (see below)

**Definition**
- Rhythm arises above the ventricles (either atrium or AV jxn) w/ narrow QRS unless pre-excitation or aberrant conduction

**History**
- H/o pulmonary or cardiac dz → AT, MAT, AFL, AF, NPJT; o/w health adult → AVNRT, AVRT
- Gradual onset → ST, AT; abrupt onset → AVNRT, AVRT

**Evaluation**
- Consider CBC, TSH, tox screen, though in most cases, ECG/rhythm strip is sufficient

### SVT Pathophysiology

<table>
<thead>
<tr>
<th>Type of SVT</th>
<th>Pathophysiology</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Atrial ST Pain, fever, anxiety, hypovolemia, PE, medication, anemia, hyperthyroid

AT Originates in atria but not SA node; a/w COPD, CAD, EtOH, digoxin

MAT Originates in atria at ≥3 separate sites

AFL Atrial macroreentry, typically R atrium

AF Multiple irregular atrial impulses typically from pulmonary veins

AV jxn AVNRT Re-entrant pathway w/i AVN

AVRT Re-entrant pathway using AVN + accessory pathway b/w atria & ventricles

NPJT Originates at AV jxn, a/w myo/endocarditis, cardiac surgery, IMI, digoxin


### Diagnosis by ECG, Vagal Maneuvers, and Adenosine (NEJM 2006;354:1039)

| Rate      | ST: Typically <150 bpm  
|           | AFL: Typically 150 bpm (2:1 AV block)  
|           | AVNRT/AVRT: Typically >150 bpm |
| Rhythm    | Irregular → AF, MAT |
| P wave    | UPRIGHT before QRS: ST, AT, MAT  
|           | Retrograde AFTER QRS: AVNRT (w/i QRS), AVRT (after QRS)  
|           | FIBRILLATION or no P wave → AF  
|           | SAWTOOTH appearance → AFL |
| Vagal/adenosine | Slows rate w/ ↑ AV block: ST, AT, MAT |
| Response  | Terminates rhythm or no response: AVNRT, AVRT  
|           | “Unmasks” sawtooth waves ↑ AV block → AFL |

### Treatment

- Cardiovert any unstable rhythm
- ST: Treat underlying condition
- AT/MAT: Treat underlying condition; consider AV nodal blocker
- AF/AFL: CCB, βB, dig, antiarrhythmic (amiodarone, lidocaine)
- AVNRT/AVRT: Vagal maneuvers, adenosine, CCB preferable to βB  
  → avoid adenosine/nodal agents if e/o pre-excitation (see WPW below)
NPJT: CCB, βB, amiodarone

Disposition
- Most pts w/ ST, AVNRT, AVRT can be d/c home once rhythm is controlled if → asymptomatic & no acute underlying condition. Admission for other rhythms is variable, but often necessary due to underlying condition.
- Consult cardiology for any pt w/ unstable SVT & those difficult to control w/ standard tx

Pearl
- MAT is often misdiagnosed as AF. Look closely at P wave morphology.

Atrial Fibrillation and Atrial Flutter
Definition *(JACC 2006;48:e149)*
- AF is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activity w/ consequent deterioration of mechanical function
- Can be 1st episode or recurrent (≥2 episodes) as well as paroxysmal (self-limited), persistent (>7 d), permanent (>1 y) &/or cardioversion has failed
- Valvular → rheumatic heart dz, or postvalve surgery
- Lone AF → <60 y/o & no e/o cardiac dz or HTN

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other</td>
<td>Idiopathic (50%)</td>
</tr>
<tr>
<td>Cardiac</td>
<td>CHF, peri/myo/endocarditis, MI/ischemia, s/p cardiac surgery, HTN</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>COPD, PNA, PE</td>
</tr>
<tr>
<td>Endo</td>
<td>Hyperthyroid, stress, infection, postop</td>
</tr>
<tr>
<td>Drugs</td>
<td>EtOH “holiday heart syndrome”, cocaine, amphetamines, sympathomimetics, caffeine</td>
</tr>
</tbody>
</table>

History
- Abrupt vs. gradual onset (palpitations, DOE, fatigue)
presyncope/syncope, CP); recent illness, drug & alcohol use

Findings
- Irregularly irregular pulse; may be regular w/ AFL

Evaluation
- ECG, CBC, lytes, Ca, Mg, PO₄; CXR
- Consider cardiac markers (if active CAD is suspected); TSH, dig level if appropriate; echo (LA size, thrombus, valves, LV fxn)
- Consider outpatient Holter in pts w/ suggestive hx who arrive in NSR
- ECG in AF: Replacement of consistent P waves by rapid oscillating or fibrillatory waves that vary in amplitude, shape, & timing, a/w irregular, frequently rapid ventricular response rate
- ECG in AFL: Atrial rate 250–350 bpm w/ ventricular response rate typically 150 bpm presence of “sawtooth” flutter (“F”) waves. Can be typical (spiky V1, negative in II, III, aVF, V5–V6) or atypical (appearance other than typical). F waves revealed via adenosine or vagal maneuvers. Most commonly 2:1 or 4:1 conduction.

Treatment
- Main objectives: Rate control, prevention of thromboembolism, & correction of rhythm
- When deciding on management strategies in the ED, several things to consider include:
  a. Is the pt stable or unstable?
  b. Is this 1st episode or recurrent episode, & is this part of a paroxysmal, persistent, or permanent duration paradigm?
  c. If 1st-episode or paroxysmal, how long have sxs been present (ie, <48 h)?
  d. What is the pt's stroke risk?
  e. Does the pt have a cardiologist/PCP w/ whom you can make joint decision or poor f/u?
- Rate control vs. rhythm control: Numerous studies have sought to answer this question, but bottom line is that there appears to be no difference in symptomatic improvement, CHF, thromboembolic cx, severe bleeding, or mortality when comparing the 2 strategies (PIAF, Lancet 2000;356:1789; AFFIRM, NEJM 2002;347:1825; STAF, J Am Coll Cardiol 2003;41:1690; HOT CAFÉ, CHEST 2004;126:476); however, rhythm control seems to be a/w increased rates of hospitalization & adverse

*Note: majority of these studies included pts w/ persistent AF, thus may not be generalizable to ED pt presenting w/ 1st episode or paroxysmal AF


![Figure 1.5 Unstable patient with afib. (Note: Mean energy level for successful cardioversion 50 J biphasic and 200 J monophasic [Am J Cardiol 2004;93:1495–1499]. There may be higher first-shock success for DVVC if initial energy used 200 J vs.100 J [BEST-AF, *Heart* 2008;94:884–887]).](image-url)

Figure 1.5 Unstable patient with afib. (Note: Mean energy level for successful cardioversion 50 J biphasic and 200 J monophasic [Am J Cardiol 2004;93:1495–1499]. There may be higher first-shock success for DVVC if initial energy used 200 J vs.100 J [BEST-AF, *Heart* 2008;94:884–887]).
Figure 1.6 Stable patient, first episode or paroxysmal afib. Note: These patients may undergo cardioversion without anticoagulation, however, consider delaying DCCV and anticoagulate for 3 wk if high risk of stroke (ie, mechanical valve, RHD, recent CVA/TIA).

Figure 1.7 Stable patient, persistent or permanent afib.
Rate control: βB or nondihydropyridine CCBs recommended as 1st-line therapy for rate control. CCB, however, should be avoided in pts w/ ADHF & AF.
- Digoxin can be added to therapy w/ βB or CCB in pts whose HR is not controlled
- Dronedarone may be added for additional rate control w/ uncontrolled ventricular rate despite above therapy
- IV administration of digoxin or amiodarone is recommended to control HR in pts w/ AF & HF
- Amiodarone for rate control should be reserved for exceptional cases in which other means are not feasible or insufficient
- IV procainamide, disopyramide, ibutilide, or amiodarone may be considered for HD stable pts w/ AF involving conduction over an accessory pathway. In this situation, IV CCB or digoxin should be avoided as they may paradoxically accelerate the ventricular response.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Initial Dose</th>
<th>Maint Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>βB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metoprolol</td>
<td>2.5–5 mg IV bolus q5min × 3</td>
<td>Start 25–100 mg PO BID</td>
</tr>
<tr>
<td>Esmolol</td>
<td>500 mcg/kg IV q4min × 3</td>
<td>60–200 mcg/kg/min IV gtt</td>
</tr>
<tr>
<td>Propranolol</td>
<td>0.15 mg/kg IV q5min × 5</td>
<td>Start 40 mg PO BID</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diltiazem</td>
<td>0.25 mg/kg IV × 1; may repeat 0.25–0.35 mg/kg IV after 15 min</td>
<td>Start 30 mg PO QID or 5–15 mg/h IV gtt</td>
</tr>
<tr>
<td>Verapamil</td>
<td>0.075–0.15 mg/kg IV; may repeat dose after 15–30 min</td>
<td>Start 40–80 mg PO TID</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digoxin (onset in hours)</td>
<td>0.25 mg IV q2h, up to 1.5 mg</td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td>150 mg IV over 10 min</td>
<td>0.5–1 mg/min IV</td>
</tr>
</tbody>
</table>

Direct current cardioversion: Recommended dose 150–200 J
biphasic waveform
- Mean energy level for successful cardioversion 50 J biphasic & 200 J monophasic \((\text{Am J Cardiol} 2004;93:1495)\). There may be higher 1st-shock success for DVVC if initial energy used 200 J vs. 100 J (BEST-AF, \text{Heart} 2008;94:884).
- Pretreatment w/ amiodarone, flecainide, ibutilide, propafenone, or sotalol can be used to enhance the success of DCCV & prevent recurrent AF.

\textbf{Pharmacologic cardioversion: } Administration of flecainide, dofetilide, propafenone, or ibutilide is recommended for pharmacologic cardioversion
- Procainamide has been shown to be effective in ED population w/ 58.3% cardioversion, w/ 91.7% success rate if followed by DCCV in nonresponders \((\text{CMEJ} 2010;12(3):181)\)
- Amiodarone is a reasonable option, but digoxin & sotalol may be harmful for cardioversion & are not recommended
- \(\beta\)B or nondihydropyridine CCBs should be given before administering class I antiarrhythmic agents

| Rhythm Control Agents for Atrial Fibrillation/Atrial Flutter |
|-----------------|-----------------|-----------------|
| **Medication**  | **Initial Dose** | **Special Considerations**               |
| Class Ia        |                 |                                             |
| Procainamide    | 15–17 mg/kg IV over 60 min | • Preferred w/ WPW  
• May cause hypotension |
| Class Ic        |                 |                                             |
| Propafenone     | 450 mg PO (<70 kg)  
600 mg PO (≥70 kg)  
2 mg/kg IV | • May cause hypotension,  
bradycardia  
CI in pts w/ ischemic HD, LV dysfxn, structurally abnl heart |
| Flecainide      | 200 mg PO (<70 kg)  
300 mg PO (≥70 kg)  
2 mg/kg IV | • May cause hypotension,  
bradycardia  
↓ dose in renal insuff  
CI in pts w/ ischemic HD, LV dysfxn, structurally abnl heart |
| Dofetilide      | 0.5 mg PO (eGFR >60)  
0.25 mg PO (eGFR 40– 60)  
0.125 mg PO (GFR 20–40)  
Cl if eGFR <20 | • 2–3% risk torsades de pointes;  
CI long QT, bradycardia  
Require hospitalization for initiation given QTc prolongation |
Class III

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose and Administration</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibutilide</td>
<td>1 mg over 10 min (&gt;60 kg) 0.01 mg/kg, 10 min (&lt;60 kg)  <em>May repeat once at same dose if doesn’t terminate</em></td>
<td>• CI in pts w/ hypokalemia, prolonged QTc, torsades de pointes</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>5–7 mg/kg IV over 30 min, then 1.2–1.8 g/day continuous IV infusion</td>
<td>• SE: Hepatotoxicity, hypothyroid, thyrotoxicosis, pneumonitis, pulmonary fibrosis, corneal microdeposits</td>
</tr>
</tbody>
</table>

- **Anticoagulation:** All pts w/ AF or AFL (paroxysmal, persistent, or permanent) should be stratified using a predictive index for stroke (ie, CHADS₂ or CHA₂DS₂-VASc) & for the risk of bleeding (ie, HAS-BLED) & most pts should receive anticoagulation
- Pts w/ very low risk of CVA (CHADS₂ = 0) should receive ASA 81–325 mg/d
- Pts w/ low risk of CVA (CHADS₂ = 1) should receive oral anticoagulation w/ either warfarin or dabigatran, but ASA is reasonable for some pts
- Pts w/ mod risk of CVA (CHADS₂ ≥ 2) should receive oral anticoagulation w/ either warfarin or dabigatran
- Most pts should receive dabigatran 150 mg PO BID preferable to warfarin when anticoagulation indicated
- Newer effective oral anticoagulants include rivaroxaban 20 mg QD (ROCKET-AF, NEJM 2011;365:883) & apixaban 5 mg PO BID (ARISTOTLE, NEJM 2011;365:981)
- Anticoagulation not recommended for pts w/ lone AF

<p>| CHADS₂ Score for Estimating Stroke Risk in Patients with AF (JAMA 2001;285:2864) |
|---------------------------------|-------------------------------------|
| CHADS₂ Risk Criteria | Score |
| CHF                              | 1       |
| HTN                              | 1       |
| Age &gt;75 y/o                      | 1       |
| Diabetes mellitus                | 1       |</p>
<table>
<thead>
<tr>
<th>Stroke or TIA (prior)</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHADS₂ Score</strong></td>
<td><strong>Adjusted Stroke Rate%/y (95% CI)</strong></td>
</tr>
<tr>
<td>0</td>
<td>1.9% (1.2–3)</td>
</tr>
<tr>
<td>1</td>
<td>2.8% (2–3.8)</td>
</tr>
<tr>
<td>2</td>
<td>4% (3.1–5.1)</td>
</tr>
<tr>
<td>3</td>
<td>5.9% (4.6–7.3)</td>
</tr>
<tr>
<td>4</td>
<td>8.5% (6.3–11.1)</td>
</tr>
<tr>
<td>5</td>
<td>12.5% (8.2–17.5)</td>
</tr>
<tr>
<td>6</td>
<td>18.2% (10.5–27.4)</td>
</tr>
</tbody>
</table>

**HAS-BLED Score for Estimating Major Bleeding Risk in Patients with AF** *(CHEST 2010;138:1093)*

<table>
<thead>
<tr>
<th>Clinical Characteristic</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTN (SBP &gt;160 mmHg)</td>
<td>1</td>
</tr>
<tr>
<td>Abnl renal or liver fxn (1 pt each)**</td>
<td>1 or 2</td>
</tr>
<tr>
<td>Stroke</td>
<td>1</td>
</tr>
<tr>
<td>Bleeding</td>
<td>1</td>
</tr>
<tr>
<td>Labile INRs</td>
<td>1</td>
</tr>
<tr>
<td>Elderly (age &gt;65 y/o)</td>
<td>1</td>
</tr>
<tr>
<td>Drugs or EtOH use (1 pt each)***</td>
<td>1 or 2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HAS-BLED Score</th>
<th>Major Bleed%/y*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.13%</td>
</tr>
<tr>
<td>1</td>
<td>1.02%</td>
</tr>
<tr>
<td>2</td>
<td>1.88%</td>
</tr>
<tr>
<td>3</td>
<td>3.74%</td>
</tr>
<tr>
<td>4</td>
<td>8.70%</td>
</tr>
<tr>
<td>5</td>
<td>12.50%</td>
</tr>
<tr>
<td>6–9</td>
<td>Not reported</td>
</tr>
</tbody>
</table>

*Major bleeding defined as any bleeding requiring hospitalization &/or causing a decrease in
Hgb of >2 g/L &/or requiring blood transfusion that was not a hemorrhagic stroke.

**Abnl renal fxn defined as chronic dialysis, renal transplant, or Cr >200 μmol/L (2.3 mg/dL). Abnl liver fxn defined as chronic hepatic dz (ie, cirrhosis), Tbilii >2× ULN, in association w/ AST/ALT. ALP >3× ULN.

***Drugs included anti-plt agents & NSAIDs.

**Disposition**
- Home: Pts who convert to sinus, or are rate controlled, & anticoagulated if necessary
- All discharged pts should get close PCP or cardiology f/u
- EDOU: Depending on local clinical protocols
- Admit: Pts w/ acute underlying illness, ongoing sx, or poor rate control

**Pearls**
- Risk of stroke is similar in all forms of AF/AFL (recurrent paroxysmal, persistent, & permanent AF, & AFL)
- Spontaneous cardioversion occurs w/i 24 h in 50–67% acute AF
- 5–8% elderly have recurrent AF

**Pre-excitation**

**Definition**
- **Accessory pathway:** A bypass tract that conducts impulses b/w
atria

- **Wolff–Parkinson–White**: Accessory conduction pathway evident on resting ECG
- **Orthodromic AVRT**: Impulse travels down AV node (fast), then conducts retrograde, up the accessory pathway (slowly) → thus narrow-complex QRS
- **Antidromic AVRT**: Impulse travels down the accessory pathway (slowly), then conducts retrograde, up the AV node (fast) → thus wide-complex QRS

**Evaluation**

- ECG & rhythm strip
- Orthodromic AVRT: Narrow complex tachycardia
- Antidromic AVRT: WCT

**Treatment**

- AVRT: Vagal maneuvers, βBs, CCB
- AF/AFL w/ pre-excitation → cardiology consult, DC cardiovert, or use procainamide; βB & CCB are ineffective & can precipitate VF

**Ventricular Tachycardia**

**Approach**

- Determine if pt is stable or unstable → use ACLS protocol for any pt w/ unstable VT
- Differentiate VT from nonsustained VT (NSVT), & other causes of WCT (see above)
- Differentiate monomorphic from polymorphic VT

**Definition**

- NSVT: VT lasting <30 s
- SVT w/ aberrancy: VT look-alike b/c abnl conduction → WCT. Caused by fixed BBB, rate-related BBB, or accessory pathway
- Torsades de pointes: Polymorphic VT + prolonged QT

**Causes**

- **Monomorphic, structurally abnl heart**: Prior MI, CMP, arrhythmogenic RV dysplasia
- **Monomorphic, structurally nl heart**: Idiopathic VT
- **Polymorphic**: Ischemia, CMP, torsades de pointes, Brugada syndrome (see below)
History
- Palpitations, lightheadedness, CP, SOB, nausea, syncope, unresponsiveness; PMH: CAD, CMP, multiple CAD RFs, & FHx sudden death all ↑ risk VT

Evaluation
- ECG, rhythm strip, lytes, Ca, Mg, PO₄, cardiac markers; CXR; digoxin level if appropriate

Treatment
- **Unstable VT**: ACLS protocol
- **Stable VT**: Use either:
  - Lidocaine: 100 mg IV load, then 1–4 mg/min
  - Amiodarone: 150 mg IV load, then 1 mg/min
- **Polymorphic VT**: Magnesium 2–4 g IV bolus
- **Other**: Replete electrolytes (Ca, Mg, PO₄); treat coincident ischemia if present

Disposition
- Admit to cardiac step-down unit or cardiac ICU

Pearls
- Assume all WCT to be ventricular unless proven o/w
- Best clinical predictors that WCT is VT → prior MI, CHF, LV dysfxn


| Brugada Criteria for WCT Suggesting VT (Circulation 1991;83:1649) |
|--------------------------|--------------------------|
| **Criterion**            | **ECG Appearance**       |
| AV dissociation          | Independent P waves, capture/fusion beats |
| Wide QRS                 | RBBB type: >140 ms       |
|                          | LBBB type: >160 ms       |
| Extreme axis deviation   | —                        |
| Atypical QRS morphology  | —                        |
| for BBB                  | —                        |
|                          | —                        |
| Concordance               | Of QRS in precordial leads w/ same pattern & direction |

**Brugada Syndrome**
Definition
- Incomplete RBBB w/ STE V1–V3 caused by alteration of the myocyte Na channel, a/w VT & sudden cardiac death

History
- Classically young, o/w healthy male, FHx sudden D; sxs: Presyncope, syncope, cardiac arrest

Evaluation
- ECG, electrolytes, Ca, Mg, PO$_4$

Treatment
- Tele; electrophysiology consult

Disposition
- If incidental finding, refer to cardiology for f/u. O/w, admit to Tele bed for EP study, possible ICD placement.

PACEMAKER AND AICD MALFUNCTION

Definition
- PM: Intracardiac device used for significant AV block &/or sinus node dysfxn
- AICD: Intracardiac device for the termination of VF/VT, & prevention of sudden cardiac death → for pts s/p VF/unstable VT arrest, persistent EF ≤30–35%, Brugada, or long QT syndrome (*Circulation* 2007;115:1170; *NEJM* 1997;337:1576)

Approach
- Obtain an ECG & rhythm strip immediately
- Obtain the make & model of the device (most pts have a card, o/w obtain AP CXR → magnify device to obtain model number → internet search for type)
- Common PM codes: DDD (dual chamber paced, sensed, & response to sensed beat) & VVI (dual chamber paced, sensed, &
inhibitory response to sensed beat)

**Evaluation**

- Magnet placed over device
- PM: Inhibits sensing, paces at fixed rate regardless of intrinsic cardiac activity
- AICD: Inhibits further firing, though not bradycardic pacing

<table>
<thead>
<tr>
<th>Pacemaker Malfunction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
</tr>
<tr>
<td><strong>Pathophysiology</strong></td>
</tr>
<tr>
<td>Failure of output → no pacer spike despite indication to pace</td>
</tr>
<tr>
<td>Failure to capture → pacing spikes <em>not</em> followed w/ depolarization</td>
</tr>
<tr>
<td>Oversensing → pacer spike despite <em>no</em> indication to pace</td>
</tr>
<tr>
<td>Undersensing → <em>no</em> pacer spike despite indication to pace</td>
</tr>
<tr>
<td>PM-mediated tachycardia</td>
</tr>
</tbody>
</table>

**History**

- Lightheadedness, palpitations, syncope

**Findings**

- ↑, ↓, &/or irregular HR, ↓ BP

**Evaluation**

- ECG, CXR (to visualize device & leads)

**Treatment**

- Transcutaneous pacing: For unstable pt
MAGNET: FOR PM-mediated tachycardia: Magnet over the PM → paces @ 80 bpm OR OVERSENSING

Disposition

Consult EP or device rep. for interrogation & reprogramming; to cath lab for lead/battery replacement

<table>
<thead>
<tr>
<th>Pt Sxs</th>
<th>AICD Interrogation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt-sensed AICD* firing</td>
<td>No firing</td>
</tr>
<tr>
<td></td>
<td>Inappropriate firing</td>
</tr>
<tr>
<td></td>
<td>Appropriate firing</td>
</tr>
</tbody>
</table>

*AICDs can also malfunction like PMs (see PM section above).

History

- **AICD firing**: Sudden jolt of pain
- **Premonitory sxs**: Palpitations, LH, dyspnea, CP
- **Precipitants**: Exercise, illness, noncompliance w/ antiarrhythmics, new meds

Evaluation

- ECG (ischemia, ↑ QT), CBC, Chem 7, cardiac markers, CXR

Treatment

- Treat 1°-illness, follow ACLS protocol for arrhythmia

Disposition

- Consult EP or device rep. for interrogation & reprogramming
- No firing (nl interrogation despite sxs): Look for other cause of sxs → d/c home
- Inappropriate firing (based on interrogation): Treat underlying condition; reprogram if necessary
- Appropriate firing (based on interrogation): Admit to Tele unit or CCU
  - Look for precipitants: VT, abnl electrolytes, ↑ QT, ischemia, medication noncompliance or abuse
Pearl

- If make/model # of device unknown, magnification of PA CXR will reveal device-sp code in small print.
Pneumonia

Definitions (Clin Inf Dis 2016;63(5):575–582)

- Community-Acquired PNA (CAP): Occurs out of hosp or w/i 48 h of admx; no HCAP factors
- Healthcare-Associated PNA (HCAP): a/w hosp admx (2+ d) w/i last 90 d; residence in long-term care or nursing home; immunosuppression; family member w/ MDR organism; or any of the following w/i 30 d: IV abx, HD, home wound care
- Hospital-/Vent-Acquired PNA (HAP/VAP): Occurs >48 h after hosp admx or intubation

History

- Typical CAP (eg, Strep, Klebsiella, Haemophilus): Fever/chills, SOB, CP, cough, sputum
- Atypical CAP (eg, Mycoplasma): Low-grade fever, mild/mod SOB, CP, dry cough, GI sx
- Influenza: Fevers/chills, myalgias, malaise, HA, sore throat, dry cough
- Legionella: Severe PNA in elderly; a/w hyponatremia, GI sx
- Ask about risk factors for special organisms:
  - TB: Homeless, HIV+/immunosuppressed, IVDA, incarceration, travel to endemic region; present w/ blood-tinged sputum, night sweats, fevers, weight loss
  - PCP: Poorly controlled HIV (CD4 <200, Lymph <1 k); presents w/ subacute tachypnea
  - MDR organisms: IV abx w/i 90 d, chronic HD, immunosuppression, recent influenza (risk for MRSA), CF/bronchiectasis (pseudomonas), asplenia

Physical Exam

- Fever, tachycardia, tachypnea, hypoxia, rales, decreased breath
sounds
- PNA less likely w/ nl VS & clear lungs, except in elderly, infants, immunosuppressed

- Who needs a CXR? Reserve for pts needing hospitalization, those w/ abnl VS or PEx, age extremes, concerning comorbidities, poor outpt f/u, high morbidity if PNA not detected
- CXR: Focal consolidation (typical); diffuse interstitial pattern (atypical); bat-wing pattern (PCP); hilar adenopathy, calcified or cavitary apical lesions (TB)
- CBC, Chem 7 +/- lactate (if suspecting sepsis), ABG & LDH (if PCP), BCx (if cavitory, parapneumonic eff., immunosupp/leukopenia, asplenia, liver dz, hx ETOH, failed outpt abx; ICU admx), Sputum cx (if cavitory, parapneumonic eff., hx severe lung dz, failed outpt abx, ICU admx), Influenza (in epidemics), Pneumococcal UAT (if asplenia, liver dz, immunosupp/leukopenia, parapneumonic eff.; Se 50–80%, Sp 90%), Legionella UAT (consider if recent travel, elderly, hypoNa, parapneumonic eff.; Se 80–95%, Sp 99%)

---

### Treatment


<table>
<thead>
<tr>
<th>Scenario/Etiology</th>
<th>Empiric Treatment Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAP, outpt</td>
<td>Healthy &amp; no recent abx w/i 90 d: macrolide or doxycycline Comorbidities or recent abx: resp. fluoroquinolone OR (macrolide + [amoxyclillin or amoxicillin/clav. or 2nd-gen cephalosporin])</td>
</tr>
<tr>
<td>CAP, inpt</td>
<td>Resp fluoroquinolone OR (macrolide + [ampicillin or 3rd-gen cephalosporin]) Consider pseudomonas &amp; MRSA coverage if severe (eg, ICU). Legionella is covered by macrolide or fluoroquinolone.</td>
</tr>
<tr>
<td>MDR risk factors</td>
<td>Vancomycin + (antipseudomonal PCN or 3rd-gen cephalosporin or fluoroquinolone or carbapenem). Refer to local antibiogram.</td>
</tr>
<tr>
<td>Suspect PCP</td>
<td>PaO$_2$ &gt;70: TMP-SMX DS 2 Tabs PO q8h OR (TMP 5 mg/kg PO TID + dapsone 100 mg PO QD) OR (clindamycin + primaquine) OR atovaquone. PaO$_2$ &lt;70: (TMP-SMX [15 mg of TMP component/kg] PO/IV q8h or [clindamycin + primaquine] or pentamidine) +</td>
</tr>
</tbody>
</table>
(Prednisone [40 mg BID] or methylprednisolone [40–60 IV Q6H] × 21 d); NNT for early steroids is 9 (Cochrane 2006:19; (3):CD006150).

**Aspiration PNA**
3rd-gen cephalosporin OR fluoroquinolone ± (clindamycin or metronidazole). If sick, b-lactam/b-lactamase inhibitor.

**Influenza A & B**
(BMJ 2009;339:b5106)
Oseltamivir (75 mg PO BID × 7 d), zanamivir
Tx only reduces sx by 1 d (must be given w/i the 48 h of onset)
Tx if critically ill, extremes of age, lung dz (inc. asthma), morbid obesity, immunosuppressed, pregnant

**Suspect TB**
INH 5 mg/kg PO QD + Vit B₆ 25–50 mg PO QD (neuropathy) + rifampin 10 mg/kg (max 600 mg) PO QD + pyrazinamide 15–30 mg/kg (max 2 g) PO QD + ethambutol 15–25 mg/kg (max 2.5 g) PO QD; ensure infectious dz f/u
Airborne precautions, negative pressure room

**Disposition**
- CAP/HCAP: See PNA Severity Index Score & CURB-65 (below), unless need for IV abx
- PCP: Inpt unless S_pO_2 >95% w/o desaturation on exertion
- TB: Inpt, report to Dept of Health

---

### Pneumonia Severity Index (NEJM 1997;336)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Points Assigned</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td>If male: (+age); if female, (+age – 10); nursing home resident (+10)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td>Neoplastic dz (+30); liver dz (+20); CHF (+10); cerebrovascular dz (+10); renal dz (+10)</td>
</tr>
<tr>
<td>Physical exam</td>
<td>AMS (+20); HR ≥125 (+20); RR &gt;30 (+20); SBP &lt;90 (+15); temp &lt;35°C or ≥40°C (+10)</td>
</tr>
<tr>
<td>Lab &amp; radiographic findings</td>
<td>pH &lt;7.35 (+30); BUN ≥30 mg/dL (9 mmol/L) (+20); Na &lt;130 (+20); glucose ≥250 mg/dL (14 mmol/L) (+10); HCT &lt;30 (+10); PaO₂ &lt;60 (+10); pl eff. (+10)</td>
</tr>
</tbody>
</table>

#### PORT Score (Recommended Triage and Prognosis) Calculated from PSI

<table>
<thead>
<tr>
<th>Class</th>
<th>Score</th>
<th>Mortality (%)</th>
<th>Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>&lt;50</td>
<td>&lt;1</td>
<td>Outpt</td>
</tr>
<tr>
<td>II</td>
<td>≤70</td>
<td>&lt;1</td>
<td>Outpt</td>
</tr>
<tr>
<td>III</td>
<td>71–90</td>
<td>2.8</td>
<td>Outpt/inpt (clinical judgment)</td>
</tr>
</tbody>
</table>
Pearls
- Special considerations: IVDU/endocarditis (multifocal PNA, esp b/l), malignancy (postobstructive PNA), postinfluenza (MRSA PNA), recent elective surgery (asp PNA risk increases w/ duration of anesthesia, periop NG tube, age [Arch Surg 1998;133(2):194–198])
- In severe PNA, high-flow NC (vs. NIPPV) reduces 30 d mortality, & may reduce need for intubation (esp. if PaO₂:FiO₂ < 200) (NEJM 2015;372(23):2185–2196)
- Consider social factors if discharging pt w/ PNA (eg, f/u, ability to comply w/ regimen)

Acute Bronchitis

Etiology
- Most commonly viral: parainfluenza, adenovirus, rhinovirus, coronavirus, RSV, influenza
- Atypical bacteria ~5% of cases (chlamydia p., mycoplasma, B. pertussis esp. in epidemics)

History
- Cough >5 d (dry or wet), low-grade fever, myalgias, wheezing, often after URI sx
- Consider pertussis: posttussive emesis, whoop, duration >1 wk (JAMA 2010;304(8):890)
- All-cause median duration of cough is 18 d; pertussis once called “100-day cough”

Physical Exam
- Fever uncommon (consider influenza or PNA); may have chest wall
tenderness from muscle strain; lungs often clear but up to 40% have bronchospasm/wheeze

**Evaluation**
- CXR nl or bronchial wall thickening; mild leukocytosis
- Labs/CXR not routinely needed: Reserve for abnl VS, extremes of age, comorbidities

**Treatment**
- Supportive care, antipyretics, antitussive (e.g., Tessalon Perles 100 mg TID)
  - No good evidence for or against OTC expectorants, decongestants, or antihistamines (*Cochrane Database Syst Rev* 2012;8:CD001831)
  - If wheezy or hx asthma: bronchodilator (albuterol MDI 2 puffs QID), can consider inhaled corticosteroids x 7 d (though no major data to support)
  - Abx not routinely indicated (*Cochrane Database Syst Rev* 2012;CD000245)
    - Abx reduce duration of sx by <1 day (*NEJM* 2006;355(20):2125–2130)
    - Reserved for elderly, significant comorbidities, *high suspicion for pertussis*
  - Pertussis: Azithromycin 500 mg Day 1 then 250 mg QD × 4 d OR doxycycline 100 mg BID × 7 d; Abx limit transmission but minimal effect on sx duration (unless in first wk)
  - See *PNA* section for influenza tx guidelines

**Disposition**
- Discharge home w/ PCP f/u as needed; pts will likely recover in 2–3 wk

---

**DYSPNEA (SHORTNESS OF BREATH)**

**Definition**
- Difficult or labored breathing (acute or progressive) often due to primary pulm or cardiovascular etiologies, but carries broad ddx (e.g., endo, heme, tox, neuromuscular)
- Always assess for respiratory distress: RR >24 or <8, tripoding, accessory muscle use, unable to speak in full sentences, altered
## Approach to the Patient

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Features</th>
<th>Eval</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common or Severe Cardiac Etiologies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial ischemia</td>
<td>Hx: Exertional, but UA can present at rest. Often w/ pain, N/V, diaphoresis, LH</td>
<td>EKG, troponin, +/- stress</td>
</tr>
</tbody>
</table>
| Arrhythmia  
  • Supraventricular 
  • Nonsustained VT | Hx: Can be paroxysmal or constant (AF). Sometimes w/ palpitations, CP, LH | EKG/Tele, troponin, lytes |
| Valve dz  
  • Left heart (AV, MV) 
  • Right heart (PV, TV) | Hx: Exertional, often indolent  
PE: Murmur, periph edema (RH), lung crackles (LH) | EKG, echo |
| **Common or Severe Upper Airway Etiologies** | | |
| Airway obstruction  
  • FB aspiration  
  • Epiglottitis  
  • Croup (pedi)  
  • Angioedema  
  • Abscess/hematoma | Hx: Often sudden, ask about vaccinations (epiglottitis)  
PE: Stridor, distress, pooled secretions (severe); check airway patency, neck ROM/swelling | XR chest &/or neck  
CT Neck if considering abscess or hematoma  
Laryngoscopy/bronchoscopy  
Caution w/i exam if concern for epiglottitis |
| **Common or Severe Pulmonary Etiologies** | | |
| Pulm. edema (2/2 CHF, left-sided valve dz, myocarditis, constrictive pericarditis, tamponade) | Hx: Exertional, orthopnea, PND, can have CP  
PE: Basilar crackles, LE edema/JVD (if RHF), murmur | CXR: edema, Kerley B lines, cephalization, eff.  
Lung u/s: B-lines  
BNP (insensitive in obese; *Int J Cardiol* 2014:176(3):611–617) |
| PTX (spontaneous [esp tall/thin or emphysema], traumatic, barotrauma [scuba, inh drugs]) | Hx: Acute onset, w/ CP  
PE: Unequal breath sounds & chest rise; tracheal deviation, JVD if tension | CXR: can be subtle  
Lung u/s: absent lung slide |
| Pulm embolism | Hx: Often acute, can have pleuritic CP, s/sx of DVT; consider RFs  
PE: If massive, hypotension, JVD | D-dimer if low pretest prob  
CXR: wedge infarct  
EKG: right heart strain  
Bedside echo: R heart strain  
CTA chest or V/Q scan |
| Obstructive lung dz  
  • Asthma | Hx: Chronic or acute irritants (allergens, URI, tobacco), hx | Decreased peak expiratory flow rate (PEFR) suggests |
<table>
<thead>
<tr>
<th>Condition/Description</th>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD</td>
<td>atopy; assess freq &amp; severity of exacerbations</td>
<td>obstructive etiology</td>
</tr>
<tr>
<td></td>
<td>PE: Wheezing, prolonged expiration, accessory muscles, air movement</td>
<td>CXR (prn to r/o PNA): nl or hyperinflated (COPD)</td>
</tr>
<tr>
<td>Bronchospasm (bronchitis, anaphylaxis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tracheomalacia (premature infants)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pl eff. (2/2 PNA, HF, cancer, cirrhosis, rarely other causes)</td>
<td>Hx: Slow onset, orthopnea (often due to atelectasis) PE: Diminished breath sounds &amp; fremitus</td>
<td>CXR: blunted costophrenic angle, layering Lung u/s: hypoechoic fluid Diagnostic thoracentesis (use Light’s criteria)</td>
</tr>
<tr>
<td>PNA</td>
<td>Hx: Fever, cough, +/- CP PE: Rales or rhonchi, tachypnea, tachycardia</td>
<td>CXR: +/- Infiltrate</td>
</tr>
<tr>
<td>Pneumonitis (drugs, XRT, environment exposure)</td>
<td>Hx: Fever, cough PE: Rales</td>
<td>CXR: +/- reticular or nodular opacities</td>
</tr>
<tr>
<td>Malignancy</td>
<td>Hx: Chronic cough, weight loss, hemoptysis, smoker PE: Cachexia, clubbing</td>
<td>CXR: +/- mass Low-dose CT chest</td>
</tr>
</tbody>
</table>

**Other Etiologies**

**Pathophysiology**

- Metabolic/endocrine
  - Hypermetabolic state (fever, thyrotoxicosis), metabolic acidosis from any cause w/ respiratory compensation (look for Kussmaul respirations), electrolyte derangements (Ca, Mg, P)
- Hematologic
  - Anemia (heme malignancy, hemolysis, occult bleeding)
- Toxins
  - Salicylate (respiratory alkalosis), organophosphate (bronchorrhea), CO (binds Hgb >O₂, inhibits O₂ delivery), cyanide (disrupts mitochondrial ox phosphorylation)
- Mechanical
  - Abd distension (e.g., pregnancy, massive ascites), morbid obesity
- Neuromuscular
  - Myasthenia gravis, Guillain–Barré, ALS, stroke, botulism, West Nile virus, phrenic nerve dysfxn (e.g., tumor infiltration, surgery)
- Psychogenic
  - Anxiety/panic attack, somatization disorder

**Asthma**

**Definition**
Chronic recurrent inflammatory disorder w/ airway hyperresponsiveness, bronchospasm, & reversible airway obstruction

**Clinical Features**

- Progressive wheezing, dyspnea, chest tightness, cough (esp nocturnal)
- Always assess sx frequency, severity, duration, home txs;
- Evaluate for triggers: Cold air, exercise, URI, stress, allergens, meds (NSAIDs, βBs), respiratory irritants (perfumes, smoke, detergents, dander, dust)
- Assess asthma hx: Past txs, baseline PEFR, no. ED visits/yr, admx/yr, prior intubations
Figure 2.1 Treatment algorithm. From NHBLI Expert Panel Report 3, 2007. NIH Pub no. 08–4051.

Physical Exam

- Tachypnea, tachycardia, inspiratory/expiratory wheezes, prolonged expiration, decreased or no air movement, use of accessory muscles, tripoding, cyanosis
Evaluation

- CXR: Avoid in routine exacerbations; order to r/o PNA/PTX, elderly, comorbidities
- PEFR: Compare to pt’s baseline if he/she is aware. Varies by age, gender, & height. Average adult female: 300–470; adult male: 400–660.
- ABGs are not routinely indicated to assess for severity, but normocarbia in severe asthma may be a sign of “tiring out,” impending respiratory failure.

Pearls

- MDI w/ spacer as effective as nebulizers (but harder for ill pts) (NEJM 2010;363(8):755–764)
- Medium-dose inh budesonide Rx (21 d × 600–1200 mcg/d) at d/c in addition to PO corticosteroids decreases 21 d relapse by 48% (NEJM 2010;363(8):755–764)

Chronic Obstructive Pulmonary Disease (COPD)

Definition

- Progressive incompletely reversible airflow obstruction, w/ impaired gas exchange, usually w/ smoking hx. Formal dx needs PFTs (postbronchodilator FEV\textsubscript{1}/FVC <70% predicted).
  - Mild (FEV\textsubscript{1} ≥ 80%), Mod (FEV\textsubscript{1} 50–80%), Sev (FEV\textsubscript{1} 30–50%), Very sev (FEV\textsubscript{1} < 30%)

History

- Cough (worse than baseline), increased sputum (purulence & volume), dyspnea, wheeze
- Precipitants: Cold weather (inc incidence in winter months), infxn (viral > bacterial), cardiopulmonary dz, PE (16% of acute exacerbations; Chest 2016), med changes

Physical Exam

- Chronic bronchitis (“Blue Bloater”): Cough w/ inc. sputum production; cyanotic, plethoric, not in overt resp distress; scattered rhonchi & rales
- Emphysema (“Pink Puffer”): Thin, anxious, dyspneic, tachypneic; noncyanotic, tripoding, pursed-lip exhalation (for auto-PEEP),
diminished breath sounds

**Evaluation**
- ECG for associated dysrhythmia (AF or MAT), cor pulmonale (P pulmonale: Big P in II)
- CXR to r/o PNA, PTX, eff., edema, malignancy
- Consider CTA Chest (2/3 of PEs in COPD are segmental or larger; *Chest* 2016)
- Blood gas to evaluate pH & P$_{aCO_2}$, BMP & CBC (esp if admitted)
  - If chronic resp acidosis present, compare PaCO$_2$ w/expected (calculated from HCO$_3$)
- Influenza (if epidemic), sputum cx (if severe COPD & PNA)
- Exacerbation severity: No resp failure (RR 20–30, no access muscles, no AMS, hypoxia FiO$_2$ <40%, nl P$_{aCO_2}$), Non–life-threatening acute resp failure (RR >30, +access muscles, no AMS, FiO$_2$ <40%, P$_{aCO_2}$ 50–60), Life-threatening acute resp failure (same, but +AMS, FiO$_2$ >40%, PaCO$_2$ >60 or pH ≤7.25) (*GOLD 2017 Report*)

**Treatment** (*GOLD 2017 Report*)
- Titrate supplemental O$_2$ (goal S$_p$O$_2$ 88–92%): Chronic hypoxemia inc. risk of O$_2$-induced hypoventilation (*Crit Care* 2012;16(5):323); ~2×mortality w/ high-flow O$_2$ (*BMJ* 2010;342:c5462)
- Albuterol (short-acting β-agonist): 2.5–5 mg neb q30min × 3, then q4h OR MDI w/ spacer
- Neb vs MDI (mild cases): no diff in sustained FEV$_1$ or admx (*Cochrane* 2016;(8):CD011826)
- Ipratropium bromide (anticholinergic): 0.5 mg nebulized q30min × 3 doses, then q4h (synergistic effect w/ albuterol, so give together)
- Steroids: Prednisone 40 mg PO QD (5–7 d) OR methylprednisolone (for severely ill pts)
- Abx recommended if increased sputum purulence & either increased SOB or sputum volume, OR life-threatening acute resp distress
  - Abx dec mortality 12% (NNT 8) & tx failure 31% (NNT 3) (*Cochrane* 2006;(2):CD004403)
  - Choice based on RFs (age >65, FEV$_1$ <50%, recent abx, heart dz); duration 5–7 d
- Outpt w/o RFs: Macrolide, amoxicillin, doxycycline, or TMP/SMX
- Outpt w/ RFs: Fluoroquinolone or amoxicillin/clavulanate
- Inpt: Fluoroquinolone (esp if pseudomonas RF) OR (3rd-gen cephalosporin + Macrolide)

Positive Pressure Ventilation (PPV):
- Noninvasive PPV (BiPAP): resp acidosis, severe SOB or fatigue; watch for PTX w/PPV
- Decreases mortality by 50% (NNT 8), intubation by 60% (NNT 3), tx failure by 50%, & hosp LOS by >3 d compared to usual care (Cochrane 2004;(3):CD004104)
- Invasive (intubation): Not tolerating BiPAP, impending resp failure, CV instability, AMS

Disposition
- Home: Mild sx, ambulatory $S_pO_2 > 90\%$, <Q4H bronchodilators, outpt f/u, home support
- Early f/u dec. mortality; 20% pts not back at prior baseline by 2 mo (GOLD 2017 Report)
- Admx: Incomplete tx response, sig. below baseline, mx comorbidities, severe COPD / freq. exacerbations, elderly, poor home support (Am J Respir Crit Care Med 2013;187(4):347)

Acute Respiratory Distress Syndrome (ARDS)

Berlin Definition (JAMA 2012;307(23):2526–2533)
- Acute (sx < 1 wk) diffuse inflammatory lung injury, characterized by vascular leak, edema, & diffuse alveolar damage; imaging w/ b/l opacities, not fully 2/2 cardiac failure or fluid overload; $PaO_2:FiO_2$ 200–300 (mild), 100–200 (mod), <300 (sev) w/ PEEP ≥ 5 cm $H_2O$

Pathophysiology
- Impaired gas exchange, poor compliance (stiff lungs), intrapulmonary shunt

Etiology
- Direct lung injury: PNA, aspiration, near-drowning, hydrocarbons, inhalational injury, embolism (thrombotic, fat, air, amniotic)
- Systemic: Sepsis, shock, DIC, trauma, burns, transfusion, pancreatitis, meds
Clinical Features

- Rapid progressive dyspnea (<1 wk), cyanosis, crackles, & eventual respiratory failure

Evaluation

- Dx requires ABG (PaO\textsubscript{2}:FiO\textsubscript{2} <300) & CXR w/ bilateral pulm edema
- May need TTE to r/o cardiac etiology, bronchoscopy to r/o diffuse alveolar hemorrhage

Treatment

- Supportive, focus on treating the underlying condition
- Minimize barotrauma: low TV (<6 mg/kg), keep P\textsubscript{Plat} <30
- Avoid hyperoxia: wean FiO\textsubscript{2}, maintain high PEEP to keep alveoli open.
- Avoid excess fluids: (CVP goal 4–6 cm if CVC present) (NEJM 2006;354(24):2564–2575)
- Excess volume initially may negate any subsequent benefit from conservative fluid management in ICU (Crit Care Med 2016;44(4):782–789)

Upper Airway Obstruction/Foreign Body (FB)

History

- Acute FB aspiration: May be witnessed but often hx is unclear in adults
  - RFs: Extremes of age, neuro disorders, syncope, szs, alcohol or sedative abuse
  - DDx: angioedema, infectious etiology (eg, epiglottitis), soft tissue abscess/hematoma
- Subacute (eg, malignancy, expanding goiter): Often a delayed Dx (eg, wheezing unresponsive to bronchodilators)

Physical Exam

- General appearance: May arrive cyanotic & in respiratory arrest if
total obstruction
- In breathing pt, respiratory exam depends on degree & location of obstruction: dec air movement, stridor, wheezing, secretion intolerance. Do not underestimate pt distress.

**Evaluation**
- CXR, XR neck rarely shows FB. Diagnostic & therapeutic flex bronchoscopy is standard.

**Treatment**
- If still breathing: Airway equipment, including cricothyrotomy kit, at bedside. Prepare for transfer to OR to remove FB in a controlled environment (bronchoscopy or DL).
- If not breathing: Attempt direct laryngoscopic visualization & removal of FB w/ forceps. If unsuccessful, perform surgical airway.
- If FB moves inferior to vocal cords but still occluding, push object into 1 lung by pressure from Ambu bag/ETT; once intubated, position ETT to ventilate contralateral lung.

**Disposition**
- Flex bronchoscopy successful in 90% cases (*Respir Care* 2015;60(10):1438–1448)
- If object is safely removed & pt stable, can discharge home

---

**HEMOPTYSIS**

**Definition**
- Expectoration of blood or blood-stained sputum from below the vocal cords
- “Massive” hemoptysis: no defined volume (generally >500 cc/d or >100 cc/h), but any volume inhibiting breathing should be treated similarly; high mortality 2/2 asphyxiation
- Bronchial arteries (high pressure) > pulm arteries (low pressure) > alveoli

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulm</td>
<td>COPD, CF, bronchiectasis, pulm HTN, PE, AVM, lung trauma</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------------------------------------------------------</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Pulm edema (eg, 2/2 CHF, mitral valve pathology)</td>
</tr>
<tr>
<td>Infectious</td>
<td>Acute bronchitis (#1 cause), PNA, TB, abscess, fungal infxn</td>
</tr>
<tr>
<td>Neoplastic</td>
<td>Malignancy (primary or met), carcinoid</td>
</tr>
<tr>
<td>Autoimmune</td>
<td>Goodpasture’s (anti-BM), granulomatosis polyangiitis (ANCA+)</td>
</tr>
<tr>
<td>Other</td>
<td>Recent instrumentation, tracheoarterial fistula (recent thoracic/vasc surgery), FB aspiration, inh cocaine, Osler–Weber–Rendu (telangiectasias), spontaneous (coagulopathy),</td>
</tr>
</tbody>
</table>

**Approach to Patient**

**History**
- Onset (sudden vs. progressive); quantity of blood; differentiate from GI or ENT source
- ROS: Fever, SOB, CP, weight loss, epistaxis (granulomatosis polyangiitis, coagulopathy)
- Identify hx or RFs for COPD, PE, TB, CHF, cancer, autoimmune dz, coagulopathy

**Physical Exam**
- Assess airway first, if compromised, proceed directly to stabilizing airway
- Lungs: May show signs of COPD, PNA, edema
- Cardiac: for signs of CHF or valve dz
- Skin: Evaluate for evidence of bleeding &/or telangiectasias

**Evaluation**
- Labs: CBC, PT, PTT; type & screen. Consider AFB, BNP, D-dimer, UA (Goodpasture, granulomatosis polyangiitis) based on clinical scenario
- Imaging: CXR if unstable; chest CT if stable (much more helpful); ±bronchoscopy

**Treatment**
- Airway: HOB >45°; lean to side of bleeding (if known), suction, supplemental O₂ prn
  - If intubation necessary: double suction, large-bore ETT (consider advancing ETT into unaffected lung; double-lumen ETT if skilled
operator), urgent bronchoscopy

- Definitive management: Minor hemoptysis can usually be managed conservatively, but if massive requires bronchoscopy or IR embolization, surgical resection if all else fails

Disposition

- Healthy, minimal bleeding: Get CXR; if negative: Home, outpt f/u
- High-risk pt, minor bleeding: Get CT, consider admit for observation, bronchoscopy
- Massive: ICU, consult pulmonology, interventional radiology, thoracic surgery
ABDOMINAL PAIN

Approach

- Assess nature of pain: Location, acute or chronic, constant or intermittent, relation to eating, associated sx such as fever, nausea, vomiting, dysuria, change in bowel habits
- Always ask about previous abd surgeries
- Labs depend on presentation. Consider CBC, BMP, UA, LFTs, lipase, hCG, lactate
- In the elderly, low threshold to evaluate for AAA w/ bedside US & ACS w/ EKG

<table>
<thead>
<tr>
<th>Location</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>RUQ</td>
<td>Cholelithiasis, acute cholecystitis, cholangitis, acute hepatitis, perforated duodenal ulcer, RLL pneumonia, pulmonary embolism (PE)</td>
</tr>
<tr>
<td>LUQ</td>
<td>Gastritis/PUD, splenic enlargement/rupture/infarction, LLL pneumonia, PE</td>
</tr>
<tr>
<td>Epigastric</td>
<td>Gastritis/PUD, pancreatitis, MI, myocarditis (see Cardiology), GERD</td>
</tr>
<tr>
<td>Lower Quadrants</td>
<td>Ruptured ectopic pregnancy, ovarian cyst/torsion, PID/TOA, endometriosis, kidney stone, incarcerated/strangulated hernia</td>
</tr>
<tr>
<td>RLQ</td>
<td>Appendicitis, Meckel’s diverticulum, psoas abscess</td>
</tr>
<tr>
<td>LLQ</td>
<td>Diverticulitis</td>
</tr>
<tr>
<td>Diffuse</td>
<td>Early appendicitis, mesenteric ischemia, gastroenteritis, peritonitis, AAA, SBO, large bowel obstruction/volvulus, spontaneous bacterial peritonitis, IBD, colitis, DKA, sickle cell crisis, irritable bowel syndrome, anaphylaxis, colon ischemia, constipation</td>
</tr>
</tbody>
</table>
**Biliary Etiologies**

<table>
<thead>
<tr>
<th>Dx</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholelithiasis</td>
<td>The presence of stones in the gallbladder</td>
</tr>
<tr>
<td>Biliary Colic</td>
<td>Intermittent obstruction of cystic duct or ampulla of Vater</td>
</tr>
<tr>
<td>Choledocholithiasis</td>
<td>Full obstruction of the CBD by a stone</td>
</tr>
<tr>
<td>Cholecystitis</td>
<td>Acute inflammation of the gallbladder due to obstruction in cystic duct, often a stone</td>
</tr>
<tr>
<td>Cholangitis</td>
<td>Infection of the CBD, 80% caused by stone</td>
</tr>
</tbody>
</table>

**Cholelithiasis**

**Presentation**
- Intermittent epigastric &/or RUQ pain, +N/V, a/w fatty meals
- Pain may radiate around to the back or to the R scapula
- In biliary colic, sxs generally resolve completely in b/w episodes (minutes to hours)
- Mild RUQ tenderness but no fever or Murphy’s sign
- In choledocholithiasis & cholecystitis, sxs will become constant

**Evaluation**
- Nl labs in biliary colic
- RUQ U/S spec/sens is 90–95% for stones.

**Treatment**
- NSAIDs, opiate analgesics, antiemetics; elective surgical management

**Disposition**
- If pain controlled, d/c home w/ surgery f/u to consider cholecystectomy
- If persistent pain, consider posisiblity of impacted stone in GB neck/impending cholecystitis

**Pearls**
- Acutely, biliary colic presents w/ diffuse upper abd pain before
localizing to the RUQ

- RFs for gallstones include female gender, increasing age & parity, & obesity

**Choledocholithiasis**

**Presentation**

- Biliary colic that becomes constant; late presentation may be a/w jaundice
- Mild RUQ tenderness but no fever or Murphy’s sign

**Evaluation**

- Obstructive LFT pattern, U/S shows dilated CBD >6 mm

**Treatment**

- ERCP-guided stone removal +/- cholecystectomy

**Disposition**

- Admit medicine. Usually initially managed by GI.

**Cholecystitis**

**Presentation**

- Persistent RUQ pain w/ N/V; may be accompanied by fever
- In elderly, delayed presentation w/ fever & poorly localized abd pain
- RUQ tenderness; Murphy’s sign (arrest of inspiration w/ RUQ palpation), or Sonographic Murphy’s sign (pain w/ palpation of visualized gallbladder w/ U/S probe); fever

**Evaluation**

- CBC (elevated WBC ± left shift), LFTs (may be elevated but are often nl), RUQ US: The presence of stones, thickened gallbladder wall (>3 mm), & pericholecystic fluid has a PPV of >90%, but early presentation may lack US findings
- HIDA scan: May be considered if US is equivocal; high sens/spec for GB duct obstruction

**Treatment**

- 2nd- or 3rd-generation cephalosporin (E. coli, Enterococcus, Klebsiella) broaden coverage if septic
- Surgical consult for cholecystectomy; may do percutaneous drain if poor surgical candidate
Disposition

- Admit for surgical management

Cholangitis

Presentation

- Charcot’s triad: RUQ pain, jaundice, fever (present in 70% of pts)
- Reynold’s pentad: Charcot’s triad + shock & MS changes (present in 15% of pts)

Evaluation

- Labs: ↑ WBC, ↑ LFTs, ↑ alk phos, positive blood cultures
- US/CT not very sens; can be suggestive
- ERCP is diagnostic & can be therapeutic if obstructing stone is found

Treatment

- Broad-spectrum abx for gram-negative enterics (eg, *E. coli, Enterobacter, Pseudomonas*): Piperacillin/tazobactam OR ampicillin/subtactam OR ticarcillin/clavulanate OR ertapenem OR metronidazole + (ceftriaxone OR ciprofloxacin)

Disposition

- Admission to medicine for IV abx ± ERCP w/ surgery consultation

Pearls

- 80% pts respond w/ conservative mgmt & abx w/ elective biliary drainage
- 20% require urgent ERCP biliary decompression, percutaneous drainage, or surgery
- 5% mortality

Pancreatitis


Etiology

- Alcohol (25–30%), gallstones (40–70%), idiopathic, hypertriglyceridermia (TG >1000), hypercalcemia, drugs (thiazides,
furosemide, sulfa, ACE-I, protease inhibitors, estrogen, acetaminophen, steroids), obstructive tumors, infection (EBV, CMV, HIV, HAV, HBV, coxsackievirus, mumps, rubella, echovirus), trauma, post-ERCP, ischemic

**Presentation**

- Epigastric pain radiating through to the back, nausea, vomiting
- Often h/o previous pancreatitis, alcohol abuse, gallstones
- A/w smoking, type 2 diabetes mellitus
- May be ill appearing, tachycardic, epigastric ttp, guarding, ↓ bowel sounds (adynamic ileus)

**Evaluation**

- Increased lipase >3× nl (amylase is not specific)
- If severe: ↑ WBC, ↑ BUN (>20 or rising), ↑ HCT (>44% or rising), ↑ creatinine
- CT scan: 100% spec but low sens. Not required; should be obtained only to r/o cx (acute fluid collection, pseudocyst, necrosis, abscess), esp after 24–48 h if no improvement
- Abd U/S: Used to evaluate for gallstones, CBD dilatation, or pseudocyst
- CXR: Pleural effusions & pulmonary infiltrates are a/w severe dz

**Treatment**

- Aggressive IV fluids (LR preferred); NPO initially, but early enteral nutrition if tolerated
- IV analgesia, antiemetics
- Prophylactic abx have unclear benefit; may use for severe necrotizing pancreatitis
- Delayed cholecystectomy for gallstone pancreatitis
- IR drainage for persistent or infected fluid collection,

**Disposition**

- Admission for supportive care if severe or not tolerating PO
- Atlanta criteria: In mild dz, there is absence of organ failure & local cxs, which are present in severe dz. Organ failure defined as GI bleeding, shock, PaO₂ ≤60%, creatinine ≥2.

---

**LOWER QUADRANT/PELVIC PAIN**
Appendicitis
(Lancet. 2015;386:1278)

History
- Classically, dull vague periumbilical pain → migrates to RLQ, localizes & becomes sharp
- Nausea, vomiting, anorexia, fever
- Greatest at 10–30 y of age but can occur at any time

Physical Findings
- RLQ (McBurney’s point) tenderness, localized rebound, & guarding
- Psoas sign: Pain w/ active flexion against resistance or passive extension of the right leg
- Obturator sign: Pain w/ internal rotation of the flexed right hip
- Rovsing sign: RLQ pain w/ palpation of the LLQ

Evaluation
- Labs: Leukocytosis (not sens or spec); cannot r/o w/ nl WBC. Check hCG.
- US: Less sens than CT but high spec. Consider esp in children young (thin) adults
- Abd CT (92% sens)—secondary signs of appendicitis (eg, fat stranding) less visible in thin pts
- MRI is a useful modality in pregnancy
- Alvarado score uses signs, sx & lab values to place pts in low risk (1–4 points), intermediate risk (5–6) & high risk (7–10) groups. High sens/low spec.
- In cases w/ strong clinical e/o appendicitis & low suspicion of alternate etiology, it may be reasonable to proceed to OR w/o imaging

<table>
<thead>
<tr>
<th>Alvarado Score for Acute Appendicitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>RLQ tenderness</td>
</tr>
<tr>
<td>Elevated temp &gt;99.1</td>
</tr>
<tr>
<td>Rebound tenderness</td>
</tr>
<tr>
<td>Migration of pain to RLQ</td>
</tr>
<tr>
<td>Anorexia</td>
</tr>
<tr>
<td>Nausea or vomitin</td>
</tr>
<tr>
<td>Leukocytosis &gt;10 K</td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td>Leukocyte left shift</td>
</tr>
</tbody>
</table>

**Management**

- **Abx:** Cefoxitin, cefotetan, fluoroquinolone/metronidazole, OR piperacillin–tazobactam
- **Admission to surgical service.** Traditionally surgically removed; treatment w/ abx alone a/w high readmission rate (25–30%) for surgery w/i 1 year

**Pearl**

- Pts at extremes of age are more likely to have atypical presentations & present w/ perforated appendicitis.

**Hernia**

*(NEJM. 2015;372:756)*

**Definition**

- Defect in the abd wall that allows protrusion of abd contents
- Incarcerated hernia: Cannot be reduced
- Strangulated hernia: Incarcerated hernia w/ vascular compromise (ischemia)

**History**

- Bulging mass in abd wall (eg, umbilical, epigastric), inguinal region, or scrotum, or inner thigh (femoral); worse w/ increased intraabdominal pressure
- Inguinal hernias are either direct or indirect; medial or lateral to the inferior epigastric vessels, respectively

**Physical Findings**

- Bulge &/or palpable defect in abd wall or groin
- Strangulated: Tenderness, fever, skin discoloration, or associated peritonitis

**Evaluation**

- If concern for strangulated hernia, consider CBC, lactate, pre-op labs
- CT scan required if concern for strangulated hernia

**Management**
Attempt reduction w/ generous analgesia/anxiolysis, pt in Trendelenburg
If easily reduced, d/c w/ analgesic, stool softener, & surgery f/u
If not reducible or if strangulated, consult surgery for operative intervention

Pearl
Be cautious about reducing a hernia that has been irreducible by the pt for more than 12 h & is difficult to reduce in the ED b/c bowel may be compromised.

Diverticulitis
(BMJ. 2006;332:271)

Definition
Inflammation of (colonic) diverticulum
Complicated diverticulitis: Associated perforation, obstruction, abscess, or fistula

Presentation
LLQ pain, fever, nausea, change in bowel habits, urinary sx
Mild LLQ tenderness, 50% of pts have heme-positive stool
Complicated may have peritonitis, septic shock

Evaluation
Clinical Dx if mild sx & typical presentation
Labs: Increased WBC
CT to confirm dx or if concern for complicated diverticulitis. May see pericolonic stranding, abscess or contained free air if micro perforation

Treatment
Mild: PO metronidazole + (cipro or TMP-SMX) for 7–10 days
Severe: NPO, IV fluids, IV ampicillin–sulbactam OR piperacillin–tazobactam OR ceftriaxone/metronidazole OR quinolone/metronidazole OR carbapenem
Most complicated diverticulitis can be managed medically +/- IR drainage
Surgery is required if medical therapy fails, large free air is present, or for large abscess that can’t be drained percutaneously. Elective surgery may be recommended for & recurrent dz (≥2 episodes)
Diffuse Pain

Abdominal Aortic Aneurysm

- If mild, d/c w/ abx, antiemetic, analgesia & PCP or general surgery f/u. If severe, admit.

Pearl

- Consider diverticulitis in older pts w/ urinary sx for but unremarkable or equivocal urine sediment

**Abdominal Aortic Aneurysm**


**Definition**

- Dilation of the abd aorta (true aneurysm, involves all layers of the vessel wall).

**History**

- Older pt w/ low back pain, abd pain, or flank pain (may mimic renal colic), syncope/hypotension

**Physical Findings**

- Pulsatile mass (often not present), early satiety due to duodenal compression
- Ruptured/leaking AAA: Hypotension, abd tenderness, decreased femoral pulses, mottling

**Evaluation**

- Abd CT if hemodynamically stable
- Bedside US may reveal enlarged aorta & free fluid

**Treatment**

- Stable, nonruptured: Surgical or endovascular repair required if >5.5 cm (1%/y risk of rupture if >5 cm) or rapidly growing; usually arranged as outpt
- Ruptured/leaking: Immediate surgical repair, allow permissive hypotension (SBP 90s)

**Disposition**

- Direct to OR/IR if unstable
Pearls
- Larger the AAA the greater the risk for rupture
- Rupture into RP can temporarily tamponade, intraperitoneal rupture is rapidly fatal, can also rupture into GI tract (aortoabdominal fistula)
- RFs: Smoking, HTN, hyperlipidemia, CAD, PVD, age ≥65 y, male (5×), FH
- 50% mortality for AAA if ruptured at presentation

Small Bowel Obstruction
*(Acad Emerg Med. 2013:20:528)*

**Definition**
- Mechanical obstruction of nl intestinal transit leading to proximal bowel dilation

**History**
- Diffuse, colicky abd pain, nausea/vomiting, abd distension, h/o abd surgeries/prior obstructions/hernia, obstipation (not passing gas)

**Physical Findings**
- Diffuse abd tenderness, distension, high-pitched bowel sounds

**Evaluation**
- Supine & upright abd x-rays (~75% sens): Multiple air–fluid levels, >3 cm small bowel dilation, more than 3 mm small bowel wall thickening
- Bedside US (~90% sens): >2.5-cm dilated loops of bowel, back & forth peristalsis
- Abd CT (~87% sens) can be diagnostic & used to characterize the obstruction (level, severity, cause)

**Treatment**
- NPO, bowel rest, gastric decompression w/ NGT placement
- IV fluids, analgesia, antiemetics
- Surgical consultation—most cases managed conservatively

**Disposition**
- Admission
- Direct to OR if high risk (e.g., closed-loop obstruction, impending perforation, e/o bowel ischemia)

Large Bowel Obstruction/Volvulus

**Definition**
- Mechanical obstruction of the large bowel usually caused by cancer (most commonly), volvulus (twisting of the large bowel on itself), intussusception, fecal impaction

**History**
- Insidious onset of diffuse, colicky abd pain, distention, constipation, N/V

**Physical Findings**
- Diffuse abd tenderness, distension, bowel sounds present early

**Evaluation**
- Supine & upright abd x-rays: Dilated large bowel (84% sens), but cannot identify underlying cause
- Abd CT: Can be helpful to distinguish from pseudo-obstruction

**Treatment**
- IV fluids & correction of electrolyte abnormalities
- NGT for proximal decompression
- Surgical consultation for likely operative reduction (particularly for cecal volvulus)

**Disposition**
- Surgical admission

**Pearls**
- Sigmoid volvulus most common in ill, debilitated, elderly pts, or pts w/ psychiatric/neurologic disorders
- Cecal volvulus common in young adults, classically marathon runners

---

**Perforated Viscus**
(Surgical Clin North Am. 2014;94:471)

**Definition**
- Perforation of hollow viscus leading to abd free air, intraluminal spillage

**History**
- Acute onset, severe abd pain, worse w/ movement
- May be consequence of bowel obstruction, diverticulitis, cancer, or
other primary GI pathology

Physical Findings
- Acute peritonitis: Rigidity, tap tenderness, rebound, hypotension, sepsis

Evaluation
- Supine & upright abd x-rays: May show pneumoperitoneum
- Abd CT: Definitive study but not required for operative management

Treatment
- Immediate surgical consult
- Broad spectrum abx to cover polymicrobial infection (enteric GNR, GPC, anaerobes)

Disposition
- Surgical admission

Pearl
- Findings may be masked in pts who are elderly or chronically immunosupressed

Mesenteric Ischemia

Definition
- Insufficient perfusion to the intestine
- Etiologies: arterial embolism (40–50%, typically SMA), arterial thrombosis (25–30%, a/w severe atherosclerosis), nonocclusive mesenteric ischemia (20%, low cardiac output state), mesenteric venous thrombosis (10–15%, a/w clotting disorders)

History
- RFs: Age >60, recent MI, AF, vascular dz (coronary, peripheral), CHF (↓ forward flow)
- May have h/o prior abd angina: Postprandial pain, food aversion
- Acute presentation w/ abd pain, anorexia, vomiting, bloody stools

Physical Findings
- Ill appearing, pain out of proportion to exam, tachycardia, fever, occult blood in stools. Late signs include peritonitis, shock.

Evaluation
Early surgical eval

- Labs: May see ↑ WBC, ↑ HCT, AG acidosis, ↑ lactate, ↑ amylase, ↑ LDH
- Abd x-ray: NI prior to infarction, “thumbprinting” of the intestinal mucosa later
- Abd CT: Colonic dilation, bowel wall thickening, pneumatosis of the bowel wall
- CT angiography: More sens than CT alone

**Treatment**

- IV fluids
- Broad spectrum abx
- Surgical consultation
- Anticoagulation for venous thrombosis & embolic dz
- IR for thrombolysis or embolectomy
- OR for resection of dead/nonviable gut

**Disposition**

- Surgical admission vs. IR/OR

**Pearl**

- 20–70% mortality; improved if dx made prior to infarct

**Colon Ischemia (Ischemic Colitis)**

*(Curr Gastroenterol Rep. 2015;17:45)*

**Definition**

- Nonocclusive microvascular dz of the colon, secondary to hypoperfusion & reperfusion injury

**History**

- Crampy abd pain over segment of colon involved (typically left), blood in stool, diarrhea, recent surgery, or illness

**Physical Findings**

- Tenderness over affected colon usually mild, peritoneal findings suggest perforation

**Evaluation**

- Labs: WBC, BUN, creatinine, LDH may be high but all nonspecific
- Abdominal CT: Nonspecific mesenteric fat stranding, bowel wall thickening, abnormal colon wall enhancement
Treatment
- Supportive care, bowel rest, hydration, pain management, abx for severe dz

Spontaneous Bacterial Peritonitis

Definition
- Infection of the ascitic fluid in pts w/ severe chronic liver dz

History
- Fever, abd pain, new or worsening ascites, hepatic encephalopathy

Physical Findings
- Stigmata of liver failure, diffuse abd pain, ascites

Evaluation
- Labs: ↑ Bili, ↓ platelets increase likelihood of dz. Coags, platelets prior to paracentesis
- Paracentesis: >250 PMN, blood:ascites pH gradient >0.1, culture

Treatment
- Abx: Cefotaxime 2 g IV OR levofloxacin 750 mg IV. Carbapenem if nosocomial, recent abx or long-term ppx abx.
- Albumin 1.5 g/kg at Dx & 1 g/kg for 3 d shows survival benefit

Disposition
- Medical admission

Pearls
- Caused by bacteria that translocate from gut. 70% GNR (E. coli, Klebsiella), 30% GPC (S. pneumoniae, Enterococcus)
- Occurs in 20% of cirrhotics
- Clinical signs unreliable; have low threshold for paracentesis in admitted pt w/ ascites. Delayed paracentesis >12 h a/w higher mortality. (Am J Gastroenterology. 2014;109:1436)

Inflammatory Bowel Disease (Ulcerative Colitis and Crohn’s Disease)
(Lancet. 2007;369:1641)
Definition

- Ulcerative colitis (UC): Inflammation of the colonic mucosa
- Crohn’s dz (CD): Transmural inflammation of the GI tract

### Inflammatory Bowel Disorder (Ulcerative Colitis and Crohn's Disease)

<table>
<thead>
<tr>
<th></th>
<th>Ulcerative Colitis</th>
<th>Crohn’s Dz</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical features</strong></td>
<td>Fever, bloody diarrhea, tenesmus, urgency, painful BMs</td>
<td>Fever, abd pain, diarrhea (less often bloody)</td>
</tr>
<tr>
<td><strong>GI involvement</strong></td>
<td>Exclusively colon (mostly rectal), continuous lesions limited to submucosa, friable mucosa; irregular, shallow ulcers; pseudopolyps; crypt abscesses; loss of haustral markings</td>
<td>Colon &amp; jejunum, but can extend to esophagus; transmural involvement; cobblestone mucosa; granulomas; skip lesions</td>
</tr>
<tr>
<td><strong>GI cx</strong></td>
<td>Toxic megacolon (&gt;8 cm, usually transverse colon), colon cancer</td>
<td>Strictures, fistulas, perianal dz</td>
</tr>
</tbody>
</table>

### History

- Women > men typically presents in 2nd or 3rd decade, weight loss, vomiting, abd pain/diarrhea (grossly bloody in UC) that flares w/ emotional stress, infections, withdrawal from steroids

### Physical Findings

- Diffuse abd tenderness (focal RLQ tenderness in CD), heme-positive stools 20% of pts have extraintestinal sxs, perianal dz (seen in CD); fissures, fistulas, abscess

### Common Extraintestinal Features

<table>
<thead>
<tr>
<th>Category</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arthritic</strong></td>
<td>Ankylosing spondylitis, tendinitis, arthritis</td>
</tr>
<tr>
<td><strong>Intraabdominal</strong></td>
<td>Primary sclerosing cholangitis, pancreatitis, nephrolithiasis</td>
</tr>
<tr>
<td><strong>Dermatologic</strong></td>
<td>Pyoderma gangrenosum, erythema nodosum</td>
</tr>
<tr>
<td><strong>Ophthalmic</strong></td>
<td>Uveitis, episcleritis</td>
</tr>
</tbody>
</table>

### Evaluation

- Labs: Low HCT (from chronic blood loss), increased WBC, hypokalemia (from diarrhea)
- Plain abd x-ray: If perforation, obstruction, or toxic megacolon
suspected
  ‣ Abd CT: May r/o cx (eg, abscess, obstruction, fistula)
  ‣ Outpt colonoscopy: If Dx not known & once acute flare resolved

**Treatment**
  ‣ IV fluids, bowel rest, surgical consult, steroids, ± 5 ASA agents (mesalamine, sulfasalazine)

**Disposition**
  ‣ Admit for severe dz or acute cx

### NAUSEA AND VOMITING

*(Emerg Med Clin North Am. 2011;29:211)*

**Approach**
  ‣ Common sxs of many dz processes (eg, intra-abd dz, metabolic derangements, toxic ingestions, neurologic dz)
  ‣ Careful attention to ROS, PMH, previous abd surgeries
  ‣ Labs: Consider CBC, BMP, UA, LFTs, lipase, hCG
  ‣ Treat underlying cause: Antiemetics (eg, ondansetron, promethazine), IVF if not taking PO

<table>
<thead>
<tr>
<th>Nausea &amp; Vomiting Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Abdominal/GU</strong></td>
</tr>
<tr>
<td>Obstruction (gastric outlet, small bowel, large bowel)</td>
</tr>
<tr>
<td>Infections (appendicitis, cholecystitis, pyelonephritis)</td>
</tr>
<tr>
<td>Gastroenteritis, food poisoning</td>
</tr>
<tr>
<td>Gastritis/ulcers</td>
</tr>
<tr>
<td>Ischemia, perforation</td>
</tr>
<tr>
<td>Torsion (testicular or ovarian)</td>
</tr>
<tr>
<td>-------------------------------</td>
</tr>
<tr>
<td>Kidney stones</td>
</tr>
</tbody>
</table>

**Gastroenteritis**

- **Definition:** Irritation of the GI tract causing vomiting & diarrhea usually caused by infections (viruses, bacteria, bacterial toxins, parasites) or due to medications or diet
- **History:** Vomiting & diarrhea, crampy abd pain, ±fever
- **Physical Findings:** Nl exam or mild diffuse abd ttp, tachycardia, dehydration
- **Evaluation:** Consider BMP if clinical concern for significant electrolyte derangement. Stool culture if systemically ill, fever, recent abx, exposure to treatable pathogen.
- **Management:** Supportive care, antiemetics. IVF if not taking PO. Home when tolerating PO. Abx & antimotility agents generally not indicated
- **Pearl:** Viral & bacterial toxins (food poisoning) are most common, typically resolve w/o tx in 48H

---

**GASTROINTESTINAL BLEED**

*(Emerg Med Clinics North Am. 2016;34:309)*

**Approach**

- Hemodynamically unstable pts should get 2 large-bore IVs (14–18 gauge), early transfusion of PRBC as well as FFP & Vit K if impaired coagulation
- ROS, PMH, previous GIB, alcohol use, liver dz
- Labs: CBC, BMP, LFTs, lipase, coagulation studies, lactate, type & screen. BUN/Cr ratio >30 indicates upper GI source

<table>
<thead>
<tr>
<th>GI Bleed Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location</strong></td>
</tr>
<tr>
<td>UGIB (bleeding proximal to the ligament of Treitz)</td>
</tr>
</tbody>
</table>
LGIB (bleeding distal to the ligament of Treitz) | Diverticulosis, angiodysplasia, colon cancer, ischemic bowel, IBD, infectious diarrhea, FB, Meckel’s diverticulum, anal fissure, hemorrhoids

**UPPER GI BLEED**

**Approach**
- Glasgow–Blatchford score was designed to predict need for transfusion or urgent endoscopy. A score of zero identifies low-risk pts who can safely be discharged w/outpt f/u *(JAMA 2012;307:1072; Lancet 2000;356:1318)*.

<table>
<thead>
<tr>
<th>Criteria for Glasgow–Blatchford Score of 0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
</tr>
<tr>
<td>Systolic BP</td>
</tr>
<tr>
<td>Heart rate</td>
</tr>
<tr>
<td>BUN</td>
</tr>
<tr>
<td>No melena, syncope, heart failure, or liver dz</td>
</tr>
</tbody>
</table>

**Bleeding Peptic Ulcer Disease (PUD) or Gastritis** *(NEJM. 2016;374:2367)*

**Definition**
- Inflammation or ulceration of the stomach or duodenal lining caused primarily by *H. pylori* infection, NSAIDs, (15–30%), alcohol

**History**
- Bloody or coffee ground emesis; dark, tarry stool

**Physical Findings**
- Epigastric tenderness, melena or heme-positive stool

**Evaluation**
- Labs: CBC, LFTs, coagulation panel, elevated BUN; *H. pylori* serology (90% sens)
- NG tube not routinely indicated

**Treatment**
- IVF resuscitation, PRBC if Hgb <7 or hypotensive, IV proton pump inhibitor ↓ need for endoscopic therapy but does not ↓ bleeding or mortality
- Emergent EGD if hemodynamically unstable

**Disposition**
- If ongoing bleeding, Blatchford >0, high risk: Admit for EGD

**Variceal Bleeds**
*(Hepatology. 2007;46:922)*

**History**
- Bright red hematemesis, diffuse abd pain, nausea, h/o portal hypertension

**Physical Findings**
- Stigmata of liver failure (jaundice, spider angiomas, ascites, caput medusae), Ill-appearing hypotension, tachycardia, melena

**Evaluation**
- Labs: CBC, LFTs, coagulation panel, type & cross

**Treatment**
- Place 2 large bore IVs, initiate IV fluid resuscitation, PRBC if Hgb <7 or active bleeding
- Octreotide bolus & drip; IV PPI
- Antibiotic prophylaxis (ceftriaxone or levofloxacin) increases survival
- Emergent EGD if hemodynamically unstable, may need emergent TIPS if still bleeding
- Balloon tamponade w/ Minnesota or Blakemore tube if exsanguinating (after intubation)

**Disposition**
- Usually ICU admission, pts can decompensate quickly

**Mallory–Weiss Tear**

**Definition**
- Tears in the mucosal membrane of the distal esophagus caused by vomiting. A/w heavy alcohol use.

**History**
- Specks of bright red blood in emesis or mild hematemesis after
forceful retching

**Physical Findings**
- Most have no physical findings, mild tachycardia

**Evaluation**
- Upright CXR if hemodynamically unstable to evaluate for subcutaneous or mediastinal air for Boerhaave syndrome (complete esophageal rupture)

**Treatment**
- Antiemetics, PO challenge

**Disposition**
- D/c w/ outpt EGD

**Pearl**
- Boerhaave syndrome can result from emesis but usually pts are ill-appearing w/ shock & require surgical management. Consider watersoluble swallow study if high suspicion.

**Aortoenteric Fistula**

**Definition**
- Fistula b/w the aorta & GI tract, most commonly in duodenum

**History**
- H/o AAA, aortic graft (usually >5 y), may have sentinel bleed or large-volume GIB

**Physical Findings**
- Rapid GIB, hemodynamic collapse

**Evaluation**
- CBC, type & cross, emergent surgical consult, CT scan if stable

**Treatment**
- IV fluid resuscitation, PRBC if indicated
- Surgical repair

**Disposition**
- Surgical ICU admission

**Pearl**
Mortality directly related to time to the OR

**Lower GI Bleed**

*Crit Care Clin. 2016;32:241*

**Diverticular Bleeding**
- **History**: Painless bright red rectal bleeding often initiated by urge to defecate
- **Physical Findings**: NL abd exam, BRBPR, no etiology found on rectal exam
- **Evaluation**: Labs: CBC, LFTs, coagulation panel, type & cross
- **Treatment**: Usually self-limited. IV fluid resuscitation, PRBC if indicated
- **Disposition**: Admit for colonoscopy

**Colorectal Cancer**

**History**
- Chronic blood in stool, change in bowel habits, anorexia, weight loss, light-headedness

**Physical Findings**
- Pale, heme occult positive stools

**Evaluation**
- Labs: CBC, LFTs, coags; CT if concern for obstruction or significant bleeding

**Treatment**
- IV fluid resuscitation, PRBC if indicated
- Surgical consultation if significant bleeding (rare)

**Disposition**
- If stable, d/c for outpt colonoscopy/oncology w/u

**Colonic Angiodysplasia**
- **Definition**: Enlarged, fragile blood vessels, usually in cecum or proximal ascending colon (10–20% of LGIB)
- **History**: >60 y/o, small frequent bleeds. Usually coagulopathy or NSAID use precipitates bleed.
Physical Findings: nl abd exam, BRBPR, or heme occult positive stools
Evaluation: CBC, coagulation panel
Treatment: IV fluid resuscitation, PRBC if indicated; endoscopic cautery or IR embolization
Disposition: Admit for observation & colonoscopy

DIFFICULTY SWALLOWING

(Nat Rev Gastroenterol Hepatol. 2015;12:259)

Definition
- Dysphagia is difficulty swallowing, odynophagia is pain w/ swallowing

Approach
- Nature: Time course, sudden or progressive, localization (oropharyngeal vs. esophageal)
- ROS, PMH, hx, or FH of GI disorders or neurologic disorders
- Labs: CBC, BMP
- Studies: Barium swallow or EGD for structural/mechanical lesions; motility studies

<table>
<thead>
<tr>
<th>Dysphagia Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysphagia</td>
</tr>
<tr>
<td>Solids (mechanical obstruction)</td>
</tr>
<tr>
<td>Solids &amp; liquids (motility disorder)</td>
</tr>
<tr>
<td>Odynophagia</td>
</tr>
</tbody>
</table>

Esophageal Food Impaction/Foreign Bodies

Definition
- Food or FB stuck in esophagus (70% lodge at the lower esophageal
sphincter)

History

- Sensation of food (often meat) or FB stuck in the esophagus, retching, unable to swallow secretions. A/w esophageal stricture, esophageal ring, or eosinophilic esophagitis

Physical Findings

- Odynophagia, neck or chest pain, respiratory distress, drooling, retching

Evaluation

- CXR (may show dilated esophagus w/ air–fluid level or FB)

Treatment

- Airway management
- Historically glucagon given however no data to support its use. Effervescents, benzos are also often used.
- Endoscopy if a dangerous object is present (batteries, sharp object), or FB doesn’t pass w/i 12–24 h

Disposition

- If tolerating PO, d/c w/ outpt EGD

---

**DIARRHEA**

*(Emerg Med Clin North Am. 2011;29:211)*

**Definition**

- Frequent, watery stools. Specifically, >3 loose stools/d OR >200 g stool/d.
- Acute ≤14 d, persistent 14–30 d, chronic >30 d

**Approach**

- Nature: Bloody, mucus present, duration, frequency, volume; recent travel or abx
- Labs: Consider BMP for electrolyte derangement; consider CBC, LFTs, heme occult
### Causes

<table>
<thead>
<tr>
<th>Infectious</th>
<th>Differential</th>
</tr>
</thead>
</table>
| **ACUTE**  | Viruses: Norovirus, rotavirus, adenovirus, CMV  
Preformed toxins (food poisoning <24 h): *S. aureus, B. cereus*  
Toxins formed after colonization: *E. coli* (ETEC), *C. difficile, C. perfringens*  
Invasive bacteria (generally +fecal WBC, +blood): *E. coli* (EIEC, EHEC), *Salmonella, Shigella, Campylobacter, Yersinia, V. parahaemolyticus*  
Parasites: *Giardia* (−blood), *E. histolytica* (+blood) |

| **CHRONIC** | *Giardia, E. histolytica, C. difficile* |

| Medications | Abx, antacids, lactulose, sorbitol, chemotherapy, colchicine, gold |
| Inflammatory | IBD, radiation enteritis, ischemic colitis, diverticulitis |
| Malabsorption | Bile salt deficiency (cirrhosis, cholestasis, ileal dz, bacterial overgrowth), pancreatic insufficiency, mucosal abnormalities (celiac sprue, tropical sprue, Whipple dz), lactose intolerance |
| Secretory | Hormonal (VIP, carcinoid tumor, medullary cancer of the thyroid, Zollinger–Ellison, glucagon, thyroxine), laxative abuse, neoplasm |
| Motility | IBS, scleroderma, hyperthyroidism, diabetic autonomic neuropathy |

---

**Infectious Diarrhea**  
(*NEJM. 2014:370:1532*)

**History**

- Diarrhea ± blood/fever, recent ingestion of meats/poultry/dairy/shellfish/sea food/unrefrigerated food, sick contacts, recent travel (last 6 mo), antibiotic use
- Invasive bacterial enteritis is a clinical Dx: Fever, blood in stool,
tenesmus, abd pain

**Physical Findings**
- Dehydration, mild abd tenderness. If invasive: Heme-positive stool, fever.

**Evaluation**
- Labs: Increased WBC (*Salmonella*), low WBC (*Shigella*), eosinophilia (parasites) hypokalemia, metabolic acidosis
- Stool culture, fecal WBC & O&P appropriate if ill appearing, severe diarrhea, extremes of age, chronic, or immunocompromised

**Treatment**
- IV fluid resuscitation if needed, electrolyte repletion
- Abx: TMP-SMX, ciprofloxacin or azithromycin (recent travel, ill appearing, fever, immunocompromised), OR metronidazole (*C. difficile, Giardia, E. histolytica*)
- Antimotility agents may be used for traveler’s diarrhea
- Constipating diet (BRAT: Bananas, rice, applesauce, toast) for a short time

**Disposition**
- Admit if unable to keep up w/ volume loss or toxic

**Pearl**
- Significant abd pain in not common & should be evaluated further

<table>
<thead>
<tr>
<th>Diarrhea Epidemiology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathogen</strong></td>
</tr>
<tr>
<td>Norovirus</td>
</tr>
<tr>
<td><em>Campylobacter</em></td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
</tr>
<tr>
<td><em>Giardia</em></td>
</tr>
<tr>
<td>Enterotoxigenic <em>Escherichia coli</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diarrhea Pathogen Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathogen</strong></td>
</tr>
<tr>
<td><em>Campylobacter</em></td>
</tr>
<tr>
<td>Pathogen</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>RFs: Day care, food (dairy, meats, poultry), exposure to young dogs &amp; cats, summer months</td>
</tr>
<tr>
<td>RFs: Food (dairy, meats, eggs), exposure to turtles, comorbidities</td>
</tr>
<tr>
<td>Duration up to 1 mo.</td>
</tr>
<tr>
<td>Enterohemorrhagic Escherichia coli</td>
</tr>
<tr>
<td>Enterotoxic Escherichia coli</td>
</tr>
<tr>
<td>Enterohemorrhagic Escherichia coli</td>
</tr>
<tr>
<td>Duration 1 d.</td>
</tr>
<tr>
<td>Duration 5–7 d.</td>
</tr>
</tbody>
</table>
Entamoeba
Duration 7–14 d. No fever, vomiting, no abd pain.
RFs: Contaminated water
Cx: Liver abscess

Irritable Bowel Syndrome
(BMJ. 2015;350:h1622)

Definition: Disorder of the colon: Causes cramping, bloating, diarrhea, constipation (F > M)
History: Recurrent abd pain >3 d/mo over the last 3 mo. Plus 2 or more of the following: Improvement w/ defecation, onset w/ change in frequency of stools, onset w/ change in form of stools. No constitutional sx.
Physical Findings: May have mild lower abd tenderness, heme-negative stools
Treatment: Fiber for constipation, antimotility for diarrhea, antispasmodics (Bentyl) for pain
Disposition: D/c, outpt management
Pearl: Dx of exclusion. Unlikely if age of onset >35 or associated constitutional sx.

CONSTIPATION
(JAMA. 2016;315:185)

Definition
› Reduced frequency of stool (<3/wk), &/or difficult passage of hard stool

Approach
› Nature: Duration, severity, character of stool, pain, fever, medication use, prior episodes

<table>
<thead>
<tr>
<th>Constipation Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Etiology</strong></td>
</tr>
<tr>
<td>Functional</td>
</tr>
</tbody>
</table>
Obstruction | Cancer, stricture, rectal FB
---|---
Medication | Opiates, anticholinergics, iron, CCBs, AEDs, antidepressants
Neurologic | Parkinson’s, MS, spinal cord lesion, stroke
Metabolic | DM, hypothyroid, hypokalemia, panhypopituitary, hypercalcemia, pregnancy

**Simple Constipation (Including Stool Impaction)**

**History**
- Poor diet, decreased fluid/fiber intake, decreased mobility, constipating medications

**Physical Findings**
- Firm stool in the rectal vault, palpable stool on abd exam, minimal abd ttp

**Evaluation**
- Abd x-ray or CT if need to r/o obstruction, or to confirm dx in high-risk pt

**Treatment**
- Manual disimpaction if needed
- Colace, magnesium citrate, enema (esp in elderly), bisacodyl (oral or suppository)
- Natural bulking agents (Metamucil) when constipation resolves

**Disposition**
- Home

**Rectal Foreign Body** *(Surgical Clin of North Am. 2010;90:173)*

**Physical Findings**
- FB in rectum on exam or anoscopy, peritonitis if perforation

**Evaluation**
- Abd x-ray to eval location/shape & presence of pneumoperitoneum

**Treatment**
- Removal w/ forceps traction while the pt bears down. Impacted object may cause proximal vacuum suction; can pass foley around object to break vacuum seal & use balloon to pull back on object.
- Removal in OR if unsuccessful or if sharp object w/ risk of
perforation

Disposition
- Home if removed

Pearl
- Procedural sedation may be needed to sufficiently dilate anus to remove FB in ED

---

**JAUNDICE**

*(Prim Care. 2011;38:469)*

**Definition**
- Yellowing of the skin as a result of elevated bilirubin (>3 mg/dL)

**Approach**
- Duration, associated pain, fever, recent travel, h/o liver dz or alcohol abuse
- Labs: CBC, BMP, UA, LFTs, lipase, ±ammonia if MS changes, paracentesis if ascites

---

<table>
<thead>
<tr>
<th>Jaundice Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperbilirubinemia</td>
</tr>
<tr>
<td><strong>Prehepatic:</strong></td>
</tr>
<tr>
<td>Increased bilirubin production or impaired conjugation</td>
</tr>
<tr>
<td><strong>Hepatocellular</strong></td>
</tr>
<tr>
<td>Intrahepatic (nonobstructive):</td>
</tr>
<tr>
<td>Intrahepatic (nonobstructive): Impaired excretion of conjugated bilirubin</td>
</tr>
</tbody>
</table>

| Extrahepatic (obstructive): | Conjugated (direct) | Cholecystitis, choledocholithiasis, cholangitis, pancreatitis, carcinoma (ampulla, gallbladder, pancreas, CBD), biliary stricture (postsurgical), sclerosing cholangitis |
| Extrahepatic (obstructive): Impaired excretion of conjugated bilirubin | Conjugated (direct) | Cholecystitis, choledocholithiasis, cholangitis, pancreatitis, carcinoma (ampulla, gallbladder, pancreas, CBD), biliary stricture (postsurgical), sclerosing cholangitis |

### Viral Hepatitis

<table>
<thead>
<tr>
<th>Dz</th>
<th>Transmission</th>
<th>Serologic Pattern</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis A</td>
<td>Fecal–oral, contaminated food/water</td>
<td>Acute: IgM anti-HAV Prior: IgG anti-HAV</td>
<td>Incubation 2–6 wk, self-limiting, tx is supportive</td>
</tr>
<tr>
<td>Acute Hepatitis B&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Blood, sex, perianal</td>
<td>IgM anti-HBc: Acute HBeAg: Active infection HBsAg: May appear before sxs</td>
<td>Incubation 1–6 mo, 70% acute infections subclinical, 30% jaundice, 1% fulminant failure, acute tx is supportive, &lt;10% persist to chronic hepatitis B</td>
</tr>
<tr>
<td>Chronic Hepatitis B&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Blood, sex, perianal</td>
<td>IgG anti-HBc</td>
<td>Major cause of hepatocellular cancer (10–390 × increased risk), tx: INF-α-2b, PEG INF-α-2b, lamivudine, adefovir, telbivudine, entecavir</td>
</tr>
<tr>
<td>Acute Hepatitis C</td>
<td>Blood, sex</td>
<td>HCV viral load</td>
<td>Incubation 2 wk–5</td>
</tr>
</tbody>
</table>
### Cirrhosis


#### Definition
- Fibrosis & nodular regeneration resulting from hepatocellular injury
- Major etiologies include viral hepatitis (esp HCV), alcoholism, nonalcoholic steatohepatitis

#### History
- Abd pain, jaundice, pruritus, abd distension

#### Physical Findings
- Liver: Enlarged palpable liver or shrunken nodular
- Signs of liver failure: Jaundice, spider angioma, palmar erythema, gynecomastia, asterixis, encephalopathy
- Signs of portal HTN: Splenomegaly, ascites, caput medusae

#### Evaluation
- New onset: LFTs, BMP, CBC (for anemia, thrombocytopenia), INR

---

<table>
<thead>
<tr>
<th>Disease</th>
<th>Mode of Transmission</th>
<th>Marker</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic Hepatitis C</td>
<td>Blood, sex</td>
<td>HCV &amp; anti-HCV</td>
<td>Major cause of cirrhosis (20–30%), 2–3% of cirrhotics develop HCC, tx: PEG INF-α-2b + ribavirin</td>
</tr>
<tr>
<td>Hepatitis D</td>
<td>Blood, sex</td>
<td>Anti-HDV</td>
<td>Exists only in association w/ hepatitis B, faster progression to cirrhosis</td>
</tr>
<tr>
<td>Hepatitis E</td>
<td>Fecal–oral (travel)</td>
<td>IgM anti-HEV</td>
<td>Self-limiting, mortality 10–20% in pregnancy</td>
</tr>
</tbody>
</table>

---


---

**Cirrhosis**

**Definition**
- Fibrosis & nodular regeneration resulting from hepatocellular injury
- Major etiologies include viral hepatitis (esp HCV), alcoholism, nonalcoholic steatohepatitis

**History**
- Abd pain, jaundice, pruritus, abd distension

**Physical Findings**
- Liver: Enlarged palpable liver or shrunken nodular
- Signs of liver failure: Jaundice, spider angioma, palmar erythema, gynecomastia, asterixis, encephalopathy
- Signs of portal HTN: Splenomegaly, ascites, caput medusae

**Evaluation**
- New onset: LFTs, BMP, CBC (for anemia, thrombocytopenia), INR
(to evaluate synthetic function), abd US if pain, tenderness, or fever present to r/o acute biliary dz or if concern for Budd–Chiari, paracentesis if new-onset ascites

- Exacerbation/decompensation of known cirrhosis: CBC, BMP, INR, ammonia. Paracentesis to r/o SBP if fever, abd pain, new hepatic encephalopathy, GIB, significant leukocytosis.

**Treatment**

- Directed at treating cultures
- Hepatic encephalopathy (failure of liver to detoxify ammonia & other agents): Protein restriction, lactulose (goal 2–4 stools/d)

**Disposition**

- Admit if decompensated (increasing ascites/edema despite compliance w/ outpt regimen), pulmonary edema, renal failure, hypotensive, encephalopathic, febrile

**Pearl**

- Cxs: Portal HTN (ascites, varices), encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome, infections (relative immunosuppression), HCC

### Acute Liver Failure

*(NEJM. 2013;369:2525)*

**Definition**

- Acute hepatic dz often w/ coagulopathy & encephalopathy
- Fulminant liver failure is when encephalopathy occurs <8 wk since onset of 1st sx
- Etiologies: Viral hepatitis (A, B, E), drugs (acetaminophen), acute ischemic injury in critically ill pts, neoplastic infiltration, acute Budd–Chiari, mushroom ingestion, Wilson’s dz

**History**

- Abd pain, jaundice, toxic ingestion, nausea, vomiting, malaise, confusion

**Physical Findings**

- Jaundice, abd tenderness, enlarged liver, encephalopathy, pulmonary edema, GIB (decreased clotting factors, DIC)

**Evaluation**
Labs: CBC (anemia, thrombocytopenia), PT/INR, BMP (electrolytes, renal function), acetaminophen level, viral serologies

**Treatment**
- Treat underlying causes (eg, acetaminophen w/ NAC)
- If etiology unclear have low threshold for NAC regardless of acetaminophen level
- Abx: Broad-spectrum (Vancomycin + 3rd-generation cephalosporin)
- Coagulopathy/GIB: Vit K, FFP, platelets, cryoprecipitate if active hemorrhage
- Cerebral edema: Consider ICP monitoring, hypertonic saline/mannitol, avoid fever
- Transplantation improves survival but not universally available

**Disposition**
- Admit medicine. ICU if fulminant, hypotensive, or otherwise unstable.

---

**RECTAL PAIN (PROCTALGIA)**

*(Medical Clin of North Am. 2014;98:609)*

**Approach**
- Nature: Duration, consistency of stools, bleeding, fevers

<table>
<thead>
<tr>
<th>Proctalgia Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bleeding</strong></td>
</tr>
<tr>
<td>Cryptitis (inflammation of epithelial pockets), hemorrhoids, anal fissure, proctitis (inflammation of the rectal mucosa)</td>
</tr>
<tr>
<td><strong>No bleeding</strong></td>
</tr>
<tr>
<td>Anorectal abscess, anal fistula, anorectal FB, proctalgia fugax (idiopathic severe brief rectal pain), pilonidal dz</td>
</tr>
</tbody>
</table>

**Anal Fissure**
- **Definition:** Superficial tear of the anoderm that begins just below the dentate line
- **History:** H/o passage of hard stools, sharp pain w/ defecation, blood on toilet paper
- **Physical Findings:** Visible fissure, painful. If not midline, eval for cancer, HIV, IBD, STDs.
Management: Sitz baths (warm baths 15 min 3×/d), high-fiber diet, lidocaine jelly, topical nitroglycerin ointment, topical diltiazem gel

Hemorrhoids
Definition
- Dilated or bulging veins of the rectum & anus. Internal hemorrhoids may prolapse & become incarcerated (irreducible) or strangulated (ischemic).

History
- Bright red-coated stool/toilet paper/dripping into the bowl, pain w/ defecation, h/o hard stools, constipation, prolonged sitting

Physical Findings
- External hemorrhoids are visible on eversion of the anal orifice, internal hemorrhoids may be palpable & are only visible w/ anoscopy

Evaluation
- CBC only if significant blood loss suspected or concerning underlying condition

Management
- Outpt w/ stool softener (Colace, Senna), Sitz baths (15 min TID & after BMs), suppositories for symptomatic relief
- Acute thrombosis (<48 h since onset of pain) can be excised at bedside in ED
- If prolapsed hemorrhoid is incarcerated w/ signs of strangulation, consult surgery

Pearl
- Hemorrhoidal bleeding rarely a cause of significant anemia
FEVER

Background
- Temp >100.4°F/38°C
- Caused by response to bacteria, viruses, inflammation; ↑ metabolic rate, meds
- Distinct from hyperthermia (caused by exogenous factors)

Approach
- Careful hx: COLDER, associated sxs (N/V, diarrhea, cough, abd pain, rash, AMS)
- Eval directed by pt hx & sx localization
- Assess VS for significant abnormalities that may indicate serious infection (↓ BP, ↑ HR)
- If immunosuppressed (HIV/AIDS, elderly, malnourished, chronic steroids, DM) or neutropenic, more intensive eval & testing: CBC, Chem, UA & cx, CXR; consider blood cx & admission
- Intermittent/relapsing fever, FUO, or occurring after foreign travel: Consider travel-related infectious etiologies, endocarditis

| Fever Differential
<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac</td>
<td>Endocarditis, myocarditis (1j)</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>Pneumonia (2b), bronchitis (2b), empyema, TB (2b), PE</td>
</tr>
<tr>
<td>GI</td>
<td>Intra-abd abscess, cholangitis (3a), diverticulitis (3a), appendicitis (3a), hepatitis (3g), cholecystitis</td>
</tr>
<tr>
<td>GU</td>
<td>UTI (6a), pyelonephritis (6b), PID (7e)</td>
</tr>
<tr>
<td>Neurologic</td>
<td>Meningitis (5d), subarachnoid hemorrhage, TBI, dysautonomia</td>
</tr>
<tr>
<td>ENT</td>
<td>Pharyngitis (13b), sinusitis (13), otitis</td>
</tr>
<tr>
<td>Toxicology</td>
<td>Neuroleptic malignant syndrome (10l), malignant hyperthermia (10l)</td>
</tr>
</tbody>
</table>
Environmental
- Hyperthermia (10k), drug-induced, vector-borne & zoonotic diseases (4h), parasitic infections (4l), Rocky Mountain spotted fever (8a)

Infectious
- Mononucleosis (4f), TB (2b), HIV (4g), rheumatic fever, viral infections (4f)

Hematologic
- DVT (1b), PE (1b), sickle cell (11e)

Orthopedic
- Osteomyelitis (19k), septic arthritis (12c)

Oncologic
- Malignancy (11), neutropenic fever, tumor lysis syndrome

Immunologic
- Autoimmune, Mediterranean fever, vasculitis, sarcoid

---

**ENDOCARDITIS**

*(NEJM. 2013;369:785)*

**History**
- RFs: IVDU, congenital or acquired valvular dz, prosthetic valves, structural heart dz, HD, indwelling venous catheters, cardiac surgery, bacteremia, HIV, previous endocarditis
- Dx difficult 2/2 nonspecific sx (lethargy, weak, anorexia, low-grade temp), or negative w/u

**Findings**
- Fever (80%), new murmur (48%), CHF, splenomegaly (11%), petechiae
- Classic physical exam findings
  - Roth spots (2%): Exudative, edematous retinal lesions w/ central clearing
  - Osler nodes (3%): Violaceous tender nodules on toes & fingers
  - Janeway lesions (5%): Nontender, blanching, macular plaques on soles & palms
  - Splinter hemorrhages (8%): Nonblanching, linear, reddish-brown under nails
  - Septic emboli (mitral valve vegetations)

**Diagnosis**

---

**Modified Duke Criteria**
Classification | Requirements for Dx
--- | ---
**Definite** | Microorganism on culture or histology of vegetation/cardiac abscess
OR
Clinical criteria: 2 major, 1 major & 3 minor, or 5 minor
---
**Possible** | 1 major & 1 minor, or 3 minor
---

**Criteria** | **Evidence**
--- | ---
**Major** | ≥2 positive blood cultures, endocardial involvement, vegetation, new valvular regurgitation
---
**Minor** | Predisposing cardiac dz, IVDU, or other RFs, fever, vascular phenomena (septic infarcts, ICH, Janeway lesions), immune phenomena (glomerulonephritis, Osler’s nodes, Roth’s spots, RF), positive blood culture not meeting major criteria
---

**Evaluation**
- EKG, CBC, Chem, coags; CXR, ↑ ESR/CRP (nonspecific), at least 3 sets blood cx
- Typically *Staph aureus* or *Strep* species, also *Enterococcus, Candida* (prosthetic). Up to 10% never have organism identified
- Echo for vegetations or valve ring abscesses; TEE more sens than TTE

**Treatment**
- Hemodynamic stabilization if valve rupture, can present w/ acute pulm edema cultures
- Immediate abx in suspected cases, preferably after blood cultures (see table)

**Disposition**
- Admit w/ continuous telemetry & IV abx, ICU if hemodynamic compromise

**Pearls**
- Infection of endothelium of heart (including but not limited to valves)
- Consider cardiac surgery consultation for heart failure, uncontrolled infection or prevention of embolic events
- Mortality w/ native valve dz: ~25%; prosthetic valve higher
  - Worse prognosis if involves aortic valve, DM, *S. aureus* (30–40%)
- Left-sided endocarditis (mitral 41%, aortic valve 31%) most common
- IVDU: Tricuspid valve endocarditis; rheumatic valve dz: Mitral, then aortic valve

### Antimicrobial Treatment of Bacterial Endocarditis

<table>
<thead>
<tr>
<th>Hx</th>
<th>Antibiotic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Native valve</td>
<td>Ampicillin-sulbactam 3 g IV q6h or Amoxicillin-clavulanate 3 g IV q6h + gentamicin 1 mg/kg IV q8h Vancomycin 15 mg/kg IV BID + gentamicin 1 mg/kg IV q8h + ciprofloxacin 400 mg IV BID (for patients allergic to beta-lactams)</td>
</tr>
<tr>
<td>Prosthetic valve (&lt;12 mo post-op)</td>
<td>Vancomycin 15 mg/kg IV BID + gentamicin 1 mg/kg IV q8h + rifampin 600 mg PO BID</td>
</tr>
<tr>
<td>Prosthetic valve (≥12 mo post-op)</td>
<td>Same as native valve</td>
</tr>
</tbody>
</table>

### ABSCESS

**Approach**
- ↓ activity of infiltrated local anesthetic agents b/c of the low pH of abscess area; consider regional nerve or field blocks + IV procedural sedation/analgesia
- Gram stain & wound cx rarely necessary for skin or perirectal abscesses
- Cx from intra-abd, spinal, or epidural abscesses usually sent from OR to guide therapy
- Pharyngeal abscess cx can also help tailor antibiotic therapy
- In diabetic, immunocompromised, w/ systemic sx, septic, obtain labs & blood cultures, start IVF & abx & admit for IV abx

### SOFT TISSUE

**Cutaneous Abscess**

(*NEJM*. 2014;370:1039)
History
- ↑ pain, tenderness & induration, usually w/o h/o fever or systemic tox
- Disruption of skin from trauma or penetrating injury, often pt cannot recall injury
- H/o IVDA/skin popping, prior MRSA abscesses

Findings
- Exquisitely tender, soft, fluctuant mass surrounded by erythema
- Most commonly *Staph* species, often polymicrobial

Evaluation
- Blood work rarely needed unless appear systemically ill; US may help w/ localization
- Culture from abscess only if tx w/ abx, severe infection, systemic illnesses, failed initial tx

Treatment
- Traditionally no abx indicated in healthy hosts unless cellulitis, systemic illness, immunosuppression, failed I&D. However, RCT of 1247 pts showed higher cure rate (80.5% v 73.6%) as well as lower rates of subsequent I&Ds, skin infections at new sites & infections in household members. (*NEJM.* 2016;374:823)
- I&D w/ regional nerve or field block ± procedural sedation
  - Create elliptical incision to prevent premature wound closure, deep enough to drain cavity. Follow tension lines to minimize scarring.
  - Break up loculations in abscess cavity w/ hemostat
  - Consider packing w/ 1/4-in gauze × 48 h (24 h if cosmetically important) for large abscesses
- Tx cellulitis if indicated (see *Cellulitis* section below)

Disposition
- D/c w/ wound care instructions, 2-d f/u
- Warm soaks TID × 2–3 d after removal of packing to allow continued wound drainage

Pearls
- Can develop essentially anywhere: Furuncle, acne, skin breakdown, insect bites
- Routine packing of abscesses after I&D is controversial
**Paronychia**  
*(J Hand Surgery. 2012;37:1068)*

**History**
- Pain & swelling lateral to nail edge; abscess beneath eponychial fold
- Usually secondary to contaminated nail care instruments, hang nail, or trauma

**Findings**
- Purulent collection lateral to nail bed w/ minimal surrounding erythema
- Most commonly *S. aureus*, *S. pyogenes*, *Pseudomonas* or *Proteus*.

**Evaluation**
- No labs necessary

**Treatment**
- Oral antibiotics (cephalexin, clindamycin, amoxicillin + clavulanate) may be used
- Digital block w/ 1% lidocaine with or without epinephrine in each web space of affected digit
- #11 blade scalpel to lift cuticle from nail on affected side & express purulent material

**Disposition**
- D/c w/ wound care instructions, 2 d f/u
- Warm soaks to finger TID × 2–3 d to allow complete drainage

**Pearls**
- Often h/o manicure/pedicure, nail biting
- If recurrent or chronic paronychia, consider *Candida* infection
- May spread to pulp space of finger (felon) or deep spaces of hand, tendon if neglected

---

**Pilonidal Cyst**  

**History**
- Painful, tender abscess in midline pit between upper part of the gluteal clefts, often in obese or hirsute individuals
- More prevalent in males; fever & systemic tox very rare

**Findings**
Painful, localized abscess in natal cleavage/midline sacrococcygeal region, 4–5 cm posterior to anal opening; surrounding erythema & fluctuance
- Mixed flora: *Staph* or *Strep* species, anaerobic cocci, mixed aerobic & anaerobic flora

**Evaluation**
- No labs necessary unless systemically ill

**Treatment**
- Same as for cutaneous abscess, I&D
- Antibiotics if overlying cellulitis, immunosuppressed or systemically ill
- Surgical referral for excision of follicle & sinus tract after acute episode subsides

**Disposition**
- D/c w/ wound care instructions, 2-d wound care f/u

**Pearl**
- Thought to be caused by hair penetrating into subcutaneous tissues creating abscess

**Bartholin Gland Cyst/Abscess**

**History**
- Severe localized pain in labia caused by obstructed Bartholin duct
- Difficulty walking & sitting secondary to pain
- Fever & signs of systemic tox are rare

**Findings**
- Painful, tender, cystic mass on inferior lateral margin of vaginal introitus, often w/ purulent drainage from sinus tract
- Typically mixed vaginal flora (*Bacteroides, E. coli, S. aureus*, gonorrhea, chlamydia)

**Evaluation**
- Culture for chlamydia, gonorrhea

**Treatment**
- I&D through mucosal surface, place Word catheter ×48 h
- Sitz baths TID for the 1st 2–3 d to assist drainage
Gyn f/u for consideration of marsupialization to prevent recurrence

Disposition
- D/c w/ wound care instructions, 2-d wound care f/u

Pearl
- Recurrence rate still 5–15% after marsupialization; consider gyn malignancy

PERIRECTAL ABSCESSES

(Emeg Med Clin North Am. 2016;34:251)

History
- Pain & swelling in rectal area w/ defecation & often w/ sitting down or walking
- High fever & signs of systemic tox are rare
- Pts often have h/o IBD, obesity, DM, hemorrhoids, or rectal trauma.

Findings
- Rectal exam essential to ensure abscess localized outside of anal sphincter & to identify upper extent of abscess
- Typically mixed flora (E. coli species, Enterococcus, Bacteroides species, S. aureus)

Evaluation
- Lab studies unnecessary unless systemically ill
- DM or immunocompromised should have Chem, CBC
- CT/MRI if concern for intersphincteric or suprallevator or postanal abscess or fistula

Treatment
- ED I&D of superficial abscesses outside the anal verge w/ visible indurated area
- Pain control; I&D extremely painful, procedural sedation often needed
- If abscess is only identified on rectal exam & no induration visible, refer to surgery for I&D under general anesthesia
- DM or immunocompromised pts should undergo I&D in OR to ensure full drainage
Pack w/ Vaseline gauze ×48 h, Sitz baths TID for 1st 2–3 d to assist drainage

- No abx for healthy host w/ superficial abscess
- Consider abx for immunocompromised, prosthetic device/valve, incomplete I&D
  - Levofloxacin 500 mg QD (ampicillin 1 g + gentamicin 80 mg q8h) + metronidazole 500 mg q8h, consider vancomycin

**Disposition**

- D/c w/ wound care instructions, 2-d wound care f/u
- Admit diabetic & immunocompromised for IV abx

**Pearls**

- 50–75% treated w/ I&D or spontaneous drainage will develop chronic anal fistula
- Consider adding stool softeners
History

- Caused by contiguous spread (sinus, ear, dental), hematogenous seeding from distant infection, (endocarditis) or post-CNS surgery/penetrating trauma. Often predisposing factor such as underlying disease (eg, HIV, transplant patients)
- HA (most common), ± fever, meningismus, photophobia, sz (25%), vomiting, AMS frequently absent, may have CN palsy, gait disorder
Subacute time course (vs. meningitis or encephalitis)

Findings
- Focal neuro deficits, low-grade fever, obtundation (mass effect), sz, AMS, nuchal rigidity, papilledema
- Wide variety of organisms depending on method of entry, 1/3 polymicrobial

Evaluation
- Blood cultures, CBC (WBC nonspecific), Chem, coags
- CT scan w/ & w/o IV contrast; MRI to help differentiate abscess from tumor
- Avoid LP if any concern for high ICP as may cause brain herniation

Treatment
- Emergency neurosurgical consult for drainage in OR; airway management, sz tx
- Early IV abx w/ good CSF penetration, tailored to likely pathogen
- Start broad-spectrum IV abx: Ceftriaxone 2 g + vancomycin 1 g + metronidazole 500 mg; consider adding coverage for toxoplasmosis, tuberculosis in immunocompromised
- Corticosteroids ONLY for tx of cerebral edema: Decadron 10 mg IV × 1 then 4 mg q6h

Disposition
- Neurosurgical intervention for operative washout, 6–8 wk IV abx then prolonged PO abx

Pearls
- Mortality 15%, unless abscess ruptures into ventricular system (mortality 27–85%)
- Morbidity from residual neuro deficits, new sz from scar tissue or neuropsych Δ (30%)

SOFT TISSUE INFECTIONS

Approach
Careful hx, associated sxs (V/D, cough, abd pain, AMS), progression
Check blood sugar if diabetic
Assess VS for significant abnormalities that may indicate serious infection (↓ BP, ↑ HR)
If immunosuppressed (HIV/AIDS, elderly, malnourished, chronic steroids) or neutropenic, more intensive eval & testing: CBC, Chem, UA & cx, CXR; consider blood cx & admission
If recent foreign travel: Consider travel-related infectious etiologies

<table>
<thead>
<tr>
<th>Soft Tissue Infections Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathophysiology</strong></td>
</tr>
<tr>
<td>Dermatology</td>
</tr>
<tr>
<td>GU</td>
</tr>
<tr>
<td>Ophthalmology</td>
</tr>
<tr>
<td>ENT</td>
</tr>
<tr>
<td>Vector-borne</td>
</tr>
<tr>
<td>Bioterrorism</td>
</tr>
</tbody>
</table>

**DERMATOLOGIC**

**Cellulitis**
*JAMA. 2016;316:325*

**History**
- Often no h/o broken skin; ± local trauma, recent surgery, FB
- May report fever, chills, malaise
- RF: Edema/lymphedema (facilitates bacterial growth)

**Findings**
- Warm, blanching erythema & tenderness to palpation, mild to moderate swelling
- May lead to dilated/edematous lymphatics (peau d’orange), bulla formation or linear streaking/lymphangitis
- ± distal skin disruption (eg, tinea pedis b/w toes w/ cellulitis of
anterior shin)

**Evaluation**
- If elevated BS, check Chem, UA; rule out abscess clinically or with bedside ultrasound
- Consider blood cultures, CBC w/ differential, chemistries, CRP, CPK in systemically ill pts
- Bacterial cultures of inflamed area not indicated; only 10–50% positive
- Most often caused by *Strep pyogenes* or *S. aureus* (including MRSA); can be from metastatic seeding

**Treatment**
- If LE cellulitis, recommend rest & elevation × 48 h, crutches if needed
- Typically aim to treat *Strep* & MSSA, but if purulent, MRSA coverage should be added. Duration of therapy 5–10 d outpt. IV therapy changed to oral after 48 h afebrile & regression from skin markings.
- Mild cellulitis:
  - Nonpurulent: Cephalexin, PCN VK, amoxicillin/clavulanate
  - Purulent: ADD trimethoprim-sulfamethoxazole, doxycycline, OR minocycline
  - PCN allergic: Clindamycin
- Moderate nonpurulent cellulitis (+ 2 SIRS criteria – T >38°C or <36°C, HR >90, RR >20, WBC >12 or <4):
  - Nonpurulent: IV cefazolin, IV ceftriaxone, IV PCN G, if PCN allergy clindamycin
  - Purulent: IV vancomycin, IV clindamycin or linezolid
- Severe nonpurulent (≥2 SIRS PLUS hypotension, immunocompromised or rapid disease progression):
  - Nonpurulent: IV vancomycin + IV piperacillin/tazobactam, IV imipenem, IV meropenem
  - Purulent: vancomycin, clindamycin, linezolid, daptomycin, tigecycline
- Pain control w/ NSAID/APAP; if severe pain, consider necrotizing infection
- Wound debridement if infected, contaminated, or devitalized wound
- Surgery consult if aggressive/necrotizing infection/gas in soft tissue
Disposition
- D/c w/ PO abx & 24–48 h f/u, strict return instructions
- Admit if signs of systemic infection, DM, immunocompromise, failure of outpt tx

Pearls
- Due to inflammation of dermal & subcutaneous tissue due to nonsuppurative bacteria, infection does not involve fascia or muscles
- Consider Doppler vascular studies in single limb w/ diffuse swelling, posterior calf or medial thigh to rule out DVT
- Mark border w/ permanent ink, write time & date
- Mimics: Stasis dermatitis (more likely if bilateral), hematoma (consider if h/o trauma), gout (consider if over joint)

Erysipelas

History
- Rapidly expanding, well-demarcated, painful plaque a/w swelling
- Extremes of age, obesity, DM, CHF, postop, nephrotic syndrome at higher risk
- Acute onset of fever, chills, malaise

Findings
- Skin painful superficial, indurated, raised; erythema w/ sharply demarcated border
- Irregular erythema w/ lymphangitis, may see desquamation, dimpling, vesicles, LAD
- Mostly found on lower extremities, sometimes on face, typically malar or “butterfly” pattern

Evaluation
- None indicated unless toxic appearing

Treatment
- Dicloxacillin, cephalaxin, if c/f MRSA trimethoprim-sulfamethoxazole, doxycycline, clindamycin
- PCN allergic: Levofloxacin

Disposition
D/c w/ PO abx & analgesics, elevate affected area, 24–48 h f/u, strict return instructions

**Pearls**
- Typically caused by group A β-hemolytic streptococcus; involves upper dermis & superficial lymphatics
- More superficial than cellulitis. Infection involving the ear “Milian’s ear sign” unique to erysipelas because ear does not contain deeper dermis tissues

**Staphylococcal Scalded Skin Syndrome (SSSS)**

**History**
- Young children <5 yr, fairly rapid progression of prodromal sore throat, conjunctivitis, fever, malaise to painful red skin w/ sloughing
- Rare in adults, a/w chronic illness, immunosuppression, & renal failure

**Findings**
- No mucous membrane involvement (vs. TEN)
- Erythematous cellulitis followed by acute exfoliation: Bullae, vesicles → large sheets of skin loss resulting in scalded-appearing skin
- General malaise, fever, irritability, tenderness to palpation, does not appear severely ill

**Evaluation**
- None indicated unless systemically ill
- Positive Nikolsky sign (epidermis separates when pressure applied)

**Treatment**
- Similar to burns (IVF, topical wound care, burn consult)
- Vancomycin is antibiotic of choice

**Disposition**
- Admit for burn care, IVF; consider ICU

**Pearls**
- Caused by exfoliative exotoxins of *S. aureus*, reports of MRSA
- Separation of epidermal layers vs. more severe TEN (necrosis at level of basement membrane)
- Prognosis: Children (<5% mortality) often w/o significant scarring;
adults (60% mortality)

**Toxic Shock Syndrome (TSS)**  

**History**
- Multiple sx: Prodrome, pain at site of infection (out of proportion to findings), fever, GI upset, myalgia, confusion, lethargy, sore throat
- Recent surgery, infrequently changed packing (tampons, nasal packing), disruption of skin, commonly no source found

**Findings**
- Clinical Dx w/ findings from all organ systems:
  - Staph TSS: Temp >38.9°C, rash (diffuse macular erythoderma including palms/soles), desquamation (1–2 wk after onset), hypotension, multisystem involvement (≥3 GI, muscular, mucous membranes, renal, hepatic, hematological, CNS), cultures negative except for blood culture for *S. aureus*
  - Strep TSS: Culture positive for Strep (blood, CSF, tissue biopsy, throat, vagina, sputum); hypotension, multisystem involvement (≥2 renal impairment, coagulopathy, hepatic involvement, ARDS, generalized erythematous macular rash, soft tissue necrosis)

**Evaluation**
- CBC w/ differential, Chem, UA, LFTs, coags, cultures (blood, urine, throat, sputum, CSF)

**Treatment**
- Remove tampon or packing if still in place, drain abscesses if present; surgical debridement of necrotizing fasciitis or myositis; burn care
- Aggressive resuscitation, pressors if needed
- Abx may not have impact (toxin-mediated process); tx any identified source
- Staph: nafcillin, vancomycin, clarithromycin, linezolid + clindamycin (to suppress bacterial toxin synthesis)
- Strep: PCN G + clindamycin OR linezolid
- IVIG (blocks T-cell activation by superantigens) may be added if no clinical response to aggressive supportive therapy in first 6 h of treatment
Disposition
- ICU admission

Pearls
- Rate ↓ w/ ↓ in use of superabsorbent tampons
- Caused by inflammatory response to superantigen from toxin-producing Gram-positive organisms (*S. aureus, S. pyogenes*)
  - *Strep*: Usually after surgery or trauma; scarlet fever-like rash; 30–44% mortality, fulminant. Blood cultures positive ~60% of cases.
  - *Staph*: More indolent, 0–20% mortality. Blood cultures positive <5% of cases.

Necrotizing Soft Tissue Infections

History
- Often diabetic, IVDU, obesity, EtOH abuse or nutritionally compromised
- Sudden onset of pain & swelling which progresses to anesthesia

Findings
- Cellulitis, skin discoloration/ecchymosis or gangrene, edema, spectrum of sensation from anesthesia to pain out of proportion
- Hemodynamic instability, crepitance (subcutaneous air due to gas-forming organisms), bullae & skin necrosis are rare but should trigger emergent surgical debridement
- Can progress to involvement of deeper layers, causing myositis or myonecrosis

<table>
<thead>
<tr>
<th>LRINEC Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Points</strong></td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>1</td>
</tr>
</tbody>
</table>
Score of ≥6  |  Sens 92.9%, spec 91.6% for necrotizing fasciitis


**Evaluation**
- CBC w/ differential, Chem, UA, CRP, coags
- Plain radiographs less sens than CT/MRI in eval of gas w/i soft tissue

**Treatment**
- Early surgical consult for debridement (definitive tx); hemodynamic support
- Early & broad spectrum IV abx
  - Piperacillin/tazobactam 3.3 g IV q6–8h + clindamycin 600–900 mg IV q8h + ciprofloxacin 400 mg IV q12h + vancomycin 15–20mg/kg IV q12h (if c/f MRSA)
- Consider hyperbaric oxygen tx, IVIG after debridement (both controversial)

**Disposition**
- ICU admission for surgical debridement

**Pearls**
- Mortality 16–46%, fatal if untreated
- Mostly *S. pyogenes* (group A), *Clostridium*, *S. aureus*, or mixed Gram + & – bacteria, anaerobes

---

**GENITOURINARY**

**Fournier Gangrene**
*(Surgeon. 2013;11:222)*

**History**
- Men (10:1), >50 yo, diabetic, chronic EtOH abuse, immunocompromised
- Recent h/o instrumentation/surgery, urethral strictures or calculi, hemorrhoids, perirectal abscess, malignancies
- Fever, lethargy prodrome
Rapidly progressing scrotal swelling, pain, erythema, warmth, possible purulent drainage

Findings
- Intensely tender, swollen, warm scrotum w/o clear fluctuance, pruritic genitalia
- Fever, chills, systemic sx(s) (tachycardia, ↓ BP), ± crepitus, drainage
- Deep-space infection is often vastly greater than skin involvement would suggest

Evaluation
- CBC w/differential, Chem, blood & urine cx, CRP, coags
- X-rays may show subcutaneous air; CT will show extent of infection & necrosis

Treatment
- Urology or general surgery consult for wide debridement & drainage
- Hemodynamic support & resuscitation w/ IVF, pressors
- Broad-spectrum abx: Vancomycin, Unasyn, Zosyn, clindamycin; Td prophylaxis
- Consider hyperbaric oxygen tx. IVIG after debridement.

Disposition
- ICU admission for surgical debridement, transfer for hyperbaric oxygen therapy

Pearls
- Mortality 3–67%; early surgical debridement most strongly correlated w/outcome
- Polymicrobial (E. coli, Proteus, Enterococcus, Bacteroides, & other anaerobes) necrotizing infection of perineum, scrotum, & penis characterized by obliterative endarteritis of the subcutaneous arteries resulting in gangrene
- Rapid destruction of fascial planes

OPHTHALMOLOGIC

(Dis Mon. 2017 Feb;63(2):30–32)

Periorbital/Preseptal Cellulitis

History
Recent infection of sinuses, periorbital skin, trauma to periorbital area, insect bites

Findings
- Unilateral eyelid swelling, erythema, warmth, discoloration of skin
- Injected sclera, conjunctival ecchymosis
- No pain w/ extraocular movements, no proptosis, normal pupillary reaction & vision

Evaluation
- CBC w/ differential, blood cultures, CT scan of orbits to evaluate for orbital extension

Treatment
- Head elevation
- Abx: Ceftriaxone or Unasyn 3 g IV q6h (if need admission) or cephalexin, dicloxacillin, clindamycin or Augmentin 500 mg PO TID × 10 d if d/c

Disposition
- Admit if appears systemically ill or has other comorbidities
- O/w d/c w/ close ophthalmology f/u (2 d)

Pearls
- Infection of soft tissue of eyelids & periorcular region anterior to orbital septum
- Most often caused by Staph & Strep, rarely H. influenza since vaccine
- Distinguish from orbital cellulitis: No pain w/ EOM or proptosis in periorbital cellulitis

Orbital Cellulitis

History
- Orbital pain increased w/ extraocular movements, ↓ vision
- Recent infection of sinuses, periorbital skin, trauma to periorbital area, facial trauma

Findings
- Fever, HA, rhinorrhea, malaise
- Proptosis & ophthalmoplegia are cardinal signs
  - Unilateral eyelid swelling, erythema, warmth, discoloration of skin
• Injected sclera, chemosis
• Tenderness on gentle globe palpation, ↑ IOP
• ↓ visual acuity, relative afferent pupillary defect, visual field abnormalities

Evaluation
• CBC w/ differential, CT scan of orbits, soft tissue aspirate if possible, blood cultures

Treatment
• Ophthalmology consult, head elevation
• Aggressive tx w/ immediate broad spectrum IV abx

Disposition
• Admission for abx

Pearls
• Infection of soft tissues of orbit posterior to orbital septum
• Most common: Strep, Staph, H. influenzae, polymicrobial
• Cx: Meningitis, brain abscess, death, cavernous sinus thrombosis (bilateral involvement, rapidly worsening, congestion of veins of face or conjunctiva)

---

**OTOLARYNGOLOGIC**

**Ludwig Angina**

**History**
• A/w dental infection, mandible fractures, tongue piercings
• Typically males, a/w DM< HIV, malnutrition, alcoholism

**Findings**
• Fever, malaise, neck swelling, trismus, drooling, pain with tongue movement, stridor
• Swelling of submandibular/sublingual space feels hard & “board like” or woody

**Evaluation**
• CBC w/ differential, Chem, UA, blood cultures, coags
• CT scan head & neck
Treatment
- If severe swelling, aggressively ↑ infection, or airway threatening, endotracheal intubation may be difficult, fiberoptic nasotracheal intubation may be the best initial approach w/ cricothyrotomy as backup
- Consultation w/ otolaryngologist for admission
- Broad spectrum IV antibiotics (clindamycin, unasyn, zosyn)

Disposition
- Admit to ICU for IV abx, airway watch

Pearls
- Rapidly spreading bilateral cellulitis of submandibular space a/w displacement of tongue causing life-threatening airway obstruction
- Polymicrobial, includes group A strep, also Staph, Fusobacterium, Bacteroides
- Surgical debridement was tx in preantibiotic era; now only if unresponsive to IV abx or e/o purulent collections

VIRAL INFECTIONS

<table>
<thead>
<tr>
<th>Viral Infections Differential</th>
<th>Pathophysiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocarditis (1j), pericarditis</td>
<td>Cardiac</td>
</tr>
<tr>
<td>Pneumonia (2b), URI/bronchitis (2b)</td>
<td>Pulmonary</td>
</tr>
<tr>
<td>Hepatitis (3g), gastroenteritis (3b), EVD</td>
<td>GI</td>
</tr>
<tr>
<td>Herpes zoster (8a), rubella (8a), measles (8a), roseola (8a), Herpes simplex (8a)</td>
<td>Dermatology</td>
</tr>
<tr>
<td>Pharyngitis (13b), sinusitis (13), diphtheria (13b), croup (13b), conjunctivitis (13d), mononucleosis</td>
<td>ENT</td>
</tr>
<tr>
<td>HIV, rabies</td>
<td>Other</td>
</tr>
</tbody>
</table>

EBOLA VIRUS DISEASE (EVD)

(Crit Care. 2016;20:217)
History
- Fever, chills, myalgias, malaise, then 5 d later GI symptoms such as severe watery diarrhea, nausea/vomiting, abd pain. Other symptoms like chest pain, SOB, HA, confusion may also develop. Bleeding is not universally present, mild bleeding (30%), frank hemorrhage is uncommon.
- 2–21 d incubation period
- Recent travel to country with outbreak (primarily West Africa, check CDC website for current updates)

Findings
- Fever, abd pain
- Diffuse erythematous maculopapular rash may develop day 5–7
- Pts with fatal disease typically die day 6–16 from complications including MSOF, sepsis

Evaluation
- CBC (leukopenia, lymphopenia, late elevated neutrophils, thrombocytopenia), ↑amylase, ↑AST/ALT, ↑PT/PTT, ↑fibrinogen, UA (proteinuria)
- RT-PCR assay specific for ebola

Treatment
- Supportive care of complications such as hypovolemia, electrolyte abnormalities, hematologic abnormalities, hypoxia, MSOF, septic shock, DIC
- Volume repletion, pressors as needed, pain control, nutritional support

Disposition
- Strick contact isolation, prevent contact or splashes with blood & body fluids, equipment & surfaces

Pearls
- Can be confused with more common diseases (malaria, typhoid, PNA, meningitis)
- Enters through mucous membranes, breaks in skin or parenterally
INFECTIOUS MONONUCLEOSIS

(NEJM. 2010;362:1993)

History
- Fever, pharyngitis, lymphadenopathy, HA, rash, nonspecific sx
- 4–6 wk incubation period, 1–2 wk prodrome: Fatigue, malaise, myalgias, low-grade temp

Findings
- Low-grade temp, pharyngitis, tonsillitis
- Tender & firm LAD for 1–2 wk, most often postcervical nodes, but can be generalized
- Rash: Papular erythematous on UE, erythema nodosum, erythema multiforme
- Splenomegaly; severe abd pain uncommon, may indicate splenic rupture
- May have petechiae, jaundice, hepatomegaly, periorbital edema

Evaluation
- CBC: ↑ WBC, ↑ atypical lymphocytes, ↓ platelets, ↑ LFTs (bilirubin, AST, ALT); monospot test
- Consider rapid strep if clinical ambiguity

Treatment
- Supportive, rest, analgesics, antipyretics
- Corticosteroids if airway edema

Disposition
- Admission rarely indicated; close PCP f/u
- Advise to avoid contact sports or vigorous exercise × 1 mo to prevent splenic rupture

Pearls
- Represents syndrome response to EBV (90% of people have EBV); most cases of mono caused by EBV but most EBV infections do not result in mono
- Secondary etiology: CMV
- Transmission through saliva; infects epithelial cells of oropharynx &
salivary glands
- B lymphocytes become infected → allows viral entry into bloodstream
- Self-limited; usually spontaneous resolution in 3–4 wk, complete in several months

---

**HIV/AIDS**


**History**
- Fever, fatigue, night sweats, pharyngitis, diarrhea, myalgia/arthritis, HA, flu-like sx

**Findings**
- Generalized maculopapular rash, oral ulcers (thrush), fever, lymphadenopathy

**Evaluation**
- CBC: Leukopenia, thrombocytopenia, ↑ LFTs
- ELISA to test for HIV Ab; if + confirm w/ Western blot (VL >100 K in acute infection)
- PCR to detect viral load, CD4 count

**Treatment**
- Counseling pre- & post-HIV testing

**Disposition**
- D/c unless systemically ill, ID f/u for antiretroviral tx

**Pearls**
- Transmitted through sexual contact (70%), IVDU; mother-to-child transmission possible during pregnancy or birth
- Untreated HIV → AIDS (CD4 <200) w/ life expectancy of 2–3 yr

---

### Opportunistic Infection Prophylaxis

<table>
<thead>
<tr>
<th>Infection</th>
<th>Indication</th>
<th>Prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB</td>
<td>+PPD (&gt;5 mm) or high-risk exposure</td>
<td>Isoniazid + Vit B6 × 9 mo</td>
</tr>
<tr>
<td>PCP PNA</td>
<td>CD4 &lt;200 or thrush</td>
<td>Bactrim QD OR dapsone 100 QD OR Atovaquone 1500 QD OR Pentamidine 300 q4wk</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Toxoplasmosis</td>
<td>CD4 &lt;100 AND + toxoplasma serology</td>
<td>Bactrim QD OR dapsone 200 QD + pyrimethamine 75 QD + leucovorin 25 qwk</td>
</tr>
<tr>
<td>MAC</td>
<td>CD4 &lt;50</td>
<td>Azithromycin 1200 qwk OR clarithromycin 500 BID</td>
</tr>
</tbody>
</table>

### Complications of HIV/AIDS

<table>
<thead>
<tr>
<th>CD4 Count</th>
<th>Cx</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;500</td>
<td>Kaposis sarcoma, lymphoma, oral hairy leukopenia</td>
</tr>
<tr>
<td></td>
<td>Candidiasis: Oral, esophageal, vaginal</td>
</tr>
<tr>
<td></td>
<td>Recurrent bacterial infections</td>
</tr>
<tr>
<td></td>
<td>Pulmonary &amp; extrapulmonary TB</td>
</tr>
<tr>
<td></td>
<td>HSV, VZV</td>
</tr>
<tr>
<td>&lt;200</td>
<td>PCP PNA, <em>Toxoplasma, Bartonella, Cryptococcus,</em> <em>Histoplasma,</em> <em>Coccidioides,</em> <em>HIV encephalopathy</em></td>
</tr>
<tr>
<td>&lt;50–100</td>
<td>CMV, MAC</td>
</tr>
<tr>
<td></td>
<td>Disseminated <em>Bartonella,</em> invasive aspergillosis</td>
</tr>
<tr>
<td></td>
<td>CNS lymphoma, PML</td>
</tr>
</tbody>
</table>

### Organ Involvement of HIV/AIDS

<table>
<thead>
<tr>
<th>Organ</th>
<th>Manifestation/Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constitutional</td>
<td>Fevers: Bacterial, MAC, CMV, PCP, TB, lymphoma, drug rxn, endocarditis</td>
</tr>
<tr>
<td>Dermatologic</td>
<td>Kaposis sarcoma, lymphoma, VZV, HSV, HPV, <em>Molluscum contagiosum</em></td>
</tr>
<tr>
<td>Ophthalmologic</td>
<td>CMV retinitis</td>
</tr>
<tr>
<td>Oral</td>
<td>Oral hairy leukopenia, Kaposis sarcoma, thrush, aphthous ulcers</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Dilated cardiomyopathy, endocarditis, myocarditis, CAD, pericardial effusion, LVH</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>PCP PNA, TB, fungal PNA (aspergillosis, <em>Cryptococcus,</em> etc.), CMV</td>
</tr>
<tr>
<td>GI</td>
<td>Oral candida, hairy leukoplakia, esophagitis, enterocolitis, GIB (CMV, Kaposis, lymphoma), proctitis, hepatitis, diarrhea</td>
</tr>
</tbody>
</table>
Cryptosporidium, Isospora

Renal
Nephropathy (drugs), HIV-associated nephropathy

Hematologic
Anemia (chronic dz), leukopenia, thrombocytopenia

Oncologic
NH & CNS lymphoma, Kaposi sarcoma, cervical cancer

Endocrine
Hypogonadism, metabolic syndrome, adrenal insufficiency, HIV wasting syndrome

Neurologic
Meningitis: Cryptococcus, bacterial, viral, TB, cocci, histoplasmosis
Neurosyphilis: Meningitis, CN palsy, dementia
Mass (toxoplasmosis), AIDS dementia, myelopathy, peripheral neuropathy, HIV encephalopathy, progressive multifocal leukoencephalopathy

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Drugs</th>
<th>Rxn</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucleoside reverse transcriptase inhibitors</td>
<td>Zidovudine (AZT)</td>
<td>Bone marrow suppression (AZT)</td>
</tr>
<tr>
<td></td>
<td>Didanosine</td>
<td>pancreatitis (didanosine)</td>
</tr>
<tr>
<td></td>
<td>Stavudine</td>
<td>Peripheral neuropathy</td>
</tr>
<tr>
<td></td>
<td>Zalcitabine</td>
<td></td>
</tr>
<tr>
<td>Nonnucleoside reverse transcriptase inhibitors</td>
<td>Nevirapine</td>
<td>Steven–Johnson syndrome</td>
</tr>
<tr>
<td></td>
<td>Efavirenz</td>
<td></td>
</tr>
<tr>
<td>Protease inhibitors</td>
<td>Indinavir</td>
<td>N/V, diarrhea, hyperlipidemia, hyperglycemia, fat redistribution</td>
</tr>
<tr>
<td></td>
<td>Atazanavir</td>
<td></td>
</tr>
</tbody>
</table>

Rabies


**History**
- Exposure to rabid (agitated, drooling, unprovoked attack) mammal (dog, cat, bat, raccoon)
- Prodrome lasts 2–10 d; nonspecific: fatigue, loss of appetite, HA, anxiety, irritability, fever

**Findings**
- Encephalitic (80%) & paralytic (20%) rabies, affects brain & spinal
Encephalitic form: hypersalivation, sweating, piloerection, hydrophobia, impaired consciousness → quadriplegia → death
Paralytic form: weakness in bitten limb, progression to quadriplegia & facial weakness, urinary incontinence → neurologic progression → death
Dog-acquired cases: hydrophobia, aerophobia, encephalopathy
Bat-acquired cases: symptoms at exposure site, abnormal neurologic findings (tremor, myoclonus, cranial nerve exam, motor/sensory exam)

**Evaluation**
- Neutralizing anti-rabies virus AB in serum (if not vaccinated), RABV antigen in tissues, RABV RNA in saliva or CSF
- CSF: pleocytosis, ↑ protein; Ab titer diagnostic, regardless of vaccine status
- Imaging (head CT, MRI) used to evaluate for other causes of encephalopathy

**Treatment**
- Supportive, palliative. Universally fatal within 14 d of initial symptoms
- No proven medical tx has been shown to be effective
- Therapeutic coma (ketamine, benzo’s) & antiviral therapy (amantadine, ribavirin) rarely a/w survival

**Disposition**
- ICU admission if neuro or resp sx w/ inpt ID consult
- Notify public health department & animal control center
- Identify others at risk & initiate postexposure prophylaxis if indicated

**Pearls**
- Caused by *Lyssavirus* in family *Rhabdoviridae* transmitted by animal bites
- IP is variable, typically 20–90 d but ranges from days to 1 year
- Dogs are the most commonly infected animals worldwide, but very rare in US & Canada
- Rabies PEP
- Wound care (soap, water, irrigation w/ povidone–iodine solution), debridement of devitalized tissue, secondary closure, update
Tetanus vaccination
- If domestic dog or cat bite, determine vaccination status of animal from owner. If animal can be observed, start PEP only if animal develops symptoms
- Assess rabies risk & need for human rabies immune globulin (HRIG) & human diploid cell vaccine (HDCV)
- HRIG: 20 IU/kg; as much as possible at exposure site, remaining administered at distant site (eg, deltoid)
- HDCV: 1 mL dose in deltoid in ED. F/u doses given days 3, 7, 14
- HDCV 5th dose on day 28 if immunocompromised
- Do not stop rabies immunization b/c of mild rxn to vaccine doses
- Rabies cases from nonbite exposures > from known bite exposures; consider prophylaxis for any contact w/ high-risk animals (eg, bats, skunks, raccoons, coyotes, foxes)

**SYPHILIS**

*(Lancet. 2017;389:1550–1557)*

**History**
- Primary syphilis: hallmark is a chancre – painless, usually solitary, indurated, clean-based ulcerative lesion 2–3 wk after contact infected lesion.
- Secondary syphilis: painless, macular rash of 1–2 cm, lesions on palms & soles; but can vary in appearance (thus the “great imitator”). May be a/w malaise, myalgia, HA (syphilitic meningitis), sore throat.
- Latent disease
- Tertiary syphilis – late neurosyphilis (general paresis, tabes dorsalis), cardiovascular syphilis (aneurysm of ascending aorta, AV insufficiency, CAD), gummatous syphilis (reactive, granulomatous processes)

**Findings**
- Primary syphilis: chancre, ± nontender LAD
- Secondary syphilis: painless rash may be associated with fever, LAD, HSM, hepatitis
- Tertiary syphilis: General paresis causes progressive dementia,
seizures, psychiatric syndromes. Tabes dorsalis “lightening” radicular pains, ataxia, Argyll Robertson pupil (small, do not react to light but accommodate), loss of reflexes, impaired vibratory sense.

Evaluation
- Treponemal test (eg, RPR, VDRL) → nontreponemal assay to confirm (eg, FT-ABS, TP-PA)
- Reactive CSF VDRL is diagnostic of neurosyphilis

Treatment
- Early (primary, secondary, or early latent): benzathine PCN G 2.4 million units IM ×1 OR doxycycline 100 mg PO BID × 14 d
- Late/unknown duration latent syphilis: benzathine PCN G 2.4 million units IM wk × 3 wk OR doxycycline 100 mg BID × 28 d
- Neurosyphilis: PCN G 3–4 million units IV q4H × 10–14d
- After treatment 30–50% patients have Jarisch–Herxheimer reaction (fever, myalgia, worsening skin rash). Will self-resolve, can tx with IVF, antipyretics.

Disposition
- Pts with neurosyphilis or cardiovascular syphilis should be admitted for antibiotics.

Pearls
- Caused by Treponema pallidum
- Increases risk of HIV infection; HIV incidence up to 20% in the decade after syphilis Dx
- Spread through direct lesion contact, small proportion through blood transfer

---

TETANUS

(Crit Care. 2014;18:217)

History
- Acute onset hypertonia, painful muscular contractions esp. the masseter (“lockjaw”) → generalized muscle spasms/rigidity, dysphagia
- RFs: Inadequate vaccination status, chronic wound, IVDU

**Findings**
- Spasms of muscles in close proximity to site of injury, cephalic, lockjaw, risus sardonicus (characteristic grimace) tetanic sz, respiratory failure
- Autonomic Dysfxn: BP ↑ or ↓, dysrhythmias, cardiac arrest
- Cx include fractures & dislocations

**Evaluation**
- No spec tests available; clinical Dx

**Treatment**
- Heavy sedation (benzos, propofol) & paralysis supported by artificial ventilation
- Magnesium sulfate has been used to control muscle spasms
- Intrathecal, intramuscular antitetanus immunoglobulin hastens clinical improvement
- Abx: Metronidazole, PCN G, or doxycycline

**Disposition**
- ICU admission

**Pearls**
- *C. tetani* is obligate anaerobe, gram-positive spore forming bacillus, resistant to heat, desiccation, & disinfectants
- DTaP (diphtheria, tetanus, pertussis; inactivated) vaccine given at 2, 4, & 6 mo, booster given b/w 15–18 mo & at 4–6 yr; booster recommended q10y or if dirty wound
- Mortality 30–45%; if received tetanus toxoid at sometime in life mortality 6
- Slow recovery over 2–4 mo, usually complete resolution of sxs

**Prevention**

<table>
<thead>
<tr>
<th>Tetanus Postexposure Prophylaxis Guide</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wound</strong></td>
</tr>
<tr>
<td>Minor, clean</td>
</tr>
</tbody>
</table>
**Immunization Status**

<table>
<thead>
<tr>
<th>All other wounds</th>
<th>&lt;3 doses of tetanus toxoid, &gt;5 yr since last dose or unknown immunization status</th>
<th>Td toxoid booster</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;3 doses of tetanus toxoid, or unknown immunization status</td>
<td>Tetanus immune globulin (250 mg or 500 IU IM)</td>
</tr>
</tbody>
</table>

- Clean & debride wound as needed
- Pts who have not completed primary immunization series should repeat Td booster in 4–8 wk & 6–12 mo

---

**SCABIES**

*(Prim Care. 2015;42:661)*

**History**
- Persistent pruritus, worse at night. Sometimes multiple family members involved
- Common in overcrowding, poor hygiene, elderly, homeless. More common in winter (survive longer on fomites, more crowded living)

**Findings**
- Small, pruritic, erythematous papules. Typically, web spaces between fingers & toes, flexor aspects of wrists, under armpits, around umbilicus, under knees, around nipples, genital region
- Burrow from mites: elevated thin red or gray line
- Secondary skin infections may also be present

**Evaluation**
- Clinical Dx. Other Dx tests (skin scrapings, shave biopsy, tape test, etc.) may increase certainty but negative results do not rule out

**Treatment**
- Permethrin 5% cream, 2 applications 1 wk apart OR oral ivermectin 200 μg/kg, 2 applications 2 wk apart
- Second line: crotamiton 10% cream, lindane 1% lotion
- Symptomatic relief, tx 2° infections & household members, clean clothes/linens
Disposition
- D/c w/ instructions for household to be treated, decontaminate clothing, bedding
- Exclude from school until treated, topical permethrin usually effective w/i 12 h

Pearls
- Caused by female mite, S. scabiei
- Delayed type IV hypersensitivity rxn to mite proteins (from saliva, feces, eggs, mite itself), symptoms initially develop 3–4 wk after exposure, then 1–2 d after re-exposure
- Skin-to-skin contact, indirect contact through bedding or clothing

**VECTOR-BORNE INFECTIONS**

<table>
<thead>
<tr>
<th>Vector-borne Infections Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathophysiology</td>
</tr>
<tr>
<td>Tick-borne</td>
</tr>
<tr>
<td>Mosquito-borne</td>
</tr>
</tbody>
</table>

**TICK-BORNE DISEASES**

**Lyme Disease (Borrelia burgdorferi)**
*(NEJM. 2014;371:684)*

**History**
- 1/3 recall h/o tick bite. Often by *I. scapularis* (deer tick) in endemic area b/w May & August, or of exposure to wooded areas, incubation period 3–31 d.
- Tick must be attached for >36 h to cause infection
- Erythema migrans (typical “bull’s eye” rash w/ central clearing, but can be uniform or enhanced central erythema w/o clearing; can last 3–4 wk if untreated); malaise, fatigue

**Findings**
Progression can result in polyarthritis (late), cardiac conduction dz, neurologic sequelae

- Rash: Erythema migrans (absent in 20–40%)
- Lyme carditis – AV block &/or myopericarditis
- Lyme meningitis; does not present as classic bacterial meningitis
  - Early: HA, Bell’s palsy, radiculoneuritis, erythema migrans
  - Late: Neurocognitive Dysfxn (ie, encephalopathy)

**Evaluation**

- Testing not recommended for pts w/ only erythema migrans, poor sensitivity
- For pts w/ nonerythema migrans presentations: First antibody screen assay (EIA), if positive, obtain immunoblot. Both results positive required to confirm Dx.
- ECG to assess for HB, CSF may be considered in pts w/ neurologic involvement

**Treatment**

- Tick removal: Using forceps or tweezers, grasp the tick as close to skin as possible, pull upward w/ steady pressure. Disinfect site, save tick for identification.
- See table, consider Rheum consult
- Avoid doxycycline in pregnant pts

**Dispositions**

- D/c w/ abx regimen, PCP f/u unless has symptomatic AV block/syncope

**Pearls**

- Deer tick tiny (head of pin) vs. dog tick (larger, more, common, don’t transmit Lyme)
- Most common tick-borne dz in US; 90% of cases in MA, CT, RI, NY, NJ, PA, MN, WI, CA

<table>
<thead>
<tr>
<th>Sxs/Findings</th>
<th>Onset After Bite</th>
<th>Tx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic exposure</td>
<td>W/i 72 h</td>
<td>Doxycycline 200 mg PO ×1</td>
</tr>
<tr>
<td>EM rash, nonspecific viral syndrome</td>
<td>Few days–1 mo</td>
<td>Doxycycline 100 mg PO BID or amoxicillin 500 mg PO</td>
</tr>
<tr>
<td>Symptom / Disease</td>
<td>Duration</td>
<td>Treatment</td>
</tr>
<tr>
<td>------------------</td>
<td>----------</td>
<td>-----------</td>
</tr>
<tr>
<td>CN palsy w/o meningitis, asymptomatic carditis</td>
<td>Days–10 mo</td>
<td>Ceftriaxone 2 g IV QD × 14 d, up to 21 d for Lyme carditis</td>
</tr>
<tr>
<td>Musculoskeletal (arthritis), neurologic (encephalitis, meningitis, neuropathy), symptomatic carditis</td>
<td>Months–years</td>
<td>Arthritis alone: PO regimen as above × 28 d Neurologic sx/s/findings: Ceftriaxone 2 g IV QD × 14–28 d</td>
</tr>
</tbody>
</table>

**Rocky Mountain Spotted Fever (Rickettsia Rickettsii)**
*(Lancet Infect Dis. 2007;7:724)*

**History**
- Tick exposure. IP 2–14 d.
- Sudden high fever, malaise, HA, myalgia, anorexia, N/V, abd pain, photophobia
- Rash 2–5 d after fever

**Findings**
- Multisystem dz; Temp >102°F, may be ↓ BP on presentation
- Rash (85–90%): Petechial rash typically starts at wrist & ankles; may be diffuse at onset. Typically moves out (palms & soles) then in (arms, legs, & trunk). By end of first week, rash is maculopapular with central petechiae, spares face. ~10% have no rash
- Multiple systems can be involved: Cardiac (myocarditis), pulmonary (cough, PNA), GI (abd pain, N/V, hepatomegaly), renal (ARF), CNS (meningismus, photophobia, confusion), ocular (conjunctivitis, retinal hemorrhage, arterial occlusion), muscular (CK elevation)

**Evaluation**
- IFA assay most commonly used, cannot distinguish between rickettsial diseases
- Ab not detectable until 7–10 d after disease onset
- CBC (thrombocytopenia, anemia), Chem (hyponatremia, ↑ BUN), LFTs, coags, blood cx
- CXR if appear toxic or abnl lung findings
- CT or MRI for AMS may show infarction, edema, meningeal enhancement
- CSF may show pleocytosis, nl glucose, elevated protein
**Treatment**
- Intubation if indicated, resuscitation; dialysis, fluids, PRBC + platelets if indicated
- Abx: Tetracyclines (doxycycline), chloramphenicol

**Disposition**
- Most require hospitalization, consider ICU (rapid progression)

**Pearls**
- *R. rickettsii* obligate intracellular bacterium spread by ticks to human endothelial cells causing small, medium vessel vasculitis
- Found in US (primarily MD, VA, NC, SC, OK, TN, AR), also western Canada, western & central Mexico, & South America
- Mortality 5% treated, 20% untreated

**Ehrlichiosis and Anaplasmosis**
*(Prim Care. 2013;40:619)*

**History**
- Travel to endemic area in spring/early summer, tick bite; 5–14 d incubation
- Fever, myalgia, HA, malaise, cough, chills, rash (10–30%)

**Findings**
- Fever, LAD (<25%), maculopapular, petechial, or macular rash on UE/trunk

**Evaluation**
- CBC (↓ WBC, ↓ plat), ↑ LFT, LDH, ↑ ESR; blood cultures not helpful
- PCR most sens during acute infection, serologies, peripheral smear
- CT/LP if severe HA to R/O meningitis, may show pleocytosis, mildly elevated protein

**Treatment**
- Analgesics, resuscitation, abx: Doxycycline 100 mg IV/PO BID × 10 d

**Disposition**
- Admit as needed for supportive tx

**Pearls**
- Obligate intracellular gram-negative bacteria; *Anaplasma* infects granulocytes (HGA), *Ehrlichia* targets monocytes (HME); distinct
epidemiologically but same clinical picture
- HGA—American deer tick; found in NE & Midwest US in summer
- HME—American dog tick, lone star tick; found in SE & south-central US, April–September

**Babesiosis**
*(NEJM. 2012;366:2397)*

**History**
- Travel to endemic areas b/w May & September, tick bite; 1–4 wk incubation
- Usually asymptomatic in healthy host; affects elderly, immunocompromised, asplenic
- Fever, weakness, fatigue, HA, photophobia, AMS, cough, SOB, N/V, abd pain, arthralgias, chills, myalgias, anorexia, cough

**Findings**
- Fevers, rigors, hepatosplenomegaly, pharyngeal erythema, jaundice, retinopathy

**Evaluation**
- CBC (hemolytic anemia), ↓ haptoglobin, ↑ LFTs, ↑ LDH, ↑ reticulocytes, ↓ platelets, UA (proteinuria or hematuria)
- Wright or Giemsa peripheral blood smear; PCR, immunofluorescence Ab testing
- Serial blood smear may show parasites

**Treatment**
- Resuscitation, symptomatic tx, airway management
- Early abx: Atovaquone IV + azithromycin IV OR clindamycin PO or IV + quinine PO
- RBC exchange transfusion if parasite load >10%, severe anemia, end-organ Dysfxn

**Disposition**
- Admit for ongoing supportive therapy, abx
- Most pts recover spontaneously in 1–2 wk, fatigue may continue for months

**Pearls**
- Protozoan parasite *Babesia* transmitted by tick or blood transfusion from infected individual
Peak in May–October; found in Europe & US (MA, NY, RI, CT, upper Midwest, Northwest)
Mortality 10% (US), 50% (Europe); if symptomatic

MOSQUITO-BORNE DISEASES

Malaria
(WHO Guidelines for the Treatment of Malaria. 3rd ed. 2015.)

History
- Travel to Central & South America, Sub-Saharan Africa, India, SE Asia, Middle East, Caribbean, South Central Asia; incubation period 7–30 d, may present months after
- Paroxysmal chills, sweats, & high fevers q48–72h
- Fever, cough, fatigue, myalgias, malaise; less common anorexia, N/V, diarrhea, HA

Findings
- Fever, hypotension, tachycardia, may see jaundice, signs of anemia, splenomegaly, icterus
- Severe malaria: AMS, ≥2 szs, pulm edema, HD unstable, >40°C, DIC, severe anemia, renal failure, hypoglycemia, hyperparasitemia, acidosis, hyperbilirubinemia
- Cerebral malaria: AMS, meningitis, szs, encephalopathy; 15–20% mortality even w/ tx

Evaluation
- CBC, Chem, haptoglobin, UA, blood cx, thick & thin blood smear, rapid antigen tests
  - Triad of thrombocytopenia, ↑ LDH, atypical lymphocytes
- Head CT/LP if AMS or encephalopathy to look for cerebral malaria
- CXR if signs of pulm edema

Treatment
- Airway management, IV access & IV fluid resuscitation, infectious dz consultation
- Prophylaxis regimen often recommended; depends on region of travel
  - Use DEET & insect repellent, bed nets w/ permethrin, long-sleeved
clothing

- Tx regimen dependent on geography, which species, & severity of dz
- Watch QT interval when giving antimalarials

Disposition

- Admit if suspected or confirmed, if child, pregnant, or immunodeficient
- ICU if end-organ sxs noted, signs of cerebral malaria
- Thin & thick blood smears should be performed qwk × 4 after d/c to ensure resolution

Pearls

- *Plasmodium (ovale, vivax, malariae, falciparum)* cause malaria, transmitted through bite of infected female *Anopheles* mosquito, causing systemic infection of erythrocytes
- *P. falciparum* most severe: Can cause cerebral malaria, pulm edema, renal failure, anemia; highest occurrence in Sub-Saharan Africa
- *P. vivax* & *P. ovale* produce dormant form in liver, usually causes uncomplicated malaria
- 2 million deaths annually, majority in kids <5 y/o, ~90% in rural Sub-Saharan Africa
- Sickle cell trait, thalassemia, Hemoglobin C disease & G6PD deficiency are protective
- Pregnant women up to 10× more likely to contract & develop severe malaria, ↑ M&M

Yellow Fever

*(Clin Infect Dis. 2007;44:850)*

History

- Travel to endemic area (Sub-Saharan Africa [90%] & South America), incubation 3–6 d
- Mild form sudden fever HA → more severe cases with high fever, chills, HA, myalgias, lumbosacral pain, anorexia, N/V, dizziness → 10–25% have severe recurrence 2 d later with multiple organ systems involved (GI, renal, cardiac, hematologic)

Findings
High fever, relative bradycardia, N/V, epigastric tenderness
- Severe cases: ↑ fever, HA, N/V, abd pain, somnolence, jaundice, hematologic complications (eg, hematemesis, melena, petechiae, epistaxis)
- Late: ↓ BP, shock, confusion, coma, DIC, hemorrhage
- Liver is the most affected organ: Hepatocellular damage (steatosis, necrosis); bleeding
- Kidney is also affected: Renal insufficiency, albuminuria, ATN
- Cardiac: Fatty infiltration of myocardium → myocarditis & arrhythmias

Evaluation
- CBC (leukopenia, thrombocytopenia), ↑ LFTs, abnl coags, ↑ BUN/Cr, fibrinogen (DIC), ↓ ESR, serology, viral IgG, IgM

Treatment
- Resuscitation, supportive, symptomatic tx; no antiviral meds approved
- Live attenuated vaccine available for prevention, extremely effective

Disposition
- Admit for supportive care

Pearls
- *Flavivirus* transmitted by *A. aegypti* mosquito during tropical wet & early dry season, causes viral hemorrhagic fever
- Up to 20–50% mortality in symptomatic patients
- Mandated reporting to WHO, local health dept

**Dengue Fever**
(*NEJM*. 2012;366:1423)

**History**
- Travel to endemic areas: Mostly SE Asia, Central America, Western Pacific, sometimes from Eastern Mediterranean, Africa
- Sxs begin after 3–7 d incubation
- High fever: Abrupt onset × 1–7 d, biphasic, w/ HA, vomiting, myalgia, joint pain
- Rash: Characteristically bright red blanching petechiae, usually 1st on lower limbs & chest → morbilliform, maculopapular & sparing palms & soles → desquamation
Findings

- Hemorrhagic fever (DHF) or shock syndrome (DSS) occur during 2nd infection by different dengue virus
- Fever, ↓ BP, rash, LAD, hemorrhage (petechiae, purpura, epistaxis, GIB, menorrhagia)
- DHF: High fever, hepatomegaly, hypotension, DIC; begins w/ sudden ↑ in temp & flu sx

Evaluation

- CBC (↑ Hct, ↓ plat, ↓ WBC), Chem (↑ BUN), ↑ LFTs, guaiac, DIC panel, ELISA, lactate
- CXR, head CT (if AMS), US, viral culture, dengue antigen tests, PCR, viral serologies

Treatment

- Aggressive supportive therapy, IVF, fluid status important 2/2 to plasma leakage, blood transfusions for severe bleeding

Disposition

- Admit for supportive tx

Pearls

- Caused by dengue virus (Flavivirus) infection, transmitted by A. aegypti mosquitoes
- Called “break-bone fever” due to acute onset severe HA, muscle & joint pains
- Benign acute febrile illness that can cause bleeding or DIC in small # of cases but can lead to lethal DHF

West Nile Disease

(MMWR. 2014;63:521)

History

- Outdoor exposures in area of outbreak during summer months, 2–14 d incubation
- Most infections asymptomatic. Symptomatic pts have fever, HA, malaise, myalgia, GI symptoms, rash.
- <1% have neuroinvasive Dx (meningitis, encephalitis, flaccid paralysis)

Findings
- Low-grade fever, hepatomegaly, splenomegaly, generalized LAD
- Rash: Erythematous maculopapular
- CNS: AMS, confusion, coma, meningismus, papilledema, CN abnormalities, flaccid paralysis, sz, ataxia, tremor, involuntary movements

**Evaluation**
- CBC (↓ WBC, ↓ lymphocytes, anemia), Chem (↓ Na), ↑ LFTs; ↑ lipase, viral IgM Ab
- CSF: Mild ↑ protein, mild ↑ leukocyte, nl glucose, serologies
- Brain MRI may be normal or show signal abnormalities in brainstem, basal ganglia, thalamus, anterior spinal cord

**Treatment**
- Supportive care, airway management, resuscitation
- Limited evidence for interferon & IVIG in case series & reports

**Disposition**
- Admit for supportive tx, may need rehabilitation from neuro cx

**Pearls**
- *Flavivirus* transmitted by several types of mosquito to horses, dogs, birds; crosses the blood–brain barrier to infect nervous system
- Has been reported throughout the world
- Excellent prognosis unless elderly or w/ other comorbid factors

**Eastern Equine Encephalitis** *(MMWR. 2006;55:697)*

**History**
- Outdoor exposure to area of outbreak in summer or early fall
- Fevers, chills, malaise, weakness, HA, myalgias; progression to confusion, coma, N/V

**Findings**
- Similar to any other encephalitis; fever, tachycardia, tachypnea
- Neuro: Papilledema, sz, nuchal rigidity, focal neuro abn, CN abnormalities, spastic paralysis

**Evaluation**
- CBC (↑ WBC), Chem (↓ Na), serologies (IgM), viral isolation from CSF, blood, tissue
Head CT: Punctuate/intraventricular hemorrhage, focal edema, meningeal enhancement
MRI, LP: CSF shows ↑ protein, ↑ RBC, ↑ WBC

Treatment
- Supportive care, airway management, resuscitation, corticosteroids, & anticonvulsants

Disposition
- Admit, likely to ICU; will need extensive rehab

Pearls
- Arbovirus transmitted subcutaneously by mosquito, birds serve as primary reservoir; virus causes acute inflammatory process mainly involving meninges
- Primarily found in North America (east of MS river; MI, MA, NY, NJ, NC, SC, FL, LA, GA); wooded areas near freshwater swamps, marshes; less commonly Central/South America
- Poor prognosis: 33–70% mortality in a few days, 90% morbidity, only 10% fully recover

Chikungunya
(Lancet. 2012;379:662)

History
- IP 1–12 d. Sudden onset fever with joint pain, HA, photophobia, rash

Findings
- Polyarthritis (can last months–years), joint swelling, fever, transient maculopapular rash

Evaluation
- CBC, viral PCR, serologies, r/o other possible culprits (eg, dengue)

Treatment
- NSAIDs for joint pain, supportive care

Disposition
- Admit as needed for supportive care

Pearls
- Caused by alphavirus transmitted by Aedes mosquitoes
- Joint pain can last years
Found in tropical/subtropical regions (African, Indian Ocean Islands, Asia)

**Zika Virus Disease**  
(*NEJM.* 2016;374:1552)

**History**
- Asymptomatic or mild Dx (fever, arthritis/arthralgia, rash, conjunctivitis, HA, myalgia)

**Findings**
- Fever, macular or popular rash, conjunctivitis

**Evaluation**
- Consider CBC, viral testing

**Treatment**
- Supportive care

**Disposition**
- Home

**Pearls**
- Caused by Flavivirus transmitted by *Aedes* mosquitoes
- Found in Southern US, central America, South America, Southeast Asia
- Temporal & geographic relationship with neurologic complications in adults such as Guillain–Barré syndrome, meningoencephalitis, as well as association with birth defects such as microcephaly. (*Lancet.* 2016;388:898)

---

**BIOTERRORISM**

(*NEJM.* 2015;372:954)

**Background**
- Characterized by low visibility, high potency, accessibility, easy delivery
- Only small amount of agent needed to kill large numbers of people
- Only plague, smallpox, & viral hemorrhagic fevers spread from person to person
Approach
- Take protective measures: Universal precautions w/ HEPA filter masks, decontaminate pt including remove clothing, shower w/ soap & water
- Isolation (negative pressure room) of affected, proper disposal of corpses

**Anthrax (Bacillus Anthracis)**

History
- Contact w/ infected goats, sheep, cattle, horses, swine, 1–6 d incubation period
- Most commonly cutaneous infection, also respiratory or GI; not human to human
- Fever, malaise, HA, cough, weakness, SOB, pruritus, N/V, diarrhea, abd pain
- Less likely than influenza to have sore throat or rhinorrhea

Findings
- Dependent on route of inoculation
- Cutaneous (most common): Incubation 1–12 d; starts as small papule → vesicle containing serosanguineous fluid (1–2 d) → vesicle rupture leaves painless necrotic lesion w/ surrounding edema → massive edema
  - Ulcer base develops 1–5 cm black eschar; after 2–3 wk separates & leaves scar
- Inhalational: Incubation 1–6 d; initial nonspecific sx & cough × 2–3 d → sudden onset respiratory distress (dyspnea, stridor, cyanosis, ↑ CP, diaphoresis) → rapid onset shock & death in 24–36 h
- GI: From ingestion of infected meat; incubation 2–5 d; local oral/tonsillar ulcer, dysphagia & respiratory distress → abd pain, hematemesis, massive ascites, diarrhea
- Injectional: Characterized by skin lesions seen in “skin popping” drug users, may progress rapidly & require surgical debridement or may disseminate.

Evaluation
Blood cultures; Gram stain or culture confirms cutaneous anthrax, serologies, rapid antianthrax antibody test can be performed w/i 1 h. Difficult to diagnose inhalational or GI anthrax. CXR (inhalational): Mediastinal widening, pleural effusion, e/o ARDS.

**Treatment**
- Early abx for cutaneous Dx: PCN, doxycycline, ciprofloxacin IV. Multiple abx if systemic/extensive dz.
- Raxibacumab injection recently FDA approved for inhalational anthrax.
- Prophylaxis: Ciprofloxacin or doxycycline PO; anthrax vaccine.
- Corticosteroids may be useful in severe edema, meningitis.

**Disposition**
- Consider admission based on clinical findings.

**Pearls**
- Large, aerobic, gram-positive, spore-forming, nonmotile, pyogenic *B. anthracis*.
- Found in animals in South & Central America, Southern & Eastern Europe, Africa, Asia, Caribbean, Middle East.
- Death from respiratory failure, overwhelming bacteremia, septic shock, meningitis.
- Mortality variable: Cutaneous <1%, inhalational 45–92%, GI 25–60%, injectional 34%.

---

**P L A G U E (Y E R S I N I A P E S T I S)**

**History**
- Contact w/ rat flea; 99% cases in SE Asia (Vietnam), rarely Southwest United States.
- Acute onset high fevers, LAD, myalgias, cough, SOB, CP, hemoptysis, sore throat, GI sx.

**Findings**
- Bacilli spread to lymph nodes → supportive lymphadenitis, producing bubo → spread to other organs (spleen, liver, lungs, skin) & septic shock if untreated.
Bubonic (85–90%): Incubation 1–8 d; buboes emerge in groin, axilla, or cervical regions w/ f/C/HA, N/V, AMS, cough → buboes visible in 24 h, severely painful
Septicemia (10–15%): Result of hematogenous dissemination of bubonic plague
Pneumonic (1%): From inhalation of aerosols or hematogenous dissemination; productive cough w/ blood-tinged sputum, rales, decreased breath sounds

Evaluation
Presence of painful bubo; Gram stain of bubo aspirate; blood, sputum, & CSF cultures, lymph node aspiration
CXR (pneumonic): Bilateral alveolar infiltrates, consolidation

Treatment
Isolate pts for 1st 48 h after tx; if pneumonic plague, isolate for 4 d
Levofloxacin recently approved
Streptomycin 15 mg/kg IM BID × 10 d ± doxycycline 200 mg IV × 1
Alternative regimens: Chloramphenicol, gentamicin, Bactrim, ciprofloxacin
Septicemia plague: Same as for other causes of sepsis
Prophylaxis: Doxycyclin or ciprofloxacin PO × 7 d; use insecticides, reduce rodent populations

Disposition
Admission, isolation

Pearls
Y. pestis: Gram-negative nonmotile nonsporulating coccobacillus; can remain viable for days → weeks in water, moist soil, grain, buried bodies; reservoir: Rodents
Mortality variable: Untreated bubonic 50%, Septic/pneumonic ~100%; tx reduced mortality to 10–15% overall

SMALLPOX (VARIOLA)

History
High fever, HA rigors, malaise, myalgias, vomiting, abd pain, back
pain, rash

Findings
- Virus multiplies in respiratory tract
- Incubation 10–14 d, spreads hematogenously → regional lymph nodes, blood vessels → skin changes
- 2 types: Major (30% mortality), minor (<1% mortality)
- 2–3 d after initial sxs, exanthema on face, hands, forearms → trunk & lower extremities
- Skin exanthem: Macules → papules (day 2) → vesicles (day 5) → umbilicated pustules (day 8); pustules form scabs after 8–14 d; death in 2nd wk from toxemia (mortality 25%)

Evaluation
- Clinical Dx; centrifugal distribution, lesions all in same stage of development, PCR

Treatment
- Isolation, hemodynamic support, skin care, vaccination w/i 4 d of exposure (after fever, before rash)

Disposition
- Isolation × 17 d; pts most infectious on day 3–6 after onset of fever, remain infectious until all scabs separated

Pearls
- Variola virus: Highly infectious by aerosol, environmentally stable, prolonged infectivity
- Transmitted through respiratory droplets, bodily fluids
- Last occurrence in Somalia in 1977; routine vaccination stopped in 1972

Botulism

History
- 6 H after inhalation pt would have descending paralysis, CN dysfunction (diplopia, dysphagia, ptosis) progresses to ventilatory failure
Evaluation
- Clinical Dx, confirmed with mouse bioassays through culture

Treatment
- Antitoxin (equine derived), available exclusively from CDC
- Respiratory support, mechanical ventilation

Disposition
- ICU

Pearls
- Not contagious
- Inhalational or gastrointestinal form could be used as weapon. Other forms occur (infantile, wound, iatrogenic).
ALTERED MENTAL STATUS

Approach

- **Definition:** Any transient or fixed change in cognition &/or arousability including but not limited to disorientation, memory impairment, behavioral changes, hallucinations
- “AMS” can describe a wide spectrum of clinical severity & be 2/2 diverse causes (see table); encompasses mild confusional states → delirium → coma, or dementia
- **Approach:** Dictated by clinical severity of AMS; if unconscious or severely altered:
  - Immediate IV access, telemetry, ABCs, O₂ for hypoxia (caution if hx severe COPD)
  - Bedside glucose measurement: If low, give immediate 1–2 amps D₅₀W
  - If concern for narcotic o/d or h/o opiate meds: Naloxone 0.4–2.0 mg IV/IM/IN
  - If h/o ETOH abuse or malnutrition: empiric thiamine 100 mg IV (can give D₅₀W first if hypoglycemia; replete thiamine before prolonged dextrose 2/2 risk of Wernicke’s)
- **History:** Start by assessing baseline MS, degree of change, acuity/timing of change, any circumstances surrounding AMS (Δ meds, intoxication/substance use, trauma), PMH
  - Eyewitness accounts helpful: Contact eyewitness if not present with patient
- **Exam:** Assess for focal neurologic sx's (if present, consider CVA, ICH, space-occupying lesion), pupil exam (toxidrome, ↑ ICP/herniation), skin exam (diaphoresis may suggest tox; dehydration may suggest lyte d/o), asterixis (CO₂ or NH₃ excess), clonus
- **Evaluation:** All patients should get CBC, Chem 10, LFTs, UA, Tox
screen, ECG, ± hcg; Consider CXR (esp if unable to give hx), TSH, VBG, NH₃, Drug levels, CO (esp if unwitnessed at home), Head CT, LP

<table>
<thead>
<tr>
<th>Category</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intracranial</td>
<td><strong>Ischemia:</strong> CVA (can cause AMS if large ± swelling, brainstem)</td>
</tr>
<tr>
<td></td>
<td><strong>Hemorrhage:</strong> Epidural (if trauma), SDH (can be atraumatic), SAH (traumatic or aneurysmal), IPH (2/2 neoplasm, HTN, AVM)</td>
</tr>
<tr>
<td></td>
<td><strong>Seizure (complex):</strong> Sz, post-ictal, or consider nonconvulsive status</td>
</tr>
<tr>
<td></td>
<td><strong>Space-occupying lesion:</strong> Neoplasm, Abscess (esp IVDU, HIV)</td>
</tr>
<tr>
<td></td>
<td><strong>Other:</strong> HTN encephalopathy, PRES, concussion (traumatic), diffuse axonal injury (traumatic), anoxic brain injury (esp if s/p ↓ O₂ or ↓ BP)</td>
</tr>
<tr>
<td>Metabolic</td>
<td><strong>Metabolic:</strong> Acidosis, ↑ CO₂, ↓ O₂, electrolyte Δ (Na, Ca), uremia, NH₃</td>
</tr>
<tr>
<td></td>
<td><strong>Endocrine:</strong> ↓ glucose, ↑ glucose (HHS, DKA), adrenal, thyroid (↑/↓)</td>
</tr>
<tr>
<td></td>
<td><strong>Nutritional:</strong> Wernicke’s, B₁₂ deficiency</td>
</tr>
<tr>
<td>Infectious</td>
<td>Sepsis, occult infection (esp in elderly: PNA, UTI, skin), fever-related delirium, meningitis/encephalitis, rarely neurosyphilis</td>
</tr>
<tr>
<td>Substances</td>
<td><strong>Depressants:</strong> Opioids, antipsychotics, sedative-hypnotics (eg, benzos), antihistamines, anticholinergics, alcohols (inc. toxic alcohols)</td>
</tr>
<tr>
<td></td>
<td><strong>Stimulants:</strong> Sympathomimetic agents, hallucinogens, w/d states</td>
</tr>
<tr>
<td>Medications</td>
<td>Psychotropic meds most often at fault, but always consider polypharmacy</td>
</tr>
<tr>
<td></td>
<td><strong>Serotonin syndrome</strong> (SSRI, NSRI, Linezolid, triptans, dextromethorphan, mepiridine, methadone, tramadol, ecstasy)</td>
</tr>
<tr>
<td></td>
<td><strong>Neuroleptic malignant syndrome</strong> (antipsychotics)</td>
</tr>
<tr>
<td>Trauma</td>
<td>Burns, electrocution, systemic inflammatory response, fat embolism, occult trauma (eg, abuse/neglect)</td>
</tr>
<tr>
<td>Environment</td>
<td>CO, cyanide</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exam Finding</th>
<th>Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>VS</td>
<td>↑ Temp                      Infxn, thyroid storm, adrenergic stim (drug o/d, w/d), SS/NMS</td>
</tr>
<tr>
<td></td>
<td>↓ Temp                      Environmental, hypothyroidism, sepsis</td>
</tr>
<tr>
<td></td>
<td>↑ RR                        Metabolic acidosis (DKA), stimulant, aspirin OD</td>
</tr>
<tr>
<td></td>
<td>↓ RR                        Narcotic o/d, CNS insult</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>↑ HR</th>
<th>Fever, sepsis, dehydration, thyroid storm, OD (stimulant, TCA, aspirin, theophylline, anticholinergic), acidosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>↓ HR</td>
<td>Heart block, ingestion (BB, CCB, digoxin), ↑ ICP</td>
</tr>
<tr>
<td>↑ BP</td>
<td>HTN emergency, preeclampsia, adrenergic stim (drug o/d, w/d), PRES, ↑ ICP, pain</td>
</tr>
<tr>
<td>↓ BP</td>
<td>Shock, sepsis, hemorrhage, toxins, GIB, adrenal crisis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Eyes</th>
<th>Miosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Opioid ingestion, clonidine</td>
</tr>
<tr>
<td></td>
<td>Mydriasis</td>
</tr>
<tr>
<td></td>
<td>Sympathomimetic or anticholinergic toxidrome</td>
</tr>
<tr>
<td></td>
<td>Asymmetric</td>
</tr>
<tr>
<td></td>
<td>Intracranial process w/ mass effect or herniation</td>
</tr>
<tr>
<td></td>
<td>Papilledema</td>
</tr>
<tr>
<td></td>
<td>↑ ICP</td>
</tr>
</tbody>
</table>

**Delirium**

- **Definition:** Acute state of temporary or fluctuating disturbance of consciousness (eg, impaired cognition, perception disturbances, reduced attention, hypo- or hyperactivity) that is caused by an organic medical condition or medication/drug (ie, not psychiatric)
- Can have many causes (see table above); w/u & tx dependent on causal etiology
- Delirium (vs. dementia or psych) suggested by: Age <12 or >40, visual hallucinations (vs. auditory), acute onset, exam abnormalities
- Dispo: Admit all pts not at baseline MS or with recent unexplained AMS; delirium in ED may independently predict 6-mo mortality *(Ann Emerg Med 2010;56(3):244–252)*

**Dementia**

- **Definition:** Progressive, unremitting decline in cognitive function due to a variety of causes (Alzheimer’s, vascular, Lewy-body, etc.), classically marked by decline in short- & eventually long-term memory, but advanced cases may have behavioral chgs (hypo- or hyperactive, agitation) or even nonverbal.
- Much more subacute than delirium, though can predispose pts to delirium from otherwise occult pathology (eg, UTI, PNA) due to poor cognitive reserve; 50% of elderly pts w/ delirium have some degree of underlying dementia *(Ann Emerg Med 2010;56(3):261–269)*
- Important to screen for elder abuse (e/o physical trauma, neglect);
EA is underdiagnosed but especially important in pts w/ dementia 2/2 inc risk of caregiver fatigue

<table>
<thead>
<tr>
<th>System</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degenerative</td>
<td>Alzheimer’s, Parkinson’s, Huntington’s, Pick’s dz</td>
</tr>
<tr>
<td>Vascular</td>
<td>Multi-infarct dementia</td>
</tr>
<tr>
<td>Infectious</td>
<td>Neurosyphilis, Creutzfeldt–Jakob dz, HIV</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>Lupus, demyelinating dz</td>
</tr>
<tr>
<td>Neoplastic</td>
<td>Primary CNS tumor, metastatic dz, paraneoplastic syndromes</td>
</tr>
<tr>
<td>Traumatic</td>
<td>TBI, SDH, anoxic brain injury</td>
</tr>
<tr>
<td>Toxic</td>
<td>Alcohol, medications, heavy metals</td>
</tr>
<tr>
<td>Metabolic</td>
<td>B₁₂/folate deficiency, thyroid, Wilson dz, lipid storage dz</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>Depression</td>
</tr>
<tr>
<td>Hydrocephalus</td>
<td>NPH, noncommunicating hydrocephalus</td>
</tr>
</tbody>
</table>

**HEADACHE**

**Approach**
- Must differentiate life-threatening HA (minority) from benign HAs (majority)
- **History:** Essential to describe timing/acuity of onset, location, quality, radiation/movement, severity, & associated sx (fever, photophobia, emesis, vision chg, eye pain, neck pain, focal neuro sx, chg in speech or cognition, sinus congestion), circumstances surrounding onset (trauma, med chgs, environment)
- **PMH:** Always ask about HA hx (if present: obtain detailed info regarding how current HA is similar/different), IVDU, immunosupp, & current/recent meds (eg, A/C)
- **Red flags** requiring neuroimaging: Sudden/rapid onset (<1 h to peak), exertional onset, worst of life, AMS, 1st severe HA >age 35, fever, neck stiffness, immunosupp, daily HA, no similar prior HAs,
abnl neuro exam, meningismus, papilledema

<table>
<thead>
<tr>
<th>Headache Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathophysiology</strong></td>
</tr>
<tr>
<td>Primary HA</td>
</tr>
<tr>
<td>Trauma</td>
</tr>
<tr>
<td>CNS Infection</td>
</tr>
<tr>
<td>Vascular</td>
</tr>
<tr>
<td>Neoplastic</td>
</tr>
<tr>
<td>CSF d/o (↑↓ ICP)</td>
</tr>
<tr>
<td>Otolaryngologic</td>
</tr>
<tr>
<td>Ophthalmologic</td>
</tr>
<tr>
<td>Environmental</td>
</tr>
</tbody>
</table>

**PRIMARY HEADACHE SYNDROMES**

**Migraine Headache & Variants**

**History, Physical Exam, & Evaluation**

- **HX**: Slow in onset (over hours), unilateral throbbing or pulsatile, often w/ N/V (>50%), photophobia; visual or sensory aura/prodrome may precede HA (15%); duration 4–72 h
- Migraine variants discussed below
- Classically have migraine hx; beware of assuming migraine if first time & age >35
- **EXAM**: Nl neuro exam (except in migraine variants)
- **DX**: No studies or consults routinely indicated unless need to exclude other cause (eg, CT, LP, MRI) as in the case of severe or prolonged sx (see Migraine Variants)

**Treatment**
Abortive: Most effective if given w/i 15 m of onset; often involves combo tx w/ IVF, NSAIDs, APAP, antiemetic (check QTc; common options inc prochlorperazine, metoclopramide; give w/ diphenhydramine to ↓ extrapyramidal sx); additional options include triptans & DHE (both c/i in preg & CAD), & dexamethasone
Prophylaxis: Indicated if >2/mo, duration > 24 h, major lifestyle disruption, failure of abortive tx; Options include AEDs, BB, TCAs, CCBs, SSRIs, behavioral/environmental chgs
Disposition
Most pts able to return home within hours; may need Observation Unit if protracted
Migraine Variants
Migraine variants are rare but can resemble other concerning conditions; often strong h/o similar events in the past, but if not, requires involved w/u to r/o other more serious dx
Hemiplegic migraine: HA a/w hemiplegia (± paresthesias); hemiplegia may resolve w/i hrs or persist days; HA may be subtle but classically pts have h/o similar prior sx
Basilar migraine: HA w/ dizziness/vertigo, ± ataxia, N/V, tinnitus, AMS
Abdominal migraine: Paroxysmal mid-abd pain a/w N/V, often w/o HA; strong h/o prior similar episodes & +FH; ddx inc. cyclic vomiting syndrome; more common in Peds
Ocular migraine: Gradual loss of vision in one eye 2/2 transient vasospasm of retinal arteries; often h/o prior similar episodes & +FH; avoid triptans & DHE
Status migrainosus: Migraine HA >72 h
Pearl
Migraine HA are independent RF for ischemic CVA (RR 1.64) & silent CVA (avoid triptans/DHE) (Neurol Sci 2017;38(1):33–40)
Tension Headache
History, Physical Exam, & Evaluation
HX: Dull, aching or throbbing “vice-like” pressure HA w/ gradual onset, bilateral frontal &/or occipito-nuchal; rarely w/ N/V or prodrome; duration 30 min to 7 d; a/w insomnia, stress, anxiety, or
depression

- **EXAM:** Normal neuro exam, no true photophobia
- **DX:** No studies or consults routinely indicated (unless need to exclude other cause)

**Treatment**

- NSAIDs or APAP, neck massage & heat, relaxation techniques, *not* narcotics

**Disposition**

- Most patients can go home within hours; if chronic HA, refer to HA specialist

**Cluster Headache**

**History, Physical Exam, & Evaluation**

- **HX:** Sudden onset unilateral, paroxysmal, sharp, stabbing severe temporal/periorbital HA that may awaken from sleep; ± ipsilateral lacrimation, flushing, rhinorrhea or nasal congestion, conj injection or Horner syndrome (30% of pts); occur in clusters of short (15–180 min) episodes (1 QOD to >8/d) for up to 6–8 wk; more common in men
- **EXAM:** Normal neuro exam or +Horner’s; may have +lacrimation, flushing, conj injection
- **DX:** No studies or consults routinely indicated (unless need to exclude other cause)

**Treatment**

- Abortive: High-flow O₂ (12–15 L/min) by mask, sumatriptan (CI in pregnancy or CAD), intranasal lidocaine, NSAIDs.
- Prophylaxis: Prednisone 60 mg ×10 d then taper, ± verapamil or valproic acid

**Pearl**

- Make sure to distinguish from acute angle-closure glaucoma

**Trigeminal Neuralgia**

**History, Physical Exam, & Evaluation**

- **HX:** Unilateral paroxysmal pain in sensory distribution of CN V, commonly involves the maxillary (V2) or mandibular (V3) branches; ± brief facial spasm or tic (“tic douloureux”); may be triggered by light
touch or vibration, shaving, face washing, chewing

- **EXAM:** No e/o CN dysfxn or other neurologic abnlty
- **DX:** Can be treated w/o w/u if characteristic hx; MRI if atypical features present (neuro deficit, age <40). Refer to neurology for outpt w/u.

**Treatment**

- Carbamazepine 100 mg BID, increase by 200 mg/d up to 1200 mg/d

**Pearl**

- Most common cause is compression of the nerve root by an aberrant vessel

---

**Acute Sinusitis**

**Overview**

- **Definition:** Inflammation of the paranasal sinuses, usually viral or allergic, though sometimes bacterial superinfxn (*S. pneumo*, nontypable *H. influenzae, M. catarrhalis*)
- **Dangerous pathogens:** Pseudomonas (esp HIV, CF, s/p instrumentation), invasive fungal sinusitis (Rhizopus) or mucormycosis (DM, immunosupp); require special tx

**History, Physical Exam, & Evaluation**

- **HX:** Consider with positional HA, worse bending forward or head movement; pts often have mucopurulent d/c, postnasal drip, sinus pressure, ± tap tenderness; may be afebrile (if +fever, more likely bacterial); progresses over 7–10 d
  - If no resolution w/i 7 d, suggests bacterial dz
- **EXAM:** May have pharyngeal erythema from postnasal drip, ± tap tenderness
- **DX:** Clinical. Imaging not routinely indicated; CT has high Se but low Sp.

**Treatment**

- Supportive (analgesics, antipyretics, decongestants, antihistamines if allergic)
- Decongestants: Neo-Synephrine nasal spray TID × 3 d, Afrin nasal spray BID × 3 d
Abx not routinely indicated: Reserve for pts w/ sxs >7 d, worsening sxs, fever, purulent d/c, or high risk for severe infection or cx

- First-line: Amoxicillin 500 mg PO TID × 10 d, TMP–SMX, or azithromycin
- If no improvement: Amoxicillin–clavulanate, fluoroquinolone, clindamycin

Disposition

- Discharge w/ PCP follow-up; Consider admx if high fever, immunosupp, poor f/u

Pearl

- Sphenoid/ethmoid sinusitis is less common than maxillary sinusitis but has significant potential cx (eg, orbital cellulitis, cavernous sinus thrombosis)

---

**Hypertensive Headache**

History, Physical Exam, & Evaluation

- **HX**: Untreated HTN or other precipitants (pregnancy, drug use, serotonin syndrome)
- **EXAM**: BP often >240/140 (unlikely w/ DBP <120); May have papilledema, encephalopathy, ± focal neuro abnormalities or sz
- **DX**: Assess for e/o end-organ damage (HTN emergency): Head CT (r/o ICH, edema), ECG, e/o aortic injury, pulm edema, renal failure

Treatment

- **IV Anti-HTN**: ↓ MAP by 25% over 1 h (Caution: ↓ BP too quickly could lead to ischemia)
- Common agents: Nitroprusside gtt (Cl in pregnancy) or Labetalol gtt

---

**Cerebral Venous Sinus Thrombosis**

Overview *(NEJM 2005;352(17):1791–1798)*

- **Pathophysiology**: Thrombosis of the sinuses of the brain (eg, sagittal, straight, occipital, transverse) with or without thrombosis of the cortical veins of the brain
- Sinus thrombosis impairs CSF absorption causing ↑ ICP (eg, HA,
AMS)

- Cortical vein thrombosis causes venous infarction & localized injury (eg, focal deficits)
- Because of cerebral injury, secondary hemorrhage may develop (40% cases)
- Prothrombotic RF (trauma, hypercoagulable state [esp preg]) present in 85%; other causes include post-LP (2/2 downward traction on cortical veins from pressure chg), sinusitis (cavernous thrombosis) otitis/mastoiditis

**History, Physical Exam, & Evaluation**

- **HX:** HA present >90%, often gradual over days but can be sudden; ± N/V, vision chgs, focal neuro deficits (see above); Assess PMH for prothrombotic RFs
- **EXAM:** Assess for papilledema, focal neuro deficits; cavernous sinus thrombosis will have CN III/IV/VI compromise, periorbital chemosis/edema, & ↓ vision ipsilaterally
- **DX:** CBC, PT/INR, PTT, Upreg, ± D-dimer; MRI/MRV more Se than CTV but balance accuracy with urgency & desire to r/o other diagnoses (eg, SAH, IPH)
  - D-dimer may help r/o CVST if low pre-TP (weighted Se 94%, Sp 90%) *(J Thromb Haemost 2012;10(4):582–589)*

**Treatment**

- Anticoagulation (heparin) preferred, often even in presence of hemorrhagic infarcts
- Endovascular thrombolysis can be used, but often reserved for those w/ worst prognosis

**Disposition**

- Admission to neurology; may warrant ICU care if e/o hemorrhagic conversion or AMS

---

**TEMPORAL ARTERITIS (GIANT CELL ARTERITIS)**

**Overview**

- **Definition:** Granulomatous inflammatory vasculitis of medium/large arteries occurring in pts > 50 y (peak incidence 70–80 y); largely
affecting branches of ECA, vertebral, distal subclavian, axillary, arteries, & thoracic aorta; causes ischemic sx by vessel occlusion

**History, Physical Exam, & Evaluation**

- **HX:** Unilateral HA, jaw/tongue claudication, malaise, low-grade fevers, visual impairment
- **RFs:** Age >50 y/o (90% >60 y/o), F > M, h/o PMR (50% of pts)
- **EXAM:** May have tenderness over temporal art. (↓ Se) or ↓ visual acuity (↓ Se)

**Evaluation** *(NEJM 2014;371:50–57)*

- ↑ ESR (Se ∼84%), ↑ CRP (Se ∼86%), combined Se of ESR & CRP may be >95%, but poorly specific in pts w/ other causes for elevation
- Temporal art. bx: high Se for even low-levels of inflammation *if present at site of bx* (requires 1.5–2.0 cm segment); given focality of dz, may need repeat bx or imaging if high pre-TP & first-bx neg
- CTA &/or MRA: Not used to make dx, but may serve as adjunct if -bx &/or assess extent of dz if +bx

**Treatment**

- Prednisone 1 mg/kg/d (if vision sx, do not wait for bx results) ∼2–4 wk, then prolonged taper
- Consult neurology, ophthalmology, rheumatology if concern for dx & to arrange f/u

**Disposition**

- Admit for visual deficits; Can be discharged on steroids w/ follow-up

---

**Pseudotumor Cerebri (idiopathic intracranial HTN)**

**Overview**

- Pathophysiology: Set of sx of unclear etiology; due to obstructed venous/CSF outflow rather than ↑ CSF production

**History, Physical Exam, & Evaluation** *(Cephalgia 2015;35(3):248–261)*

- **HX:** Gradual onset, global, daily/constant HA (>90%) or retrobulbar pain, ±, N/V, ↓ vision (∼70%; may be transient), intracranial noises (∼60%); sx can be worst in morning
- **RFs:** Young obese females, recent weight gain; some meds
(tetracyclines, retinoids)

- **EXAM**: NI neuro exam (except possible CN VI palsy), check vision & for papilledema
- **DX**: Can be clinical dx (sx, papilledema); LP for opening pressure (>25 cm H$_2$O in lateral decubitus) confirms dx; Neuroimaging may be normal (or show swelling of optic discs)

**Treatment**
- Neuro consult (± ophthalmology) if new dx or refractory to tx
- Weight loss remains most effective treatment
- Diuretics to decrease ICP: Acetazolamide 1 mg PO QD
  - May need repeated high-volume LPs; refractory cases may need VP shunt
- Use of steroids controversial & may worsen weight gain

---

**Dural Leak/Post-LP Headache**

**Overview**
- **Definition**: HA caused by ICP caused by loss of CSF from recent dural injury (eg, due to LP, myelogram, spinal anesthesia, vigorous coughing)

**History, Physical Exam & Evaluation**
- **HX**: Occipital HA radiating to shoulders/neck, worse with sitting/standing (± alleviated w/ supine); Worsened by activities that ↑ ICP (eg, coughing, sneezing, Valsalva); Usually present 48–72 h postdural injury (but can be >1 wk); ± N/V, LH, photophobia, tinnitus
- **EXAM**: Nonfocal neuro exam; HA improved w/ lying flat, worse w/ sitting up
- **DX**: None spec; evaluate for other causes of HA, if indicated

**Treatment**
- As much as 8% will resolve w/o tx; tx indicated for severe or prolonged (>72 h) sx
- Epidural blood patch (clot forms to seal dural defect): 70–98% success
- Methylxanthine derivatives (caffeine IV, aminophylline) may be helpful, limited data
Surgical closure of dural gap is last-resort effort if blood patch &/or other options fail

**Pearls**
- Minimize risk of post-LP HA w/ small caliber spinal needle (24–27G), bevel alignment w/ dural fibers, atraumatic needles, minimized number of attempts
- Severe cases can precipitate Sz & SDH (2/2 ↓ ICP → brain pulled → bridging vein strain)

**INTRACRANIAL NEOPLASM**

- **Definition:** Any of a spectrum of neoplasms, each with distinct biology, epidemiology, natural history, & management, & prognosis; often cause acute sx due to mass effect of tumor, vasogenic edema, or secondary hemorrhage on neural tissue, or sz
- Tumors either extraparenchymal (meningioma, pituitary neoplasm) or intraparenchymal
  - Intraparenchymal most commonly glioma (eg, oligodendroglioma, mixed glioma, astrocytoma), primary CNS lymphoma, or metastatic non-CNS primary cancer

**History, Physical Exam, & Evaluation**
- **HX:** Subacute onset, often daily morning HAs (2/2 ↑ ICP), ± N/V, focal deficits, chgs in personality or speech, sz; alleviation w/ NSAIDs/APAP does not help r/o dx
- **EXAM:** Look for signs of herniation:
  - Uncal (most common): ↓ mental status, blown unilateral pupil, decerebrate posturing
  - Central: AMS, yawning, Cheyne–Stokes breathing, miosis. Decorticate → decerebrate.
  - Tonsillar (posterior): Bradycardia, coma, respiratory arrest
  - Cushing reflex (due to ↑ ICP): HTN, bradycardia, irregular breathing
- **DX:** Neuroimaging w/ CT, usually followed by MRI (w/ contrast); In those suspected w/ pituitary tumors, check lytes, cortisol, TSH
  - Treatment & prognosis depend on tumor phenotype & grade
Treatment (glioma)
- Dexamethasone 4 mg TID for mass effect/minimize edema
- Antiepileptic treatment
- Consult NSGY (consideration of resection), Neuro-oncology

Disposition
- Admit all patients w/ new dx of intracranial neoplasm; or transfer to facility w/ NSGY
- Prognosis heavily dependent on phenotype & grade (mos to yrs)

CNS INFECTIONS

Meningitis
Overview
- **Definition:** Inflammation of the meninges overlying the brain due to either infectious (bacterial, fungal, viral) or noninfectious etiology; sx & tx differ widely based on etiology
- Bacterial meningitis rare in developed nations; common bacteria include *S. pneumoniae, N. meningitidis, H. influenzae type b, L. monocytogenes* (infants, elderly, pregnant), *staph* (VPS, trauma, NSGY); seeding of subarachnoid space 2/2 hematogenous spread (eg, from resp tract) or direct spread (eg, sinusitis, acute OM)
- Causes of noninfectious “aseptic” meningitis include drugs (eg, antimicrobials, vaccines, NSAIDs), inflammatory dz (SLE, Behcet); rarely malignancy can p/w leptomeningeal dz

History
- Bacterial: Typically acute (<1 d), high-grade fever, HA, nuchal rigidity, ill appearing, AMS
  - RFs: Extremes of age, immunosupp (esp HIV, steroids, MM/blood ca), crowded living environment (dorms, shelters), splenectomy, ETOH abuse / cirrhosis, IVDU, recent illness (esp sinusitis/OM), dural defect (recent trauma, surgery; congenital, VPS)
  - Classic triad for bacterial etiology: Neck stiffness, fever, AMS (3 of 3 present <50%, 2 of 3 present >95%) *(Lancet* 2016;388(10063):3036–3047)
- Viral: Typically subacute (1–7 d), also w/ HA, fever, photophobia;
unless HSV, usually normal mental status; HSV usually w/ AMS

- Fungal/TB: Subacute (>1 wk), HA, low-grade fever, weight loss, night sweats, ± AMS

**Physical Exam**

- May have nuchal rigidity, disorientation/AMS, photophobia
  - Brudzinski sign (hip flexion elicited by passive neck flexion) & Kernig sign (inability or reluctance to extend knee when hip is flexed to 90): High Sp, but Se only 5%
- Petechial/purpuric rash suggests meningococcus (*N. meningitidis*)
- Expect subtle presentation in elderly or immunocompromised pts; may be AMS only

**Evaluation**

- LP is gold standard for dx but should not delay abx if high pre-TP for bacterial/HSV
  - See table below for indications for CT prior to LP
  - LP tubes: (1 & 4) cell count & diff, (2) gluc & protein, (3) Gram stain, cx ± HSV PCR
  - Gram stain Se depends on etiology: *S. pneumoniae* (Se >90%), *H. influenzae* (75%), *N. meningitidis* (50%), *L. monocytogenes* (33%); GS & Cx yield may ↓ by 40% if performed after abx, improved by PCR (*Clin Infect Dis* 2004;39(9):1267; *Lancet* 388:3036–3047)
  - BCx, full infectious w/u (CBC, CXR, UA); thrombocytopenia suggests meningococcus

**Treatment** (*Clin Infect Dis* 2004;39(9):1267)

- Respiratory precautions if suspect bacterial
- Empiric abx based on suspected etiology (see table); acyclovir 10 mg/kg q8h if c/f HSV
- Early steroids may ↓ inflammatory cascade in bacterial meningitis; therefore, if proven or high pre-TP bacterial etiology, give dexamethasone 0.15 mg/kg w/i 20 min of 1st abx (↑ favorable neuro outcomes & ↓ mortality)
- Consult NSGY in all pts w/indwelling hardware (eg, VPS): removal improves tx success
- Postexposure ppx (if +*N. meningitidis*): Ciprofloxacin 500 mg PO × 1. Ceftriaxone 250 mg IM (peds), or Ceftriaxone 150 mg IM
(pregnancy).

- If viral (non-HSV): Supportive care only, prophylaxis not needed

**Disposition**
- Admit bacterial, HSV, fungal; Non-HSV viral: D/C vs. Observation based on sx severity

---


<table>
<thead>
<tr>
<th>Indication</th>
<th>CT Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;60</td>
<td>Any neurologic abnormalities: ↓ GCS*, CN ability, abnl visual fields, pronator drift, abnl language (eg, aphasia)</td>
</tr>
<tr>
<td>Immunocompromised</td>
<td></td>
</tr>
<tr>
<td>History of CNS/neurologic dz</td>
<td></td>
</tr>
<tr>
<td>Recent seizure w/i 1 wk of presentation</td>
<td>Inability to follow two consecutive commands</td>
</tr>
<tr>
<td>Papilledema</td>
<td>Inability to answer two consecutive questions</td>
</tr>
</tbody>
</table>

*No clear data on precise GCS cut-off; some studies suggest CT for any GCS <13, while others suggest CT only if GCS <8. Others simply use “alert” or “not alert” (NEJM 2001;345:1727–1733).*

---

**Interpretation of LP Results**

<table>
<thead>
<tr>
<th>CSF Test</th>
<th>Normal</th>
<th>Implications of Abnormal Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>&lt;5 WBC &lt;1 PMN</td>
<td>Bacterial: Marked ↑ WBC (usually &gt;1000), ↑ PMN Viral: Usually ↑ WBC but &lt;500, mononuclear Traumatic tap: if serum WBC nl, expect 1 WBC for every 700 RBC (limited data)*</td>
</tr>
<tr>
<td>RBC</td>
<td>None</td>
<td>↑↑ RBC: traumatic LP (if T1 &gt; T4) or SAH (T1–T4) ↑ RBC (&amp; ↑ WBC): Consider HSV Xanthochromia indicates RBCs present 4 h prior</td>
</tr>
<tr>
<td>CSF:Serum Gluc</td>
<td>0.6:1</td>
<td>↓ in bacterial/fungal meningitis or hyperglycemia</td>
</tr>
<tr>
<td>Protein</td>
<td>15–45 mg/dL</td>
<td>↑ in bacterial/fungal meningitis, syphilis, neoplasm, demyelination, bleed (SAH)</td>
</tr>
<tr>
<td>Opening pres.**</td>
<td>&lt;20 mmH2O</td>
<td>↑ in bacterial, fungal or TB</td>
</tr>
<tr>
<td>Gram stain</td>
<td>Negative</td>
<td>Positive in 80% of bacterial meningitis (see above)</td>
</tr>
</tbody>
</table>

*Limited data from adult population. In infants 0–60 d, may be safe to use ratio of 1 WBC: 877 RBCs (Ann Emerg Med 2016;pii:S0196-064(16)31223–31229).

**Can be elevated 2/2 noninfectious etiologies as well.**
<table>
<thead>
<tr>
<th>Age</th>
<th>Common Pathogens</th>
<th>Empiric Antibiotic Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1 mo</td>
<td>Group B strep, <em>E. coli</em>, <em>L. monocytogenes</em>, <em>Klebsiella</em></td>
<td>Ampicillin AND (Cefotaxime OR Gentamicin)</td>
</tr>
<tr>
<td>1–24 mo</td>
<td>Group B strep, <em>S. pneumonia</em>, <em>H. influenzae</em>, <em>N. meningitidis</em></td>
<td>Vancomycin AND Ceftriaxone</td>
</tr>
<tr>
<td>2–50 yr</td>
<td><em>S. pneumonia</em>, <em>N. meningitidis</em></td>
<td>Vancomycin 1 g AND Ceftriaxone 2 g</td>
</tr>
<tr>
<td>&gt;50 yr</td>
<td><em>S. pneumonia</em>, <em>N. meningitidis</em>, <em>P. aeruginosa</em>, <em>L. monocytogenes</em></td>
<td>Vancomycin 1 g AND Ceftriaxone 2 g AND Ampicillin 150 mg/kg/d div q4h</td>
</tr>
<tr>
<td>Surgery/Trauma</td>
<td><em>S. aureus</em>, <em>S. epidermidis</em>, <em>P. aeruginosa</em></td>
<td>Vancomycin 1 g AND Cefepime 2 g</td>
</tr>
</tbody>
</table>

## Encephalitis

### Overview

- **Definition:** Inflammation of brain parenchyma usually due to infection (often viral); rarely autoimmune/paraneoplastic (*Lancet Neurol* 2016;15(4):391–404)
- HSV (5–10% encephalitis) life-threatening (>70% mortality w/o tx) (*BMJ* 2012;344:e3166)

### History & Physical Exam

- **HX:** Acute onset fever (>90% w/ HSV), HA (>80% w/ HSV), behavior chgs (>70% w/ HSV), hallucinations/altered awareness (>60% w/ HSV), confusion/impaired memory (25% w/ HSV); ± diffuse or focal neuro sx (weakness, ataxia, speech disturbance), seizure, or e/o meningeal involvement (+photophobia, +neck stiffness) (*BMJ* 2012;344:e3166)
- Absence of fever or HA strongly suggests against the dx of HSV encephalitis
- HSV encephalitis often preceded by nonspecific viral prodrome (fever, malaise, N/V)
- Assess for immunosupp, recent travel, tick/mosquito bites
- **EXAM:** AMS (may progress to coma), more likely to have focal
neuro deficits than isolated meningitis (may progress to diffuse paralysis &/or ataxia); may have e/o concurrent meningeal involvement

**Evaluation** *(BMJ 2012;344:e3166)*
- LP: CSF ↑ WBC, ± ↑ RBC/xanthochromia, ± ↑ protein levels, nl glucose
  - Important to send HSV PCR, but should not defer tx
- MRI: Imaging modality of choice & helps r/o CI to LP; Se 90% in HSV encephalitis
- EEG: Se 84%, Sp 32% for HSV encephalitis (may help guide need for AEDs)

**Treatment**
- If concern for HSV encephalitis: Acyclovir 10 mg/kg q8h IV, AEDs
- If low concern for HSV: Supportive ± anticonvulsants, steroids

**Disposition**
- Admit if confirmed/suspected HSV, not at baseline (eg, AMS), immunosupp

**Abscess**

**Overview**
- **Definition:** Purulent collections w/i the CNS (intraparenchymal, epidural, subdural, spinal); form by contiguous spread (sinus, dental) or hematogenous seeding (PNA, endocarditis)
- RFs: Immunosupp, IVDU, trauma/surgery, local infxn (mastoiditis, sinusitis, dental), & RFs for systemic infxn (eg, endocarditis, line infxn, bacteremia)
- Certain medical conditions predispose to certain pathogens: HIV (*Toxoplasma gondii, M. tuberculosis*), solid-organ tpx (aspergillus, candida), post-surgical (staph, gram-neg)

- **HX:** HA (most common), ± low-grade fever; neuro sx only late in dz; AMS often absent
  - Up to 25% of pts may p/w seizures
  - Assess for RFs & ROS suggesting possible source infxn
- **EXAM:** May have nl neuro exam depending on site of abscess &
timing of presentation

› **DX:** ↑ WBC, ↑ ESR, blood cultures. CT w/ contrast ("ring-enhancing" lesion)
  
  • Owing to risk of brain herniation & low Se (25%), LP not routinely performed
  
  • NSGY consultation for diagnostic stereotactic aspiration for cx & decompression
  
  • Antitoxoplasma IgG can confirm toxoplasma dx in HIV pts (no need for aspiration)

**Treatment**

› Although diagnostic NSGY aspiration aims to decompress maximally, therapeutic NSGY aspiration (eg, if pathogen already known) indicated only for large abscesses or those w/ e/o IV abx failure (*NEJM* 2014;371(5):447–456)
  
  › Early abx (before diagnostic aspiration, esp if acute or severe)
  
  › Low threshold to intubate (may progress rapidly)

**Disposition**

› Admit all pts; may require ICU

---

**Empiric Antibiotics for Brain Abscess** (*NEJM* 2014;371(5):447–456)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Standard</strong></td>
<td>Ceftriaxone* 2 g AND Metronidazole 500 mg ± Vancomycin 1 g</td>
</tr>
<tr>
<td><strong>Transplant patients</strong></td>
<td>Ceftriaxone* 2 g AND Metronidazole 500 mg ± Vancomycin 1 g AND Voriconazole AND Trimethoprim-Sulfamethoxazole</td>
</tr>
<tr>
<td><strong>HIV-positive patients</strong></td>
<td>Ceftriaxone* 2 g AND Metronidazole 500 mg ± Vancomycin 1 g AND Pyrimethamine AND Sulfadiazine Consider TB tx (INH, Rifampin, Pyrazinamide, Ethambutol)</td>
</tr>
</tbody>
</table>

*Meropenem can be substituted for cephalosporin if allergies present

---

**SEIZURE**

**Overview**

› **Definition:** Spontaneous or provoked abnl synchronous cortical electrical activity; recurrent unprovoked seizures referred to as “epilepsy” (*Ann Emerg Med* 2014;63(4):437–447)
- **Simple vs. Complex:** Refers to degree of change of mental status; simple sz cause no chg in mental status, while complex can cause AMS or complete LOC
- **Partial vs. Generalized:** Refers to location(s) of brain involved & corresponding sx; partial sz are limited to one area of one hemisphere, while generalized are bilateral
- **Status epilepticus:** >20 min continuous generalized sz activity or continued intermittent sz w/o return to baseline mental status (*Ann Emerg Med* 2014;63(4):437–447)
  - May be provoked by numerous etiologies (see table)

<table>
<thead>
<tr>
<th>Common Etiologies Provoking Seizure</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNS</td>
</tr>
<tr>
<td>Ischemia (eg, CVA), ICH, Vascular malformations (aneurysm, AVM), Neoplasm (primary, met), Sinus thrombosis, Trauma, PRES, HTN enceph, inherited conditions (NF, Tub. sclerosis, Sturge–Weber, etc.)</td>
</tr>
<tr>
<td>Infection</td>
</tr>
<tr>
<td>Febrile sz (peds), meningitis, encephalitis, brain abscess, HIV OIs, HIV enceph, neurocysticeriosis, neurosyphilis, malaria</td>
</tr>
<tr>
<td>Toxic</td>
</tr>
<tr>
<td>W/D (ETOH, benzo, barb), OD (sympathomimetic, TCA, anticholinergic, SSRI/NSRI, lidocaine, INH), Caffeine</td>
</tr>
<tr>
<td>Metabolic</td>
</tr>
<tr>
<td>↑↓ glucose, ↑↓ Na, ↓ Ca, ↓ Mg, ↓ O2, uremia, liver failure, thyrotoxicosis</td>
</tr>
<tr>
<td>Obstetric</td>
</tr>
<tr>
<td>Eclampsia</td>
</tr>
<tr>
<td>Environmental</td>
</tr>
<tr>
<td>Heat stroke, Stress, Lack of sleep</td>
</tr>
<tr>
<td>Neonatal</td>
</tr>
<tr>
<td>CMV, congenital syphilis, rubella, inborn errors of metabolism (eg, PKU)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Common Types of Seizures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location</strong></td>
</tr>
<tr>
<td>Generalized</td>
</tr>
</tbody>
</table>
**Absence**
- Abrupt LOC; Staring spells or rhythmic blinking; no incontinence
- Minimal post-ictal state but patients unable to recall event
- School-aged children (usually resolves by adulthood)

**Partial (focal)**

**Simple**
- Isolated unilateral motor (eg, convulsions, automatisms) or sensory (eg, loss or change), or autonomic activity
- No LOC, change in behavior or mental status, or post-ictal state; patients can recall event

**Complex**
- Isolated unilateral motor (eg, convulsions, automatisms) or sensory (eg, hallucinations), or autonomic activity
- No LOC, but does have behavior change ± postictal confusion

### Approach
- If actively seizing: Immediate IV access, roll patient into decubitus (avoid aspiration), suction airway, supplemental O₂, fingerstick glucose, magnesium (if pregnant), antiepileptic agents (IV, IO, IM, IN)
- If not actively seizing: Assess return to baseline mental status, focal deficits

### History
- Description of events before, during, & after sz: prodrome, associated sxs (fever, vomiting, HA, trauma, photophobia, visual chg), any focal neuro sxs, AEDs given, type of sz (partial vs. generalized; if partial: simple vs. complex) & duration, post-ictal state
- **First-time Sz:** Assess possible causal etiologies (see above)
- **Breakthrough Sz:** Assess similarities &/or differences from prior sz, typical sz frequency, last sz prior to presentation, any changes in AEDs, outpt provider, factors that may lower sz threshold (stress, sleep, noncompliance, new meds, toxins, alcohol, infxn)
- Differentiate from syncope (may have myoclonic jerks, no incontinence or tongue-biting, quick return to baseline mental status)
- Assess for sx of traumatic injury

### Physical Exam
- Assess GCS, orientation, & memory (compare with baseline), neuro
deficits
  ▪ Evaluate for e/o trauma (inc tongue biting) or ingestion; if persistent 
    AMS & unwitnessed sz w/ e/o head trauma or fall, may need 
    temporary C-spine immobilization until cleared

  ▪ If active seizing: Defer evaluation until cessation of sz (see 
    Approach)
  ▪ First-time Sz & back to baseline:
    • Labs: CBC, BMP (glucose, Na), HCG; ± lactate, CPK (↑ lactate & ↑ 
      CPK can help differentiate b/w unwitnessed convulsive sz & 
      syncope w/ myoclonus), LP if immunosupp (even if afebrile); PRN 
      based on hx: Tox screen, LFTs, LP
    • Neuroimaging: Obtain noncontrast CT in ED if feasible
      • May defer neuroimaging to o/p if: Age <40 y, normal neuro exam, 
        no concern for intracranial path (no trauma, no hx malignancy or 
        immunosupp, no fever, no HA, no A/C use), & good o/p f/u; 
        preferred o/p study is MRI w/contrast
      • MRI w/contrast > CT for evaluation of tumors (esp in elderly, hx 
        cancer), but can be done as o/p in most pts if CT negative
    • EEG: May be performed as outpt; indicated only for persistent 
      AMS, SE, dx of viral encephalitis, intubated/paralyzed, r/o 
      nonconvulsive SE
  ▪ Breakthrough sz:
    • Labs: Electrolytes, UA, AED levels, ± CXR; ± lactate, CPK (↑ 
      lactate & ↑ CPK can help differentiate b/w unwitnessed convulsive 
      sz & syncope w/ myoclonus)
    • Neuroimaging: Consider if different from prior sz, prolonged 
      duration since recent sz, trauma, or other c/f intracranial pathology
    • Keep differential broad even if known sz d/o, esp if therapeutic med 
      levels

Treatment
  ▪ Airway: Nasal trumpet, supplemental O₂, suction, positioning, may 
    need to intubate if SE
  ▪ Abortive meds: Benzodiazepines 1st line (available IV, IM, IN,
buccal, PR); ongoing investigations to establish optimal second-line agent

- IV lorazepam vs. IM midazolam: IM midazolam is noninferior & may be superior to IV lorazepam w/ regard to sz termination/need for rescue tx, & is quicker if no IV access (Epilepsia 2015;56(2):254–262; NEJM 2012;366(7):591–600)

- IV lorazepam vs. IV diazepam: IV lorazepam superior to IV diazepam w/ regard to sz termination / need for rescue tx (Cochrane 2014;(9):CD003723)

- Special cases w/ alternative 1st-line tx: Pregnant (Mg 4g IV), INH tox (pyridoxine 1g)

  - If not seizing, tx w/AED depends on risk of recurrence: (Ann Emerg Med 2014;63(4):437–447)
  - First-time sz (provoked or unprovoked): No AED indicated if back to baseline mental status, no current or known h/o structural brain disease/injury
  - If h/o sz d/o & ↓ AED levels, load w/ AED (PO or IV; home agent preferred)
  - If h/o sz d/o & nl AED levels (& no clear provoking trigger): Contact o/p prescriber to discuss ↑ o/p AED dose

<table>
<thead>
<tr>
<th>Step</th>
<th>Antiepileptic</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Lorazepam OR</td>
<td>2–4 mg (0.1 mg/kg), repeat q5–10min if sz persists</td>
</tr>
<tr>
<td></td>
<td>Diazepam OR</td>
<td>5–10 mg (0.2 mg/kg), repeat q5–10min if sz persists</td>
</tr>
<tr>
<td></td>
<td>Midazolam</td>
<td>5–10 mg (0.2 mg/kg), repeat q5–10min if sz persists</td>
</tr>
<tr>
<td>2</td>
<td>Phenytoin OR</td>
<td>1–1.5 g (10–15 mg/kg) over 20 min</td>
</tr>
<tr>
<td></td>
<td>Fosphenytoin OR</td>
<td>1–1.5 g (15–20 mg/kg) over 5–10 min</td>
</tr>
<tr>
<td></td>
<td>Valproic acid</td>
<td>25–45 mg/kg (absence sz)</td>
</tr>
<tr>
<td></td>
<td>Levetiracetam</td>
<td>1–1.5 g (under study; not included in AAN/ACEP guidelines)</td>
</tr>
<tr>
<td>3</td>
<td>Phenobarbital</td>
<td>200–600 mg slow push, then 10–20 mg/kg if no resolution</td>
</tr>
<tr>
<td>4</td>
<td>General anesthesia w/ propofol, midazolam, or pentobarbital ± paralytics</td>
<td></td>
</tr>
</tbody>
</table>
Provoked sz: Disposition depends on underlying cause; if underlying cause cannot be rapidly reversed & pt remains at risk for recurrent provoked sz, admx vs. observation
Unprovoked sz: Most can be safely discharged w/ close neuro f/u if nl mental status, exam, & w/u (above)
If on long-term meds or 2nd sz, discuss w/ neurology regarding dose adjustments or starting a long-term med
Explicit instructions to not drive, operate hazardous machinery or perform tasks where recurrent sz may cause harm; some states have mandatory reporting to DMV
Admit all pts with 2+ sz in pre-hospital/ED or SE; may need ICU

Pearl
• Treat alcohol w/d sz w/ BZD, almost never responsive to phenytoin

---

**VERTIGO**

**Definition**
• The sensation of disorientation in space combined w/ sensation of motion/spinning
• May be due to benign (usually peripheral) or life-threatening (usually central) causes
  • Central comprise ~10% of cases; CVA comprises ~4% *Mayo Clin Proc* 2008;83:765–777
  • RFs for central vertigo: Older age, males, HTN, CAD, DM, AF, h/o CVA/TIA

<table>
<thead>
<tr>
<th>Differential Diagnosis for Vertigo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Peripheral</strong></td>
</tr>
<tr>
<td>FB, cerumen impaction, acute otitis media, labyrinthitis, benign paroxysmal positional vertigo, Ménière’s dz, vestibular neuronitis, perilymphatic fistula, trauma, motion sickness, acoustic neuroma, ototoxic medications (eg, gentamicin, furosemide)</td>
</tr>
<tr>
<td><strong>Central</strong></td>
</tr>
<tr>
<td>Infection (encephalitis, meningitis, cerebritis), vertebrobasilar art. insufficiency, subclavian steal syndrome, cerebellar or brainstem hemorrhage or infarction, vertebrobasilar migraine, trauma (temporal bone fracture, postconcussive syndrome), tumor (brainstem or cerebellum), MS, temporal lobe epilepsy</td>
</tr>
</tbody>
</table>
History & Physical Exam

- **HX:** Onset & duration of sx; changes with position & direction; associated sx (HA, neuro sx, dysarthria, chg in hearing, CP/LH, palpitations); circumstances surrounding onset (trauma, torsional neck inj, neck manipulation, new meds); PMH including meds
  - Distinguish b/w vertigo & pre-syncope or light-headedness
- **EXAM:** Assess for neuro deficits, nystagmus, cerebellar exam, gait, ± Dix Hallpike; listen for carotid bruits, otoscopy, cardiac murmurs

### Historical & Exam Features of Central vs. Peripheral Vertigo

<table>
<thead>
<tr>
<th></th>
<th>Peripheral</th>
<th>Central</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Timing</strong></td>
<td>Acute-onset (seconds)</td>
<td>Gradual-onset (min–hr)</td>
</tr>
<tr>
<td></td>
<td>Can be intermittent or constant</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Often self-resolves (sec–hrs)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Present early in course</td>
<td></td>
</tr>
<tr>
<td><strong>Intensity</strong></td>
<td>Severe</td>
<td>Mild–moderate</td>
</tr>
<tr>
<td><strong>Nystagmus</strong></td>
<td>Always present: Unidirectional, fatigable horizontal or rotatory (never vertical)</td>
<td>May be absent, can be bidirectional. Vertical nystagmus almost always central in origin.</td>
</tr>
<tr>
<td><strong>Associated sx</strong></td>
<td>Intense N/V</td>
<td>Mild nausea, often HA</td>
</tr>
<tr>
<td></td>
<td>Provoked by movement/position</td>
<td>Not affected by movement</td>
</tr>
<tr>
<td></td>
<td>± hearing loss or tinnitus</td>
<td>Usually no auditory sx</td>
</tr>
<tr>
<td></td>
<td>NI brainstem/cerebellar exam</td>
<td>May have abnl neuro exam</td>
</tr>
</tbody>
</table>

### Evaluation

- **ECG** (r/o arrhythmia), glucose & electrolytes, UA, HCG (if child-bearing age)
- Neuroimaging: Preferred modality is MRI; head CT PRN to r/o hemorrhage (eg, HA, trauma, A/C), limited utility for cerebellum/brainstem
  - Consider CTA or MRA to evaluate for vascular dz (carotid, vertebrobasilar)

### Treatment

- **Central:** Symptomatic relief (antiemetics, benzodiazepines); Neurology consult, ASA (if ischemic CVA); NSGY (if hemorrhagic
CVA) & anticoagulation reversal

- **Peripheral:** usually supportive care w/ antivertigo medications (Diazepam 2–4 mg IV/5–10 mg PO, meclizine 25 mg PO, diphenhydramine, promethazine)
- For BPPV, consider trying Epley maneuver (or modified self-Epley maneuver at home)
- For acute bacterial labyrinthitis: ENT consult, IV abx, usually need admission
- For Ménière’s: Supportive medications, encourage decreased salt intake, close ENT f/u

**Disposition**

- Home once sx improve w/ PCP/ENT f/u
- Admit if (a) central/CVA, (b) peripheral w/ refractory sx, (c) acute bacterial labyrinthitis

**Pearl**

- More than half of pts presenting to ED with a chief complaint of “dizziness” or “vertigo” may have nonneurologic processes (*Mayo Clin Proc* 2008;83:765–777)

---

### Common Causes of Peripheral Vertigo

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benign paroxysmal positional vertigo</td>
<td>• Due to otolith disruption w/i semicircular canals (often posterior)</td>
</tr>
<tr>
<td></td>
<td>• Most common cause of peripheral vertigo (lifetime prev 2.4%; annual rate of recurrence 15%) (<em>NEJM</em> 2014;370:1138–1147)</td>
</tr>
<tr>
<td></td>
<td>• <strong>HX:</strong> Brief (sec/min) spinning sensation, episodic (&lt;1 min each), precipitated by chg in head position (eg, rolling over in bed), severe, a/w N/V</td>
</tr>
<tr>
<td></td>
<td>• <strong>DX:</strong> Dix-Hallpike causes sx &amp; unidirectional nystagmus in &gt;70% pts, depending on canal involved: start in seated position, rapidly lie flat on back, extend pt’s head back 45°, then immediately to left or right 45°, keep pt’s eyes open, monitor nystagmus &amp; sx, repeat on other side.</td>
</tr>
<tr>
<td></td>
<td>• <strong>TX:</strong> Usually resolves w/o tx (median duration 7 d w/ horizontal canal, 17 d w/ posterior canal); Epley’s maneuver may cure sx in &gt;80% w/ one cycle &amp; &gt;92% w/ four cycles</td>
</tr>
<tr>
<td>Labyrinthitis - Viral - Acute bacterial - Toxic</td>
<td>• Inflammatory d/o of inner ear 2/2 infection or external toxin</td>
</tr>
<tr>
<td></td>
<td>• Distinguished from vestibular neuronitis by hearing involvement</td>
</tr>
<tr>
<td></td>
<td>• <strong>Viral/Serous:</strong> Usually coexisting or recent URI/OM, may have hearing loss; usually nontoxic, may have mild fever; r/o VZV (Ramsay Hunt) requiring IV acyclovir &amp; admx; usual tx is supportive care</td>
</tr>
</tbody>
</table>
Acute bacterial: Coexisting OM ± cholesteatoma (esp if s/p abx); severe sx, hearing loss; toxic, w/ fever; tx w/ IV abx, ± ENT consult for myringotomy; admit (only cause of peripheral vertigo that usually needs admx)

Toxic: Due to medication ototoxicity; progressive sx, often w/ hearing loss, tinnitus, NO nystagmus.

Vestibular neuronitis
- Noninflammatory d/o of vestibular system (unclear etiology)
- HX: Sudden onset, severe, isolated vertigo (no auditory sx); progressive over hours & then gradually subsides, but may have persistent mild sx for wks/mos; May have h/o prior infxn/toxin; ± nystagmus.

Ménière’s Dz
- Increased pressure w/l inner ear endolymphatic system, either due to known cause (metabolic, endocrine, trauma, meds, etc.) or idiopathic
- HX: Classic tetrad: Episodic severe vertigo (a/w N/V, lasting min to hrs, often most severe sx), unilateral chgs in hearing, tinnitus, & sensation of ear fullness or pressure; sx followed nonspecific fatigue & nausea × days, then prolonged sx-free remission
- TX: Supportive care, trigger avoidance, if severe may warrant trial of diuretics or steroids (limited supporting data)

Acoustic neuroma
- Intracranial benign neoplasm arising from Schwann cells encasing vestibular or cochlear nerve; cause sx both by affecting signal transmission on affected nerve or by mass effect
- HX: Gradual onset, progressive unilateral sensorineural hearing loss (most common sx), ± tinnitus, HA, imbalance (rarely frank vertigo), facial weakness/numbness
- DX: Unlike other causes of peripheral vertigo, dx requires neuroimaging (MRI w/ contrast)
- TX: Observation (if few sx), surgical excision, stereotactic XRT

FACIAL DROOP

Approach
- **Definition:** Unilateral weakness of the facial muscles, w/ or w/o other neuro deficits; either due to central (upper motor neuron) or peripheral (lower motor neuron) etiologies
- Strength of eye closure & eyebrow elevation helps differentiate central vs. peripheral:
  - Central etiology *spares* forehead due to bilateral innervation → w/u f/ stroke
Bedside fingerstick blood glucose early b/c hypoglycemia can cause this

<table>
<thead>
<tr>
<th>Differential Diagnosis for Facial Droop</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location</strong></td>
</tr>
<tr>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Peripheral</td>
</tr>
<tr>
<td>Central</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Localizing the Lesion in Facial Droop</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location</strong></td>
</tr>
<tr>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Cortex****</td>
</tr>
<tr>
<td>Subcortical****</td>
</tr>
<tr>
<td>Pons</td>
</tr>
<tr>
<td>CPA</td>
</tr>
<tr>
<td>IAC proximal to geniculate gang</td>
</tr>
<tr>
<td>IAC/FC distal to geniculate gang</td>
</tr>
<tr>
<td>FN distal to SMF</td>
</tr>
</tbody>
</table>

*Lacrimation innervated from nucleus superior salivatory nerve in pons, via nervus intermedius (traverses w/ CN VII in internal auditory canal).

**Salivation innervated from nucleus superior salivatory nerve in pons, via nervus intermedius (traverses w/ CN VII in IAC) & chorda tympani (traverses w/ CN VII in FC).

***Taste innervated from nucleus of fascia solitarius in pons, via nervus intermedius (traverses w/ CN VII in IAC) & chorda tympani (traverses w/ CN VII in FC).
**Bell’s Palsy**

**History**
- Acute onset (over hours) painless unilateral facial droop not sparing the forehead, ± aching of ear (60%), taste disturbances (60%), hyperacusis (30%), dry eye, ± cheek/mouth paresthesias (but true sensory loss suggests central lesion)
- RFs: Adult, diabetics, pregnancy, tick exposure
- Evaluate risk for more concerning pathology: RFs for TIA/CVA, sx of neoplasm, etc.
- Accounts for ~50% of all facial palsies. Can be bilateral, but this requires further w/u.
- Unclear etiology (proposed: ischemic mononeuropathy, HSV reactivation in geniculate g.)

**Physical Exam**
- Paralysis *must include forehead*; inability to smile or close eye, drooling, hyperacusis
- Assess for changes in lacrimation, salivation, & taste (see above)
- Look for findings of spec etiology; eg, erythema migrans (Lyme), vesicles (HSV)

**Evaluation**
- Labs & imaging not routinely indicated if typical presentation
- If atypical presentation, other signs, systemic sx: Neuroimaging & neuro consult

**Treatment** *(Neurology 2012;79(22):2209)*
- Artificial tears, tape eyelid before sleeping to prevent corneal injury (cannot close lids)
- Prednisone 60 mg QD × 5, then slow taper (NNT 11) *(Cochrane 2010;3:CD001942)*
- *No empiric abx*, but consider if concerned or severe: Acyclovir (HSV), doxycycline (Lyme)
- No clear benefit of antiviral tx in Bell’s *(Cochrane 2009;4:CD001869)*

****Cortical and subcortical lesions contralateral to sx (all others ipsilateral).**
Disposition
- Home w/ reassurance, neuro f/u if paralysis persists for months
- Prognosis: 80–90% complete recovery in 2–3 mo, 10% permanent, 14% recurrence.

INTRACRANIAL HEMORRHAGE

Overview

Approach
- Immediate IV access; low threshold for intubation if GCS <8 or declining; assess for e/o herniation (give empiric hyperosmolar tx); emergent neuroimaging, NSGY/neurology c/s
- Attend to concurrent life-threatening pathology (eg, ATLS, ACLS)
- Pts w/ ICH can decompensate rapidly 2/2 ↑ ICP

History & Physical Exam
- HX: Acuity/timing of onset, position, severity, duration, circumstances surrounding onset (trauma, exertion, Valsalva, cocaine), associated sx (HA, N/V, vision chgs, focal neuro sx, speech or behavior chg, fatigue, neck pain), PMH (HTN, cancer, connective tissue d/o), FHx (ICH, aneurysm/AVM, PCKD), Meds (A/C, anti-plt agents)
- EXAM: VS; Assess GCS, motor/sensory & coordination, meningeal signs, e/o trauma
  - Signs of impending herniation: Asymmetric nonreactive pupil, decorticate/decerebrate posturing, Cushing’s reflex (↑ BP, ↓ HR)

Evaluation
- CBC, BMP, PT/INR, PTT, Type & Screen
- STAT Noncontrast CT head to evaluate location & extent of bleeding; based on type of ICH, CTA may help clarify vascular etiology (eg, AVM, aneurysm)
- NSGY consultation: if ↑ ICP & ↓ GCS, may need bolt, drain, craniotomy vs. craniectomy

Treatment
- Reverse anticoagulation: See section on Anticoagulation Reversal
Optimize BP (SBP 90–140 mmHg): Nicardipine, Labetalol, Esmolol gtt first-line; Consider IV enalaprilat if unable to take PO but no need for continuous gtt

Cerebral protection: HOB elevation to 30 degrees, minimize ↑↓ glucose, hyperthermia, ↓ BP, ↓ O₂, ↑ CO₂, seizures

Subarachnoid Hemorrhage

Overview

Definition: Acute bleed into subarachnoid space between pial & arachnoid mater; can be traumatic (often focal) or atraumatic (eg, ruptured aneurysm, AVM; often generalized)

- 80% of atraumatic SAH from ruptured aneurysm, but 30–50% of these may have had prior sentinel bleed (eg, leak); important to consider sentinel bleed in ddx of HA

<table>
<thead>
<tr>
<th>Grade</th>
<th>GCS</th>
<th>Clinical Appearance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>15</td>
<td>No motor deficit</td>
</tr>
<tr>
<td>2</td>
<td>13–14</td>
<td>No motor deficit</td>
</tr>
<tr>
<td>3</td>
<td>13–14</td>
<td>Motor deficit</td>
</tr>
<tr>
<td>4</td>
<td>7–12</td>
<td>With or without motor deficit</td>
</tr>
<tr>
<td>5</td>
<td>3–6</td>
<td>With or without motor deficit</td>
</tr>
</tbody>
</table>

History & Physical Exam

HX: Classically sudden “thunderclap” HA, max pain w/i 1 h, “worst HA of life”, ± neck pain, N/V, photophobia, syncope or AMS, focal neuro deficits, sz

- Red flags: Exertional/Valsalva, neck pain, arrival by ambulance, LOC, N/V
- RFs: Age >60, FH (4× risk), HTN, smoking, alcohol, cocaine, amphetamine use, PCKD, collagen/connective tissue d/o

EXAM: Ranges based on severity; if sentinel bleed with low-grade, may have nl neuro exam, or if high-grade with low GCS, may be obtunded; Assess for photophobia & nuchal rigidity; May have ocular
motor palsy 2/2 aneurysm compression.

**Evaluation**

- Noncontrast head CT: In pts with low pre-TP (*low risk* by hx & *nl* neuro exam): Se 100% (−LR 0.01) if performed w/i 6 h & read by neuroradiologist, 89% after 6 h (*BMJ* 2011;343:d4277; *Acad Emerg Med* 2016;23(9):963–1003).
- LP (gold standard): ↑ opening pressure (>20 cm H$_2$O), Xanthochromia (100% Se if >12 h)
- No established “lower limit” for RBCs: Multiple “test thresholds” have been studied, including visible xanthochromia (Se 31%, Sp 98%), RBC <1 K × 10$^6$/L in Tube 4 (pooled Se 76%, Sp 88%; +LR 5.7, −LR 0.21); Spectrophotometric bilirubin (Se 100%, Sp 95%; +LR 28.8, −LR 0.22) (*Acad Emerg Med* 2016;23(9):963–1003)
- CTA: Reaches sens of 98% for bleed, but is improving & will likely play greater role; obtain CTA if SAH is diagnosed in order to localize aneurysm/AVM
- Conventional angiography: gold standard for localizing aneurysm/AVM if CTA neg

**Treatment**

- See Approach above; early consultation to NSGY critical
- 70% of SAH will have vasospasm (usually 3–21d, peak 7–10d), causing delayed cerebral ischemia; nimodipine (60 mg q4h PO) should be started w/i 96h of SAH

**Disposition**

- Admit, may need ICU; prognosis dependent on WFNS Grade/GCS

**Subdural & Epidural Hematoma**

**Overview**

- **Definition:** Bleeding into the subdural or epidural spaces due either to trauma (EDH, SDH) or tearing of the bridging veins from rapid acceleration/deceleration injury (SDH), occasionally, no h/o trauma present (SDH)
- Both cause sx as a result of mass effect on brain parenchyma & are NSGY emergencies

**History, Physical Exam, Evaluation, Treatment**
Nontraumatic Intraparenchymal Hemorrhage

Overview

- **Definition:** Hemorrhage often within the subcortical white matter or (less likely) brainstem, causing sx due to mass effect, vasogenic edema & localized inflammation
- Classified as either primary (HTN, amyloid angiopathy) or secondary (coagulopathy, AVM, neoplasm, cerebral venous sinus thrombosis, hemorrhagic conversion of ischemic infarct)

<table>
<thead>
<tr>
<th>Cause</th>
<th>Typical Location</th>
<th>Typical Appearance</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTN</td>
<td>Int capsule, thalamus, cerebellum/pons</td>
<td>Round, homogenous</td>
</tr>
<tr>
<td>CAA</td>
<td>Lobar (cortical/subcortical)</td>
<td>Round, homogenous</td>
</tr>
<tr>
<td>Coagulopathy</td>
<td>Lobar</td>
<td>Irregularly shaped</td>
</tr>
<tr>
<td>*Neoplasm</td>
<td>Variable; may be multiple</td>
<td>Surrounding edema</td>
</tr>
</tbody>
</table>

*Common neoplasms: Primary CNS tumors, melanoma, lung, breast (Semin Roentgenol 2014:49(1):112–126)

History, Physical Exam, Evaluation, Treatment

- See Approach above to ICH

Disposition

- Admit to neurology if no e/o aneurysm/AVM; often require ICU

**ISCHEMIC STROKE**

Overview

Approach

- Requires immediate & rapid assessment; utility of thrombolysis is time-limited
- Immediate IV access, telemetry, supplemental O₂ if hypoxic, neuro
c/s if tPA candidate

- Quick assessment of ABCs: if GCS < 8 but RR & O₂ nl, weigh risk-benefits of sending pt to CT scan w/o intubation, intubate if concern for imminent deterioration
- If possible, obtain patient advanced directive (goals of care) to guide resuscitation
- All patients need STAT fingerstick glucose to r/o hypoglycemia as cause of sx
- Goal to R/O TIA, Sz, & ICH ASAP & provide lytics if w/i eligible time frame

**History**

- Establish time of onset (if unwitnessed, establish time “last seen nl”), sx progression (stable vs. improving), circumstances surrounding onset (recent health, trauma, sz, toxins)
- Complaints may be vague (AMS, numb, weak, vision Δ, dysarthria)
- Assess RFs for ischemic CVA (HTN/HLD, DM, AF, CAD/PVD, CHF, Valve dz, hypercoagulable states, PFO [5–10% of pop w/ clinically significant PFO])
- Assess for other causes (see table), inc. recrudescence (“unmasking”) of old CVA

### Differential Diagnosis for Ischemic Stroke

<table>
<thead>
<tr>
<th>Category</th>
<th>Differential Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CNS</strong></td>
<td>TIA, ICH, Neoplasm, Seizure (Todd’s paralysis), Recrudescence of prior CVA (eg, 2/2 infxn, metabolic, GIB; may not have known CVA hx), Complex migraine, Cerebral venous sinus thrombosis</td>
</tr>
<tr>
<td><strong>Vascular</strong></td>
<td>Aortic dissection, Cervical arterial dissection (carotid, vertebral), Endocarditis, HTN encephalopathy</td>
</tr>
<tr>
<td><strong>Tox/Metabolic</strong></td>
<td>↓ glucose, ↑↓ Na, Wernicke’s encephalopathy, Drug toxicity</td>
</tr>
<tr>
<td><strong>Hematologic</strong></td>
<td>TTP</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>Bell’s palsy, Conversion d/o, Cryptogenic (no known cause; 25%)</td>
</tr>
</tbody>
</table>

**Physical**

- Quick but detailed neuro exam using NIH Stroke Scale (see below)
- Check for arrhythmia, murmur, bruits, & rectal for occult blood if considering lytics
<table>
<thead>
<tr>
<th>Variable</th>
<th>Finding</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consciousness</td>
<td>Alert, keenly responsive</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Arouses w/ minor stimulation</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Arouses w/ repeat or painful stimulation</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Coma</td>
<td>3</td>
</tr>
<tr>
<td>Orientation (month, age)</td>
<td>Answers both correctly</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Answers one correctly</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Answers none correctly</td>
<td>2</td>
</tr>
<tr>
<td>Commands (close eyes, grip)</td>
<td>Performs both correctly</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Performs one correctly</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Performs none correctly</td>
<td>2</td>
</tr>
<tr>
<td>Best gaze</td>
<td>nl</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Partial palsy (no forced deviation)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Total gaze paresis or forced deviation</td>
<td>2</td>
</tr>
<tr>
<td>Visual fields</td>
<td>No visual loss</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Partial hemianopsia</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Complete hemianopsia</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Bilateral hemianopsia (blind)</td>
<td>3</td>
</tr>
<tr>
<td>Facial palsy</td>
<td>None</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Minor paralysis (eg, flattened nasolabial fold)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Partial paralysis (near total in lower face)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Complete paralysis (total lower/upper face)</td>
<td>3</td>
</tr>
<tr>
<td>Motor arm (10 s drift)</td>
<td>No drift</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Drift but does not hit bed</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Some effort but drifts to bed</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>No effort against gravity</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>No movement</td>
<td>4</td>
</tr>
<tr>
<td>Motor leg (5 s drift)</td>
<td>No drift</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Drift but does not hit bed</td>
<td>1</td>
</tr>
<tr>
<td>Ataxia (finger/nose, heel/shin)</td>
<td>Absent</td>
<td>0</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>Present in 1 limb</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Present in 2 limbs</td>
<td>2</td>
</tr>
<tr>
<td>Sensory</td>
<td>nl</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Mild–Moderate loss (“pinprick feels less sharp”)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Severe–total loss</td>
<td>2</td>
</tr>
<tr>
<td>Language (writing if intubated)</td>
<td>nl, no aphasia</td>
<td>0</td>
</tr>
<tr>
<td>(Naming objects, pictures)</td>
<td>Some loss of fluency or comprehension</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Severe aphasia; fragmented</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Mute, global aphasia</td>
<td>3</td>
</tr>
<tr>
<td>Dysarthria (Have pt read list of words)</td>
<td>nl</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Slurs some words but understandable</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Severe, unintelligible</td>
<td>2</td>
</tr>
<tr>
<td>Extinction/Inattention (Bilateral stimulation)</td>
<td>No abnlt</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Inattention or extinction to bilateral stimulation</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Profound hemi-inattention</td>
<td>2</td>
</tr>
</tbody>
</table>

Score <5 = minor, Score>20 = severe neurologic deficit

**Evaluation:**
- CBC, BMP, PT/INR, Troponin, UA, T & S
- ECG: May reveal AF; cerebral T waves (deep symmetric precordial) suggest ↑ ICP (rare)
- Noncontrast CT: r/o hemorrhage & exclude other etiologies; eval for early e/o infarction (hyperdense vessel segment; loss of grey-white differentiation, gyral effacement)
- CT Angiography: r/o arterial dissection; localize thrombus & map vasculature limitations (eg, stenosis, tortuosity) to help guide potential IA tx
- MRI: Highest Se & Sp for CVA in acute setting (initially ↑ DWI & ↓
ADC signal; after 6 h ↑ T2 FLAIR; after 16 h ↓ T1 signal), but often not immediately available

- Echocardiography: Eval for atrial/LV thrombus, mitral valve pathology, myxoma, PFO; diagnostic yield 4–10% (TTE) & 11–41% (TEE), but +findings often chg long-term mgmt; most useful in pts w/ abnl ECG or c/f embolic source (Postgrad Med J 2014;90(1066):434–438).
- Once CVA dx’ed: addx tests to evaluate RF (HgbA1c, Lipid panel) & guide 2° prevention

**Transient Ischemic Attack**

**Overview:**

- **Definition:** Acute focal neurologic dysfxn 2/2 ischemia from arterial occlusion (thrombotic or embolic) but completely resolving within 24 h (usually <1 h) & not a/w residual tissue infarction; signals ↑ CVA risk 2/2 shared underlying pathophysiology w/ CVA
- Etiologies: Often thromboembolic event (AF, PFO, Atherosclerosis), small vessel dz, or fixed large-vessel stenosis w/ transient ↓ BP
- Risk of CVA after TIA: 3% w/i 2 d, 5% w/i 7 d; ABCD$^2$ Score may predict individual risk, but should not supplant clinical judgment (see footnotes in table) or dictate f/u urgency

### ABCD$^2$ Score: Stroke Risk after TIA

<table>
<thead>
<tr>
<th>Factor</th>
<th>Criteria</th>
<th>Pts</th>
<th>7-d CVA Risk*</th>
<th>7-d CVA Risk**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Age &gt;60</td>
<td>1</td>
<td>0 pts</td>
<td>0%</td>
</tr>
<tr>
<td>BP</td>
<td>First BP &gt;140/90</td>
<td>1</td>
<td>1 pt</td>
<td>0%</td>
</tr>
<tr>
<td>Clinical signs</td>
<td>Motor weakness ± speech</td>
<td>2</td>
<td>2 pts</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td>Isolated speech disturbance</td>
<td>1</td>
<td>3 pts</td>
<td>0%</td>
</tr>
<tr>
<td>Duration</td>
<td>&gt;60 min</td>
<td>2</td>
<td>4 pts</td>
<td>2.2%</td>
</tr>
<tr>
<td></td>
<td>10–59 min</td>
<td>1</td>
<td>5 pts</td>
<td>16.3%</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Requiring meds/insulin</td>
<td>1</td>
<td>6 pts</td>
<td>35.5%</td>
</tr>
</tbody>
</table>


**Pooled meta-analysis of 29 cohorts (Neurology 2015;85(4):304–305). Up to 1/3 of pts w/ TIA-mimics may have ABCD$^2$ ≥4, and 1/3 of pts w/ true TIA have ABCD$^2$ <4. Additionally, 1/5 pts w/ ABCD$^2$ <4 have >50% carotid stenosis, needing urgent f/u. Thus, score should accompany clinical judgement, eval of other CVA RFs (cervical arterial stenosis), and strong consideration should be given to ED neurology c/s to guide mgmt & urgency of f/u.
History & Physical Exam
- See Approach; If acute, emphasis should be placed on assessing degree of resolution

Evaluation
- If sx not fully resolved (NIHSS > 0): W/U as acute CVA (Noncontrast CT & CTA)
- If sx fully resolved (NIHSS = 0): May defer CT & obtain MRI/MRA w/i 24 h, unless c/f other etiologies (eg, partial sz 2/2 underlying neoplasm)
- Need to find etiology of TIA (echo, carotid imaging, Holter, MRI/MRA), usually as inpt

Treatment (Stroke 2013;44(3):870–947; Stroke 2014;45(7):2160–236)
- Tx focuses on short- & long-term risk reduction
- ASA (325 mg QD) ± clopidogrel (75 mg QD) based on severity of intracranial stenosis
- BP control: In acute setting, may be reasonable to avoid active BP control for >24 h unless markedly elevated (>220/120) or concurrent medical condition requiring ↓ BP; if BP remains elevated after first several days, tx w/ goal BP < 140/90
- Statin therapy if LDL-C >100 mg/dL
- Anti-coagulation if e/o Afib/Aflutter (VKA or NOAC); if CI to A/C, ASA ± clopidogrel
- Carotid revascularization: Recommended for high-grade (>70%) & moderate (50–69%, NNT 15; if not otw high surgical risk) stenosis no risk reduction if stenosis <50%; if able to undergo CEA, CEA preferred over CAS (Cochrane 2012;9:10:662–668)
- Lifestyle modifications: Weight loss, diet/low-salt, exercise, ↓ ETOH, ↓ tobacco

Disposition
- Admit if 1st TIA, mx TIAs in short time, cardiogenic, or posterior circulation
  - In some stroke centers, select cases can be managed outpt (eg, recent full w/u)
- ABCD² is a useful data point but not well validated as a disposition tool
Pearl
- Recurrent TIAs w/ different sx are likely cardiac emboli; if same sx, likely cerebral

Ischemic Stroke
Overview
- **Definition:** Acute focal neurologic dysfxn 2/2 ischemia causing tissue infarction, often due to acute arterial occlusion (embolic >25% thrombotic > vascular dissection, etc) or fixed stenosis w/ hypotension

History, Physical Exam, & Evaluation
- See Approach; If acute, initial assessment should not delay imaging & decision to provide lytic tx (apart from reviewing CIs)
- Sxs & exam findings will depend on arterial distribution affected (see table)
  - Anterior circulation: Unilateral motor/sensory deficit (eg, numbness, weakness, facial droop, monocular blindness [amaurosis fugax], aphasia)
  - Posterior circulation: Nonlateralizing sx (eg, diplopia, dysarthria, dysphagia, ataxia)

<table>
<thead>
<tr>
<th>Stroke Location</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmic Art.</td>
<td>Transient painless monocular vision loss (often embolic from ICA)</td>
</tr>
<tr>
<td>Internal Carotid Art.</td>
<td>See ACA &amp; MCA: profound motor &amp; sensory deficits</td>
</tr>
<tr>
<td>Ant. Cerebral Art.</td>
<td>C/L hemiparesis &amp; sensory loss (leg, perineum &gt; arm, face) ± impaired judgment/confusion, ± incontinence (pelvic floor weakness), ± disconnection syndrome (↓ awareness of I/L body, 2/2 corpus callosum infarction)</td>
</tr>
<tr>
<td>Mid. Cerebral Art.</td>
<td>C/L hemiparesis &amp; sensory loss (face, arm &gt; leg, perineum) ± aphasia (if dominant hemisphere; Broca/receptive [frontal] or Wernicke/expressive [temporal]) or neglect (if nondominant)</td>
</tr>
<tr>
<td>Post. Cerebral Art.</td>
<td>Homonymous hemianopsia ± cortical blindness ± Agnosia (object recognition), alexia (word recognition), prosopagnosia (face recognition), memory deficits</td>
</tr>
</tbody>
</table>
Prominent contralateral sensory chgs w/o paralysis (thalamus)

Lacunar Art.
Pure hemiplegia (pons/internal capsule), pure sensory (thalamus), clumsy hand & dysarthria syndrome (pons), unilateral leg paresis & ataxia (pons/internal capsule)

<table>
<thead>
<tr>
<th>Common Posterior Fossa Syndromes (QJM 2013;106(7):607–615)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Post. Inf. Cerebellar Art.</strong> (Lateral Medullary Synd, Wallenberg)</td>
</tr>
<tr>
<td>NO motor deficits</td>
</tr>
<tr>
<td>Sensory: <em>Crossed</em> sensory loss on I/L face, C/L arm/leg</td>
</tr>
<tr>
<td>Ataxia: I/L limb &amp; truncal (veer/lean) ataxia</td>
</tr>
<tr>
<td>Oculobulbar: Ocular (diplopia, nystagmus, ocular torsion), bulbar (dysarthria, dysphagia, hiccups, uvular deviation)</td>
</tr>
<tr>
<td>Autonomic sx: Horner syndrome</td>
</tr>
<tr>
<td><strong>Ant. Inf. Cerebellar Art.</strong> (Lat Pontine Synd.)</td>
</tr>
<tr>
<td>I/L facial weakness &amp; sensory loss</td>
</tr>
<tr>
<td>I/L sensorineural hearing loss (labyrinthine art.)</td>
</tr>
<tr>
<td>Ataxia, nystagmus</td>
</tr>
<tr>
<td><strong>Basilar Art.</strong> (pontine)</td>
</tr>
<tr>
<td>Impaired or alternating responsiveness (may present w/ coma)</td>
</tr>
<tr>
<td>Various B/L motor sxs, including bulbar</td>
</tr>
<tr>
<td>± Visual impairment/cortical blindness</td>
</tr>
<tr>
<td>“Locked-in syndrome”: Only ocular muscles remain intact</td>
</tr>
</tbody>
</table>

**Treatment** (Stroke 2013;44(3):870–947; Stroke 2014;45(7):2160–236)

- Early Neurology C/S & imaging: Recommended door-to-physician, ≤10 min; door-to-stroke team, ≤15 min; door-to-CT initiation, ≤25 min; door-to-CT interpretation, ≤45 min
- ASA 325 mg PO/PR. May use clopidogrel, ticlopidine, or warfarin per neurology.
- BP control: Labetalol (IV) & Nicardipine (gtt) first-line, use short-acting IV agents
  - If TPA candidate: BP goal <185/110 (lysis contraindicated if >185/110 after 2 doses)
  - If not TPA candidate: Treat only if persistently >220/120, s/sx other end-organ damage (eg, AMI), or alternative med condition needing BP control; lower ≤10–20%
- Fibrinolytic therapy (rtPA 0.9 mg/kg): In selected pts w/i appropriate timeframe & w/o CIs
  - Odds of favorable recovery decrease with time after sx onset (see table)
  - Risks of tPA: ICH (6% risk, clinically significant 1–2%), angioedema
(1-5), systemic bleeding; ↑ 7 d mortality, but no ↑ mortality at final f/u (Lancet 2012;379(9834):2364–2372)

- See table below for inclusion criteria, absolute & relative CIs
- Intra-arterial tPA (available at some stroke centers) may be preferred (w/ or w/o prior IV tPA) for proximal lesions (distal ICA, MCA, basilar), severe sx, CI to systemic tPA, or delayed presentation after sx onset (4.5–6 h, investigations ongoing 6–12 h)
- Thrombectomy (typically w/ tPA) (eg, Merci retrieval system): Recanalization w/ Merci retrieval 57%, in combo w/ IA tPA 70%; ICH risk 7–10% (Stroke 2008;39(4):1205–1212)
- If arterial dissection or suspected cardioembolic stroke, may consider heparin

<table>
<thead>
<tr>
<th>Pooled Odds of Favorable Outcome After TPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time of TPA administration after sx</td>
</tr>
<tr>
<td>Odds of favorable neuro recovery at 3 mo</td>
</tr>
</tbody>
</table>

Data pooled from 6 RCTs (Lancet 2004;363(9411):768–774); no change in mortality w/ different timing of tx.

<table>
<thead>
<tr>
<th>Criteria for Thrombolysis in Acute Stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion Criteria</td>
</tr>
<tr>
<td>- Age &gt;18</td>
</tr>
<tr>
<td>- Clinical Dx of acute ischemic stroke w/ measurable neuro deficit</td>
</tr>
<tr>
<td>- Time of onset &lt;3 h (well established), or &lt;4.5 h in some centers</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Absolute CIs to Lysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>- CTH shows ICH or very large stroke (&gt;33% of hemisphere)</td>
</tr>
<tr>
<td>- High clinical suspicion for SAH (even w/ nl CTH)</td>
</tr>
<tr>
<td>- Active internal bleeding (eg, GIB)</td>
</tr>
<tr>
<td>- Bleeding diathesis (PLT &lt;100000, heparin in past 48 h, anticoagulation w/ INR &gt;1.7)</td>
</tr>
<tr>
<td>- Stroke, intracranial surgery, or head trauma in past 3 mo</td>
</tr>
<tr>
<td>- LP in past 1 wk</td>
</tr>
<tr>
<td>- Recent arterial puncture at noncompressible site</td>
</tr>
<tr>
<td>- Prior ICH, AVM, or aneurysm</td>
</tr>
<tr>
<td>- Refractory HTN (SBP &gt;185 mmHg &amp; DBP ≥110 mmHg despite tx)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Relative CIs (weigh risk–benefit)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Minor or rapidly resolving sxs</td>
</tr>
<tr>
<td>- Witnessed sz at time of stroke onset</td>
</tr>
</tbody>
</table>
Acute MI in past 3 mo
Recent GI/GU hemorrhage in past 3 wk
Major surgery or serious trauma in past 2 wk
Pregnancy

Additional Relative CIs (for use after 3 h & before 4.5 h)

- Age >80
- NIHSS >25 (suggests large stroke)
- Oral anticoagulant use (regardless of INR)
- Combination of prior ischemic strokes & diabetes mellitus

Disposition
- Admit all patients; Large strokes may need ICU (risk of edema, hemorrhagic conversion)

Pearls
- Inpt w/u includes carotid imaging, echo, Holter monitor, advanced serology (hypercoagulability, lipids, bleeding diathesis, ESR, ANA)
- NIHSS correlates w/ neurologic outcome at 3 mo but poor predictor for posterior CVAs

NEUROMUSCULAR SYNDROMES

MYASTHENIA GRAVIS

Overview
- **Definition:** Autoimmune d/o (Abs against postsynaptic ACh nicotinic receptors) causing progressive weakness of incremental muscle groups, with intermittent crises marked my potential need for ventilatory support
- Epidemiology: Most commonly affects women in 20s–30s, men in 60s–70s (peak)
- DDx includes Lambert–Eaton syndrome (similar pathophysiology, paraneoplastic)

History
- Gradual onset, symmetric, fluctuating proximal & ocular muscle weakness
• Common: Extraocular/ptosis (present in 50% initially), bulbar, limb (prox > distal); however, w/i 1 y most pts have generalized involvement
• Sx least severe in morning; worsen w/ repetitive activity & throughout day
  ‣ Assess for triggers of crisis: Stress, infection, pregnancy, surgery, meds (abx, steroids)
  ‣ If advanced dz: Obtain clear goals of care in case need for intubation

Physical Exam
  ‣ Proximal weakness & fatigability worse w/ repetitive activity, relieved by rest
  ‣ CN affected early (ocular: Ptosis, diplopia; bulbar: Dysarthria, dysphagia)

Evaluation
  ‣ Neuro C/S: if new onset, poor o/p f/u, or probable need for admx
  ‣ If new dx: AChR Ab test has high Sp, but poor Se, esp in localized dz; Tensilon (edrophonium) test (2 mg IV over 15 s; binds to AChE, blocking ACh hydrolysis)
  ‣ Tensilon test may precipitate bradycardia or heart block – have atropine at bedside
  ‣ If known dx: Differentiate MG crisis from cholinergic crisis (most pts on cholinergic meds)
  ‣ Cholinergic tox: lacrimation, salivation, perspiration, bronchorrhea, N/V, diarrhea, brady
  ‣ Measuring NIF (negative inspiratory force) can identify pts at risk of respiratory failure; NIF <20 cm H₂O suggests severe resp weakness

Treatment
  ‣ Ventilatory support as indicated (NIPPV, intubation)
  ‣ Long term txs include AChE-inh (pyridostigmine) & immunomod (steroids, etc.)
  ‣ Corticosteroids given in crisis but can worsen sx initially; minimal short-term effect
  ‣ Plasmapheresis & IVIG: mainstays of tx for acute crisis

Disposition
- Admit all pts w/myasthenia crisis
- If no e/o crisis & good o/p f/u, can d/c with close o/p f/u

**GUILLAIN–BARRÉ SYNDROME**

**Overview**
- **Definition:** Acute autoimmune demyelinating peripheral neuropathy, often in response to external infectious exposure & characterized by loss of peripheral nerve reflexes
- Common associated pathogens: *Campylobacter* (~30%), EBV, HSV, HIV, *Mycoplasma*
- Slow recovery (can take mo in worst affected); 5% die from cx (sepsis, PE, dysautonomia)

**History, Physical Exam, & Evaluation**
- **HX:** Progressive ascending weakness; can start w/ numbness/paresthesias or pain in LE’s, f/b symmetric b/l weakness over hrs to wks
  - Usually (2/3) heralded by recent URI or diarrheal illness days – wks prior to sx
- **EXAM:** Acute ascending symmetric weakness, sensory chgs, ↓ DTRs (however, 10% of early cases will have DTRs), 20% will have autonomic dysfxn & potentially-fatal arrhythmias; ± CNS (hallucinations, psychosis, vivid dreams) *(NEJM* 2012;366: 2294–2304)
  - Miller-Fisher variant = ataxia, areflexia, ophthalmoplegia.
- **DX:** Clinical dx; w/u generally to r/o other dx
  - CPK nl (acute myopathy may present similarly but nl sensation & ↑ CPK)
  - LP (can r/o lyme, lymphoma): Albuminocytologic dissociation (↑ protein, no WBCs or bacteria) only present 50% of cases in 1st wk, 75% by 3rd wk *(NEJM* 2012;366:2294–2304)

**Treatment** *(NEJM* 2012;366:2294–2304)
- Consult neurology
- Hemodynamic stabilization: telemetry (risk for arrhythmia; some pts may need PPM), rapidly titratable vasoactive agents as needed for dysautonomia
Respiratory support as indicated (25% pts need intubation): avoid succinylcholine for RSI
- Plasmapheresis & IVIG equally effective; combo not superior
- Steroids have limited effectiveness in speeding recovery

**Disposition:**
- Admit until no e/o progression; ICU if respiratory compromise
- Prognosis: Full recovery can take mo & can be c/b mx dz (PNA, sepsis, PE, etc)

---

**Amyotrophic Lateral Sclerosis (ALS)**

**Overview**
- **Definition:** Degenerative dz of UMNs & LMNs
- **Epidemiology:** Age >40, M = F

**History, Physical Exam, & Evaluation**
- **HX:** Progressive motor weakness & atrophy, fasciculations, spasm; NO sensory loss.
  - Assess pt goals of care regarding life-support interventions including airway
- **EXAM:** UMN & LMN findings, initially distal; fasciculations 2/2 denervation; may have bulbar findings (dysphagia, dysarthria) in advanced dz, spasticity, ↑ DTRs, +Babinski
  - Bladder & bowel sphincters & ocular muscles often spared
- **DX:** If new onset, neuro consult & consider MRI brain & spinal cord

**Treatment**
- Supportive care (Respiratory support, antispasmodics)
- In pts w/ known dx, treat cx (DVT from immobility, asp PNA, UTI, decubitus ulcers)

**Disposition**
- Depends on respiratory status, acuity

---

**Multiple Sclerosis (MS)**

**Overview**
**Definition:** Progressive chronic immune-mediated demyelinating dz of the CNS
- Generally follows relapsing-remitting (85–90%; may not have complete recovery b/w relapses) or primary progressive course (usually w/o relapses)
- Epidemiology: Relapsing-remitting presents young (30 y) & F>M (3:1); primary-progressive presents older (40 y) & F=M; ↑↑ risk if 1st-degree relative also affected
- Dx requires 2+ distinct episodes w/ differential neurologic sxs (ie, diff anatomic lesion)

**History**
- Acute episodes develop over hours–days (also remit over same time course)
- Look for precipitating factors for exacerbation (eg, infection, hyperthermia)
- Sx can be highly variable: vision, sensation, mobility/balance, cognition, sphincter control
- See table for typical presentations, ocular sx common
- Uhthoff phenomenon: Sxs worsen w/ ↑ body temp (exercise, hot bath, fever)

<table>
<thead>
<tr>
<th>Typical Multiple Sclerosis Presentations (Lancet 2017;389(10076):1336–1346)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute unilateral optic neuritis*</td>
</tr>
<tr>
<td>Diplopia (2/2 INO or CN VI palsy)*</td>
</tr>
<tr>
<td>Facial sensory loss or trigeminal neuralgia</td>
</tr>
<tr>
<td>Cerebellar ataxia, nystagmus</td>
</tr>
<tr>
<td>Partial myelopathy</td>
</tr>
</tbody>
</table>

*Optic Neuritis: Painful EOM, afferent pupillary defect, decreased visual acuity, ± papilledema.
**INO: Inter-nuclear ophthalmoplegia (affected eye is able to abduct but not adduct; unaffected eye EOM nl) due to MLF lesion; Lhermitte’s sign: Electric-shock sensation travelling down spine with neck flexion.
Evaluation *(Lancet* 2017;389(10076):1336–1346)*
- Neuro consult indicated due to clinical benefit of early dx
- MRI Brain (Se 80% in pts w/ isolated syndrome): multifocal T2 hyperint white matter lesions
- MRI Spine (Se 50% in pts w/ isolated syndrome; mostly c-spine): indicated if sx localize to spinal cord or MRI Brain nondiagnostic
- LP: Indicated only if uncertainty based on MRI findings; may show pleocytosis (50%) & IgG oligoclonal bands (85–95%)

Treatment
- Treat any reversible underlying triggers (eg, infxn, dehydration, fevers)
- High-dose corticosteroids are 1st line for acute relapses; may consider addition of 2nd-line plasmapheresis in fulminant cases *(Neurology* 2011;76(3):294–300)
- Supportive: spasticity (baclofen, benzo), pain (carbamazepine/TCA), fatigue (amantadine)

Disposition
- Admit all new-dx for further w/u
- Most pts are admitted for relapses; can D/C if mild sx, nonprogressive, & close neuro f/u

Pearl
- Due to complexity of dx, rates of mis-dx pts (ie, w/o dz) may be as high as 10% *(Lancet* 2017;389(10076):1336–1346)

---

**Transverse Myelitis**

Overview *(NEJM* 2010;363:564–572)
- **Definition:** Acute or subacute inflammation & varying demyelination of a limited length of spinal cord causing motor, sensory, & autonomic dysfxn w/ sx correlating to level affected
- Often >2 vertebral seg involved; MS-associated TM can be <2 seg & partial cord
- Epidemiology: All ages affected; bimodal peak (10–19y & 30–39y); M = F; unrelated to FHx
- Etiologies: Postvaccination (60% in children), postinfection, systemic
autoimmune dz, or acquired demyelination dz (eg, MS), neuromyelitis optica, idiopathic (15–30%)

**History, Physical Exam, & Evaluation**

- **HX:** Acute or subacute paraplegia, sensory changes (with definitive spinal cord level), & sphincter loss (below level); onset over hours to days; bilateral but often asymmetric, often w/ neuropathic back/midline pain
  - Ask about recent viral illness, immunization, FHx of MS, vision sx (NMO)
- **EXAM:** Symmetric or asymmetric weakness & sensory loss referable to a spinal cord level, hyperreflexia, +Babinski, +Lhermitte’s sign (+electric radiating back pain w/ neck flexion)
- **DX:** MRI entire spine w/ contrast; Neurology consult; If confirmed by imaging, may need LP (+pleocytosis) to help differentiate etiology & prognosticate

**Treatment**

- Ventilatory support as indicated by level of cord involvement & sx
- Supportive care: Analgesia (TCA, carbamazepine), Spasticity (baclofen, benzos), fatigue
- High-dose steroids (1-g methylprednisolone QD IV) are 1st-line, esp for postinfectious or demyelinating etiology (*NEJM* 2010;363:564–572)
- May consider plasmapheresis if fulminant or refractory to steroids; limited data

**Disposition**

- Admit to neurology
- Prognosis depends on etiology: Most recovery takes mo to yr
  - MS-associated TM: Quicker & complete recovery; but ↑ risk of relapse c/w idiopathic, post-viral, or post-immunization
DYSURIA

(Am Fam Phys. 2015;92:778)

Definition

- Sensation of pain, burning, or discomfort on urination; generally indicates infection or inflammation of the bladder &/or urethra

Approach to the Patient

History

- ROS (fever, trauma, flank pain, abdominal or suprapubic pain, joint/back pain)
- PMH (STDs or PID, DM or immunocompromised)
- MEDS (topical irritants)
- SOCIAL (recent intercourse, multiple sexual partners)

Physical Exam

- Most pts should have at least an assessment of costovertebral angle tenderness & an abdominal exam
- Women: Consider pelvic exam if at risk for STDs, w/ vaginal sxs, postmenopausal
- Men: Should perform penile exam, testicular exam & prostate exam given risk of complicated dz

Evaluation

- Urine studies (clean catch UA, hCG ± culture, NAAT for GC/Chlamydia); CBC/Chemistries rarely indicated, unless suspected complicated dz (see below)
- Consider vaginal/urethral studies (smear w/ wet mount, cx), renal u/s, IV pyelography, CT abdomen/pelvis if warranted
- Further studies may include urine cytology, voiding
cystourethrography, cystoscopy, urodynamic testing, but not routinely performed in ED

<table>
<thead>
<tr>
<th>Dysuria Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathophysiology</strong></td>
</tr>
<tr>
<td>Structural</td>
</tr>
<tr>
<td>Infectious</td>
</tr>
<tr>
<td>Meds</td>
</tr>
<tr>
<td>Neoplastic/autoimmune</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

**URINARY TRACT INFECTIONS**

*(Emerg Med Clin North Am. 2011;29:539)*

**Definitions**

UTIs are classified according to a spectrum of dz & the predominant clinical sxs: Asymptomatic bacteriuria, uncomplicated lower UTI (cystitis), uncomplicated pyelonephritis, complicated UTI w/ or w/o pyelonephritis, recurrent UTI

**Asymptomatic bacteriuria:** Absence of urinary sxs w/ Ucx $\geq 10^5$ cfu/mL uropathogen. Screening/ tx not recommended except in pregnant women

**Acute uncomplicated UTI:** Acute dysuria, urgency, frequency, suprapubic pain w/ UA $\geq 10$ WBC/mm$^3$ & Ucx $\geq 10^3$ cfu/mL

**Acute uncomplicated pyelonephritis:** Fever, chills, flank pain in the absence of alternative Dx & urologic abnlty w/ UA $\geq 10$ WBC/mm$^3$ & Ucx $\geq 10^4$ cfu/mL

**Complicated UTI:** Features of uncomplicated UTI/pyelonephritis AND 1 or more of the following—pregnancy, diabetes, male gender, immunosuppression (eg, chemo, AIDS), functional GU abnlty (indwelling catheter, neurogenic bladder), structural GU abnlty
Recurrent UTI: At least 3 episodes of uncomplicated UTI documented by culture in the last 12 mo in the absence of structural/functional abx

Male urogenital tract infections: Urethritis, prostatitis, epididymitis, orchitis

Asymptomatic Bacteriuria

Definition

- Absence of urinary sx of UTI w/ UA ≥10 WBC/mm³ & Ucx ≥10⁵ cfu/mL of the same uropathogen in 2 consecutive midstream urine samples ≥24 h apart; however, a single positive midstream urine is generally accepted as adequate & more practical
- USPSTF recommends screening for asymptomatic bacteriuria w/ Ucx for pregnant women at 12–16 wk gestation given increased risk of pyelonephritis, preterm labor & low birth weight
- USPSTF recommends against screening for asymptomatic bacteriuria in men or nonpregnant women
- The IDSA recommends against routine screening for or tx of asymptomatic bacteriuria in diabetic women, older persons >65 y/o residing in the community or institutionalized residents of long-term care facilities, spinal cord injury, & pts w/ indwelling urethral catheters

Treatment (Asymptomatic Bacteriuria in Pregnancy)

- 3–7-d course of nitrofurantoin or cephalosporin (cephalexin, cefpodoxime, cefdinir, cefaclor)

Pearl

- Given the high PPV of leukocyte esterase & nitrites on UA for bacteriuria, a positive test result in an asymptomatic pregnant pt in the ED should be considered for tx pending culture data

Acute Uncomplicated Urinary Tract Infection (Acute Cystitis)
Definition
Acute dysuria, urgency, frequency, suprapubic pain w/ UA ≥10 WBC/mm³ & Ucx ≥10⁵ cfu/mL, but ≥10⁷ cfu/mL also used to define UTI; absence of structural/functional UG tract abnormalities
Occurs when uropathogen from bowel or vagina colonize periurethral mucosa & ascend through urethra & bladder
Predominant uropathogens: *E. coli* (75–95%), *K. pneumoniae*, *P. mirabilis*, *E. faecalis*, *S. saprophyticus*, & *S. agalactiae* (group B Strep); rarely *P. aeruginosa*, *Ureaplasma* species
Probability of dz in pts presenting w/ 1 or more UTI sxs is ~50%

History
- Combination of dysuria, frequency, hematuria, fever, back pain, &/or self-diagnosis all increase the probability of UTI, whereas their absence decreases its probability
- Vaginal d/c or irritation w/o the above sxs decreases probability of UTI
- RFs: Prior UTI, family h/o UTI, sexual intercourse, new sex partner (w/i 1 yr), use of spermicide

Physical Exam
- ±Fever; tenderness w/ suprapubic palpation; CVA tenderness
- GU exam if vaginal d/c or irritation present

Evaluation
- CBC/Chemistries rarely indicated
- Urine hCG, UA (+leukocyte esterase AND +nitrite has best diagnostic utility, where *either* +LE or +nitrite helpful w/ high pretest probability pts)
- Routine Ucx not needed in uncomplicated cases

Treatment
- Spontaneous resolution observed in 25–42% of untreated women
- Antibiotic regimens:
  1st-line:
  - Nitrofurantoin 100 mg BID × 5 d
  - Trimethoprim–sulfamethoxazole 160/800 mg (1 DS tablet) BID × 3
d (if <20% resistance in community)
- Fosfomycin 3 g in a single dose
- Alternative regimens:
  - Fluoroquinolones (ofloxacin, ciprofloxacin, levofloxacin) for 3 d
  - β-lactams (amoxicillin–clavulanate, cefdinir, cefaclor, cefpodoxime) for 3–7 d
- Symptomatic tx: NSAIDs, phenazopyridine (variable efficacy)

**Disposition**
- Home

**Pearls**
- Probability of cystitis >90% in women w/ sx of UTI in the absence of vaginal d/c or irritation, thus consider empiric tx w/o UA or w/ nl UA (negative LE & nitrites do not reliably r/o UTI)
- UTI in males is rare thus consider STD, prostatitis
- Increasing *E. coli* resistance to amoxicillin & trimethoprim–sulfamethoxazole

**Acute Uncomplicated Pyelonephritis**

**Definition**
- Upper UTI of renal pelvis & kidney secondary to ascending lower UTI (see *Acute Uncomplicated UTI for Pathogenesis & Uropathogens*)
- Fever, chills, flank pain in absence of alternative Dx & urologic abnlty w/ UA ≥10 WBC/mm³ & Ucx ≥10⁴ cfu/mL

**History**
- Highest incidence 15–29 y/o, followed by infants & elderly
- Combination of constitutional sx (fever, chills, malaise), lower urinary tract sx (dysuria, frequency, hematuria) & upper urinary tract sx (flank pain); N/V
- RFs: Prior UTI, sexual intercourse (esp ≥3/wk in last 30 d), new sex partner (w/ i 1 yr), use of spermicide, stress incontinence in previous 30 d, diabetes mellitus

**Physical Exam**
- ±Fever, tachycardia, hypotension; CVA tenderness (~25% bilateral)

**Evaluation**
CBC may show leukocytosis, but can be nl (rarely guides decision making)
Chemistries (esp BUN/Cr) if renal impairment suspected
Urine hCG, UA (+leukocyte esterase AND + nitrite has best diagnostic utility, where either + LE or + nitrite helpful w/ high pretest probability pts; WBC casts)
Ucx & susceptibility should always be performed (usually reveals ≥10⁵ cfu/mL of single uropathogen)
Routine blood cultures not indicated
Diagnostic imaging usually not indicated; can be considered to r/o alternative Dx, if complicated dz suspected, if sxs do not improve, or if recurrence → CT abdomen/pelvis study of choice over u/s

Treatment

Outpt tx:
- Ciprofloxacin 500 mg PO BID × 7 d
- Levofoxacin 750 mg PO QD × 5 d
- Trimethoprim–sulfamethoxazole 160/800 mg (1 DS tablet) BID × 14 d
- Oral β-lactam for 10–14 d

*Above regimens can be given w/ (esp if resistance in community is known to exceed 10% or Bactrim/β-lactam are used) or w/o an initial 400 mg IV dose of ciprofloxacin, 1 g IV dose ceftriaxone, or consolidated 24-h dose of aminoglycoside

Inpt tx:
- IV fluoroquinolone, an aminoglycoside (w/ or w/o ampicillin), an extended spectrum cephalosporin or PCN (w/ or w/o an aminoglycoside), or a carbapenem

Disposition
- Home: Most cases in o/w well appearing, healthy women
- ED Obs: Persistent emesis requiring IVFs or antiemetics
- Admit: Inability to take PO/intractable vomiting, age >65 y/o, toxic appearance, suspected sepsis, obstructive uropathy, inadequate f/u, poor social disposition (ie, homeless)

Pearl
- Cx: Emphysematous pyelonephritis, perinephric abscess, urosepsis,
ARF, renal scarring

**Complicated Urinary Tract Infection**

**History**
*(See Uncomplicated Cystitis & Pyelonephritis)*

**Physical Exam**
*(See Uncomplicated Cystitis & Pyelonephritis)*

**Evaluation**
- CBC may show leukocytosis, but can be nl (rarely guides decision making)
- Chemistries (esp BUN/Cr)
- Urine hCG, UA (+leukocyte esterase AND + nitrite has best diagnostic utility, where *either* + LE or + nitrite helpful w/ high pretest probability pts; WBC casts)
- Ucx & susceptibility should always be performed (usually reveals ≥10^5 cfu/mL of single uropathogen when positive)
- Routine blood cultures not indicated, but should be obtained in suspected sepsis
- Diagnostic imaging should be considered → CT abdomen/pelvis study of choice over u/s
- Urology consultation: Esp w/ known or suspected structural/functional abx, recent urologic procedure, UG tract FB, obstructive uropathy, UTI in male

**Treatment**
- Empiric parenteral therapy w/ fluoroquinolone, carbapenem (ie, ertapenem, meropenem, or imipenem), or 3rd-generation cephalosporin (ie, ceftriaxone, cefotaxime), or piperacillin/tazobactam
- Duration: 7–10 d for complicated cystitis; 10–14 d for complicated pyelonephritis

**Disposition**
- Typically admit

**Catheter-associated UTI (CA-UTI)**
Definition

- **CA-UTI:** Sxs or signs compatible w/ UTI w/ no other identifiable source of infection w/ \( \geq 10^3 \) cfu/mL uropathogen in pts w/ indwelling urethral, suprapubic, or intermittent straight catheter in urine sample obtained w/i 48 h of removal
- **Catheter-associated asymptomatic bacteriuria (CA-ASB):** Presence of \( \geq 10^5 \) cfu/mL uropathogen in a catheter urine specimen in a pt w/o sxs
- Pt scenarios may include pts transferred from long-term care facilities w/ chronic indwelling foley/suprapubic catheters, paraplegic pts w/ chronic indwelling catheters, pts w/ urinary obstruction w/ temporary foley catheter or intermittent straight catheterization, etc.

History

- New onset or worsening fever, rigors, AMS, malaise, or lethargy w/o identifiable cause in pt w/ catheter
- Dysuria, frequency, urgency, suprapubic pain, flank pain, hematuria in those whose catheters were recently removed

Physical Exam

- ±Fever, tachycardia, hypotension; CVA tenderness; suprapubic tenderness
- Cloudy/malodorous urine should not be used to differentiate CA-UTI & CA-ASB

Evaluation
(See *Complicated UTI*)

Treatment
(See *Complicated UTI for Antimicrobials*)

- Screening for & tx of CA-ASB are not recommended except pregnant women
- 3-d regimen may be considered in CA-UTI pts ≤65 y/o w/o upper tract sxs
- 5-d regimen of levofloxacin may be considered in CA-UTI pts not severely ill
- 7-d regimen recommended for CA-UTI pts w/ prompt resolution of sxs
- 10–14-d regimen recommended in those w/ delayed response
Prevention

- Strongly consider indication for catheter insertion, limit catheterization changes, aseptic technique w/ placement, among others

Disposition

- Home in majority of cases
- Admit: Age >65 y/o, toxic appearance, suspected sepsis, immunocompromised (DM, sickle cell, cancer on chemotherapy, organ transplant recipient, immunosuppressives), inadequate f/u, poor social disposition (ie, homeless)

Recurrent Urinary Tract Infection

(Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J. 2011;5:316)

Definition

- At least 3 episodes of uncomplicated UTI documented by culture in the last 12 mo in the absence of structural/functional abx
- **Relapse** (5–10% women) occurs w/i 2 wk of completing antimicrobial therapy & is caused by persistence of the same uropathogen, suggesting antibiotic resistance
- **Reinfection** occurs >2 wk after completing antimicrobial therapy & is generally secondary to infection w/ different organism or strain

History

(See Uncomplicated Cystitis and Pyelonephritis)

Physical Exam

(See Uncomplicated Cystitis and Pyelonephritis)

Evaluation

- CBC/Chemistries rarely indicated
- Urine hCG, UA (+leukocyte esterase AND + nitrite has best diagnostic utility, where *either* + LE or + nitrite helpful w/ high pretest probability pts)
- Ucx should be obtained on representation to assess for antimicrobial resistance
- Postvoid residual if incomplete emptying suspected
- Imaging: Renal u/s, IV pyelography, CT abdomen/pelvis if warranted although not routine needed on emergent basis
Further studies may include voiding cystourethrography, cystoscopy, urodynamic testing, but not routinely performed in ED

**Treatment**  
*(See *Uncomplicated UTI for Antimicrobials*)

- Consider starting prophylactic, continuous low-dose abx for 6-mo duration:
  - Nitrofurantoin 50–100 mg PO QD
  - Fosfomycin 3 g sachet PO q10d
  - Ciprofloxacin 125 mg PO QD
  - Cephalexin 125–250 mg PO QD, cefaclor 250 mg PO QD
  - Trimethoprim–sulfamethoxazole 40/200 mg QD or 3 times weekly
- May alternatively consider postcoital antimicrobial prophylaxis w/ a single dose w/i 2 h after intercourse (esp if UTI temporally a/w coitus):
  - Nitrofurantoin 50–100 mg
  - Trimethoprim–sulfamethoxazole 40/200 mg or 80/400 mg
  - Cephalexin 250 mg
- Self-start antibiotic therapy is an additional option (pt must be instructed to contact a medical provider w/i 48 h if sx do not resolve)

**Disposition**

- Home w/ urology f/u to assess for anatomical/functional etiology

**Urethritis**  

**Definition**

- Urogenital inflammatory condition characterized by urethral inflammation which can result from infectious & noninfectious etiologies
- Infectious causes include gonococcal (*N. gonorrhoeae*) & nongonococcal (*C. trachomatis, M. genitalium, T. vaginalis, HSV, adenovirus*)
- Rare causes include syphilis, CMV, & enteric bacteria

**History**

- Highest prevalence in adolescent, sexually active men
- Dysuria, urethral pruritus, mucopurulent or purulent urethral d/c;
however, asymptomatic infections are common
- Urinary frequency & urgency typically absent
- Sexual hx: Current sexual activity, type (oral, vaginal, anal), MSM, number of sex partners, condom use, h/o STDs (esp GC/Chlamydia), sex w/ prostitutes
- Systemic sxs? (Fever, sore throat, arthritis, rash, back pain)

Physical Exam
- GU exam: Urethral meatus for skin lesions, erythema, d/c; milk urethra for d/c; testicular/epididymal exam in men, pelvic exam in women

Evaluation
- First-void ("dirty") UA (may reveal + LE & ≥10 WBC/hpf), urine hCG
- Gram stain of urethral secretions w/ ≥5 WBC/hpf (presence of gram-negative intracellular diplococci c/w gonococcal dz) & culture
- Urine NAAT for N. gonorrhoeae & C. trachomatis most sens

Treatment
- GC & Chlamydia coinfection common so therapy should be geared toward both:
  - Azithromycin 1 g orally in a single dose OR doxycycline 100 mg PO BID × 7 d -AND-
  - Ceftriaxone 250 mg in a single IM dose
- Abstain from intercourse for 7 d & until all sex partners (w/i previous 60 d) are evaluated or empirically treated

Disposition
- Home w/ PCP referral for counseling & further STD testing

Pearl
- GC & Chlamydia are reportable to state health department


Male Urogenital Tract Infections

Acute Bacterial Prostatitis
(Curr Opin Infect Dis. 2016;29:86)

Definition
The NIH consensus classification of prostatitis syndromes includes 4 categories:

- I. Acute bacterial prostatitis
- II. Chronic bacterial prostatitis (≥3 mo of sxs)
- III. Chronic bacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS)
  - A. Inflammatory
  - B. Noninflammatory
- IV. Asymptomatic inflammatory prostatitis

Acute bacterial prostatitis is an acute bacterial infection of prostate w/ + Ucx, lower urinary tract sxs, obstructive voiding sxs, & systemic sxs.

Bacterial prostatitis can be spontaneous or secondary to urologic intervention.

Bacterial spectrum similar to uropathogens seen in other UTIs (see Uncomplicated UTI); however, uropathogens of prostatitis carry greater number of virulence factors. Also, C. trachomatis, T. vaginalis, U. urealyticum, N. gonorrhoeae, & viruses rare causes.

History

- Typical age 20–45 y/o; most common urologic Dx in men <50 y/o
- Acute onset fevers, chills, malaise, frequency, dysuria, poor urine stream, feeling of incomplete bladder emptying, & lower back/abdominal/pelvic pain
- Sexual Dysfxn (ejaculatory discomfort & hematospermia) may be present
- RFs: Recent urologic intervention/instrumentation, urethral stricture, urethritis

Physical Exam

- ±Fever; suprapubic abdominal discomfort
- Testicular exam should be performed to r/o epididymitis/orchitis
- DRE w/ warm, tender, swollen prostate

Evaluation

- Consider CBC & Bcx, esp if toxic appearing
- UA (+nitrites & LE, PPV 95%, NPV ~70%), Ucx
- Consider post-void residual urine measurement, urinary retention may not be evident
Consider transrectal u/s if prostate abscess suspected (poor response to abx)
Prostate biopsy as an outpt

**Treatment**

- Systemically ill pts should receive parenteral abx: IV ciprofloxacin 400 mg BID, IV levofloxacin 500 mg IV QD OR ceftriaxone 2 g IV QD
- Clinically stable pts may be treated w/ oral therapy (usually fluoroquinolone)
  - Ciprofloxacin 500 mg PO BID or levofloxacin 500–750 mg PO QD × 2–4 weeks
  - Trimethoprim–sulfamethoxazole 160/800 mg (1 DS tablet) BID × 2–4 weeks
  - Sexually transmitted: Ceftriaxone 250 mg IM × 1 AND doxycycline 100 mg BID × 14 d

**Disposition**

- Home w/ urology f/u
- Admit if systemically ill, known antibiotic resistant pathogen, etc.

**Pearls**

- 10% men w/ acute bacterial prostatitis go on to suffer chronic prostatitis, & 10% progress to chronic prostatitis/chronic pelvic pain syndrome
- Cx: Chronic prostatitis (10%), acute urinary retention, prostatic abscess (~2%), sepsis

**Epididymitis/Orchitis**


**Definition**

- Epididymitis & orchitis are inflammation of the epididymis & testes, respectively, w/ or w/o infection
- Can be acute (<6 wk), subacute (6 wk–3 mo), or chronic (>3 mo) based on symptom duration
- Orchitis usually occurs when inflammation spreads from epididymis to adjacent testicle (epididymo-orchitis), but isolated orchitis w/o epididymitis can be seen w/ mumps
- Epididymitis can be sexually transmitted, caused by *N. gonorrhoeae*
or *C. trachomatis*, or by ascending lower UTI by common uropathogens (*see Uncomplicated UTI*); *M. tuberculosis* should be considered in high-risk pts, & fungal or viral causes found in pts w/ immunodeficiency

- Noninfectious causes of epididymitis include postinfectious inflammatory rxn to pathogens (*ie, M. pneumoniae, adenoviruses*), vasculitides, meds (*ie, amiodarone*)

**History**

- Primarily affects young men aged 18–35 y/o, bimodal distribution 16–30 y/o & 50–70 y/o
- Testicular pain, swelling usually beginning posteriorly overlying epididymis; lower urinary tract sxms may be present
- RFs: Unprotected intercourse (*esp anal*), MSM, increased number of sex partners, h/o STDs (*esp GC/Chlamydia*), sex w/ prostitutes, structural/functional GU abnlty, urinary tract instrumentation

**Physical Exam**

- ±Fever; assess for CVA tenderness, suprapubic pain as e/o other urinary tract dz
- Testicular exam: Palpation of epididymis, testes, cremasteric reflex; tender, erythematous, swollen spermatic cord & testicular contents c/w epididymitis-orchitis
  - Prehn sign: Relief of pain w/ elevation of testes can be seen w/ epididymitis. Inguinal exam for hernia or swollen, tender nodes.

**Evaluation**

- First-void (*“dirty”*) UA (+LE & ≥10
- WBC/hpf suggests urethritis, favoring Dx of epididymitis); Ucx
- Gram stain of urethral secretions w/ ≥5 WBC/hpf (presence of gram-negative intracellular diplococci c/w gonococcal dz) & culture
- Urine NAAT for *N. gonorrhoeae* & *C. trachomatis* most sens
- Imaging: Testicular color Doppler ultrasonography (Findings: Thickened epididymis w/ increased blood flow suggesting hyperemia)

**Treatment**

- Sexually active men <35 y/o & older men w/ RFs for STDs:
  - Ceftriaxone 250 mg IM × 1
-AND-

- Doxycycline 100 mg PO BID × 10 d
- Abstain from intercourse for 7 d & until all sex partners (w/i previous 60 d) are evaluated or empirically treated
- Men >35 y/o or no RFs for STDs (thus likely caused by enteric organisms):
  - Levofloxacin 500 mg PO QD × 10 d
  - Ofloxacin 300 mg PO BID × 10 d

*Note: Above fluoroquinolones have activity against C. trachomatis & favorable UG tissue Penetration

- Supportive: NSAIDs for pain, ice/elevation of testes while at rest

Disposition
- Home

Pearl
- Pts <35 y/o likely to have an STD organism as etiology; >35 y/o more likely enteric pathogen

---

FLANK PAIN

Approach to the Patient

History
- Onset (sudden vs. progressive)? Location?
  - Dysuria/hematuria/urinary frequency? Prior h/o similar sx(s)
- ROS (fever, rash, trauma, nausea, vomiting, weakness, abdominal pain), PMH (kidney stones, gout, cancer, AAA, congenital kidney dz, cardiac or vascular dz)

Evaluation
- CBC, Cr; consider renal u/s or noncontrast abdominal CT

<table>
<thead>
<tr>
<th>Flank Pain Differential</th>
<th>Pathophysiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal</td>
<td>Nephrolithiasis, urolithiasis, retroperitoneal hematoma, ruptured renal cyst, ureteral stricture</td>
</tr>
<tr>
<td>Infectious</td>
<td>Pyelonephritis, perinephric abscess, psoas abscess,</td>
</tr>
</tbody>
</table>
Urolithiasis (Nephrolithiasis and Ureterolithiasis)


**Definition**
- Urolithiasis denotes calculi (of mineral or organic solids) that form anywhere in the urinary tract; nephrolithiasis & ureterolithiasis more specifically denote calculi present in the kidney or ureter, respectively
- Kidney stones form when urine becomes saturated with stone-forming salts
- Types of calculi:
  - Calcium oxalate stones (~80%): Predisposing conditions include hypercalciuria (hyperparathyroidism, sarcoidosis, type I RTA, hypercalcemia of malignancy, thiazides) & hyperoxaluria (Crohn’s dz other ileal dz)
  - Magnesium ammonium phosphate (struvite) stones (~15%): Requires combination of ammonia & alkaline urine. Source of ammonia from splitting of urea by urease-producing bacteria (*Proteus, Klebsiella, Pseudomonas, & Staphylococcus*)
  - Uric acid stones (~5–10%): Secondary to hyperuricosuria (gout, DM2, HTN)
  - Cystine stones: Secondary to inherited defects of tubular amino acid reabsorption
  - Drug-induced calculi: 2/2 metabolic abnormalities that favor stone formation or crystallization of drug or metabolites
- Stones lodged in ureter are typically found in 3 locations: Ureteropelvic junction, at the level of the iliac vessels, & ureterovesicular junction

**History**
- M:F, 2:1; Caucasian > Hispanic > Asian > African; peak incidence 20–50 y/o
Renal colic (acute, spasmodic, unilateral flank pain radiating to groin/testes/labium) & visceral sx (N/V/diaphoresis)
Distal stones may cause lower abdominal pain & lower urinary tract sx (dysuria, frequency, hematuria)
PMH: FH nephrolithiasis, hyperparathyroidism, sarcoidosis, RTA, malignancy, Crohn’s, jejunointestinal bypass, recurrent UTI, gout, DM2, HTN, structural urologic abnormalities
Meds: Indinavir, loop/thiazide diuretics, laxatives, carbonic anhydrase inhibitors, ciprofloxacin, sulfonamides have been a/w drug-induced calculi

Physical Exam
- Fever? Tachycardic? Generally uncomfortable appearing, diaphoretic, cool/clammy skin
- CVA tenderness; lower abdominal/pelvic tenderness (if stone has migrated)
- Assess for midline spinal TTP, acute abdomen, etc. which suggest alternative dx

Evaluation
- UA (may show +RBCs, though sens 84% spec 48% for stone; proteinuria, crystalluria), Ucx
- Consider BUN/Cr; CBC usually nonspecific & not helpful
- Imaging:
  Renal U/S (sens 45%, spec 94% for stones; sens 85–90% spec 90–100% for hydro):
  - May be initial radiographic exam w/ high pretest probability or if CT not possible (pregnancy); esp useful for detection of hydronephrosis or ureteral dilatation; not sens stones <5 mm; can be done point-of-care
  Nonenhanced helical CT (sens 96–98%, spec 100%)
  - Usefual as initial radiographic exam, particularly w/ 1st presentation of suspected stone or low-moderate probability; able to make alternative diagnoses; modality of choice when available

*Indinavir stones not visible on CT

Treatment
- Data suggests IVFs likely not useful for acute renal colic from urolithiasis, but consider if pt appears dehydrated or has AKI
Pain control: NSAIDs (ibuprofen 600 mg PO TID or ketorolac 15–30 mg IV if unable to take PO [caution in renal insufficiency]) & morphine 0.1 mg/kg × 1 then titrated for further relief

Medical expulsive therapy: Tamsulosin 0.4 mg PO QD × 14 d or until stone passage; other alpha-antagonists (doxazosin, terazosin, alfuzosin) & nifedipine still used by many. SUSPEND trial (RCT 1167 pts tamsulosin, nifedipine or placebo) showed no increase in stone passage with MET. *(Health Tech Assess. 2015;19:1)*

Urology consult: For concomitant infection, renal insufficiency, or low likelihood of stone passage (>10 mm)

**Disposition**

- Home: Adequate pain control in ED, nl Cr; f/u w/ urology in 24–48 h if stone >5 mm
- Admit: Intractable pain, unable to tolerate POs, renal failure, infection, renal transplant, single kidney, comorbid conditions (DM, baseline CRI), infected stone w/ obstruction

**Pearls**

- Presence or absence of hematuria alone cannot be used to diagnose or exclude nephrolithiasis
- Most stones ≤5 mm (70–98%) will pass spontaneously. Stones >5 mm have smaller chance (25–51%) of spontaneous passage & are more likely to need urologic intervention. *(J Urol. 2015;194:1009)*
- Send pts home w/ strainer, esp 1st-time stone formers for stone analysis
- Cx: Obstructed infected kidney (urologic emergency requiring urgent decompression), renal insufficiency, failed expulsion

**HEMATURIA**


**Definition**

- Hematuria is blood in the urine. Gloss hematuria is visible. Microscopic hematuria is ≥3 RBCs/hpf in urine sediment.
Hematuria must be distinguished from pigmenturia (discoloration of urine). Pigmenturia can be caused endogenously by melanin, porphyrins, bilirubin, myoglobin, or hemoglobin or exogenously by meds (ie, warfarin, rifampin, phenazopyridine, phenytoin, etc.), beets

**History**
- Onset (sudden vs. chronic)? Dysuria/urinary frequency/renal colic? During entire or part of urine stream? (hematuria at beginning of urination → urethral; throughout urination → upper urinary tract or proximal bladder; end of urination → bladder neck or prostatic urethra)
- Painless hematuria should raise suspicion for genitourinary malignancy
- ROS (fever, weight loss, night sweats, rash, sore throat, abdominal pain, N/V, recent viral infection or UTI; trauma; excessive exercises; pelvic radiation)
- PMH (kidney stones, HTN, cancer, congenital kidney dz, vascular dz, bleeding diathesis, SCD, hereditary spherocytosis)
- MEDS:
  - Drugs that cause pigmenturia: Warfarin, rifampin, phenazopyridine, phenytoin, azathioprine, deferoxamine, doxorubicin, riboflavin
  - Drugs that cause myoglobinuria: Amphotericin B, barbiturates, cocaine, diazepam, ethanol, heroin, methadone, statins
  - Drugs that cause hematuria: NSAIDs, anticoagulations, busulfan, cyclophosphamide, OCPs, quinine, vincristine
- Social (smoking, benzene or aromatic amine exposure)

**Physical**
- Evaluate for HTN, petechiae, arthritis, rash
- Assess for suprapubic & CVA tenderness; thorough GU exam including prostate exam
- Postvoid residual if concern for urinary retention

**Evaluation**

**Key question: Is this truly hematuria?**
- Urine dipstick + blood (can be seen w/ hematuria, hemoglobinuria, myoglobinuria, or other pigmenturias); urine sediment necessary to confirm >5 RBCs/hpf as well as identify protein, RBC casts (suggests glomerulonephritis), & crystalluria (suggests urolithiasis)
Other urine studies: Urine cytology  
CBC, BUN/Cr, coags (if isolated hematuria—erythrocytes in sediment, but no protein—suggests bleeding diathesis)  
Outpt imaging: CT urography (1st line), renal u/s, MRI. Cystoscopy if ≥35 y/o.

Disposition
Large, gross hematuria may warrant continuous monitoring of HCT & urology eval. If microscopic, can obtain further outpt eval by nephrology or urology.

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structural</td>
<td>Urolithiasis, BPH, PKD, analgesic nephropathy, papillary necrosis, menstruation</td>
</tr>
<tr>
<td>Infectious</td>
<td>UTI, STDs, renal TB, malaria</td>
</tr>
<tr>
<td>Vascular</td>
<td>AVM, renal artery dz (thrombosis, dissection, malignant HTN), renal vein thrombosis, sickle cell crisis</td>
</tr>
<tr>
<td>Meds</td>
<td>Cyclophosphamide, anticoagulants</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>Glomerulonephritides (poststrep, postinfectious, IgA nephropathy, lupus nephritis, Alport's syndrome, thin basement membrane dz, etc.), vasculitis (HSP, granulomatosis w/ polyangiitis, etc.), transfusion rxn</td>
</tr>
<tr>
<td>Trauma/Other</td>
<td>Renal trauma, urethral or ureteral trauma, recent instrumentation, paroxysmal nocturnal hemoglobinuria, vigorous exercise</td>
</tr>
<tr>
<td>Neoplastic</td>
<td>Renal Ca, urethral Ca, bladder Ca, prostate Ca</td>
</tr>
</tbody>
</table>

**ACUTE KIDNEY INJURY**

*(Lancet. 2012;380:756)*


**Approach to the Patient**

**Definition & Staging**
AKI is defined as any of the following:
Increase in serum Cr by ≥0.3 mg/dL (≥26.5 μmol/l) w/i 48 h; or
Increase in serum Cr by ≥1.5 times baseline, which is known or presumed to have occurred w/i prior 7 d; or
Urine volume <0.5 mL/kg/h for 6 h

AKI is staged for severity according to the following criteria:

<table>
<thead>
<tr>
<th>Stage</th>
<th>RIFE Criteria</th>
<th>Serum Cr</th>
<th>Urine Output</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Risk</td>
<td>1.5–1.9 times baseline -OR- GFR decrease &gt;25%</td>
<td>&lt;0.5 mL/kg/h for 6–12 h</td>
<td>D/c nephrotoxins · Ensure volume status/perfusion pressure · Monitor Cr &amp; UOP · Avoid hyperglycemia · Consider alternative to using radiocontrast · Noninvasive w/u · Consider invasive w/u</td>
</tr>
<tr>
<td>2</td>
<td>Injury</td>
<td>2–2.9 times baseline -OR- GFR decrease &gt;50%</td>
<td>&lt;0.5 mL/kg/h for ≥12 h</td>
<td>-AND- · Check for changes in drug dosing · Consider RRT · Consider ICU admit</td>
</tr>
<tr>
<td>3</td>
<td>Failure</td>
<td>3 times baseline -OR- ↑ in serum Cr to ≥4 mg/dL -OR- GFR decrease &gt;75%</td>
<td>&lt;0.3 mL/kg/h for ≥24 h -OR- Anuria for ≥12 h</td>
<td>-AND- · Avoid subclavian catheters if possible</td>
</tr>
</tbody>
</table>

Loss

Persistent ARF = complete loss of kidney function for >4 wk

ESKD

End-stage kidney disease (>3 mo)

History

ARF is usually asymptomatic & diagnosed when labs reveal renal abnormalities

Sxs may include decreased urine output, weight gain, fluid retention (peripheral edema, anasarca, ascites), fatigue, anorexia, N/V, pruritus, altered sensorium, thirst/orthostasis (prerenal)
- ROS (fever, rash, flank pain, hematuria)
- PMH: Baseline renal impairment, CHF, liver dz, SLE, multiple myeloma
- MEDS (ACEI/ARB, NSAIDs, aminoglycosides, other abx, cisplatin, amphotericin B, diuretics)

**Physical**
- Assess volume status; myoclonus, pericardial or pl rub, rash, mental status, edema
- Stigmata of CHF, liver dz, collagen vascular dzs

**Evaluation**
- CBC, Chem 10 (BUN/Cr ratio), serum osmolality; consider VBG w/ STAT potassium
- Urinalysis/sediment, urine lytes (urine Na, urine K, urine Cr, urine osmolality)
  - \[ \text{FE}_{\text{Na}} \% = \frac{(\text{Urine Na} \times \text{Plasma Cr})}{(\text{Plasma Na} \times \text{Urine Cr})} \times 100 \]
- Consider LFTs, BNP if indicated
- EKG for cardiac electrical instability from potential electrolyte abx
- Consider point-of-care cardiac, IVC, renal u/s
- Imaging: Renal u/s (r/o obstruction, assess flow); consider CT abdomen if c/f pelvic mass, Doppler u/s of renal vasculature
- Other studies: Renal biopsy

<table>
<thead>
<tr>
<th>Differential Diagnosis of AKI/ARF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathophysiology</strong></td>
</tr>
<tr>
<td>Prerenal</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Intrinsic renal</td>
</tr>
<tr>
<td>Glomerular Dz:</td>
</tr>
</tbody>
</table>
Glomerulonephritis, vasculitis, malignant HTN, preeclampsia, DIC, collagen vascular dzs (SLE, scleroderma)

**Intratubular Obstruction:**
Multiple myeloma, uric acid, acyclovir, MTX, indinavir

**Acute Tubular Necrosis:**
Profound ischemia, infection, radiocontrast, calcineurin inhibitors, 
abx (ie, aminoglycosides), antifungals (amphotericin B), chemo 
(ie, cisplatin), ethylene glycol, rhabdomyolysis, HUS/TTP

**Interstitial Nephritis:**
Allergic nephritis (β-lactams, fluoroquinolones, sulfa, NSAIDs), pyelonephritis, leukemia/lymphoma, sarcoid

---

**Postrenal**

**Ureter:**
Calculi, clot, cancer (pelvic mass), external compression

**Bladder Neck:**
Calculi, clot, cancer (pancreatic), BPH, neurogenic bladder

**Urethra:**
Stricture, valves

---

### Interpreting Laboratory Data in AKI/ARF

<table>
<thead>
<tr>
<th></th>
<th>BUN/Cr</th>
<th>FE_{Na}</th>
<th>Urine_{Na}</th>
<th>SpGrav</th>
<th>Urine_{osm}</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prerenal</strong></td>
<td>≥20</td>
<td>&lt;1%</td>
<td>&lt;10 mmol/L</td>
<td>&gt;1.018</td>
<td>&gt;500</td>
<td>Hyaline casts</td>
</tr>
<tr>
<td><strong>Intrinsic renal</strong></td>
<td>10–20</td>
<td>&gt;1%</td>
<td>&gt;20 mmol/L</td>
<td>&lt;1.015</td>
<td>300–500</td>
<td>- Muddy brown casts (ATN)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- RBC casts (glomerular injury, tubulointerstitial nephritis)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- WBC casts (interstitial nephritis)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Broad granular casts (CKD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Eosinophiluria (allergic nephritis)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Uric acid crystals (urate nephropathy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Oxalate/Hippurate crystals (ethylene glycol tox)</td>
</tr>
<tr>
<td><strong>Postrenal</strong></td>
<td>&lt;10</td>
<td>&gt;1%</td>
<td>—</td>
<td>—</td>
<td>&lt;350</td>
<td></td>
</tr>
</tbody>
</table>
Treatment

- **Prerenal:** Correct volume status/perfusion pressure (IVFs, pressors, PRBCs if indicated, diuresis/inotropes if cardiorenal)
- **Intrinsic:** Eliminate nephrotoxins, treat underlying cause, consider glucocorticoids
- **Postrenal:** Transurethral or suprapubic catheter placement; may require ureteric stents or percutaneous nephrostomy tube placement
- Consider sodium bicarbonate if pH < 7.2 or HCO$_3$ < 15 mmol/L as bridge to dialysis

**Indications for Emergent Dialysis and Renal Replacement Therapy “A, E, I, O, U”**

- Acidosis (pH < 7.1)
- Electrolyte imbalance (hyperkalemia, hypocalcemia, hyperphosphatemia)
- Intoxication (lithium, salicylates, ethylene glycol, methanol, among others)
- Overload (volume overload)
- Uremia (pericarditis, encephalopathy, neuropathy, bleeding)

**Disposition**

- Home: Mild prerenal azotemia may be adequately treated w/ hydration; pts w/ postobstructive ARF can be sent home if obstruction is relieved (ie, w/ bladder catheter) & no significant comorbidities
- Admit: Pts w/ uremia, significant electrolyte abnormalities, volume overload, severe metabolic acidosis, unexplained ARF

**Pearl**

- Cx: Intravascular volume overload, hyponatremia, hyperkalemia, hyperphosphatemia, hypocalcemia, hypermagnesemia, metabolic acidosis, uremia, anemia, arrhythmias

**TESTICULAR TORSION/TORSION OF TESTICULAR APPENDIX**

History

Testicular Torsion
- Sudden onset pain (± swelling) in scrotum w/ radiation into abdomen; pain may be intermittent; N/V; most commonly in puberty

Torsion of Appendix
- Similar presentation to testicular torsion but pain can be localized to superior pole of testicle; benign condition

Physical Exam

Testicular Torsion
- Ill appearing, very tender/swollen/elevated testicle that may lie horizontally or anteriorly rotated; presence of cremasteric reflex does not r/o dz

Torsion of Appendix
- Normal-appearing testes; tenderness localized to superior pole of testicle; may have nodular “blue dot” at superior pole of testicle

Evaluation
- Labs: Preop labs if surgery anticipated
- Imaging: Scrotal duplex u/s to assess flow to testicle, but imaging should not delay time to OR; HRUS if duplex equivocal

Treatment
- Consult urology immediately if concern for testicular torsion as time to OR is critical for survival of testicle; if delay to OR, may attempt manual detorsion in medial to lateral direction (“open book” technique)
- Analgesia
- Antiemetics

Pearls
- >90% salvage rate if detorsion occurs <6 h
- Continuous pain >24 h is a/w an infarcted testicle

PHIMOSIS AND PARAPHIMOSIS
History

Phimosis
- Inability to retract the distal foreskin over the glans penis; “ballooning” of the prepuce during urination; painful erection, preputial pain, weak urinary stream

Paraphimosis
- Inability to completely reduce foreskin distally back to natural position over glans penis. Entrapped foreskin forms constricting band, leads to pain & swelling.
- A/w vigorous sexual activity & chronic balanoposthitis
- Occurs exclusively in uncircumcised males & is a urologic emergency
- Pediatric: Often seen w/ forceful retraction or forgetting to reduce foreskin after bathing/voiding; irritability may be the only sign in nonverbal children

Physical Exam

Phimosis
- Inability to retract foreskin proximally over glans penis

Paraphimosis
- Foreskin retracted behind the glans & cannot be replaced to nl position; proximal shaft is soft (unless there is accompanying infection) w/ glans appearing erythematous/edematous & eventually blue/black & firm

Treatment
- If significant manipulation is expected, you may perform a penile block. On the dorsal aspect of the penis in the 2- & 10-o’clock positions, deposit 1% lidocaine; subsequently complete a ring block by depositing anesthetic circumferentially around the proximal shaft.

Phimosis
- No acute intervention needed unless infection suspected. Consider topical steroids (0.05–0.1% betamethasone) × 4–6 wk for mild–moderate cases.

Paraphimosis
Compress the foreskin & glans by snugly grasping it with the palm of the hand & apply pressure for several minutes. Other methods to reduce edema include:

- **Dundee micropuncture technique:** Make ~20 puncture holes in edematous foreskin tissue with a small needle (27 gauge) & express the fluid
- **Hyaluronidase technique:** Inject 1 cc of hyaluronidase (150 U/mL) using a tuberculin syringe into the site of edematous foreskin
- **Sugar technique:** Soak a swab of 50 mL of 50% dextrose solution & leave it wrapped around the foreskin for 1 h

Attempt manual reduction by placing index fingers on dorsal border of glans behind retracted prepuce & thumbs on glans; may facilitate with ice, elastic bandage over glans or spreading hyperosmolar agents (such as sugar/dextrose) over glans to reduce swelling

Consult urology if manual reduction unsuccessful

**Disposition**

- Home: Phimosis ± abx for accompanying infection; paraphimosis if skin is in the retracted position. Urology f/u for all paraphimoses.
- Admit: Paraphimosis not reduced by conservative methods

**Pearls**

- Educate parents/caretakers of children on importance of avoiding forcible retractions & of gentle reduction of foreskin after bathing & voiding
- Paraphimoses that are not immediately treated are at risk for necrosis & autoamputation

---

**PRIAPISM**


**Definitions**

- Priapism is defined as a prolonged erection lasting generally >4 h in the absence of sexual stimulation
- Ischemic (low-flow) priapism is the most common subtype & is due to painful engorgement of the corpora cavernosa. This can lead to
intracavernosal acidosis, sludging of blood, thrombosis of cavernal arteries, & impotence

- Nonischemia (high-flow) priapism is rare, painless, & is caused by increased arterial inflow to the penis as a result of traumatic arterial–cavernosal fistulas

**History**

- Painful, persistent erection lasting >4 h, not relieved by ejaculation
- RFs: impotence agents (sildenafil), SCD, leukemia, urogenital malignancies (prostate, bladder), CVA, spinal cord injury antihypertensives (hydralazine, prazosin, doxazosin), antidepressants (trazodone, fluoxetine, sertraline), antipsychotics (phenothiazines & atypicals), phosphodiesterase inhibitors, cocaine, toxins (scorpion, black widow, CO)

**Physical Exam**

- Obvious erection, generally involving only the corporal cavernosa & flaccid corpora spongiosum

**Evaluation**

- Labs: Preoperative labs if contemplating OR
- May send a blood gas from penile aspirate

**Treatment**

- Pain control
- To reduce flow/vasoconstriction:
  - Oral/IM: Terbutaline 5 mg PO x 1; terbutaline 0.25–0.5 mg IM x 1 (unclear benefit)
  - Intracavernosal phenylephrine injection: Using a 25- or 27-gauge needle (or tuberculin syringe), inject 0.2–0.5 mg of phenylephrine into corpus q10–15min (maximum 4–5 doses) 2 cm distal to origin of shaft on dorsal penis at 2- or 10-o’clock position
  - **Note:** Must dilute phenylephrine solution. Take phenylephrine 1% solution (10 mg/mL) & extract 1 mL (10 mg) from solution. Add this 1 mL to 9 mL of saline, which will give you 1 mg/mL of phenylephrine solution. You can then extract 0.2–0.5 mL (0.2–0.5 mg) of this for intracavernosal injection.
  - If unsuccessful, aspiration/irrigation technique:
- Perform penile nerve block: On the dorsal aspect of the penis in the 2- & 10-o’clock positions, deposit 1% lidocaine; subsequently complete a ring block by depositing anesthetic circumferentially around the proximal shaft
- Prep & drape penis in sterile fashion
- At 2- or 10-o’clock position insert a 16–18 g needle (also consider 18-gauge dialysis butterfly access needle), & using a 10–30 mL syringe, slowly aspirate while milking corporus w/ other hand until return if bright red blood & detumescence occurs
- If this fails, you can attempt to irrigate by injecting 20–30 mL of phenylephrine & NS solution (10 mg phenylephrine in 500 mL NS) as exchange for 20–30 mL aspirate
- W/ sickle cell crisis: IVFs, O₂, pain control, consider exchange transfusion
- Consult urology for refractory priapism (may necessitate surgical decompression)

**Disposition**
- Recommended to observe for at least 2 h to assess for recurrence
- Home: Once detumescence achieved. Recommended to d/c w/ 3-d course of oral α-adrenergic agent (pseudoephedrine)
- Admit: If priapism not responsive to ED tx

**Pearls**
- >12 h of priapism a/w onset of tissue demise w/ >24 h a/w permanent impotence
- Cx: Hematoma, infection, systemic absorption of vasoactive agents (severe HTN), recurrence, impotence (this risk should be discussed w/ pt & is a possibility despite efforts & timeliness of therapy)

---

**EMERGENCIES IN DIALYSIS PATIENTS**


**Definition**
- Any complication involving dialysis catheters or fistulas as well as infection, electrolyte imbalances, cardiac complaints, or signs of fluid
overload among others

- Common complaints & special considerations include:

<table>
<thead>
<tr>
<th>Chief Complaint</th>
<th>Differential/*Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>PNA (healthcare associated), UTI, bacteremia, *peritonitis (particularly w/ peritoneal dialysis), *Access-related infection (hematogenous spread can lead to endocarditis, septic pulmonary emboli, septic arthritis, vertebral osteomyelitis, epidural abscess)</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>*Fluid overload/pulmonary edema, *high-output cardiac failure (AV fistula), *pl effusion (uremic, chronic fluid overload), *anemia (decreased EPO production), PTX (after subclavian or IJ HC access), *pericardial effusion (uremic), PE</td>
</tr>
<tr>
<td>Chest pain</td>
<td>ACS, PE, AD, *uremic pericarditis, *uremic pleuritis</td>
</tr>
<tr>
<td>Syncope</td>
<td>*Intradialytic hypotension, *uremic autonomic neuropathy, *dysrhythmias, other frequent causes of syncope</td>
</tr>
<tr>
<td>Hypotension</td>
<td>*Intradialytic hypotension, dysautonomia, antihypertensives, pericardial effusion/tamponade, sepsis, *anaphylaxis (oversulfated chondroitin sulfate contaminants in heparin)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>Consider common causes of abdominal pain, *uremic gastritis/colitis, *peritonitis (particularly w/ peritoneal dialysis), *abdominal wall hernias (from increased abdominal pressures w/ ascites)</td>
</tr>
<tr>
<td>Headache/AMS</td>
<td>*Dialysis dysequilibrium syndrome, *uremic/HTN encephalopathy, *hypertensive emergency, ICH, CVA, *medication effects from altered pharmacodynamics (benzodiazepines, morphine, meperidine, etc.), hyponatremia</td>
</tr>
<tr>
<td>Skin changes</td>
<td>*Uremic pruritus, *prurigo nodularis, *calciphylaxis (cutaneous uremic artiolopathy)</td>
</tr>
<tr>
<td>HD access sx</td>
<td>AV access “steal syndrome,” AV fistula/catheter access vein thrombosis, AV fistula hemorrhage</td>
</tr>
<tr>
<td>Other</td>
<td>Electrolyte abnormalities (hyperkalemia, hyperphosphatemia, hypermagnesemia, hypocalcemia, hyponatremia), metabolic acidosis, uremic polyneuropathy (restless leg syndrome, paresthesias)</td>
</tr>
</tbody>
</table>

**Approach to the Patient**

**History**
Should focus on assessing for common causes of respective chief complaints, w/ attention to special considerations unique to ESRD pt

Physical
- Attention to abnl vital signs
- Pulmonary & cardiac exam including assessment of friction rub, rhonchi, & rales
- Abdominal exam, esp in pts w/ PD catheters
- Extremity exam & JVP for signs of fluid overload
- Skin exam for e/o calciphylaxis
- Assess graft site for thrill & signs of bleeding, infection, edema, & bruising; assess tunneled catheter site for e/o cellulitis or underlying abscess formation

Diagnostics
- CBC, Chem 10; consider ABG w/ STAT potassium & to assess acid–base status
- Consider LFTs, BNP, cardiac markers if indicated
- Consider contacting PD access nurse for sample of PD dialysate fluid (cell count [WBC >50–100 cell/mm³ suggest peritonitis], Gram stain, culture)
- EKG for cardiac electrical instability from potential electrolyte abx, ischemia
- Consider point-of-care cardiac & lung u/s & FAST exam to assess for effusion & ascites, respectively
- Imaging: Appropriate imaging for respective complaints; Doppler imaging of AF fistula site if concern for thrombosis

Treatment
- Refer to appropriate sections for tx of conditions noted above
- Special considerations:
  - **Peritonitis**: Vancomycin 2 g AND cefepime/ceftazidime 1 g each added to 1 bag of dialysate infused into & allowed to dwell in the peritoneal cavity for 6 h
  - **Dialysis disequilibrium syndrome**: Reduce ICP (HOB elevation >30°, hyperosmolar therapy [mannitol, hypertonic saline], euglycemia, eutherma, eunatremia, MAP > 65, CO₂ 40 mmHg, CPP 50–70 mmHg); renal consult
  - **Clotted AV graft/fistula**: Immediate vascular surgery consultation
for consideration of catheter-directed thrombolysis, pharmacomechanical thrombolysis, surgical thrombectomy

- **Clotted Vascular Access Catheters**: Consult institutional policies; if feasible, attempt catheter-directed tPA via infusion of 2 mg tPA into occluded lumen & fill remainder w/ saline. After 15 min, inject 0.3 mL saline to move the active enzyme toward the tip of the catheter. After another 15 min, inject another 0.3 mL to move the active enzyme toward the tip of the catheter. After another 15 min, try to aspirate catheter. If unsuccessful, send pt for catheter exchange.

- **Vascular Access Hemorrhage**: Apply direct pressure for 10–15 min; if occurs w/ hours of dialysis, consider protamine 1 mg per 100 U heparin received (or 10–20 mg if dose unknown) to reverse heparin anticoagulation; consider application of gelfoam, surgical, or other hemostatic agent; immediate vascular surgery consultation for uncontrolled hemorrhage

**Disposition**

- Depends upon presenting complaint, but most will invariably require admission

**Pearls**

- BP measurement over & use of AV fistula sites for blood draw/administering therapy is contraindicated
- BNP levels are not reliable in diagnosing fluid overload/HF in dialysis pts as basal BNP levels are typically elevated & increased BNP levels from baseline may not correlate w/ clinical HF
- Chronically elevated troponin common & a/w increased mortality; makes assessment of ACS challenging; however, the National Academy of Clinical Biochemistry (NACB) recommends a 20% change in troponin concentration from baseline for Dx of AMI
VAGINAL BLEEDING


History

Diagnostics
- CBC, type & screen (Rh), urine hCG; quantitative hCG if pt is pregnant; crossmatch (if heavily bleeding); consider pelvic u/s

Pearls
- Average pad holds 5–15 cc of blood
- Average tampon holds 5 cc of blood

<table>
<thead>
<tr>
<th>Vaginal Bleeding Differential</th>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathophysiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonpregnant</td>
<td></td>
<td>Abnl uterine bleeding, PCOS, IUD or oral contraceptives, endometritis, cervicitis, fibroids, uterine polyps, adenomyosis, endometrial hyperplasia or cancer, coagulopathies, postcoital bleeding</td>
</tr>
<tr>
<td>1st trimester</td>
<td></td>
<td>Implantation bleeding, miscarriage, ectopic pregnancy, hydatidiform mole</td>
</tr>
<tr>
<td>2nd/3rd trimester</td>
<td></td>
<td>Placenta previa, vasa previa, placental abruption, uterine rupture</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>Postpartum hemorrhage, retained products of conception</td>
</tr>
</tbody>
</table>

Miscarriage
History
- Vaginal bleeding ± passage of clots or tissue at <20 wk; abd pain/cramps

Physical Exam
- Speculum & bimanual exam to assess for passage of blood/POC & whether os is open or closed. (If copious bleeding, remove POC w/ gentle traction to allow uterus to clamp.)

Evaluation
- Labs: UA, quant hCG, HCT, type & screen (crossmatch if HD unstable). If products expelled, send to pathology.
- Imaging: Pelvic u/s to determine location of pregnancy

Classification of Miscarriage
- Threatened: Os closed, no passage of POC, viable fetus w/ heart tones, mild cramping/bleeding (~20% will eventually abort)
- Inevitable: Os dilated & effaced; POC not passed; cramps, moderate bleeding
- Complete: POC expelled, cervical os closed; little cramping or bleeding
- Incomplete: Some, but not all products have passed. Retained fetal or placental tissue
- Missed: Pregnancy loss after development of embryo/fetus, os closed

Treatment
- ED:
  - Supportive management: IVFs, O₂, monitoring, position on L side
  - Blood products: Transfuse if HD unstable
- Medication therapy:
  - Rh immunoglobulin: 50 mcg <12 wk, 300 mcg >12 wk if Rh-negative
  - Consult: Gyn service if HD unstable or if need for D&C anticipated (inevitable, incomplete or missed abortion)
- Home management:
  - Hormonal therapy: Methotrexate may be indicated under guidance of OB/Gyn
  - Consider prophylaxis w/ doxycycline or testing for STD if
discharging home w/ open os

Disposition
- Home: Stable pts w/ complete or threatened abortion; f/u w/ OB/Gyn w/i 72 h to monitor hCG levels
- Admit: Uncontrolled bleeding or pts requiring immediate D&C

Pearl
- Threatened & missed abortions can only be distinguished by pelvic u/s

Ectopic Pregnancy

History
- Unruptured: abd pain, cramping, amenorrhea or abd pain.
- Ruptured: hypotension, tachycardia, abd pain
- RFs: H/o PID, IUD, fertility tx, recent abortion or prior ectopic

Physical Exam
- Assess for HD stability. Signs of peritonitis if rupture has occurred.
  Speculum & bimanual exam may reveal pelvic tenderness &/or adnexal mass.

Evaluation
- Labs: Quant hCG, HCT, Rh screen, PT/PTT & type & crossmatch 4 U (if HD unstable)
- Imaging: Pelvic US (TVUS should identify IUP at 5.5 wk); if HD unstable, FAST exam to assess for free fluid

Treatment
- Supportive: 2 large-bore IVs, IVF resuscitation, monitor
- Transfusion: If HD unstable
- Rh immunoglobulin: 50 mcg <12 wk, 300 mcg >12 wk if Rh-negative
- Consult: Urgent Gyn eval for consideration of medical (MTX) vs. surgical (laparoscopy/laparotomy) tx options

Pearl
- Heterotopic pregnancies (co-occurrence of IUP & ectopic) have incidence of 1/30,000 in spontaneous pregnancies but 1/100 in assisted pregnancies.

Placenta Previa and Abruptio Placentae
History

- Placenta previa: Placental implantation adjacent to or over os. Presents as painless, bright red, vaginal bleeding usually after 28 wk. RFs: Multiple gestation, multiparity, advanced maternal age, previous placenta previa/C-section, maternal smoking, HTN
- Abruptio placentae: Separation of implanted placenta b/w 20 wk & delivery. Presents as painful, dark red bleeding (80%); may also present w/ signs/sxs of DIC. RFs: Eclampsia, DM, HTN, abdominal trauma, cocaine, cigarette smoking

Physical Exam

- Check fundal height, contractions, & uterine tenderness:
  - Firm/tender uterus = placental abruption until proven o/w
- AVOID SPECULUM & VAGINAL EXAM

Evaluation

- Labs: CBC, Chem 7, LFTs, PT/PTT, fibrinogen (r/o DIC), UA, type/crossmatch 2 U
- Imaging: Doppler u/s (fetal heart tones); bedside abdominal u/s to assess placenta & signs of fetal movement, though may not always detect abruption

Treatment

- Supportive: Place on L side, 2 large-bore IVs, IVF resuscitation, monitor pt & fetus
- Transfusion: Blood products ± FFP (HD unstable or signs of DIC)
- Medications: Rh immunoglobulin 300 mcg if Rh-negative, magnesium for fetal neuroprotection if emergent delivery under 32 wk
- Consult: Urgent Gyn eval for possible STAT C-section

Disposition

- Admit: All pts to the OB service even if HD stable for close monitoring

Retained Products of Conception and Postabortion Sepsis

(Ob Gyn. 2015;125:1042)

History

- Infection of placenta &/or POC which can spread to the uterus →
systemic

- Retained POC: Cramping, heavy bleeding
- Postabortion sepsis: Cramping, bloody or purulent d/c, fever

**Physical Exam**

- Fever, vaginal bleeding or purulent/bloody d/c, uterine tenderness

**Evaluation**

- Labs: Quant hCG, type & cross, preop labs
- Imaging: Pelvic u/s

**Treatment**

- Supportive: Stabilize (see *Sepsis chapter*), correct coagulopathy/anemia
- Abx: If suspected infection, clindamycin 900 mg IV q8h PLUS gentamicin 5 mg/kg/d OR ampicillin 2 g q4h PLUS gentamycin PLUS metronidazole 500 mg q8h OR levofloxacin 500 mg QD PLU metronidazole OR piperacillin–tazobactam 4.5 g q8h.
- Consult: Gyn service for D&C

**Disposition**

- Admit: All pts to OB/Gyn for D&C

**Postcoital Bleeding**

**History**

- Trauma during intercourse? Vaginal d/c, assess domestic violence or abuse.
- RFs: Cervical abnormalities, STDs, postmenopausal

**Physical Exam**

- Ongoing bleeding; vaginal lacerations, abrasions

**Evaluation**

- Labs: Urine hCG, GC/Chlamydia testing; HCT

**Treatment**

- ED:
  - Abx: Treat STI appropriately (see *Vaginal Discharge* below)
  - Consult: Gyn service for laceration requiring extensive repair; social services if concern for domestic violence
PREECLAMPSIA AND ECLAMPSIA

(EMERG MED CLIN NORTH AM. 2012;30:903)

Definition
- Chronic HTN: Systolic BP >140/90 before 20 wk gestation or longer than 12 wk postpartum
- Gestational HTN: BP >140/90 on 2 occasions after 20 wk gestation.
- Preeclampsia: Gestational HTN & proteinuria, can be classified as mild to severe based on end-organ damage
- Eclampsia: Preeclampsia w/ szs or coma; generally 3rd trimester or postpartum

Approach to the Patient

History
- HA, visual disturbances, mental status changes, abd pain, edema.
  ROS plural gestation? PMH (prior preeclampsia, nulliparity, extremes of age, HTN, obesity, antiphospholipid antibody syndrome, DM, chronic renal dz, connective tissue disorder)

Physical Exam
- HTN, abdominal tenderness, hyperreflexia/clonus, peripheral edema, papilledema, AMS

Evaluation
- UA, CBC, Chem 7, LFTs, LDH, uric acid, coags, type & cross, fetal/maternal monitoring

Treatment
- BP: Hydralazine, labetalol, or nifedipine (goal BP <140/90)
- Sz prophylaxis: Magnesium 2–6 g IV load + 1–2 g/h
- Szs: Magnesium (2–4 g IV q5–10min); refractory szs: Diazepam (5 mg IV q5min up to 20 mg) OR phenobarbital (200 mg IV)
- Consult: Gyn for all pts; delivery = only definitive tx for eclampsia

Disposition
- Home: Mild preeclampsia; schedule OB f/u in 24 h
- Admit: Eclamptic & most severe preeclamptic pts need urgent delivery (pending BP & sz control) & ICU admission
HYPEREMESIS GRAVIDARUM

(JAMA. 2016;316:1392)

**Definition:** Nausea & vomiting that result in weight loss or failure to gain weight

**History:** Pregnancy (1st trimester, usually week 8–12), nausea/vomiting, inability to PO

**Physical Findings:** Tachycardia, dehydration

**Evaluation:** Labs: Electrolytes, UA; often have ketosis & electrolyte derangements

**Treatment:** IV fluids (w/dextrose), antiemetics (metoclopramide, doxylamine, pyridoxine). Ondansetron in 1st trimester may ↑risk of cardiac malformations. *(Reprod Toxicol. 2014;50:134)*

**Disposition:** Home if tolerating PO, admit if severe dehydration

EMERGENCY DELIVERY


**Definition**

- True labor: Regular uterine contractions of increasing intensity at decreasing intervals
- 1st stage: Cervical dilatation & effacement (up to 12 h)
- 2nd stage: Complete cervical dilatation, culminating in delivery (up to 2 h)

**Approach to the Patient**

**History**

- Frequency & intensity of contractions, rupture of membranes, fetal movement, has pt had prenatal care for eval of cx of pregnancy, screening tests, etc.

**Physical Exam**

- External exam: Assess for crowning or active bleeding (if so, defer speculum/bimanual exam)
Sterile speculum exam: Confirm ROM by checking for ferning &/or Nitrazine test

Bimanual exam: Assess cervical effacement & dilatation (10 cm = complete), position, presentation (fetal part in canal), lie (relation of long axis to mother → longitudinal or transverse), & station (−3 to +3; 0 is at level of ischial spines); cord prolapse?

Diagnostics

Abdominal u/s if placenta previa of concern

Treatment

Basics of Delivery

- Cord prolapse: Manually place hand in vaginal vault, lift presenting part away from cord; place pt in knee–chest position or deep Trendelenburg. Administer tocolytics (magnesium 4–6 g IV, terbutaline 0.25 mg SQ).
- Vaginal delivery: Place mother in lithotomy position; cleanse/drape perineum if possible; w/ contractions, ask mother to “bear down”
- Head: One hand on occipital area & other on perineum, maintain fetal head in flexed position; if cord wrapped at neck reduce over head or bring cord caudally over shoulders & deliver baby through cord. In extreme circumstances can cut cord first.
- Shoulders: Rotate head & exert gentle pressure until anterior shoulder delivered; lift head upward to deliver posterior shoulders, attempt to guide posterior shoulder over perineum.
- Body: Support head & catch body w/ the other hand. Suction mouth & nose.
- Cord: Clamp cord twice & cut, send cord blood for serology & Rh. Clamp cord 1–3 cm distal to navel.
- Placenta: Apply pressure above symphysis w/ minimal traction on cord (too much traction will cause uterine inversion); sudden gush of blood & lengthening cord will signify imminent placental delivery.
- Aftercare: Massage uterus ± oxytocin 20 U IV (can be given as 10 U IM if no IV access for ongoing hemorrhage); inspect & repair lacerations of cervix, vagina
- Infant care: Suction mouth & nose, stimulate with warm blanket. BVM if no spontaneous respirations. If pulse <60 start CPR,
neonatal resusc per PALS. Obtain Apgar scores at 1 & 5 min.

- Shoulder Dystocia:
  - McRoberts: Hyperflexion of hips to abdomen w/ external rotation & slight abduction
  - Rubin I maneuver: Downward pressure just proximal to symphysis pubis
  - Woods screw maneuver: Insert hand into vagina & apply pressure to anterior aspect of posterior shoulder to abduct/extend shoulder & free it
  - Delivery of the posterior arm: Insert hand into vagina, flex posterior arm of the fetus, bringing it across the chest. Deliver posterior arm & then rotate fetus out
  - Gaskin position: Place Mom in hands-and-knees position, allows gravity to help open space

- Breech: Ideally OB present, or delivery in OR for c/s. If imminent, touch fetus as little as possible & let delivery happen spontaneously, do not pull on fetus which can entrap fetal head. If head becomes entrapped, uterine relaxant like terbutaline can be given.

- Perimortem delivery: >23 wk gestational age (obvious gravid uterus), should initiate w/i 5 min of maternal arrest. *(Emerg Med Clin North Am. 2012;30:937)*
  - Vertical incision from epigastrum to pubic symphysis & extend through all layers to the peritoneal cavity.
  - Uterus is exposed & incised at bladder reflection, retract bladder caudally
  - Incision extended to uterine fundus, with operator’s hand used to palpate fetal parts & prevent damage. Infant extracted, clamp & cut umbilical cord.

**FEMALE PELVIC PAIN**


**History**

- Dyspareunia, vaginal bleeding or d/c? Urinary sx, ROS PMH (STDs, recent procedure) MEDS (contraceptive devices, hormonal
therapy), social (domestic violence)

**Physical Exam**
- Abdominal exam; Gyn exam (d/c or bleeding, masses or tenderness)

**Diagnostics**
- Labs: UA, GC/Chlamydia, Wet mount
- Imaging: Pelvic US (assess flow, torsion, mass, fluid)

**Ovarian Cyst**

**History**
- Dull, vague, unilateral sensation of pelvic pain or dyspareunia
- Rupture: Sudden, unilateral, sharp pelvic pain; can also present as diffuse peritonitis

**Physical Exam**
- Lower quadrant abdominal tenderness, adnexal tenderness/mass, vaginal bleeding

**Evaluation**
- Labs: CBC, type & screen (crossmatch if HD unstable)
- Imaging: Pelvic u/s to assess for size, complexity, torsion, presence of free fluid. Bedside FAST if HD unstable.

**Treatment**
- Supportive: IVFs, transfuse if HD unstable
- Analgesia: NSAIDs, Narcotics prn
- Consult: Gyn Service for persistent pain, large-volume hemorrhage

**Disposition**
- Home: Stable, pain well controlled; f/u w/ Gyn or PCP in 1–2 mo for repeat u/s to reassess size
- Admit: HD unstable

**Ovarian Torsion**

**History**
- Acutely worsening unilateral lower abd/pelvic pain, N/V
- Can present as intermittent torsion w/ intermittent sx
- RFs: Ovarian cysts, dermoid & other tumors, pregnancy

**Physical Exam**
Nonspecific & variable; Gyn exam reveals unilateral, adnexal mass in majority of cases ± tenderness (though tenderness absent ~30% of the time)

**Evaluation**
- Labs: Urine hCG, pre-op labs
- Imaging: Pelvic US to assess for ovarian edema, cyst/mass, blood flow

**Treatment**
- Analgesia/antiemetics
- Consult: Gyn service for urgent laparoscopy

---

**VAGINAL DISCHARGE (SEXUALLY TRANSMITTED INFECTION)**


**History**
- RFs: Multiple sexual partners & unprotected intercourse

**Physical Exam**
- External: Inspect for lesions, ulcerations; adenopathy
- Speculum: Vaginal wall inflammation/d/c; cervical inflammation/d/c
- Bimanual: If cervical motion tenderness or adnexal tenderness, think PID (see below)

**Evaluation**
- Labs: GC/Chlamydia testing; wet mount

**Treatment**
- *N. gonorrhoeae*: Ceftriaxone 125 mg IM × 1
- *C. trachomatis*: Azithromycin 1 g PO × 1 OR doxycycline 100 mg PO BID × 7 d OR levofloxacin 500 mg PO QD × 7 d
- *T. vaginalis*: Metronidazole 2 g PO ×1 OR 500 mg PO BID × 7 d
Bacterial vaginosis: metronidazole 500 mg PO BID × 7d OR metronidazole 0.75% gel intravaginally 5 g/d × 5 d OR clindamycin 2% cream intravaginally 5 g × 7 d
Candidiasis: Topical azoles (over the counter) × 7 d OR fluconazole 150 mg PO × 1

Pearls
- Educate pts on safe sex practices & advise pts to tell their partners to get tested/treated
- Encourage HIV testing outpt if not offered in ED
- Drinking alcohol on metronidazole can cause disulfiram-like reaction (flushing, ↑ HR, ↓ BP)

PELVIC INFLAMMATORY DISEASE AND TUBO-OVARIAN ABSCESS


Definition
- Spectrum of inflammatory disorders, any combination of endometritis, salpingitis, tubo-ovarian abscess & pelvic peritonitis.
- Commonly a/w gonorrhea, chlamydia but <50% of pts with PID test positive for these organisms. Involves other bacteria (eg, GNR, anaerobes) & viruses (eg, *M. genitalium*).
- Cx include abscess, perihepatitis (Fitz-Hugh–Curtis), sepsis, chronic pain, increased risk of ectopic pregnancy, infertility

History
- Lower abd pain, vaginal d/c, dysuria, dyspareunia, nausea ± fevers
- RFs: Age <25, multiple sexual partners, unprotected sex, h/o PID, IUD placement in the last month, recent instrumentation of the cervix, douching, smoking

Physical Exam
- Lower abdominal tenderness, cervical discharge, cervical friability, cervical motion tenderness, adnexal tenderness/fullness
- Clinical exam has poor sensitivity; presentation is often atypical
**Evaluation**
- Labs: Always check pregnancy test; cervical cultures, UA, CBC (not sens)
- Abdominal CT or pelvic US only required if TOA is suspected (unilateral tenderness or palpable mass, systemically ill)

**Treatment**
- Low threshold for empiric tx: Minimum criteria in sexually active young women or others at risk are pelvic pain & cervical, uterine or adnexal tenderness
- Outpt: Ceftriaxone 250 mg IM × 1 + doxycycline for 14 d
- Consider adding metronidazole for anaerobes
- Azithromycin is considered insufficient for PID; may be used in isolated cervicitis or 2nd line
- If severe PCN allergy, options are hospitalization or azithromycin &/or levofloxacin depending on regional antibiogram
- Inpt: (Cefotetan or cefoxitin) + doxycycline OR clindamycin + gentamicin
- Consult: Gyn service if concern for TOA

**Disposition**
- Admit if toxic appearing, severe vomiting, TOA, failure of outpt therapy, pregnancy, immunocompromised, young age, poor f/u w/i 72 h
- Discharged pts need f/u in 3 d to ensure sx resolving. Partners should be tested.

**Pearls**
- Given ↑ resistance to antibiotic regimens, CDC updates recommendations frequently
- PID in pregnancy is rare but does happen; alternative diagnoses should be considered
RASH

Definition

- One or more skin lesions originating from a common cause (often over a short prd) & having a spec distribution & morphology

Approach

- HPI: Onset (timing, location); evolution (distribution, morphology); periodicity (constant vs waxing & waning, temporal associations); sxs (pain, pruritus, burning, fever, bleeding); new exposures or inciting events (topical or systemic exposures, recent travel, occupational exposures, sick contacts, animals, sexual hx)
- PMH & Meds (including immunizations, new formulations or doses, supplements, illicits)
- Ensure a good ROS (rashes can be first sign of an occult internal process)
- PE: Determine distribution, shape (if applicable), morphology, & secondary changes
  - Distribution: Localized/grouped/regional/generalized, central/peripheral, flexor/extensor surface, dermatomal, acral, intertriginous, follicular, mucosal, sun-exposed areas
  - Shape (if applicable): Annular (ring), round/nummular/discoid (coin), targetoid, arcuate (arc), linear, serpiginous, reticular (net-like/lacey), whorled (marble-like), polycyclic (coalescing circular/ring-shaped lesions)
  - Morphology & secondary changes: See tables

<table>
<thead>
<tr>
<th>Common Dermatologic Morphologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flat</td>
</tr>
<tr>
<td>Macule</td>
</tr>
<tr>
<td>Flat circumscribed area of discoloration (compared to surrounding skin) &lt;1.0 cm diam</td>
</tr>
<tr>
<td>Patch</td>
</tr>
<tr>
<td>Flat circumscribed area of discoloration (compared to surrounding skin) &gt;1.0 cm diam, or similarly sized confluence of macules</td>
</tr>
<tr>
<td>Raised</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td>Plaque</td>
</tr>
<tr>
<td>Nodule</td>
</tr>
<tr>
<td>Wheal</td>
</tr>
<tr>
<td>Fluid-filled</td>
</tr>
<tr>
<td>Pustule</td>
</tr>
<tr>
<td>Bulla</td>
</tr>
<tr>
<td>Cyst</td>
</tr>
<tr>
<td>Vascular</td>
</tr>
<tr>
<td>Purpura</td>
</tr>
<tr>
<td>Depressed</td>
</tr>
<tr>
<td>Erosion</td>
</tr>
<tr>
<td>Ulcer</td>
</tr>
</tbody>
</table>

**Common Secondary Changes**

<table>
<thead>
<tr>
<th>Scaling</th>
<th>Thickened outer epidermis (stratum corneum), usually white</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crusting</td>
<td>Dried liquid debris (eg, serum, blood, exudates), usually yellow–brown</td>
</tr>
<tr>
<td>Lichenification</td>
<td>Thickening of epidermis w/ accentuated skin lines/markings</td>
</tr>
<tr>
<td>Typical Manifestations of Common or Critical Acute Disseminated Rashes</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Viral Etiologies</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Acute HIV</strong></td>
<td>Pink <strong>maculopapular</strong> 2–3 wk after initial infxn; a/w const sx</td>
</tr>
<tr>
<td><strong>Dengue fever</strong></td>
<td>Pink <strong>maculopapular/confluent macules</strong> w/ islands of sparing a/w high fever, HA, retro-orbital &amp; severe body pain; lasts 2–3 d</td>
</tr>
<tr>
<td><strong>Measles</strong></td>
<td>Pink <strong>maculopapular</strong>, starts behind ears &amp; face/neck, spreads to trunk &amp; extremities (w/ palms/soles), ± confluence; a/w fever, cough, coryza, conjunctivitis; lasts 3–7 d, leaves as arrived</td>
</tr>
<tr>
<td><strong>Mononucleosis</strong></td>
<td>Pink maculopapular; no palms/soles; a/w const sx</td>
</tr>
<tr>
<td><strong>Parvovirus B19</strong></td>
<td>Red (“slapped”) cheeks w/ circumoral pallor (lasts 1–4 d), then generalized reticular/lacey rash, esp extensor surfaces (spares palms/soles) w/ progression to trunk/buttocks (can last 3 wk)</td>
</tr>
<tr>
<td><strong>Pityriasis rosea</strong></td>
<td>Pink/salmon small oval plaques distributed on lines of cleavage on trunk/prox extremities (spares face, palms, soles); often 1–3 wk after herald patch (single 2–4 cm pink plaque w/ fine scaling borders &amp; depressed pale center); rash lasts 5 wk – 5 mo</td>
</tr>
<tr>
<td><strong>Roseola</strong></td>
<td>Pink macules; starts neck/trunk after defervescence &amp; spreads to face/extremities; lasts 1–2 d</td>
</tr>
<tr>
<td><strong>Rubella</strong></td>
<td>Pink <strong>maculopapular</strong>, starts on face/forehead then to trunk/extremities, ± coalesce; a/w fever, HA, arthralgias; lasts ~3 d</td>
</tr>
<tr>
<td><strong>Varicella (Chicken pox)</strong></td>
<td>Pruritic macules, progress to papules &amp; vesicles, crusting w/i 48 h; trunk/face &gt; extremities; ± mucous membranes; crusts fall off after 1–2 wk; may leave hypopigmented scars long-term</td>
</tr>
<tr>
<td><strong>Bacterial Etiologies</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Gonococcemia</strong></td>
<td>Few scattered hemorrhagic pustules (often over joints) occurring after mucosal infxn; a/w arthralgias &amp; low-grade fever; tx w/ CTX (1 g IV QD × 7d) &amp; azithromycin (1 g PO ×1); admx</td>
</tr>
<tr>
<td><strong>Leptospirosis</strong></td>
<td>Initially warm &amp; flushed, can develop transient petechia, later purpura; a/w fever, HA, myalgias, GI sx, subconjunctival hem; sx can be bimodal; severe dz (Weil syndrome) a/w liver</td>
</tr>
<tr>
<td>Condition</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Lyme</td>
<td>Mx <strong>erythema migrans</strong> in 20% of primary lyme; Secondary lyme (3–10 wk after infxn) small pink oval macules/patches, a/w neuro (CN), visual, cardiac (get ECG), msk complications</td>
</tr>
<tr>
<td>Meningococcemia</td>
<td>Rapidly progressive <strong>petechia &amp; purpura</strong>; pt toxic-appearing; ±2–3 d prodrome of HA, URI sx (but 20% pts present w/ sepsis); tx w/ CTX × 7d; mortality 10–15% w/ tx (<a href="#">Intern Med 2016;55(6):567–572</a>)</td>
</tr>
<tr>
<td>RMSF</td>
<td>Numerous red <strong>macules w/ central petechia</strong> start on wrists/ankles, then palms/soles, then arms/legs/trunk; 10–15% may not have rash; a/w abrupt fever, severe HA, N/V, abd pain, myalgias</td>
</tr>
<tr>
<td>Scarlet fever</td>
<td>Diffuse fine erythematous <strong>coalescent “sandpaper” eruption</strong>; starts on neck &amp; spreads to trunk/extremities, becomes <strong>macules coalescing into patches</strong>; flushed face w/ circumoral pallor; a/w recent strep infxn; lasts 7 d then fine desquamation</td>
</tr>
<tr>
<td>Staph scalded skin syndrome</td>
<td>Diffuse painful <strong>light erythema w/ widespread exfoliation</strong> of thin sheets of skin; no mucous membranes; a/w malaise, fever</td>
</tr>
<tr>
<td>Secondary syphilis</td>
<td>Diffuse <strong>macules, papules (± pustules)</strong>, including on palms/soles &amp; mucous membranes</td>
</tr>
<tr>
<td>Toxic shock syndrome</td>
<td>Diffuse erythematous <strong>coalescent “sandpaper” macules &amp; patches, ± hemorrhagic bullae</strong>; mucous membranes involved; a/w fever, GI sx, confusion, multiorgan failure</td>
</tr>
<tr>
<td>Arthropod Bites</td>
<td></td>
</tr>
<tr>
<td>Bed bugs</td>
<td>Painless pruritic red <strong>papules</strong> on exposed areas; occasionally wheals, hemorrhagic nodules, vesicles 2/2 bug proteases</td>
</tr>
<tr>
<td>Lice</td>
<td>Painless pruritic red <strong>papules &amp; wheals</strong>, often concentrated in covered areas (axilla/groin/trunk) &amp; sparing extremities</td>
</tr>
<tr>
<td>Scabies</td>
<td>Painless pruritic red <strong>papules</strong>, often clustered, starts on hand/foot, spreads to trunk; look for intertriginous burrows</td>
</tr>
<tr>
<td>Vascular/Hematologic</td>
<td></td>
</tr>
<tr>
<td>HSP</td>
<td>Erythematous <strong>macules &amp; papules</strong> becoming <strong>purpuric</strong> (palpable purpura) symmetrically on lower extremities; spares soles; a/w abd pain &amp; joint pain</td>
</tr>
<tr>
<td>ITP</td>
<td><strong>Petechia</strong>, esp in lower extremities &amp; palette; can be asx</td>
</tr>
<tr>
<td>TTP</td>
<td><strong>Petechia</strong>, a/w fever, AMS/neuro deficits, ± jaundice</td>
</tr>
<tr>
<td>Condition</td>
<td>Description</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>DIC</strong></td>
<td><strong>Petechia, purpura, hemorrhagic bullae,</strong> acral cyanosis, localized necrosis/gangrene (inc. extremities); a/w multiorgan failure</td>
</tr>
<tr>
<td><strong>Hypersensitivity Reactions</strong></td>
<td></td>
</tr>
<tr>
<td>Acute generalized pustular psoriasis</td>
<td>Diffuse small sterile pruritic pustules on erythematous base, a/w fever; trunk &amp; intertriginous areas common (no mucous membranes); may have multiorgan dysfxn</td>
</tr>
<tr>
<td>Allergic contact dermatitis</td>
<td><strong>Poison Ivy/Oak:</strong> Wheals &amp; vesicles (± bullae) on exposed areas <strong>Topical (eg, hair dye): Vesicles &amp; papules</strong> w/ crusting, edema</td>
</tr>
<tr>
<td>Bullous pemphigoid</td>
<td>Acute or subacute pruritic, diffuse, tense bullae on nl, erythematous, or urticarial base; many causal associations (diuretics, NSAIDs, captopril); bx dx</td>
</tr>
<tr>
<td>DRESS Syndrome</td>
<td><strong>Maculopapular, papulosquamous, pustular, bullous,</strong> or urticarial exanthem; a/w fever, LAN, systemic sx; 2/2 drug</td>
</tr>
<tr>
<td>Erythema multiforme</td>
<td>Diffuse erythematous macules/papules w/ evolving morphology (become targetoid, then polycyclic &amp; annular configuration); trunk, extremities (inc palms/soles), face (mucous memb ∼70%)</td>
</tr>
<tr>
<td>Erythema nodosum</td>
<td>Painful pink/purple, round, oval nodules (1–6 cm diam), can coalesce; symmetric &amp; usually anterior tibia (also knees, ankles, thighs, forearms); self-resolves after 1–6 wk</td>
</tr>
<tr>
<td>Erythroderma</td>
<td><strong>Generalized erythema</strong> (&gt;90% TBSA; spares palms/soles), progresses to scaling &amp; desquamation; pruritic; often w/ edema; LAN ± e/o high-output HF, hepatomegaly, splenomegaly</td>
</tr>
<tr>
<td>Morbilliform drug eruption</td>
<td>Diffuse erythematous morbilliform macules/papules (less commonly erythroderma, pustules, targetoid lesions), can coalesce &amp; become edematous; trunk, extremities, face</td>
</tr>
<tr>
<td>Pemphigus vulgaris</td>
<td>Diffuse small or confluent painful flaccid blisters &amp; erosions on erythematous base (+Nikolsky); inc on mucous membranes</td>
</tr>
<tr>
<td>SJS/TEN</td>
<td>Diffuse erythematous dusky confluent purpuric macules or patches, rapidly evolve to coalesce &amp; blister (+Nikolsky); often starts on trunk &amp; spreads to extremities (inc palms/soles) &amp; face (inc mucous membranes); eventually generalized sloughing</td>
</tr>
<tr>
<td>Scromboid</td>
<td>Diffuse macular or papular erythema w/ urticaria &lt;30 min after ingesting scombroid fish; a/w HA, N/V, palpitations</td>
</tr>
</tbody>
</table>
### Serum-sickness & serum sickness-like rxn
- Diffuse urticarial or serpiginous macules & patches, well-demarcated w/ intense red border & central clearing; trunk, face, extremities (no palms/soles), a/w arthralgias

### Sweet syndrome
- Tender, violaceous, well-demarcated painful papules & plaques (± central pustules, bullae, or ulcers), can evolve to coalesce; common esp on upper body (inc face, mucous memb), a/w fever

### Urticaria
- Pruritic, pink-erythematous wheals, ranging in size from a few mm to several cm in size; may be round or irregular in shape

### Miscellaneous

<table>
<thead>
<tr>
<th>Condition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guttate psoriasis</td>
<td>Diffuse dewdrop-like 1–10 mm salmon-colored papules w/ fine scaling; can coalesce; may be preceded by URI or grp A strep infxn</td>
</tr>
<tr>
<td>Photosensitive rash</td>
<td>Erythema or bulla (inc hemorrhagic) at area of UV exposure</td>
</tr>
<tr>
<td>Pityriasis versicolor</td>
<td>Subacute hypo- or hyperpigmented macules &amp; patches, often neck/trunk/UEs; 2/2 malassezia fungus, not contagious; RFs are humidity, immunosupp, OCPs, poor nutrition; tx topically for localized dz (azole, terbinafine), systemic for extensive dz (azoles)</td>
</tr>
</tbody>
</table>

### VIRAL EXANTHEMS

#### Measles (Rubeola; “First Disease”)

**Definition** *(Lancet 2012;379(9811):153–164)*
- Highly contagious dz caused by the measles virus, spread by droplet contact
- Epidemiology: Usually nonimmunized or immunosupp (1° vaccine failure <0.2%); can occur in immunized adults (2° vaccine failure 5% >15 yr after vaccination) esp if no herd immunity (though often milder); winter/spring common; incubation prd ~1 wk

**History & Physical Exam**
- Assess vaccination status
- Prodrome (lasts 3 d): Acute febrile illness, cough, coryza (nasal mucosal inflammation), conjunctivitis, Koplik spots (small irreg-shaped blue-white macules on buccal mucosa)
Exanthem (lasts 3–7 d): Starts behind ears, on face/neck as discrete purple-red macules & papules; spreads to trunk & extremities (inc palms/soles), becoming confluent; disappears in same order as arrived

Evaluation
- Routine labs rarely indicated (CBC may show leukopenia)
- Lab confirmation: Measles serologies (enzyme immunoassay for measles IgG & IgM), throat or nasopharyngeal swab for viral isolation/RT-PCR. Contact lab specialist.

Treatment
- Supportive, consult ID
- Two-dose Vit A may reduce mortality in children <2 yr (Cochrane 2005; 4):CD001479)

Complications
- During/post-infxn: Otitis media (most common) & mastoiditis, keratitis, corneal ulcerations & blindness, croup, PNA (most common severe complication), myopericarditis, TTP, febrile sz, encephalomyelitis (1:1000 incidence ~2 wk after infxn; 2/2 autoimm demyelination; fever/sz / various neuro sx) (Lancet 2012;379(9811):153–164)
- Late complications (rare): Inclusion body encephalitis (mo after infxn; fatal), subacute sclerosing panencephalitis (yrs after infxn; fatal)

Disposition
- Home if absence if cx
- Notifiable infectious dz at national level by CDC; requires notification w/i 24 h

Rubella (German Measles; Three-day Measles; “Third Disease”)

Definition
- Contagious dz of childhood caused by rubella virus, spread by droplet contact
- Epidemiology: Usually children, but adults can get too (long-term vaccine failure <10%); winter/spring common; incubation prd 2–3 wk (Lancet 2004;363(9415);1127–1137)
- Rubella infxn in children/adults is distinct from congenital rubella syndrome (CRS), a severe teratogenic congenital infxn (not
discussed here)

**History & Physical Exam**
- Assess vaccination status
- Prodrome: Malaise, low-grade fever, HA, sore throat, adenopathy, arthralgias
- Exanthem: Erythematous macules & papules begin on face/forehead, spread to trunk/extremities, may coalesce; typically lasts 3 d then resolves

**Evaluation**
- Routine labs rarely indicated (CBC may show leukopenia, thrombocytopenia)
- Lab confirmation: Rubella serologies (enzyme immunoassay, latex agglutination, IFA), throat or nasopharyngeal swab for viral isolation/RT-PCR. Contact lab specialist.
  - Confirmation important in pregnant patients

**Treatment**
- Supportive

**Complications**
* (Lancet 2004;363(9415);1127–1137)
- During/post-infxn: Inflammatory arthritis (most common), encephalopathy (1:5000–1:30,000), transient thrombocytopenia, hemolytic anemia (rare), GBS
- If pt is pregnant: Congenital rubella syndrome (highest risk in first trimester)

**Disposition**
- Home, avoid contact w/ pregnant women (severe congenital defects)
- Notifiable infectious dz at national level by CDC; requires notification w/i 24 h

**Erythema Infectiosum (“Fifth Disease”)**

**Definition**
- Highly contagious dz caused by Parvovirus B19, spread by respiratory droplets
- Epidemiology: Mainly school-age children (2–14 y/o); winter/spring common; incubation prd 1–2 wk; transmission via blood products
rare (virus lives in RBC precursor)

**History & Physical Exam**
- Prodrome: Malaise, low-grade fever, HA, arthralgias
- Exanthem: Intensely red face ("slapped cheek") w/ circumoral pallor (lasts 1–4 d), then generalized reticular/lacey rash, esp extensor surfaces (spares palms/soles) w/ progression to trunk/buttocks (can last 3 wk); rash uncommon in adults

**Evaluation**
- Routine labs rarely indicated; consider CBC, reticulocyte count, & haptoglobin in pts w/ hx hemolytic anemia (eg, hereditary spherocytosis) or hemoglobinopathies (ie, SCD)
- Lab confirmation: Serologic testing, DNA assays (direct hybridization)

**Treatment**
- Supportive
- If complicated (see below), can consider course of IVIG in consultation w/ hematology

**Complications**
- During infxn: Inflammatory arthritis (most common, esp adults), transient aplastic crisis (esp in pts w/ hemolytic anemias & hemoglobinopathies), pure red cell aplasia
- Parvovirus temporarily shuts down RBC production during infxn
- In pregnant pts, risk of fetal loss 5–10%; greatest in 2nd trimester *(CMAJ 2005;172(6):743)*

**Disposition**
- Home; CDC does not recommend avoidance of school or workplace

**Roseola Infantis (Exanthema Subitum; “Sixth Disease”)**

**Definition**
- Dz of children 6–36 mo (95%) caused by HHV-6 & HHV-7, spread by salivary secretions
- Three stages of infxn: acute, latent, reactivation
- Epidemiology: Acute dz is most common viral exanthem in children <3 yr (10–20% of all acute febrile illnesses in this age), no seasonality, incubation prd 1–2 wk; Reactivation can be severe in

**History & Physical Exam**
- Prodrome: Abrupt high fevers (± febrile sz), HA, coryza, periorbital edema
- Exanthem: Begins after defervescence; erythematous macules; starts neck/trunk & spreads to face/extremities; clears in 1–2 d

**Evaluation**
- Routine labs rarely indicated (CBC may show leukopenia)
- Primary infxn w/ HHV-6 is difficult to confirm diagnostically

**Treatment**
- Supportive for primary infxn
- Reactivation in immunosuppressed: May tx w/ ganciclovir or foscarnet

**Complications**
- Primary infxn: febrile sz (most common complication)
- Reactivation infxn (most severe in transplant pts, esp recent HSCT): encephalitis, bone marrow suppression, pneumonitis, hepatitis, transplant failure, GVHD

**Disposition**
- Home

**Herpes Simplex 1 and 2 (HHV-1 and HHV-2)**

**Definition**
- Historically, HSV-1 a/w orofacial dz & HSV-2 a/w genital dz; now both can cause both dz; transmission by contact w/ active lesions, but also by resp droplets & infected secretions
- Three stages: primary, latent (asx), reactivation; reactivation triggers include illness or fever, menstruation, sun exposure, psychological stress (but usually spontaneous)
- **Herpes gingivostomatitis**: Affects oral/perioral mucous membranes, usually 1° infxn
- **Herpes labialis**: Affects perioral skin & mucous membranes; difficult to distinguish 1° & 2° dz; latent virus lives in trigeminal ganglion; reactivation in >1/3 pts
- **Herpes genitans**: Affects genitals (inc suprapubic, perineum, thighs,
perianal) & mucous membranes; difficult to distinguish 1° & 2° dz; 60–70% of primary infxn can be asx; reactivation is common & can be sx (1-yr reactivation 20–50% [HSV-1], 70–90% [HSV-2]) or asx (80–90% of HSV-2 pts have transient asx shedding); up to 25% of infected pts unaware they have dz (NEJM 2016;375(7):666–674)

**History & Physical Exam**

- **Herpes gingivostomatitis & labialis:**
  - Prodrome: Malaise, fever, localized pruritus/tingling/burning, dysphagia if intraoral
  - Rash (gingivostomatitis): Oral/perioral vesicles, oral ulcers, gingivitis (lasts 1–2 wk)
  - Rash (labialis): Clustered vesicles on erythematous base, often outside of mouth at vermillion border (but can be on nose); ± LAN & sore throat; distinguish from aphthous stomatitis (canker sore), which are discrete painful intraoral lesions
- **Herpes genitalis:**
  - Prodrome: Malaise, fever, HA, tender LAN; localized burning/pain in genital region
  - Rash: Clustered vesicles on erythematous base, crusted ulcers if on dry skin
  - Risk factors: Number lifetime sexual partners, mx partners, h/o STI/HIV

**Evaluation**

- Generally not needed in ED; if recurrent, determining HSV-1 vs HSV-2 guides prog & tx
- PCR (best), Tzanck smear (can’t differentiate HSV-1 vs HSV-2), viral cx (slow), biopsy

**Treatment**

- Pain control, hydration
- **Herpes labialis:** Topical therapy (docosanol 10% cream, penciclovir 1% cream, acyclovir 5% ointment, cidofovir 0.3 or 1% gel) & oral therapy (Acyclovir, Famciclovir, Valacyclovir) may decrease sxs & time to healing; sunscreen may decrease relapses.
- **Herpes genitalis:** Tx differs for first infxn, recurrent infxn, & suppressive tx
  - First infxn: Acyclovir 400 mg TID, Famciclovir 250 mg TID,
Varicella ("Chickenpox," HHV-3)

Definition
- Primary infxn w/ VZV; highly contagious (~90% transmission among household contacts; 10–35% w/ limited exposure); transmission by resp droplets or vesicle secretion
- Epidemiology: Mostly children (5–10 y/o), but can affect infants & adults (esp if from tropical regions, 2/2 childhood dz less common); mortality low, but ~4× higher in infants & ~25× higher in adults, including most among immunocompetent; winter/spring common; incubation prd ~14 d (Lancet 2006;368(9544):1365–1376)

History & Physical Exam
- Exanthem: Pruritic macules, progress to papules & vesicles, crusting w/i 48 h; trunk/face > extremities; crusts fall off after 1–2 wk; may leave hypopigmented scars long-term
- Mucous membranes can be involved: conjunctiva, genitals, oropharynx
- “Breakthrough varicella” in immunized pts is similar but mild (ie, <50 lesions)

Evaluation
• Routine labs rarely indicated (CBC may show lymphopenia & transaminitis)

Treatment
• Healthy children: Supportive (calamine lotion, colloidal oatmeal baths; AVOID salicylates 2/2 Reye syndrome); oral acyclovir w/i 24 h of dz onset may reduce fever by 1 d & sx severity by 15–30%, but not recommended by CDC (Lancet 2006;368(9544):1365–1376)
• High-risk groups (infants, age >12, pregnant, steroids (inc inhaled) or any immunosupp, chronic skin or pulm dz, long-term ASA use, pregnant) or complicated dz: IV acyclovir
• Precautions: put pts on airborne (neg pressure) & contact precautions until crusted
  • Pts should not be managed by providers w/o immunity or those who are pregnant

Complications
• Bacterial superinfxn (impetigo, cellulitis; most common); invasive bacterial infxns (PNA, arthritis, osteomyelitis, necrotizing fasciitis, sepsis) & varicella PNA; neuro cx (cerebellar ataxia [1:4000], encephalitis, myelitis); heme cx (thrombocytopenia, purpura fulminans); vasculitis (inc intracranial); hepatitis (Lancet 2006;368(9544):1365–1376)
• In rare cases, maternal varicella in early gestation can result in a congenital varicella syndrome (microcephaly, mental retardation limb hypoplasias, cutaneous defects, etc.); later in pregnancy, varicella can cause preterm delivery & neonatal varicella

Postexposure Prophylaxis
• Antivirals not recommended for PEP
• If eligible for VZV vaccine: give vaccine w/i 3–5 d of exposure, if no e/o prior immunity
• If not eligible for VZV vaccine (allergy, immunosupp, pregnancy, infant): Varicella zoster immune globulin can prevent varicella or lessen severity, give w/i 96 h of exposure

Disposition
• Home for uncomplicated cases
• Admission for high-risk groups or those w/ complications
**Herpes Zoster (“Shingles,” HHV-3)**

**Definitions** *(NEJM 2013;369(3):255–263; Cochrane 2008;1:CD005582)*

- Reactivation of VZV from sensory ganglia; 20–50% lifetime risk (if nonvaccinated)
- **Herpes zoster ophthalmicus:** (V1 branch of CN V) Rash on forehead, periocular, nose
- **Herpes zoster oticus (Ramsay Hunt syndrome):** (CN VII/geniculate ganglion) Rash on ear, hard palate, anterior 2/3 of tongue; can get ipsilateral facial nerve palsy; a/w variable other CN findings (tinnitus, hearing loss, N/V, vertigo, nystagmus, etc.)
- Zoster sine herpete: Clinical features similar to VZV but w/o rash

**History & Physical Exam**

- Risk factors: Previous VZV infxn, age, immunosupp, neoplastic disease (esp hematologic)
- Prodrome (may be absent): 2–3 d of localized skin sensations (tingling, hot/cold sensation, pruritus, burning pain) prior to rash; can be a/w HA, photophobia, malaise,
- Exanthem: Grouped vesicles on erythematous base, eventually crusting; pain; distributed in dermatomal pattern, not crossing midline; overlap adjacent dermatomes in 20% cases
- Sensory changes vary: Paresthesias (tingling), dysesthesia (altered), allodynia (pain), hyperesthesia (exaggerated), pruritus

**Evaluation**

- Clinical dx; testing may be indicated if rash is atypical or pt has comorbidities
- DFA for VZV Ag (~80% Se), PCR (lesion base) (95–100% Se) *(NEJM 2013;369(3):255–263)*

**Treatment**

- Antivirals indicated if w/i 72 h of rash onset, but recommended even >72 h if new vesicles forming, complications present (inc eye), or pt risk factors (immunosupp, elderly)
- Antivirals (valacyclovir, acyclovir, famciclovir) decrease course & neuralgic pain
  - Acyclovir 800 mg PO q4h 5 times daily × 7–10 d
  - Valacyclovir 1000 mg PO q8h × 7 d (may have better bioavailability)
Famciclovir 500 mg PO q8h × 7 d (may have better bioavailability than acyclovir)

- Corticosteroids: Data equivocal; may accelerate healing & possibly reduce pain; may not help prevent postherpetic neuralgia (NEJM 2013;369(3):255–263; Cochrane 2008;1:CD005582)
- Herpes zoster ophthalmicus: Consult ophthalmology
- Supportive care (NSAIDs/acetaminophen; may need opiates during acute rash)
- Postherpetic neuralgia: tx disappointing (<50% pts have >50% reduction in pain); topical agents (lidocaine patch [NNT 2.0], capsaicin cream [NNT 3.3]), systemic tx (gabapentin [NNT 4.4], pregabalin [NNT 4.2], TCAs [NNT 2.6]); combo tx better than mono-tx (if tolerated); pain specialist c/s if considering opiates (NEJM 2014;371(16):1526–1533)


- Postherpetic neuralgia (pain >90 d after rash, can be long-term; ~20% incidence after VZV, risk inc w/ age); bell’s palsy; transverse myelitis, cerebrovascular disease; disseminated dz (pneumonitis, hepatitis, pancreatitis, CNS) esp in immunosupp
- Herpes zoster ophthalmicus: ~50% can have ocular comp (eg, iritis, episcleritis, keratitis)

Disposition

- Home unless disseminated

Pityriasis Rosea (associated HHV-6 and HHV-7)

Definition

- Acute, self-healing exanthema of unclear etiology: may be viral (a/w HHV-6 & HHV-7), but can also be a/w drugs (esp if no herald patch & longer duration) (BMJ 2015;351:h5233)
- Epidemiology: Mainly adolescents/young adults (age 10–35); a/w asthma, eczema, URIs

History & Physical Exam

- Const sx in only ~50%: Fever, HA, arthralgia, cough, N/V, LAN (BMJ 2015;351:h5233)
- Herald patch present in 40–75%: Single pink/salmon-colored oval
plaque 2–4 cm diam w/ fine scaling borders & pale depressed center; precedes rash by up to 3 wk

- Exanthem: Numerous lesions similar in appearance to herald patch on trunk & prox. extremities but in characteristic lines of cleavage (“Christmas tree pattern”); spares face, scalp, palms, & soles typically; lasts 5 wk but can last up to 5 mo

**Treatment**
- Supportive (oatmeal baths & emollients may help): No recommended role for steroids, abx, or antivirals including acyclovir. In severe cases, topical agents may be tried locally, & if improvement can then use widely. *(BMJ 2015;351:h5233)*

**Disposition**
- Home; can f/u w/ dermatology esp if >3 mo duration

**Molluscum Contagiosum (associated Poxvirus)**

**Definition**
- Benign, self-limiting but long-lasting eruption 2/2 poxvirus; spread by fomite, skin-to-skin, & sexual contact & auto-inoculation
- Can serve as marker or opportunistic infxn in pts w/ HIV

**History & Physical Exam**
- Exanthem: Nonpainful smooth tan dome-shaped papules (2–5 mm diam) w/ umbilicated center on face, trunk, extremities (but can see in axilla, groin, a/c fossa, etc.); can last up to 12–18 mo

**Treatment**
- Self-limited & asx: no tx needed; can refer to dermatology for lesion eradication to dec risk of spread (cryotherapy, laser, curettage, imiquimod cream, trichloroacetic acid, or tretinoin), esp if numerous or HIV+ *(Curr Opin Pediatr 2016;28(2):250–257)*

**Disposition**
- Home ± dermatology f/u

---

**BACTERIAL EXANTHEMS**

Refer to Chapter 4 (“Soft Tissue Infections”) for the following: Cellulitis,
**Erysipelas, Staph Scalded Skin Syndrome, Toxic Shock Syndrome, & Necrotizing Fasciitis**

**Scarlet Fever (Scarlatina, “Second Disease”)**

**Definition**
- Rash in children (3–12 yr) 2/2 erythrogenic toxin-producing strains of gpr A β-hemolytic streptococci; transmitted via airborne droplets & fomites from ppl w/ dz & asx carriers; incubation prd 1–4 d; winter/spring common

**History, Physical Exam, & Evaluation**
- **PRODROME**: Acute onset sore throat, fever, HA, vomiting, ± abd pain (can be severe)
- **EXAM**: Diffuse fine erythematous coalescent “sandpaper” eruption (“goosebump” appearance); starts on neck/axilla/groin & spreads to trunk/extremities (w/o palms/soles), becomes macules coalescing into patches; lasts 7d then fine desquamation
- **Characteristic features**: Flushed face w/ circumoral pallor; inc intensity at flexor folds (Pastia lines are transverse red streaks in skin folds); strawberry tongue; beefy red pharynx & tonsils w/ or w/o exudate
- **DX**: Rapid strep test (Se 60–90%, Sp 90%), throat cx; CBC rarely indicated but usually leukocytosis w/ PMN predominance present

**Treatment**
- PCN VK QID × 10 d, benzathine PCN 1.2 million U IM × 1, or macrolide in PCN-allergic

**Disposition**
- Home

**Impetigo**

**Definition**
- Highly contagious superficial infxn 2/2 S. aureus & group A β-hemolytic streptococci; transmitted via direct contact (inc autoinoculation) & fomites; summer common
- Two types: Nonbullous (majority of cases; represents host response to infxn), Bullous (caused by bacterial toxins, esp staph exfoliative toxins)
Epidemiology: Affects mainly children (2–5 yr; most common pediatric bacterial skin infxn)

**History & Physical Exam**
- Nonbullous impetigo: Begins as red macule or papule that becomes a vesicle; vesicle ruptures to form an erosion, & its contents dry to form honey-colored crusts; usually on face (cheeks or under lips) or extremities; self-limited over 2 wk
- Bullous impetigo: Begins as rapidly enlarging vesicles that form sharply demarcated bullae w/ little to no surrounding erythema; these rupture, forming yellow oozing crusts; usually moist intertriginous areas involved (neck fold, axilla, groin, perineum); self-limited

**Evaluation**
- Dx is clinical; gram stain & culture rarely indicated

**Complications**
- Cellulitis, lymphangitis, poststreptococcal GMN, TSS, SSSS; invasive bact infxn

**Treatment** *(Cochrane 2012;1:CD003261)*
- Most will resolve spontaneously, but abx recommended
- Topical abx equally if not more effective than oral abx (mupirocin 2% ointment TID 3–5 d)
- Oral abx may be indicated in those who cannot tolerate topical tx or w/ extensive dz: Amoxicillin/clavulanate, dicloxacillin, cephalexin, macrolide for PCN-allergic pts

**Disposition**
- Home w/ instruction to prevent spreading

---

**FUNGAL EXANTHEMS**

**Dermatophytoses**

**Definitions**
- Superficial fungal infxn involving the stratum corneum, hair, or nails:
- **Tinea capitis**: infxn of hair & scalp
- **Tinea corporis**: infxn of smooth, hairless skin (except palms, soles, & groin)
- **Tinea cruris**: infxn of groin, genitals, pubic area, or perineum
- **Tinea pedis**: infxn of feet, commonly interdigital regions
- **Tinea manuum**: infxn of hand, commonly interdigital regions
- **Tinea unguium/Onychomycosis**: infxn of the nail

<table>
<thead>
<tr>
<th>Clinical Features and Treatment of Dermatophytoses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dermatophytosis</strong></td>
</tr>
<tr>
<td><strong>Tinea capitis</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Tinea corporis</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Tinea cruris</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Tinea pedis</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Tinea manuum</strong></td>
</tr>
</tbody>
</table>
Tinea unguium/onychomycosis

Hx: RFs include nail trauma (tight shoes), immunosupp, DM, communal bathing
PE: Toenail varies from discoloration & thickening of proximal, distal/subungal, or superficial portions of nail plate

- Topical tx only for limited dz (<50% distal nailbed), may have poor cure rates:
  - Ciclopirox (not as monox)
- Systemic tx preferred:
  - Terbinafine (preferred)
  - Itraconazole

*Most tx regimens last from 2–6 wk. Onychomycosis can take months to adequately treat, thus pts require f/u w/ their primary provider or dermatologist.

Disposition
- Home w/ primary care or dermatology f/u

Pearl
- Dermatophytid rxn: Delayed-type hypersensitivity rxn to fungal antigens in pts w/ dermatophytosis; pts p/w pruritic papules or vesicles on hands & feet; respond to tx of primary dermatophytosis infxn

Cutaneous Candidiasis/Intertrigo

Definition
- Fungal infxn by Candida species (C. albicans); predilection for colonizing skin folds (intertriginous areas) where the environment is warm & moist

History & Physical Exam
- Risk factors: Obesity, DM, occlusive clothes, immunosupp, poor hygiene
- Exanthem: Moist, red, shiny patch w/ scalloped borders & satellite macules & pustules, often in intertriginous areas (groin, axilla, pannus folds, gluteal fold, web spaces); can be pruritic, burning, or asx

Physical Findings
- Moist, red, shiny macules/patches w/ scalloped borders, adjacent satellite pustules

Treatment
- Keep dry, topical antifungals (Various preparations: Creams, lotions,
Pemphigus Vulgaris

Definition
- Rare but potentially life-threatening acute progressive autoimmune (2/2 autoantibodies) bullous dz involving skin/mucosa; mortality 5–10% w/ tx (Clin Dermatol 2013;31(4)374–381)
- Idiopathic, but a/w PMH/FH autoimmune dz

History, Physical Exam, & Evaluation
- HX: Subacute-onset (over dys to wks) additive blisters on mucosa & skin (mucosa may precede skin by wks/mos); pain > pruritus; ask about PMH/FH autoimmune dz
- EXAM: Small or confluent flaccid blisters & erosions on erythematous base (+Nikolsky); diffuse, inc on mucous membranes (oropharynx, conjunctiva, anogenital)
- DX: Histologic dx (c/s derm for bx); labs to r/o other causes or complications

Treatment
- Supportive: analgesia, wound care
- Steroids (1 mg/kg/d pred or equiv); c/s derm, ENT, ophthalmology based on lesions

Duration & Disposition
- Duration can be lifelong, or can remit (w/ tx) w/ risk of recurrence
- If rapid progression or extensive dz, admit; c/s derm on all cases in ED
**Erythroderma (Generalized Exfoliative Dermatitis)**

**Definition** *(Clin Dermatol 1993;11(1):67–72)*
- Rare but potentially life-threatening acute generalized red rash, affecting >90% TBSA; more common in males; a/w high-output HF
- Idiopathic (25%) or 2/2 meds, malignancy, psoriasis, uncontrolled dermatitis, among others
- Common associated drugs: ACE inh, allopurinol, anticonvulsants, beta-blockers, beta-lactam abx, CCBs, furosemide, minocycline, NSAIDs, sulfonamides, others

**History, Physical Exam, & Evaluation**
- HX: Subacute-onset (over dys to wks) generalized rash w/ scaling, a/w malaise, chills ± fever; pruritic commonly; always ask about meds, recent infxn sx, PMH/FH inflamm dz & malignancy
- EXAM: Generalized erythema (>90% TBSA; spares palms/soles), progresses to scaling & desquamation; often w/ edema; LAN ± e/o high-output HF, hepatomegaly, splenomegaly
- DX: Elevated ESR, hypoalbuminemia, hyperglobinemia (2/2 antibodies), mild anemia; may see e/o heme malignancy necessitating additional w/u; consult dermatology

**Treatment**
- Tx underling cause or d/c causal drug if known
- Supportive: skin moisture, antihistamines, topical steroids; systemic steroids usually warranted (unless c/f SSSS or underlying h/o psoriasis); watch fluid balance (given risk of both dehydration & HF)

**Duration & Disposition**
- Resolution depends on cause & ability to control/remove it
- Admit, esp if rapid or unstable; consult dermatology

**Acute Generalized Exanthematous Pustulosis (AGEP)**

**Definition**
- Rare but life-threatening immunologically-mediated diffuse acute pustular exanthema, often w/ multiorgan dysfxn in ~17% (esp elderly) *(J Am Acad Dermatol 2015;73(5):843–848)*
- Common associated drugs: Beta-lactam abx, quinolones,
sulfonamides, carbamazepine, terbinafine, diltiazem, hydroxychloroquine, others


- **HX:** Acute-onset (w/ hrs) diffuse pustular rash; often occurs w/i 48 h of starting drug (or longer if not 2/2 abx); pruritic; always ask about meds, recent infxn sx
  - May also have sx of systemic organ involvement: SOB, abd pain, N/V, skin infxn
- **EXAM:** Numerous small sterile pustules on erythematous base, a/w fever; trunk & intertriginous areas common (rarely mucous membranes); pruritic
  - Assess for systemic dz: pleural effusions/hypoxia, hepatic dysfxn, rarely systemic superinfxn & DIC
- **DX:** CBC w/ leukocytosis (± eosinophilia), LFTs, ± CXR; c/s dermatology for bx

**Treatment**

- D/C causal drug or tx underlying infxn
- Supportive: Moist dressings & antiseptic solutions; high-potency topical steroids may help pruritus, but no role for systemic steroids; ± empiric abx if unstable

**Duration & Disposition**

- 5% mortality, mostly 2/2 superinfxn *(J Am Acad Dermatol 2013;68(5):709)*
- Resolves days after causal drug d/c-ed
- Admit (may need ICU)

**Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)**

**Definition**

- Rare but potentially life-threatening immune-mediated diffuse rash with multiorgan dysfxn
- Common associated drugs: Allopurinol, anticonvulsants, sulfonamides, others

**History, Physical Exam, & Evaluation**

- **HX:** Prodrome of pruritus & fever, f/b acute-onset (hrs to dys) diffuse
rash; occurs within 2–6 wk of starting drug
- EXAM: Diffuse erythematous morbilliform macules/papules (less commonly erythroderma, pustules, targetoid lesions), can coalesce & become edematous; trunk, extremities, face (can involve mucous membranes)
  - Eval for multiorgan dysfxn: liver (>70% of pts; major source of morbidity/mortality), hematologic, lymphatic, renal, pulm (pneumonitis, ARDS), cardiac (myocarditis), gastroenteritis, meningoencephalitis (*J Am Acad Dermatol* 2013;68(5):693)
- DX: CBC w/ diff (WBC can be >50 k/L; Eos >1.5 k/L; +atypical lymphs), Chem 20 (Cr, lytes, LFTs), Troponin, CXR, dermatology c/s for bx

**Treatment** (*J Am Acad Dermatol* 2013;68(5):693)
- D/C causal drug
- Supportive: antihistamines, tx underlying organ dysfxn
- Systemic steroids w/ gradual taper over 3–6 mo

**Duration & Disposition**
- 10% mortality, esp immunosupp (*J Am Acad Dermatol* 2013;68(5):693)
- Resolves months after causal drug d/c-ed
- Admit (may need ICU)

**Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN)**

**Definition** (*Am J Clin Dermatol* 2015;16(6):475–493)
- Acute generalized mucocutaneous desquamative eruption with various associated causes; immune-mediated but precise mechanism unknown
  - Mucous membranes a dz hallmark: 80% cases (first sx in 30%); oropharyngeal, ocular (80% cases), anogenital, GI, endotracheal/bronchial; all w/ severe complications
- Differentiation b/w SJS & TEN depends on TBSA desquamated:
  - SJS: <10% TBSA w/ detachable epidermis w/ horizontal shear (“+Nikolsky sign”)
  - SJS/TEN overlap: 10–30% TBSA w/ +Nikolsky
  - TEN: >30% TBSA w/ +Nikolsky
- Idiopathic (20%), but often a/w meds (most common cause), infxn
(M. pneumoniae, HSV), less likely food additives, fumigants, malignancy
• Common associated drugs: Allopurinol, anticonvulsants, beta-lactam abx, nevirapine, piroxicam, sulfonamides, others

History, Physical Exam, & Evaluation
• HX: Flu-like prodrome (fever, malaise, HA, sore throat, rhinitis, myalgias) f/b acute-onset (over dys) diffuse rash ± mucosal sx (dysphagia, etc.): pain; always ask about meds (usually w/i 4 wk), recent infxn sx, PMH/FH inflamm dz & malignancy
• EXAM: Diffuse erythematous dusky confluent purpuric macules or patches, rapidly evolve to coalesce & blister (+Nikolsky); often starts on trunk & spreads to extremities (inc palms/soles) & face (inc mucous membranes); eventually generalized sloughing
  • Extent of TBSA w/ +Nikolsky dictates SJS (<10%) vs SJS/TEN (10–30%) vs TEN (>30%)
• DX: CBC, BMP, Lactate & blood cx (esp if hypotensive), derm c/s for bx

Treatment
• Treat underlying cause or D/C causal drug
• Supportive: analgesia, thermoregulation (28–32°; esp important if high TBSA), IVF, airway protection prn, nutritional support (helps healing) wound care (debridement, bacitracin)
• Limited high-quality data supports specific systemic tx modalities:
  • Cyclosporine may improve survival over IVIG (J Am Acad Dermatol 2014;71(5):941–947)
  • TNF inhibitors currently being investigated

Complications
• Mostly from mucosal ulcerations in trachea & bronchi (resp distress), esophagus (GIB, malnutrition), eyes (uveitis, ulceration, blindness), genitourinary (dysuria, retention)
- Sepsis can occur 2/2 superinfxn from skin breakdown

**Duration & Disposition**
- Mortality 5–30%; TEN prognosis predictable using SCORTEN (see table)
- All patients get admitted; TEN requires burn unit admission
- ED or early intp c/s to ophthalmology, urology (early foley), ± GI, pulm

<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Point</strong></td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td><strong>Score</strong></td>
</tr>
<tr>
<td>0–1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
</tbody>
</table>

**OTHER EXANTHEMS**

**Allergic/Urticarial Reactions**

**Definition**
- Acute (can be chronic or recurrent) histamine-mediated exanthem, often due to IgE, direct mast cell activation, complement, or dysmetabolism of arachidonic acid (eg, NSAIDs)
- Triggers: systemic exposures (foods, meds, insect stings, contact w/ external allergens, parasites), physical triggers (eg, cholinergic, exercise, pressure, aquagenic, cold, etc.)
- Common associated drugs: ASA, ACE inh, beta-lactam abx, NSAIDs, sulfonamides, others

**History, Physical Exam, & Evaluation**
- HX: Acute-onset (over mins) diffuse urticaria, ± SOB, N/V, LH; pruritus (no pain); usually occurs within hrs of trigger
- EXAM: Diffuse or localized erythematous wheals, variably sized (mm to cm), round or irregular in shape, can be excoriated 2/2 pruritic nature; occur anywhere on skin
  - Assess for signs of anaphylaxis (wheezing, hypotension)
- DX: Clinical dx; if +myalgias, LFTs to r/o acute hepatitis

**Treatment**
- D/C causal drug or other trigger
- Antihistamines (H1 & H2), steroids for severe cases, epinephrine if anaphylaxis

**Duration & Disposition**
- Resolves hours after trigger removed; no mortality risk (unless anaphylaxis)
- Home; RX EpiPen in case recurrence; F/U with allergy for allergen testing &/or desensitization

**Serum Sickness & Serum Sickness-like Reactions**

**Definition**
- Acute diffuse immune-mediated (type III hypersensitivity) rash, often 2/2 drug exposure
- Common associated drugs: Barbiturates, beta-lactam abx, fluoxetine, sulfonamides, thiazides, vaccines/anti-serum, others

**History, Physical Exam, & Evaluation**
- HX: Fever, severe arthralgias, malaise, & acute-onset (over hrs) diffuse rash; pain > pruritus; usually occurs within 2 wk of starting drug
- EXAM: Diffuse urticarial or serpiginous macules & patches (though other morphologies possible), well-demarcated w/ intense red border & central clearing; trunk, face, extremities (no palms/soles); joint ROM limited 2/2 pain
- DX: Clinical dx, no testing indicated

**Treatment**
- D/C causal drug or other trigger
- Supportive: antihistamines, NSAIDs for pain
Steroids for severe dz

Duration & Disposition
- Resolves 2–3 wk after trigger removed; no mortality risk
- Home if pain controlled; F/U with allergy

Exanthematous (Morbilliform) Eruption

Definition
- Acute diffuse immune-mediated rash (type IV hypersensitivity) 2/2 drug exposure
- Common associated drugs: Allopurinol, anticonvulsants, beta-lactam abx, NSAIDs, sulfonamides, others

History, Physical Exam, & Evaluation
- HX: May have low-grade fever, f/b acute-onset (over hrs–dys) diffuse rash; pruritus > pain; usually occurs within 2–6 wk of starting drug
- EXAM: Diffuse erythematous macules or papules (but can be pustular or bullous), becoming confluent; viral (morbilliform) appearance; trunk & extremities (no palms/soles & face)
- DX: Clinical; elevated CRP, CBC may have mild eosinophilia (if markedly elevated eosinophils, consider DRESS), LFTs nl (if elevated, consider DRESS)

Treatment
- D/C causal drug (if unknown, d/c all non-necessary drugs); rarely, the causal medication can be continued through the rash if it is essential; discuss with dermatology
- Supportive care: antihistamines
- Steroids for severe dz

Duration & Disposition
- Resolves ~2 wk after med d/c-ed; no significant mortality risk
- Home; F/U with dermatology

Fixed Drug Eruptions

Definition
- Acute but recurrent localized immune-mediated skin eruption 2/2 repeat drug exposure
- Common associated drugs: ASA, NSAIDs, quinine, sedatives,
sulfonamides, tetracyclines, others

**History, Physical Exam, & Evaluation**

- **HX:** Rash w/o systemic sx; pruritic; occurs within hrs–dys of starting drug; on repeat exposure, lesions occur in same location as prior (new lesions may be present as well)
- **EXAM:** Solitary or small group of erythematous or hyperpigmented oval macules evolving to plaques (may become brown); pruritus; common sites include lips, extremities, genitals
- **DX:** Clinical

**Treatment**

- D/C causal drug (hyperpigmented area may remain)
- Supportive: antihistamines

**Duration & Disposition**

- Resolves days after med d/c-ed; no significant mortality risk
- Home; F/U with dermatology

**Erythema Multiforme**

**Definition**

- Acute (but sometimes recurrent or persistent) diffuse immune-mediated rash which can have mucosal involvement
  - *Erythema multiforme major* – mucosal involvement
  - *Erythema multiforme minor* – no mucosal involvement
- Idiopathic, but can be a/w infxn (90% cases; esp HSV, *M. pneumonia*, HCV, EBV), meds, malignancy, XRT, inflamm dz (*Int J Dermatol* 2012;51(8):889–902)
- Common associated drugs: Anticonvulsants, beta-lactam abx, NSAIDs, phenothiazines, sulfonamides, others

**History, Physical Exam, & Evaluation**

- **HX:** Prodrome (fever, malaise) present in EM major, f/b acute-onset (over dys) diffuse rash (see exam); always ask about meds, recent infxn sx, PMH/FH inflamm dz & malignancy
- **EXAM:** Diffuse erythematous macules/papules w/ evolving morphology (become targetoid, then polycyclic & annular configuration); trunk, extremities (inc palms/soles), face (mucous memb ~70%) (*Int J Dermatol* 2012;51(8):889–902)
Compared to SJS: Less purpuric, less truncal, less painful, less mucosa

- DX: Clinical & histopathologic dx (c/s derm for bx); labs inc HSV PCR/IgM (esp if recurrent episode), ± CXR to r/o causes & complications

### Treatment
- Tx underlying cause or d/c causal med if known
- Supportive: antihistamines, analgesia, ± oral anesthetic solutions/antiseptic rinses
- Topical steroids if mild, systemic steroids if severe dz (esp mucosal);
- Consider long-term valacyclovir in pts if recurrent (Br J Dermatol 1995;132(2):267–70)

### Duration & Disposition
- Resolves w/i weeks; no significant mortality risk, but can progress to SJS/TEN if offending agent not removed
- Home; f/u w/ dermatology & ophthalmology (if ocular involvement)

#### Erythema Nodosum

### Definition
- Panniculitis (inflam of subcutaneous fat) w/ unknown mechanism; thought 2/2 immune complex deposition in connective tissue (Clin Dermatol 2007;25(3):288–294)
- Idiopathic ~30%, infxn ~30% (TB, recent Grp A strep infxn), sarcoidosis ~20%, inflmm dz, malignancy, pregnancy, drugs
- Common associated drugs: Sulfonamides, OCPs/estrogens, others

### History, Physical Exam, & Evaluation
- HX: Prodrome (fever, fatigue, malaise, polyarthralgia (symmetric, additive, Ig joint), HA, GI sx), f/b acute-onset (over dys to wks) generally-localized rash, ± fever, fatigue, malaise, polyarthralgia (symmetric, additive, Ig joint), HA, GI sx; painful; always ask about meds, recent infxn sx, PMH/FH inflam dz & malignancy
- EXAM: Scattered tender erythematous or purple oval nodules (1–6 cm diam), can coalesce; symmetric & usually anterior tibia (also knees, ankles, thighs, forearms)
- DX: Clinical; labs prn for underlying dz (CBC, ESR/CRP, CXR [r/o e/o Tb, sarcoidosis])
Treatment
- Supportive: NSAIDs for pain
- Short course oral corticosteroids in severe dz

Disposition
- Most cases self-resolve w/i 6 wk, but EN may recur; no significant mortality risk (Clin Dermatol 2007;25(3):288–294)
- Home; f/u w/ dermatology or rheumatology

Leukocytoclastic Vasculitis

Definition
- Acute, chronic, or intermittently recurrent immune-mediated (immune complex, ANCA) rash, sometimes w/ systemic organ involvement
- Idiopathic (~50%), or a/w recent infxn (viral [esp HBV/HCV], bacterial, parasites, fungi), inflam dz, meds (see table), illicits, malignancy (J Am Acad Dermatol 2003;48(3):311–340)
- Common associated drugs: Allopurinol, abx, anticoagulants (oral), anticonvulsants, NSAIDs, thiazide diuretics, thiouracil, others

History, Physical Exam, & Evaluation
- HX: Acute-onset (over dys) rash; ± systemic sx (fever, arthralgias, GI sx [diarrhea, abd pain], hematuria, hemoptysis); pruritic/burning; always ask about meds, recent infxn sx, PMH/FH inflamm dz & malignancy
- EXAM: Diffuse or localized tender palpable purpura or purpuric urticaria, can evolve to coalesce to form plaques or bullae; often lower extremities
- Multiorgan involvement possible: MSK, GI, cardiac, lungs, ocular, kidneys
- DX: Clinical; labs to r/o systemic dz (CBC, ESR/CRP, Chem 20, UA, ± CXR)

Treatment
- Tx definitive cause (if known) or d/c causal drug
- Supportive (elevation of legs, compression stockings), antihistamines, analgesia w/ NSAIDs
- Colchicine (± dapsone) if no response to NSAIDs (0.6 mg BID); short-course steroids if still refractory (J Am Acad Dermatol 2003;48(3):311–
Duration & Disposition

- Resolves w/i 2 wk if 2/2 drug; if 2/2 underlying dz may persist or recur
- Home if no systemic indications for admx; refer to dermatology & rheumatology

Sweet’s Syndrome (Acute Febrile Neutrophilic Dermatosis)

Definition

- Rare presumed immune-mediated acute erythematous skin rash characterized histologically by dense neutrophilic infiltrates (J Am Acad Dermatol 1994;31(4):535–560)
- Idiopathic (~2/3 cases; F>M); malignancy (second most common cause; often undx’ed), inflam dz, infxn (esp URI, GI sx, others), meds, pregnancy (Dermatol Online J 1999;5(1):8)
- Common associated drugs: Vaccines, G-CSF, TMP-SMX, minocycline, others

History, Physical Exam, Evaluation

- HX: Acute-onset (over hrs) rash w/ fever (may precede rash), a/w arthralgias, HA; painful
- EXAM: Tender, violaceous, well-demarcated papules & plaques (can get central pustules, bullae, or ulcers – esp if paraneoplastic), can evolve to coalesce; common esp on upper body (inc face, mucous memb)
- DX: Bx required for dx; elev ESR (>90%), CBC (WBC >8 k in 80%, +bands), anemia, low plts; LFTs, ± CXR; ± imaging to eval for malignancy dx (Dermatol Online J 1999;5(1):8)

Treatment

- Supportive: Analgesia
- Systemic steroids for acute dz; mx agents used for suppressive tx

Duration & Disposition

- Rapid resolution w/ steroids (w/o tx may persist wks to mo); can recur
- Home if pain controlled & stable; f/u w/ dermatology

Photosensitive Reaction
Definition

- Any exanthem appearing in photodistribution after exposure to UV light
- Drug-related causes: exaggerated sunburn, photosensitive drug rxn (phototoxic, photoallergic), pseudoporphyria
- Common associated drugs: Diuretics, NSAIDs, phenothiazines, quinolones, sulfonamides, sulfonylureas, tetracyclines, others
- Not drug-related: porphyria cutanea tarda (PCT), inflamm dz (lupus, dermatomyositis)

History, Physical Exam, & Evaluation

- HX: Acute-onset (over hrs) rash localized to sun-exposed areas; h/o UV exposure (tanning booth, phototherapy, sunlight); always ask about meds (usually w/i 4 wk), recent infxn sx, PMH/FH inflamm dz
- Phototoxic rxn: Onset min–hrs after UV
- Photoallergic rxn: Onset 24–72 h after UV
- Pseudoporphyria: Onset hrs after UV
- EXAM: Exanthem only present on sun-exposed area, morphologically diverse:
  - Phototoxic drug rxn: Exaggerated sunburn response (erythema, edema ± blistering)
  - Photoallergic drug rxn: Erythema ± eczematous changes
  - Pseudoporphyria: Erythema, tense bulla (inc hemorrhagic) & erosions (as opposed to PCT, lacks chronic pigment, hair, or sclerodermal chgs)
- DX: Clinical; further testing prn to r/o PCT or inflamm dz (eg, porphyrins, ANA, etc.)

Treatment

- Supportive: Sun protection (clothing, high-SPF sunscreen), cool compresses, wound care
- Topical steroids, systemic steroids for severe dz

Duration & Disposition:

- Resolution variable, but drug-induced pseudoporphyria may take months
- Home; F/U w/ dermatology & rheumatology prn to exclude PCT or inflammatory causes

**Dermatitis**
- Class of skin inflammatory-mediated skin dz marked by similar s/sx: erythema, pruritus, scaling, fissures, varying degrees of lichenification & blistering
- Usually chronic/subacute, but pts may come to ED if bad flare (esp if recent long remission)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Presentation</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atopic dermatitis <em>(J Allergy Clin Immunol 2013;131:295–299)</em></td>
<td>Definition: Chronic, relapsing/remitting; mostly children (10–20% of kids; 1–3% of adults), most w/i first 1 yr. RFs: Hx/FH atopy (asthma, allergic rhinitis, food allergies) Triggers: Temp, humidity, irritants, infxn, foods, allergens, stress Exam: Dry pruritic erythematous papulovesicular w/ excoriations &amp; serous exudate ± lichenification; in kids often on face, neck, extensor surf; in adults often flexor folds</td>
<td>Skin hydration: Soaking baths f/b moisturizer w/i 10 min Topical Steroids: Low-potency for maintenance, mid- &amp; high-potency for flares Antihistamines: For pruritus; do not use topical agents 2/2 risk of skin sensitization Prevention: Avoid irritants F/U w/ derm: May need tx w/ topical calcineurin inhibitors</td>
</tr>
<tr>
<td>Contact dermatitis <em>(allergic)</em> <em>(Ann Allergy Asthma Immunol 2006;97:S1–38)</em></td>
<td>Definition: Inflammatory rxn 2/2 direct contact w/ exogenous agent &amp; subsequent type IV hypersensitivity rxn; in Allergic CD, antigen reacts w/ proteins in skin to cause inflammation; in irritant CD, antigen chemically abrades or damages skin to cause inflammation Triggers: Latex, plant</td>
<td>Avoid any suspected trigger Sx relief: cold compresses, colloidal baths, emollients Topical steroids: Start w/ high-potency if localized (not on face, genitals), then transition to mid- or low-potency as sx improve Systemic steroids for severe or extensive dz Evaluate &amp; tx superinfxn Antihistamines can be</td>
</tr>
<tr>
<td>Condition</td>
<td>Definition</td>
<td>Treatment</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Nummular dermatitis             | **Definition:** Morphologically unique type of atopic dermatitis; can occur older in adulthood; M>F  
|                                 | **Risk factors:** Dry skin, atopy, skin injury/abrasion, poor vascular flow, Vit A containing meds  
|                                 | **Exam:** Round/oval pink/brown pruritic papulovesicular rash w/ serous exudate, evolving to plaque (2–10 cm diam) w/ crust then scale; often on extremities (but can be torso)  
|                                 | See [atopic dermatitis](#)                                                  |                                                                           |
| Seborrheic dermatitis           | **Definition:** Dz of the sebum-rich areas (scalp/face/trunk), possibly 2/2 abnl immune response to nl skin fungus (Malassezia); often in infants (cradle cap) & elderly, but also AIDS & Parkinson dz; 20% of pts have h/o dandruff; worse in winter  
|                                 | **Exam:** Pink oily flaking patches of skin on scalp, face (nasolabial folds, eyebrows, ears), chest, flexural skin  
|                                 | Frequent bathing w/ keratolytic shampoos (eg, selenium, zinc-based), reduce oil  
|                                 | Antifungal: Ketoconazole shampoo or creams  
|                                 | Topical steroids: Low-potency creams (if not on scalp)                     |                                                                           |
| Xerotic dermatitis              | **Definition:** Skin dz characterized by changes 2/2 dry skin; common among elderly  
|                                 | **Exam:** Dry skin w/ erythematous superficial cracks & excoriations, often  
|                                 | Skin hydration: Soaking baths f/b moisturizer w/i 10 min  
|                                 | Topical Steroids: Low-potency & short duration                             |                                                                           |
### Pompholyx

**Definition:** Subtype of eczema
- 2/2 edematous fluid accumulation in areas with thick epidermis; affecting palmoplantar skin; acute, recurrent, or chronic
- Triggers: a/w atopic & contact dermatitis, drug rxns, stress, id rxn in pts w/ tinea pedis

**Exam:** Nonerythematous pruritic vesicles or bulla on palms or soles

**Topical steroids:** High-potency systemic steroids if severe
- F/U w/ derm: May need tx w/ topical calcineurin inhibitors

### Topical Steroid Preparations by Potency (Generic)

<table>
<thead>
<tr>
<th>High Potency</th>
<th>Upper-Mid Potency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clobetasol propionate&lt;sup&gt;C,G,O,So&lt;/sup&gt;</td>
<td>Fluocinonide&lt;sup&gt;C,G,O&lt;/sup&gt;</td>
</tr>
<tr>
<td>Betamethasone dipropionate&lt;sup&gt;C,G,O,So&lt;/sup&gt;</td>
<td>Betamethasone valerate&lt;sup&gt;O&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Mometasone furoate&lt;sup&gt;C,O&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Lower-Mid Potency</strong></td>
<td><strong>Low Potency</strong></td>
</tr>
<tr>
<td>Triamcinolone acetonide&lt;sup&gt;C,O,Sp&lt;/sup&gt;</td>
<td>Fluticasone propionate&lt;sup&gt;C,L,O&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hydrocortisone valerate&lt;sup&gt;C,O&lt;/sup&gt;</td>
<td>Hydrocortisone 1%, 2.5%&lt;sup&gt;C,L,O,Sp&lt;/sup&gt;</td>
</tr>
<tr>
<td>Desonide&lt;sup&gt;C,L,O&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

### Special Notes on Administration

1. **Vehicles:** Ointment (O) most soothing for dry skin. Cream (C) most cosmetically acceptable. Lotion (L), gel (G) & solution (So) most ideal for scalp. Spray (Sp) in unique circumstances.
2. **Avoid high potency or prolonged upper-mid potency for pediatric pts (high absorption), skin folds inc genitals (causes striae), and face (causes atrophy/rosacea/ocular complications).**
ACID–BASE DISORDERS

Approach to the Patient

Diagnostics

- BMP; consider LFTs, CBC, urine electrolytes, ABG/VBG, & serum osmoles

Note: HCO₃⁻ from ABG is calculated & should be w/i 2 mmol/L of BMP total CO₂

Step-wise Approach

- **Step 1:** Is there an acidemia or alkalemia?
  - Acidemia: pH < 7.36; Alkalemia: pH > 7.44
- **Steps 2 & 3:** Is the primary disturbance metabolic or respiratory? Is there compensation?

### Assessing Primary Metabolic Disturbances and Physiologic Compensation

<table>
<thead>
<tr>
<th>Primary Disorder</th>
<th>pH</th>
<th>pCO₂</th>
<th>HCO₃⁻</th>
<th>Compensation Formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic acidosis</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Decr pCO₂ = 1.25 × ΔHCO₃⁻</td>
</tr>
<tr>
<td>Metabolic alkalosis</td>
<td>High</td>
<td>High</td>
<td>High</td>
<td>Incr pCO₂ = 0.75 × ΔHCO₃⁻</td>
</tr>
<tr>
<td>Acute respiratory acidosis</td>
<td>Low</td>
<td>High</td>
<td>High</td>
<td>Incr HCO₃⁻ = 0.1 × ΔPCO₂⁻</td>
</tr>
<tr>
<td>Acute respiratory alkalosis</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
<td>Decr HCO₃⁻ = 0.2 × ΔPCO₂⁻</td>
</tr>
<tr>
<td>Chronic respiratory acidosis</td>
<td>NI or low</td>
<td>High</td>
<td>High or nl</td>
<td>Incr HCO₃⁻ = 0.4 × ΔPCO₂⁻</td>
</tr>
<tr>
<td>Chronic respiratory alkalosis</td>
<td>NI or high</td>
<td>Low</td>
<td>Low or nl</td>
<td>Decr HCO₃⁻ = 0.4 × ΔPCO₂⁻</td>
</tr>
</tbody>
</table>

- **Step 4a:** Is there an anion gap?

  **Anion gap acidosis:** (NA – (Cl + bicarb)) > 14 (see chart)

Note: Needs to be corrected for albumin; a fall in serum albumin 1
g/dL from the nl value (4.2 g/dL) decreases the anion gap by 2.5 meq/L. Corrected AG = AG + (2.5 × [4.2 – albumin]).

- **Step 4b:** If an anion gap is present, is there an osmolar gap?
  
  **Osmolar gap:** Measured serum Osm – Calculated Osm >10 mOsm/L, where Calculated Osm = (2 × [Na⁺]) + glucose/18 + BUN/2.8 + Ethanol/4.6

- **Step 4c:** If no anion gap is present, what is UAG?
  
  **Urinary anion gap:** Na + K – Cl

Note: The UAG can help differentiate GI & renal causes of non-AG (hyperchloremic) metabolic acidosis, as base can be lost from the gut or kidney (negative UAG: GI loss [i.e., diarrhea, small bowel fistula, ileostomy]; positive UAG: Renal loss, particularly RTA types I & IV)

- **Step 5:** What is the delta ratio, also known as the “delta/delta”?

  \[
  \frac{(AG – nl \ AG)}{(nl \ HCO_3 – HCO_3)}, \text{or simply} \ \frac{(AG – 12)}{(24 – HCO_3)}
  \]

  If delta/delta >+6, suggests concomitant metabolic alkalosis, or prior compensated respiratory acidosis
  If delta/delta = 0, suggests uncomplicated AG metabolic acidosis
  If delta/delta <–6, suggests concomitant hyperchloremic non-AG metabolic acidosis

<table>
<thead>
<tr>
<th>Metabolic Acidosis</th>
<th>Nonanion Gap Acidosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anion Gap Acidosis</td>
<td>Nonanion Gap Acidosis</td>
</tr>
<tr>
<td>“A CAT’S MUDPILE”</td>
<td>“FUSED CARD TIP”</td>
</tr>
<tr>
<td>Alcoholic ketoacidosis</td>
<td>Fanconi syndrome</td>
</tr>
<tr>
<td>Carbon monoxide, cyanide</td>
<td>Ureteroenterostomy</td>
</tr>
<tr>
<td>Aspirin</td>
<td>Small bowel fistula</td>
</tr>
<tr>
<td>Toluene</td>
<td>Excessive Cl⁻ (NaCl, Ammonium Cl⁻)</td>
</tr>
<tr>
<td>Starvation ketoacidosis</td>
<td>Diarrhea</td>
</tr>
<tr>
<td>Methanol, metformin, methemoglobinemia</td>
<td>Carbonic anhydrase inhibitors</td>
</tr>
<tr>
<td>Condition</td>
<td>Cause</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Uremia</td>
<td>Addison’s dz</td>
</tr>
<tr>
<td>DKA</td>
<td>Renal tubular acidosis</td>
</tr>
<tr>
<td>Paraldehyde, phenformin, propylene glycol</td>
<td>Drugs (spironolactone, amiloride, cholestyramine, triamterene)</td>
</tr>
<tr>
<td>Isoniazid, iron</td>
<td>Toluene (chronic, secondary to RTA)</td>
</tr>
<tr>
<td>Lactic Acidosis types A &amp; B</td>
<td>Ileostomy</td>
</tr>
<tr>
<td>Ethylene glycol</td>
<td>Pancreatic fistula, parenteral nutrition, posthypocapnia</td>
</tr>
</tbody>
</table>

### Osmolar Gap Causes

**Toxic Alcohols:**
- Methanol
- Ethylene glycol

**Others:**
- Acetone
- Mannitol
- Sorbitol
- Glycerol
- Ether trichloroethane

### Low Anion Gap (<6)

- Lab error
- Lithium tox
- Bromide tox
- Hypoalbuminemia
- Paraproteinemias
- Severe hypercalcemia/hypermagnesemia

### Metabolic Alkalosis

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exogenous HCO₃</td>
<td>- Acute alkali administration: Citrate loads from blood transfusions, acetate loads from TPN, administration of NaHCO₃ solution, excessive antacids</td>
</tr>
<tr>
<td></td>
<td>- Milk–alkali syndrome</td>
</tr>
<tr>
<td>NaCl responsive conditions ≪ urine Cl</td>
<td>- GI loss of H⁺: V/D, NGT drainage, adenomas</td>
</tr>
</tbody>
</table>
| <1<0–1<5 mEq/L) | -Renal loss of H⁺: Diuretic use  
|                | -Posthypercapnia  
| NaCl unresponsive conditions <(urine Cl⁻) >1<5 mEq/L) | -Volume expansion/hypertensive/mineralocorticoid excess:  
|                | Hyperaldosteronism, Cushing syndrome, exogenous mineralocorticoid, licorice, renal artery stenosis  
|                | -Volume contraction/normotensive/2° hyperaldosteronism:  
|                | Hypokalemia, hypomagnesemia, hypercalcemia/hypoPTH, Bartter’s syndrome, Gitelman’s syndrome  
|                | -Volume expansion/hypertensive/hypoaldosteronism: Liddle’s syndrome |

### Respiratory Acidosis

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central respiratory depression</td>
<td>Drugs (opioids, sedatives), brainstem infarct, high C-spine injury, obesity hypoventilation syndrome (ie, Pickwickian syndrome)</td>
</tr>
<tr>
<td>Nerve or muscular disorders</td>
<td>Paralysis, muscular dystrophy or other myopathies, myasthenia gravis, toxins (ie, organophosphate, snake envenomations), Guillain–Barré, ALS</td>
</tr>
<tr>
<td>Airway issues</td>
<td>Upper airway obstruction, laryngospasm, bronchospasm</td>
</tr>
<tr>
<td>Respiratory issues</td>
<td>Asthma, COPD, CHF, pneumonia, ILD, aspiration, ARDS, inadequate mechanical ventilation</td>
</tr>
<tr>
<td>Chest wall trauma</td>
<td>Flail chest, PTX, hemothorax, diaphragmatic paralysis, kyphoscoliosis</td>
</tr>
</tbody>
</table>

### Respiratory Alkalosis

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac, respiratory</td>
<td>Pulmonary edema, pulmonary embolus, restrictive lung dz, mechanical hyperventilation</td>
</tr>
<tr>
<td>Psychiatric, neurologic</td>
<td>Hyperventilation syndromes (eg, anxiety, pain, stress), meningoencephalitis, tumor, trauma, CVA</td>
</tr>
<tr>
<td>Infection</td>
<td>Fever, pneumonia, sepsis</td>
</tr>
<tr>
<td>GI</td>
<td>Liver failure</td>
</tr>
<tr>
<td>Meds, other</td>
<td>Salicylates, hyperthyroidism, high altitude, anemia, pregnancy</td>
</tr>
</tbody>
</table>

### Treatment and Disposition
- Both will largely depend on severity & underlying etiology of the
disorder
◆ Limited role for bicarbonate in the absence of hemodynamic collapse

ABNORMAL ELECTROLYTES

Hyponatremia

Definition
◆ Na <135, excess of water relative to sodium, usually from elevated ADH; generally not symptomatic at Na >125

History
◆ Most sxns are nonspecific: Fatigue, weakness, muscle cramps, thirst, or postural dizziness. Severe sxns include confusion, agitation, delirium, lethargy, somnolence, coma, or sxns.
◆ Other helpful historical features include h/o CHF, cirrhosis, renal dz, cancer, adrenal or pituitary dysfxn, recent GI surgery, thiazide or loop diuretics use, alcoholism

Physical Exam
◆ Look for signs to assess pt fluid status:
  • Hypervolemia: Elevated JVP, peripheral edema, crackles, ascites, anasarca
  • Hypovolemia: Tachycardia, hypotension, dry mucous membranes, oliguria, poor skin turgor, IVC collapsibility
◆ Look for signs of profound hyponatremia: Lethargic, disoriented/abnl sensorium, depressed reflexes, hypothermic, pseudobulbar palsy, Cheyne–Stokes respiration

Diagnostics
◆ Labs: BMP, FSG, urine electrolytes (Na, Cr, Osm), serum Osm, albumin
◆ VBG w/ stat sodium & Osm may provide more rapid turnaround
◆ Corrected $\text{Na}_{\text{glucose}} = \text{Serum Na} + [0.016 \times (\text{serum glucose} – 100)]$ up to 400 mg/dL
◆ for glucose >400 mg/dL, 4 mEq/L should be added to every additional 100 mg/dL
### Step-wise Approach to Hyponatremia

1. **Step 1:** What is the serum osmolality?

<table>
<thead>
<tr>
<th>Causes of Hyponatremia by Serum Osmolality</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypertonic HypoNa</strong></td>
</tr>
<tr>
<td>Hyperglycemia</td>
</tr>
<tr>
<td>Mannitol</td>
</tr>
<tr>
<td>Glycerol</td>
</tr>
<tr>
<td>Sorbitol</td>
</tr>
</tbody>
</table>

NI serum osmolality = 275–290 mosmol/kg

2. **Step 2:** What is the pt’s volume status? Hypervolemic, euvoletic, or hypovolemic?

3. **Step 3:** What are the urine Na, urine Osm, & FeNa values?

- **Fractional Excretion of Sodium** = \( \text{FeNa} = \frac{\text{Na}_{\text{urine}} \times \text{Cr}_{\text{serum}}}{\text{Na}_{\text{serum}} \times \text{Cr}_{\text{urine}}} \)

<table>
<thead>
<tr>
<th>Assessing Causes of Hypotonic Hyponatremia by Volume Status and Urine Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Volume Status</strong></td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>Hypervolemic</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Euvolemic</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Hypovolemic</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
**Treatment**

- Asymptomatic or mild sx of hyponatremia: Correct serum Na at \( \leq 0.5 \text{ mEq/L/h} \)
- Severe manifestations of hyponatremia: RAPID correction serum Na at 2 mEq/L/h × 2–3 h OR until sx resolve

### IV Fluid Management

<table>
<thead>
<tr>
<th>Total Body Water (TBW)</th>
<th>= Weight (kg) × 0.6 (use 0.5 if female or elderly, 0.6 for infants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate of Infusion (cc/h)</td>
<td>( \frac{1000 \times [\text{TBW} \times (\text{desired Na} - \text{serum Na})]}{[\text{Na(mmol/L)}_{\text{infusate}} \times \text{time(h)}]} )</td>
</tr>
</tbody>
</table>

Infusate concentrations:
- LR: 130 mmol/L
- NS: 154 mmol/L
- 3% NS: 513

Requires checking serum Na *(& Glu) q1h

- Euvolemic hyponatremia
  - Asymptomatic: Free water restrict (500–1000 mL/day)
  - Symptomatic: See above
- SIADH
  - Free water restrict + treat underlying cause
  - Caution if using hypertonic or nl saline esp if IVF Osm < urine Osm, serum sodium may worsen (higher Osm will draw out fluid)
  - Consider lithium or demeclocycline – nephrogenic DI ((NEJM 2007;356:2064)
- Hypovolemic hyponatremia
  - Volume replete w/ nl saline, as above (once dehydration resolved, stimulation of ADH will decline & Na will correct)
- Hypervolemic hyponatremia
  - Free water restrict (0.5–1.5 L/d)
  - Increase arterial volume: W/ vasodilators (Nitro), loop diuretics; consider albumin in cirrhosis
  - Severe hyponatremia: Consider diuresis + Na replacement

### Disposition

- Home: Mild asymptomatic hyponatremia
Admit: Symptomatic, comorbidities, elderly. May require ICU admission if severe.

Pearl
- Rapid correction >10–12 mEq/L/d may result in central pontine myelinolysis (dysarthria, szs, quadriparesis due to focal myelin destruction in pons & extrapontine areas)

Hyponatremia

Definition
- Na >145, usually from free water loss or sodium gain (eg, infusion of hypertonic fluid)
  - Appropriate response to hyponatremia is increased free water intake stimulated by thirst & renal excretion of a minimal volume of maximally concentrated urine as regulated by ADH

History
- Mild sx: increased thirst or polyuria
- Severe sx: AMS (irritability, lethargy, confusion, delirium, coma)
- RFs: Elderly, infants, debilitated. Endocrine pathology; cardiac, renal, liver dz; psychiatric disorder (see etiology of Central and Nephrogenic Diabetes Insipidus); MEDS (see below chart), living situation (access to free water).

Physical Exam
- Look for signs to assess pt fluid status:
  - Hypervolemia: Elevated JVP, peripheral edema, crackles, ascites, anasarca
  - Hypovolemia: Tachycardia, hypotension, dry mucous membranes, oliguria, poor skin turgor, IVC collapsibility
- Severe hypernatremia: Lethargy, muscle spasticity, tremor, hyperreflexia, respiratory paralysis, ataxia

Diagnostics
- Labs: BMP, FSG, urine electrolytes (Na, Cr, Osm), serum Osm, albumin
- VBG w/ stat sodium & Osm may provide more rapid turnaround
- Corrected $Na_{glucose} = \text{Serum Na} + [0.016 \times (\text{serum glucose} – 100)]$ up to 400 mg/dL
• For glucose >400 mg/dL, 4 mEq/L should be added to every additional 100 mg/dL

**Step-wise Approach to Hypernatremia**

- **Step 1:** What is the serum osmolality?
  - NI serum osmolality = 275–290 mosmol/kg

- **Step 2:** What is the pt’s volume status? Hypervolemic, euvolemic, or hypovolemic?

- **Step 3:** What are the urine Na & urine Osm values?

<table>
<thead>
<tr>
<th>Volume Status</th>
<th>Urine Na</th>
<th>Urine Osm</th>
<th>Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypervolemic</td>
<td>&gt;20</td>
<td></td>
<td>Increased Sodium Absorption: Cushing dz, adrenal hyperplasia, exogenous steroids, mineralocorticoid excess</td>
</tr>
<tr>
<td>Euvolemic</td>
<td>&lt;300</td>
<td>300–600</td>
<td>Complete DI (central &amp; nephrogenic)*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;600</td>
<td>Partial DI (central &amp; nephrogenic)*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Exogenous Sodium Intake: Hypertonic saline, sodium bicarb tablets, sea water ingestion, concentrated infant formula</td>
</tr>
<tr>
<td>Hypovolemic</td>
<td>&gt;20</td>
<td>300–600</td>
<td>Renal Water Losses: Loop diuretic, osmotic diuresis (mannitol, urea)</td>
</tr>
<tr>
<td></td>
<td>&lt;20</td>
<td>&gt;600</td>
<td>Extrarenal Water Losses: Vomiting, diarrhea, NGT drainage, szs, exercise, severe burns, fever, 3rd spacing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Decreased Water Intake: Defective thirst mechanism, dementia, AMS, infancy, intubation</td>
</tr>
</tbody>
</table>

Treatment

### IV Fluid Management*

<table>
<thead>
<tr>
<th>Equation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Free water deficit (Liters) = Total Body Water × [1 – (140/serum Na)]</td>
<td></td>
</tr>
<tr>
<td>Total body water (TBW) = Weight (kg) × 0.6 (use 0.5 if female or elderly; 0.6 for children)</td>
<td></td>
</tr>
<tr>
<td>Hourly maintenance (mL/h) = Free Water Deficit (mL)/24 h</td>
<td></td>
</tr>
<tr>
<td>Rate of Infusion (cc/h) = [rac{1000 \times [TBW \times (serum \ Na - desired \ Na)]}{[Na]_{infusate} \times time (h)}]</td>
<td></td>
</tr>
</tbody>
</table>

Infusate concentrations

- D5W: 0 mEq
- ¼ NS: 38 mEq
- ½ NS: 77 mEq

*Requires checking serum Glucose & Na q1h. Rate of Na correction should NOT exceed 0.5 mEq/L/h to avoid cerebral edema. Urine output: >0.5 cc/kg/h.

- Hypervolemic hypernatremia
  - Treat underlying disorder
  - Replace free water deficit (as above)
- Euvolemic hypernatremia
  - Replace free water deficit (as above)
  - Treat underlying etiology
  - Central DI: Vasopressin 10 U SQ
- Hypovolemic hypernatremia
  - Restore volume 1st then replace free water deficit (as above); add 40 mEq KCl IV to fluid replacement once pt is urinating

### Disposition

- Home: Mild hypernatremia which can be corrected in <24 h
- Admit: Likely admit

### Hypokalemia

#### Definition

- K+ <3.5 mEq/L (ie, decreased intake, shift into cells, loss); 98% of potassium is intracellular

<table>
<thead>
<tr>
<th>Hypokalemia Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathophysiology</td>
</tr>
<tr>
<td>-------------------</td>
</tr>
</tbody>
</table>
**GI**
- Poor oral intake; diarrhea, vomiting, & NG tube drainage

**Endocrine**
- High insulin levels, hyperaldosteronism, alkalosis, DKA, Cushing dz, hypomagnesemia

**Renal**
- Renal tubular acidosis (type 2), renovascular dz, Bartter syndrome, Liddle syndrome

**Meds/toxins**
- Thiazide & loop diuretics, insulin, β-2 agonists, α-antagonists, amphotericin B, laxative abuse, exogenous mineralocorticoid use, massive blood transfusions, barium tox, toluene tox

---

**History**
- Usually not symptomatic until K⁺ < 3 mEq/L
- Nausea, vomiting, weakness, fatigue, myalgia, muscle cramps.
- Pts at highest risk for electrocardiac cx of hypokalemia include those w/ acute ischemia, prolonged QT syndrome, & those taking digoxin

**Physical Exam**
- Paresthesias, depressed reflexes, proximal muscle weakness, ileus
- Severe hypokalemia: Hypoventilation, spasm, paralysis, rhabdomyolysis, myoglobinuria
- ARF, polymorphic VT, asystole

**Diagnostics**
- **Labs:** BMP, UA, urine electrolytes, urine Osm; consider blood gas, CPK, serum Osm
- Urine K⁺ < 15 mmol/d suggests extrarenal, while urine K⁺ > 15 mmol/d suggests renal etiology
- Transtubular K⁺ concentration gradient (TTKG) is helpful, but rarely used in the ED: \[ TTKG = \frac{(\text{Plasma}_{\text{Osm}} \times \text{Urine}_{K^+})}{(\text{Plasma}_{K^+} \times \text{Urine}_{\text{Osm}})} \]

Note: Hypokalemia w/ TTKG > 4 suggests renal K⁺ loss due to distal K⁺ secretion
- **ECG:** T-wave flattening/inversion, ST depression, U-waves, prolonged QT/QU interval; may also see PR prolongation, decreased voltage, QRS widening, atrial/ventricular dysrhythmias

---

**Treatment**
- **ED**
  - Potassium replacement: Potassium chloride, Potassium
bicarbonate, Potassium phosphate

(Drop 1 mEq/L = 200–400 mEq total body loss)
Mild (K\textsuperscript{+} >2.8 mEq/L): 40 mEq K\textsuperscript{+} PO q4–6h
Moderate/severe: 40 mEq K\textsuperscript{+} PO q4h (if tolerating oral) + KCl 10 mEq/h IV, recheck K\textsuperscript{+} q4h

- Treat underlying cause
- Replace Mg as needed (*Note: Concurrent Mg & K\textsuperscript{+} deficiency could lead to refractory K\textsuperscript{+} repletion)
- Goal K\textsuperscript{+} = 4 mEq/L in pts at highest risk
  - Home
    - Counsel pts to increase dietary intake of K\textsuperscript{+} (dried fruits, nuts, avocados, wheat germ lima beans, vegetables [spinach, broccoli, cauliflower, beets, carrots], fruits [banana, kiwi, etc])
    - Discuss w/ PCP: Decrease diuretic dose; start/substitute for K\textsuperscript{+}-sparing med (βB, ACE, ARB, K\textsupersparing diuretic)
    - Potassium replacement: KCl 20 mEq PO QD for prevention; KCl 40–100 mEq PO QD for tx

Disposition
  - Home: Mild hypokalemia w/ close f/u to recheck labs
  - Admit: Moderate/severe hypokalemia, acid–base abnormalities, arrhythmia, severe sx

Pearl
  - Avoid dextrose solutions (stimulate insulin & inward shift of K\textsuperscript{+})


Hyperkalemia

Definition
  - K\textsuperscript{+} >5 mEq/L (ie, K\textsuperscript{+} release from cells, decreased renal losses, iatrogenic)

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocrine/metabolic</td>
<td>Hypoaldosteronism, DKA, other acidoses</td>
</tr>
</tbody>
</table>
Renal insufficiency, end-stage renal failure, renal tubular acidosis (type 4), diabetic nephropathy, Gordon’s syndrome

Tumor lysis syndrome, hemolysis, rhabdomyolysis, *pseudohyperkalemia (hemolyzed blood sample, prolonged tourniquet), exercise

NSAIDs, ACE−, ARBs, heparin, TMP–SMX, pentamidine βBs, digoxin poisoning, K+ sparing diuretics, exogenous KCl supplements, cyclosporine, *succinylcholine

*Pseudohyperkalemia should be suspected in o/w asymptomatic pts w/o underlying causes. Repeated K+ should be obtained prior to initiating tx in such cases.

History
- Weakness, muscle cramps, paresthesias, nausea, palpitations.
  Meds (see Differential table).

Physical Exam
- Paresthesias, tetany; assess fluid status
- Severe hyperkalemia: Flaccid paralysis, hypoventilation, PEA arrest, or asystole

Diagnostics
- Labs: BMP; consider blood gas w/ stat K+, UA, urine electrolytes, urine Osm, CPK
- ECG: Early: Peaked & symmetric T waves, flattened P waves, PR prolongation, 1° AVB. Late: Widening/slurring of QRS → sinusoidal waveform → VFib or asystole

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Dose</th>
<th>Onset</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium gluconate OR</td>
<td>1–2 amps IV</td>
<td>Few minutes</td>
<td>Stabilizes cell membrane; used in pts w/ cardiac conduction abnormalities (no direct effect on K+)</td>
</tr>
<tr>
<td>Calcium chloride***</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>1–2 amps</td>
<td>15–30 min (up to 2 h)</td>
<td>Transient K+ into cells in exchange for H+ (may ↓ K+ 0.47 mmol/L)</td>
</tr>
<tr>
<td>Albuterol (β-agonist)</td>
<td>10–20 mg inh or 0.5–2.5 mg IV</td>
<td>30–90 min</td>
<td>Transient K+ into cells (↓ K+ 0.3–0.99 mmol/L)</td>
</tr>
<tr>
<td>Insulin + D&lt;sub&gt;50W&lt;/sub&gt;</td>
<td>10 U IV + 1 amp D&lt;sub&gt;50W&lt;/sub&gt;</td>
<td>15–30 min, lasts 2–4 h</td>
<td>Transient K&lt;sup&gt;+&lt;/sup&gt; into cells (↓K&lt;sup&gt;+&lt;/sup&gt; 0.45–1 mmol/L)</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------------------</td>
<td>------------------------</td>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>Kayexalate***</td>
<td>30–90 g PO/PR</td>
<td>90 min for PO, 30 min for PR</td>
<td>Decreases total body K&lt;sup&gt;+&lt;/sup&gt; by exchanging Na for K&lt;sup&gt;+&lt;/sup&gt; in gut</td>
</tr>
<tr>
<td>Diuretics (Furosemide)</td>
<td>≥40 mg IV</td>
<td>30 min</td>
<td>Decreases total body K&lt;sup&gt;+&lt;/sup&gt;</td>
</tr>
<tr>
<td>HD (emergent)</td>
<td></td>
<td></td>
<td>Decreases total body K&lt;sup&gt;+&lt;/sup&gt; (pts w/ cardiac cx or new/worsened renal failure)</td>
</tr>
</tbody>
</table>

*Standard teaching is not to use calcium in digitalis tox → hypercalcemia may potentiate the tox; however, recent data shows that this may be inaccurate.

**Calcium chloride contains 3 times more calcium ion, onset in seconds to minutes & lasts 30 min, but much more caustic to veins than Calcium gluconate.

***May cause intestinal necrosis in pts w/ postoperative ileus; may also worsen pulmonary edema in pts w/ fluid overload; data on its efficacy at reducing total body potassium is poor.

**Treatment**
- Continuous cardiac monitoring
- Treating underlying cause
- Check electrolytes every 2–4 h until normalized

**Disposition**
- Home: Only if mild, stable hyperkalemia with good outpatient f/u
- Admit: Most pts will require admission; may require ICU admission

**Pearls**
- Think “ABCD” (albuterol, bicarbonate, calcium, dextrose/insulin, dialysis, diuretics)
- Combination therapy is proven more efficacious than any therapy alone
- HD is the most rapid & effective way of lowering plasma K<sup>+</sup>

**Hypocalcemia**

**Definition**
- Ca <8.5 mg/dL (2 mmol/L) OR ionized Ca <4.5 mg/dL (1.1 mmol/L); 50% bound to albumin, 40% is free, 10% complexed to anions
Hypocalcemia Etiology

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>PTH</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocrine</td>
<td>↓</td>
<td>Hypoparathyroidism [familial, autoimmune, infiltrative, iatrogenic: Surgery, neck irradiation], DiGeorge syndrome, hypomagnesemia</td>
</tr>
<tr>
<td>Vit D deficiency</td>
<td>↑</td>
<td>Nutritional/sunlight deprivation; malabsorption; drugs (anticonvulsants, rifampin, ketoconazole, 5-FU/leucovorin); genetic; renal insufficiency (impaired production)</td>
</tr>
<tr>
<td>Renal</td>
<td>↑</td>
<td>Chronic renal failure, ARF (elevated phosphorous)</td>
</tr>
<tr>
<td>Neoplasm</td>
<td>↑</td>
<td>Osteoblastic metastases, tumor lysis (elevated phosphorous)</td>
</tr>
<tr>
<td>Other</td>
<td>↑</td>
<td>Pancreatitis, multiple blood transfusions, rhabdomyolysis, burns, prematurity, pseudohypoparathyroidism</td>
</tr>
</tbody>
</table>

History
- Weakness, muscle cramps, paresthesias, irritability, depression, tetany, AMS. Meds (see Differential table).

Physical Exam
- Paresthesias; Chvostek sign (tap over facial nerve causing facial twitching); +Trousseau sign (inflate a BP cuff to 20 mmHg above systolic BP over bicep × 3 min to cause carpal spasm); may also see psychosis, szs, ↑ ICP, bronchospasm, laryngospasm

Diagnostics
- Labs: BMP w/ Ca/Mg/Phosphorus testing. Check ionized calcium level, albumin, consider PTH for continued inpt w/u:

  \[
  \text{Corrected Ca} = \text{measured serum calcium (mg/dL)} + [0.8 \times (4-\text{serum albumin (g/dL)})]
  \]

- ECG: Prolonged QTc, heart blocks, ventricular dysrhythmias, torsade

Treatment
- Asymptomatic: Oral elemental Ca (1–3 g/d in divided doses)
- Symptomatic: [10% Calcium gluconate (1–2 g IV over 20 min) OR]
10% Calcium chloride (1–2 g IV diluted in 100 cc D5W to decrease tissue irritation)], ± Vit D, ± Mg (50–100 mEq/d)

Disposition
› Home: Asymptomatic, w/ oral regimen described above & PCP f/u in 5–7 d to recheck electrolytes
› Admit: Severe hypocalcemia, comorbid conditions, HD unstable

Hypercalcemia
Definition
› Ca >10.5 mg/dL; usually asymptomatic at levels up to 11.5 mg/dL

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>PTH</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excess PTH prod</td>
<td>↑</td>
<td>1° hyperparathyroidism* (adenoma, hyperplasia, rarely adenoCa), 3° hyperparathyroidism (renal insufficiency), FHH</td>
</tr>
<tr>
<td>Vit D excess</td>
<td>↓</td>
<td>Sarcoidosis, TB, histoplasmosis, Wegener granulomatosis, Vit D intoxication, lymphoma</td>
</tr>
<tr>
<td>↑ bone resorption</td>
<td>↓</td>
<td>Hyperthyroidism, immobilization</td>
</tr>
<tr>
<td>Neoplasm*</td>
<td>↓</td>
<td>PTHrP-producing solid tumors (squamous cell, renal bladder), lytic lesions (breast, myeloma), Paget dz</td>
</tr>
<tr>
<td>Other</td>
<td>↓</td>
<td>Meds (lithium, Vit A, thiazides, Ca-based antacids), massive dairy, consumption (milk–alkali syndrome), TPN, endocrine d/o (adrenal insufficiency, VIPoma)</td>
</tr>
</tbody>
</table>

*Most common causes of hypercalcemia.

History
› Polyuria, polydipsia, dehydration, nausea, vomiting, depression, confusion, coma, AMS; abdominal pain, anorexia, constipation, bone pain, Meds (see Differential table)
› May cause pancreatitis, nephrolithiasis, pathologic fractures thus suspect hypercalcemia in pts presenting w/ sxns consistent w/ these diagnoses

Physical Exam
› General weakness, epigastric tenderness, depressed deep tendon
reflexes, coma

**Diagnostics**

- Labs: BMP w/ Ca/Mg/Phosphorus testing, ionized Ca, lipase (if considering pancreatitis), urine electrolytes, albumin (see corrected Ca equation above), consider PTH
- ECG: *Shortened QTc*, PR prolongation, QRS widening; rarely BBB, sinus bradycardia or high-degree AV block

**Treatment**

- Address/treat underlying causes

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Dose</th>
<th>Onset/Duration</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>NS</td>
<td>4–6 L/d</td>
<td>Hours</td>
<td>Promote calcium excretion (Ca can drop 2 mEq)</td>
</tr>
<tr>
<td>Furosemide</td>
<td>20–60 mg IV q6h</td>
<td>Hours</td>
<td>Promotes calcium excretion; hold if intravascularly dry</td>
</tr>
<tr>
<td>Bisphosphonates (pamidronate, zoledronic acid, alendronate)</td>
<td>Variable</td>
<td>Days</td>
<td>Inhibit osteoclasts (esp useful in malignancy), caution in renal failure pt</td>
</tr>
<tr>
<td>Hypercalcemic antidote (calcitonin, plicamycin)</td>
<td>Calcitonin: 4 IU/kg q12h Plicamycin: 25 mcg/kg IV over 4 h</td>
<td>Hours, lasts days</td>
<td>Direct RNA inhibitor, may develop tachyphylaxis</td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>200–300 mg IV QD</td>
<td>Days</td>
<td>Useful only for Vit D toxic pts, multiple myeloma, sarcoid &amp; lymphoma pts</td>
</tr>
<tr>
<td>HD</td>
<td></td>
<td></td>
<td>Useful in renal failure pts</td>
</tr>
</tbody>
</table>

**Disposition**

- Home: Mild stable hypercalcemia
- Admit: Most will need admission until resolution

**Pearl**

- Hypercalcemia = stones, bones, moans, abdominal groans, & psychiatric overtones
Hypomagnesemia

Definition
- Mg <0.7 mmol/L

<table>
<thead>
<tr>
<th>Hypomagnesemia Differential</th>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac</td>
<td>CHF</td>
<td></td>
</tr>
<tr>
<td>GI</td>
<td>V/D, NGT suctioning, malabsorption</td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>Chronic renal failure (causing tertiary hypoparathyroidism)</td>
<td></td>
</tr>
<tr>
<td>Endocrine</td>
<td>Hyperaldosteronism, Vit D deficiency</td>
<td></td>
</tr>
<tr>
<td>Other/Meds</td>
<td>Alcoholism, pregnancy, thiazide &amp; loop diuretics, aminoglycosides, amphotericin, gentamicin, pentamidine, tobramycin</td>
<td></td>
</tr>
</tbody>
</table>

History
- Weakness, AMS, muscle cramps. Meds (see Differential table).

Physical Exam
- Tetany, Chvostek/Trousseau signs, papilledema, hyperreflexia

Diagnostics
- Labs: BMP w/ Ca/Mg/Phosphorus testing, ionized Ca, albumin, consider PTH for continued inpt w/u.
- ECG: Similar to hypokalemia & hypocalcemia (prolonged intervals, T-wave flattening, widening of QRS, U waves)

Treatment
- Address underlying cause
- Magnesium replacement: 50% magnesium sulfate 2–4 g (16.6–33 mEq) IV over 30 min. Oral form may cause diarrhea (eg, magnesium citrate, milk of magnesia).
- Alcoholics: Consider thiamine; phosphorous & potassium replacement as needed

Disposition
- Home: Mild hypomagnesemia
- Admit: Severe hypomagnesemia w/ other associated electrolyte abnormalities (potassium, calcium), comorbid conditions
Pearl
› Most exogenously administered Mg will be excreted in urine; full Mg replacement takes days

Hypermagnesemia
Definition
› Mg >3 mEq/L

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>GI</td>
<td>Chronic constipation, bowel obstruction</td>
</tr>
<tr>
<td>Renal</td>
<td>Acute or chronic renal failure</td>
</tr>
<tr>
<td>Autoimmune/endocrine</td>
<td>DKA, adrenal insufficiency, hyperparathyroidism, hypothyroidism</td>
</tr>
<tr>
<td>Other/Meds</td>
<td>Hemolysis, lithium, exogenous Mg infusions, opioids, anticholinergics, tumor lysis syndrome, milk–alkali syndrome, rhabdomyolysis</td>
</tr>
</tbody>
</table>

History
› Nausea, vomiting, lethargy, weakness, AMS; depends on level (renal insufficiency, GI motility disorder, adrenal insufficiency, hyperparathyroidism), Meds (anticholinergic, narcotic, lithium)

Physical Exam
› Depends on level
• Mg >3 mEq/L: N/V cutaneous flushing
• Mg >4 mEq/L: Hyporeflexia
• Mg >5 mEq/L: Hypotension
• Mg >9 mEq/L: Respiratory depression, shock, coma
• Mg >10 mEq/L: Asystole

Diagnostics
› Labs: BMP w/ Ca/Mg/Phosphorus testing, ionized Ca, albumin
› ECG: QRS widening, QT prolongation, prolonged AV conduction → complete block

Treatment
› Calcium:
• Immediate: Calcium gluconate IV or Calcium chloride (see hypocalcemia)
• Continuous: 10% Calcium gluconate 2–4 mg/kg/h if indicated
  ‣ Diuretics: Loop diuretics + aggressive hydration (improve excretion)
  ‣ Dialysis: Particularly for pts in renal failure

**Disposition**
  ‣ Home: Asymptomatic, stable
  ‣ Admit: All need admission until sx's & lab values have normalized

**Pearls**
  ‣ Magnesium abnormalities are often seen w/ K⁺ or calcium abnormalities
  ‣ Check serial DTRs to assess toxicity in preeclamptic pts receiving Mg

**Hypoglycemia**

**Definition**
  ‣ Glucose <60 mg/dL; however, clinical hypoglycemia is any plasma glucose level low enough to cause sx's or signs c/w hypoglycemia (see below). Usually <55 mg/dL causes sx.
  ‣ Whipple’s triad: Sign/sx's of hypoglycemia, low plasma glucose, resolution of sx when plasma glucose is raised

<table>
<thead>
<tr>
<th>Hypoglycemia Differential</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathophysiology</strong></td>
<td><strong>Differential</strong></td>
</tr>
<tr>
<td>Medications*</td>
<td>Insulin, sulfonylureas (glyburide, glipizide, glimepiride), Meglitinides (repaglinide, nateglinide), alcohol</td>
</tr>
<tr>
<td>GI</td>
<td>Liver failure, post-gastrectomy/gastric bypass</td>
</tr>
<tr>
<td>Renal</td>
<td>ARF</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Hypothyroidism, insulinoma (including MEN-1), hypopituitarism, adrenal insufficiency, insulin autoimmune hypoglycemia (Ab to insulin or its receptor)</td>
</tr>
<tr>
<td>Other</td>
<td>Sepsis, starvation, accidental/surreptitious/malicious hypoglycemia</td>
</tr>
</tbody>
</table>

*Most common cause of hypoglycemia.
History

- Neurogenic/autonomic sx: Agitation, tremor, diaphoresis, palpitations, pallor, hunger
- Neuroglycopenic sx: Fatigue, HA, AMS, lethargy, somnolence, coma, sz
- Take detailed med hx (see Differential table); consider new meds, med dose changes, incorrect use, intentional/accidental overdose, OTC/naturopathic meds, AKI
- Diabetics: Inquire recent FSG values (if taken), last meal, dietary changes, excess exercise
- ROS of contributing causes: Fever, chills, cough, abdominal pain, diarrhea, urinary sx, etc.
- RFs: Diabetics (esp on insulin), alcoholics, infants, elderly, s/p gastric bypass, critically ill

Diagnostics

- Labs: FSG, BMP; consider infectious w/u (CBC, UA, CXR)

* In o/w healthy, nondiabetics, consider LFTs, TSH, insulin, β-hydroxybutyrate, proinsulin, & C-peptide (low in exogenous insulin, high in insulinoma or sulfonylureas) in consultation w/ an endocrine specialist

- Serial glucose assessments may be necessary when prolonged hypoglycemia is expected in pts unable to communicate (eg, dementia, delirium, comatose, infants)

Treatment

- Glucose replacement:
  - PO: Glucose paste/tablets (20 g), fruit juice, soft drinks, candy, a meal, etc.
  - IV: 1 amp D50; infusion may be needed
  - IM: 0.5–1 mg IM or SC glucagon (may cause N/V)

Disposition

- Home: Identifiable cause, does not need further monitoring
  - Prompt f/u w/ primary care or endocrinologist should be arranged
  - Pts should keep a glucose diary & should become concerned about the possibility of developing hypoglycemia when self-monitored glucose levels fall rapidly or is no greater than 70 mg/dL
- Admit: Long-acting hypoglycemic agents, unable to tolerate POs,
HD unstable

**Pearls**
- βBs can mask adrenergic signs of hypoglycemia
- Efforts should be made to contact pt’s primary physician or endocrinologist


---

### HYPERGLYCEMIC EMERGENCIES (DKA/HHS)

<table>
<thead>
<tr>
<th>Criteria for Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State</th>
<th>DKA (glucose &gt;250 mg/dL)</th>
<th>HHS (glucose &gt;600 mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mild</td>
<td>Moderate</td>
</tr>
<tr>
<td>Arterial pH</td>
<td>7.25–7.30</td>
<td>7–&lt;7.24</td>
</tr>
<tr>
<td>Serum bicarbonate (mEq/L)</td>
<td>15–18</td>
<td>10 to &lt;15</td>
</tr>
<tr>
<td>Urine ketone</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Serum ketone</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Serum osmolality</td>
<td>Variable</td>
<td>Variable</td>
</tr>
<tr>
<td>Anion gap</td>
<td>&gt;10</td>
<td>&gt;12</td>
</tr>
<tr>
<td>Mental status</td>
<td>Alert</td>
<td>Alert/drowsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


### Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State

**Definition**
See above for consensus diagnostic criteria. DKA characterized by uncontrolled hyperglycemia, metabolic acidosis, & increased ketone body concentration. HHS characterized by profound hyperglycemia & serum hyperosmolality, nl arterial pH & bicarbonate, & AMS. Marked by insulin deficiency & increased counter-regulatory hormones. HHS generally occurs in Type II diabetes; DKA generally occurs in Type I diabetes, but may occur in Type II diabetes w/ stressors:

### 5 I's of DKA

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin deficiency</td>
<td>New-onset T1DM, failure to take enough insulin</td>
</tr>
<tr>
<td>Infection*</td>
<td>Pneumonia, UTI, cellulitis, etc.</td>
</tr>
<tr>
<td>Inflammation</td>
<td>Pancreatitis</td>
</tr>
<tr>
<td>Intoxication</td>
<td>Alcohol, drugs</td>
</tr>
<tr>
<td>Iatrogenesis</td>
<td>Glucocorticoids, thiazides, sympathomimetics, antipsychotics</td>
</tr>
<tr>
<td>Other</td>
<td>AMI, CVA, eating d/o in pts w/ T1DM</td>
</tr>
</tbody>
</table>

*Most common precipitating factor.

### History

- DKA often more acute in onset, c/w HHS which evolves over days to weeks
- Polyuria, polydipsia, N/V, dehydration, weight loss, abdominal pain, visual changes, AMS
- Take detailed med hx (see *Differential table*); consider new meds, med dose changes, incorrect use, intentional/accidental overdose, OTC/naturopathic meds, insulin pump use
- ROS of contrib causes: Fever, chills, cough, abdominal pain, diarrhea, urinary sx, depression
- RFs: Insulin pump users

### Physical Exam

- Appears dry, Kussmaul respiration, lethargy, coma; abdominal tenderness (ileus)
**Evaluation**

- Labs: FSG, BMP (elevated anion gap acidosis, pseudohyponatremia, total body K⁺ generally depleted despite lab value), Ca/Mg/Phosphorus, urine/serum ketones, β-hydroxybutyrate, nitroprusside test, UA, CBC, lactate, lipase, LFTs, serum osmolality, VBG, urine hCG; ABG if HD unstable or comatose; blood cultures, urines cultures if clinically indicated

**Equations**

<table>
<thead>
<tr>
<th>Equation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anion gap (AG) = (Na – (Cl + bicarb))</td>
<td></td>
</tr>
<tr>
<td>Corrected AG = AG + (2.5 × [4.2 – albumin])</td>
<td></td>
</tr>
<tr>
<td>Calculated Osm = (2 × [Na⁺]) + glucose/18 + BUN/2.8 + Ethanol/4.6</td>
<td></td>
</tr>
<tr>
<td>Corrected Na = Serum Na + [0.016 × (serum glucose – 100)]</td>
<td>(&lt;up to 400 mg/dL; for glucose &gt;400 mg/dL, 4 mEq/L should be added to every additional 100 mg/dL)</td>
</tr>
</tbody>
</table>

- ECG: If older than 30 yr
- Imaging: CXR (r/o infection); may need abdominal CT or U/S if clinically indicated

**Treatment**

- Supportive: Continuous cardiac monitoring, 2 large-bore IVs
- Electrolyte monitoring: Glucose fingerstick q1h; BMP, Ca/Mg/Phosphorus, VBG q2–4h

**Acute Treatment**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dose/Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV hydration***</td>
<td>NS bolus + NS 15–20 cc/kg/h (adjust for dehydration &amp; cardiovascular status); usually 1–1.5 L during 1st hour →Continue NS 250–500 cc/h if corrected Na low →Δ IVF to ½ NS 250–500 cc/h if corrected Na nl or high →Δ IVF to D5 ½ NS 150–250 cc/h when glucose ≤200 mg/dL</td>
</tr>
<tr>
<td>Insulin</td>
<td>0.1 U/kg (regular insulin) IV push × 1, followed by 0.1 U/kg/h Persistent anion gap: Continue drip Resolution of anion gap: Change to SC insulin (overlap IV w/ SC by 1–2 h) →When glucose ≤200 mg/dL in DKA &amp; ≤300 mg/dL in HHS, reduce insulin infusion to 0.02–0.05 U/kg/h IV, or Δ to rapid</td>
</tr>
</tbody>
</table>
acting insulin at 0.1 U/kg q2h

| Electrolyte repletion | Potassium: Goal to maintain K⁺ 4–5 mEq/L → Add 20–40 mEq/L IVFs if serum K⁺ <4.5 (insulin promotes K⁺ entry into cells, but careful w/ renal pts) → Hold insulin & give K⁺ 20–40 mEq/h if K⁺ <3.3 HCO₃⁻: If cardiac unstable or pH <7 Phosphate: Replete if <1 (20–30 mEq/L KPhos added to IVF) |

*After volume resuscitation, choice of fluid replacement will depend on hemodynamics, hydration status electrolytes, etc.

**IVF volume should be used w/ caution in pts w/ cardiac or renal impairment.


Disposition
- Home: None
- Admit: All pts will require admission, may need ICU monitoring

Pearls
- ~10% of the DKA population may present w/ glucose ≤250 mg/dL
- An initial insulin bolus may not be necessary as some pts respond to fluid resuscitation
- Consider increasing continuous insulin dose if glucose does not decrease 50–75 mg/dL/h
- Tx w/ SC rapid-acting insulin q1–2h is an effective alternative to IV regular insulin
- Cx: Hypoglycemia, hypokalemia, fluid overload, cerebral edema

THYROID EMERGENCIES

Hypothyroidism/Myxedema Coma

Definition
- Hypothyroidism is characterized by insufficient production of thyroid hormone by the thyroid gland. Cretinism is a form of hypothyroidism found in infants.
- Hypothyroidism can be classified on the basis of its time of onset
(congenital or acquired), the level of endocrine Dysfxn (1° [thyroid] or 2° [pituitary or hypothalamic]), & its severity (subclinical, clinical, severe [myxedema coma])

- Myxedema coma is a rare, extreme expression of severe hypothyroidism. Myxedema coma typically occurs in pts who develop systemic illness superimposed on previously undiagnosed hypothyroidism.

### Hypothyroidism Differential

<table>
<thead>
<tr>
<th>Cause</th>
<th>Endocrine</th>
<th>Iatrogenic</th>
<th>Meds/toxins</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hashimoto (autoimmune thyroiditis), subacute thyroiditis (de Quervain’s thyroiditis), lymphocytic thyroiditis (postpartum thyroiditis), hypothalamic or pituitary failure, iodine deficiency</td>
<td>Surgical removal &amp; XRT</td>
<td>Radioactive iodine (therapeutic or environmental), amiodarone, lithium, stavudine, interferon α, polybrominated/polychlorinated biphenyls, resorcinol (textile workers)</td>
<td>Congenital hypothyroidism (endemic iodine deficiency, thyroid gland dysgenesis, defective thyroid hormone biosynthesis); hemochromatosis</td>
</tr>
</tbody>
</table>


### Factors Precipitating Myxedema Coma

- Infection (sepsis, PNA, UTI)
- CVA
- CHF
- Hypothermia
- GIB
- Trauma, burns
- Metabolic disturbances (hypoglycemia, hyponatremia, acidosis, hypercapnia, hypercalcemia)
- Meds (anesthetics, sedatives, opioids, amiodarone, lithium, withdrawal of L-thyroxine)
- Ingestion of raw bok choy


### History

- Hypothyroidism: Weakness, fatigue, myalgias, HA, depression, cold intolerance, weight gain, constipation, menorrhagia, dry skin, brittle
Myxedema coma: Severely altered mental status/coma
Meds (see Differential table)
RFs: Postpartum women, family h/o autoimmune thyroid disorders, prior H&N surgery or irradiation, other autoimmune disorders (ie, Type 1 DM, adrenal insufficiency, autoimmune polyendocrine syndrome types 1 & 2 etc.), Down’s syndrome, Turner’s syndrome

Physical Exam
- Hypothyroidism: Obese, delayed DTRs, diastolic HTN, dry, thick skin SQ tissue (myxedema), bradycardia, pl/pericardial/peritoneal effusion, hypothermia, hypotension, hypoventilation, altered sensorium
- Myxedema coma: Hypothermia & severely altered mental status/coma are hallmark
- Vitals/Pulm/CV: Hypothermia, hypoventilation, hypoxia, hypotension, or bradycardia
- HEENT: Facial swelling, periorbital edema, macroglossia
- Neuro: Lethargy → comatose, cerebellar signs, poor memory & cognition, delayed reflexes
- Psych: “Myxedema madness” disorientation, paranoia, depression, hallucinations, etc.

Evaluation
- Labs: TFTs (TSH elevated); BMP (hyponatremia, hypoglycemia), CBC (anemia); consider T4, free T4, T3, antimicrosomal Ab, antithyroid peroxidase Ab, antithyroglobulin Ab
  - ↑ TSH, ↓ free T4 confirms primary hypothyroidism of any cause
  - ↑ TSH, ↓ free T4, +antithyroid abs confirms Hashimoto thyroiditis
  - variable TSH, ↓ free T4 consistent w/ secondary hypothyroidsm disorders
  - mild ↑ TSH, nl free T4, & subtle sx consistent w/ subclinical hypothyroid
- ECG: Myxedema-bradycardia, AV block, low voltage, flattened/inverted T-waves, prolonged QTc, atrial/ventricular dysrhythmias.
- Bedside cardiac u/s: Pericardial effusion/tamponade may be seen in myxedema
Treatment (Only Start Empiric Treatment if Severely Symptomatic/Coma)

- Thyroid replacement: (Start in ED if severely symptomatic/coma)
  - Levothyroxine: 5–8 mcg/kg IV × 1, then 50–100 mcg QD; consider synthetic T3 5–10 mcg IV q8h (b/c peripheral conversion impaired, but is more arrhythmogenic)
  - Adrenal replacement: Hydrocortisone 100 mg IV × q8h (decreased reserve in coma)

Disposition

- Home: Discuss w/ PCP prior to starting any thyroid medications; usual starting dose of Levothyroxine 1.8 μg/kg PO QD (required repeat TFTs at 4–6 wk)
- Admit: All pts w/ severe hypothyroidism/myxedema; may require ICU admission

Thyrotoxicosis/Hyperthyroidism/Thyroid Storm

Definition

- Thyrotoxicosis is a disorder of excess thyroid hormone
- Hyperthyroidism specifically describes overproduction & secretion of excess of free thyroid hormones: Thyroxine (T₄), triiodothyronine (T₃), or both
- Thyroid storm/crisis is a rare, extreme expression of severe thyrotoxicosis
- Precise criteria for thyroid storm have been defined (Endocrinol Metab Clin North Am 1993;22: 263–277)

<table>
<thead>
<tr>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyrotoxicosis w/ Hyperthyroidism</td>
</tr>
<tr>
<td>Endocrine</td>
</tr>
<tr>
<td>Neoplasm</td>
</tr>
<tr>
<td>Other/Meds</td>
</tr>
</tbody>
</table>

Thyrotoxicosis w/o Hyperthyroidism
### Thyroiditis

<table>
<thead>
<tr>
<th>Thyroiditis</th>
<th>Early Hashimoto (autoimmune thyroiditis), subacute thyroiditis (de Quervain’s thyroiditis), lymphocytic thyroiditis (postpartum thyroiditis), acute infectious thyroiditis, drug-induced thyroiditis (amiodarone, lithium, interferon α), radiation thyroiditis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other</td>
<td>Exogenous thyroid hormone, “Hamburger” thyrotoxicosis, infarction of thyroid adenoma</td>
</tr>
</tbody>
</table>

*Most common cause of hyperthyroidism caused by autoantibodies to & stimulation of TSH receptors.

**Next most common causes of hyperthyroidism caused by autonomous overproduction of thyroid hormone secondary to activating mutations in TSHR or a focus of functional autonomy, respectively.


### Factors Precipitating Thyroid Storm

<table>
<thead>
<tr>
<th>Factors Precipitating Thyroid Storm</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Infection (sepsis)</td>
</tr>
<tr>
<td>• Sz</td>
</tr>
<tr>
<td>• PE</td>
</tr>
<tr>
<td>• Parturition</td>
</tr>
<tr>
<td>• Emotional stress</td>
</tr>
<tr>
<td>• Trauma (including vigorous thyroid palpation), burns</td>
</tr>
<tr>
<td>• Postthyroidectomy</td>
</tr>
<tr>
<td>• Metabolic disturbances (hypoglycemia, DKA)</td>
</tr>
<tr>
<td>• Meds (amiodarone, radioactive iodine tx, iodinated contrast, thyroxine/triiodothyronine OD, ASA OD, withdrawal of PTU/methimazole)</td>
</tr>
</tbody>
</table>


### History

- Neck fullness, double vision, restlessness, anxiety, palpitations, sweating, heat intolerance, tremor, weight loss, diarrhea, irregular menses, periodic paralysis, lethargy, hair thinning/loss
- Thyroid storm: AMS (delirium, agitation, coma), sz, fever, tachycardia, N/V, diarrhea
- Meds (see Differential table; assess h/o hyperthyroidism)

### Physical Exam

- Thyrotoxicosis: Cachexia, diaphoretic, agitation, tremor, tachycardia, AFib, systolic HTN, widened pulse pressure
- Thyroid storm: Hyperthermia & severely AMS are hallmark
- Vitals/Pulm/CV: Hyperthermia, hyperventilation, tachycardia
- GI: Nausea, vomiting, diarrhea, diffuse abdominal pain (may mimic acute abdomen)
Neuro: AMS (delirium, agitation, coma), sz
Psych: Disorientation, paranoia, psychosis, etc.

Evaluation
- Labs: TSH (low) w/ elevated free T4 (if TSH low & free T4 nl, free or total T3 concentration should also be measured to identify potential T3 toxicosis; consider thyroxine-binding globulin in pregnancy); BMP/Ca/Mg/Phosphorus, LFTs, UA, urine hCG; consider TRH or thyroid peroxidase
- ECG: Tachycardia, supraventricular ectopy, AFib

Treatment (Only Start ED Treatment if Severely Symptomatic/Thyroid Storm)
- Thyrotoxicosis: Therapies include antithyroid meds (methimazole/PTU), radioiodine, surgery
- Thyroid storm: βB → PTU or methimazole → iodine or lithium → steroids w/ supportive care
  - βB: Propranolol or esmolol (improve α-adrenergic activity & tachycardia)
    - Propranolol 1 mg IV over 10 min, then 1–3 mg boluses q3h
    - Propanolol 60–80 mg q4h if taking PO
    - Esmolol 250–500 mcg/kg loading dose, then 50–100 mcg/kg/min
  - PTU: Blocks hormone synthesis, inhibits peripheral conversion of T4 to T3
    - Loading dose of 500–1000 mg, then 250 mg q4h
    - Preferred to methimazole, particularly if pregnant & 1st trimester
  - Methimazole: Blocks hormone synthesis
    - Dose 20 mg q4h (60–80 mg/d)
    - Pts should receive baseline CBC & LFTs prior to tx
  - Iodine: Blocks thyroid hormone release but give >1 g after PTU (can potentiate thyroid storm if given before)
    - Potassium iodide 5 drops (0.25 mL or 250 mg) PO q6h
    - For iodine allergic pts, can use lithium carbonate 300 mg 6 h
  - Steroids: Hydrocortisone 100–300 mg IV bolus, then 100 mg IV × q8h (can decrease conversion of T4–T3)
  - Consider plasmapheresis & therapeutic plasma exchange (Graves’ dz)
Supportive care: Hyperpyrexia – APAP as needed; avoid aspirin (can increase T3 conversion)
- Treat underlying precipitant (often infection)

**Disposition**
- Home: TSH low but no severe sx: F/u w/ PCP or endo RE: outpt meds ± surgery.
- Admit: All pts w/ severe hyperthyroidism. Pts w/ thyroid storm require ICU admission.


**ADRENAL INSUFFICIENCY**

**Definition**
- Condition in which the adrenal glands, do not produce adequate amounts of steroid hormones, primarily cortisol, but may also include impaired aldosterone production.
- Primary adrenal insufficiency (Addison’s dz) refers to pathology of the adrenal cortex, where secondary adrenal insufficiency may occur as a result of pituitary or hypothalamic dzs.

<table>
<thead>
<tr>
<th>Adrenal Insufficiency Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cause</strong></td>
</tr>
<tr>
<td>Infiltrative dz</td>
</tr>
<tr>
<td>Tuberculosis, CMV, histoplasmosis/cryptococcosis/blastomycosis, amyloidosis, sarcoidosis, histiocytosis AIDS (opportunistic dz)</td>
</tr>
<tr>
<td>Vascular*</td>
</tr>
<tr>
<td>Hemorrhage, thrombosis, necrosis (meningococcemia, sepsis, <strong>APLAS)</strong></td>
</tr>
<tr>
<td>Endocrine</td>
</tr>
<tr>
<td>Autoimmune adrenalitis (alone or as component of autoimmune polyglandular syndromes types 1 &amp; 2), pituitary failure</td>
</tr>
<tr>
<td>Neoplasm</td>
</tr>
<tr>
<td>Metastatic dz (lung, breast, kidney), lymphoma, pituitary tumor (primary or mets), craniopharyngioma, hypothalamic tumors</td>
</tr>
<tr>
<td>Meds</td>
</tr>
<tr>
<td>Ketoconazole, etomidate, rifampin, anticonvulsants, megestrol, glucocorticoid withdrawal</td>
</tr>
</tbody>
</table>
Other* | Trauma (esp head trauma, burns) postpartum pituitary necrosis (Sheehan’s syndrome), empty sella syndrome, pituitary radiation/surgery

*Causes of acute onset adrenal insufficiency.
**APLAS: Antiphospholipid antibody syndrome.

- Dysfn of the hypothalamic–pituitary–adrenal axis in critical illness is termed critical illness-related corticosteroid insufficiency (CIRCI)

**History**
- Weakness, fatigue, anorexia, nausea, vomiting, presyncope, craving for salt
- Meds (see Differential table); also elicit if pt is on chronic steroids at baseline

**Physical Exam**
- Orthostatic hypotension, hyperpigmentation, vitiligo

**Evaluation**
- Labs: BMP (may see hypoglycemia, hyponatremia, hyperkalemia, acidosis), CBC (may see mild normocytic anemia, lymphocytosis, & eosinophilia); send serum cortisol/ACTH level for inpt w/u
  - Serum cortisol >25 μg/dL in a pt requiring intensive care likely rules out adrenal insufficiency
  - CIRCI is best diagnosed by a delta cortisol (after 250 μg cosyntropin) of <9 μg/dL or a random total cortisol <10 μg/dL
  - ACTH stimulation test is rarely used in the ED
- Imaging: Consider head MR (assess pituitary), adrenal CT

**Treatment (Only Start ED Treatment if Symptomatic/Hypotensive)***
- Steroids: Hydrocortisone 100 mg IV bolus, followed by continuous infusion at 10 mg/h; may also give 200 mg/d in 4 divided doses
- IV hydration: Volume resuscitation w/ nl saline
- Steroids (particularly, hydrocortisone) should be considered in the management strategy of pts w/ septic shock, particularly those pts who have responded poorly to fluid resuscitation & vasopressors (SBP <90, despite IVF & vasopressors)
Disposition

- Home: Stable, already on meds
- Admit: All pts w/ new onset adrenal insufficiency; may require ICU admission if concomitant infection or HD unstable

Pearls

- Acute adrenal insufficiency should be suspected in the presence of fluid & pressor-refractory hypotension, esp in a pt w/ signs & sx as noted above
- Pts w/ known adrenal insufficiency & concomitant febrile illness should be instructed to increase their home dose of steroid by 2–3 times until recovery to prevent possible adrenal crisis. Stress dose steroids can be given in the ED prior to disposition.

DEHYDRATION

Approach
- Careful hx: Understand whether pt has had excessive fluid loss or inadequate intake
- Attempt to quantify fluid deficit
- Check FSG to r/o hypoglycemia, electrolytes

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac</td>
<td>Arrhythmia (1f)</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Adrenal insufficiency, DI, DKA, SIADH, thyroid Dysfxn</td>
</tr>
<tr>
<td>Infectious</td>
<td>Encephalitis (4b), meningitis (4b), Lyme dz (4h), sepsis (16b), syphilis (4)</td>
</tr>
<tr>
<td>GI</td>
<td>Bowel obstruction, diarrhea, gastroenteritis, intestinal volvulus, vomiting, GIB</td>
</tr>
<tr>
<td>FEN/GU</td>
<td>Electrolyte disturbances, renal insufficiency</td>
</tr>
<tr>
<td>Neurologic</td>
<td>GBS, myasthenia gravis, ALS, stroke, migraine</td>
</tr>
<tr>
<td>Hematologic/oncologic</td>
<td>Metastatic dz</td>
</tr>
<tr>
<td>Toxic</td>
<td>Drug induced</td>
</tr>
<tr>
<td>Environmental</td>
<td>Hyperthermia</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>Anorexia, bulimia, laxative abuse, psychosis</td>
</tr>
</tbody>
</table>

History
- Excessive fluid loss (V/D, sweating, polyuria, diuretic/laxatives, bowel regimen), inadequate intake (debilitated, institutionalized, NM d/o, H&N pathology), altered thirst mechanism (intoxication, systemic illness, malignancy, antipsychotic use)

Findings
• ↑ HR w/ standing (Δ >20 bt/min lying → standing) 75% sens & spec; skin tenting, dry MM

Evaluation
• CBC (hemoconcentration), BMP (↓ bicarb, ↑ BUN/Cr, abnl Na, K), ECG abnl
• UA: Ketones, hyaline casts, spec grav >1.02: Uroconcentration, >1.03 = Severe dehydration

Treatment
• Initial fluid resuscitation w/ NS or LR (avoid NS if concern for hyponatremia), then tailor to electrolyte abnlty/pathology (labor: Nonglucose IVF, malnourishment: D5 NS)
• nl LV fxn: 2–3 L NS, follow clinical sxss, VS, UOP
• Compromised LV fxn: 500 cc/h, watch pulmonary status (O₂ sat, SOB)
• Consider antiemetic if N/V contributes to dehydration

Disposition
• Home once dehydration adequately treated unless concerning electrolyte abnormalities, pt able to maintain hydration status
• Consider care coordination/placement if pt lives alone & unable to hydrate self

Pearls
• Up to 30% of healthy pts are orthostatic w/o dehydration (βBs, autonomic Dysfxn (DM))
• Oral rehydration w/ glucose to facilitate intestinal absorption of Na & water if pt tolerates, “recipe” is 2 tbl sugar: 0.5 tsp salt: 1 quart water; ½ dilute apple juice also effective
• Healthy adults tolerating PO rarely require IVF & PO rehydration is usually adequate

<table>
<thead>
<tr>
<th>Types of Dehydration</th>
<th>Losses</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypotonic</td>
<td>Na loss &gt; water loss</td>
<td>Diuretics</td>
</tr>
<tr>
<td>Isotonic</td>
<td>Na loss = water loss</td>
<td>Vomiting, diarrhea</td>
</tr>
<tr>
<td>Degrees of Dehydration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Degree</strong></td>
<td><strong>Fluid Deficit</strong></td>
<td><strong>Sxs</strong></td>
</tr>
<tr>
<td>Mild</td>
<td>30 cc/kg (3%)</td>
<td>Thirst, fatigue</td>
</tr>
<tr>
<td>Moderate</td>
<td>50–60 cc/kg (5–6%)</td>
<td>Dry mucous membranes, ↓ skin turgor, symptomatic when standing</td>
</tr>
<tr>
<td>Severe</td>
<td>70–90 cc/kg (7–9%)</td>
<td>Symptomatic when lying down, ↓ mentation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Composition of Resuscitation Fluids</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1 L Fluid</strong></td>
</tr>
<tr>
<td>NS</td>
</tr>
<tr>
<td>Ringer’s lactate</td>
</tr>
<tr>
<td>D$_5$W</td>
</tr>
<tr>
<td>D$_5$W ½ NS</td>
</tr>
<tr>
<td>3% NS</td>
</tr>
</tbody>
</table>

**BITES AND STINGS**

**Approach**
- Treat anaphylaxis; give tetanus prophylaxis
- Consider x-ray for underlying fx or FB
- Assess for joint space violation, copious wound irrigation/wash out w/ NS; if heavily contaminated, do not close
- 24–48 h wound check for high-risk bites, esp in kids or unreliable pts
- National Poison Control Center (PCC): (800) 222-1222
**Human & Animal Bites**

**Human**

**History**
- Laceration near MCP joint during altercation should be considered a human bite (“fight bite”); bacteria spread along tendon sheath deep into hand

**Evaluation**
- Consider x-ray to assess for fracture, air in joint, tooth fragments; no serology needed
- Extend & explore periarticular MCP joint injuries, including in that position that injury occurred

**Treatment**
- Preferred regimen: Amoxicillin/Clav acid) 875/125 mg BID × 5–10 d
- Alternatives: Doxycycline or TMP-SMX or pen VK or fluoroquinolone or cefuroxime PLUS clindamycin or metronidazole
- If late/complicated/needs admit, IV ampicillin/sulbactam 1.5 g q6h
- Delayed 1° closure if closure needed

**Disposition**
- Scheduled strict f/u in 24–48 h

**Pearl**
- *Eikenella* (most common), *Staph/Strep* species found in mouth, anaerobes

**Cat**

**Evaluation**
- Consider x-ray to assess for fracture, air in joint, tooth fragments
- Extend & explore joint injuries including in the position that injury occurred

**Treatment**
- Amoxicillin/Clav Acid 875/125 mg BID, cefuroxime 500 mg BID or doxycycline 100 mg BID
- Delayed 1° closure only if cosmetically needed; 80% of cat bites become infected!
Disposition
- Scheduled strict f/u in 24 h

Pearls
- *Pasteurella multocida* most common organism
- Consider cat-scratch dz if pt has tender LAD 1 wk after bite/scratch
- Very high infection rate despite abx use
- Consider rabies prophylaxis (rabies immunoglobulin + vaccine) if unknown cat (4i)

Dog
Evaluation
- Consider x-ray to assess for fracture, air in joint, tooth fragments

Treatment
- Amoxicillin/Clav acid 875/125 mg BID or clindamycin 300 QID + ciprofloxacin 500 mg BID
- 1° closure after copious irrigation possible except on hand/foot; only 5% become infected

Disposition
- Scheduled strict f/u in 24 h

Pearls
- Polymicrobial infections
- Consider rabies prophylaxis if unknown dog as above w/ cats (4i)

Snake Bites

Crotalinae/Pit Vipers (*Rattlesnakes, Copperheads, Water Moccasins*)

History
- Pain & swelling around fang marks, attempt identification of snake if possible

Findings
- Local (pain, swelling, ecchymosis), systemic (↓ BP, ↑ HR, paresthesias), coagulopathy (↓ PLTs, ↑ INR, ↓ fibrinogen), pulmonary edema, acidosis, rhabdomyolysis, neuromuscular
weakness if Mojave rattlesnake

**Evaluation**
- Consult PCC/toxicologist; CBC, BMP, coags w/ fibrinogen & split products, CK, T&C, x-rays to r/o retained fang; watch compartment pressures

**Treatment**
- Remove rings, constrictive clothing, general wound care, tetanus
- Antivenom (Crotalidae) if systemic effects or coagulopathy; surgical assessment if compartment syndrome; supportive care; no proven benefit w/ abx or steroids

**Disposition**
- D/C if absence of any findings 8–12 h post bite envenomation in healthy adults, 12–24 h in children/elderly, 12–24 h if concerns for Mojave rattlesnake
- ICU admission if antivenom given

**Pearls**
- Avoid oral or mechanical suction of wound, tourniquets, incision, & suction
- 25% of bites are “dry strikes” (no effect); pit vipers identified by 2 fangs

<table>
<thead>
<tr>
<th>Grade</th>
<th>Signs/Sxs</th>
<th>Vials of Antivenom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>Local pain, edema. No signs of systemic tox. nl labs.</td>
<td>None</td>
</tr>
<tr>
<td>Moderate</td>
<td>Severe local pain, edema &lt;50 cm around wound. Systemic tox: N/V. Labs abnl (↓ Hct, ↓ PLTs).</td>
<td>4–6</td>
</tr>
<tr>
<td>Severe</td>
<td>Generalized petechiae/ecchymosis, compartment sx, bleeding, ↓ BP, AMS, renal dysfxn, markedly abnl coags</td>
<td>Initial dose 8–12</td>
</tr>
</tbody>
</table>

**Elapidae/Coral Snake (Micrurus fulvius)**

**History**
- Bitten by brightly colored snake (black, red, & yellow bands), primarily in tx, FLA

**Findings**
- Neurotoxic effects from venom: Tremor/sz, ↑ salivation, respiratory paralysis, bulbar palsy (dysarthria, diplopia, dysphagia), usually less local tissue damage than Crotalinae

**Evaluation**
- Consult PCC/toxicologist; CBC, BMP, coags/DIC eval not usually indicated, consider pulmonary fxn testing

**Treatment**
- Consult PCC before giving antivenom as higher risk for allergic rxn; surgical assessment if concern for compartment syndrome; supportive care (esp respiratory support)

**Disposition**
- 12–24 h observation; ICU admission if antivenom given or respiratory compromise

**Pearl**
- True coral snakes have red on yellow banding, nonvenomous snakes have red band on black background: “Red on yellow: Kill a fellow. Red on black: Poison lack.”

---

**SCORPION BITES**

**Scorpion (Centruroides exilicauda)**

**History**
- Burning & stinging w/o visible injury at bite site

**Findings**
- Usually no visible local injury; possible systemic effects include roving eye movements (pathognomonic), opisthotonos, ↑ HR, diaphoresis, fasciculations
- Mydriasis, nystagmus, hypersalivation, dysphagia, restlessness
- Severe envenomation may cause pancreatitis, respiratory failure, coagulopathy, anaphylaxis

**Evaluation**
- “Tap test”: Exquisite tenderness w/ light tapping in exilicauda stings; consult PCC/toxicologist
- CBC, BMP, coags, LFTs, CK, ECG
Treatment
- Most bites are self-limited, provide supportive care
- BZD for muscle spasm/fasciculations, pain control, tetanus, reassurance
- If severe systemic sxhs, 1–2 vials scorpion antivenom; avail from AZ PCC

Disposition
- Admission for observation; ICU admission if antivenom given

Pearl
- Only *C. exilicauda* (bark scorpion) found in Western US produces systemic toxicity

---

**Spider Bites**

**Brown Recluse (*Loxosceles reclusa*)**

**History**
- Pt may not remember bite & initially have no pain; pain & pruritus develops over 2–8 h
- Severe rxn: Immediate pain & blister formation, necrosis & eschar over next 3–4 d
- Loxoscelism: Systemic rxn 1–3 d after envenomation; N/V, f/c, muscle/joint aches, sz, rarely renal failure, DIC, hemolytic anemia, rhabdomyolysis

**Findings**
- Necrotic blister w/ surrounding erythema, petechiae

**Evaluation**
- Consult PCC/toxicologist, surgery/plastics consult for lesion >2 cm
- CBC, BMP, coagulation profile, UA

**Treatment**
- No antivenom; wound care, tetanus, supportive care (eg, hydration, abx, transfusion, HD), local debridement
- May consider dapsone 50–100 mg BID to prevent necrosis, hyperbaric O₂, steroids (all are controversial)
- Dapsone causes hemolysis, hepatitis; monitor LFTs, check G6PD
Disposition
- Admission for observation

Pearl
- Located in S. Central & SW (desert) of US; violin-shaped marking on back

**Black Widow (Latrodectus mactans)**

History
- Immediate pain, then swelling, possible target-shaped lesion, can have unexplained severe abd/back pain, muscle cramps w/i 1 h
- Pain may continue intermittently for 3 days, is often a/w muscle weakness & spasm for wk to mo

Findings
- Severe rxns: HTN, respiratory failure, abd rigidity, fasciculations, shock, coma

Evaluation
- CBC, BMP, CK, coagulation profile, UA, abd CT (r/o acute abdomen), ECG

Treatment
- Antivenom if severe rxn: 1–2 vials over 30 min (after cutaneous test dose)
- Wound care, tetanus, supportive care: BZD, analgesia

Disposition
- Consider admission for observation & pain control

Pearls
- Painful abd muscle cramps can mimic peritonitis
- Red hourglass-shaped marking on spider’s abdomen

---

**Hymenoptera (Bee, Wasp, Stinging Ant)**

History
- Immediate pain & swelling at site of bite

Findings
Local & systemic signs of allergic rxn can occur

**Treatment**
- Treat anaphylaxis/allergic rxn; local rxn treated w/ cleansing, ice packs, & elevation
- If present, stinger should be removed immediately by scraping it from the wound (bees)

**Disposition**
- Close wound care f/u; prescribe epinephrine auto-injectors in cases of anaphylaxis

**Pearls**
- The more rapid onset of sxes, the more severe the rxn; IgE-mediated allergic rxn
- Rapid onset: 50% D in 30 min, 75% in 4 h; usually see fatal rxn following prior mild rxn
- Delayed rxn similar to serum sickness can present 10–14 d after a sting/bite

---

**JELLYFISH STINGS**

**History**
- Swimming in seawater w/ jellyfish

**Findings**
- Painful papular lesions & urticarial eruptions last min to h
- Systemic rxns rare; vomiting, muscle spasm, paresthesias, weakness, fever, respiratory distress, Irukandji syndrome: Rare, severe chest/abd/back pain, HTN, GI sx

**Evaluation**
- CBC, BMP, CK, coagulation profile, ECG

**Treatment**
- Analgesia, supportive care
- Tentacles should be removed w/ forceps; nematocysts should be scraped off w/a knife/blade after dusting w/ talcum powder & covering w/ shaving cream
Analgesia & after nematocyst removal wash w/ hot (40°C) salt water (helps w/ pain)
Antivenom available for serious systemic effects (cardiopulmonary arrest, severe pain) from the Commonwealth Serum Laboratory in Melbourne, Australia

Disposition
D/C if mild & pain controlled, admission for observation o/w

Pearls
Box jellyfish are severely toxic, can induce respiratory & myocardial arrest in min
Use seawater/acid/vinegar (not urine!) to wash; freshwater causes nematocysts to fire

OCCUPATIONAL EXPOSURE

Approach
Institutional guidelines vary regarding occupational exposures of HC workers to bodily fluids
Refer to CDC/local experts for recs on postexposure prophylaxis (PEP)
National Clinicians’ Postexposure Prophylaxis Hotline (PEPline): (888) 448-4911

History
Any percutaneous injury, mucous membrane exposure, or exposure of nonintact skin to any blood & other bodily fluids considered potentially infectious
RFs: High-risk procedures, use of equipment w/o newer safety designs, failure to follow universal precautions

Findings
Physical examination nl; should be documented for future reference

Evaluation
Consent & test source pt for HIV, HBsAg, Hep C Ab (direct viral
assays not rec)
• Test HC worker for HIV & Hep C Ab, draw HBsAb titers if unknown immune status
• Check serum hCG, CBC, BMP, LFTs, & UA before starting prophylaxis
• If source pt is HIV+, ID consult for appropriate regimen based on source pt’s regimen

Treatment
• HIV: 2 drug regimen (Combivir) × 4 wk; 3 drug regimen (Nelfinavir) for high-risk exposures
• Hep B: Start vaccination series if unvaccinated, Hep B immune globulin (HBIG) if HBsAg+
• Multiple doses HBIG w/i 1 wk of exposure provides 75% protection from infection
• Hep C: CDC does not recommend use of interferon or ribavirin for HCV exposure
• Consider interferon & ribavirin tx as soon as HCV seroconversion is documented

Disposition
• F/u w/ ID specialist; fully inform risks & benefits of tx & nontx

Pearls
• ~80% ↓ rate of transmission w/ immediate initiation (w/i 2 h) of HIV PEP
• Rates of occupational transmission after percutaneous exposure
• HIV + source pt: 0.3%; Hep B + source pt: 5–20%; Hep C + source pt: 1–10%

<table>
<thead>
<tr>
<th>Antiretrovirals for HIV Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
</tr>
<tr>
<td>Combivir [Zidovudine (AZT)/Lamivudine (3TC)]</td>
</tr>
<tr>
<td>Nelfinavir (Viracept)</td>
</tr>
</tbody>
</table>
### Occupational Exposure Risk Assessment

<table>
<thead>
<tr>
<th>Low-risk Exposure</th>
<th>High-risk Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Instrument used for giving injection</td>
<td>Instrument visibly contaminated w/ source pt blood, directly placed in pt vein/artery</td>
</tr>
<tr>
<td>Superficial puncture in employee</td>
<td>Deep puncture in employee</td>
</tr>
<tr>
<td>Splash or mucosal exposure in employee</td>
<td>Terminal source pt (high viral load)</td>
</tr>
</tbody>
</table>


### BURNS

#### Approach
- Early airway assessment, determine need for intubation (soot in airway, edema, voice Δ, deep facial burns, ↓ O₂ sat; transfer to burn center if intubated)
- 100% O₂ or O₂ by NRB mask until CO (10e) & other inhalation tox assessed
- Evaluate for concomitant trauma (fall, blast injury); maintain c-spine precautions
- Start IVF resuscitation early (almost universally required)
- Keep room warm to ↓ insensate losses

#### History
- How burn occurred (explosion? closed space?), duration of exposure, type of burn

#### Findings
- Assess burn

#### Evaluation
- Mental status on extrication, assess degree of burn, % of total body surface area
- Check CO level (10e), CBC, BMP, lactate, ABG, LFTs, coags, tox,
T&S, UA, CXR

Treatment
- Early & generous analgesia: Morphine IV q5–10min titrated to pain
- Airway management: Intubate early
  - Toxic inhalation (cough, dyspnea, carbonaceous sputum, soot in oropharynx): Intubate or perform fiberoptic airway exam early; delay could cause ↑ airway edema → airway compromise, difficult/impossible intubation
- If >15% TBSA, aggressive IVF resuscitation, 2 LBlV through unburned skin
  - Parkland formula calculates IVF requirement in 1st 24 h after burn:
    - 4 mL × weight (kg) × BSA (2nd- & 3rd-degree burns)
    - Give ½ over 1st 8 h, other ½ over next 16 h; use LR to avoid NAGMA w/ NS
  - Urinary catheter placement: Target urine output: 30–50 mL/h
  - Burn mgmt: Irrigate w/ NS, remove debris, clothing, jewelry, & ruptured blisters (prevent future infection)
  - Apply silver sulfadiazine (antipseudomonal) ointment to denuded areas
  - Bacitracin only on face (silver sulfadiazine may cause discoloration)
  - Immediate escharotomy for full-thickness circumferential burns that compromise distal neurovascular status or significantly ↓ chest compliance
- Tetanus prophylaxis, no role for steroids or immediate IV abx

Disposition
- Admit 2nd-degree burns 10–20% BSA (or 5–10% if <10 y/o), circumferential or if meet criteria below

Pearls
- Burns often progress in severity, watch for worsening burns
- Remove tar (asphalt burns) w/ mineral oil
- Consider cyanide w/ industrial/closed space fires, check lactate, treat w/ hydroxocobalamin
### Burn Clinical Findings by Degree

<table>
<thead>
<tr>
<th>Degree</th>
<th>Clinical Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st: Epidermis</td>
<td>Painful, erythematous, indurated area w/o blisters</td>
</tr>
<tr>
<td>2nd: Dermis</td>
<td>Blisters, painful, erythematous or mottled, indurated</td>
</tr>
<tr>
<td>3rd: Full-skin thickness</td>
<td>Charred, leathery, mottled/white, painless</td>
</tr>
<tr>
<td>4th: Full-tissue thickness</td>
<td>Includes SQ tissue, muscle, fat, blood vessels &amp; nerves, to bone. Catastrophic.</td>
</tr>
</tbody>
</table>

### Criteria for Transfer to Burn Unit

- Burns >20% BSA (or >10% if age <10 or >50)
- 3rd-degree burns >5% BSA or 2nd-degree burns >20% BSA
- Burns involving face, eyes, ears, hands, feet, or perineum
- Burns a/w significant electrical, chemical, inhalational, or traumatic injury
- Burns suspected to be related to abuse
- Burns to pts w/ special psychosocial or rehabilitative care needs
CARBON MONOXIDE POISONING

Approach
- Early airway assessment, determine need for intubation (AMS)
  - 100% O\textsubscript{2} or O\textsubscript{2} by NRB mask until CO assessed
  - Pulse oximetry not useful b/c it will detect carboxyhemoglobin (COHgb) as oxyhemoglobin

History
- Exposure to CO from combustion, faulty heating, closed-space fire, defective automobile exhaust; often multiple people exposed/symptomatic
  - Mild poisoning: Frontal HA, N/V, DOE, dizziness/confusion
  - Severe exposure: Syncope, coma, or sz

Findings
- Mild confusion progressing to agitation, sz, coma
- May have subtle psychomotor abnormalities: Ataxia, muscle rigidity, tachycardia, hypotension, retinal hemorrhage, ↓ visual acuity, cyanosis, or pallor
- Neurologic findings primarily cerebellar: Dysmetria, ataxia, etc.

Evaluation
- ABG alone not useful b/c pO\textsubscript{2}, a measure of dissolved O\textsubscript{2}, will be nl; check ABG for COHgb via co-oximetry
  - Level is weakly correlated w/tox but it confirms significant exposure
  - Level of <10–15% may be nl in smokers
  - Higher risk for myocardial injury: Check ECG esp if baseline CAD, risk fx, or high CO
- Assess for suicidal gesture; may need psychiatry consult

Treatment
- O\textsubscript{2} via NRB (60% O\textsubscript{2}) at least, ideally deliver 100% O\textsubscript{2}
- Airway management: If AMS, hypoxemia or shock → intubate
- Cardiac monitoring; admission if dysrhythmia or e/o ischemia on
ECG
- Hyperbaric O₂ tx controversial but recommended by Undersea & Hyperbaric Med Society, potential long-term neuro sequelae benefit
- Fetal Hgb has higher affinity for CO than adult Hgb; lower threshold for hyperbaric O₂ in pregnant women

Disposition
- Admission based on level & clinical findings; D/C asymptomatic pt w/ HbCO <10%

Pearls
- CO is the most common cause of D from acute poisoning & fires; reversibly binds Hb more avidly than O₂ → functional anemia
- May see delayed neurologic sequelae (personality Δ, HA, sz, parkinsonian Δ) 2–40 d after exposure; virtually universally resolve w/i 6 mo
- Half-life of COHgb: 300 min on RA, 90 min on 100% NRB, 30 min hyperbaric

<table>
<thead>
<tr>
<th>Indications for Hyperbaric O₂ in CO Poisoning</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transient or prolonged unconsciousness (syncope, coma)</td>
</tr>
<tr>
<td>CO level &gt;25–40%</td>
</tr>
<tr>
<td>Persistent neurologic disturbances</td>
</tr>
<tr>
<td>Cardiovascular Dysfxn</td>
</tr>
<tr>
<td>Severe acidosis</td>
</tr>
<tr>
<td>Pregnancy w/ CO level &gt;20% or signs of fetal distress</td>
</tr>
</tbody>
</table>

DYSBARISM

Background
- Atmospheric pressure at sea level = 760 mmHg = 14.7 psi: 1 atm
  - Each descent of 33 ft under water ↑ pressure by 1 atm
  - Dive tables & computers set standards for rate & depth of ascent to avoid dysbarism
**Approach**
- Careful hx: Length, depth, # of dives, interval btw dives, comorbid dz, sinus pain during dive, intoxication, onset of sx, dive relative to decompression limits
- Divers Alert Network, Duke University: (919) 684-8111, 24-h med advice

---

**DECOMPRESSION SICKNESS (DCS)**

**History**
- Improper dive time, depth, & ascent; sx can develop during or after (1–24 h) ascent, longer if air travel

**Findings**
- Fatigue, AMS, visual defects, lingual pallor, tachypnea, tachycardia, N/V, ↓ UOP, sz, neuro Δ, joint pain, lymphedema, pruritus

**Evaluation**
- Cardiac monitor, CBC, CMP, O₂ sat, tox screen, CO level, coags, CXR, head CT

**Treatment**
- 100% O₂ (NRB mask), place pt in L lateral decub & mild Trendelenburg, hyperbaric O₂, IVF (UOP 1.5 mL/kg/h) for recompression
- Goal of recompression to ↓ mechanical obstruction of air bubbles, ↑ tissue O₂ delivery
- Sx tx: Intubation (inflate cuff w/ saline), needle decompression, sz control

**Disposition**
- Ground transport, or low-flying air transport (cabin pressure <1000 ft)
- Admit to institution w/ hyperbaric O₂ capability

**Pearls**
- Spectrum of illness: Formation of small nitrogen gas bubbles in blood & tissues
- Depends on location & degree of bubble formation
- ↑ freq w/ longer & deeper dives, comorbid illness (COPD, CAD, PFO, asthma)
- Residual paralysis, myocardial necrosis, other ischemic injuries possible; early recognition & tx imperative
- Wait >12–48 h btw diving & flying, no diving for 7 d after DCS I, 28 d after DCS II

<table>
<thead>
<tr>
<th>Types of Decompression Sickness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type I: Pain “the bends”</td>
</tr>
<tr>
<td>- Extremity/joint pain w/o localized tenderness or erythema</td>
</tr>
<tr>
<td>- Skin: Pruritus, rash, mottling or marbling of skin, violaceous rash</td>
</tr>
<tr>
<td>- Lymphatics: Venous stasis</td>
</tr>
<tr>
<td>- Inflate BP cuff to 150 mmHg over affected joint; if relieves pain, confirms dx</td>
</tr>
<tr>
<td>Type II: CNS or pulm gas embolism</td>
</tr>
<tr>
<td>- Pulmonary sxs: Pleuritic pain, respiratory distress, nonproductive cough</td>
</tr>
<tr>
<td>- Hypovolemic shock: Tachycardia, postural hypotension, cyanosis</td>
</tr>
<tr>
<td>- Nervous system: Mimics spinal cord trauma; ext weakness &amp; paresthesias, moves proximally, focal neuro deficit, plegia, AMS, sz</td>
</tr>
</tbody>
</table>

**MIDDLE EAR BAROTRAUMA**

**History**
- Usually occurs on descent; ↑ pain w/ ↑ water pressure on TM, equilibration via Eustachian tubes, rupture occurs b/w 5 & 17 ft → pain relief; vertigo, N/V, hearing loss

**Findings**
- Reversible Bell palsy from increased pressure to facial nerve in severe cases

**Evaluation**
- Concomitant eval for inner ear barotrauma

**Treatment**
- Nasal vasoconstrictor drops/spray to open fluid from middle ear;
antihistamines, analgesia, pinch nose & swallow to displace fluid through Eustachian tube

**Disposition**
- ENT f/u in 2 wk

**Pearl**
- No benefit w/ abx; use occlusive earplugs when diving/showering until TM healed

<table>
<thead>
<tr>
<th>Other Dysbarisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inner ear barotrauma</td>
</tr>
<tr>
<td>- Occurs during descent; nausea, vertigo, tinnitus, hearing loss</td>
</tr>
<tr>
<td>- Insufflation in ear canal using otoscope produces nystagmus</td>
</tr>
<tr>
<td>- Conservative mgmt, 1 wk bed rest, elevated HOB, no Valsalva</td>
</tr>
<tr>
<td>Nitrogen narcosis</td>
</tr>
<tr>
<td>- “Rapture of the deep” from ↑ tissue nitrogen concentration</td>
</tr>
<tr>
<td>- Euphoria, false sense of well being, confusion, loss of judgment, disorientation, inappropriate laughter, ↓ motor control, paresthesias</td>
</tr>
<tr>
<td>- Start around 100 ft, resolves w/ ascent</td>
</tr>
<tr>
<td>Facial barotrauma</td>
</tr>
<tr>
<td>- Neg. pressure generated in airspace created by mask over face</td>
</tr>
<tr>
<td>- If pt doesn’t force exhale through nose, get conjunctival edema, petechial hemorrhages over face, subconjunctival hemorrhages</td>
</tr>
<tr>
<td>Arterial gas embolism (AGE)</td>
</tr>
<tr>
<td>- “The chokes” occur when diver doesn’t exhale properly during ascent</td>
</tr>
<tr>
<td>- Sudden onset stroke sxs in 10 min of surfacing, dyspnea, hemoptysis</td>
</tr>
<tr>
<td>- Look for PFO, shouldn’t dive again, emergent recompression</td>
</tr>
<tr>
<td>PTX/Pneumomediastinum</td>
</tr>
<tr>
<td>- Results from barotrauma, seen on CXR</td>
</tr>
<tr>
<td>- Pleuritic pain, dyspnea, subcutaneous emphysema/crepitus</td>
</tr>
<tr>
<td>- Unless hemodynamic compromise or tension, not life-threatening</td>
</tr>
</tbody>
</table>

**ELECTRICAL INJURY**
Background
- Current: Measure of amount of energy flowing through an object; in amperes (A)

Approach
- Early & continuous cardiac monitoring for dysrhythmias
- Evaluate for concomitant trauma (fall, injury); maintain c-spine precautions
- Divided in low voltage <500 & high voltage

History
- Usually obvious & reported (eg, occupational injury of electrician, home handyman); pt reports minor shock (tingling) related to home appliance use
- “3rd rail” contact from light-rail mass transportation system
- Toddler w/ burns to corners of mouth (chewing) or hands (playing w/ socket)
- Bimodal distribution w/ most pts <6 or adult workers

Findings
- VF more common w/ low voltage AC, asystole w/ high voltage AC or DC
- Respiratory arrest via chest wall paralysis or respiratory center of brain possible
- Skin wounds may appear minor & entry/exit wounds may be present (examine bottoms of feet for exit); may be more severe than they appear due to deep-tissue injury
- Long-bone fx, scapular fx, shoulder dislocation, spinal fx from mechanical trauma caused by whole body tetanic contractions or trauma of being blown back
- Perforated TMs, delayed cataracts in 6% of pts

Evaluation
- ECG, CBC, BMP, cardiac enzymes (rhabdomyolysis), UA (myoglobin)

Treatment
- Resuscitate, eval for trauma, immobilize c-spine, continuous cardiac monitoring
- High-volume IV crystalloid (NS, avoid K-containing fluids)
- Urinary catheter placement: Target urine output: 0.5–1 mL/kg/h
- If rhabdomyolysis (↑ CK, +UA dip), maintain high UOP until urine dip neg.
- Goal serum pH 7.45–7.55
- Alkaline urine (pH > 6.5) to ↑ excretion of acidic myoglobin by ↑ solubility; D5W + 150 mEq NaHCO3 OR D5 ¼ NS or D5 ½ NS + 100 mEq NaHCO3
- Diuresis w/ Lasix 20–40 mg IV or mannitol 25 g IV (then 12.5 g/kg/h) prn
- Treat wounds the same as thermal burns (10 d)
- Compartment pressures ± fasciotomy if sx of compartment syndrome
- Splint injured extremities in best “position of fxn” to minimize contractures

**Disposition**
- If asx & nl exam, can be D/C
- If mild cutaneous burns & nl ECG, nl urine dip, observe for 2 h, then D/C
- ECG Δ, myoglobinuria, entry/exit burns, partial/full thickness burns: Admit burn center

**Pearls**
- Electrical injuries are often minor, but may be more serious than they 1st appear. If any concern, observe for 6–12 h.
- Pediatric oral “bite” burns may develop delayed labial artery bleed at 2–3 wk

<table>
<thead>
<tr>
<th>Types of Current</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct current (DC)</td>
<td>Occupational, high voltage: Current flows in 1 direction only; most pts are “blown” from this exposure &amp; suffer blunt trauma</td>
</tr>
<tr>
<td>Alternating current (AC)</td>
<td>Home, low voltage: 3× more dangerous than DC of same voltage due to continuous muscle contraction/tetany from current alternating direction of flow; pt “can’t let go”</td>
</tr>
<tr>
<td>Arc injury</td>
<td>Pt trapped in electrical arc b/w 2 objects; mostly serious b/c of ↑ risk of blunt trauma &amp; temp as high as 2500–5000°C causing burn</td>
</tr>
</tbody>
</table>
HIGH-ALTITUDE ILLNESS

Background
- Caused by acute exposure to hypobaric hypoxia (low PO₂) usually above 8K ft
- Altitude illness is generally considered as a progressive spectrum from AMS to HACE
- Acclimatization allows body to minimize effects of hypoxia; ↑ RR (↓ PaCO₂), ↑ CO, ↑ hematopoiesis & 2,3-DPG production (favors O₂ release to tissues)
- Takes 5–7 d for full effect; inherent acclimatization ability varies by individual

Approach
- O₂, descent, symptomatic relief; HAPE can be fatal w/i h unless treated

History
- Rapid ascent to altitude >8K ft, risk increased by exertion, past h/o altitude illness
- Flu-like sx, “hangover,” HA, fatigue, DOE, sleep disturbance, N/V, dizziness, paresthesias
- Sxs manifest 6–12 h after ascent, subside in 1–2 d or may progress to HAPE, HACE
- Watch for sx of HAPE (dry cough, fever, SOB at rest) or HACE (ataxia, emesis, LOC)

Findings
- Depends on severity of altitude illness
- HAPE: Tachycardia, tachypnea, rales/wheeze, fever, orthopnea, pink/frothy sputum
- HACE: AMS, ataxia, sz, slurred speech, stupor, coma, D from brain herniation

Evaluation
Clinical Dx
- HAPE: CXR (patchy infiltrates), US (comet tails), pulse oximetry (relative hypoxia)
- HACE: Head CT neg., MRI (white matter Δ showing ↑ edema)

Treatment
- Descent! If unable: O₂, symptomatic relief, bed rest
- Hyperbaric O₂ chamber: Used as temporizing measure until descent
- Meds: Unclear benefit but low risk:
  - Acetazolamide: 125–250 mg PO q12h; for ppx start 1d prior to ascent
  - Dexamethasone: 8 mg PO × 1, then 4 mg PO q6h
- In HAPE:
  - Nifedipine (pulm vasodilation): 10 mg PO q6h, SR 30 mg PO q8–12h (<90–120 mg/d)
  - Inhaled β-agonist (Salmeterol; clears alveolar fluid): Inhalation q12h
  - PDE-5 inhibitors (tadalafil, sildenafil) have shown efficacy in HAPE ppx & can be considered in tx: Tadalafil 10 mg q12h, sildenafil 50 mg q8h

Disposition
- Admit if hypoxic, dyspnea at rest; prognosis excellent for survivors

Pearls
- Avoid abrupt ascent, spend 1–2 nights at intermediate elevation, descend to sleep
- Underlying medical conditions (COPD, CAD, HTN, SSD, pregnancy) affected more
- Consider other causes of sxs: PNA (HAPE does not usually cause fever), PE, SDH, CVA
- Descent is the mainstay of any tx

<table>
<thead>
<tr>
<th>Summary of High-Altitude Illnesses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dz</strong></td>
</tr>
<tr>
<td>AMS</td>
</tr>
<tr>
<td>System</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

# HYPOTHERMIA

## Background
- Multiple classifications of hypothermia based on severity & etiology

## Approach
- Careful hx: Determine etiology of hypothermia: Environmental exposure vs. medical
- Environmental hypothermia can occur even in the absence of freezing weather (malnourished pt, elderly)
- Many medical etiologies: Hypothyroidism (myxedema coma), hypoglycemia, hypoadrenalism, sepsis, hypothalamic lesion (eg, 2/2 trauma, tumor, stroke), dermatologic conditions that prevent heat conservation (burns, erythrodermas)
- If unresponsive, check BS/give D50, give naloxone 2 mg

## History
- Environmental exposure, drug use, trauma, comorbid illnesses

## Findings
- Based on degree of hypothermia (table below)

## Evaluation
- Obtain core temp (bladder, rectum, esophagus: All may be inaccurate)
Cardiac monitor, CBC (Hct ↑ 2% for every 1° ↓ temp), CMP (↑ K bad sign), tox screen, coags, CXR, lipase (cold-induced pancreatitis), CK, UA (rhabdo), ABG, head CT

- ECG shows Osborn waves (J pt deflection in same direction as QRS), <32°C/90°F
- Interval prolongation (PR, QRS, QT), AF w/ slow ventricular response (common)

**Treatment**

- Rewarm as per table below; intubate as needed, remove wet clothing
- Maintain horizontal position, avoid movement, limit manipulation to essential tasks. However, this should not prevent CPR or other critical interventions.
- Monitor ECG, check for pulse q1min; chest compressions may cause ventricular dysrhythmias, perform only if no pulse
- If no cardiac activity, start CPR
  - VF or VT: Defibrillate up to 3 times
  - Core temp <30°C, cont compressions/rewarming, no ACLS meds/shock until >30°C
  - Core temp >30°C, ACLS protocol w/ meds/shock, allow longer time b/w doses
  - Cont resuscitation until core temp >32°C/90°F
    - Consider hydrocortisone 250 mg IV or levothyroxine 250–500 μg if doesn’t rewarm w/ above

**Disposition**

- Based on severity of hypothermia (table below)

**Pearls**

- Hypothermic bradycardia is refractory to atropine since not vagally mediated; no indication for temporary pacing
- Core temp afterdrop: Peripheral vasodilation from rewarming extremities may cause return of cooler peripheral blood to core
- Consider femoral line placement if needed to avoid cardiac stimulation (vs. IJ, SC)
- “You’re not dead until you’re warm & dead”; aggressively rewarm before stopping efforts
## Classifications of Hypothermia

<table>
<thead>
<tr>
<th>Classification</th>
<th>Physiologic Response</th>
<th>Clinical Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild (90–95°F, 32–35°C)</td>
<td>Increased: HR, BP, CO, RR, metabolic activity, shivering, cold diuresis</td>
<td>Dizziness, lethargy, confusion, amnesia, apathy, dysarthria, nausea, ataxia, loss of fine-motor skills</td>
</tr>
<tr>
<td>Moderate (86–90°F, 30–32°C)</td>
<td>Decreased: HR, BP, CO, RR, metabolic activity, cold diuresis, shivering stops</td>
<td>Delirium (paradoxic undressing), stupor, pupillary dilatation, ↓ reflexes</td>
</tr>
<tr>
<td>Severe (&lt;86°F, &lt;30°C)</td>
<td>Decreased: HR, BP, CO, RR, metabolic activity, no shivering</td>
<td>Unresponsive, fixed &amp; dilated pupils, rigid, very cold skin, coma, pulm edema; ↑ risk of ventricular fibrillation &amp; asystole</td>
</tr>
</tbody>
</table>

## Rewarming Strategies by Severity of Hypothermia

<table>
<thead>
<tr>
<th>Rewarming Strategy</th>
<th>Tx</th>
<th>Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Passive rewarming (PR)</td>
<td>Warm blankets, heat lamps, ACLS if cardiac arrest</td>
<td>Likely D/C</td>
</tr>
<tr>
<td>Passive rewarming (PR)</td>
<td>Warm blankets, heat lamps, ACLS if cardiac arrest</td>
<td>Likely D/C</td>
</tr>
<tr>
<td>PR, active external rewarming (AER) to trunk only</td>
<td>Hot water bottles (45–65°C) to axilla &amp; groin, ACLS for cardiac arrest</td>
<td>Admit, cardiac monitoring</td>
</tr>
<tr>
<td>PR, AER, active internal rewarming</td>
<td>Warm IVF (NS 45°C), warm humidified O₂ (45°C), If cardiac arrest, shock (no ACLS meds); CP bypass/pl lavage, central venous “radiator” cath</td>
<td>Admit, likely ICU</td>
</tr>
</tbody>
</table>

### Frostbite

**History**
- Cold exposure, numbness of body part → loss of sensation
Findings
- Distal body part most commonly affected (fingers, nose, toes, ears)
- Caused by both immediate cell D from cold & delayed injury from inflammatory response
- Skin initially white, waxy, insensate → erythematous, edematous, painful 48–72 h after rewarming → bleb formation, devitalized tissue demarcation over weeks

Evaluation
- Check core temp to look for systemic hypothermia
- Superficial: Areas of pallor & edema, local anesthesia, potentially clear blisters, erythema, no tissue loss
- Deep: Hemorrhagic blisters, eschar, if severe extends to muscle/bone, mummification

Treatment
- Handle tissue gently, keep extremity elevated, sterile/nonadherent dressing
- Rapid rewarming of frozen extr in gentle warm water bath (40–42°C), ROM exercise in bath, avoid water temp falling outside of range; 30 min if superficial/
  60 min if deep
- Consider intra-arterial tPA in severe cases
- Topical aloe vera q6h
- Aspirate & débride clear blisters, only aspirate (do not débride) hemorrhagic blisters to avoid desiccation, infection of deeper tissues
- Tetanus prophylaxis, consider ppx abx
- Early surgical intervention not indicated other than escharotomy for circumferential limb lesions (very uncommon)

Disposition
- Refer to burn service; consider admission for 24–48 h to observe for progression

Pearls
- Long-term cx: Cold insensitivity, paresthesias, nail loss, joint stiffness
- Avoid refreezing, if unable to maintain warmth to affected part (e.g.
prehospital) do not rewarm

## HYPERTHERMIA

### Background
- Spectrum of heat-related illnesses including heat rash, cramps, syncope, stroke

### Approach
- Careful hx: Determine etiology of hyperthermia: External (environmental) or internal (toxic/metabolic) factors, environmental hypothermia can occur even in absence of exertion (malnourished pt, chronically ill, elderly)
- Look for medication related hyperthermia: MH, NMS, SS
- Use rectal thermometer to determine core temperature

---

## EXTERNAL HEAT EMERGENCIES

### Heat Cramps

#### History
- Brief, intermittent, severe muscle cramping usually following cessation of strenuous activity. Often in abd or calf muscles.

#### Findings
- Euthermic, clinical signs of dehydration

#### Evaluation
- BMP (↓ Na, ↓ Cl), urine lytes optional (↓ urinary Na & Cl from sweating)

#### Treatment
- Oral salt or electrolyte repletion tablets or sports drinks; IV hydration rarely required

#### Disposition
- Home after observation for sx relief

#### Pearl
Related to electrolyte deficiency; electrolyte enhanced sports drinks may be helpful although may cause diarrhea due to the high sugar content.

**Heat Edema**

**History**
- Swollen feet/ankles after long periods of sitting/standing due to hydrostatic pressure, vasodilation & orthostatic pooling → vascular leak, interstitial fluid accumulation
- No underlying hepatic, lymphatic, cardiac, or venous dz

**Findings**
- Euthermic, B LE pitting edema w/o signs of CHF or renal failure

**Evaluation**
- BMP, UA for proteinuria, CXR for pulm edema, ECG for e/o LVH, RH strain

**Treatment**
- Elevate lower extremities, provide support hose
- No evidence that diuretics help

**Disposition**
- Home after reassurance, PCP f/u

**Pearl**
- Dx of exclusion

**Heat Rash (Prickly Heat, Miliaria, Lichen Tropicus)**

**History**
- Sweat gland blockage w/ localized inflammatory response
- Often seen in pts newly arrived to subtropical/tropical areas or during heat waves

**Findings**
- Euthermic, erythema w/ pruritic vesicles, primarily in intertriginous areas, then becomes anhidrotic
- Occasionally will become superinfected, usually *Staph*

**Evaluation**
- None
Treatment
- Treat pruritus: Diphenhydramine 25–50 mg PO or hydroxyzine 25 mg PO
- Desquamate skin w/ chlorhexidine antibacterial soap or salicylate-containing topical scrub

Disposition
- Home, PCP f/u

Pearl
- Avoid routine talcum powder application, which may block sweat glands

Heat Syncope

History
- Syncopal event in warm/humid weather or following strenuous activity
- Heat → vasodilation → peripheral intravascular blood pooling, ↓ central venous return

Findings
- Euthermic, nl exam

Evaluation
- EKG, eval for other causes of syncope (see 1c)
- Syncope/presyncope sx should resolve w/i 30 min, if not consider further w/u

Treatment
- PO or IV hydration

Disposition
- Home, PCP f/u

Pearl
- Dx of exclusion, diagnose only in young healthy pts w/ no cardiac dz

Heat Exhaustion

History
- Gradual onset, extreme fatigue in warm/humid weather following strenuous activity, profuse sweating, dizziness, N/V; often pale w/
cool, moist skin
- Inadequate PO intake

**Findings**
- Mild hyperthermia, may reach 40°C (104°F), nl mental status

**Evaluation**
- BMP for electrolyte imbalance, UA (rhabdomyolysis uncommon)

**Treatment**
- IV hydration (PO if pt tolerates), replace w/ NS (or alternate w/ ½ NS if ↑ Na)

**Disposition**
- Observation w/ continued hydration until normothermic w/ good UOP

**Pearl**
- No value w/ fever-reducing medications

**Heat Stroke**

**History**
- Acute onset when compared to heat exhaustion
- Classic: Occurs during heat waves, affects susceptible pts: Elderly, chronically ill, scleroderma, CF, burns, alcoholics, homeless, mentally ill, on diuretics or anti-chol
- Exertional: Occurs in pts who are overwhelmed by heat overproduction: Athletes, military recruits, thyroid storm, pheochromocytoma, sympathomimetic overdose

**Findings**
- Hyperthermia >41°C/106°F, CNS Dysfxn: Confusion, disorientation, delirium
- Classic: Anhidrotic, tachypnea
- Exertional: Diaphoretic until “sweat gland fatigue”
- Muscles usually flaccid in HS, if rigid consider NMS, etc.

**Evaluation**
- BMP (electrolyte imbalance, ↓ blood sugar), LFTs (hepatic damage common), coags (DIC possible but uncommon), CK & UA (rhabdo common in exertional heat stroke)

**Treatment**
Aggressive fluid resuscitation: Cooling procedures → vasoconstriction, can ↑ BP so may need to guide fluid status by UOP, IVC US, CVP, etc.
- Rapid cooling indicated, ↓ by 0.2°C/min → 39°C/102.2°F to avoid overshooting
- Ice water immersion: Can ↓ core temp in 10–40 min
- Evaporation: Spray water mist & use fan, maintains cutaneous vasodilation, avoids heat generation by shivering, 7× more efficient than ice packing but 2× as fast
- Adjunctive cooling strategies: Strategic ice packs near large blood vessels (ant neck, axilla, groin), ice water gastric lavage at NS 200 mL/h
- Mannitol 50–100 g IV ↑ renal blood flow, ↓ cerebral edema
- Treat rhabdo w/ IVF, HD if anuric, tx coagulopathy w/ FFP

Disposition
- Admit for ongoing tx & cooling

Pearls
- Avoid alcohol sponge baths, dantrolene
- Avoid antipyretics (APAP damages liver, salicylates aggravate bleeding)
- Avoid α-adrenergic drugs (promote vasoconstriction, ↑ hepatic/renal damage, CO same)
- Avoid atropine/anticholinergics that ↓ sweating; use BZD to stop shivering
- Avoid neuroleptics (chlorpromazine): ↓ sz threshold, interfere w/ thermoregulation, etc.

---

**INTERNAL HEAT EMERGENCIES**

**Malignant Hyperthermia (MH)**

**History**
- Acute ↑ body temp after administration of inhaled anesthetic or succinyllcholine
- Genetic abnlty of skeletal muscle sarcoplasmic reticulum → inappropriate Ca release → severe tetany & spasm (heat); often FH of adverse rxn to anesthesia
Findings
- Acute hyperthermia after anesthetic, hypercapnia (early sign), muscular rigidity, masseter muscle spasm, acidosis, tachycardia, rhabdomyolysis

Evaluation
- Check core temp, electrolytes, CK

Treatment
- Stop offending agent, increase ventilation rate, dantrolene 2.5 mg/kg bolus IV, repeat doses of 1 mg/kg until sx subsides; MH protocols

Disposition
- Usually occurs in OR, admission for supportive care

Pearl
- MH hotline: 1-800-MH-HYPER (1-800-644-9737), ask for “Index Zero”

Neuroleptic Malignant Syndrome (NMS)

History
- Antipsychotic use (phenothiazines, butyrophenones, thioxanthenes, lithium, TCAs); recent initiation or dose ↑ (³/₄ of cases in 1st wk)
- Anti-Parkinson medication withdrawal
- Dopamine receptor blockade → severe muscle spasticity & dystonia, heat overproduction

Findings
- Triad: Hyperthermia, muscular rigidity (lead pipe), autonomic Dysfxn
- AMS, dyskinesia, tachycardia, dyspnea, diaphoresis, dysphagia, tremor, incontinence

Evaluation
- UA for myoglobin, CK for rhabdomyolysis, ↑ WBC, Chem, tox

Treatment
- Stop offending agent, mainstay is supportive tx: IVF, BZDs
- May consider dantrolene (as for MH), whole body cooling w/ evaporating fans
- Dopamine antagonists (bromocriptine 2.5 mg PO q8h, amantadine 200 mg PO q12h)
Treat rhabdomyolysis w/ IVF, alkaline urine (pH > 6.5) to ↑ myoglobin excretion
Keep Na in IVF close to 154 mEq/L; add NaHCO₃

Disposition
- Admission; mortality 10–20%

Pearl
- NMS hotline: 1-888-667-8367

Serotonin Syndrome (SS)

History
- Drug & food interactions: MAOI + tyramine (found in aged cheese, wine, etc.); caused by excessive serotonin activity in spinal cord & brain

Findings
- Hunter criteria: Combination of clonus, hyperthermia, agitation, diaphoresis, ocular clonus, hyperreflexia, tremor, hypertonia
- Diarrhea, cramps, hypersalivation (similar to NMS), autonomic Dysfxn

Evaluation
- UA for myoglobin, CK for rhabdomyolysis, CBC, Chem, tox
- Clinical dx, must confirm h/o 2 serotonergic agents, r/o toxic, metabolic, infectious cause

Treatment
- Stop offending agent, supportive tx, whole body cooling, treat rhabdo w/ IVF**
- BZD: May require high doses
- Dantrolene not recommended: May ↑ central serotonin metabolism & production
- Nonsp serotonin inhib: Cyproheptadine 12 mg PO then 2 mg PO q2h

Disposition
- Admission; most resolve w/ no sequelae in 24–36 h after starting tx

Pearl
- Pts must stop MAOI for 6 wk prior to starting SSRI
Differentiating NMS and Serotonin Syndrome

<table>
<thead>
<tr>
<th></th>
<th>NMS</th>
<th>SS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etiology</td>
<td>• A/w neuroleptic use&lt;br&gt;• Idiosyncratic rxn to therapeutic doses</td>
<td>• A/w serotonergic agents&lt;br&gt;• Manifestation of tox; often from combination of 2 serotonergic drugs</td>
</tr>
<tr>
<td>Timing</td>
<td>• Slow onset (days → weeks)&lt;br&gt;• Slow progression (24–72 h)</td>
<td>• Rapid onset &amp; progression</td>
</tr>
<tr>
<td>Sxs</td>
<td>• Bradykinesia, lead-pipe rigidity</td>
<td>• Hyperkinesia, less rigidity</td>
</tr>
<tr>
<td>Tx</td>
<td>• BZD&lt;br&gt;• Dantrolene&lt;br&gt;• Dopamine antagonists</td>
<td>• BZD&lt;br&gt;• Serotonin inhibitors&lt;br&gt;• NOT dantrolene</td>
</tr>
</tbody>
</table>

LIGHTNING INJURY

Background

› Acts as direct current → asystole; heart’s intrinsic automaticity usually restarts in SR but CNS injury & concussion may cause respiratory arrest w/ secondary cardiac arrest

Approach

› Early & continuous cardiac monitoring for dysrhythmias
› Evaluate for concomitant trauma (fall, injury); maintain c-spine precautions
› Reverse triage in field: Lightning victims that appear dead should get CPR as pts can be pulseless w/ fixed, dilated pupils & still have good survivability

History

› Usually obvious, reported lightning strike near pt; often witnessed collapse

Findings

› TM rupture, transient vasospasm (cool ext), symp nervous system instability
› Various burn patterns
• Linear: Caused by steam production during flashover (charge passes over surface of body only) where sweat accumulates
• Punctate: Multiple cigarette-like burns
• Feathering: Not actual burns; electron showers make a ferning pattern on skin (Lichtenberg figures)
• Thermal: Usually from burnt clothing
  ‣ Ocular pathology: Corneal lesions, hyphema, vitreous hemorrhage, retinal detachment, cataracts develop long term
  ‣ Keraunoparalysis: Transient paralysis that can occur, likely 2/2 vasospasm, LE > UE, usually resolves in hours, still will need eval for true spinal cord pathology 2/2 trauma

Evaluation
  ‣ ECG, CBC, BMP, CK (rhabdomyolysis), UA (myoglobin), head CT if unresponsive

Treatment
  ‣ Resuscitate, eval for trauma, immobilize c-spine, continuous cardiac monitoring
  ‣ High-volume IV crystalloid (NS); same tx as electrical injury (10f)
  ‣ Urinary catheter placement: Target urine output 1–1.5 mL/kg/h (200–300 mL/h)
  ‣ If rhabdomyolysis (↑ CK, +UA dip), maintain high UOP until urine dip neg.
  ‣ Treat wounds the same as thermal burns (10 d), tetanus, wound care, etc.
  ‣ Splint injured extremities in best “position of fxn” to minimize contractures & edema

Disposition
  ‣ If asx & nl exam, can be discharged; good prognosis if survive in field
  ‣ ECG Δ, myoglobinuria, entry/exit burns, partial/full thickness burns: Admit to burn center

Pearl
  ‣ Lightning causes ~50–300 Ds in US each year, 25–30% of lightning strike victims die, of those that survive ~75% have permanent
Background

- AHA guidelines suggest a broad definition of drowning to include D from drowning, near drowning (no longer used!), wet drowning, etc.
- Definition: Respiratory impairment from being submerged under a liquid
- >4000 drowning Ds annually in US; toddlers & teenage boys at greatest risk
- Freshwater vs. saltwater vs. chlorinated pool water: No difference, theoretical diff only
- 1° insult to lung; water moves across alveolar–capillary membrane, destroys (freshwater) or washes out (salt water) surfactant → hypoxia
- Diving reflex = immersion of face in water <68°F, blood shunts from periphery → brain & heart → apnea, bradycardia, hypothermia → ↓metabolic demand prevents/delays severe cerebral hypoxia

Approach

- Careful hx: Possible diving (cervical spine or head) injury vs. 1° drowning, intoxicants, comorbidity, submersion time, water temp, initial rescuer response (ACLS)
- Extricate pt, remove wet clothing, ABCs, ACLS, intubation as appropriate
- Bedside glucose or D50 if AMS
- Cervical spine immobilization if suspicion for head or neck injury (diving, pool accident)

History

- Submersion event

Findings

- Variable presentation (awake, coma, cardiac arrest)
- Wheezes/rales/rhonchi, ecchymosis/crepitus/other signs of trauma on exam
Evaluation
- CBC, BMP, LFTs, tox, CXR may show pulmonary edema or aspiration 2–6 h after event, CT head & c-spine if concern for trauma, AMS

Treatment
- ABCs, intubation or supplemental O\textsubscript{2}, CPR, ACLS, Foley placement
- Measure core temp, treat for hypothermia if indicated to temp 30°C/86°F
- Ventilator PEEP 5–10 mm H\textsubscript{2}O to ↓ intrapulmonary shunting

Disposition
- Admission for continued tx, watch for signs of ARDS/VALI
- May develop pulm Δ even after mild submersion, observe asx pts for at least 8 h

Pearls
- Prophylactic abx & steroids not indicated
- Artificially induced hypothermia does not improve outcome

BOTULISM

Background
- Caused by neurotoxin produced by anaerobic gram-positive rod \textit{C. botulinum}
  - Spore-forming bacterium found in soil & water, particularly in CA, UT, PA
  - Blocks ACh release at neuromuscular jxn & autonomic ganglions (nicotinic receptors)

Approach
- Early airway management & ventilatory support
- Contact CDC Botulism center (404-639-2206/3311) for antitoxin, BabyBIG from CA

History
- 3 main etiologies: Infant, foodborne, or wound; also potential for
bioterrorism

- Infant: Consumption of unpasteurized honey or likely exposure to endemic spores (feeding through a nipple dropped on the ground, sucking on fingers after playing in dirt)
- Foodborne (adult): Ingestion of food contaminated w/ spores, usually home-canned goods
- Wound: Spores infiltrate skin wounds, germinate, & release tox into the bloodstream

Findings

- Weakness, flaccid paralysis, respiratory arrest, autonomic dysfxn; CN affected 1st
- Infant: Weak cry, poor sucking, flaccid/hypotonic muscles
- Foodborne (12–36 h) & wound (several days): Autonomic dysfxn, descending symmetric motor paralysis, nl sensorium

Evaluation

- None needed prior to intervention
- Collect serum, stool, wound, & food samples for CDC testing

Treatment

- ABCs, intubation or supplemental O₂
- Administer antitoxin 1 vial IV to adults & children
- Infants need only supportive care, no antitoxin

Disposition

- Admission to ICU for ventilatory support

Pearls

- Consider botulism in all infant sepsis workups
- Artificially induced hypothermia does not improve outcome
- AGs, magnesium contraindicated as they potentiate neuromuscular blockade
- Recovery of strength may take ~4 mo; may require respiratory support for months
ANAPHYLAXIS AND ANGIOEDEMA

Approach
- Eval & treat anyone w/ potential anaphylaxis immediately; can deteriorate rapidly
  - Anaphylaxis median time to resp/card arrest: 5 min (2/2 drug), 15 min (2/2 venom), 30 min (2/2 food) (Curr Opin Allergy Clin Immunol 2013;13(3):263)

Definition
- Anaphylaxis – acute-onset occasionally life-threatening IgE-mediated rxn causing multisystem Dysfxn: skin (eg, urticaria), mucosa (eg, angioedema), GI (eg, n/v), respiratory (eg, bronchospasm), circulatory (eg, hypotension, syncope), neuro (eg, AMS)
  - Absence of cutaneous sx rare (J Allergy Clin Immunol 2005;115:S485)
- DDx: anaphylactoid rxn, angioedema, neurocardiogenic syndromes, malignancies a/w flushing (eg, carcinoid), scombroid toxicity, systemic mastocytosis, other causes of shock or respiratory collapse (J Allergy Clin Immunol 2005;115:S485)

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaphylaxis</td>
<td>IgE-mediated rxn → urticaria, hypotension, &amp; bronchospasm</td>
</tr>
<tr>
<td></td>
<td>(mx causes; requires repeat exposure but not always known)</td>
</tr>
<tr>
<td>Anaphylactoid rxn</td>
<td>Non–IgE-mediated rxn, can appear identical to anaphylaxis, but doesn’t require prior exposure (eg, iodine-contrast)</td>
</tr>
<tr>
<td>Angioedema</td>
<td>Subdermal/submucosal edema, typically of the face, airway, &amp; GI tract (eg, 2/2 ACEI, C1-esterase deficiency, idiopathic)</td>
</tr>
</tbody>
</table>
History

- Sx: sudden-onset is key; sx can involve many organ sx – hives, swelling of tongue/throat, hoarseness, dyspnea, N/V, abd cramps, presyncope
- Assess recent exposures: Foods (nuts, egg, shellfish), meds (abx, NSAIDs, vancomycin, iodine contrast; ACEi for angioedema), enzymes (insulin, trypsin, etc), airborne allergens (pollen, mold), venoms (bees, fire ants, snakes), exercise-induced, latex, idiopathic
- Check PMH for atopy, hypersensitivity syndromes, or hereditary angioedema

Physical Exam

- Urticaria, conjunctival injection, diffuse erythema, facial or oropharyngeal swelling, drooling, hoarseness, stridor, wheezing, ↓BP

Evaluation & Treatment

- Labs not routinely indicated; consider serum tryptase during acute event esp if idiopathic or dx uncertain (tryptase elevation sp but insensitive for IgE-mediated rxns)

<table>
<thead>
<tr>
<th>Tx</th>
<th>Type of rxn</th>
<th>Tx Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Most allergic</strong> rxns</td>
<td>Remove allergen</td>
</tr>
<tr>
<td></td>
<td>H1-blocker: Diphenhydramine 25–50 mg PO or IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>H2-blocker: Ranitidine 150 mg PO or 50 mg IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prednisone 60 mg or Methylprednisolone 125 mg IV</td>
<td></td>
</tr>
<tr>
<td>Intubation: Consider early, consider fiberoptic/awake</td>
<td><strong>Anaphylaxis</strong> (<a href="https://doi.org/10.1016/j.jaci.2005.08.017">J Allergy Clin Immunol</a>; <a href="https://doi.org/10.1016/j.annemergmed.2006.02.036">Ann Emerg Med</a>)</td>
<td><strong>All txs for allergic rxn</strong> (IV)</td>
</tr>
<tr>
<td>IVF bolus</td>
<td>Epinephrine: (Repeat prn, ± infusion)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IM: 0.3–0.5 mg (1:1000)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV: 0.1–0.25 mg (1:10000) if severe (IM is safer)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neb: 0.5 mL 2.25% epi in 2.5 mL NS (No IV)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epi gtt: 1–4 μg/min (titrate to stability)</td>
<td></td>
</tr>
<tr>
<td>C1 esterase deficiency: FFP</td>
<td><strong>Angioedema</strong> (<a href="https://doi.org/10.1016/j.analle/.2006.01.004">Ann Allergy</a>)</td>
<td></td>
</tr>
</tbody>
</table>
ACEI-induced: Stop ACEI, give icatibant if available (reduces time to resolution) (NEJM 2015;372(5):418).

Stable: Fiberoptic eval ± intubation

Unstable: Cricothyrotomy

- H1-blocker + H2-blocker > H1-blocker alone for urticaria (NEJM 2004;351:2203)
- Epi IM vs. SC: IM preferred → more rapid absorption (J Allergy Clin Immunol 2001;108:871)
- Epi IM vs. IV: IM preferred → safer (World Allergy Organ J 2015;8(1):32)
- Epi & cardiac dz: Place on monitor → epi is relatively contraindicated w/ CAD, but mortality of anaphylaxis w/o epi >> mortality from arrhythmia 2/2 epi
- Epi vs. glucocorticoids: Epi first-line in anaphylaxis; glucocorticoids best for delayed sx, but evidence on acute benefit inconclusive (Cochrane 2012;4:CD007596)

Disposition

- Home: pts w/ either local rxns (w/o airway involvement) or delayed-presentation generalized rxn (w/o airway involvement)
  - Provide EpiPen Rx (esp if unknown cause) & allergist f/u
- Biphasic rxns: may occur in up to 20% of cases; median onset 11–15 h after initial sx resolve; risk reduced if 2/2 food, & increased if 2/2 drug or idiopathic; higher risk if initially hypotensive (Immunol Allergy Clin North Am 2007;27(2):309; J Allergy Clin Immunol Pract 2015;3(3):408; Ann Allergy Asthma Immunol 2015;115(4):312)
  - Risk of clinically important biphasic rxn small (<0.5%) (Annals Emerg Med 2014;63(6):736)
- Consider observation if required epi or if high risk for biphasic rxn; however, there is no clear data on recommended duration of observation, & early d/c may be appropriate (Allergy 2014;69(6):791)
- Admit to ICU: Severe anaphylactic rxn (mx epi, epi gtt, airway compromise)

Pearls

- ACEI can cause angioedema at any time, independent of length of use
PCN allergy: IgE-mediated allergy confers low (~1%) risk of cross-reactivity w/ cephalosporins; however, avoid if rxn is severe (NEJM 2006;354:601)

ONCOLOGIC EMERGENCIES

See also Chapter 1 (Cardiac tamponade), Chapter 2 (Respiratory distress, Hemoptysis), Chapter 5 (Altered mental status, Seizure, Brain tumor, CNS infections), Chapter 9 (SIADH, Hypercalcemia), Chapter 12 (Cauda equine syndrome)

NEUTROPENIC FEVER

Overview (Clin Infect Dis 2011;52(4):e56)

- Definition: Fever (single temp >38.3°C or temp >38°C for 1 h) + Neutropenia (ANC <500 or predicted <500 w/i 24 h or “functional neutropenia” [eg, AML])
- Approach: Early IV access, IVFs, & abx; most pts will not end up having identifiable infxn (only 20–30%), but those who do can deteriorate quickly
- Etiology: Infxn found in 20–30% (bacteremia in 10–25%); fungal infxn rare unless neutropenia >1 wk; consider also viral, drugs (chemo)

<table>
<thead>
<tr>
<th>Category</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial</td>
<td>HEENT (sinusitis, mucositis, otitis, pharyngitis), Pulm (PNA, TB, pneumonitis), GI (colitis, mucositis, hepatobiliary), GU (UTI, pyelo), cardiac (endocarditis), neuro (meningoencephalitis, epidural abscess), skin (cellulitis, line-related infxn, abscess [inc perianal])</td>
</tr>
<tr>
<td>Viral</td>
<td>Influenza (in epidemics), RSV, other viral pathogens, HSV, CMV, EBV</td>
</tr>
<tr>
<td>Fungal</td>
<td>Candidiasis, aspergillosis (most common life-threatening)</td>
</tr>
<tr>
<td>Drug-related</td>
<td>Many chemo agents can cause immune-mediated febrile rxns</td>
</tr>
</tbody>
</table>

History
- Date of fever onset & last chemo (ANC nadirs 10–14 d after chemo); thorough ROS
- Assess RFs warranting inpt care: MASCC score (see Disposition)

**Physical Exam**
- Examine skin, mouth, lung, abdomen, catheter/surgical sites, perirectal area (No DRE)

**Evaluation**
- CBC w/ diff, Chem 20, coags, UA/urine cx, blood cx (at least 2 + any catheter port if present), ± CXR if resp sx
- ±Additional labs: Coags, culture (stool/sputum/peritoneal/CSF)
- Imaging: Consider imaging of chest, abdomen/pelvis, sinuses, brain

<table>
<thead>
<tr>
<th>Low-risk Criteria for Neutropenic Fever</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults (J Clin Oncol 2000;18:3038)</td>
</tr>
<tr>
<td>Pediatrics (≤16 y/o) (J Clin Oncol 2000;18:1012)</td>
</tr>
</tbody>
</table>

**Treatment** (Clin Infect Dis 2011;52(4):e56)
- Empiric tx depends on risk level (see above): low-risk (PO, outpt) vs. high-risk (IV, inpt)
  - Low risk: Ciprofloxacin + (amoxicillin/clavulanate or clindamycin [if PCN allergic])
  - If no RFs, mortality & tx failure w/ oral tx = similar to iv tx (Cochrane 2013;10:CD003992)
- High risk: Antipseudomonas (ceftazidime, cefepime, carbapenem [not ertapenem])
  - If PCN-allergic: levofloxacin + aztreonam or AG
  - If cx: Can add AG or quinolone for additional GNR synergy
  - If line-infxn, PNA, hypotension: Add vancomycin
  - If MDRO, consider carbapenem (if ESBL), vancomycin (if MRSA), linezolid (if VRE)
  - Antifungals generally not indicated except if strong hx, shock, or recent HSCT

**Disposition**
- Admit all high-risk pts; low-risk pts can be d/c-ed only if close outpt f/u guaranteed
- CISNE score may outperform MASCC Risk Index in identifying low-risk pts who present to ED for eval (Ann Emerg Med 2015;PMID 28041827)

<table>
<thead>
<tr>
<th>Multinational Association for Supportive Care in Cancer (MASCC) Risk Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Criteria</td>
</tr>
<tr>
<td>No or mild sxs</td>
</tr>
<tr>
<td>No hypotension (SBP &gt; 90 mmHg)</td>
</tr>
<tr>
<td>No active COPD (O2, steroids, bronchodilators)</td>
</tr>
<tr>
<td>No solid tumor or hx of previous fungal infxn</td>
</tr>
<tr>
<td>No dehydration</td>
</tr>
<tr>
<td>Moderate sx burden</td>
</tr>
<tr>
<td>Outpt status</td>
</tr>
<tr>
<td>Age &lt;60 yr</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Clinical Index of Stable Febrile Neutropenia (CISNE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Criteria</td>
</tr>
<tr>
<td>ECOG performance status ≥2*</td>
</tr>
<tr>
<td>Stress-induced hyperglycemia</td>
</tr>
<tr>
<td>Active COPD</td>
</tr>
<tr>
<td>Chronic cardiovascular dz</td>
</tr>
<tr>
<td>Mucositis NCI grade ≥2**</td>
</tr>
<tr>
<td>Monocytes &lt;200/μL</td>
</tr>
</tbody>
</table>

*ECOG Performance Status: 0 (fully active, able to carry on all predisease performance w/o restriction), 1 (restricted in physically strenuous activity but ambulatory & able to carry out work of a light or sedentary nature), 2 (ambulatory & capable of all self-care but unable to carry out work activities; up & about more than 50% of waking hours), 3 (capable of only limited self-care; confined to bed or chair more than 50% of waking hours), 4 (completely disabled; cannot carry on any self-care; totally confined to bed or chair). Source: Am J Clin Oncol 1982;5:649. **NCI Mucositis Grades: 0 (none), 1 (painless ulcers, erythema, or mild soreness in absence of lesions), 2 (painful erythema, edema, or ulcers but eating/swallowing possible), 3 (painful erythema, edema, or ulcers requiring IV hydration), 4
TUMOR LYSIS SYNDROME


- **Definition:** ≥2 metabolic abnlty (>25% ↑ K, ↑ PO₄, ↓ Ca, ↑ uric acid) w/i 3 d before or 7 d after the start of chemo, AND e/o AKI (GFR ≤ 60), arrhythmia, or sz
- **Etiology:** Rapid destruction neoplastic cells → release of nucleic acids, K, PO₄ → uric acid (from nucleic acids), AKI (2/2 uric acid), ↓ Ca (2/2 PO₄)
  - Typically 48–72 h after starting cytotoxic cancer tx, a/w large, rapidly proliferating, tx-responsive tumors (esp acute leukemia, NHL, Burkitt)

- **Approach:** Obtain ECG immediately (look for signs ↑ K), & put on cardiac monitor

History

- Diverse sx (need high index of suspicion prior to labs): Lethargy, edema, CHF, hematuria, cardiac dysrhythmia, sz, muscle cramps, tetany, syncope, sudden D
- Assess last chemo, but may be presenting signs of malignancy

Evaluation

- Serial Chem 10 (↓ Ca, ↑ PO₄, ↑ BUN/Cr, ↑ K), ↑ uric acid (draw on ice), ↑ LDH (marker of tumor proliferation), UA (urine pH), CBC w/diff, VBG, Foley or close UOP measurement

Treatment (NEJM 2011;364(19):1844)

- Correct electrolyte d/o (↑ K, ↑ PO₄, ↓ Ca), except: use Ca tx in hyperK cautiously (may worsen CaPO₄ crystals in kidneys & worsen AKI) (see also Chapter 9)
- Maintain UOP > mL/kg/h: IVF ± loop diuretic PRN
- Reduce uric acid: allopurinol (prevents uric acid formation) or rasburicase (more effective; breaks down existing uric acid); give rasburicase in consultation w/oncology
• Rasburicase (compared to allopurinol): lowers mean peak PO\textsubscript{4} & uric acid, less AKI, reduces need for HD; superior in mx trials
  ‣ Avoid NaHCO\textsubscript{3} for urine alkalinization: ↓ uric acid crystals, but also ↑ CaPO\textsubscript{4} crystals
• Consider only if no rasburicase available AND nl serum PO\textsubscript{4}
  ‣ HD: If persistent ↑ K, severe acidosis, volume overload, uremia, severe ↑ PO\textsubscript{4} or ↓ Ca

Disposition
  ‣ Admit (floor vs. ICU, depending on severity)

SUPERIOR VENA CAVA SYNDROME

Overview
  ‣ **Definition:** Intrinsic/extrinsic SVC obstruction causing upstream high venous pressures
  ‣ **Etiology:** Malignancy (eg, lung, mediastinum) in 90%, thrombosis (eg, a/w implantable device), rarely TB & syphilitic aortitis (*NEJM* 2007;356(18):1862)

History
  ‣ Subacute onset (usually wks) of facial swelling ± laryngeal edema (cough, hoarseness, stridor), cerebral edema (HA, confusion), or ↓ venous return (hypotension)
  ‣ Severity of sx, acuity of worsening, & type of malignancy dictate intervention & urgency

Physical Exam
  ‣ Check for facial/oropharyngeal edema, JVD, abnml lung sounds, neuro deficits

Evaluation
  ‣ Chem 10, CBC, CXR, CT Chest (w/ IV contrast) ± CT Head (r/o ICH), bedside echo

Treatment (*NEJM* 2007;356(18):1862; *Crit Care Med* 2012;40:2212)
  ‣ Elevate head of bed (decrease ICP), intubate if impending airway
If 2/2 malignancy: Chemo, XRT, Endovascular stenting (if no tissue dx)
- Glucocorticoids commonly used to reduce swelling, but uncertain benefit
- If 2/2 thrombosis: anticoagulation (if concurrent HA: r/o ICH first), remove line if able
- If cerebral edema or airway obstruction: c/s Rad-Onc, Interventional Radiology from ED

Disposition
- Admit for expedited w/u (eg, bx) & tx

**NEUTROPENIC ENTEROCOLITIS (TYPHILITIS)**

**Overview** (*World J Gastroentrol* 2017;23(1):42)
- **Definition:** Rare life-threatening dz of neutropenic pts, characterized by mucosal injury, bowel edema & distention, bacterial translocation; cecum ± ileum & other colon
- **Approach:** Early IV access, IVF, abx, surgical consultation

**History**
- Abd pain (RLQ or diffuse), diarrhea, fever; ± N/V, distention, GIB
- Onset corresponds to WBC nadir (10–14 d after chemo)

**Physical Exam**
- Always assess for rebound tenderness; No DRE given neutropenia

**Evaluation**
- CBC, Chem 20, lactate, blood cx, CT A/P (bowel thick/dilated, pneumatosis), ±Upright abd XR if CT delay (can show intramural gas) or c/f perforation (subdiaphragmatic air)

**Treatment** (*World J Gastroentrol* 2017;23(1):42)
- Supportive: IVF, analgesia, antiemetics, NGT for bowel decompression
- Early abx as for neutropenic fever (see above); add flagyl if hx or c/f Cdif
May need surgical intervention if e/o perforation or bowel necrosis

**Disposition**
- Admit, may need ICU

---

**Hyperviscosity Syndrome** *(Emerg Med Clin N Am 2014:32:495)*

**Overview**
- **Definition:** Rise in serum viscosity 2/2 proteins, causing low-flow & prolonged bleeding
- Most common in Waldenström macroglobulinemia (leading cause; can be presenting sx), multiple myeloma, acute leukemia (2/2 cellular proteins)
- **Approach:** Early IV access, IVF, abx, surgical consultation

**History**
- Classic triad: mucosal bleeding, visual deficits, focal neuro signs; can also see CHF, pulm edema, AKI, confusion

**Physical Exam**
- Assess mucosal bleeding, fundoscopic exam, neuro findings

**Evaluation**
- CBC w/ diff, Chem 20, lactate ± NCHCT (if neuro sx), BNP, Troponin, CXR

**Treatment**
- Supportive: IVF
- Consultation w/ oncology for emergent plasmapheresis or expedited chemotx

**Disposition**
- Admit, may need ICU

---

**Sickle Cell Disease**

**Overview**
Pathophysiology: Recessive β-globin mutation → structurally abnl HbS → deoxygenated form polymerizes → RBC sickles → hemolysis/microvascular occlusion → tissue ischemia

<table>
<thead>
<tr>
<th>Acute Presentations of SCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute anemia</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Vaso-occlusive crisis (VOC)</td>
</tr>
<tr>
<td>Acute chest syndrome (ACS)</td>
</tr>
</tbody>
</table>

Approach: Initiate empiric IVF & analgesia early, can decompensate quickly; maintain high index of suspicion for infection from encapsulated organisms 2/2 functional asplenia

History & Physical Exam

HX: Assess location, duration, & severity of pain; similarity to prior crises; infectious sx

PE: Assess joint ROM in areas affected; respiratory status; neuro deficits; priapism

Evaluation

CBC w/ diff (compare to baseline), Chem 20 (↑ bili in hemolysis), reticulocyte count (↑ in hemolysis or sequestration; ↓ in aplastic crisis), LDH (elevated), ABG (if hypoxic)

Imaging as directed by sx: CXR (if CP or c/f ACS), x-ray/MRI (osteomyelitis or avascular necrosis), CTA chest (PE); CTA/MRI (stroke)

Treatment

<table>
<thead>
<tr>
<th>Acute tx in SCD (Chest 2016;149(4):1082)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aplastic crisis</td>
</tr>
<tr>
<td>Hyperhemolytic crisis</td>
</tr>
</tbody>
</table>
Splenic sequestration | pRBC transfusion
---|---
VOC | $O_2$, IVF, Analgesia (check pain plan w/ outpt hematologist if possible), pRBC transfusion if below baseline
Acute chest syndrome | $O_2$, IVF, Abx (CTX/azithromycin), exchange transfusion; pRBC transfusion if delay to exchange transfusion
Acute stroke | $O_2$, IVF, exchange transfusion; pRBC transfusion if delay to exchange transfusion
Other severe organ injury (eg, hepatic) | $O_2$, IVF, pRBC transfusion, discuss exchange transfusion w/ hematology
Sepsis (any cause) | Broad-spectrum abx, esp if indwelling line

### Chronic

### Disposition
- Home: If pain controlled, no e/o hemolysis; close hematology f/u
- Admit: Any acute cx as detailed above

## ABNORMAL BLEEDING

### Overview
- Etiology & tx depend on nature of problem (plt count, plt fxn, clotting time, combo)

### Differential Dx for Abnl Bleeding

<table>
<thead>
<tr>
<th>1° Problem</th>
<th>Potential Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>↓ plt count</td>
<td>ITP, HUS/TTP, DIC, HELLP syndrome (if pregnant), SLE, HIT, splenic sequestration (eg, NHL, myelofibrosis, cirrhosis), bone marrow failure (eg, aplastic anemia, heme malignancy), massive transfusion/dilution, chronic systemic dz</td>
</tr>
<tr>
<td>↓ plt fxn</td>
<td>vWD, meds (eg, ASA/NSAIDs, clopidogrel, GP IIb/IIA inhibitor), chronic systemic dz (eg, uremia, cirrhosis, leukemia/MDS)</td>
</tr>
<tr>
<td>↓ clotting</td>
<td>DIC, meds (eg, coumadin, DOACs), factor deficiency (eg, hemophilia),</td>
</tr>
</tbody>
</table>
cascade  |  chronic systemic dz (eg, malnutrition, cirrhosis), massive transfusion/dilution

**History & Physical Exam**

- Bleeding syndromes can present in many organ systems, including several at once:

<table>
<thead>
<tr>
<th>System</th>
<th>Manifestation</th>
<th>System</th>
<th>Manifestation</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEENT</td>
<td>Gingival bleeding, epistaxis</td>
<td>GU</td>
<td>Hematuria, menorrhagia</td>
</tr>
<tr>
<td>CNS</td>
<td>ICH, epidural hematoma</td>
<td>MSK</td>
<td>Hematoma, hemarthrosis</td>
</tr>
<tr>
<td>Pulm</td>
<td>Hemoptysis</td>
<td>Skin</td>
<td>Petechiae, purpura, ecchymosis</td>
</tr>
<tr>
<td>GI</td>
<td>Hematemesis, melena, hematochezia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Physical exam may suggest sp bleeding problem:
  - Petechiae: ↓ plt count
  - Purpura: ↓ plt count, ↓ plt fxn, problem w/ blood vessels or connective tissue
  - Ecchymosis: ↓ clotting cascade, problem w/ connective tissue, trauma

**Evaluation**

- CBC w/ diff, Chem 7, Coags; consider LFTs, peripheral blood smear, DIC panel (fibrinogen, D-dimer, LDH, haptoglobin), direct Coombs

---

**Immune Thrombocytopenia**

**Overview**

- **Definition**: Immune Ab-mediated destruction of PLTs (PLT count <100 k/μL); either 1° (idiopathic) or secondary (2/2 virus, meds, autoimmune dz, pregnancy, vaccine)
- Common associated meds: quinine, antimicrobials (linezolid, rifampin, vancomycin, sulfa), anticonvulsants (phenytoin, VPA, carbamazepine), thiazides, H2-blockers, NSAIDs/tylenol, chemotx
**Dx of exclusion:** r/o TTP/HUS, HIT, hematologic d/o (eg, malignancy, MDS, HIV)

**History & Physical Exam**
- Acute/subacute petechiae ± e/o bleeding (see above; assess for ICH, GIB, etc.); always ask about new meds, recent infectious sx, pregnancy

**Evaluation** *(Blood 2010;115(2):168)*
- CBC w/ diff (↓ plt count, otw nml), peripheral smear (no schistocytes), Coags (nml), T+S
- HIV/HCV recommended on all pts to r/o alt cause, *H. pylori* can be associated as well
- If dx confirmed or highly suspected: obtain baseline IgG/A/M levels, direct antiglobulin

**Treatment** *(Blood 2010;115(2):168; NEJM 2007;357(6):580)*
- Adults: If asx, tx rarely indicated if PLTs >50k & no bleeding, trauma, or surgery
- Children: Manage mild cases expectantly, treat if PLTs <20k or active bleeding

<table>
<thead>
<tr>
<th>Tx for ITP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Children</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
Transfuse platelets as per guidelines below (see Transfusion section)

- Steroids: 50–75% response, often by 3 wk
- IVIG: Equivalent but quicker remission compared to steroids; consult w/ hematology
- Anti-D Ig: As effective as IVIG, but shorter infusion, longer response; consult w/ hematology
- Second-line tx should be discussed w/ consultant: azathioprine, cyclosporine, cyclophosphamide, dapsone, mycophenolate, rituximab, splenectomy, others
- No role for plasmapheresis in tx of ITP

Disposition
- Home: If no active bleeding, PLTs >20k
- Admit: Any pt w/ PLTs <20k &/or active bleeding
- Long-term relapse is common (>70%) despite tx modality (NEJM 2007;357(6):580)

HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)

Overview
- **Definition:** TCP (<150k) or 30–50% drop in plt count after starting heparin
  - More common w/ unfractionated heparin, but occurs as well w/ LMWH
- **Pathogenesis:** Heparin-dependent IgG binds PF4 → plt activation → ↑ thrombosis
  - Thrombosis causes sx in 50% pts: PE, DVT > limb ischemia, stroke > MI

History & Evaluation
- Can have sx of TCP (if plts very low), thrombosis (even w/ nl plt count), or be incidental discovery; very rarely causes bleeding
- Usual occurrence 5–10 d after starting heparin, more rapid onset if recent heparin exposure
- Anti-PF4 enzyme assays highly se, poorly sp (good NPV); combine lab testing w/ clinical probability (hi, med, low) based on: Δ plt count
Treatment (NEJM 2006;355:809; NEJM 2001;344:1286)
- STOP heparin + any device/flush that contains heparin (even if thrombotic cxs)
- Initiate nonheparin a/c (even if no thrombosis): argatroban (first-line), bivalirudin, lepirudin
  - Avoid vitamin-K antagonists, as will decrease protein C → ↑ thrombosis
- Avoid PLT transfusions unless bleeding or high risk of bleeding
- Recurrence w/ future heparin may be low if neg. for PF4 Ab >100 d after Dx

Disposition
- Admit for monitoring & intravenous anticoagulation

Hemolytic-Uremic Syndrome (HUS) & Thrombotic Thrombocytopenic Purpura (TTP)
(NEJM 2006;354(18):1927; NEJM 2014;371(7):654)

Overview
- **Definition:** Systemic (TTP) or intrarenal (HUS) microvascular occlusive d/o 2/2 PLT aggregation → MAHA + TCP
- **Pathogenesis:** TTP a/w ADAMTS13 dysfxn (ADAMTS13 normally cleaves vWF, resultant inability to cleave vWF → plt activation → microthrombi); HUS a/w *E. coli* O157:H7

History & Physical Exam
- TTP: Acute/subacute, can be subtle & non-sp (classic pentad rare); adults > children
  - MAHA: Vague sx (abd pain, nausea, weakness) 2/2 diffuse microvascular thrombi
  - TCP: e/o bleeding, skin findings (petechial, purpura)
  - Neuro sx: AMS, stroke, szs; neuro sx present only 50%
  - AKI: Can be mild
  - Fever: Uncommon, low-grade when present); no other cause
- HUS: Acute-onset, bloody diarrhea & abd pain, f/b TCP & renal
failure
- Classic triad: MAHA + TCP + Renal failure
  - Always ask about triggers: HUS (contaminated food), TTP (meds, systemic dz, HSCT)

Evaluation
- CBC w/ diff (↓ Hct, ↓ Plt), Chem 20 (↑ Cr, ↑ LFTs), peripheral smear (schistocytes), coags (nml), ↑ LDH, ↓ haptoglobin, fibrinogen, D-dimer, UA

Treatment *(NEJM 2006;354(18):1927; NEJM 2014;371(7):654)*
- Consult hematology, consider renal consult early
- TTP: Plasma exchange (↑ survival @ 6 mo, 78%), FFP (if delay to plasma exchange), Steroids (prednisone 1–2 mg/kg/d, methylprednisolone 1 g/d, data on efficacy limited)
- HUS: Supportive; pts commonly need dialysis
- Do not give PLTs → ↑ microvascular thrombosis

Disposition
- Admit, may require ICU
- Risk of relapse is low in acquired TTP, but can occur even years after initial episode
- HUS in kids often resolves w/o long-term renal dz (but >45% mortality in adults)

---

**DISSEMINATED INTRAVASCULAR COAGULATION (DIC)**

Overview
- **Definition:** Acquired life-threatening consumptive coagulopathy a/w diverse dz
- **Pathogenesis:** Widespread activation of coagulation → thrombosis of small/midsized vessels → organ dysfxn, ↓ PLTs/coagulation factors → bleeding & thromboembolism

<table>
<thead>
<tr>
<th>Causes of DIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer (top cause)</td>
</tr>
<tr>
<td>Solid tumors, hematologic malignancy, metastasis</td>
</tr>
<tr>
<td>Infectious dz</td>
</tr>
<tr>
<td>Sepsis, viremia</td>
</tr>
<tr>
<td>Trauma</td>
</tr>
<tr>
<td>----------------------------</td>
</tr>
<tr>
<td>Obstetrics</td>
</tr>
<tr>
<td>Immunologic</td>
</tr>
</tbody>
</table>

**History, Physical Exam, Evaluation**
- Underlying systemic dz is necessary for dx (see above)
- Assess for s/sx of bleeding, end-organ damage
- CBC w/ diff (∇ PLTs [usually <100]), ↑ PT, ↑ PTT, ↑ D-dimer, ↓ fibrinogen, ↑ LDH, ↑ Fibrin degradation products, e/o end-organ damage (↑ lactate, ↑ Cr); imaging PRN by sx
- Different scoring systems used to help in dx of DIC (*Thromb Haemost* 2011;105(1):40)

**Treatment**
- Treatment of underlying disorder is mainstay of tx
- Transfuse if bleeding, risk of bleeding, or need for procedure: PLTs (if bleeding + plt <50k, or plt <20k), FFP (if INR >1.5; beware large doses may be required [15–30 mL/kg]), cryoprecipitate (if fibrinogen <1.5 g/dL despite FFP), prothrombin complex concentrate (if bleeding & FFP delayed/not possible [eg, volume])
- Heparin/LMWH if thromboembolism predominates (LMWH may be superior to UH)

**Disposition**
- Admit to ICU

**von Willebrand Disease (vWD)**

**Overview**
- **Definition:** Most common inherited bleeding d/o caused by ↓ vWF (↓ quantity [type 1, 3] or fxn [type 2]); vWF carries factor VIII & enables plt adhesion/aggregation; rarely acquired
- **Etiology:** Precursor vWF cleaved by ADAMTS13 (see TTP above) → circulating vWF activated by vascular damage → vWF binds collagen → plt aggregation
• ↓ vWF leads to ↓ plt aggregation & ↑ factor VIII degradation

**History & Physical Exam**
- Mucocutaneous bleeding, menorrhagia, bruising, epistaxis, hemarthrosis, hematomas
- 5–20% of pts w/ menorrhagia will have vWD (sometimes requiring TAH)
- Most pts aware of their hx (60–80% will have bleeding after surgery)

**Evaluation**
- CBC w/ diff, T&S, coags (↑ PTT); ↓ vWF Ag, ↓ vWF activity, ↓ factor VIII activity

**Treatment**
- Desmopressin (DDAVP): Most useful in Type 1 vWD, where sufficient & functional vWF exists in noncirculating form; DDAVP causes endothelial release of vWF & ↑ circulating vWF levels (no chg in overall vWF); efficacy variable; dose 0.3 μg/kg IV
- vWF replacement: most useful in Type 2 or 3, where endogenous vWF either dysfxnal or absent; options in include cryoprecipitate (requires up to 8–12 bags), plasma-derived vWF/factor VIII concentrate (Humate-P), or recombinant vWF + factor VIII
- Life-threatening bleeds: Important to increase levels of both vWF & factor VIII
- Adjunct tx: Antifibrinolytic amino acids (eg, TXA); high-quality data lacking

**Disposition**
- If severe or significant bleeding, admx; if d/c, f/u w/ hematology

---

**Hemophilia A/B**


**Overview**
- Definition: X-linked (males) d/o 2/2 ↓ factor VIII (hemophilia A) or factor IX (hemophilia B)
<table>
<thead>
<tr>
<th>Severity</th>
<th>Factor Concentration (% of nml)</th>
<th>Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>5–40 IU/dL</td>
<td>Spontaneous IM bleeding</td>
</tr>
<tr>
<td>Moderate</td>
<td>1–5 IU/dL</td>
<td>Severe bleeding w/ minor trauma</td>
</tr>
<tr>
<td>Severe</td>
<td>&lt;1 IU/dL</td>
<td>Severe bleeding w/ major trauma</td>
</tr>
</tbody>
</table>

**History & Physical Exam**
- Bleeding (GI, GU, mucosa), hematoma, hemarthroses, bruising

**Evaluation**
- CBC, nml INR, ↑ PTT, T&S, Imaging PRN

**Treatment**
- Minor bleeds: desmopressin/DDAVP (0.3 μg/kg IV, 150 μg IN kids/300 μg IN adults) increases factor VIII concentration 3–5 × 2/2 release of vWF; transexamic acid (25–50 mg/kg/d); DDAVP for hemophilia A, TXA for hemophilia A/B
  - If severe (eg, ICH), give factor even prior to diagnostic testing
  - If pts have developed inhibitors to factor VIII, consider use of factor VIIa or prothrombin complex (bypass factor VIII in clotting cascade)

---

**TRANSFUSIONS**

*See Chapter 18 for transfusions in trauma.*

**Overview**
- **Approach:** Obtain type/screen for any pt suspected of needing transfusion

<table>
<thead>
<tr>
<th>Transfusion Product Sp</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irradiated</td>
<td>Use for pts w/ cellular immunosuppression (eg, neonates, HSCT, congenital immune def); destroys donor T-cells (↓ GVHD)</td>
</tr>
<tr>
<td>Leuko-reduced</td>
<td>Use for tpx pts or pts requiring mx transfusions; removes WBCs (↓ infxn [eg, CMV], ↓ rejection against donor product)</td>
</tr>
<tr>
<td>Washed</td>
<td>Use for pts w/ hx of transfusion allergic rxns; removes plasma</td>
</tr>
</tbody>
</table>

- **When to give:** restrictive strategies ↓ adverse events, mortality
  
  (Cochrane 2012;(4):CD002042)
  - All pts: Hgb ≤7, Hgb >7 + acute, ongoing, or significant sx
  - Cardiovascular dz: Hgb ≤8, Hgb >8 + acute, ongoing, or significant sx

- **What to give:** always obtain T&S in anyone who may need transfusion
  - Emergent transfusion: O neg. blood to females, O positive to males
  - In massive transfusion (expected >10 U PRBC/d), give FFP & PLTs as well

- **How much to give:**
  - Neonates: ↑ Hgb by 3 g/dL for 10–15 mL/kg of PRBCs
  - Adult: ↑ Hgb by 1 g/dL or Hct by 3%, for each 1 U PRBCs

- **What to monitor:**
  - Electrolytes: esp if large volume PRBC (↑ K, ↓ Ca)
  - O₂: Pts w/ CHF may require concurrent diuresis

Platelet Transfusion

- **When to give:**
  - PLT < 10K: regardless of s/sx of bleeding or comorbidities
  - PLT < 20K: non-bleeding but high risk if deteriorates (eg, chronically ill, high-risk onc)
  - PLT < 50K: active bleeding or need for invasive procedure
  - PLT < 100K: need for ophthalmologic or neurosurgical procedure

- **How much to give:** ↑ PLTs by 5000–10000 for each 1 U PLTs

Fresh-Frozen Plasma Transfusions (Transfusion 2010;50(6):1227)

- **When to give:** Mass transfusion (see Trauma section); reversal of warfarin; coagulopathy (eg, DIC); TTP/HUS (if delay to plasmapheresis); replacement of factor deficiencies

- **How much to give:** 10–20 mL/kg will ↑ coagulation factors by 20–30% (1U FFP = 200 mL); consider giving concurrent diuretic if e/o or known hx of CHF
Cryoprecipitate Transfusions

- How much to give: fibrinogen level <1 g/dL; factor XIII deficiency; hemophilia or vWD
- How much to give: 1 U/5–10 kg body weight to maintain fibrinogen >1 g/L

Anticoagulation Reversal

Approach

- Hold further doses of anticoagulant
- Supportive care: Gastric lavage or activated charcoal (if overdose w/i 1 h), apply pressure to site of bleeding if possible, transfuse (as indicated)
- Agent-sp reversal: If significant/life-threatening bleeding (eg, ICH, hemoptysis, GIB) or need for emergent procedure/surgery

<table>
<thead>
<tr>
<th>Reversal of Common Anticoagulants</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiplatelet agent</strong></td>
</tr>
<tr>
<td>Minor bleed</td>
</tr>
<tr>
<td>Weigh risks/benefits of holding antiplatelet</td>
</tr>
<tr>
<td>Severe bleed</td>
</tr>
<tr>
<td>Hold antiplatelet agent</td>
</tr>
<tr>
<td>Consider plt transfusion (though new data suggests may cause harm in case of ICH)¹,²</td>
</tr>
<tr>
<td><strong>Heparin</strong></td>
</tr>
<tr>
<td>Protamine (1 mg/90–100 U heparin in last 2–3 h; max 50 mg)²</td>
</tr>
<tr>
<td><strong>LMWH</strong></td>
</tr>
<tr>
<td>Protamine may be partially (60–80%) effective (dosing above)² Andexanet may be effective (under study)³</td>
</tr>
<tr>
<td><strong>Warfarin</strong>³</td>
</tr>
<tr>
<td>INR &lt;5</td>
</tr>
<tr>
<td>No bleeding</td>
</tr>
<tr>
<td>Decrease or omit single warfarin dose F/U for INR check w/i 48–72 h</td>
</tr>
<tr>
<td>INR 5–9</td>
</tr>
<tr>
<td>No bleeding</td>
</tr>
<tr>
<td>Omit 1–2 warfarin doses Vitamin K 2.5 mg PO × 1 if risk for bleeding F/U for INR check w/i 24–48 h</td>
</tr>
<tr>
<td>INR &gt;9</td>
</tr>
<tr>
<td>No bleeding</td>
</tr>
<tr>
<td>Hold warfarin (until F/U INR recheck) Vitamin K 5 mg PO × 1 F/U for INR check w/i 12–24 h</td>
</tr>
<tr>
<td>INR &gt;1.5</td>
</tr>
<tr>
<td>Serious bleed</td>
</tr>
<tr>
<td>Hold warfarin Vitamin K 5–10 mg IV (risk of anaphylactoid rxn) Prothrombin clotting complex (25–50 IU/kg) FFP (10–20 mL/kg) only if PCC unavailable</td>
</tr>
</tbody>
</table>
DOAC | Dabigatran | Idarucizumab reverses bleeding w/i minutes$^5$
| | | 4-factor PCC may have effectiveness
Rivaroxaban | 4-factor PCC may have effectiveness
| | Andexanet may be effective (under study)$^6$
Apixaban | 4-factor PCC may have effectiveness
| | Andexanet may be effective (under study)$^6$

NOTE: At time of publishing, several additional DOACs & reversal agents are under investigation. Data is limited.


Pearls
- Irreversible antiplatelet agents inhibit life of platelet (7–10 d)
- Vitamin K takes 6 (IV) to 24 (PO) hours to reverse warfarin; IV may cause anaphylactoid rxn in rare instances (push slowly over 30 min)
- 4F-PCC superior to FFP, may have fewer adverse events (Lancet 2015;385(9982):2077)
  - Adverse events: w/ 4F-PCC mostly 2/2 thrombosis; w/ FFP mostly 2/2 volume

TRANSFUSION COMPLICATIONS

Approach
- Always obtain consent if possible before giving a transfusion
- If e/o rxn: Stop transfusion, check bag, label, & send remaining products to blood bank
  - May be possible to resume transfusion in mild allergic rxn only (see below)
- If febrile, obtain CBC, smear, direct Coombs, UA, gram stain, BCx (pt & product)

<table>
<thead>
<tr>
<th>Common or Critical Transfusion rxns</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rxn</td>
</tr>
<tr>
<td>Febrile (nonhemolytic)</td>
</tr>
<tr>
<td>Condition</td>
</tr>
<tr>
<td>-----------</td>
</tr>
</tbody>
</table>
| Allergic | | | Histamine-mediated; more common w/ platelet transfusion  
**DX:** Pruritus, urticaria ± angioedema, e/o anaphylaxis  
**TX:** H1B; if anaphylaxis then add H2B, glucocorticoids, IM epi; can restart transfusion if sx were local only & full resolution (stop if recurs)  
**Pearls:** If hx of transfusion allergic rxn, consider washed products & H1B premed; no role for steroid premed |
| Febrile (acute hemolytic) | 1:10,000 | | Blood product error (eg, ABO incompatibility, incorrect preparation): can be immune or nonimmune  
**DX:** Fever (first sign) → flank pain, AKI, hemoglobinuria, anemia, DIC, shock w/i 24 h  
**TX:** If fever, monitor for other sx; IVF/diuretics for UOP  
**Pearls:** Differs from delayed hemolytic rxn (1:2.5K [1:10 in SCD]; 2/2 Abs against non-ABO groups; occurs 1 wk after transfusion; dx by Hgb not rising as expected, +Coombs, ↑ Bili; no tx needed) |
| TRACO (transfusion-associated circulatory overload) | 1:10,000 | | Excess volume/rate of transfusion, ↑ risk if hx of CHF, CKD, large volume or rapid rate (eg, hemorrhage)  
**DX:** SOB, ↑ BNP, ↑ CVP, pulm edema w/i 6 h of transfusion  
**TX:** O₂, diuresis, NIPPV prn, restart transfusion slowly  
**Pearl:** Give diuresis w/t fusion high-risk for TRACO |
| TRALI (transfusion-related lung injury) | 1:100,000 | | Proposed etiology: donor Abs bind recipient WBCs → pool in pulm capillaries → ↑ permeability → edema  
**DX:** SOB, ↓ O₂, CXR w/ b/l infiltrates; fever/hypothermia, hypotension/HTN; w/i 72 h of transfusion  
**TX:** Supportive (O₂, low tidal-volume vent if intubated) |
| Septic | 1:100,000 | | Infected blood product, most common w/ platelets  
**DX:** Fever, rigors, hypotension; +BCx (pt &
Infectious Complications

- Incidence is 25–80% in 1st year after transplant
- Can be subtle: Immunosuppression can diminish classic sx (eg, fever, localizing sx), radiographic signs, or serology results; maintain high index of suspicion
- Timing of infection after tpx a/w type of infection
  - Nosocomial: Asp PNA, wound infxn, UTI (Foley), donor infxn, line infxn, C, difficile
  - Opportunistic: PJP, Histoplasma, Coccidioides, Cryptococcus, HBV, HCV, BK polyomavirus, CMV, TB, EBV; assess if pt is on ppx (eg, PJP, CMV, fungal ppx)
  - Community: PNA, Influenza, EBV, RSV, Legionella, UTI
- If septic, strongly consider adjunct stress-dose steroids

<table>
<thead>
<tr>
<th>Infections in Posttransplant pts</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–1 mo posttransplant</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>1–6 mo posttransplant</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>&gt;6 mo posttransplant</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Graft Rejection

- Recipient immune-mediated rxn against transplanted organ (esp microcirculation)
- Frequency & sx of rejection vary by organ tpx type
• 20% kidney; 64% (acute)/23% (late) liver tpx, 30% cardiac (acute), 30% lung (first yr)
  ‣ Essential to involve transplant team if considering rejection
  ‣ TX: High-dose intravenous steroids; may require additional tx

<table>
<thead>
<tr>
<th>Signs &amp; sx of Transplant Rejection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal (20%)</td>
</tr>
<tr>
<td>SX: Often asx; fever, malaise, oliguria, graft pain; HTN</td>
</tr>
<tr>
<td>DX: Labs (↑ BUN/Cr, abnml lytes); urine lytes (r/o other dx);</td>
</tr>
<tr>
<td>Renal US w/ ↑ resistive indices</td>
</tr>
<tr>
<td>Liver (60% &lt;6 mo; 25% late)</td>
</tr>
<tr>
<td>SX: Fever, malaise, abd pain, organomegaly, ascites</td>
</tr>
<tr>
<td>DX: Labs (↑ LFTs); RUQUS (r/o other dx [eg, thrombosis])</td>
</tr>
<tr>
<td>Cardiac (30% &lt;6 mo)</td>
</tr>
<tr>
<td>SX: SOB, orthopnea, palpitations, near-syncope, GI sx if R</td>
</tr>
<tr>
<td>heart predominance (RUQ pain, nausea)</td>
</tr>
<tr>
<td>DX: Labs (↑ Troponin, BNP), ECG w/ ST/Tw chgs, BSUS w/</td>
</tr>
<tr>
<td>systolic/diastolic dysfuxn; CXR w/ edema (if L heart)</td>
</tr>
<tr>
<td>Lung (30% &lt;1 yr)</td>
</tr>
<tr>
<td>SX: SOB, cough, lung exam variable</td>
</tr>
<tr>
<td>DX: Labs (↑ eos), CXR can be nml, Chest CT</td>
</tr>
</tbody>
</table>

Organ-specific Complications

Renal Transplant
  ‣ UTI (most common): always cx; consider strongly dual-abx & admx
  ‣ Arterial stenosis (10%): HTN, ↓ UOP, edema; U/S w/ flow limitation; tx w/ stent
  ‣ Venous thrombosis (4%): Graft pain/erythema, ↓ UOP, N/V; U/S (may need contrast CT); often results in graft failure & need for graft replacement
  ‣ Ureteral obstruction (3–6%): ↓ UOP, edema; U/S w/ hydronephrosis; if no correction w/ Foley, may need percutaneous intervention for urinary drainage
  ‣ Urinary leakage (2–5%): ↓ UOP, perineal leakage; U/S w/ peritpx fluid collxn; urology c/s
  ‣ Lymphocele (5–15%): abd swelling; US w/ hydrocele (CT for definitive dx)

Liver Transplant
  ‣ Hepatic artery thrombosis (4–12%): Doppler U/S 90% Se; mortality 80% w/o tx
  ‣ Hepatic artery stenosis (14%): Doppler U/S 70% Se; may require
angiography for dx

- Pseudoaneurysm: Can cause hemobilia, hemoperitoneum, GI bleed; dx w/ U/S or CT
- Biliary strictures: May be asx 2/2 denervation; U/S (Se 66%), MRCP (Se 95%); tx stent
- Biliary leaks (2–25%) & bilomas: tx w/ stenting over leak, drain & abx (if biloma)

Cardiac Transplant

- Allograft vasculopathy (30–70%): Chronic & progressive; rapid atherosclerosis in tpx organ; may have s/sx of ischemia, or be asx 2/2 denervation (inc sudden cardiac arrest)
- Bradycardia: 2/2 sinus or AVN trauma; refractory to atropine 2/2 loss of vagal innervation
- Tachyarrhythmias: BB > CCB for Afib/flutter (2/2 med interaction); half-dose adenosine 2/2 sensitivity of transplanted heart

Lung Transplant

- Airway anastomotic stenosis, tracheobronchomalacia (increase in granulation tissue), necrosis; SOB/stridor; CT may help, but bronch is definitive dx; may need stent
- Fistula: Depending on tract, may present w/ PTX, crepitus, hemoptysis
- Pulm artery stenosis: Early & late after tpx; SOB, ↓ O₂, LE edema, ↓ BP; dx w/ CTA chest
- Pulm vein thrombosis: Early after tpx; SOB, ↓ O₂, LE edema, ↓ BP; dx w/ CTA chest
- Phrenic nerve injury (3–9% lung tpx; 40% heart–lung tpx): SOB; CXR ↑ hemidiaphragm
LEG PAIN AND SWELLING

Approach
- Careful hx: Anatomic distribution, unilateral vs. bilateral, acute vs. chronic, a/w erythema or dermatologic findings; hx of trauma
- Assess for paresthesia, hyperesthesia, or neuropathy
- Complete neurologic & vascular exam, assess for motor weakness

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac</td>
<td>CHF (edema, venous stasis)</td>
</tr>
<tr>
<td>Vascular</td>
<td>DVT (see Ch. 1), PVD, arterial occlusion, vascular ulcers, thrombophlebitis</td>
</tr>
<tr>
<td>Infection</td>
<td>Osteomyelitis, necrotizing fasciitis, septic joint, cellulitis/abscess (see Ch. 4)</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Fracture, sprain, dislocation, hematoma, compartment syndrome; spinal stenosis (pseudoclaudication)</td>
</tr>
<tr>
<td>FEN/GU</td>
<td>Electrolyte abnlts, glomerulonephritis, nephritic syndrome</td>
</tr>
<tr>
<td>OB/GYN</td>
<td>Pregnancy, HELLP syndrome</td>
</tr>
<tr>
<td>Neurologic</td>
<td>Guillain–Barré, peripheral neuropathy</td>
</tr>
<tr>
<td>Environmental</td>
<td>Heat edema</td>
</tr>
<tr>
<td>Neoplasm</td>
<td>Sarcoma, SVC syndrome</td>
</tr>
</tbody>
</table>

PERIPHERAL VASCULAR DISEASE

Claudication

History
- Ischemic muscle pain reproducible w/ exertion, improves w/ rest
- Pts often place legs in dependent position to improve flow
1–2% have chronic critical limb ischemia: Pain at rest, nonhealing ulcers, dry gangrene

**Findings:** May have nl exam at rest w/ or w/o ↓ peripheral pulses; shiny, smooth skin

**Evaluation**
- ABI <0.9 is diagnostic of PVD (sens & spec)
- Careful pulse exam, w/ Doppler if difficult to palpate
- Look for signs of critical ischemia (rest pain, nonhealing ulcers)

**Management:** If concern for critical ischemia or acute dz, consult vascular surgery

**Disposition**
- Admit acute dz
- D/C home if chronic w/ vascular surgery f/u, strict return instructions

**Acute Extremity Arterial Occlusion**

**History**
- Known PVD +/- or RFs (HTN, tobacco, known CAD, AF)
- Abrupt onset of pain w/ distal paresthesias
- Late (concerning findings): poikilothermia, pallor, paresthesia, pulselessness

**Findings**
- Cold, mottled extremity, ↓ pulse, motor weakness, ± bruit
- Tenderness to palpation out of proportion of exam or ↓ sensation

**Evaluation**
- Bedside Doppler of all pulses, including unaffected extremities; ABI
- Labs: CBC, BMP, baseline coags, ± lactate
- U/S can demonstrate level of occlusion
- CTA or angiography
- ECG for arrhythmia, may need echo to look for embolic source

**Treatment**
- Immediate vascular surgery consultation for possible embolectomy
- Anticoagulation (discuss w/ vascular): Heparin 18 U/kg/h IV w/o bolus

**Disposition**
- Transfer to facility w/ vascular surgery capability if none available
Pearl

- Ischemic tissue D starts by 4 h; sooner in pts w/ chronic arterial insufficiency

<table>
<thead>
<tr>
<th>Measurement of Ankle–Brachial Indices (ABIs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
</tbody>
</table>

**TRAUMA**

**Compartment Syndrome**

**History**

- Can occur in any closed fascial space, most commonly in distal lower extremity (calf)
- Hx of trauma (esp crush), burns, rhabdomyolysis, tight cast/dressing, hemorrhage (anticoagulants, coagulopathy), postischemic swelling, snakebites, IVDU

**Findings**

- Pain out of proportion to exam, pain w/ passive stretch of muscles that run through compartment (see the table below), paresthesias, pallor of the extremity, taut or rigid compartment. LATE: Decreased pulse, sensory/motor deficits.

**Evaluation**

- Measure compartment pressures: nl <8 mmHg; emergent fasciotomy if >30 mmHg
- Stryker instrument: Enter each compartment perpendicular to the skin
- A-line manometer: Attach 18G needle to A-line manometer; check that the compartment pressure being measured is at the same
height as the manometer transducer

**Treatment**
- Immediate orthopedic/surgical consult for fasciotomy

**Disposition**
- Admit to ortho for serial manometry & neurovascular checks if compartment pressures <30 mmHg but evolving compartment syndrome suspected

**Pearls**
- Nl compartment pressure does not r/o compartment syndrome; clinical Dx
- 6% incidence w/ open tibia fx; 1% in closed tibia fx; 30% w/ arterial injury; 14% w/ venous

<table>
<thead>
<tr>
<th>Lower-Extremity Compartments &amp; Associated Muscles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deep posterior</td>
</tr>
<tr>
<td>Superficial posterior</td>
</tr>
<tr>
<td>Lateral</td>
</tr>
<tr>
<td>Anterior</td>
</tr>
</tbody>
</table>

**LOWER BACK PAIN**

**Approach**
- Careful hx: Anatomic distribution, unilateral vs. bilateral, acute vs. chronic, fever, abd pain, groin pain, syncope hx of trauma; worse at rest or at night; incontinence?

<table>
<thead>
<tr>
<th>Historical Red Flags for Back Pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>For fracture</td>
</tr>
<tr>
<td>For malignancy</td>
</tr>
<tr>
<td>For infection</td>
</tr>
<tr>
<td>For aortic/vascular</td>
</tr>
</tbody>
</table>
• Physical exam w/ thorough neurologic exam, straight leg raise, pulses, rectal tone, gait
• Always check urine pregnancy test in females of childbearing age
• X-rays not routinely indicated: Use for red flags above, abnl exam, point tenderness
• Most require only analgesia & f/u but always consider life- & limb-threatening conditions

<table>
<thead>
<tr>
<th>Differential Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>GI (see Ch. 3)</td>
<td>Abd aneurysm/dissection, pancreatitis, cholecystitis, ulcer (±perforation)</td>
</tr>
<tr>
<td>Trauma</td>
<td>Acute lumbosacral strain, vertebral compression fracture, retroperitoneal bleed (minor/no trauma but on anticoagulant)</td>
</tr>
<tr>
<td>Infectious</td>
<td>Spinal epidural abscess, discitis, osteomyelitis, pyelonephritis/perinephric abscess</td>
</tr>
<tr>
<td>Neurologic</td>
<td>Cauda equina syndrome, herniated disc, spinal stenosis</td>
</tr>
<tr>
<td>Rheumatologic</td>
<td>Rheumatoid arthritis, ankylosing spondylitis, OA</td>
</tr>
<tr>
<td>FEN/GU</td>
<td>Nephrolithiasis</td>
</tr>
<tr>
<td>Vascular</td>
<td>Spinal hematoma/dissection</td>
</tr>
<tr>
<td>Neoplasm</td>
<td>Malignancy (multiple myeloma in elderly), bony metastasis</td>
</tr>
</tbody>
</table>

**TRAUMA**

**Acute Lumbosacral Strain**

**History**

• Usually hx of precipitating event: twisting, lifting, new workout.
  • Acute/subacute onset
• Should have no fever or radicular sxss

**Findings:** Paravertebral muscle spasm & tenderness, nl neuro exam

**Evaluation:** No indication for imaging acutely

**Treatment**

• NSAIDs; if severe, short course opioids or BZD; early activity (no
bed rest!

- Muscle relaxants of no proven value, many side effects
  (anticholinergic, dependence)

**Disposition:** D/C home w/ PCP f/u, strict return instructions

**Pearl:** Lumbar strain is the #1 cause of LBP in ED but a dx of exclusion

**Vertebral Compression Fracture**

**History:** Acute-onset LBP usually in elderly pts w/ osteopenia, smoking, on steroids

**Findings:** Focal tender area on spine, usually no neuro findings

**Evaluation:** Plain film of affected thoracic, lumbar, or sacral spine

**Treatment**

- Usually stable fractures; analgesia ± brace for comfort
- Consult ortho or spine for >50% compression or multiple fractures

**Disposition:** Admit for intractable pain, any neuro findings, >50% compression, multiple fractures

**Pearl:** Look for neoplastic cause if no other RFs or hx, esp in elderly

---

**NEUROLOGIC**

**Cauda Equina Syndrome**

**Definition:** Large central disk herniation of distal spinal cord – *neurosurgical emergency*

**History**

- Severe LBP shooting down 1 or both legs & neuro sxs: Saddle paresthesias, urinary retention w/ overflow incontinence, loss of bowel control or sexual Dysfxn; pts w/ recent trauma or cancer w/ possible mets

**Findings:** ↓ rectal tone, urinary retention, saddle anesthesia, areflexia, weakness

**Evaluation**

- MRI is imaging test of choice
- Postvoid residual is the most sens initial finding

**Management:** Emergent neurosurgery consult, admit
**Lumbar Spinal Stenosis**

**Definition:** Narrowing of lumbar spinal canal from degeneration, facet arthritis, or subluxation

**History:** 40+ y/o, bilateral low back pain, pseudoclaudication (pain w/ walking), age >40, improves w/ rest & flexion of back (walk hunched over to keep back flexed)

**Findings:** nl exam, nl SLR, pain w/ back extension

**Evaluation:** Emergent imaging not needed if nl neuro exam; CT, MRI are diagnostic

**Treatment:** Pain mgmt w/ NSAIDs; hip flexor & abd exercises; surgery if severe

**Disposition:** Close f/u w/ PCP, spine

**Herniated Disc**

**History**
- 30–40 y/o, hx of waxing/waning back pain shooting down leg (past the knee) ± paresthesias
- Exacerbated by leaning forward, coughing, sneezing, & straining (stretches nerve root)

**Findings**
- See table below (L4–5 is most common)
- SLR test correlates w/ nerve root irritation only if reproduced sx extend below knee; Ipsilateral is sens, contralateral is spec.

**Management**
- Neuro intact: Analgesia, DC home. MRI or CT myelogram if no improvement in 4–6 wk.
- Neuro deficits (or acute traumatic herniation): MRI to eval for cord involvement

**Disposition:** D/C if no cord findings; o/w needs spine consultation

**Pearl:** Sciatica is lumbar disc herniation impinging on sciatic nerve

<table>
<thead>
<tr>
<th>Root</th>
<th>Pain</th>
<th>Sensory Loss</th>
<th>Weakness</th>
</tr>
</thead>
<tbody>
<tr>
<td>L4</td>
<td>Hip, anterior thigh</td>
<td>Anteromedial thigh to medial aspect of foot</td>
<td>Weak quadriceps; ↓ knee jerk</td>
</tr>
<tr>
<td>L5</td>
<td>Lateral thigh/calf; dorsal</td>
<td>Lateral calf, dorsal foot,</td>
<td>↓ extensor hallucis longus</td>
</tr>
</tbody>
</table>
Spinal Epidural Abscess

History
- Classic triad of fever, local spine tenderness, extremity neurologic deficit
- High-risk population: IV drug abusers, immunocompromised, recent instrumentation, DM

Findings
- Classic sequence: Back pain → root pain/radiculopathy → motor weakness, sensory Δ, bowel/bladder dysfxn → paralysis

Evaluation: MRI w/ IV contrast is test of choice

Treatment
- Cover *Staph, Strep*, gram-neg. organisms: (nafcillin 2 g OR oxacillin) & (ceftriaxone 2 g OR ciprofloxacin) ± vancomycin, + antipseudomonal abx if instrumentation hx
- Spine surgery consultation; ±steroids; may want biopsy prior to abx

Disposition: Admit, usually to spine surgery; operative washout

Pearl: Avoid LP to prevent introduction of organisms into CSF unless meningitis highly suspected

Neoplastic

Bony Metastasis

History: >50 y/o, 1 mo of sx, weight loss. Commonly breast, lung, kidney, prostate, thyroid

Findings: Tenderness of lumbar spine to palpation

Evaluation
- Plain film. CT/MRI/bone scan if plain film not definitive
MRI & spine/oncology consultation if cord syndrome or findings

**Treatment**
- Pain control, Oncology referral
- If cord compressed, administer dexamethasone 10 mg IV or methylprednisolone 30 mg/kg IV, immediate consult

**Disposition:** Tx per spine surgery; possible operative decompression

**Pearls**
- 1° malignancy (esp multiple myeloma) should also be considered, esp in elderly
- Many bony mets missed on x-rays/CT; review films w/ radiologist specifically

---

**JOINT PAIN**

**Approach**
- Careful hx; anatomic distribution, single vs. multiple joints, acute vs. chronic, a/w fevers, skin Δ; hx of trauma
- Eval for systemic sxs in conjunction w/ chief complaint of joint pain
- If considering septic arthritis, evaluate need for arthrocentesis

---

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trauma</td>
<td>Fracture, dislocation, hemarthrosis, osteonecrosis, tenosynovitis</td>
</tr>
<tr>
<td>Infectious</td>
<td>Non-GC septic arthritis, GC septic arthritis, reactive arthritis, tenosynovitis, Lyme dz (see Ch. 4)</td>
</tr>
<tr>
<td>Rheumatologic</td>
<td>Gout, pseudogout, rheumatoid arthritis, OA</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Bursitis, tendinitis</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Region</th>
<th>Type</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shoulder</td>
<td>Rotator cuff injury</td>
<td>Inflammation or tear of rotator cuff tendons from direct trauma or overuse Pain in deltoid area of shoulder, worse w/ moving arm</td>
</tr>
<tr>
<td>Condition</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| Overhead or w/ direct pressure (sleeping) | Tenderness to palpation  
"Empty Can Test": Pain & weakness w/ resisted abduction of arm elevated at 90°, adducted forward 30°  
Tx w/ NSAIDs, avoidance of aggravating movements, PT, subacromial steroid injections if no improvement |
| Frozen shoulder (adhesive capsulitis) | Gradual ↓ ROM (active & passive) of glenohumeral joint due to joint capsule pathology; no known injury  
Pain at extremes of ROM  
Tx w/ NSAIDs, PT, 2–4 wk oral corticosteroids |
| Acromioclavicular syndrome | Arthritis or injury to AC ligaments  
Acute or chronic, possible hx of trauma  
TTP & swelling of AC joint, pain worse w/ ↓ traction or forced passive adduction  
Acute injury tx w/ sling |
| Elbow Lateral epicondyilitis (tennis elbow) | Pain along lateral epicondyle at attachment of extensor tendons of forearm  
↑ pain w/ resisting wrist dorsiflexion  
Tx w/ rest, NSAIDs, ±steroid injections |
| Medial epicondyilitis (golfer elbow) | Less common than tennis elbow  
Pain along medial epicondyle at insertion of common flexor tendon  
Resistance to wrist flexion w/ elbow in extension ↑ pain  
Tx w/ rest, NSAIDs, ±steroid injections |
| Hip Trochanteric bursitis | Most common cause of pain in hip (lateral aspect)  
Pain ↑ w/ walking, squatting, climbing stairs, ↓ at rest  
Resisted abduction of hip reproduces pain  
Tx w/ NSAIDs, corticosteroid injections |
| Knee Patellar tendonitis (jumper's knee) | Pain at inferior aspect of patella during repetitive running, jumping, kicking  
Tx w/ rest, NSAIDs, knee brace, PT, strengthening exercises for quads & hamstrings |
| Ankle Achilles tendonitis | Pain, swelling, tenderness, over Achilles tendon from repetitive trauma & microscopic tears from overuse (ballet, distance running, basketball)  
↑ pain w/ passive dorsiflexion  
Tx w/ rest, heat, NSAIDs, shoe modification, heel lift to ↓ tendon stretching, PT, stretching exercises |

**Tenosynovitis**
**Definition**

- Inflammation of the tendon & tendon sheath. Can result in chronic disability, ↓ ROM, chronic pain, amputation if not treated appropriately.

<table>
<thead>
<tr>
<th>Types of Tenosynovitis</th>
<th>Hx &amp; Findings</th>
<th>Management &amp; Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Quervain tenosynovitis</td>
<td>Repetitive pinching of thumb &amp; fingers, Pain improved w/ rest; no hx of acute trauma, Most common in middle-aged women, Pain at radial aspect of wrist, worse w/ passive ROM of thumb, ulnar deviation of wrist w/ thumb cupped in closed fist (Finkelstein test)</td>
<td>Rest, NSAIDs, Thumb spica, Steroid injection, Surgery if needed, Good prognosis, DC home w/ f/u</td>
</tr>
<tr>
<td>Stenosing flexor tenosynovitis (trigger finger)</td>
<td>Locking of thumb or ring finger in flexion followed by sudden release, pain radiates to fingers, Most common in middle-aged women, diabetics, Pain in proximal tendon sheath in distal palm ±Palpable tendon thickening or nodularity, May require manipulation to release</td>
<td>NSAIDs, Splint 4–6 wk ±Steroid injection, Surgical release if injection fails, Good prognosis, D/C home w/ f/u</td>
</tr>
<tr>
<td>Infectious tenosynovitis</td>
<td>Puncture wound, laceration, bite, cracked skin, high-pressure injury; usually <em>S. aureus</em>, <em>Strep</em> (Kanavel signs): 1. Fusiform (“sausage”) swelling of finger 2. Flexed position of finger 3. Severe pain w/ passive extension 4. Tenderness along flexor tendon sheath</td>
<td>Admit ortho/hand Abx, Splint &amp; elevation, Fair prognosis even w/ abx, surgery</td>
</tr>
</tbody>
</table>

**Gout**

**History**

- Middle-aged pt w/ abrupt (often recurrent) onset single joint pain, swelling, erythema, warmth; may be precipitated by minor trauma or illness
- 75% monoarticular, classically affects 1st MTP joint (aka “podagra”)
Findings
- Red, swollen, tender, warm joint (MTP > ankle > dorsal area > knee); mimics cellulitis
- Tophi overlying effected joints indicate chronic gouty dz

Evaluation
- Arthrocentesis if: 1st episode (no prior tap), unclear Dx, concern for septic joint
- Joint fluid: Needle-shaped, neg. birefringent crystals; always send for culture
- Serum uric acid level is of no value; 30% will have nl levels
- X-ray findings in chronic gout include bony erosions, punched out lesions, calcified tophi

Treatment
- NSAIDs (no aspirin). Eg, indomethacin 50 mg PO TID for duration of attack (~3–10 d).
- Alternatively: Colchicine (0.5 mg PO q1h up to 8 mg; if nl renal fxn) OR steroids
- Allopurinol for chronic prevention but has no role in acute mgmt of gout attack

Disposition
- D/C home w/ pain control unless intractable pain

Pearl
- Gout is a result of monosodium urate crystal deposition

PSEUDOGOUT

History
- Elderly pt w/ abrupt-onset, single-joint pain, swelling, erythema, warmth; precipitated by minor trauma or illness; usually in large joints (unlike gout)

Findings
- Red, swollen, tender, warm joint (knee > wrist > ankle = elbow)

Evaluation
If unclear Dx, concern for septic joint, perform arthrocentesis
Joint fluid: Rhomboid-shaped, positively birefringent crystals
X-ray findings: Chondrocalcinosis, subchondral sclerosis, radiopaque calcifications

**Treatment**
- Same as gout

**Disposition**
- D/C home w/ pain control

**Pearls**
- Pseudogout is the result of calcium pyrophosphate crystal deposition
- Most common cause of new monoarticular arthritis in pts >60 y/o
- RFs: ↑ Ca, ↓ Mg, ↓ PO₄, hemochromatosis, hemosiderosis, parathyroid dz

---

**Bursitis**

**Definition**
- Inflammation of bursa, which are flattened sacs lined w/ synovial fluid that helps facilitate movement; bursitis is usually due to overuse, trauma, or OA, but can be septic

**History**
- Discrete area of pain, swelling, erythema, warmth over a joint
- Less than half of bursitis is septic, but 70% of septic bursitis has preceding trauma
- Most common in joints that are subject to repetitive stresses (elbow, knee), but can be deep (hip) esp in setting of instrumentation (eg, acupuncture, surgery)

**Findings**
- Warm, swollen, fluid-filled pocket outside the joint ± erythema
- Tenderness, fever, associated cellulitis suggest septic bursitis
- Should have minimal pain w/ passive ROM; o/w consider septic arthritis

**Evaluation**
If any concern for septic bursitis, perform bursa aspiration (WBC >5K is suggestive)
- Deep bursae may require aspiration by ortho or IR
- Often clinically difficult to differentiate from septic arthritis; may need arthrocentesis

**Treatment**
- Rest, ice, elevation, analgesia, ± steroid injection
- If septic bursitis: Abx for *Staph* coverage (ie, dicloxacillin, TMP–SMX, or clindamycin)
- Consult ortho for f/u as these have high outpt failure rate & may need surgical bursal excision or serial aspirations

**Disposition**
- D/C w/ pain control if no ortho intervention, ± abx
- Admit for fulminant infection, immunocompromised pt, significant surrounding cellulitis

**Pearl**
- Prepatellar (carpet layer’s knee) & olecranon bursitis (student’s elbow) are usually due to *Staph* infection from local trauma

---

**INFECTIOUS**

**Septic Arthritis (Nongonococcal)**

**History**
- Acute onset of painful, swollen, warm, tender joint, often w/ fever
- Hallmark is severe pain w/ any passive ROM
- All joints are at risk but most commonly knee > hip. In peds, hip is most common.
- High-risk groups include IV drug users, immunocompromised

**Findings**
- Usually single joint involvement; can see multijoint in disseminated GC dz
- Pain w/ minimal passive ROM or axial load; warmth, redness, swelling

**Evaluation**
- X-ray to identify effusion, FB, fracture, or osteomyelitis
- Arthrocentesis: Gram stain & culture, cell count, protein & glucose, crystal analysis, synovial lactate; positive: WBC >50000 w/ PMN predominance
- Labs: Consider ESR, CRP, blood cx to isolate; UA, CXR for infectious w/u

**Management**
- Arthrocentesis (hip may need orthopedics or IR), ortho consult, splint in physiologic position
- Supportive care: hydration, antipyretics, pain control
- Abx after arthrocentesis & blood cultures taken; *S. aureus* is most common
- Adults: Vancomycin & 3rd-generation cephalosporin OR quinolone
- Children <14 yr: Vancomycin & 3rd-generation cephalosporin
- Prosthesis, immunocompromised: Vancomycin & antipseudomonal (piperacillin/tazobactam OR fluoroquinolone)

**Disposition:** Admit for abx, ortho observation, likely need for operative washout

**Pearls**
- Septic hips do not present w/ classic signs; can be very subtle
- Presence of crystals in the joint fluid does NOT r/o a septic joint
- Overlying cellulitis is relative CI for arthrocentesis; avoid cellulitic area during tap
- If hardware is present, discuss risk/benefit w/ orthopedics prior to arthrocentesis
- Intra-articular steroid injection for pain relief in septic arthritis is contraindicated

**Gonococcal Septic Arthritis**

**History**
- Young, sexually active pt usually c/o single painful, swollen, warm, & tender joint
- May be polyarticular or migratory; smaller joints (elbow, wrist, ankle) commonly involved
- Urethral or vaginal D/C of GC infection may be present
Findings
- Any clinical manifestations of *Neisseria* GC infection (cervicitis, malodorous, purulent vaginal D/C in female or dysuria & penile D/C in male)
- Swollen, tender, warm, & extremely painful small joint(s), usually slightly flexed at rest, more painful w/ ROM; may have tenosynovitis
- A painless diffuse maculopapular rash w/ necrotic/pustular centers may be present
- RUQ abd pain may indicate Fitz-Hugh–Curtis syndrome

Evaluation
- Same as non-GC septic arthritis + cervical (female) & urethral (male) cultures; blood, pharynx & rectal cultures to ↑ likelihood of definitive dx

Treatment
- Arthrocentesis, ortho consult, splint joint in physiologic position for comfort
- 3rd-generation cephalosporin (ceftriaxone 1 g IV QD) OR quinolone, add doxycycline for chlamydia
- Supportive care: Hydration, antipyretics, pain control

Disposition: Admit for abx, ortho observation, possible need for operative washout

Pearls
- GC septic arthritis is the only septic arthritis that does not necessarily need operative washout; however, serial arthrocentesis to remove fluid may be indicated
- Gram stain & culture from GC septic arthritis more often neg. than non-GC septic joints
- Intra-articular steroid injection for pain relief in septic arthritis is contraindicated
EAR PAIN

Approach

- Nature of pain, associated sx(s), duration, fevers, hearing loss; diabetes

<table>
<thead>
<tr>
<th>Ear Pain Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location</strong></td>
</tr>
<tr>
<td>Outer ear</td>
</tr>
<tr>
<td>Middle ear</td>
</tr>
<tr>
<td>Mastoid air cells</td>
</tr>
</tbody>
</table>

Otitis Externa (Swimmer’s Ear)

**Definition**

- Infection (Acute: *Pseudomonas, S. aureus, S. epidermidis*; Chronic: *Aspergillus, Candida*) of the outer ear due to breakdown of natural barriers

**History**

- Summer, water exposure, cotton swab trauma, hearing aids, pain/itching/drainage

**Physical Findings**

- Pain w/ movement of tragus/helix, localized LAD, redness/exudate in canal, white/gray debris, ±green d/c/yellow crusting, ±abscess, conductive hearing loss if severe

**Treatment**

- Remove debris, dry canal w/ suction, drain abscess if present
- Mild infections: Cleanse w/ 2% acetic acid, hydrogen peroxide, OR sterile saline; no good evidence for these. Avoid w/ ruptured TM
- Severe infections: Topical abx (eg, ofloxacin) + steroid × 7 d
• Use wick (cotton, gauze, or cellulose) 10–12 mm into canal × 2–3 d to allow med delivery
• If TM rupture, consider oral abx
  ‣ No swimming × 48 h, keep ear dry in shower × 1 wk (ear plugs or Vaseline gauze seal)

Disposition
  ‣ Home: Diabetics w/ simple OE should get close f/u

Malignant (Necrotizing) Otitis Externa
Definition: Aggressive infection (95% Pseudomonas) of the outer ear canal to skull base/bony structures, usually in diabetics/immunocompromised
History: Ear pain extending to TMJ (pain w/ chewing), nocturnal pain, swelling, otorrhea
Physical Findings: Granulation tissue, severe inflammation, may have CN palsy
Evaluation: Consider CT scan to eval extent, underlying osteomyelitis, & intracranial extension
Treatment
  ‣ 1st line: IV ciprofloxacin; Increasing rates of resistance; 2nd line: Ceftazidime, imipenem, OR piperacillin/tazobactam
  ‣ Consider amphotericin B or voriconazole for aspergillus in HIV/immunocompromised

Disposition: Admission for IV abx ± operative débridement
Pearls
  ‣ 10% mortality
  ‣ Cx: Cerebral/epidural abscess, osteomyelitis, dural sinus thrombophlebitis, meningitis

Otitis Media
Definition
  ‣ Inflammation of the middle ear
  ‣ Acute OM: Infection (50% S. pneumoniae, 20% H. influenzae, 10% M. catarrhalis, viral 50–70%) + effusion <3 wk
  ‣ Chronic OM: Effusion w/o infection
**History:** Unilateral ear pain, fever (25%), winter/spring, 2–10 y/o, URI

**Physical Findings:** Bulging TM, loss of light reflex/TM mobility (most sens), effusion, erythema (not sufficient alone to diagnose OM), purulent drainage

**Treatment**
- Many improve w/ no abx w/o cx
- Pain control: APAP/ibuprofen, auralgan (topical)
- Nonsevere acute OM: Amoxicillin to start in 2–3 d if sx do not improve
- Severe (<6 mo, bilateral, bulging TM, otorrhea, fever >39°C, systemically ill) = immediate abx
- Pediatric: Amoxicillin 80–90 mg/kg/d (1st line) 7–10 d, amoxicillin/clavulanate if recent abx or concurrent conjunctivitis
  
  *(Pediatrics 2010;125(2):384)*
- Adult: Amoxicillin 500 mg BID (mild to mod), 875 mg BID (severe), Cefpodoxime OR cefuroxime if PCN allergic

**Disposition:** Home, PCP f/u 2–3 d

**Pearls**
- Cx (rare): Meningitis, mastoiditis, persistent effusion → hearing loss
- TM perforation does not require any Δ in management

**Mastoiditis**

**Definition:** Extension of infection from the middle ear into the mastoid air cells

**History:** Unilateral ear pain, fever, HA

**Physical Findings:** Tenderness, erythema, fluctuance over mastoid, outward bulging pinna

**Evaluation:** CT scan to eval extent/destruction of the septa of the air cells, MRI for intracranial cx, ENT consult

**Treatment**
- Abx: Nafcillin/cefuroxime/ceftriaxone
- ±Myringotomy/tympanostomy; mastoidectomy (if 50% of air cells involved)

**Disposition:** Admission, possible operative débridement

**Pearl:** Cx include meningitis, dural sinus thrombosis, brain abscess,
subperiosteal abscess, hearing loss

HEARING LOSS

Approach
• Nature, acuity of onset, unilateral/bilateral, associated pain/systemic sxs

<table>
<thead>
<tr>
<th>Hearing Loss Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cause</strong></td>
</tr>
<tr>
<td>Infections</td>
</tr>
<tr>
<td>Vascular</td>
</tr>
<tr>
<td>Metabolic</td>
</tr>
<tr>
<td>Conductive</td>
</tr>
<tr>
<td>Medications</td>
</tr>
<tr>
<td>Neoplasm</td>
</tr>
</tbody>
</table>

Cerumen Impaction/Foreign Body
Definition: Buildup of earwax or FB in the external canal
History: Unilateral hearing loss, placement of FB in ear, drainage, pain
Physical Findings: Visualization or cerumen/FB in ear
Treatment
• Irrigate the external canal w/ room temperature NS (cold/hot NS can cause nystagmus/vertigo/nausea), past FB if possible. Do not irrigate batteries
• For live insects, consider liquid lidocaine, isopropyl alcohol, or mineral oil to asphyxiate prior to removal
• For cerumen: Instill colace, cerumenex, or $\text{H}_2\text{O}_2$ for 15 min to dissolve, then irrigate
For FB: Alligator forceps OR cyanoacrylate (glue) to cotton-tipped applicator, hold against object for 60 sec; OR try suction for smooth objects

Re-examine ear postextraction for TM rupture, canal damage, or residual FB. Consider topical abx if canal damaged

Disposition: D/c

Ruptured Tympanic Membrane
Definition: Rupture of the TM. Etiologies include trauma (open hand slap over ear, lightening), FB (cotton swab, pipe cleaner), barotrauma (high altitude, diving), infection (OM)
History: Pain, hearing loss
Physical Findings: Perforation of TM, ±blood in the canal
Treatment
- Keep ear dry (earplugs during shower, no swimming)
- Abx needed if pre-existing infection; treat as usual OM; consider abx if contaminated water exposure
- Operative repair if >¼ of TM damaged

Disposition
- D/c, ENT f/u 2–4 d for audiogram; perforations usually heal in 2–3 mo
- Admit in acute trauma w/ associated facial nerve injury, incapacitating vertigo

SORE THROAT

Approach
- Nature, acuity of onset, duration, associated sxs (cough, fever, drooling, voice Δ, dysphagia, difficulty breathing)

<table>
<thead>
<tr>
<th>Sore Throat Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cause</strong></td>
</tr>
<tr>
<td>Infections</td>
</tr>
</tbody>
</table>
**Group A Streptococcus Pharyngitis ("Strep Throat")**

**Definition:** Infection of the oropharynx caused by GABHS

**History:** Sore throat, odynophagia, myalgias, fever; no cough

**Physical Findings:** Erythematous oropharynx, tonsillar exudate, cervical LAD

**Evaluation**
- Centor criteria: Fever >38°C, tonsillar exudate, tender LAD, absence of cough
- Rapid strep: Sens 60–90%, spec 90% (send culture if neg. given low sens)
- GABHS culture: 90% sens
- Consider culture for gonorrhea (if oral sex exposure), or Monospot for EBV

**Treatment**
- There are multiple conflicting guidelines (*NEJM* 2011;364:648). One reasonable approach:
  - If 0–1 Centor criteria met: No testing, no tx
  - If 2–3 Centor criteria met: Rapid strep, treat if positive, confirm w/ culture
  - If all Centor criteria met: No testing, yes tx
- Abx
  - Benzathine penicillin 25000 U/kg max 1.2 million U IM ×1 OR penicillin VK, OR amoxicillin OR azithromycin. If refractory: Clindamycin, augmentin
  - Dexamethasone 8 mg ×1 may ↓ time to pain relief (*J Emerg Med* 2008;35(4):363)

**Disposition:** D/c
Pearl: Treat w/ abx to prevent scarlet fever, rheumatic fever, abscess, mastoiditis. Poststrep glomerulonephritis is not prevented w/ abx

Croup (Laryngotracheobronchitis)
Definition
› URI in children (6 mo–6 yr) usually by parainfluenza virus causing inflammation/exudate/edema of subglottic mucosa

History: Barky cough, worse at night, low-grade fever, following 2–3 d of URI sx

Physical Findings: High-pitched inspiratory stridor, barking cough, hoarse voice, tachycardia, tachypnea

<table>
<thead>
<tr>
<th><strong>Croup Severity Score (Westley Score)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inspiratory stridor</td>
</tr>
<tr>
<td>Retractions</td>
</tr>
<tr>
<td>Air entry</td>
</tr>
<tr>
<td>Cyanosis</td>
</tr>
<tr>
<td>Level of alertness</td>
</tr>
<tr>
<td>Score ≤2 = mild, 3–5 = moderate, &gt;6 = severe</td>
</tr>
</tbody>
</table>

Evaluation: Neck film is typically of no clinical value → narrowing of subglottic trachea (“steeple sign”)

Treatment
› Calm child, monitor pulse oximetry
› Cool mist (no clear benefit)
› Dexamethasone 0.3–0.6 mg/kg (↓ time to improvement) (Cochrane Syst Rev 2004;(1):CD001955)
› Moderate–severe or stridor at rest: Nebulized racemic epinephrine 0.5 mL of 2.25%

Disposition
› Admit if no improvement in ED, hypoxic, persistent stridor at rest, <6 mo old, unable to tolerate PO, requiring multiple doses of epinephrine
› Croup severity score ≤4 can usually be D/C, score >6 may require ICU
**Pearl:** If epinephrine given, should observe for >3–4 h for rebound stridor

### Epiglottitis

**Definition**
- Inflammation of the epiglottis caused by *H. influenzae* >> *Staph/Strep, B. catarrhalis*
- Can lead to rapidly progressing, life-threatening airway obstruction

**History**
- Sore throat, muffled “hot potato” voice, odynophagia, respiratory distress, fever
- ↓ Pediatric incidence since vaccination, now more common in adult diabetics

**Physical Findings:** Dysphonia, stridor, drooling, sitting in tripod position

**Evaluation**
- Lateral neck XR (90% sens): Epiglottis >7 mm ("thumbprint"), loss of vallecular air space
- Adult: If nl x-ray → indirect or fiberoptic laryngoscopy (have surgical airway ready)
- Pediatric: Avoid agitation (↑ risk of acute airway obstruction), do NOT attempt to visualize in the ED. To OR for DL w/ anesthesia & ENT/surgery

**Treatment:** Abx (ceftriaxone OR ampicillin–sulbactam, add clindamycin or vancomycin if concern for MRSA); no proven benefit w/ steroids

**Disposition:** ICU admission

### Pertussis (Whooping Cough)

**Definition:** Lower respiratory tract infection by *B. pertussis* (gram-neg. rod)

**Presentation**
- Commonly a prolonged course (aka “hundred-day cough”)
- Stages: (1) *Catarrhal* (most infectious): 2 wk mild URI sx; (2) *Paroxysmal*: 1–2 wk intense paroxysmal cough ± posttussive
emesis, inspiratory “whoop”; (3) Convalescent: Several weeks of chronic cough
- ↑ Risk if unvaccinated, but immunity wanes after ~12 yr; ↑ morbidity if <6 mo old

**Evaluation**
- Rapid PCR may be useful esp during epidemics
- May develop PNA; consider CXR if refractory to abx

**Treatment**
- Droplet precautions × 7 d, abx (only effective in catarrhal stage)
- Azithromycin or clarithromycin, albuterol prn, treat household contacts
- Low threshold for empiric tx in infants, pregnant, healthcare workers

**Disposition:** Admit <6 mo–1 y/o or ill appearing

**Lemierre Syndrome**

**Definition**
- Suppurative thrombosis of internal jugular vein w/ *F. necrophorum*
- Septic emboli to lung are common (can be confused w/ R-sided endocarditis)

**History**
- Usually previously healthy young adults w/ high fever, sore throat ± cough
- Typical course is pharyngitis that improves & then followed by severe sepsis

**Physical Findings:** Unilateral neck swelling, tenderness, induration
**Evaluation:** Contrast CT of neck
**Treatment:** Abx: Ampicillin–sulbactam, piperacillin–tazobactam or a carbapenem. Consider adding vancomycin if catheter-associated. Anticoagulation is controversial
**Disposition:** Admit
Acute Sinusitis

Definition
- Inflammation of the paranasal sinuses
- Usually viral or allergic
- Common bacterial etiologies: S. pneumoniae, nontypable H. influenzae, M. catarrhalis
- Pseudomonas is seen in HIV, cystic fibrosis, or after instrumentation
- Mucormycosis is invasive fungal sinusitis (Rhizopus) in diabetics or immunocompromised

Presentation
- Mucopurulent d/c, postnasal drip, cough, sinus pressure, HA, ±fever
- Typically progresses over 7–10 d & resolves spontaneously
- Sxs >7 d, worsening course, or worsening after improving, all suggest bacterial dz
- Consider sinusitis w/ positional HA that is worse when bending forward
- Sphenoid sinusitis is a difficult Dx, often presents late; classically worse w/ head tilt

Evaluation
- Clinical, no routine imaging. CT sens but not spec, can r/o cx
- Cx include orbital cellulitis, osteomyelitis, cavernous sinus thrombosis, cerebral abscess, meningitis, frontal bone abscess (Pott puffy tumor)

Treatment
- Supportive (analgesics, antipyretics, decongestants, antihistamines if allergic)
- Decongestants: Neo-Synephrine nasal spray TID × 3 d, Afrin nasal spray BID × 3 d
- Abx not routinely indicated. Reserve for pts w/ sxs >7 d, worsening sxs, fever, purulent d/c, or high risk for severe infection or cx
  - Amoxicillin–clavulanate 500 mg PO TID × 5–7 d
  - RFs for resistance: high-dose amoxicillin–clavulanate (2000 mg BID)

Disposition
- Vast majority are managed outpt
Admit if toxic, severe HA, high fever, immunocompromised, poor f/u

Pearl
- Sphenoid/ethmoid sinusitis is less common than maxillary sinusitis but has significant potential cx (eg, orbital cellulites, cavernous sinus thrombosis)

---

**EPISTAXIS**

**Definition:** Bleeding from the nose. 90% of cases are anterior & involve Kiesselbach plexus on the septum. 10% of cases are posterior & arise from a branch of sphenopalatine artery

**History**
- Etiologies include URI (most common), trauma, nose picking, environmental irritants (dry air), intranasal drug use, neoplasm, FB, polyps, anticoagulation/TCP
- RFs: Alcoholism, diabetes, anticoagulation, HTN, hematologic disorder

**Physical Findings**
- Evaluate w/ nasal speculum after having pt blow nose to express clots

**Evaluation**
- Can usually identify anterior source on exam; posterior bleeds are heavy, brisk, can cause airway compromise. If still bleeding after anterior packing, consider posterior source
- Check hematocrit if extensive/prolonged bleeding, INR if on warfarin

**Treatment**
- If significantly hypertensive, consider antihypertensive to help w/ hemostasis
- **Anterior:** Start w/ oxymetazoline (Afrin) 3 sprays & hold pressure for 15 min
  - May also insert cotton pledgets soaked in cocaine/lidocaine/epinephrine/phenylephrine
  - Once vasoconstricted, try to identify a focal bleeding site, then use
silver nitrate cautery in ring around bleeding (will not work on active bleeding; caution on septum)

- If bleeding has stopped, observe for 60 min; if recurs, insert a lubricated nasal tampon or vaseline gauze packing
- If nasal tampon is not successful, pack the contralateral side
  - *Posterior:* Bleeding can cause airway compromise & be life-threatening
- Commercial double balloon device OR pass Foley catheter through nose into posterior pharynx, fill balloon, hold gentle traction

**Disposition**

- *Anterior:* D/c w/ 48 h f/u, typically w/ prophylactic abx for TSS (unproven) (eg, clindamycin, augmentin, or dicloxacillin)
- *Posterior:* Admit w/ ENT consult

---

## EYE PAIN/REDNESS

**Approach**

- Ask about FB exposure, chemicals, trauma, contact lens use, freshwater exposure
- *Always* check visual acuity. Use topical anesthetics (tetracaine, proparacaine) for exam
- Complete eye exam: Visual acuity (corrected), visual fields, external inspection, periorbital soft tissue & bones, extraocular movement, pupils (including swinging light test for afferent pupillary defect), pressure (tonometry), slit lamp (lids, conjunctiva, sclera, cornea w/ fluorescein, anterior chamber, iris, lens), fundoscopy

**Acute Angle-closure Glaucoma**

**Definition:** Increased IOP due to ↓ aqueous outflow. Generally due to reduction in the angle of the anterior chamber in setting of the dilated pupil pushing against trabecular meshwork

**History**

- Sudden onset of severe unilateral pain, HA, N/V, blurry vision, halos
- May be triggered by dim light, mydriatic drops, stress, sympathomimetics
Physical Findings
- Unilateral perilimbal eye injection, ↓ VA, “steamcy” (cloudy) cornea, nonreactive midsize pupil (5–7 mm), shallow anterior chamber, ↑ IOP >22 mmHg, firm globe

Treatment
- *Immediate optho consult; need for urgent laser peripheral iridotomy*
- *Reduce aqueous production:* Timolol 0.5% 1–2 drops q30min (avoid if Cl to systemic βB), acetazolamide 500 mg IV, then 250 q6h (avoid in sulfur-allergic pts) or brimonidine 1 drop TID
- *Facilitate aqueous outflow* (miotics): Pilocarpine 2% 1 drop q15min until pupil constricts
- *Decrease vitreous volume* (osmotics): Mannitol 1–2 mg/kg IV over 30–60 min

Disposition
- Per optho recommendations. Admit for intractable vomiting or need for systemic agents

<table>
<thead>
<tr>
<th>Critical Dx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etiology</td>
</tr>
<tr>
<td>Caustic injury (chemical)</td>
</tr>
<tr>
<td>Acute angle-closure glaucoma</td>
</tr>
<tr>
<td>Retrobulbar hematoma</td>
</tr>
<tr>
<td>Penetrating trauma/scleral penetration</td>
</tr>
<tr>
<td>Etiology</td>
</tr>
<tr>
<td>----------------------------------</td>
</tr>
</tbody>
</table>
| Orbital cellulitis (vs. preseptal cellulitis) | Orbital cellulitis: Posterior to orbital septum, drains into cavernous sinus

**Both orbital & preseptal:**
- May have fever, leukocytosis
- Lid swelling, erythema, warmth
- Eye tenderness
- ± Conjunctivitis, chemosis

**Suspect orbital cellulitis if:**
- Ill appearance, high fever
- Pain w/ EOM movement
- Ophthalmoplegia/diplopia
- Visual impairment
- Proptosis
- Increased IOP
| Immediate optho consult for orbital cellulitis
IOP > 20: Optho emergency
CT orbit to r/o FB, abscess
Obtain blood cx
Start IV abx (vancomycin + ceftriaxone or ampicillin/sulbactam)
In diabetics, consider mucormycosis
Admit all orbital cellulitis
If preseptal cellulitis, outpt abx w/ amoxicillin/clavulanate & optho recheck in 1 d
Cx: vision loss, cavernous sinus thrombosis, CNS involvement, abscess, osteomyelitis

---

<table>
<thead>
<tr>
<th>Emergent Diagnoses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyphema</td>
</tr>
<tr>
<td>Hx: Pain, ↓ visual acuity, usually after blunt trauma</td>
</tr>
<tr>
<td>PE: Gross or microscopic blood layering in anterior chamber, ± fixed &amp; dilated pupil</td>
</tr>
</tbody>
</table>
| First r/o open globe
Discuss w/ optho-“eight ball” hyphema requires urgent f/u
IOP > 30: Treat as glaucoma
IOP > 20: Use cycloplegic to prevent iris motion
Elevate HOB 45 degrees
Screen for FH of sickle cell
Most can be D/C home w/ 1–2 d recheck |
<table>
<thead>
<tr>
<th>Corneal abrasion/FB</th>
<th>Hx: Pain worse w/ blinking, photophobia, FB sensation PE: Conjunctival injection. Evert lids to look for FB. Use fluorescein to eval -Rust ring = metallic FB -Seidel test to r/o corneal penetration</th>
<th>If high velocity: XR or CT to r/o ocular penetration If embedded FB, remove w/ 25 g needle tip under magnification, or burr Give tetanus prophylaxis Abx (erythromycin), use quinolone if contact use or freshwater exposure DC home w/ optho f/u in 1–2 d for recheck, rust ring removal if needed. No contacts until resolved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior uveitis/iritis</td>
<td>Def: Inflammatory process involving anterior chamber, iris, ciliary body, or choroid Hx: Usually due to trauma, autoimmune dz, or infection (HSV, Lyme). Unilateral painful red eye, “deep” pain, blurred vision, photophobia Physical Findings: Perilimbal injection, photophobia (consensual suggests iritis), ± ↓ visual acuity, slit lamp shows anterior chamber cell &amp; flare</td>
<td>• Traumatic iritis: Cycloplegic for comfort, optho f/u in 1–2 d • Inflammatory: Cycloplegics, consult optho for possible steroids</td>
</tr>
</tbody>
</table>

### Other Causes of Red Eye

| Conjunctivitis (allergic, viral > bacterial) | Def: Inflammation of mucus membranes that line sclera/lids. Usually viral Hx: Drainage, irritation, pruritus, crusting, concurrent URI PE: Injection/edema, usually sparing limbus nl exam o/w Gonorrhea = copious, green exudate | Culture if neonate or concern for *Chlamydia, gonorrhea* Warm soaks, artificial tears Antihistamine if allergic Abx if concern for bacterial: - Erythromycin, Polytrim - Quinolone if contact lens or freshwater exposure D/c home, optho f/u in 2 d if not improving Consult optho if gonorrhea suspected |

### Etiology

| Lid disorders (blepharitis, chalazion, dacrocystitis, | **Blepharitis**: Inflamed eyelid margins | **Blepharitis**: Warm compresses **Chalazion**: Warm compresses, |
hordeolum/stye)

**Chalazion:** Inflamed meibomian gland (subcutaneous lid nodule)
**Dacrocystitis:** Inflamed lower eye lid w/ redness, tenderness
**Hordeolum (stye):** Abscess in eyelash follicle or lid margin (can be external or internal)

gentle massage

**Dacrocystitis:** R/o periorbital or orbital cellulitis. If mild, d/c w/ clindamycin & warm compresses. Admit if systemically ill

**Hordeolum:**
- External: Warm compresses ± abx ointment for Staph
- Internal = PO abx for Staph

---

**VISION CHANGE & VISION LOSS**

**Approach**

- Complete eye exam: Visual acuity (corrected), visual fields, external inspection, periorbital soft tissue & bones, extraocular movement, pupils (including swinging light test for afferent pupillary defect), pressure (tonometry), slit lamp (lids, conjunctiva, sclera, cornea w/ fluorescein, anterior chamber, iris, lens), fundoscopy, & full neurologic exam

<table>
<thead>
<tr>
<th>Differential of Vision Δ &amp; Loss</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Differential</strong></td>
</tr>
<tr>
<td><strong>Painful</strong></td>
</tr>
<tr>
<td><strong>Painless</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Differential of Diplopia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Differential</strong></td>
</tr>
<tr>
<td><strong>Monocular</strong></td>
</tr>
<tr>
<td><strong>Binocular</strong></td>
</tr>
</tbody>
</table>
Central Retinal Artery Occlusion

**Definition:** Retinal artery occlusion, most commonly embolic

**History**
- Sudden painless, monocular vision loss (or visual field cut if branch of retinal artery), may have transient loss prior to complete loss (amaurosis fugax)
- RFs: HTN, DM, CVA, AF, carotid dz, hypercoagulable, vasculitis, endocarditis, sickle cell anemia

**Physical Findings**
- Afferent pupillary defect, funduscopic exam shows cherry-red spot at fovea (spared), pale disc (late finding)
- May have carotid bruit, irregular HR, murmur; r/o temporal arteritis

**Evaluation**
- CBC, ESR
- For embolic w/u: Neuroimaging (CT/CTA or MRI/MRA), carotid imaging, echo, EKG

**Treatment**
- Initiate immediately (>2 h = irreversible vision loss)
- *Immediate ophthalmologic consult*
- Intermittent globe massage (to try to dislodge embolus & move it further downstream)
- Reduce IOP as in glaucoma (eg, acetazolamide, mannitol, timolol)
- Anterior chamber paracentesis
- Surgical decompression, anticoagulation, intra-arterial thrombolysis, hyperbaric $O_2$

**Disposition:** Admit

**Pearl:** Cardiac embolus most common in >40 y/o, coagulopathies most common in <30 y/o

Central Retinal Vein Occlusion

**Definition:** Retinal vein occlusion, usually thrombotic

**History**
- Sudden painless monocular vision loss (may be gradual onset)
- RFs: CAD, HTN, glaucoma, venous stasis, hypercoagulable, DM, vascular dz
**Physical Findings:** Afferent pupillary defect, funduscopic exam w/ retinal hemorrhages/disk edema (“blood & thunder”), cotton wool spots

**Management:** *Immediate optho consult.* Start ASA, outpt hypercoagulability w/u

**Disposition:** Home

**Temporal Arteritis (Giant Cell Arteritis)**

**Definition:** Granulomatous inflammatory vasculitis of medium/large arteries

**History**
- Unilateral HA, jaw/tongue claudication, malaise, low-grade fevers, visual impairment
- Usually >50 y/o (90% >60 y/o), F > M, hx of PMR (50% of pts)

**Physical Findings:** Tenderness over temporal artery, decreased visual acuity, afferent pupillary defect

**Evaluation:** ↑ ESR, ↑ CRP, temporal artery biopsy

**Management**
- If visual deficits: IV methylprednisolone 1g daily × 3 days
- No visual deficits: Prednisone 60 mg/d (do not withhold pending biopsy results) & biopsy w/i 2 wk. Consult rheumatology, ophthalmology

**Disposition:** Admit only for visual deficits

**Pearls**
- Failure to diagnose & treat may result in permanent blindness
- 75% of pt w/ visual deficits in one eye will develop contralateral deficits w/i 3 wk
- 20× higher risk of thoracic aortic aneurysm

**Optic Neuritis**

**Definition**
- Inflammation of the optic nerve usually due to focal demyelination
- A/w MS (¼ pts will be diagnosed w/ MS), but also sarcoidosis, SLE, leukemia, alcoholism, syphilis, idiopathic, postviral
**History:** Vision loss (minimal → complete), ↓ color perception, pain w/ eye movement

**Physical Findings**
- ↓ Visual acuity, afferent pupillary defect, central scotoma, funduscopic exam
- Disk swelling/pallor

**Evaluation:** MRI shows inflammation of optic nerve, 20% have other demyelinating lesions

**Treatment:** Immediate ophthalmology/neurology consult, steroids

**Disposition:** Admit

---

**Retinal Detachment**

**History**
- Painless, classically “curtain-like” visual field deficit, “coal dust” or “spider webs,” floaters, photopsia (scintilla)
- RFs include myopia, trauma, surgical hx (cataract removal), DM, HTN, malignancy (breast CA, melanoma, leukemia), SCD, eclampsia, prematurity

**Physical Findings:** Visual field cut, “billowing” retina, may see pigmented vitreous or visible line demarcating detachment (usually by indirect ophthalmoscopy)

**Evaluation:** Bedside ED ocular U/S highly sens for detachment

**Management**
- Immediate optho consult if suspected
- If macula still attached, surgical repair indicated w/i 24–48 h
- Most inflammatory retinal detachments are treated medically (NSAIDs, steroids), but sometimes require emergent surgery depending on etiology, size, location

**Disposition:** Admit if acute
**Dental Fractures**

**Definition**
- Ellis I: Enamel; Ellis II: Enamel + dentin; Ellis III: Involves pulp (+ bleeding)

**Evaluation:** Consider CXR in trauma pt for aspirated fragments

**Management**
- Dental blocks & oral analgesia
- Ellis I: Smooth sharp edges if needed, dental f/u in 2–3 d
- Ellis II: Cover w/ calcium hydroxide paste, zinc oxide paste, glass ionomer composites (pulp necrosis 1–7%), *dental f/u in 24 h*
- Ellis III: Cover w/ calcium hydroxide paste, zinc oxide paste, glass ionomer composites (pulp necrosis 10–30%), dental consult or urgent referral for pulpotomy/pulpectomy
- High risk infection. Rx abx
- Need urgent (<24 h) dental f/u
- If bleeding → gauze soaked in epinephrine, inject lidocaine w/ epinephrine into pulp

**Tooth Subluxation & Avulsion**

**Definition:** Loose teeth or loss of teeth due to trauma

**Evaluation:** X-ray if mobility suggests alveolar fracture

**Management**
- Dental blocks & oral analgesia
- Minimal mobility: Soft diet 1–2 wk, dental f/u in 2–3 d
- Grossly mobile: Stabilize w/ periodontal paste or splint, *dental f/u in*
Avulsion: Only permanent teeth. Transport tooth in Hank’s solution or milk (preserves up to 8 h), do not clean tooth, replace tooth to socket w/ stabilization if w/i <60 min. 1% loss of tooth survival for every minute out. Immediate dental consult w/ f/u in 24 h

Dental Caries
Definition: Bacterial infection of hard tooth structure (enamel, dentin, & cementum)
Presentation: Tooth pain, poor dentition
Management: Dental block & oral analgesia, dental f/u in 1–2 d

Periapical Abscess
Definition: Bacterial infection of alveolar space
Presentation: Severe tooth pain, often fluctuant abscess
Management: Dental block. I&D if fluctuant. Abx (penicillin V or clindamycin), warm saline rinses, dental f/u in 1–2 d.

Acute Necrotizing Ulcerative Gingivitis (Trench Mouth)
Definition
› Polymicrobial infection of gums causing bleeding, deep ulcers, & necrotic gums
› RFs: Poor oral hygiene, local trauma, smoking, immunodeficiencies
Presentation
› Rapid onset diffuse mouth pain, halitosis, fever, gum bleeding
› Gingival erythema/edema, interdental papillae ulceration, gray pseudomembrane

Management: Oral anesthetic solution (viscous lidocaine), dilute hydrogen peroxide rinses QID or chlorhexidine, abx if extensive or systemic (penicillin, clindamycin), dental f/u in 1–2 d

Pearl: Cx: Vincent angina–spread to pharynx & tonsils

Alveolar Osteitis (Dry Socket)
Definition: Irritation of bone exposed to the oral cavity after premature disintegration of blood clot 3–5 d after tooth extraction

History: Sudden onset, severe pain after dental extraction, foul
odor/taste

**Management:** Dental block, oral analgesia, irrigate socket, pack w/ iodoform gauze soaked in medicated dental paste or eugenol. Abx (penicillin, clindamycin). *Dental f/u in 1–2 d.*
RESUSCITATION

Broselow Tape (equipment size & drug doses based on child length), Handtevy method

Airway: RSI (See 17-1)
- Pretreatment: Atropine (0.02 mg/kg, max 1 mg) prn bradycardia; lidocaine (1.5 mg/kg) prn if ↑ ICP
- Sedation: Etomidate (0.3 mg/kg); thiopental (3–5 mg/kg); ketamine (1–2 mg/kg)
- Paralysis: Succinylcholine (1–2 mg/kg); rocuronium (0.6–1.2 mg/kg)
- ETT size: 3 mm cuffed (newborns); (age/4 + 4) – 0.5 mm cuffed (>1 mo); depth (cm) = ETT size × 3
- Laryngoscope size: 0 (<2.5 kg); 1 (<3 yr); 2 (3–12 yr); 3 (12 yr to adult)

Shock
- nl SBP (mmHg) = 70 + (age in years × 2) b/w 1 & 10 yr
- Start w/ 20 cc/kg NS, up to 3 boluses
- Dopamine (2–20 μg/kg/min); epinephrine (0.05–1 μg/kg/min) for cold shock; norepinephrine (0.05–1 μg/kg/min) for warm shock; dobutamine (2–20 μg/kg/min) for cardiogenic shock
- Consider hydrocortisone if at risk for adrenal insufficiency
- In trauma, start w/ 20–40 mL/kg NS; then add 10–20 mL/kg PRBCs

ABDOMINAL PAIN

Approach
- Nature of pain: Location, constant or intermittent, relation to eating, associated sxs
- PMH: Previous abd surgeries, prematurity
- Exam: Always perform genital exam in males to r/o testicular torsion
Labs: CBC, CRP, BMP, UA, LFTs, lipase if in the upper abdomen

### Abd Pain Differential

<table>
<thead>
<tr>
<th>Location</th>
<th>Infancy</th>
<th>Childhood/Adolescence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanical</td>
<td>Malrotation w/ midgut volvulus, intussusception, hernia, Meckel diverticulum, Hirschsprung</td>
<td>Constipation, hernia, Meckel diverticulum, bowel obstruction (3a)</td>
</tr>
<tr>
<td>Inflammatory/infectious</td>
<td>NEC</td>
<td>Gastroenteritis, appendicitis, HSP, pancreatitis, gastritis, biliary tract dz (3a), colitis (3a), pancreatitis</td>
</tr>
<tr>
<td>GU</td>
<td>UTI (14bb)</td>
<td>UTI (14bb), renal colic (6b), pregnancy/ectopic (7), PID (7), testicular/ovarian torsion (7)</td>
</tr>
<tr>
<td>Other</td>
<td>Colic, trauma (abuse)</td>
<td>DKA (14r), trauma, sickle cell (14aa), toxic ingestions, PNA, strep pharyngitis</td>
</tr>
</tbody>
</table>

### APPENDICITIS

**Definition**

- Inflammation of the appendix

**History**

- Diffuse/periumbilical pain → localizing to RLQ, anorexia, N/V, irritability (may be the only sx in age <2), fever

**Physical Findings**

- RLQ tenderness, rebound/guarding, Rovsing sign (RLQ pain w/ palpation in LLQ), psoas sign (RLQ pain w/ hip extension), obturator sign (RLQ pain w/ leg flexion + internal hip rotation)

**Evaluation**

- Labs: CBC, UA (sterile pyuria/mild hematuria), hCG
- Imaging: U/S (90% sens: Much lower if perforated/large habitus/operator dependent), abd plain films (fecalith 10%), CT scan (95% sens/spec)
Treatment
- Surgical consult for operative management, abx (ampicillin 50 mg/kg, gentamicin 1 mg/kg + metronidazole 15 mg/kg or cefoxitin 20–40 mg/kg)

Disposition
- Admit

Pearls
- 90% of children <2 y/o have perforation at presentation (thinner walled/looser omentum → ↑ perforation)
- Young children may not have anorexia

INTUSSUSCEPTION

Definition
- Invagination of bowel into another, most commonly ileocolic (most frequent cause of SBO in <6 y/o)

History
- Age 3 mo–3 yr (peak 5–9 mo), M > F, lethargy, vomiting, intermittent fussiness/crying/inconsolability w/ drawing legs to chest, cramping abd pain

Physical Findings
- Not tender b/w episodes, abd tenderness, RUQ sausage-like mass, heme + stool, “currant jelly” stool (late finding in <1/3 of pts)

Evaluation
- Upright plain abd film to r/o free air, crescent sign, U/S (95% sens/spec): Target, bull’s eye, doughnut, pseudokidney sign; barium/air/water enema: Diagnostic/therapeutic (90% successful)

Treatment
- Barium/air/water enema, NGT, surgical consult for operative management in case barium enema fails, hydration (severe dehydration is common), NPO

Disposition
Admission for 24 h observation

Pearls
- <3 y/o likely idiopathic
- Barium enema is contraindicated if peritoneal signs
- If >2 y/o, consider abnl lead point (tumor, Meckel’s, polyp)

MALROTATION WITH MIDGUT VOLVULUS

Definition
- Malrotation & weak fixation of the duodenum & colon during embryologic development → twisting of the mesentery causing duodenal obstruction/SMA compression → necrosis

History
- Neonate (3 y/o) acute abd pain, bilious vomiting, ±distension, irritability/lethargy, FTT, mostly occur w/i 1st year of life

Physical Findings
- Ill appearing/dehydration, heme + stool/grossly bloody, abd tenderness, often peritoneal

Evaluation

Treatment
- Immediate surgical consult for operative management, NGT, NPO, abx, fluids

Disposition
- Admission

INCARCERATED/STRANGULATED HERNIA

Definition
Defects in the abd wall that allow protrusion of abd contents through the inguinal canal

**History**
- More commonly male, abd/groin/testicular pain, inguinal fullness w/ prolonged standing/coughing, vomiting, irritability in infants

**Physical Findings**
- Intestine/BS in scrotal sac

**Evaluation**
- Scrotal/abd U/S if physical exam is unclear, x-ray can be used to r/o free air

**Treatment**
- Reduction: Place in Trendelenburg → gentle pressure ± ice analgesic/BZD; >12 h concern for perforation/gangrene → surgical management

**Disposition**
- Admission if operative management required

---

**MECKEL DIVERTICULUM**

**Definition**
- Omphalomesenteric duct remnant w/ 60% containing heterotopic gastric (80%) or pancreatic tissue

**History**
- Any age (sxs usually begin <2 y/o), ±LLQ pain, melanotic stool (acid secretion → ulceration/erosion of mucosa), vomiting, sx of SBO, intussusception

**Physical Findings**
- LLQ mass, heme + stool/brisk bleeding, abd distension

**Evaluation**
- Technetium scan (Meckel scan): Identifies heterotopic gastric tissue (90% sens)
**Treatment**
- Type & cross/transfuse for brisk bleeding, surgical consult for Meckel diverticulectomy

**Disposition**
- Admit

<table>
<thead>
<tr>
<th>Meckel’s Rule of 2s</th>
</tr>
</thead>
<tbody>
<tr>
<td>2% of the population</td>
</tr>
<tr>
<td>Only 2% of those w/ Meckel are symptomatic</td>
</tr>
<tr>
<td>2 in long</td>
</tr>
<tr>
<td>2 ft proximal from ileocecal valve</td>
</tr>
<tr>
<td>Presents in the 1st 2 yr of life</td>
</tr>
<tr>
<td>2 types of epithelium: Gastric &amp; pancreatic</td>
</tr>
</tbody>
</table>

**NECROTIZING ENTEROCOLITIS (NEC)**

**Definition**
- Inflammatory condition of intestinal wall due to bacterial overgrowth w/ translocation

**History**
- Preterm neonate (90%), age < 1 mo (usually first days of life), bilious vomiting, abd distension, bloody stool, feeding intolerance

**Physical Findings**
- Ill appearing, hypotension, lethargic, abd tenderness, heme + stools, diarrhea

**Evaluation**
- Abd x-ray: Pneumatosis intestinalis (75%), portal venous air; barium enema if x-ray is ambiguous

**Treatment**
- NPO, hydration/transfusion, NGT, abx (ampicillin/gentamicin/metronidazole), surgical consult
Disposition
- Admit

Pearls
- Bell stages: I. Vomiting/ileus, II. Intestinal dilation/pneumatosis on x-ray, III. Shock/perforation
- Cx: DIC, strictures, obstruction, fistulas, short gut syndrome

HIRSCHSPRUNG DISEASE

Definition
- Absence of ganglion cells in the myenteric plexus of the colon → constant contraction & proximal dilation → constipation, obstruction (4:1 male predominance)

History
- Chronic constipation, delayed 1st meconium, FTT, abd distension, vomiting

Physical Findings
- Sx in 1st days to weeks of life, palpable stool in abdomen, tight sphincter, fecal mass in LLQ, no stool in rectal vault, “squirt” – explosive release of stool when finger is withdrawn

Evaluation
- Abd plain film: Dilated colon/fecal impaction/air fluid levels; barium enema; Dx → biopsy (aganglionosis) or anal manometry

Treatment
- Outpt surgical eval

Disposition
- D/c unless cx: Toxic mega colon, perforation, enterocolitis

CYANOSIS

Approach
Differentiate cyanosis that is central (mucous membranes, tongue, trunk, 2/2 right-to-left shunt) vs. peripheral (feet, hands, lips, 2/2 peripheral vasoconstriction)

**Definition**
- Acrocyanosis: Blueness in hands/feet only seen in newborns, 2° perfusion of the extremities → nl & resolves w/i 1st few days of life
- Breath-holding spell: Prolonged period w/o attempt to breathe a/w intense crying from pain, anger, fright → benign, but Dx of exclusion

<table>
<thead>
<tr>
<th>Cyanosis Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathophysiology</strong></td>
</tr>
<tr>
<td>Hypoventilation</td>
</tr>
<tr>
<td>Respiratory</td>
</tr>
<tr>
<td>Cardiovascular</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

**History**
- Age of onset, central or peripheral, med ingestion, recent illness, environmental exposures
- Δ w/ crying: Improvement → respiratory etiology (↑ alveolar recruitment); exacerbation → cardiac etiology (↑ CO)

**Findings**
- Appearance (ill or well), VS, respiratory distress, heart murmur

**Evaluation**
- Provide $O_2$, obtain CXR, ECG
- Hyperoxygenation test: Compare ABG on RA on 100% $O_2$ for 10 min, $P_{O_2}$ of >250 excludes hypoxia 2/2 congenital heart dz
- Improvement in $O_2$ sat w/ $O_2$, lack of murmur, nl ECG → pulmonary process
- No Δ in $O_2$ sat w/ $O_2$, murmur, abnl ECG → cardiac cause → obtain echo (see 14-19)

**Treatment**
O₂, identify then tx underlying condition
Consider PGE₁ for pts <2 wk of age in circulatory failure

Disposition
- Admit any pt who is ill appearing, low O₂ sat or PaO₂
- Consult cardiology for any pt w/ suspected congenital cardiac dz

PEDIATRIC FEVER

Approach
- Fever (38°C or 100.4°F) management is different in pediatric population compared to adults
- ABCs, check O₂ saturation, rectal temperature
- Need for abx & hospitalization depends on age, tox, exposures, immune status, identified source, seriousness of source
- Introduction of *H. influenzae* & pneumococcal vaccines have changed the incidence & etiology of febrile illness in pediatric populations

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary</td>
<td>Bronchiolitis, croup, pertussis, pharyngitis, PNA</td>
</tr>
<tr>
<td>GI</td>
<td>Appendicitis, gastroenteritis, rotavirus</td>
</tr>
<tr>
<td>GU</td>
<td>UTI, pyelonephritis</td>
</tr>
<tr>
<td>Noninfectious</td>
<td>SCD, Kawasaki’s Dz, rheumatologic &amp; oncologic etiologies</td>
</tr>
<tr>
<td>Misc infections</td>
<td>Cellulitis, HIV, sepsis, varicella, epiglottitis, measles, meningitis, mumps, OM, omphalitis, roseola, rubella, scarlet fever, osteomyelitis, HSV, enterovirus, bacterial conjunctivitis, nonsp viral syndromes</td>
</tr>
</tbody>
</table>

**FEBRILE INFANT 0–90 D OLD**

History
- Difficult to obtain localizing hx; standardized w/u to Dx serious
bacterial illnesses, high-risk 2/2 immature immune sz
- Exposures (travel, ill family members) & immunizations are helpful

**Findings**
- Fever >38°C or 100.4°F rectal considered standard; fussy, irritable, poor feeding
- Assess frequency & # of wet diapers, cap refill, fontanelles, tears, to estimate dehydration
- Ask about any rashes (viral exanthems, meningococcus)

**Evaluation**
- Sepsis w/u: See table

**Treatment**
- Less than 1 mo: Cefotaxime 50 mg/kg IV q12h + ampicillin 25–50 mg/kg IV q8h
- 1–3 mo: Ceftriaxone 50 mg/kg IV q24h, consider IM ceftriaxone 50 mg/kg if being D/C
- Higher doses for suspected meningitis, consider adding acyclovir 20 mg/kg IV (see 14-16)
- Treat other identified bacterial source appropriately
- If LP was not performed, consider withholding abx in well-appearing infant w/ nl WBC

**Disposition**
- If <30 d or <90 d & toxic appearing, admit & follow cx even if all labs nl
- Can d/c 30–90 d w/ neg. sepsis w/u & well appearing/feeding w/ f/u in 24 h. Consider 1 dose ceftriaxone prior to d/c

**Pearl**
- Due to inability to localize source of infection, relative immaturity of immune systems, & prevalence of occult bacteremia, all pts receive extensive sepsis w/u

---

**FEBRILE CHILD 3–36 MO**

**History**
Vulnerable immune system, esp to encapsulated organisms’ exposures
Exposures (travel, ill family members) & immunizations helpful

Findings
- Irritable, poor feeding; elicit hydration status via # of wet diapers, tears, fontanelle, cap refill
- Ask about any rashes (viral exanthems, meningococcus)

Evaluation
- See table

Treatment
- If ill appearing w/ fever, 1 dose ceftriaxone (50 mg/kg IV & 24-h admission for cx)
- Treat identified bacterial source appropriately

Disposition
- If well appearing w/ neg. w/u & fully immunized, d/c home w/ close f/u
- If well appearing w/neg. w/u & incomplete immunization:
  - WBC >15K (ANC >9000), give empiric abx (ceftriaxone IV or IM) &24 h f/u or admit if f/u uncertain
  - WBC <15K (ANC <9000), d/c w/o abx, but close f/u in 24–48 h

Pearl
- Prevalence of occult bacteremia in well-appearing children <36 mo is now 0.25–0.4% (Acad Emerg Med 2009;16(3):220; Arch Dis Child 2009;94(2):144)

<table>
<thead>
<tr>
<th>EVAL of Pediatric Fever by Age</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
</tr>
</tbody>
</table>
| 0–90 d | >38°C | Any | Straight cath urine & culture  
CBC w/ differential, blood culture, CRP  
CXR if ↑ RR, respiratory sx s  
CSF culture, cell count, glucose/protein, ±HSV/enterovirus PCR  
Stool culture if diarrhea is present |
| 3–36 mo | <39°C | Any | UA & Ucx  
CXR if ↑ RR, resp sx s |
JAUNDICE

Definition

- Yellowish discoloration of the skin/tissue/body fluids caused by ↑ bilirubin production or ↓ excretion

Approach

- Bilirubin: Formed from degradation of hemoglobin → bound to albumin in blood (unconjugated/indirect) → conjugated in liver by glucuronyl transferase (conjugated/direct) → excreted in bile

History

- Differential depends on age (neonates ≤4 wk), gestational age, breast-feeding status
- Time of onset of sx: Yellowing of skin, dark urine

Physical Findings

- Scleral icterus, jaundice

Labs

- Total/fractionated bilirubin (visible >5 mg/dL in neonates), LFTs, CBC (hemolysis/anemia → Coombs test, smear, ABO/Rh type), reticulocyte count, serum haptoglobin
- Neonates → unconjugated (can be physiologic, treat to prevent kernicterus)/ conjugated (always pathologic)

<table>
<thead>
<tr>
<th>&gt;39°C</th>
<th>Well</th>
<th>UA &amp; Ucx</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CBC w/ differential, blood culture, CRP</td>
<td>CXR if ↑ RR, resp sx</td>
</tr>
<tr>
<td>III</td>
<td>UA &amp; Ucx</td>
<td>CBC w/ differential, blood culture, CRP</td>
</tr>
<tr>
<td></td>
<td>If neg., LP</td>
<td>CXR if ↑ RR, resp sx</td>
</tr>
</tbody>
</table>
### Hemolytic disorders
- ABO incompatibility
- G6PD deficiency
- Sickle cell anemias
- Thalassemias
- Hereditary spherocytosis
- HUS

### Enterohepatic recirculation
- Hirschsprung dz, pyloric stenosis, GI obstructions

### Other
- Cephalohematoma, birth trauma, hypothyroidism, Down syndrome, polycythemia, Gilbert syndrome, Crigler–Najjar syndrome (deficiencies in glucuronyl transferase)

---

### Physiologic Jaundice

**Definition**
- Elevated unconjugated bilirubin in the 1st wk of life, 60% newborns will be jaundiced (peaks 2–5 d), due to low activity of glucuronyl transferase, increased production, & increased enterohepatic circulation

**Evaluation**
- Total/fractionated bilirubin, CBC (hemolysis/anemia → Coombs test, smear, ABO/Rh type), total bilirubin usually <6 mg/dL, up to 12 mg/dL in premature infants

**Treatment**
- No tx necessary

**Disposition**
- Home

**Pearls**
- Pathologic: In the 1st 24 h of life, peak >17 mg/dL in breast-fed/>15 mg/dL in formula-fed infants, persists beyond 1st wk of life, ↑ bilirubin >5 mg/dL/d
- Cx of severe hyperbilirubinemia: kernicterus (bilirubin deposition in basal ganglia → neurodevelopmental deficits)
Sepsis can rarely present as jaundice

**BREAST-FEEDING JAUNDICE**

**Definition**
- ↑ unconjugated bilirubinemia in breast-fed infants possibly due to hormonal mediators or altered intestinal secretion/absorption of bile, early onset after birth
- May be related to caloric deprivation or insufficient frequency of feeding

**Evaluation**
- Total/fractionated bilirubin, CBC

**Treatment**
- No tx necessary if bilirubin <17 mg/dL, encourage breast feeding, phototherapy

**Disposition**
- Home

**BREAST MILK JAUNDICE**

**Definition**
- Due to substances in breast milk that prevent conjugation & excretion of bilirubin. Occurs after 3–5 d of life, persists for weeks.

**Evaluation**
- Total/fractionated bilirubin, CBC

**Treatment**
- If bilirubin <17 mg/dL, continue breast feeding, phototherapy
- If >17 mg/dL, stop breast feeding, will not recur when resumed

**Disposition**
- Home

**ABO AND RH INCOMPATIBILITY/HEMOLYTIC DISEASE**
**Definition**
- Hemolytic dz caused by maternal antibodies against fetal A or B type proteins or maternal Rh antibodies (sensitized from previous pregnancy) against Rh-positive fetus (Rh incompatibility)

**History**
- Yellowing of skin w/i 1st 24 h of life, dark urine, lethargy

**Physical Findings**
- Severe jaundice, scleral icterus, ill appearing

**Evaluation**
- Total/fractionated bilirubin, CBC (hemolysis/anemia → Coombs test, smear, ABO/Rh type)

**Treatment**
- Phototherapy, exchange transfusion (see table)

**Disposition**
- Admit

---

### Indications for Therapy in Unconjugated Hyperbilirubinemia

<table>
<thead>
<tr>
<th>Age</th>
<th>Consider Phototherapy (mg/dL)</th>
<th>Phototherapy (mg/dL)</th>
<th>Consider Exchange Transfusion if Phototherapy Fails (mg/dL)</th>
<th>Exchange Transfusion (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤24 h</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>25–48 h</td>
<td>≥12</td>
<td>≥15</td>
<td>≥20</td>
<td>≥25</td>
</tr>
<tr>
<td>49–72 h</td>
<td>≥15</td>
<td>≥18</td>
<td>≥25</td>
<td>≥30</td>
</tr>
<tr>
<td>≥72 h</td>
<td>≥17</td>
<td>≥20</td>
<td>≥30</td>
<td>≥30</td>
</tr>
</tbody>
</table>

**CONJUGATED HYPERBILIRUBINEMIA**

**Definition**
- Pathologic increase in direct bilirubin leading to jaundice (conjugated
bilirubin >20% of total, or >2 mg/dL)

**History**
- Yellowing of skin, dark urine, lethargy, ±genetic syndrome/metabolic syndromes/sepsis

**Physical Findings**
- Severe jaundice, scleral icterus, ill appearing

**Evaluation**
- Total/fractionated bilirubin, CBC, blood cultures, blood smear, LFTs, blood type, KUB if signs of obstruction, U/S: Biliary obstruction, UA, Ucx

**Treatment**
- Hydration, tx based on cause (see below)

**Disposition**
- Admit

<table>
<thead>
<tr>
<th>Differential Dx of Conjugated Hyperbilirubinemia in Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biliary obstruction</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Infections</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Metabolic</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Drugs</td>
</tr>
</tbody>
</table>
APAP
Iron
Sulfa
Miscellaneous
Reye syndrome
Neonatal lupus
Neonatal hepatitis, autoimmune hepatitis

**LIMP**

**Approach**
- Examine abdomen, genitalia, spine, hips, long bones, knees, ankle, feet; observe gait
- Careful hx from pt & care giver: Acute vs. chronic, fevers, skin Δ; trauma
- Obtain x-rays although pain is often referred (classically, knee pain referred from hip)
- Consider systemic sxs in conjunction w/ chief complaint of joint pain

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trauma</td>
<td>Fracture, dislocation, sprains, hemorrhrosis, back pain</td>
</tr>
<tr>
<td>Hematologic</td>
<td>Sickle cell anemia (14aa), hemophilia</td>
</tr>
<tr>
<td>Neuromuscular</td>
<td>Peripheral neuropathy, muscular dystrophy, myositis</td>
</tr>
<tr>
<td>Infectious</td>
<td>Septic arthritis, toxic synovitis, osteomyelitis, PID, diskitis, epidural abscess</td>
</tr>
<tr>
<td>Rheumatologic</td>
<td>Juvenile rheumatoid arthritis, gout, pseudogout, lupus, rheumatic fever</td>
</tr>
<tr>
<td>GI/GU</td>
<td>Psoas abscess, testicular torsion, orchitis, appendicitis</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Legg–Calvé–Perthes dz, SCFE, Osgood–Schlatter dz</td>
</tr>
<tr>
<td>Neoplastic</td>
<td>Leukemia, Ewing sarcoma, osteosarcoma, osteochondroma</td>
</tr>
</tbody>
</table>

**INFECTIONOUS**
Septic Arthritis of the Hip

History
- Most commonly in children <3 y/o, but can occur at any age
- Limp or refuse to walk, hx of fever & irritability (sxs may be far more subtle in infants)

Findings
- Febrile & toxic appearing
- Flexed, externally rotated, abducted hip; antalgic gait (if walking)
- Significant pain w/ ROM but not necessarily warm, swollen or erythematous

Evaluation
- ↑ WBC, ↑ CRP, ↑ ESR; arthrocentesis shows ↑ WBC, +Gram stain & culture
- X-rays & U/S may show effusion

Treatment
- Orthopedic consultation for drainage & washout in the OR
- Abx: β-lactamase–resistant PCN (IV nafcillin or oxacillin 50–100 mg/kg/d QID) & 3rd-generation cephalosporin (cefotaxime or ceftriaxone 50 mg/kg); consider vancomycin
- Pain control

Disposition
- Admit for surgical wash-out

Pearl
- Hip > knee > elbow likely to be septic in children

Toxic (Transient) Synovitis

History
- 3–6 y/o, M:F 2:1, acute or chronic unilateral hip, thigh, or knee pain
- May be mildly febrile, possibly recent URI

Findings
- Nontoxic appearing
- Limited hip ROM 2/2 pain; mild restriction of passive ROM to internal rotation & extension; most sens to log roll
- Antalgic gait, painful to palpation
Evaluation
- X-ray of hip nl; may show effusion
- WBC & ESR nl or slightly ↑; afebrile children w/ nl labs can avoid arthrocentesis
- U/S can diagnose effusion, but cannot differentiate type

Treatment
- Pain control w/ NSAIDs, heat, & massage

Disposition
- Orthopedic f/u, crutches to keep weight off hip until pain resolves

Pearls
- Most common cause of acute hip pain in children from 3–10 yr; arthralgia & arthritis secondary to transient inflammation of the synovium of the hip
- Recurrence rate <20%, most develop w/i 6 mo, no ↑ risk for juvenile chronic arthritis, may go on to develop Legg–Calvé–Perthes dx

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>16.9</td>
<td>0.2</td>
</tr>
<tr>
<td>1</td>
<td>36.7</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>62.4</td>
<td>40</td>
</tr>
<tr>
<td>3</td>
<td>82.6</td>
<td>93.1</td>
</tr>
<tr>
<td>4</td>
<td>93.1</td>
<td>99.6</td>
</tr>
<tr>
<td>5</td>
<td>97.5</td>
<td></td>
</tr>
</tbody>
</table>

Factors: Temp >38.5°C, WBC >12, ESR >40, refusal to bear weight ± CRP >20 (if using modified Kocher criteria)

**MUSCULOSKELETAL**

**Legg–Calvé–Perthes Disease (Avascular Necrosis of Femoral Head)**

History
Most commonly in 5–7 y/o w/ limp & pain in groin, thigh, or knee; worse w/ ↑ activity
No fever or irritability, no hx of trauma

Findings
- Nontoxic appearing, antalgic gait
- ↓ Hip ROM secondary to pain w/ possible thigh atrophy, ↑ w/ internal rotation & abduction

Evaluation
- WBC & ESR nl
- X-rays often nl initially; frog-leg views helpful
  - Widening of cartilage space, diminished ossific nucleus
  - Subchondral stress fx of femoral head; linear lucency in femoral head epiphysis
  - Femoral head opacification & flattening known as coxa plana
  - Subluxation & protrusion of femoral head from acetabulum

Treatment
- Goal is to avoid severe degenerative arthritis, maintain ROM, relieve weight bearing
- Orthopedic eval; bone scan & MRI more rapidly diagnostic than x-rays

Disposition
- Orthopedic f/u, crutches to keep weight off hip until pain resolves

Pearls
- Idiopathic osteonecrosis of capital epiphysis of femoral head; 15–20% bilateral
- Caused by interruption of blood supply to capital femoral head → bone infarction
- Better prognosis at younger onset; proportional to degree of radiologic involvement

Slipped Capital Femoral Epiphysis (SCFE)

History
- 12–15-y/o boy or 10–13-y/o girl, c/o limp & groin, thigh, or knee pain
- If sxs >3 wk, considered chronic
- If unable to bear weight, considered unstable (higher cx rate)
Findings
- Affected leg externally rotated, shortened w/ pain when flexing hip; antalgic gain

Evaluation
- nl temp, WBC, ESR
- X-ray: Femoral head is displaced posteriorly & inferiorly in relation to femoral neck w/i confines of acetabulum; AP & frog-leg views best

Treatment
- Orthopedic consult for operative internal fixation; goal to prevent AVN of femoral head

Disposition
- Admission for orthopedic surgery

Pearls
- Obesity is the RF; genetics play role; bilaterality more common in younger pts who also tend to have metabolic/endocrine disorders
- If traumatic hip injury w/ obvious external rotation & shortening of the leg, do not force ROM as this can worsen epiphyseal displacement

Osgood–Schlatter Disease
Definition
- Microtrauma to the tibial tubercle tuberosity apophysis occurring during use

History
- Preteen boy w/ knee pain, worse w/ activity & better w/ rest

Findings
- Edema & pain of tibial tubercle; enlarged & indurated tibial tuberosity
- Tender over anterior knee, esp over thickened patellar tendon
- Pain reproduced by extending knee against resistance, stressing quads or squatting w/ knee in full flexion, running, jumping, kneeling, squatting, stairs

Evaluation
- Clinical dx. X-ray may show swelling over tuberosity & patellar tendon; no effusion

Treatment
Guided by severity: Range from decreasing activity in mild cases to rest in severe cases
NSAIDs for pain control, ice, ±crutches

Disposition
D/c home w/ pain control

Pearls
One of the most common causes of knee pain in adolescent; benign & self-limited
Bilateral in 25% of cases; 50% give hx of precipitating trauma

PEDIATRIC SEIZURE

Definition
Abn, paroxysmal d/c of CNS neurons leading to abn neurologic fxn

Approach
ABCs, check O₂ saturation, temperature, determine if still seizing
Immediate bedside glucose fingerstick & tx, consider administering empiric glucose
If actively seizing, quickly administer suppression medications
Careful hx: Description of events before & after sz, associated sxs (HA, photophobia, vomiting, visual Δ, ocular pain), focal neurologic sxs
Assess for head or neck trauma, meningismus, skin finding (petechiae, café-au-lait spots, port-wine stain, ash leaf spots), ↑ICP (bulging fontanelle)
Thorough neurologic exam; Todd paralysis: Transient paralysis after a sz
CBC, CMP, tox screen, UA, CXR: Tox screen, anticonvulsant levels, infectious w/u
Consider CT if persistent AMS, neurologic deficit, or trauma
Consider LP after head CT if persistently AMS, fever, & therapeutic med levels
1st-time sz w/u: Consider head CT, ECG, CBC, CMP, tox screen, LP
EEG days to weeks after sz unless concern for nonconvulsant status epilepticus
- Status epilepticus is recurrent or continuous sz activity lasting >30 min w/o return to baseline MS
- Can result in cerebral hypoxia, lactic & respiratory acidosis, hypercarbia, hypoglycemia
- Disposition: Admission for abnl neuro exam, others w/ neurology f/u

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurologic</td>
<td>1° sz, status epilepticus, febrile, sz degenerative CNS dz (neurofibromatosis, tuberous sclerosis, Sturge–Weber syndrome), epilepsy, cerebral palsy</td>
</tr>
<tr>
<td>Head injury</td>
<td>IPH, SAH, SDH, epidural (19b)</td>
</tr>
<tr>
<td>Infection</td>
<td>Meningitis (5d, 14i), encephalitis (5d), brain abscess, toxoplasmosis, tetanus, neurocysticercosis</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Hypoglycemia, hyperglycemia, hyponatremia, hypernatremia, hypocalcemia, hypomagnesemia, alkalosis (5e), pyridoxine deficiency</td>
</tr>
<tr>
<td>Toxic</td>
<td>Lead, PCP, amphetamine, cocaine, aspirin, CO, organophosphates, theophylline, lidocaine, lindane, drug withdrawal (anticonvulsants), s/p DPT immunization</td>
</tr>
<tr>
<td>Neoplasm</td>
<td>Brain tumor</td>
</tr>
<tr>
<td>Pediatric</td>
<td>Reye syndrome, CMV, congenital syphilis, maternal rubella, PKU</td>
</tr>
<tr>
<td>Vascular</td>
<td>Embolism, infarction, HTN encephalopathy, malformations</td>
</tr>
<tr>
<td>Other</td>
<td>Psychological, hyperventilation, breath-hold spells, inadequate drug level, neurocutaneous syndromes, inborn errors of metabolism</td>
</tr>
</tbody>
</table>

**Primary Seizures**

**History**
- Presence/absence of aura, abrupt onset & termination of sz activity, stereotyped purposeless behavior, fecal or urinary incontinence, postictal confusion or lethargy
Findings
› Depends on type of sz, LOC secondary to simultaneous activation of entire cerebral cortex

Evaluation
› As above

Treatment
› Acute vs. chronic meds, airway mgmt often w/ only nasal trumpet, supplemental O₂
› Abortive tx
   • BZD are 1st line (lorazepam 0.1 mg/kg up to 4 mg IV)
   • BZD: Diazepam (t₁/₂ 15–20 min), lorazepam (t₁/₂ 12–24 h), midazolam (t₁/₂ <12 h)
   • 2nd-line: fosphenytoin (20 PE/kg IV)
   • Phenobarbital (20 mg/kg IV load), 1st line in neonates, watch for hypotension & bradypnea
   • If refractory szs, give pyridoxine 100 mg IV; consider thiamine 100 mg IV in adolescents

Long-term Anticonvulsant Medications
› If known sz disorder & subtherapeutic levels, load w/ chronic med
› Long-term anticonvulsants not routinely indicated in 1st unprovoked sz

Disposition
› Explicit instructions to not drive, operate hazardous machinery, or perform tasks where recurrent sz may cause harm; some states have mandatory reporting to department of motor vehicles

Pearls
› Keep differential broad even if known sz d/o, esp if tx med levels
› If meningitis suspected, give abx pre-emptively while awaiting confirmation
› Pseudosz is Dx of exclusion
› Tx EtOH withdrawal sz w/ BZD, almost never responsive to antiepileptic meds
› Consider Neurology consult if starting new long-term med in 1st-time sz (will need close f/u)
## Pediatric Sz Suppression Steps

<table>
<thead>
<tr>
<th>Tx of Sz</th>
<th>Step</th>
<th>Antiepileptic</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>Lorazepam (slower)</td>
<td>0.1 mg/kg IV or prn, repeat 0.05 mg/kg q5min</td>
</tr>
<tr>
<td></td>
<td>2 (&gt;30 min)</td>
<td>Phenobarbital (consider intubating)</td>
<td>20 mg/kg (&lt;20 kg) or 10 mg/kg (&gt;20 kg) IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phenytoin</td>
<td>20 mg/kg IV at 1 mg/kg/min</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fosphenytoin</td>
<td>20 mg PE/kg at 3 mg PE/kg/min</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Levetiracetam</td>
<td>20 mg/kg IV</td>
</tr>
<tr>
<td></td>
<td>3 (&gt;1 h)</td>
<td>Pentobarbital, midazolam, valproic acid, propofol infusions, general anesthesia</td>
<td></td>
</tr>
</tbody>
</table>

### Epilepsy

#### History
- Typical sz recurrence, may be a/w lip biting, incontinence of bowel or bladder followed by lethargy/combativeness & confusion (postictal period)

#### Findings
- Depends on type of sz, LOC secondary to simultaneous activation of entire cerebral cortex

#### Evaluation
- As above

#### Treatment
- Acute vs. chronic meds, airway mgmt often w/ only nasal trumpet, supplemental O₂

#### Disposition
- Neurology f/u for medication adjustment if indicated

#### Pearls
- Keep differential broad even if known sz d/o, esp if tx med levels
- Systemic illness such as URI or fever can lower sz threshold

## Cerebral Palsy

#### History
Nonprogressive lesion sustained during brain development → motor, speech, & learning disabilities, high risk (50%) for szs. Prematurity is the biggest RF

**Findings**

- Depends on type of CP:
  1. Quadriplegia: Hypotonic trunk & spastic extremities
  2. Diplegia: Spastic lower extremities, ↑ DTRs, clonus, & “scissoring”
  3. Hemiplegia: Unilateral spasticity, usually UE > LE
  4. Athetoid: Writhing, involuntary movements of extremities
  5. Ataxic: Unsteady, uncoordinated movements
  6. Hypotonic: Lacking muscle tone

**Evaluation**

- Head CT if new onset sz or recent trauma
- Outpt EEG if new onset sz or Δ in sz pattern or frequency

**Treatment**

- Standard sz tx

**Disposition**

- Neurology f/u for medication adjustment if indicated

**Pearls**

- Pts w/ CP often have breakthrough sz & low sz thresholds, look for underlying illness (URI, PNA, UTI, etc.), adjust outpt meds w/ 1° neurologist
- CP pts also commonly present to the ED w/ chronic aspiration, PNA, feeding difficulties, G-tube malfunction, UTIs

<table>
<thead>
<tr>
<th>Pediatric Sz Types</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generalized absence</td>
<td>Staring spell w/ loss or motor/speech activity, w/ brief LOC</td>
</tr>
<tr>
<td>Generalized tonic–clonic</td>
<td>Contracted posture followed by rhythmic jerking movements of extremities in pts w/ impaired consciousness</td>
</tr>
<tr>
<td>Myoclonic</td>
<td>Repetitive, rhythmic muscular contractions</td>
</tr>
<tr>
<td>Simple partial</td>
<td>Unilateral tonic–clonic movements, nl consciousness</td>
</tr>
<tr>
<td>Complex partial</td>
<td>Unilateral tonic–clonic movements w/ impaired consciousness, both cerebral hemispheres involved</td>
</tr>
</tbody>
</table>
### Febrile Seizures

#### History
- T $\geq 38.3^\circ$C (101°F) in child b/w 6 mo & 5 yr of age
- No hx of sz; 1 generalized sz lasting $< 15$ min a/w rapidly ↑ temp

#### Findings
- Generalized sz activity, usually lasts $< 15$ min; high fever, postictal period
- Complex febrile sz: Last $> 15$ min, $> 1$× in 24-h period, or focal component

#### Evaluation
- Evaluate for underlying (infectious) cause: CXR, UA, labs, bedside glucose, ±LP

#### Treatment
- Antipyretic, observation until pt back to baseline, parental reassurance
- Anticonvulsants like BZD & phenobarbital are not indicated

#### Disposition
- 1st febrile sz, nonfocal exam, neg. ED w/u can be D/C w/ neuro f/u

#### Pearls
- Focal sz do not present as simple febrile sz
- Consider meningitis/encephalitis in unvaccinated children
- Febrile sz not a/w an epilepsy or brain damage
- Incidence of another febrile sz is 35
- $> 2$ febrile sz/yr or $> 3$ total febrile sz must be evaluated for other etiologies
**Approach**
- Common sx of many dz processes (eg, intra-abd causes, metabolic derangements, toxic ingestions, neurologic causes)

**History**
- Relation to eating, bilious (require eval for obstruction), ability to tolerate POs, urine output (making wet diapers), presence of bloody stools, HA, AMS

**Labs**
- BMP, serum glucose (↑ risk of hypoglycemia)

**Treatment**
- Treat underlying cause, antiemetics, hydration (PO or IV)

---

### Nausea & Vomiting Differential

<table>
<thead>
<tr>
<th>Location</th>
<th>Infancy</th>
<th>Childhood/Adolescence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanical</td>
<td>GERD, malrotation w/ midgut volvulus (14a), intussusception (14a), pyloric stenosis</td>
<td>Constipation, hernia (14a), Meckel diverticulum (14a), bowel obstruction (3a)</td>
</tr>
<tr>
<td>Inflammatory/ infectious</td>
<td>NEC (14a), gastroenteritis, sepsis (14j), meningitis (14i), PNA, OM</td>
<td>Gastroenteritis, OM, appendicitis (14a), pancreatitis (14a), HSP (14a), biliary dz (3a)</td>
</tr>
<tr>
<td>GU</td>
<td>UTI (14bb)</td>
<td>UTI (14bb), renal colic (6b), pregnancy/ectopic (7), PID (7), testicular/ovarian torsion (7)</td>
</tr>
<tr>
<td>CNS (persistent vomiting w/o systemic/GI sx)</td>
<td>Hydrocephalus, intracranial injury/tumor (18b)</td>
<td>Hydrocephalus, intracranial injury/tumor (18b), migraine (5d)</td>
</tr>
<tr>
<td>Metabolic</td>
<td>DKA (14r), urea cycle defects, fatty acid oxidation disorders, amino acidopathies, organic acidurias</td>
<td>DKA (14r), urea cycle defects, fatty acid oxidation disorders, RTA, adrenal insuf</td>
</tr>
<tr>
<td>Other</td>
<td>Toxic ingestions, trauma, Reye syndrome</td>
<td>Trauma, sickle cell (14aa), toxic ingestions</td>
</tr>
</tbody>
</table>
**Pyloric Stenosis**

**Definition**
- Hypertrophy of the antrum of the stomach, 5:1 male-to-female ratio

**History**
- 2–5 wk of age (rare after 3 mo), nl feeding after birth → nonbilious/+blood streaked projectile vomiting after feeding, weight loss, lethargy

**Physical Findings**
- RUQ olive-size mass, dehydration (loose skin, sunken eyes, dry mucous membranes)

**Evaluation**
- BMP (hyperchloremic metabolic alkalosis), U/S (+ pylorus >4 mm thick, >16 mm long, 95% sens, study of choice), upper GI series: “String sign,” abd x-ray: Dilated stomach

**Treatment**
- Hydration, surgical consult for pyloromyotomy

**Disposition**
- Admit

---

**Gastroesophageal Reflux Disease**

**Definition**
- Loose esophageal sphincter → retrograde passage of food into esophagus

**History**
- <2 y/o, nonbilious vomiting/spitting during/after eating, type of formula (cow vs. soy)

**Physical Findings**
- Sandifer syndrome: Startled/jerky movements after eating, often confused for sz
**Evaluation**

- Outpt w/u: 24 pH probe (most sens), nuclear milk scan, barium swallow, heme + stools (if esophagitis present), bloody diarrhea can indicate formula allergy

**Treatment**

- Small feeding volumes w/ burp breaks, keep semiupright for 30–40 min after eating, thicken feeds by adding cereal
- Acid-reducing agents: Ranitidine 2–4 mg/kg/d divided q8h, PPI, metoclopramide 0.1–0.2 mg/kg q12h

**Disposition**

- Home

**Pearls**

- Cx: FTT, apnea, laryngospasm, esophagitis, PNA
- Usually resolves by 1 yr

---

**Gastroenteritis**

**Definition**

- Vomiting & diarrhea caused by infectious source

**History**

- Vomiting, diarrhea, sick contacts, recent abx, travel

**Physical Findings**

- Lethargy, dehydration (skin turgor, cap refill, mucus membranes, tears, VS)

**Evaluation**

- BMP (if severely dehydrated), stool culture/ova/parasites (protracted/bloody diarrhea)

**Treatment**

- Electrolyte correction, hydration (PO preferred, IV prn), most self-resolve, avoid antimitotility agents (↑ pain/cramping/prolonged sx)
- Ondansetron prn; zinc supplementation (10–20 mg/d × 10–14 d) reduces severity, duration, & incidence of diarrheal illnesses in

**Disposition**
- Home or admit (severe dehydration, bicarb <16 mEq/L, inability to tolerate POs)

<table>
<thead>
<tr>
<th>Agents</th>
<th>Classic Hx &amp; Findings</th>
<th>ED Intervention</th>
<th>Clinical Pearls</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Viral</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td>Watery diarrhea, in fall (Southwest)/winter (Northeast) months; common among children attending daycare or preschool</td>
<td>Hydration</td>
<td>~70% of children under age 2 yr admitted for diarrhea dehydration are infected w/ rotavirus; very infectious</td>
</tr>
<tr>
<td>Adenovirus</td>
<td>Watery diarrhea w/ concurrent respiratory illness usually in spring or early summer</td>
<td>Hydration</td>
<td></td>
</tr>
<tr>
<td>Norwalk virus</td>
<td>Watery diarrhea w/ fever, HA, &amp; myalgia</td>
<td>Hydration</td>
<td>Major cause of diarrhea epidemics</td>
</tr>
<tr>
<td><strong>Bacterial</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. jejuni</td>
<td>Watery or bloody diarrhea w/ fever &amp; crampy abd pain</td>
<td>Hydration &amp; azithromycin, erythromycin, or ciprofloxacin</td>
<td>Contracted through contaminated food or water</td>
</tr>
<tr>
<td>Shigella</td>
<td>Diarrhea possibly w/ blood/mucus/pus a/w fever, HA, &amp; abd pain</td>
<td>Hydration; fluoroquinolones, Bactrim, ampicillin, or azithromycin</td>
<td>Contracted through contaminated food or water; increasing abx resistance</td>
</tr>
<tr>
<td>Salmonella</td>
<td>Bloody diarrhea w/ fever</td>
<td>Hydration; ciprofloxacin, azithromycin, ampicillin, or Bactrim</td>
<td>Abx can induce a carrier state. Treat only if risk of invasive dz (&lt;3 mo of age, sickle cell, immunosuppression)</td>
</tr>
<tr>
<td><strong>E. coli</strong></td>
<td>Watery diarrhea</td>
<td>Hydration; fluoroquinolones, azithromycin, or Bactrim</td>
<td>Tx w/ abx may trigger HUS in pts w/ E. coli 0157 (controversial)</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------</td>
<td>-----------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>V. cholerae</strong></td>
<td>Watery diarrhea</td>
<td>Hydration; tetracycline or erythromycin</td>
<td></td>
</tr>
<tr>
<td><strong>V. parahaemolyticus</strong></td>
<td>Rice-water diarrhea in pt who ingested inadequately cooked seafood</td>
<td>Bactrim 10 mg (TMP/kg/24 h BID for 7–10 d in severe cases</td>
<td></td>
</tr>
<tr>
<td><strong>Y. enterocolitica</strong></td>
<td>Diarrhea possibly w/ blood/mucus/pus a/w fever, vomiting, &amp; RLQ pain</td>
<td>Hydration</td>
<td>Mimics appendicitis</td>
</tr>
<tr>
<td><strong>C. difficile</strong></td>
<td>Diarrhea a/w recent abx use</td>
<td>Metronidazole 15–30 mg/kg/24 h PO TID or vancomycin 40 mg/kg/24 h PO q6h</td>
<td>Toxic megacolon very rare in children, but possible</td>
</tr>
<tr>
<td><strong>S. aureus</strong></td>
<td>Foodborne toxin mediated w/ abrupt, dramatic onset of sxs w/i 2–6 h of ingestion</td>
<td>Hydration, supportive care</td>
<td></td>
</tr>
</tbody>
</table>

**Parasitic**

| **G. lamblia** | Watery diarrhea & excessive, particularly malodorous, flatulence in pt exposed to children in daycare or mountain streams | Hydration & supportive care; metronidazole 15–30 mg/kg/24 h PO TID for 5 d | |
| **E. histolytica** | Diarrhea w/ blood & mucus | Hydration; metronidazole 15–30 mg/kg/24 h TID | A/w hepatic abscesses Consider paromomycin to treat intraluminal infection |

QID, 4 times daily; BID, twice daily; q6h, every 6 h; CBC, complete blood count; BUN, serum urea nitrogen; Cr, creatinine; RLQ, right lower quadrant; TMP, trimvibrio colethoprim; PO, by mouth; TID, 3 times daily.
PEDIATRIC MENINGITIS (SEE 5D)

History
- HA, fever, neck stiffness, lethargy (AMS), N/V, rash, irritability, sz, somnolence

Findings
- Meningismus (stiff neck) occurs <15% of the time in children <18 mo old, petechial rash, irritability/lethargy, hemodynamic instability, fever, sz

Evaluation
- If bacterial etiology suspected, abx should be given immediately, then LP (see 4d)

Treatment
- Dexamethasone 0.15 mg/kg IV before 1st dose of abx (↓ ICP, risk of hearing loss 2/2 H. influenzae)
- Abx
  - <1 mo: Ampicillin (100 mg/kg) + gentamicin (2.5 mg/kg) OR cefotaxime (50 mg/kg)
  - 1–2 mo: Ampicillin + ceftriaxone (100 mg/kg) OR cefotaxime
  - >2 mo: Vancomycin (15 mg/kg) + ceftriaxone OR cefotaxime
- Consider adding acyclovir 20 mg/kg IV

Clinical Pearl
- Ampicillin necessary to cover Listeria in infants

NEONATAL COMPLAINTS

Approach
- Differentiate nervous parents from a child w/ true dz

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Complaint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Neonatal Presentations</td>
<td></td>
</tr>
</tbody>
</table>


GI | Poor feeding, reflux/regurgitation, vomiting, diarrhea, constipation, jaundice
---|---
Infectious dz | Fever
Other | Crying/colic, ALTE, sudden infant death syndrome (SIDS)
Respiratory | Stridor, apnea, cyanosis

**History**
- Events during pregnancy, delivery, gestational age & weight @ birth, alertness, diet, frequency of diaper Δ, crying patterns, color Δ; FH

**Findings**
- Weight, VS, color; undress baby → full exam

**Pearl**
- Many signs/sxs are nonsp: Abnl tone, weak suck, decrease PO intake, jaundice, abnl breathing, peripheral cyanosis, vomiting

---

**POOR FEEDING**

**Approach**
- Check for appropriate weight gain (5–7% wt loss during 1st week nl, then gain 1 oz/d for 1st 3 mo), take a careful hx/physical exam to identify any other abnlty

**Treatment**
- If weight gain is appropriate & pt has no other issues, attempt feeding trial

**Disposition**
- Pts w/ appropriate wt gain who tolerate POs in ED may be D/C home w/ parental reassurance & outpt f/u; all other pts require further eval (see w/u for inconsolability below)

---

**CONSTIPATION**

**Approach**
- Differentiate functional (no underlying condition) from pathologic
constipation

<table>
<thead>
<tr>
<th>Constipation Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathophysiology</strong></td>
</tr>
<tr>
<td>Obstruction</td>
</tr>
<tr>
<td>Metabolic</td>
</tr>
<tr>
<td>Neuro</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

**History**
- Sx time course, Δ in stool consistency, baseline stooling patterns, 1st meconium passage after birth (>24–48 h = abnl), recent illness, V/D, fever, ingestion of honey

**Findings**
- Abd (distension), rectal exam (patency, stool @ vault), neuro exam (CNs, muscular tone)

**Evaluation**
- KUB (if obstruction is suspected); consider Chem 7, TSH, Ca, heavy metal screen

**Treatment**
- For functional constipation: Glycerin suppository, disimpaction, increased water b/w feedings, consider bisacodyl, lactulose, enemas, high fiber diet in older children
  - Fleets enemas may cause hypocalcemia, avoid in young infants

**Disposition**
- Functional constipation → d/c w/ PCP f/u: Pathologic causes warrant further w/u & may require admission

---

**Crying and Colic**

**Definition**
Colic: Recurrent pattern of inconsolable crying & irritability lasting >3 h/d on >3 d/wk, 3 wk–3 mo of life. Benign GI colic is Dx of exclusion.

Approach

Excessive crying/colic are nonsp complaints that can be the presenting signs of benign GI distress or life-threatening dz

<table>
<thead>
<tr>
<th>Colic Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>System</strong></td>
</tr>
<tr>
<td>CNS</td>
</tr>
<tr>
<td>HEENT</td>
</tr>
<tr>
<td>Cardiac</td>
</tr>
<tr>
<td>GI</td>
</tr>
<tr>
<td>GU</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

History

Timing of crying, trauma, fever, medication ingestion, feeding hx, complete ROS & PMH

Findings

Observe behavior, thorough physical exam

Evaluation

UA; consider further testing (eg, abd U/S, x-ray, LP, tox screen) to r/o spec etiologies

Treatment

Treat the underlying d/o

Disposition

Home: If etiology is thought to be benign & pt has cry-free period in ED
Admit: Any pt w/o clear etiology identified & no cry-free period in ED

**Definition**
- Observed episode frightening to the observer & characterized by ≥1 of the following: Apnea, color Δ, Δ in muscle tone, choking, &/or gagging
- Separate clinical entity from SIDS & represents a wide spectrum of etiologies

<table>
<thead>
<tr>
<th>ALTE Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathophysiology</strong></td>
</tr>
<tr>
<td>Cardiac</td>
</tr>
<tr>
<td>GI</td>
</tr>
<tr>
<td>Infectious</td>
</tr>
<tr>
<td>Metabolic</td>
</tr>
<tr>
<td>Neuro</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Respiratory</td>
</tr>
</tbody>
</table>

**History**
- Obtain 1st-hand account of event when possible, appearance of child (central vs. peripheral cyanosis, pallor, etc.), preceding sx, prior episodes, presence of apnea or gagging, muscle tone, sz-like activity, spontaneous or facilitated recovery

**Findings**
- Through physical exam

**Evaluation**
- No standard diagnostic strategy exists. Testing should be guided by hx & physical exam. Consider: CBC, Chem 7, Ca, UA, urine/blood cx, ECG, RSV swab; CT head/LP (based on clinical suspicion); also consider ABG, serum/urine tox, pertussis screen, EEG
Disposition
› Observe in the ED; pts w/o true ALTE (eg, breath-holding spell) can be D/C w/ f/u in 24 h
› Infant w/ hx of apnea, pallor, cyanosis, limp, unresponsive req stimulation or CPR or have inadequate f/u require admission for observation & further revaluation

Pearl
› Definitive etiology of the ALTE is found in only ~50% of pts

---

SIDS

Definition
› D of child <12 mo of age that is unexplained after careful investigation, autopsy, exam of the D scene, & hx; most common @ 2–5 mo

Approach
› Approach parents of SIDS pts w/ sympathy, as child abuse rare in SIDS (<1–5%)

<table>
<thead>
<tr>
<th>Risk Factors for SIDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category</td>
</tr>
<tr>
<td>Infant</td>
</tr>
<tr>
<td>Maternal</td>
</tr>
</tbody>
</table>

Prevention
› Remind parents to lay their children in the supine position, avoid smoking, head covering, soft sleeping surfaces, & multiple layers to reduce risk
CONGENITAL HEART DISEASE

Approach

- Consider Dx in pts w/ sudden onset cyanosis, hypoxemia, &/or shock, typically in the 1st 1–2 wk of life, though some pts present weeks to years later
- Differentiate cyanotic vs. noncyanotic, & ductal vs. nonductal dependent congenital heart dz
- Hyperoxia test: Compare ABG on room air & on 100% O\textsubscript{2} for 10 min, P\textsubscript{O2} of >250 makes hypoxia 2/2 congenital heart dz unlikely
- Give PGE\textsubscript{1} to any pt w/ suspected ductal-dependent lesion & circulatory compromise

Definition

- Cyanotic lesions: Congenital cardiac dz w/ right-to-left shunt
- Ductal dependent lesions: Congenital cardiac dz in which fetal life depends on a PDA, either from impaired systemic or pulmonary blood flow

<table>
<thead>
<tr>
<th>Type of Lesion</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noncyanotic</td>
<td>PDA, ASD, VSD, AS, *aortic coarctation, PS</td>
</tr>
</tbody>
</table>

*Ductal dependent.

History

- Cyanosis, fussy baby, poor feeding

Findings

- ↓ O\textsubscript{2} sat, cyanosis, ↓ BP, cardiac murmur, hepatomegaly, check 4-extremity BPs

Evaluation
Treatment
- $O_2$, consider PGE$_1$ (alprostadil): 0.05–0.1 μg/kg/min (max 0.4 μg/kg/min) if ductal-dependent lesion suspected, side effects: bradycardia, hyperthermia, hypotension, & apnea
- Inotropic support w/ milrinone, dopamine, or dobutamine & intubation prn

Disposition
- Cardiology consult, ±cardiac surgery consult, admit

Pearls
- Pts w/ ductal-dependent lesions p/w circulatory failure, usually during 1–2 wk of life
- Acyanotic lesions may p/w CHF

---

TETRALOGY OF FALLOT

Approach
- Recognize/tx Tet spells

Definition
- PA stenosis, VSD, RV hypertrophy, & deviation of aortic origin to the right (overriding); degree of severity dictated by degree of RV outflow tract obstruction

History
- Presentation usually w/i 1st few years of life, though occasionally into adulthood
- Cyanosis (often during feeds), ↓ PO intake, agitation, ↑ RR; ↑ sxs w/ exercise, szs, CVA
- “Tet” spell: Infundibulum spasm $\rightarrow$ ↑ RV outflow obstruction $\rightarrow$ cyanosis, respiratory distress

Findings
- $\downarrow$ O$_2$ sat, systolic ejection murmur, cyanosis, squatting pt

Evaluation
See above, ECG (RAD, RVH, RAE, RBBB), CXR (boot-shaped heart), CBC, VBG

Treatment
- See above, 100% O₂, calm child, bring knees to chest; consider morphine & IV fluid bolus, correct hypoglycemia, consider propranolol, phenylephrine, intubation

Disposition
- Cardiology, cardiac surgery consult, admit

Pearl
- Onset determined by slowly ↑ infundibulum hypertrophy → ↑ RV outflow tract obstruction → ↑ RV hypertrophy → ↑ right-to-left shunt; thus presentations at later age have poorer long-term outcomes

RESPIRATORY COMPLAINTS

Pneumonia

History
- Fever, cough; quality of sputum usually unascertainable (children often swallow secretions); recent URI, malaise, lethargy, N/V, SOB, nasal flaring & grunting
- Older children: Abd pain, neck stiffness
- Infants/neonates: Difficulty feeding, tachypnea, restlessness, or lethargy
- RFs: Lack of immunizations/incomplete immunizations, travel, daycare

Bacterial (10–40%)
- Abrupt, follows URI, appearing ill, usually <5 yr

Atypical
- Fever, malaise, & myalgia, HA, photophobia, sore throat, & gradually worsening nonproductive cough

Viral
Nontoxic, associated upper airway sx (runny nose, nasal congestion)

**Physical Exam**
- Fever, tachypnea (most sens), $O_2$ saturation; full pulmonary exam (rales, rhonchi, decreased breath sounds)

**Evaluation**
- **Labs:** Chem 7 (severe dehydration), CBC (elevated WBC), blood cultures (if seriously ill); consider viral panel (including RSV)
- **Imaging:** CXR

**Treatment**
- Supportive: IVFs (if dehydrated), $O_2$ monitoring & therapy
- Viral: Supportive
- Abx (duration is 14 d for neonates, o/w 7–10 d), add vancomycin if critically ill
  - Neonate – ampicillin + gentamicin inpt
  - 1–3 mo – 3rd-generation cephalosporin + macrolide inpt
  - 3 mo–5 yr – 3rd-generation cephalosporin + macrolide (inpt) or high-dose amoxicillin (outpt)
  - 5–18 yr – 3rd-generation cephalosporin + macrolide (inpt) or macrolide alone (outpt)

**Disposition**
- Home: Immunizations up to date, HD stable, on room air, >3 mo
- Admit: <3 mo, temp >38.5°C, tachypnea (>70 breaths in <12 mo & >50 breaths in older children), retractions in infants, respiratory distress, nasal flaring, cyanosis or hypoxemia ($O_2$ <92%), intermittent apnea, grunting, poor POs, signs of dehydration, social concerns, inadequate f/u, sepsis, immunosuppressed, comorbidities, cx, virulent pathogens (*Thorax* 2002;57(suppl 1))

**Asthma and Bronchiolitis**

**History**
- **Asthma**
Cough (usually early), dyspnea & wheezing (generally worse at night). Consider frequency, severity, duration, home txs, required past txs, baseline peak flow, number of ED visits, hospitalizations, ICU admissions, intubations
- Triggers: Exercise, infection, cold air, allergens, any respiratory irritant

**Bronchiolitis (usually <2 yr of age)**
- Fever (usually ≤38.3°C), cough, wheezing, mild respiratory distress; etiology from viral exposure (usually RSV, but also parainfluenza, adenovirus, influenza, rhinovirus). Often preceded by a 1–3-d hx of nasal congestion & mild cough
- RFs for severity: Prematurity, low birth weight, <12 wk old, congenital dz, immunodeficiency, neurologic dz

**Physical**

**Asthma**
- Tachypnea, tachycardia, inspiratory/expiratory wheezes, decreased or no air movement, use of accessory muscles, anxious/agitated, signs of dehydration

**Bronchiolitis**
- Same as asthma; may hear crackles & have signs of other infections such as OM

**Evaluation**
- **Pulse ox:** Continuous, unless very mild sx
- **Labs:** Usually not necessary, consider RSV testing (bronchiolitis) if admission
- **Imaging:** CXR only if concomitant PNA suspected or 1st-time wheezer
- **Peak flow** (asthma): In children >6 yr (compare to predicted based on height)

**Treatment**
- Supportive: ABCs, O₂ therapy (O₂ sat >90%)

**Asthma**
- Mild/moderate:
  - **Albuterol:** 0.15 mg/kg (max 5 mg) q20–30min × 3 doses (short
acting β-agonist)

- **Ipratropium bromide**: 250 μg/dose (<20 kg) OR 500 μg/dose (>20 kg) q20–30min × 3 doses may decrease need for hospitalization
- **Steroids**: Prednisolone/prednisone 2 mg/kg PO (max 60 mg) OR methylprednisolone 1–2 mg/kg IV (max 125 mg) OR dexamethasone 0.6 mg/kg PO (max 16 mg)
  - Severe (add):
    - **Albuterol**: As above but may be used continuously
    - **Magnesium**: 75 mg/kg IV (max 2.5 g) over 20 min (optimal dose unknown)
    - **Heliox**: 80% helium/20% O₂. Use only if O₂ saturation can be maintained above 90%
    - **Terbutaline or epinephrine**: Terbutaline 0.01 mg/kg SC (max 0.4 mg) q20min × 2 doses &/or epinephrine 0.01 mg/kg SC (max 0.4 mg) q20min × 3 doses then repeated q4–6h
  - Ventilation:
    - **Noninvasive** (BiPAP): May reduce respiratory fatigue & improve oxygenation/ventilation
    - **Intubation**: For impending respiratory failure; use large ETT; consider permissive hypercapnia (increased expiratory time & low VTs to prevent barotraumas). Consider ketamine for induction (bronchodilating properties)

### Bronchiolitis
- Supportive tx is the mainstay including humidified O₂, suctioning, oral hydration
- Trial of albuterol, can continue only after documented response
- Nebulized hypertonic saline not a/w decreased hospital LOS after controlling for heterogeneity *(JAMA Pediatr 2016;170(6):577)*
- Racemic epinephrine may be helpful
  - <2 yr: 0.25 mL of 2.25% solution via nebulizer diluted in 3 mL NS
  - ≥2 yr: 0.5 mL of 2.25% solution via nebulizer diluted in 3 mL NS
- Consider ribavirin if documented RSV bronchiolitis w/ severe dz or immunosuppression &/or HD unstable

### Disposition

#### Asthma
Reassess pt in 3 h (more frequent if sx more severe) after nebulizers, steroids, O₂ therapy

Home: Improved peak flow (to >70% predicted), significant improvement in RR/O₂ saturation; d/c w/ inhaled β-agonist, steroid burst × 5 d (see Adult Asthma Table for further home management) w/ close f/u

Admission:
- Floor: Persistent wheezing w/ nasal flaring, tachypnea, hypoxia, & unable to tolerate POs
- ICU: If pt maintains severe wheezing/poor air movement w/ peak flow <50% & worsening tachypnea or possible impending respiratory fatigue, PCO₂ >42 mmHg, intubated, requiring continuous nebs, heliox, or terbutaline

**Bronchiolitis**
- Home: Age >2 mo, no hx of intubation, eczema, RR <45, no/mild retractions, O₂ sat >93%, tolerating PO, fewer albuterol/epinephrine txs in 1st hour (*Pediatrics* 2008;121(4):680)
- Admission: Age <6 wk, hypoxia, persistent respiratory distress, significant comorbidities, or immunosuppression

---

**B**ronchopulmonary **D**ysplasia

**Definition**
- Chronic lung dz in preterm neonates w/ hx of ICU, malnutrition, exposure to high O₂ concentrations, inflammation, infection (sepsis, chorioamnionitis, funisitis, postnatal infections), & PPV → impaired alveolar/pulmonary vascular development

<table>
<thead>
<tr>
<th>Dz Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Severity of BPD</strong></td>
</tr>
<tr>
<td>Mild</td>
</tr>
<tr>
<td>Moderate</td>
</tr>
<tr>
<td>Severe</td>
</tr>
</tbody>
</table>
History
- Preterm birth, hx of ICU stay w/ mechanical ventilation, recent respiratory infection, poor feeding, increased O₂ requirement

Physical Exam
- Abnl VS, nasal flaring, retractions, grunting, wheezes, rales, decreased breath sounds

Evaluation
- CXR – hyperinflation, cystic areas, scarring; RSV testing will identify those who require hospitalization

Treatment
- Supportive; O₂, consider inhaled & systemic corticosteroids, abx (see Pediatric Pneumonia), bronchodilators (see Pediatric Asthma), furosemide (1 mg/kg q6–12h, titrate to effect)

Disposition
- Admission: If increased respiratory distress, hypoxia, hypercarbia, new pulmonary infiltrates, inability to maintain oral hydration, RSV infection

---

UPPER AIRWAY EMERGENCIES

Definition
- Actual or impending obstruction of the upper airway

Approach to the Patient

History
- Agitation or fidgeting, cyanosis, AMS, choking, SOB, increased work of breathing, panic, unconscious, unusual breathing noises
- ROS (fever, drooling), PMH/MEDS (see differential chart)

Diagnostics
- CXR or neck films, esp if abnl O₂ sat & temp

Treatment
- O₂, calm the child, head tilt, chin lift, “position of comfort” (upright while leaning forward)
Disposition
› Largely will depend on hemodynamic stability & airway issues

<table>
<thead>
<tr>
<th>UAE Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathophysiology</strong></td>
</tr>
<tr>
<td>Structural</td>
</tr>
<tr>
<td>Infectious</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

**FOREIGN BODY/UPPER AIRWAY OBSTRUCTION (SEE ADULT RESPIRATORY SECTION)**

**Croup (Laryngotracheobronchitis)**

**Definition**
› Viral infection primarily of the larynx & trachea (often parainfluenza), age 6 mo–6 yr

**History**
› Hoarseness, barking cough, & inspiratory stridor w/ variable degree of respiratory distress; preceded by nonsp respiratory sx (rhinorrhea, sore throat, cough); fever is usually low grade

**Physical Exam**
› Inspiratory stridor, retractions, decreased air entry

**Evaluation**
› Labs: None
› Imaging: not routinely indicated
› CXR: PA view may show steeple sign, (subglottic narrowing), lateral view may reveal a distended hypopharynx (ballooning) during inspiration

**Treatment**
› Supportive: Humidified air, O₂, keep child as comfortable as possible
› Steroids: Dexamethasone (0.6 mg/kg ×1, max of 10 mg)
› Racemic epinephrine: Below dosing mixed w/ 3 cc NS (may repeat
q20–30min), for children w/ stridor at rest, requires 2–3 h observation for “rebound stridor”
- <20 kg: 0.25 mL
- 20–40 kg: 0.5 mL
- >40 kg: 0.75 mL

Disposition
- Home: If maintaining O₂ saturation; advise symptomatic tx w/ Tylenol & humidified air
- Admit: If hypoxia, depressed sensorium, moderate to severe respiratory distress, stridor at rest, poor oral intake, dehydration

Epiglottitis
Definition
- Pharyngeal infection classically due to H. influenzae; incidence in children has declined since introduction of H. influenzae vaccine, most common organisms now include S. pyogenes, S. aureus, S. pneumoniae, Moraxella

History
- Fever is usually 1st sx w/ abrupt onset sore throat, stridor, labored breathing, drooling muffled/hoarse voice, age 2–7 yr, lack of cough

Physical Exam
- Toxic, irritable, anxious, sitting in tripod or sniffing position (chin hyperextended & leaning forward), drooling, retractions, adenopathy; may visualize edematous epiglottis on oral exam

Evaluation
- Labs: Postpone IV & labs until airway secured; CBC, blood cultures, Chem 7
- Imaging: Lateral neck x-ray: Swollen epiglottis (ie, thumbprint sign), thickened aryepiglottic folds, obliteration of the vallecula, & dilation of the hypopharynx

Treatment
- Supportive: O₂ therapy, keep child as comfortable as possible; place child & mom in a quiet & controlled for complete eval/tx
- Airway: Preferable secured in OR under controlled environments but if not available, consider partial sedation & fiberoptic intubation.
Cricothyrotomy kit at bedside for emergent surgical airway; tracheostomy.

- Abx: Ceftriaxone 100 mg/kg IV q12h (max 2 g/d) + Vancomycin OR clindamycin if concern for MRSA
- Consult: ENT or anesthesia for STAT OR airway

**Disposition**
- Admit: All to the ICU

**Pearls**
- Avoid procedures which may cause distress to the pt & further thereby compromise airway
- Give child or parent Yankauer suction to maintain secretions & alleviate associated anxiety

**Bacterial Tracheitis**

**Definition**
- Infection of subglottic region causing edema, pseudomembrane formation; polymicrobial (S. aureus, S. pneumoniae, H. influenzae, Pseudomonas, Moraxella), average age 3 yr

**History**
- Preceding URI infection w/ rapid deterioration, high fevers, age 3 mo–5 yr

**Physical Exam**
- Stridor, retractions, tachypnea, barking cough, wheezing, high fevers, toxic appearing

**Evaluation**
- Labs: None
- Imaging: X-ray shows subglottic & tracheal narrowing, irregular tracheal margins, PNA

**Treatment**
- Supportive: O₂, frequent suctioning, use one size smaller ETT
- Broad spectrum abx (3rd-generation cephalosporin, vancomycin)

**Disposition**
- ICU
DIABETIC KETOACIDOSIS

History
- Fatigue & malaise, N/V, abd pain, polydipsia, polyuria, polyphagia, weight loss, AMS/HA (may be signs of cerebral edema), fever/sxs of infection (cough, URI sxs, dysuria, rash); toddlers may not present w/ classic sxs
- RFs: Infection, poor compliance w/ insulin, puberty, inadequate caregiver

Physical Exam
- AMS, tachycardia, tachypnea, Kussmaul respirations, normo- or hypotensive, delayed capillary refill, mottled, lethargy/weakness, fever, N/V, acetone on breath (metabolic acidosis)

Evaluation
- Labs: FSG, Chem 10 (elevated anion gap acidosis, pseudohyponatremia, total body K generally depleted despite lab value, ↓ phosphorus, ↓ Mg), urine/serum ketones, β-hydroxybutyrate, UA, CBC, lactate, lipase, LFTs, urine hCG, VBG; ABG if HD unstable or comatose; blood & Ucxs if febrile
  - Corrected Na = measured Na + [1.6 × (measured glucose – 100)/100]
  - Definition: Glucose >200, venous pH <7.3 or bicarb <15, ketonemia & ketonuria
- ECG: T wave Δ (hyper/hypokalemia)
- Imaging: If concern for focal infection

Treatment
- Supportive: Continuous cardiac monitoring, O₂ sat monitoring, 2 large-bore IVs, intubate if necessary, evaluate & treat sources of infection
- Electrolyte monitoring: Glucose fingerstick q1h (goal = 150); Chem 7, Ca, Mg, phosphorus q2h

<table>
<thead>
<tr>
<th>Acute Tx</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Medication</td>
</tr>
<tr>
<td>----------------------------</td>
</tr>
<tr>
<td>IV hydration</td>
</tr>
<tr>
<td>Insulin</td>
</tr>
<tr>
<td>Electrolyte repletion</td>
</tr>
<tr>
<td>Mannitol or hypertonic saline (signs of cerebral edema)</td>
</tr>
</tbody>
</table>

**Disposition**
- Admit: All pts; HD unstable, pts w/ cerebral edema/AMS or newly diagnosed diabetes pts should go to the ICU

**Pearl**
- Children more likely than adults to develop cerebral edema; carry a 25% mortality rate; avoid insulin bolus & large-volume isotonic fluid boluses

### HYPOGLYCEMIA

**Definition**
- Glucose <50 in children; glucose <40 w/ age 3–24 h; glucose <45 in infants >24 h of age

<table>
<thead>
<tr>
<th>Hypoglycemia Differential</th>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Congenital</strong></td>
<td>Glycogen storage disorders, disorders of gluconeogenesis, disorders of fatty acid or amino acid metabolism</td>
</tr>
<tr>
<td></td>
<td><strong>Autoimmune/ endocrine/ neoplasm</strong></td>
<td>Hypothyroidism, insulinoma, hypopituitarism, adrenal insufficiency, glucagon deficiency, GH deficiency</td>
</tr>
</tbody>
</table>
**Approach to the Patient**

**History**
- Irritability, sweating, jitteriness, feeding problems, lethargy, cyanosis, tachypnea, &/or hypothermia. May be a/w sepsis, congenital heart dz, ventricular hemorrhage, tox, & respiratory distress syndrome, PMH/meds (see chart)

**Physical Exam**
- Hypotonia, lethargy, cyanotic, hypothermic, apneic, tachycardic, pallor, vomiting, tremulousness, ataxia, sz, diplopia, signs of CVA

**Evaluation**
- **Labs:** FSG, Chem 7, LFTs, serum insulin, UA (ketones), C-peptide (low in exogenous insulin, high in insulinoma or sulfonylureas); growth hormone, cortisol, glucagon levels; tox screen if indicated

**Treatment**
- Glucose replacement
  - PO: Glucose paste, fruit juice (preferred)
  - Infants: IV bolus: 10% dextrose: 2 mL/kg followed by infusion at 6–9 mg/kg/min
  - Children: IV bolus: 10% dextrose at 5 mL/kg followed by infusion at 6–9 mg/kg/min
  - IM: Glucagon 0.03–0.1 mg/kg/dose SC q20min prn; not to exceed 1 mg/dose

**Disposition**
- Home: Obvious cause treated, sx reversed, after high-carbohydrate meal
- Admit: No obvious cause, toxic ingestion w/ oral hypoglycemic, long acting insulin, persistent sxs

---

**GI**
- Liver pathology, Reye syndrome

**Other/meds**
- Oral hypoglycemics, pentamidine, alcohol ingestion, βB, salicylates, INH, sepsis, burns, cardiogenic shock

**FLUID AND ELECTROLYTE ABNORMALITIES**
**Definition**

- See *Adult Metabolic Abnormalities* for etiologies

**History**

- **Hyponatremia**: Fatigue, weakness, lethargy, agitation, szs; ask re: renal dz or GI distress
- **Hypernatremia**: Irritability, lethargy, szs, fever, over or lack of urination
- **Hypokalemia**: Weakness, smooth muscle dysfxn, lethargy, confusion, decreased GI motility, respiratory insufficiency, rhabdomyolysis, polyuria
- **Hyperkalemia**: Asymptomatic to generalized weakness, paralysis, paresthesias
- **Hypocalcemia**: Tetany, weakness, fatigue, paresthesias, laryngospasm, sz, irritability
- **Hypercalcemia**: Weakness, respiratory distress, apnea, HA, sz, abd pain, lethargy, anorexia, constipation, bone pain, signs of kidney stones, pancreatitis, N/V, psychosis
- **Hypomagnesemia**: Anorexia, nausea, weakness, nonsp psychiatric sxs
- **Hypermagnesemia**: Lethargy, confusion, respiratory distress

**Physical Exam**

- **Hyponatremia**: May appear euvolemic, dehydrated or hypervolemic; severe hyponatremia = lethargy, hyporeflexia, Cheyne–Stokes respiration
- **Hypernatremia**: Poor skin turgor, increased muscle tone, altered sensorium; severe hypernatremia = spasticity, lethargy, hyperreflexia, respiratory paralysis
- **Hypokalemia**: Skeletal muscle weakness, hyporeflexia, lethargy, confusion
- **Hyperkalemia**: Paralysis, hyporeflexia, confusion
- **Hypocalcemia**: Tetany, wheezing/inspiratory stridor, Chvostek/Trousseau
- **Hypercalcemia**: Respiratory distress, apnea, hyporeflexia, epigastric tenderness, ↑ BP
- **Hypomagnesemia**: Anorexia, nausea, weakness, clonus, tetany,
Chvostek/Trousseau
  ‣ Hypermagnesemia: Lethargy, hyporeflexia, hypotension, respiratory failure

**Evaluation**
  ‣ Labs: R/o spurious lab draws, hemolysis (hyperkalemia); CBC, Chem 7, Ca/Mg/phosphorus, urine electrolytes; ABG if acidotic & respiratory decline, UA, lipase
  ‣ ECG: U wave (hypokalemia), peaked T/widened QRS/ventricular tachycardia (hyperkalemia), prolonged QT (hypocalcemia), shortened QT (hypercalcemia), ventricular arrhythmia/torsades de pointe (hypomagnesemia)

**Treatment**
  ‣ Supportive: Continuous cardiac monitoring, O\textsubscript{2} sat monitoring, 2 large-bore IVs
  ‣ Electrolyte monitoring: Chem 7, Ca, Mg, phosphorus q4h
  ‣ Electrolyte correction:
    • Hyponatremia: See *Adult Metabolic section*; determine volume status; children should not be corrected >10 mEq/L/d in hypovolemia; acute onset <48 h hyponatremia can be corrected more quickly over 24 h; 3% NS 3–5 mL/kg for severe neuro sx (ie, szs); consider loop diuretics; tx underlying cause
    • Hypernatremia: See *Adult Metabolic section* for Na correction (goal Na reduction rate of 0.5–1 mEq/L/h); consider vasopressin/DDAVP for DI
    • Hypokalemia: Correct alkalosis, hypomagnesemia
      • IV: 0.5–1 mEq/kg/h IV (max 40 mEq/dose) over 1–2 h. Goal ↑ potassium by 0.3–0.5 mEq/L (require ECG monitoring)
      • PO: 1–4 mEq/kg/d PO in divided doses (max 20 mEq/dose)
    • Hyperkalemia:
      • Calcium gluconate: 50–100 mg/kg/dose IV, up to adult dose
      • Calcium chloride (code situation): 10–20 mg/kg/dose IV, up to adult dose over 2–5 min
      • Glucose + insulin: 1 g/kg IV of D\textsubscript{25}W + 0.25 U/kg IV insulin
      • Sodium bicarbonate: 1–2 mEq/kg/dose IV over 5–10 min
      • Albuterol: 2.5–5 mg nebulized
• Furosemide: 1–2 mg/kg IV/PO; hydrochlorothiazide 1 mg/kg PO up to 200 mg
• Kayexalate: 1 g/kg PO
• Dialysis
• Hypocalcemia: Send ionized calcium
  • Symptomatic:
    • Calcium gluconate 10%: 50–100 mg/kg IV slowly over 5–10 min to control szs; IV infusion at 50–75 mg/kg/d over 24 h; use calcium chloride (dose as in hyperkalemia) in code situation
  • Asymptomatic:
    • Calcium carbonate: Neonates: 30–150 mg/kg/d PO divided QID; children: 20–65 mg/kg/d PO divided BID/QID
• Hypercalcemia: Send ionized calcium
  • NS: (Weight-based bolus + 1.5 times maintenance); furosemide
  • Consider bisphosphonates, calcitonin
  • Dialysis: In extreme hypercalcemia & renal failure
• Hypomagnesemia:
  • PO: Magnesium gluconate 10–20 mg/kg TID/QID
  • IV: Magnesium sulfate 25–50 mg/kg IV over 2–4 h
• Hypermagnesemia:
  • NS infusion, furosemide 1 mg/kg/dose q6–12h; titrate to effect
  • Calcium gluconate/calcium chloride (same dose as hyperkalemia)
  • Dialysis: Severe renal failure, cardiac or neuromuscular Dysfxn

Disposition
• Home: Mild, asymptomatic electrolyte abnlty may be D/C home w/ PCP f/u in 1–2 d for repeat labs
• Admit: All pts w/ symptomatic electrolyte abnlty should be admitted & monitored; consider ICU level care for HD unstable or those w/ severe cardiac or neurologic disturbances

PEDiATRIC ExANTHEMS

Erysipelas
**Definition**
- Infection caused most commonly by group A *Strep*

**History**
- Any age but > in children <3 yr

**Physical Findings**
- Red/hot tender area of skin, purulent d/c at entry site, ±fevers

**Treatment**
- Penicillin G, dicloxacillin

**Disposition**
- Home

---

**Viral Exanthem**

**Definition**
- Diffuse rash caused by nonpolio enteroviruses (coxsackievirus, echovirus, enterovirus) & respiratory viruses (adenovirus, parainfluenza virus, influenza, RSV)

**History**
- Any age, recent viral illness

**Physical Findings**
- Diffuse blanchable erythematous macules on trunk & extremities

**Treatment**
- Supportive

**Disposition**
- Home

---

**Hand-Foot-and-Mouth Disease**

**Definition**
- Caused by coxsackievirus B
**History**
- Summer/fall, 1–4 y/o

**Physical Findings**
- Ulcerative oral lesions on soft palate, macular → pustular → crusted lesions on palms/soles, resolves in 5–6 d

**Treatment**
- Supportive

**Disposition**
- Home

---

**Impetigo**

**Definition**
- Secondary infection in pts w/ underlying dermatoses caused by *S. aureus* & group A *Strep*

**History**
- Warm humid summer months, any age

**Physical Findings**
- Papule/vesicle → golden crusted lesions commonly around mouth & on cheeks

**Treatment**
- Topical abx (2% mupirocin, dicloxacillin, 1st-generation cephalosporins)

**Disposition**
- Home

---

**Kawasaki Disease**

**Definition**
- Systemic vasculitis of microvessels of unknown etiology, often self-limited
**History**
- Febrile illness, peak onset 18–24 mo, usually in children <5 yr of age

**Physical Findings**
- To make the Dx, requires unexplained fever × 5 d + 4 of the following:
  - Edema/desquamation of extremities
  - Bulbar conjunctivitis
  - Polymorphous rash
  - Cervical LAD
  - Mucous membrane Δ (ie, strawberry tongue)

**Evaluation**
- CBC (↑ WBC, ↑ PLT), ↑ LFTs, ↑ ESR, ↑ CRP, sterile pyuria, ECG, echocardiography, RUQ U/S

**Treatment**
- High-dose ASA 100 mg/kg/d divided QID
- IVIG 2 g/kg infused over 8–12 h single dose (reduces risk of coronary artery aneurysms)

**Disposition**
- Admit

**Complications**
- #1 cause of acquired heart dz in children
- Cx: coronary artery aneurysm, CHF, MI, dysrhythmias, valvular insufficiency, gallbladder hydrops, uveitis

---

**SERUM SICKNESS**

**Definition**
- Immune-complex–mediated type III hypersensitivity rxn

**History**
- Any age but > in children <3 yr, fever, arthralgias, rash, possible etiologies include blood products, antitoxins (ie, spider or snake envenomations), clostridial infections, meds
Physical Findings
- Fever, rash (urticarial, serpiginous)

Treatment
- Supportive as dz is self-limited, resolves in 2–3 wk, discontinue offending agent
- Short course of corticosteroids can be used for severe arthralgias

Disposition
- Home

HENOCH–SCHÖNLEIN PURPURA

Definition
- Small-vessel vasculitis

History
- Age 2–11 yr; preceding respiratory infection (Group A β-hemolytic Strep); fever, arthralgia, abd pain, bloody stools, hematuria

Physical Findings
- Palpable purpura in dependent regions, fever, joint swelling, guaiac positive, scrotal edema

Diagnosis
- Clinical; CBC (↑ WBC, ↑ PLT, anemia), ↑ ESR, antistreptolysin antibodies (+ in 50%), UA (hematuria, proteinuria, pyuria), abd U/S (intussusception), scrotal U/S

Treatment
- Majority is self-limiting w/ resolution in a few weeks; supportive, NSAIDs, treat underlying infection
- Corticosteroids does not prevent recurrences, which occur in 50%; but can be used for severe arthritis, renal involvement, GI, scrotal or CNS cx

Disposition
- Home unless cx: HTN, oliguria, obstruction, intussusception, GIB
Complications
- Bowel obstruction, perforation, intussusception, renal failure, hypertensive encephalopathy, acute scrotum (mimics torsion), pancreatitis, CNS cx (sz, coma, neuro deficits)

**URINARY TRACT INFECTION**

*(Pediatrics 2011;128;595)*

**History**
- Adolescents: Dysuria, urgency, frequency, hematuria; fever; flank pain, abd pain
- Younger children: Enuresis, foul-smelling urine, abd pain, N/V
- Infants: Fever, irritability, poor feeding, vomiting, jaundice, FTT

**Physical Exam**
- Fever, suprapubic tenderness, bladder fullness; CVA tenderness; GU exam to assess for vaginitis

**Evaluation**
- **Labs:** UA/Ucx (may require straight cath for clean specimen); Chem 7 (dehydration), CBC/blood cultures (if considering sepsis)
- Renal U/S in febrile infant or young child b/w 2 mo & 2 yr w/ 1st UTI
- VCUG for recurrent infections, poor urinary stream, palpable kidneys, unusual organism, HTN, bacteremia or sepsis that fails to respond to abx, unusual presentation, or hydronephrosis/scarring seen on renal U/S

**Treatment**
- Supportive: Oral rehydration if child able to tolerate o/w establish IV for hydration
- Abx (usually *E. coli*):
  - IV: Cefotaxime, ceftriaxone, gentamicin
  - PO: Augmentin, Bactrim, cefixime, cefpodoxime

**Disposition**
- Home: Stable, tolerating POs, nontoxic appearing; PCP f/u in 2–3 d
Admit: <2 mo old, toxic appearing, unable to tolerate POs, signs of urinary obstruction, suspected sepsis, underlying comorbidities, ↑ Cr
**PSYCHIATRIC PATIENT**

**Approach**
- Always consider medical disorders → esp if no previous psych hx
- Anticipate need for psychiatry consult & restraints (meds, physical) early to assure safety

**Definition**
- Medical clearance: An ambiguous term suggesting no “organic” cause for pt’s psych complaint; however, pts can have medical condition that exacerbates their psychiatric presentation (ie, drug abuse, infection)
- Focused medical assessment: The process of excluding medical illnesses that require acute care to determine who is medically stable *(Ann Emerg Med 2006;47:79)*

<table>
<thead>
<tr>
<th>“Organic” Disorders That Mimic Psychiatric Dz</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathophysiology</td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>Neurologic</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Infections</td>
</tr>
<tr>
<td>Medications</td>
</tr>
<tr>
<td>Toxicologic</td>
</tr>
<tr>
<td>Metabolic/endocrine</td>
</tr>
</tbody>
</table>

**Depression/Suicidality** *(Emerg Med Clin North Am 2015;33:765)*

**History**
- Ask open-ended questions about thoughts, feelings, personal
relationships; drug use; prior hospitalizations/psych hx; psych medications; physical/sexual abuse

- Sxs (SIG E CAPS): Sleep, Interest, Guilt, Energy level decreased, Concentration, Appetite, Psychomotor activity, Suicidal ideation
- SI/HI: Access to weapons, plan, prior SI/HI or attempt; command hallucinations
- Risk of suicide (SAD PERSONS): Sex (male), Age (<19, >45), Depression, Previous attempt, EtOH abuse, Rational thinking loss, Social support lacking, Organized plan, No spouse, Sickness

**Findings**

- Abnl VS; appearance, mental status exam
- Head-to-toe exam: E/O trauma, pupils, nystagmus, thyroid, pulm/cardiac/abdomen, skin
- Neuro: CNs, DTRs, motor, sensory, cerebellar, asterixis, gait, catatonia

**Evaluation**

- There is no data to support routine use of lab testing in psych pts whose H&P exclude significant medical illness
- βhCG (all women reproductive age), consider ECG & psych med levels (ie, Li)
- Tox: If concern for unreported drug abuse or ingestion (ie, APAP)
- Psychiatry consult: If needed for hospitalization, suicide/homicide attempt, uncertain at risk of danger to self/others
- Other labs: If concern for “organic” d/o or required for psych hospital: CBC, Chem 7, LFTs, UA, TSH, ammonia, CXR
- More thorough w/u is necessary for new onset psych Dx: Consider RPR, CT head, LP, EEG

**Treatment**

- Treat any underlying medical illness
- Typically antidepressants are not initiated by the ED physician

**Anxiety/Panic Disorder**

**History**

- Associated physical sxs (CP, SOB), substance use, prior similar episodes, current life stressors
SI/HI (see above)

Findings
- Look for clues for underlying medical conditions: abnl VS (tachycardia, hypoxia), trauma, thyroid, nystagmus, cardiopulmonary exam

Evaluation
- Consider EKG, CXR or other cardiopulmonary testing

Treatment
- Treat any underlying medical illness
- BZD may help in acute setting but are a/w possible abuse & rebound

Psychosis
(Emerg Med Clin North Am 2015;33:739.)

History
- Often challenging if pt is unable to interact appropriately
- Hallucinations? Delusions? Disorganized thoughts or speech?

Findings
- Look for clues for underlying medical conditions: abnl VS, trauma, nystagmus, thyroid, asterixis, focal neurologic deficits, fluctuating sxes, nonauditory hallucinations

Evaluation
- There is no data to support routine use of lab testing in psych pts whose H&P exclude significant medical illness
- βhCG (all women reproductive age), consider ECG & psych med levels (ie, Li)
- Tox: If concern for unreported drug abuse or ingestion (ie, APAP)
- Psychiatry consult: If needed for hospitalization, suicide/homicide attempt, uncertain at risk of danger to self/others
- Other labs: If concern for “organic” d/o or required for psych hospital: CBC, Chem 7, LFTs, UA, TSH, ammonia, CXR
- More thorough w/u is necessary for new onset psych Dx: Consider RPR, CT head, LP, EEG

Treatment
- Nonpharmacologic strategies: creating a safe environment,
seclusion, verbal de-escalation

- **Medications:**
  - Haldol (IM/IV), ziprasidone (IM), olanzapine (PO/SL/IM); side effects ↑QT, akathisia, dystonia
  - Lorazepam/diazepam (PO/IV/IM): preferred for drug-related agitation; avoid in the elderly

- **Physical restraints:** Soft/leather (1–4 point), posy, mitts. Use as temporizing measure in conjunction w/ pharmacologic tx & sitter.
- Should attempt to use least restrictive strategies for the shortest time possible

**Pearls**

- Signs suggestive of “organic disorder”: Age >40 w/ no prior psychiatric hx, abnl VS, recent memory loss, clouded consciousness
- Engage family members/friends/partners for collateral whenever possible
GENERAL APPROACH TO THE INTOXICATED PATIENT

Approach

- (1) ABCs, resuscitate/stabilize → (2) decontaminate (GI tract, skin, eyes)/enhance elimination (charcoal, dialysis) → (3) treat w/ antidote, if available & indicated
- Consider empiric naloxone, dextrose, thiamine in pts w/ depressed MS. Use flumazenil w/ caution as it may precipitate sz
- Call Poison Control Center: 1 (800) 222-1222

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Toxidrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticholinergics</td>
<td>↑ Temp, ↑ HR, dry skin, mydriasis, dry MM, AMS, urinary retention, sz, coma</td>
</tr>
<tr>
<td>Sympathomimetics</td>
<td>↑ Temp, ↑ HR, diaphoresis, mydriasis, agitation, dysrhythmia, sz, coma</td>
</tr>
<tr>
<td>Sympatholytic</td>
<td>↓ HR, ↓ BP, miosis, ↓ peristalsis</td>
</tr>
<tr>
<td>Opioids</td>
<td>AMS, ↓ RR, miosis</td>
</tr>
<tr>
<td>Anticholinesterases</td>
<td>DUMBELS* + muscle weakness, AMS, sz, coma</td>
</tr>
<tr>
<td>Sedative-hypnotics</td>
<td>↓ BP, ↓ RR, AMS, ↓ temp, slurred speech, ataxia</td>
</tr>
<tr>
<td>Alpha-adrenergic</td>
<td>↑ BP, ↓ RR, mydriasis, moist skin</td>
</tr>
</tbody>
</table>

*Defecation, urination, miosis, bronchorrhea, bronchospasm, bradycardia, emesis, lacrimation, salivation

History

- Always consider Drug, Dose, & Pt: timing, quantity of
ingestion/exposure, access to household chemicals/other meds, coingestions, enteric-coated/extended-release substances

**Physical Exam**
- VS, pupils, skin, neuro findings (AMS, nystagmus, myoclonus, tremor), peristalsis, smell

**Evaluation**
- ECG, FSG, CBC, BMP, LFTs, UA, ABG, hCG, osmolar/anion gap
- Drug levels
  - Exposures for which drug level is useful: APAP, salicylates, theophylline, lithium, Dig, EtOH, carboxyhemoglobin, methemoglobin, iron, methanol, ethylene glycol, lead, mercury, arsenic, organophosphate, anticonvulsants

**Treatment**

<table>
<thead>
<tr>
<th>GI Decontamination</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tx</strong></td>
</tr>
<tr>
<td>Activated charcoal</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Whole bowel</td>
</tr>
<tr>
<td>irrigation</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Dermal Decontamination**
- Irrigation w/ copious volumes of H₂O (unless metallic Na, K, or phosphorus)

**Ocular Decontamination**
- Irrigation w/ copious volumes of H₂O, check pH after irrigation

**Enhanced Elimination**
- Urinary alkalinization w/ NaHCO₃ (eg, salicylates, phenobarbital, formic acid)
- HD (eg, ethylene glycol, methanol, lithium, salicylates, severe acidosis)

<table>
<thead>
<tr>
<th>Tx</th>
<th>Toxicologic Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antivenom</td>
<td>Snake, black widow spider, brown recluse spider, scorpion envenomation</td>
</tr>
<tr>
<td>Botulinum antitoxin</td>
<td>Clostridium botulinum</td>
</tr>
<tr>
<td>Calcium</td>
<td>CCB, ↑ K, ↑ Mg, ↓ Ca, hydrofluoric acid</td>
</tr>
<tr>
<td>Edetate calcium disodium</td>
<td>Lead</td>
</tr>
<tr>
<td>Cyanide kit (amyl nitrite,</td>
<td>Cyanide, smoke inhalation</td>
</tr>
<tr>
<td>sodium nitrite,</td>
<td></td>
</tr>
<tr>
<td>thiosulfate);</td>
<td></td>
</tr>
<tr>
<td>Cyanocobalamin</td>
<td></td>
</tr>
<tr>
<td>Deferoxamine</td>
<td>Iron</td>
</tr>
<tr>
<td>Dig antibody fragments</td>
<td>Dig</td>
</tr>
<tr>
<td>Dimercaprol</td>
<td>Arsenic, lead, mercury</td>
</tr>
<tr>
<td>ETOH</td>
<td>Ethylene glycol, methanol</td>
</tr>
<tr>
<td>Flumazenil</td>
<td>Benzos</td>
</tr>
<tr>
<td>Fomepizole</td>
<td>Ethylene glycol, methanol</td>
</tr>
<tr>
<td>Glucagon</td>
<td>βB, CCB</td>
</tr>
<tr>
<td>Hyperinsulinemia–</td>
<td>βB, CCB</td>
</tr>
<tr>
<td>euglycemia therapy</td>
<td></td>
</tr>
<tr>
<td>N-acetylcysteine</td>
<td>APAP</td>
</tr>
<tr>
<td>Naloxone</td>
<td>Opioids</td>
</tr>
<tr>
<td>Octreotide</td>
<td>Sulfonylureas</td>
</tr>
<tr>
<td>Physostigmine</td>
<td>Anticholinergics</td>
</tr>
<tr>
<td>Pralidoxime</td>
<td>Organophosphates</td>
</tr>
<tr>
<td>Protamine</td>
<td>Heparin</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
<td>TCAs</td>
</tr>
<tr>
<td>Succimer</td>
<td>Arsenic, lead, mercury</td>
</tr>
<tr>
<td>Vitamin K</td>
<td>Coumadin</td>
</tr>
</tbody>
</table>
Disposition
- Admit for any significant ingestion/exposure; consider transfer for complex presentations & inadequate hospital resources

Pearl
- Hospital tox screens vary → know your hospital’s screen to guide your practice

ANTICHOLINERGIC INGESTION

Definition
- Antagonists @ *muscarinic* cholinergic receptor → inhibit parasymp system

<table>
<thead>
<tr>
<th>Class</th>
<th>Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belladonna alkaloids</td>
<td>Atropine, scopolamine, ipratropium</td>
</tr>
<tr>
<td>Antiparkinsonian agents</td>
<td>Benztropine</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>Diphenhydramine (Benadryl), meclizine (Antivert), promethazine (Phenergan), hydroxyzine (Atarax), dimenhydrinate (Dramamine)</td>
</tr>
<tr>
<td>Cyclops</td>
<td>Cyclobenzaprine (Flexeril)</td>
</tr>
<tr>
<td>Psychopharmacologics</td>
<td>TCA, phenothiazines</td>
</tr>
</tbody>
</table>

History
- AMS w/ medication exposure, ingestion hx, teas, supplements, or polypharmacy

Differential
- Sympathomimetic OD, EtOH/benzo withdrawal, thyroid storm, sepsis, meningitis, hypoglycemia

Findings
- ↑ HR, ↑ temp, dilated pupils, dry MM/skin, ↓ bowel sounds, urinary retention, myotonic activity, choreoathetosis, confusion/delirium, sz;
“blind as a bat, dry as a bone, hot as a hare, mad as a hatter, red as a beet, bloated as a toad”

**Evaluation**
- ECG (↑ QRS, QT\(_c\) → TCAs, neuroleptics); electrolytes; total CK (rhabdomyolysis); tox screen → r/o other ingestions; pulse ox; tele

**Treatment**
- **Supportive**: IV hydration, external cooling
- **Decontamination/elimination**: Activated charcoal (1 dose, w/i 1 h), HD
- **BZD (IV)**: For agitation, szs
- **Physostigmine (IV)**: Reverses anticholinergic effects via acetylcholinesterase inhibition
  - NOT for routine use due to risk of intractable szs, AV block, asystole
  - Half-life of physostigmine often shorter than toxidrome!

**Disposition**
- Admit; ICU for pts w/ cardiac instability or szs

**Pearl**
- Rarely fatal unless significant hyperthermia is present

---

**PSYCHOPHARMACOLOGIC INGESTION**

**Selective Serotonin Reuptake Inhibitors and Serotonin Syndrome**

**Approach**
- Spectrum for serotonin intoxication ranges from mild lethargy to serotonin syndrome
- Consider serotonin syndrome for anyone on meds w/ serotonin activity, esp ≥2 agents
- Greatest risk w/i minutes to hours after starting new med or increasing dose of old med

**Definition**
- SSRI: Selective serotonin reuptake inhibitors; SRIs: Serotonin
reuptake inhibitors (also exhibit activity on epinephrine, norepinephrine, dopamine)

### Common Drugs That Inhibit Serotonin Reuptake

<table>
<thead>
<tr>
<th>SSRIs</th>
<th>SRIs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluoxetine, paroxetine, sertraline, citalopram</td>
<td>Venlafaxine, duloxetine, mirtazapine, bupropion</td>
</tr>
</tbody>
</table>

### Drugs w/ Serotonin Activity

<table>
<thead>
<tr>
<th>Antidepressants</th>
<th>Illicit Drugs</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSRIs, SRIs, MAOIs, lithium</td>
<td>Amphetamines, cocaine, LSD, MDMA</td>
<td>Buspirone, levodopa, carbidopa, triptans, tramadol, dextromethorphan, trazodone, mirtazapine</td>
</tr>
</tbody>
</table>

### Differential for Serotonin Intoxication

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxic ingestion</td>
<td>Sympathomimetics (16f), MAOIs, lithium, salicylates (16g), anticholinergics (16b), NMS</td>
</tr>
<tr>
<td>Chemical withdrawal</td>
<td>EtOH (16e), sedative-hypnotics (16d)</td>
</tr>
<tr>
<td>Infection</td>
<td>CNS (4c), SIRS (1f)</td>
</tr>
<tr>
<td>Other</td>
<td>Thyrotoxicosis (9d), tetanus (4i), malignant hyperthermia (10k)</td>
</tr>
</tbody>
</table>

### History
- Akathisia, AMS, szs

### Findings
- ↑ HR, ↑ temp, ↑ reflexes, diaphoresis, mydriasis, ↑ ↓ BP, tremor, clonus, neuromuscular rigidity, ataxia

### Evaluation
- VS, CBC, BMP, CK (rhabdo), ECG (↑ QRS, ↑ QT_c, torsades), pulse ox, Tele

### Treatment
**Acute Overdose**
- Activated charcoal, admit for monitoring
Serotonin Syndrome

- Supportive: IV fluids, electrolyte correction, external cooling (may require sedation/paralysis for severe hyperthermia)
- Benzos (IV): For agitation, rigidity, szs
- (Controversial) Consider cyproheptadine (12 mg initially, 4 mg PO q1h), chlorpromazine 25–50 mg IV for severe sx$s$

Pearls

<table>
<thead>
<tr>
<th>Signs &amp; Sxs</th>
<th>Serotonin Syndrome</th>
<th>NMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset</td>
<td>Sudden</td>
<td>Often over days to weeks</td>
</tr>
<tr>
<td>Resolution</td>
<td>w/i 24 h</td>
<td>Over ~1 wk</td>
</tr>
<tr>
<td>Hyperthermia</td>
<td>Common</td>
<td>VERY common</td>
</tr>
<tr>
<td>AMS</td>
<td>Common</td>
<td>VERY common</td>
</tr>
<tr>
<td>Autonomic dysfxn</td>
<td>Common</td>
<td>VERY common</td>
</tr>
<tr>
<td>Muscle rigidity</td>
<td>Common</td>
<td>VERY common</td>
</tr>
<tr>
<td>↑ Total CK</td>
<td>Uncommon</td>
<td>VERY common</td>
</tr>
<tr>
<td>Metabolic acidosis</td>
<td>Uncommon</td>
<td>VERY common</td>
</tr>
<tr>
<td>↑ Reflexes</td>
<td>VERY common</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Myoclonus</td>
<td>VERY common</td>
<td>Uncommon</td>
</tr>
</tbody>
</table>

**NEUROLEPTICS, NEUROLEPTIC MALIGNANT SYNDROME**

**Definition**

- Characterized by $D_2$ antagonism ± serotonin receptor antagonism

<table>
<thead>
<tr>
<th>Common Neuroleptics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Typical Neuroleptics</td>
</tr>
<tr>
<td>Chlorpromazine, haloperidol</td>
</tr>
</tbody>
</table>

**History**
- Slurred speech, sedation, anticholinergic toxidrome, extrapyramidal sx (dystonia, akathisia, parkinsonism, tardive dyskinesia)
- **NMS:** ↑ HR, rigidity, AMS, szs, autonomic instability, metabolic acidosis, rhabdomyolysis

**Evaluation**
- CBC, BMP, CK (rhabdo), ECG (↑QTc, torsades, dysrhythmia), UA (myoglobin)

**Treatment**
- Dystonia/akathisia: Diphenhydramine, benztropine, BZD
- **NMS:** External/Internal cooling, IV fluids, benzos, nondepolarizing neuromuscular blockade, dantrolene, bromocriptine, amantadine

---

**Lithium**

<table>
<thead>
<tr>
<th>Clinical Effects</th>
<th>System</th>
<th>Side Effects</th>
<th>Acute Overdose</th>
<th>Chronic Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>System</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GI</td>
<td></td>
<td>N/V, diarrhea, abd pain</td>
<td>N/V, diarrhea</td>
<td>N/V</td>
</tr>
<tr>
<td>Neurologic</td>
<td></td>
<td>Tremor, weakness</td>
<td>Tremor, rigidity, clonus, ↑ reflexes, lethargy, sz, coma</td>
<td>Tremor, rigidity, pseudotumor cerebri, tinnitus, ataxia, blurred vision, sz, coma</td>
</tr>
<tr>
<td>CV</td>
<td></td>
<td>Sinus node dysfxn</td>
<td>↓ BP</td>
<td>↓ BP, ↓ T-wave, ↓ ST seg, sinus node dysfxn, ↑ QTc</td>
</tr>
<tr>
<td>Renal</td>
<td></td>
<td>Polyuria</td>
<td>—</td>
<td>Nephrogenic DI (↑Na), interstitial nephritis, renal acidosis</td>
</tr>
<tr>
<td>Endocrine</td>
<td></td>
<td>Goiter, ↓ thyroid</td>
<td>—</td>
<td>Goiter, ↑ or ↓ thyroid, ↑ Ca</td>
</tr>
</tbody>
</table>

**History**
- Acute tox: GI sx initially; neurologic findings may develop later
- Chronic tox: Neurologic sx
### Severity of Lithium Toxicity

<table>
<thead>
<tr>
<th>Grading of Toxicity</th>
<th>Tx</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>N/V, tremor, ataxia, muscle weakness, ataxia</td>
</tr>
<tr>
<td>2</td>
<td>Rigidity, hypertonia, ↓ BP, stupor</td>
</tr>
<tr>
<td>3</td>
<td>Coma, sz → D</td>
</tr>
</tbody>
</table>

### Evaluation
- VS, ECG, CBC, BMP, Ca, Mg, PO4, TSH, free T4, UA
- Lithium level: Not useful in acute ingestion (development of neurologic sx is better reflection of tox); in chronic tox, level >1.5 mEq is significant
- Assess for causes of decreased lithium clearance (eg, dehydration, renal failure)

### Treatment
- IV fluids: Decreases tox & promotes Li excretion, NS bolus then ½ NS
- GI decontamination: Activated charcoal ineffective, whole bowel irrigation may be useful
- Sodium polystyrene sulfonate (Kayexalate), consider thiazides, indomethacin, or amiloride for nephrogenic DI
- BZD for szs (avoid phenytoin, which ↓ Li renal excretion)
- HD: For pts w/ severe neurologic sx &/or clinical deterioration, Li level >3.5

### Disposition
- Admit all pts w/ sustained release ingestions, Li level >1.5 mEq, or new neurologic signs; lesser ingestions can be treated & observed 4–6 h → re× level ± psychiatry eval

### Pearl
- Li has very narrow therapeutic window; consider Li tox in pts w/ ARF/↓ UOP
TRICYCLIC ANTIDEPRESSANTS

Approach

- Sxs of overdose almost always occur w/i 6 h of ingestion

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Clinical Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histamine antagonist</td>
<td>Sedation, coma</td>
</tr>
<tr>
<td>ACh (muscarinic) antagonist</td>
<td>↑ HR, ↑ BP, mydriasis, dry skin, ileus, urinary retention</td>
</tr>
<tr>
<td>α1-adrenergic antagonist</td>
<td>Sedation, orthostatic ↓ BP, miosis (can counteract muscarinic mydriasis)</td>
</tr>
<tr>
<td>Amine reuptake inhibition</td>
<td>↑ HR, myoclonus, ↑ reflexes</td>
</tr>
<tr>
<td>Na channel inhibition</td>
<td>↑ PR/QRS intervals, RAD, ↓ cardiac contractility, heart block</td>
</tr>
<tr>
<td>K channel antagonist</td>
<td>↑ QT interval → torsades de pointes</td>
</tr>
<tr>
<td>GABA-A antagonist</td>
<td>Szs</td>
</tr>
</tbody>
</table>

Severity of TCA Toxicity

<table>
<thead>
<tr>
<th>Degree of Toxicity</th>
<th>Clinical Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild to mod</td>
<td>Drowsiness, confusion, slurred speech, ataxia, dry MM, ST, urinary retention, myoclonus, ↑ reflexes</td>
</tr>
<tr>
<td>Severe</td>
<td>SVT, ↑ QRS, ↑ PR, ↑ QT, VT, ↓ BP, sz, coma</td>
</tr>
</tbody>
</table>

Evaluation

- ECG, CBC, BMP, Ca/Mg/PO4, CK, UA tox screen, pulse ox, Tele

Treatment

- Supportive: IV fluids
- GI decontamination/elimination: Activated charcoal ± gastric lavage, intralipid for clomipramine
- Sodium bicarbonate: 1–2 mEq/kg boluses titrated to pH 7.45–7.55
- Indications: QRS >100, new RAD, ↓ BP, &/or ventricular dysrhythmia
- BZD: For szs
Lidocaine: For ventricular dysrhythmias refractory to NaHCO₃, avoid procainamide or other type Ia or Ic antiarrhythmics
Lipid emulsion: Case reports only, 1.5 mg/kg bolus followed by 400 mL infusion over 30 min

Disposition
- Admit all pts w/ e/o cardiotoxicity or sz; d/c pts w/o sxs at 6 h after ingestion

Pearl
- Antimuscarinic effects are absent in many cases of TCA overdose

### ALCOHOLS

**Definition**
- Ingestions of toxic alcohols

**Approach**
- Hx
- Type of alcohol ingested, time of ingestion, coingestants
- PE: Monitor for airway protection, occult trauma (head injury)
- Labs: FSG (may be all that’s needed), consider BAL (declines ∼20 mg/dL/h), anion gap, serum/urine tox (if coingestants suspected), osmolar gap for alcohols other than EtOH
- Osmol calc = 2 × Na + BUN/2.8 + glucose/18 + EtOH/4.6
- Osmol gap = Osmol measured − osmol calc
- Tx: Charcoal doesn’t bind alcohol, ±thiamine/folate

<table>
<thead>
<tr>
<th>Alcohol</th>
<th>Toxic Metabolites</th>
<th>Anion Gap Acidosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>EtOH</td>
<td>Acetaldehyde</td>
<td>No (unless alcoholic ketoacidosis)</td>
</tr>
<tr>
<td>Methanol</td>
<td>Formic acid</td>
<td>Yes</td>
</tr>
<tr>
<td>Ethylene glycol</td>
<td>Oxalic acid</td>
<td>Yes</td>
</tr>
<tr>
<td>Isopropyl alcohol</td>
<td>Acetone</td>
<td>No</td>
</tr>
</tbody>
</table>
**ETHANOL**

**History**
- EtOH ingestion, found down, lethargy, N/V, ± associated trauma, ± aspiration, gastritis

**Physical Findings**
- CNS, respiratory depression, slurred speech, ataxia, nystagmus

**Evaluation**
- FSG (hypoglycemia common in alcoholics), ± BAL (if ingestion uncertain), ± CBC/BMP/LFTs/lipase, ± ECG (if pulse if irregular), ± magnesium level

**Treatment**
- Maintain airway, serial exams, ± IVF/thiamine/folate (given but may not be necessary)

**Disposition**
- Ambulating w/o ataxia + speaking clearly → d/c

**Pearls**
- R/o head trauma, CNS infection, Wernicke encephalopathy, alcoholic ketoacidosis, hypoglycemia, alcohol withdrawal/DT, coingestions, SI/HI
- Known EtOH ingestion/intoxication in pt w/ hx of same does not require lab & can be observed until clinically sober

---

**METHANOL**

**Definition**
- Ingestion of methanol (peak levels 30–60 min, 24–30 h ½ life, hepatic metabolism)

**History**
- Drinking: Paint solvents/antifreeze/windshield-washing fluid/canned fuels/gasoline additives, shellac/copy machine fluid/home heating fuels
Physical Findings

- CNS depression, vomiting, papilledema/hyperemia, visual Δ/loss, gastritis

Evaluation

- ↑ Methanol level, ↑ Osmol gap, ↑ anion gap (profound), BMP, ABG

Treatment

- Based presumptive Dx if levels delayed, maintain airway
- Fomepizole: Loading dose (15 mg/kg in 100 mL D5W over 30 min)
  → maintenance (10 mg/kg q12h × 4 doses → 15 mg/kg q12 to methanol concentration <20/dL)
- Folate 50 mg IV q4h until resolution of acidemia (cofactor to convert formic acid → CO2 + H2O)
- Dialysis: Absolute indications → visual impairment + detectible methanol level or >50 mL/dL, osmol gap >10, ingestion >1 mg/kg, severe acidosis, renal failure

Disposition

- Admit

---

**ETHYLENE GLYCOL**

Definition

- Ingestion of ethylene glycol (peak levels 30–180 min, 3–7 h ½ life, 70% hepatic metabolism)

History

- Drinking: Antifreeze, coolants, paint, polishes, detergents, fire extinguishers

Physical Findings

- 3 phases: <12 h → ↓ CNS (like EtOH), gastritis; 12–24 h → ↑ HR/RR/BP/SOB; >12 h → ATN (oxalate crystal deposition)

Evaluation

- Ethylene glycol level, ↑ osmol gap, ↑ AG, calcium oxalate crystals in urine, beta-hydroxybutyrate (used to distinguish from alcoholic
ketoacidosis)

**Treatment**

- Based presumptive Dx if levels delayed, maintain airway
- Fomepizole: Loading dose (15 mg/kg in 100 mL D₅W over 30 min) → maintenance (10 mg/kg q12h × 4 doses → 15 mg/kg q12h to ethylene glycol concentration <20/dL)
- Folate/thiamine 100 mg IV q6h/pyridoxine 50 mg IV q6h until resolution of acidemia (cofactors in oxalic acid metabolism)
- HD: Severe acidosis (pH <7.25) + osmol gap >10, renal failure (Cr >1.2 mg/dL), ethylene glycol level >50 mg/dL, deterioration despite supportive care

**Disposition**

- Admit

**Clinical Pearl**

- Urine/gastric contents fluoresce w/ Wood lamp due to antifreeze additives (early)

---

**ISOPROPYL ALCOHOL**

**Definition**

- Ingestion of isopropyl alcohol (peak levels 30–180 min, 3–7 h ½ life, 80% hepatic metabolism, lethal dose 2–4 mL/kg)

**History**

- Drinking: Rubbing alcohol, paint thinner, solvents, skin/hair products, nail polish remover

**Physical Findings**

- Profound ↓ CNS (2–4 × EtOH), fruity odor on breath, respiratory depression, ↓ BP, gastritis

**Evaluation**

- BMP, UA, FSG, isopropyl level, nl AG, ↑ osmol gap, falsely ↑ Cr (from acetone)

**Treatment**
Based presumptive Dx if levels delayed
- Supportive (rarely lethal)
- Dialysis: Refractory hypotension, levels >500 mg/dL

**Disposition**
- Admit if severe toxicity, may D/C 2 h after resolution of sx if no coingestions or SI

---

**Alcohol Withdrawal**

**Definition**
- Abrupt cessation or significant reduction in alcohol intake (begins 6–24 h/peaks 48–72 h after last drink)

**History**
- Heavy alcohol use w/ cessation, insomnia, anorexia, N/V, restlessness, diaphoresis, sz

**Physical Findings**
- Tremulousness, szs (25% of pts at 6–48 h), delirium, hallucinations (visual > auditory), autonomic hyperactivity (tachycardia, HTN, irritability, hyperreflexia), delirium tremens (rare/serious, 24 h–5 d after last drink): Tremor/autonomic hyperactivity/confusion/hallucinations/low-grade fever

**Evaluation**
- FSG, CBC, BMP, LFTs/coags (if liver dysfxn suspected), BAL

**Treatment**
- Glucose (if hypoglycemic), thiamine, lorazepam 2 mg IV for sz, IV/IM/PO long-acting BZD (ie, lorazepam 1–4 mg IV q10–30min to sedation, diazepam 5–10 mg IV q5–10min to sedation, chlordiazepoxide 25–100 mg PO q1h), phenobarbital as 2nd-line

**Disposition**
- Admit if requiring IV medication/DTs ± ICU

**Clinical Pearls**
- Rarely fatal (increased w/ aspiration due to sz) when treated
appropriately
- May require very large doses of IV BZD to control/treat

## DRUGS OF ABUSE

<table>
<thead>
<tr>
<th>Focused Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
</tr>
<tr>
<td>Sedative-hypnotics</td>
</tr>
<tr>
<td>Stimulants/sympathomimetics</td>
</tr>
</tbody>
</table>

### BENZODIAZEPINES

**Definition**
- GABA agonists

**History**
- Usually suicidal gesture or abuse, hypnotic/sleep agents (zaleplon, zolpidem, eszopiclone) have similar effects as BZD in overdose

**Physical Findings**
- CNS, respiratory depression, slurred speech, ataxia, hyporeflexia, midpoint/small pupils, hypothermia, hypotension

**Evaluation**
- FSG, consider ABG, Serum/urine tox, ETCO₂ monitor, Tele, pulse ox if severe toxicity

**Treatment**
- Supportive (airway protection if needed), Flumazenil 0.1–0.2 mg, repeat up to 3 mg → may precipitate szs, indications are rare, use
only to reverse when known benzo is overadministered as part of procedural sedation & must be reversed for life-threatening sxs, monitor for resedation after 1–2 h, may require repeat dose
- Decontamination: Activated charcoal if ingestion occurred w/i 30 min

Disposition
- Home (rarely require admission) if resolution of sxs after monitoring & if no SI

Pearls
- Monitor for withdrawal, which is similar in presentation (agitation, szs) & tx to EtOH withdrawal
- Isolated benzo OD rarely life-threatening although usually presents as polysubstance OD

---

**GAMMA-HYDROXYBUTYRATE (GHB)**

Definition
- GABA & GHB receptor agonist

Physical Findings
- Initial euphoria, AMS/obtundation, hypothermia, bradycardia, hypotension, sz, respiratory depression, myoclonus, aspiration, rarely pulmonary edema & sz

Evaluation
- FSG, ± Serum/urine tox screen (rapidly metabolized → GHB levels not readily available)

Treatment
- Supportive, maintain airway, recovery w/i 2–4 h, resolution w/i 8 h

Disposition
- Home

---

**OPIOIDS**

Definition
- Opioid receptor agonist

**History**
- Witnessed or reported use of opioids (heroin, methadone, morphine, hydromorphone, fentanyl, oxycodone)

**Physical Findings**
- ↓ CNS, ↓ RR/BP, apnea, ± miosis, track marks, aspiration, noncardiogenic pulmonary edema

**Evaluation**
- Glucose, serum/urine tox screen (for coingestants), end-tidal CO$_2$ monitor, Tele, pulse ox

**Treatment**
- Maintain airway
- Naloxone (titrate to effect) 0.2–0.4 mg IV → 1 mg IV → 2 mg IV → IV drip (duration 1–2 h)
- Activated charcoal (recent ingestion), whole bowel irrigation (long-acting opioid)

**Disposition**
- May require ICU admission for long-acting opioid toxicity on naloxone drip

**Pearls**
- Pts die from untreated apnea, often in prehospital setting
- Pts w/ hypoxia/cyanosis have risk of aspiration/ARDS
- Pts w/ recurrent apnea after naloxone likely have longer-acting opioid

**Opioid Withdrawal**

**Definition**
- Cessation or rapid reduction of opioid use in a dependent individual

**History**
- Chronic opioid use, anxiety, N/V, abd pain, diarrhea, myalgias

**Physical Findings**
- Yawning, rhinorrhea, mydriasis, piloerection, tachycardia
Treatment
- Clonidine 0.1 mg PO q30–60min (central α-agonist) → ↓ duration, methadone (not indicated in the ED), IVF

Disposition
- Home or detox

Pearl
- Not life-threatening, do not require admission, may be precipitated by administration of naloxone & caution should be used before treating w/ additional opioids

---

**Cocaine**

**Definition**
- Snorting, injecting, smoking, ingesting (body packing vs. stuffing) cocaine (peak 5–15 min, duration 1–4 h, releases norepinephrine/blocks reuptake)

**History**
- Cocaine use, anxiety, CP, focal weakness (CVA/ICH), sz, psychosis

**Physical Findings**
- ↑ HR, ↑ BP, hyperthermia, diaphoresis, agitation, nasal septal perforation, mydriasis

**Evaluation**
- Serum/urine tox screen, cardiac markers (if CP present), ECG (↑ QRS, ischemia), Cr (renal failure), CK (rhabdomyolysis), head CT (if ICH suspected), consider aortic dissection, intestinal infarction, stroke

**Treatment**
- Supportive care, BZD for anxiety/agitation/CP, treat hyperthermia (ice packs, cooling blankets, cooling mist), avoid βBs (unopposed α-adrenergic stimulation)
- Activated charcoal (recent ingestion), whole bowel irrigation (packers/stuffers)

**Disposition**
Varies depending on severity & mechanism of toxicity

Pearl
- Cocaine wash-out syndrome: After cocaine binging, MS (lethargy, obtundation), lasts up to 24 h

**Methamphetamine ("Meth")**

**Definition**
- Norepinephrine release, dopaminergic (causes addiction)

**History**
- Ingestion, snorting, smoking, injection, rectal insertion of methamphetamines & derivatives (LSD, bath salts), ADHD, & narcolepsy medications

**Physical Findings**
- ↑ HR, ↑ BP, hyperthermia, diaphoresis, agitation, poor dentition ("meth mouth"), poor hygiene, compulsive scratching lesions ("meth mites"), tremors, sz

**Evaluation**
- Serum/urine tox screen, ECG, consider CT head (ICH), UA, CK (rhabdomyolysis), BMP, cardiac enzymes (CP), Tele

**Treatment**
- Supportive care, BZD for anxiety/agitation/CP, cool hyperthermic pts (ice packs, cooling blankets, cooling mist)
- Activated charcoal (recent ingestion), whole bowel irrigation (packers/stuffers)

**Methylenedioxymethamphetamine (MDMA, “Ecstasy”), Lysergic Acid Diethylamide (LSD)**

**Definition**
- Serotonergic

**History**
Ingestion of MDMA, LSD, other hallucinogens

**Physical Findings**
- ↑ HR, ↑ BP, hyperthermia, anxiety, mydriasis, hallucinations, sz, diaphoresis, bruxism

**Evaluation**
- Serum/urine tox screen, BMP (↓ Na due to excessive water ingestion), ECG, consider CT head (ICH), INR, UA, CK (rhabdomyolysis), cardiac enzymes (CP), Tele

**Treatment**
- Supportive care, BZD & haloperidol for agitation, cool hyperthermic pts (ice packs, cooling blankets, cooling mist)
- ± Activated charcoal (recent ingestion)

---

**ANALGESIC OVERDOSE**

**ACETAMINOPHEN (APAP) POISONING**

**History**
- Witnessed or reported ingestion of any APAP-containing meds (many Rx & OTC drugs)
- Often coingestions w/ other substances

**Findings**
- 4 stages of APAP poisoning
  i. Asymptomatic (0–24 h)
  ii. GI upset, N/V, abd pain (24–72 h)
  iii. Jaundice, fulminant liver failure, encephalopathy (3–5 d)
  iv. Recovery (1 wk after) if survive phase III or multisystem organ failure

**Evaluation**
- APAP level 4 h after ingestion, serum/urine tox for coingestants, baseline LFTs & coags, BMP for calculation of anion gap, preop labs if potential for need for transplant, ECG
Treatment

- N-acetylcysteine (NAC) is glutathione substitute used as antidote
- Cardiac monitor, 2 large-bore IVs, ± NGT for anticipated NAC tx (PO NAC noxious), antiemetics
- Begin NAC if (acute ingestion, APAP level >140 μg/mL), (chronic ingestion of >200 mg/kg, 150 mg/kg, 100 mg/kg over 1, 2, 3 d, or ↑ LFTs, detectable serum APAP, or high risk)
- NAC 140 mg/kg per NGT × 1, then 70 mg/kg PNGT or 150 mg/kg IV × 1, then 50 mg/kg IV q4h × 5 doses, prolong therapy past initial 20 h if persistent serum APAP detected or ↑ LFTs until improvement in LFTs
- Activated charcoal (recent ingestion), HD (APAP >1,000 mg/L + coma/hypotension)

Disposition

- Admission to hospital vs. ICU based on clinical picture; transfer to transplant facility
- Consider Psych eval

Pearls

- Maximal safe APAP dose 15 mg/kg (up to 1000 mg) QID, max daily dose 3–4 g/24 h
- APAP metabolism produces NAPQI (toxic metabolite) → direct hepatocyte damage
- When coupled to glutathione, NAPQI made inert & is excreted in urine; APAP tox results from overwhelmed/depleted glutathione stores
- Many unintentional APAP OD from confusion b/w pediatric vs. infant APAP preparations
- Infant: 80 mg/0.8 mL = 100 mg/mL; children: 160 mg/5 mL (5 mL = 1 tsp) = 32 mg/mL
**Figure 16.** Relation between plasma APAP level and hepatotoxicity correlated with time after ingestion. Reprinted with permission from Helms RA, Quan DJ. *Textbook of Therapeutics: Drug and Disease Management*. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.

---

**SALICYLATE POISONING (ASA)**

**History**
- Witnessed or reported ingestion of ASA or ASA-containing meds
- Often coingestions w/ other substances, occasionally inadvertent
Suspect ASA poisoning in any pt who reports tinnitus

**Findings**
- 1st 8–12 h: Fever, hyperventilation (respiratory alkalosis + metabolic acidosis), hyperpnea, tachycardia, hypotension, diaphoresis, dysrhythmias, N/V, epigastric pain, confusion
- By 24 h: Coma, cerebral edema, szs, noncardiogenic pulmonary edema, DIC

**Evaluation**
- Serum tox screen for ASA level & coingestants, BMP for anion gap, CBC, baseline coags, ABG, CXR, ECG
- Check ASA level q4h to ensure that levels are not rising due to bezoar formation or enteric-coated formulation delayed metabolism
- Bedside ferric chloride test (sens but not spec), serum quantitative assay preferred
- Add 2–4 drops 10% ferric chloride to 2 mL urine: Bluish purple color indicates + ASA; acetone & phenylpyruvic acid cause false + (pt w/ DM, ketoacidosis alcoholics)
- Ferric chloride testing will be + if as little as 2 ASA tablets ingested 24 h prior to test; takes 2 h from time of ingestion for ASA to be renally cleared

**Treatment**
- Airway protection if pt tires, hyperventilate & maintain respiratory alkalosis w/ vent
- Cardiac monitor, 2 large-bore IVs, Foley to monitor UOP & pH, dextrose for hypoglycemia
- Alkalinize urine to enhance ASA excretion
- 3 amps NaHCO₃ to 1 L D₅W or 2 amps NaHCO₃ to 1 L ½ NS, bolus over 30 min
- Continue NaHCO₃ IV fluid to maintain serum pH >7.45, <7.55, UOP 1.5 mL/kg/h
- Add 20–40 mEq K⁺ to replete K⁺ exchanged into cells for H⁺ ions; hypokalemia prevents effective alkaline diuresis
- Activated charcoal (recent acute ingestion), consider whole bowel irrigation
Arrange for HD for symptomatic pt, if chronic ASA poisoning w/ ASA >60 mg/dL or acute ASA poisoning w/ ASA >90 mg/dL w/ severe acidosis

Disposition

› Admission to floor vs. ICU (if symptomatic), observe for at least 6 h (asymptomatic, nonenteric-coated, smaller ingestions), screen for SI/psych eval if indicated

Pearls

› ASA uncouples oxidative phosphorylation, causes a 1° metabolic acidosis & 1° (centrally mediated) respiratory alkalosis
› Methyl salicylate (found in BenGay, Icy Hot muscle balm, oil of wintergreen food flavoring) produces ASA tox in very small amounts (1 tsp of oil of wintergreen contains 7 g of ASA)
› Done nomogram created for ASA in the same way as the APAP-tox nomogram; considered to be inaccurate & of no clinical value due to the wide metabolic swings that occur w/ salicylate tox; is no longer used

<table>
<thead>
<tr>
<th>Amount Ingested</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;150 mg/kg</td>
<td>None → mild tox</td>
</tr>
<tr>
<td>150–300 mg/kg</td>
<td>Mild → mod tox</td>
</tr>
<tr>
<td>301–500 mg/kg</td>
<td>Serious tox</td>
</tr>
<tr>
<td>&gt;500 mg/kg</td>
<td>Potentially lethal tox</td>
</tr>
</tbody>
</table>

CARDIAC MEDICATION OVERDOSE

α-Blocker (βB) Overdose

History

› Witnessed or reported overingestion of βB
› Children who have been at homes of older relatives taking
prescribed medications

Findings
- Symptomatic bradycardia, hypotension, AMS, weakness, bronchospasm
- Lipid-soluble βB (propranolol) – sz; sotalol – ↑ QTc, torsades de pointes
- May have hypoglycemia, N/V, hyperkalemia

Evaluation
- ECG shows bradycardia, AV or intraventricular block, asystole
- Check cardiac enzymes, BMP; drug levels not available

Treatment
- Continuous Tele, 2 large-bore IVs, place transcutaneous pacer pads on pt
- Place a cordis in the R IJ or L subclavian vein if transvenous pacing indicated
- For symptomatic or refractory βB OD, administer:
  - Atropine 0.5–1 mg IV (ACLS protocol) for severe bradycardia &/or hypotension
  - Glucagon 5–10 mg IV bolus followed by infusion of 1–5 mg/h if hypotensive
  - Pressors if indicated (epinephrine), cardiac pacing prn
  - Sodium bicarbonate 1–2 mEq/kg for wide-complex conduction defects
  - Consider hyperinsulinemia–euglycemia therapy &/or IV lipid emulsion (benefit in animals & case reports)
- No role for activated charcoal or whole bowel irrigation unless massive recent OD
- HD only useful for βB w/ low volume of distribution (acebutolol, atenolol, nadolol, timolol, sotalol) if unresponsive to medical intervention, or if pressors/glucagon necessary to maintain BP

Disposition
- Admission to floor vs. ICU (if symptomatic)
- Clinically significant βB OD develop sxs w/i 6 h; if remain asymptomatic, can be D/C unless ingested sustained release
CALECIUM CHANNEL BLOCKER (CCB) OVERDOSE

**History**
- Witnessed or reported overingestion of CCB
- Children who have been at homes of older relatives taking prescribed medications

**Findings**
- Symptomatic bradycardia, hypotension, AMS, N/V, weakness
- Transient hyperglycemia; sz rare

**Evaluation**
- ECG shows bradycardia, ventricular escape rhythm, 2nd- or 3rd-degree AV block; usually nl QRS complex (vs. βB OD)
- Check cardiac enzymes, BMP; drug levels not available

**Treatment**
- Continuous Tele, 2 large-bore IVs, place transcutaneous pacer pads on pt
- Place a cordis in the R IJ or L subclavian vein if transvenous pacing indicated
- Continue supportive therapy including volume resuscitation & pressors for hypotension & depressed inotropy
- For either symptomatic βB or CCB OD, administer:
  - Atropine 0.5–1 mg IV (ACLS protocol)
  - Glucagon 5–10 mg IV bolus followed by infusion of 1–5 mg/h if hypotensive
  - Calcium gluconate 3 g slow IV push or calcium chloride 1 g IV q5–10min prn
    - Can reverse depression of cardiac contractility; no effect on sinus node depression or peripheral vasodilation; variable effect on AV node conduction
  - Pressors if indicated (dopamine, norepinephrine, amrinone)
- For CCB OD, hyperinsulinemia–euglycemia therapy can provide fuel for enhanced myocardial contractility
- If glucose <200 mg/dL, give dextrose 0.25 g/kg D25 up to 1 amp D50
- If K+ <2.5 mEq/dL, administer 40 mEq IV; monitor & replete K+ prn
- Administer regular insulin 0.5–1 U/kg IV bolus, followed by infusion of 0.5–1 U/kg/h
- Start D10 ½ NS at 80% maintenance rate
- Recheck glucose q20min × 1 h, then qh; titrate insulin infusion to maintain glucose b/w 100 & 200
- Consider IV lipid emulsion (promising in animal studies & case reports), glucagon
- No role for activated charcoal or whole bowel irrigation unless massive recent OD of extended-release formulation; then use multidose charcoal
- HD not useful for CCB OD due to extensive protein binding

**Disposition**
- Admission to floor vs. ICU (if symptomatic)
- CCB should be monitored for 6 h or 24 h for sustained release formulations

---

**Digoxin Overdose**

**History**
- Usually in pts on chronic Dig, occasional acute intentional OD occurs
- Weakness, fatigue, palpitations, syncope, AMS, N/V, diarrhea, HA, paresthesias
- Yellow-green vision or other vision disturbances pathognomonic in chronic OD (not always present)
- Recent worsening renal fxn, dehydration, electrolyte abn, recent addition of new med

**Findings**
- GI sxs (common), generalized neuro sxss, visual Δ w/ few objective findings
- Hemodynamic instability related to dysrhythmias or acute CHF

**Evaluation**
- ECG may show a number of cardiac dysrhythmias (see table)
- Dig level, cardiac enzymes, BMP (↑ K in acute OD, nl or ↓ K, ↓ Mg in chronic OD)

**Treatment**
- Continuous Tele, trend Dig & serum K levels w/ ECG & clinical picture
- Correct electrolyte abnl
- Acute overdose
  - ↑ K is bad prognostic sign; treat immediately w/ calcium, glucose/insulin & bicarb (the notion that calcium is contraindicated in Dig overdose is based on very weak evidence from animal models)
  - Magnesium, lidocaine, antiarrhythmic until Digibind available
  - Dig spec Ab (antidote) if level >6, K >5, high-deg AV block, ventricular arrhythmias, AMS, hemodynamic compromise
  - Each vial of Dig spec Ab binds 0.5 mg of Dig
  - # of Dig spec Ab = (serum Dig [ng/mL] × TBW [kg])/100
  - For unknown amount/level, empirically treat w/ 10 vials, repeat once prn for acute ingestion, 6 vials for chronic ingestion
  - Phenytoin & lidocaine safe to control tachydysrhythmias
  - Activated charcoal (if recent ingestion), dialysis ineffective due to large Vd
- Chronic tox
  - Stop Dig
  - Verify need for Dig spec Ab, check Cr, electrolytes

**Disposition**
- Admission to floor vs. ICU (if hemodynamic instability, refractory dysrhythmia)
- If asymptomatic, no cardiac dysrhythmias, nl K & dig level, can d/c after 6 h

**Pearl**
- Many drug interactions (BZD, βB, CCB, diuretics, succinylcholine, some abx)

<table>
<thead>
<tr>
<th>Dysrhythmias Suggestive of Dig Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PVCs (most common); bigeminy or trigeminy</td>
</tr>
<tr>
<td>Slow AF w/ regularized ventricular rate (AV dissociation)</td>
</tr>
<tr>
<td>---------------------------------------------------------</td>
</tr>
<tr>
<td>NPJT (rate 70–130)</td>
</tr>
<tr>
<td>AT w/ block</td>
</tr>
<tr>
<td>Bidirectional ventricular tachycardia</td>
</tr>
<tr>
<td>Asystole or ventricular fibrillation</td>
</tr>
</tbody>
</table>

---

### CAUSTIC INGESTIONS

#### Background
- Cause tissue injury by acidic or alkaline chemical rxn
- pH <2 is considered strong acid, pH >12 considered strong base
- Severity of tissue injury determined by duration of contact, pH, concentration, type of substance (liquid vs. solid)

#### Approach
- Careful hx: Spec agent, amount, duration, pH, & timing of ingestion, coingestants
- Often a suicidal gesture; assess mental state as well as physical
- Rapid physical exam: Look for respiratory compromise, stridor, hoarseness, oropharyngeal burns, drooling, subcutaneous air, acute peritonitis (signs of perforation), hematemesis
- Do NOT induce emesis; re-exposure could worsen injury
- Do NOT attempt to neutralize ingestions due to possible exothermic rxn

---

### ACID/ALKALINE INGESTIONS

#### History
- Alkaline: Ingestion of ammonia, cleaning agents: drain, oven, swimming pool, dishwasher detergents, bleach, cement, hair relaxers
- Acid: Ingestion of battery liquid, toilet bowl cleaners, rust or metal cleaning products, drain cleaners, cement cleaning products

#### Findings
Alkaline: Liquefactive necrosis – severe injury starts rapidly after ingestion, w/i min of contact, tissues that 1st contact alkali are most severely injured (oropharynx, hypopharynx, esophagus). Tissue edema occurs immediately, may persist for 48 h, progress → airway obstruction. Over 2–4 wk get scar tissue thickening → strictures (depends on depth of burn).

Acid: Coagulation necrosis → desiccation → eschar formation; stomach most commonly affected, small bowel exposure possible. Eschar sloughs in 3–4 d, then granulation tissue development. Perforation after 3–4 d as eschar sloughs; gastric outlet obstruction if scar tissue contracts over 2–4 wk. Pyloric sphincter spasm may delay gastric emptying & ↑ contact time to 90 min.

In hydrofluoric acid (HF) ingestion, ↓ Ca may lead to arrhythmias, sudden cardiac arrest

Both may cause esophageal perforation

Evaluation
- pH of product & of saliva, CBC, BMP, ABG, baseline LFTs, UA, preop labs, tox screen; cardiac monitoring, ECG; x-rays, consider CT for extraluminal air
- Endoscopy if symptomatic, small child, AMS but not if e/o perforation or airway edema

Treatment
- Airway protection, large-bore IV access; surgical/GI consultation, antiemetics
- Gastric lavage controversial
- Activated charcoal not helpful due to poor adsorption
- Dilution w/ small amts of water/milk may be beneficial if done w/i 30 min after ingestion
- Abx if e/o perforation, pain control

Disposition
- Admit to ICU if symptomatic

CELLULAR ASPHYXIATES
Etiology
- By-product of nitroprusside, acrylonitrile (nail polish, plastics, some tattoo ink), cyanogenic glycosides (apricot pits, cassava), cyanide gas (house fires)
- Mechanism: Binds to cytochrome oxidase, blocks aerobic utilization of \( O_2 \), leading to cellular asphyxia

History
- Difficulty breathing, confusion, HA, n/v, AMS, syncope, sz, cardiovascular collapse
- Sxs develop immediately after inhalational exposure, delayed sxs after exposure to nitroprusside, cyanide salts, acrylonitrile, cyanogenic glycosides

Physical Exam
- \( O_2 \) saturation often nl; dyspnea/tachypnea, confusion, tachycardia; agonal respirations & cardiovascular collapse a/w severe poisoning
- “Bitter almond” smell (unreliable), bright red venous blood due to high venous \( O_2 \) content

Evaluation
- **Labs**: BMP, ↑↑ lactate, ABG (metabolic acidosis), VBG (assess venous/arterial \( O_2 \) gradient), cyanide level, carboxyhemoglobin (if smoke inhalation)

Treatment
- Supportive: Maintain airway, \( O_2 \) therapy, IV fluids
- Activated charcoal (presenting <2 h)
- Cyanide antidote:
  - Cyanocobalamin adult: 5 g (child: 70 mg/kg) IV over 15 min
  - Cyanide kit (amyl nitrite, sodium nitrite, sodium thiosulfate) – causes methemoglobinemia

Disposition
- Admit: All pts; consider ICU for pts w/ szs, coma, acidosis, hypotension
Etiology

**Carbon Monoxide**
- Smoke inhalation, methylene chloride exposure
- Mechanism: Reduces $O_2$ carrying capacity, shifts $O_2$ dissociation curve to L

**Methemoglobinemia**
- Nitrites, dapsone, sulfa drugs, lidocaine/benzocaine, antimalarials, water contamination
- Mechanism: Disequilibrium of methemoglobin to hemoglobin; overwhelmed methemoglobin reductase

History

**Carbon Monoxide**
- Mild: Mild HA, DOE; mod: HA, N/V, dizziness, poor concentration; severe: CP, syncope, coma, LOC & persistent AMS

**Methemoglobinemia**
- SOB, HA, light-headedness, fatigue, nausea, tachycardia, CP, syncope

Physical Exam

**Carbon Monoxide**
- Lethargy, szs, tachycardia, tachypnea, rales, confusion, red skin, or cyanosis

**Methemoglobinemia**
- “Chocolate” cyanosis, tachycardia; coma, sz, D a/w severe exposure

Evaluation

- ABG & Pulse ox: May be falsely reassuring

Labs

- CO
  - CO oximeter, CO level (mild: 10–20%, mod: 20–40%, severe: >40%), urine hCG; mod/severe: ABG (metabolic acidosis), BMP, CBC, cardiac enzymes, UA, CPK, lactate, consider cyanide level
  - ECG: Arrhythmias, signs of MI

- Methemoglobinemia
• CO oximeter, methemoglobin level; severe exposure: ABG, hemolysis labs (LDH, peripheral smear, haptoglobin, reticulocyte count), type & crossmatch
• Bedside test: Drop of blood on white filter paper will turn chocolate brown (compared to regular venous blood)

**Treatment**

**Carbon Monoxide**

- \( \text{O}_2 \): 100% NRB until sxs improved
- Hyperbaric \( \text{O}_2 \): Sz, respiratory failure, LOC, CO level >25% (if pregnant, >15%), infants, severe acidosis, neuro deficits, CV dysfxn, exposure >24 h, age >36 yr

**Methemoglobinemia (symptomatic exposures, level >20%)**

- Methylene blue (reducing agent): 1–2 mg/kg of 1% solution IV qh × 2 doses
- Exchange transfusion/hyperbaric \( \text{O}_2 \): Severe sxs not responsive to methylene blue or if methylene blue is contraindicated (eg, G6PD deficiency)

**Disposition**

- Admit if CO level >25%, methemoglobin level >20%, dapsone tox, LOC, pts w/ underlying cardiac/neurologic/respiratory dz

**Pearls**

- Do NOT use methylene blue in pts w/ G6PD deficiency (hemolytic anemia)
- Large amounts of methylene blue may paradoxically elevate methemoglobin levels

---

**HYPOGLYCEMICS**

**History**

- Oral ingestion of sulfonylureas, meglitinides (eg, repaglinide), or SC/IV insulin (oral insulin is not toxic)
- Agitation, coma, convulsions, confusion, blurry vision, n/v, rapid heartbeat, sweating, tingling of tongue & lips, tremor, dizziness, poor feeding; children may show sxs w/i 5 min of ingestion
RF: Extremes of age, polypharmacy, renal or hepatic dz, suicide attempt

**Physical Exam**
- AMS, generalized weakness, diaphoresis, tachycardia, tachypnea, transient neurologic deficit, pallor, sz, cyanosis, coma, hypothermia

**Evaluation**
- **Labs:** FSG q1h, BMP, urine hCG; tox screen (if intentional overdose or ingestion unknown), C-peptide (present w/ endogenous insulin secretion)

**Treatment**
- Supportive: ABCs, activated charcoal if recent ingestion
- Dextrose:
  - Oral: Glucose paste, juice
  - IV: 0.5–1 g/kg IV D\(_{50W}\) (adults), D\(_{25W}\) (children), D\(_{10W}\) (neonates) × 1 dose; persistent hypoglycemia: 0.5 g/kg/h D\(_{10W}\) (titrate to glucose >100)
- Glucagon: 1 mg/dose IV/IM/SC (if <20 kg, 0.5 mg/dose)
- Octreotide for sulfonylurea or meglitinide overdose

**Disposition**
- Home: Pts w/ unintentional isolated insulin overdose may be treated & released after effect of insulin wears off depending on rapid vs. long-acting
- Admit: Pts w/ sulfonylurea overdose must be monitored for at least 8 h

---

**OTHER INGESTIONS**

<table>
<thead>
<tr>
<th>Etiology, Hx, &amp; Sxs of Other Ingestions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overdose</strong></td>
</tr>
<tr>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Insecticides</td>
</tr>
<tr>
<td>Compound</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td><strong>miosis, bronchorrhea, tachycardia, HTN, sz, respiratory depression, garlic-like odor; AVOID succinylcholine</strong></td>
</tr>
<tr>
<td><strong>Carbamates</strong> (used to treat myasthenia gravis)</td>
</tr>
<tr>
<td><strong>Chlorinated Hydrocarbons</strong> (DDT, chlordane, lindane)</td>
</tr>
<tr>
<td><strong>Iron</strong></td>
</tr>
<tr>
<td><strong>Phenytoin/fosphenytoin</strong></td>
</tr>
<tr>
<td><strong>Hydrocarbons/volatiles</strong></td>
</tr>
<tr>
<td><strong>Herbicides</strong></td>
</tr>
<tr>
<td><strong>Overdose</strong></td>
</tr>
<tr>
<td><strong>Heavy metals</strong></td>
</tr>
</tbody>
</table>
| Rodenticides | Red squill, strychnine, yellow phosphorous, warfarin type/brodifacoum | Red squill: Cardiac glycoside-like sxs  
Strychnine: Sz-like appearance w/ extensor posturing, rhabdomyolysis  
Yellow phosphorous: Garlic odor, oral burns, vomiting, phosphorescent smelling feces, GIB, electrolyte abnl, sz, arrhythmias, renal/hepatic failure  
Warfarin type/brodifacoum: Long-acting anticoagulation, bleeding risk |
| --- | --- | --- |
| Household products | Acids (toilet bowel cleaners), bases (bleach, ammonia), detergents, all-purpose cleaners (glass cleaner, pine oil, turpentine), chlorine, cosmetics | Bases/ acids: GI irritation  
Bases: Pneumonitis, pneumomediastinum  
Perfume/mouthwash: Depends on alcohol level  
Pine oil/turpentine: Hemorrhagic pulmonary edema  
Detergents: GI irritants/corrosives, pulmonary edema  
Glass cleaner: Ocular, o/w well tolerated |

### Eval & Tx of Other Ingestions

<table>
<thead>
<tr>
<th>Overdose</th>
<th>Labs/Imaging</th>
<th>Tx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organophosphates</td>
<td>BMP, ECG, plasma cholinesterase level, lactate, CK, LFTs, CXR</td>
<td>Decontamination; atropine (2–5 mg) IV q5min (endpoint = dried secretions); 2-PAM 1–2 g IV over 30–60 min, 500–1000 mg/h (will not work on skeletal muscle); BZD (prn szs/agitation)</td>
</tr>
<tr>
<td>Carbamates</td>
<td>Same as organophosphates</td>
<td>Supportive, decontamination, atropine (dose same as organophosphates)</td>
</tr>
<tr>
<td>Chlorinated hydrocarbons</td>
<td>Electrolytes (metabolic acidosis, ATN), ECG (arrhythmias), CK (rhabdomyolysis)</td>
<td>Supportive, decontamination, activated charcoal, cholestyramine (do not use in bowel obstruction), BZD (prn sz/agitation), ßB</td>
</tr>
<tr>
<td>Iron</td>
<td>Fe level q4h; check BMP, LFTs, lactate, CBC, coags if symptomatic; KUB may show radiopaque tablets</td>
<td>Decontamination &amp; whole bowel irrigation; supportive/IVFs; deferoxamine 15 mg/kg/h (max 1 g/h) over 6 h (for severe sx, may induce hypotension)</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Phenytoin/fosphenytoin</strong></td>
<td>Check phenytoin or fosphenytoin level; calculate free phenytoin level, albumin level, ECG, BMP</td>
<td>Supportive, activated charcoal, treat hypotension w/ fluids/pressors</td>
</tr>
<tr>
<td><strong>Hydrocarbons &amp; other Volatiles</strong></td>
<td>BMP (renal tubular acidosis, hypokalemia), ECG, LFTs (elevated); CXR (infiltrate, bronchovascular markings)</td>
<td>Remove all exposed clothing; supportive care – if intubated, PEEP beneficial</td>
</tr>
<tr>
<td><strong>Overdose</strong></td>
<td><strong>Labs/Imaging</strong></td>
<td><strong>Tx</strong></td>
</tr>
<tr>
<td><strong>Herbicides</strong></td>
<td>BMP (tubular necrosis, hyponatremia), lipase, CK, urine myoglobin, ECG (dysrhythmias), LFTs, CXR</td>
<td>Irrigate all areas of exposure (skin, eyes, gastric lavage), IVFs, electrolyte replacement, BZD (sz, agitation); activated charcoal Paraquat/Diquat/Glufosinate: Hemoperfusion Chlorophenoxy: Alkaline diuresis via 1–2 amps bicarb + KCl (urine output: 4–6 cc/kg/h) Pentachlorophenols/nitrophenolic: Aggressive cooling, treat hyperkalemia/rhabdomyolysis</td>
</tr>
<tr>
<td><strong>Heavy metals</strong></td>
<td>Send off individual levels, BMP (electrolyte abnl, renal failure), CBC (HCT), CXR (pneumonitis)</td>
<td>Supportive; may require intubation BAL: Copper, arsenic, lead, mercury NAC: Chromium, cobalt D-Penicillamine: Copper EDTA: Cobalt, lead MDAC: Thallium Prussian Blue: Thallium Selenium: Silver Succimer: Lead, copper, arsenic</td>
</tr>
<tr>
<td><strong>Rodenticides</strong></td>
<td>CXR, BMP, LFTs, EKG, CXR, CK, Urine hCG, PT/PTT, may check individual levels</td>
<td>Decontaminate, activated charcoal, whole bowel irrigation, supportive, renal failure may require dialysis, exchange transfusion for severe hemolysis</td>
</tr>
<tr>
<td>Household material</td>
<td>BMP (hypernatremia w/ bleach), CXR (aspiration PNA)</td>
<td>Supportive: IVFs, intubation if necessary; copious irrigation of skin, eye. Ingestion: Water, milk to reduce irritation; Pine oil/turpentine: GI decontamination, endoscopy</td>
</tr>
</tbody>
</table>
AIRWAY MANAGEMENT

Approach
- Assess need for intubation

<table>
<thead>
<tr>
<th>Indications for Intubation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inability to oxygenate</td>
</tr>
<tr>
<td>Inability to ventilate</td>
</tr>
<tr>
<td>Impending clinical course</td>
</tr>
</tbody>
</table>

- Anticipated need for airway management in pts at risk for deterioration
- Assess difficulty of intubation early
- In pts w/ acute respiratory failure, BVM ventilation or noninvasive positive pressure ventilation (NiPPV) can be a bridge, but not a substitute, to intubation
- **Choose appropriate intubation algorithm**

<table>
<thead>
<tr>
<th>Airway Algorithms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Presentation</strong></td>
</tr>
<tr>
<td>Standard</td>
</tr>
<tr>
<td>Anticipated difficult airway</td>
</tr>
<tr>
<td>Failed airway: Can’t intubate</td>
</tr>
<tr>
<td>Failed airway: Can’t intubate, can’t ventilate</td>
</tr>
<tr>
<td>Crash airway (near D)</td>
</tr>
</tbody>
</table>

- **Choose appropriate intubation tool**
  - VL: 1st choice, if available; higher 1st pass success rate vs. DL
  - DL: Most commonly used (Mac or Miller blade)
- Awake sedated airway (when difficult laryngoscopy is anticipated): Inhalation ± topical application of local anesthetic, parenteral sedation, evaluate airway, intubate via VL or fiber optic, paralyze/sedate when airway established → requires cooperative pt, noncrash airway

**Pearls**

- Have rescue devices at the ready: EGD, cricothyrotomy kit
- Consider glycopyrrolate 0.2 mg IV to w/ ketamine to minimize secretions
- Good BVM technique saves lives

---

**RAPID SEQUENCE INTUBATION**

The “7 Ps”

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Preoxygenation</th>
<th>Pretreatment</th>
<th>Positioning</th>
<th>Paralysis w/ induction</th>
<th>Placement w/ proof</th>
<th>Postintubation management</th>
</tr>
</thead>
</table>

- Preparation
  - Monitor O₂ sat, BP, rhythm, ≥1 IV
  - BVM, **suction**, ET CO₂ detector, oral airway, Bougie
  - Intubation equipment (eg, laryngoscope): Blade, backup blade, check video monitor/light
  - ETT: 7.5–8 (male), 7–7.5 (female); check cuff, load stylet/10-cc syringe; pediatrics tube size: = 4 + (age in y/4) → or use Broselow tape
  - RSI medications/doses
  - Assess for difficult BVM, difficult intubation, & difficult cricothyrotomy → prepare appropriately

---

**Assessing Difficult BVM → MOANS**

<table>
<thead>
<tr>
<th>Measure</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>M – mask seal</td>
<td>Beard, lower facial trauma</td>
</tr>
<tr>
<td>O – obesity, obstruction</td>
<td>Includes angioedema, Ludwig angina, trauma, etc.</td>
</tr>
<tr>
<td>Measure</td>
<td>Comment</td>
</tr>
<tr>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>A – age</td>
<td>Age &gt;55 yr</td>
</tr>
<tr>
<td>N – no teeth</td>
<td>Difficulty obtaining seal</td>
</tr>
<tr>
<td>S – stiff</td>
<td>Stiff lungs (asthma/COPD, PNA, ARDS, etc.)</td>
</tr>
</tbody>
</table>

### Assessing Difficult Airway → LEMON

<table>
<thead>
<tr>
<th>Measure</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>L – look externally</td>
<td>Overall gestalt of difficulty</td>
</tr>
<tr>
<td>E – evaluate 3-3-2</td>
<td>Can fit 3 fingers into open mouth, 3 fingers b/w tip of chin &amp; chin/neck jxn, 2 fingers b/w chin/neck jxn &amp; thyroid notch</td>
</tr>
<tr>
<td>M – Mallampati class</td>
<td>From I (soft palate, uvula, pillars seen) to IV (only hard palate seen)</td>
</tr>
<tr>
<td>O – obesity/obstruction</td>
<td>Look for muffled voice, difficulty handling secretions, stridor, sense of dyspnea</td>
</tr>
<tr>
<td>N – neck mobility</td>
<td>Eg, C-spine immobilization, ankylosing spondylitis, RA</td>
</tr>
</tbody>
</table>

### Assessing Difficult Cricothyrotomy → SHORT

<table>
<thead>
<tr>
<th>Measure</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>S – surgery</td>
<td>Eg, Halo device, recent thyroid surgery</td>
</tr>
<tr>
<td>H – hematoma</td>
<td>Anything distorting neck anatomy (includes infection, abscess)</td>
</tr>
<tr>
<td>O – obesity</td>
<td>Also consider short neck, SC emphysema</td>
</tr>
<tr>
<td>R – radiation</td>
<td>Distorts anatomy</td>
</tr>
<tr>
<td>T – tumor</td>
<td>Distorts anatomy, ↑ bleeding</td>
</tr>
</tbody>
</table>

- Preoxygenation: BVM (provides ~100% FiO₂) × 3 min or 8 vital capacity breaths
- Consider passive/apneic oxygenation: Place NC on high flow throughout intubation, prolongs time to desaturation
- Pretreatment: Give 3 min prior to intubation—lidocaine 1.5 mg/kg IV (↓ ICP, in pts w/ ↑ ICP, ↓ bronchospasm in pts w/ reactive airway dz); fentanyl 3 μg/kg IV (↓ ICP in pts w/ ↑ ICP, ↓ HTN response in pts w/ cardiac ischemia, aortic dissection, head bleed)
- Paralysis w/ induction: Always induce prior to paralysis
- Induction: Etomidate (0.3 mg/kg IV), midazolam (0.3 mg/kg IV), ketamine (1–3 mg/kg IV), thiopental (3 mg/kg IV)
Paralysis: Succinylcholine (1.5 mg/kg IV, if no CI), rocuronium (1–1.2 mg/kg IV)
- Succinylcholine CIs: Large burns, paralysis, crush injury (w/ in 3 d–6 mo), abd sepsis (>3 d), elevated ICP or intraocular pressure, hx of MH, neurologic d/o (muscular dystrophy, MS, Amyotrophic Lateral Sclerosis)
- Rocuronium has no CIs but longer half-life often leads to delayed sedation
- Positioning: ± Cricoid pressure (prevents gastric regurgitation but may worsen DL view) before/during intubation until tube placement confirmed
- Placement w/ proof: Insert ETT via direct visualization of vocal cords, inflate cuff
- Confirm placement: ET CO₂ detector, auscultate lungs (assess for R-side intubation)
- Secure ETT, release cricoid pressure
- Postintubation management: Oral gastric tube, CXR, sedation (benzos, propofol) ± paralytics (vecuronium 0.1 mg/kg IV), analgesia (fentanyl), initiate mechanical ventilation

CRICOTHYROTOMY

Purpose
- Failed airway (can’t intubate/can’t oxygenate or ventilate); severe facial trauma, trismus, upper airway obstruction

Equipment
- Scalpel (11 blade), Trousseau dilator, tracheal hook, Bougie, tracheostomy tube (6.0–6.5 ET tube if none immediately available)

Positioning
- Pt supine, hyperextend neck if no CI

Procedure
- Sterile technique if time allows; see RSI for preparation & postintubation management
Open Technique:
- Hold larynx w/ nondominant hand
- Make **vertical incision** w/ dominant hand from thyroid cartilage to cricoid membrane (2–3 cm), through skin & soft tissue
- Palpate cricothyroid membrane through incision using nondominant index finger, **not** visualization
- Make **horizontal incision** <1 cm through cricothyroid membrane
- Place finger into stoma, then replace w/ tracheal hook-pointed caudad, then rotate cephalad. Alternatively, place Bougie (instead of tracheal hook) deep into stoma then slide ETT over Bougie & into place.
- Place Trousseau dilator in stoma w/ handle **perpendicular** to neck & dilate **vertically**
- Rotate dilator **parallel** to neck, then place tracheostomy tube w/ obturator in place, thumb over the obturator or ET tube
- Remove obturator (if tracheostomy tube), inflate cuff, suture in place

Complications
- Bleeding, misplaced tube, vocal cord damage
- Contraindicated in children <10 y/o, consider needle cricothyrotomy in peds

Pearl
- The hardest part of performing cricothyrotomy is deciding to do it → therefore, always consider this procedure in your airway algorithm
# PRIMARY SURVEY

## Definition
- Initial survey of the trauma pt for rapid identification of life-threatening injuries

## Approach
- Eval in ABCDE order: Airway, breathing/ventilation, circulation, disability, exposure/environmental control

<table>
<thead>
<tr>
<th>1° Survey</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Airway maintenance w/c-spine immobilization</strong></td>
<td>Talking → airway patent → frequent reassessment&lt;br&gt;Unable to talk → eval for FB/facial fractures/tracheal/laryngeal injury/other obstruction → if obstruction not reversible w/ chin lift jaw/thrust or GCS &lt;8 → intubation w/c-spine immobilization&lt;br&gt;Severe facial/neck trauma be prepared for surgical airway (see Chapter 17 for further details of airway management)</td>
</tr>
<tr>
<td><strong>Breathing/ventilation</strong></td>
<td>Eval chest wall excursion/bilateral breath sounds/chest wall (flail chest, crepitance, open chest wound, tracheal injury) → identify/repair injuries that impair ventilation; tension ptx (needle decompression/finger or tube thoracostomy), flail chest w/ pulm contusion, massive hemothorax (tube thoracostomy → &gt;1500 cc blood out or &gt;200 cc/h or unstable HD → OR), open ptx</td>
</tr>
<tr>
<td><strong>Circulation</strong></td>
<td>Hypotension/altered MS/confusion/mottled skin/thready pulse/diminished pulse = hemorrhage/hypovolemia until proven o/w → place multiple large-bore IVs/control external hemorrhage → resuscitate w/ 2 L NS → persistent hypotension; transfuse PRBC (males O+, females O−), consider massive transfusion protocol (1 PRBC:1 FFP:1 PLTs) if persistent transfusion requirements, consider permissive hypotension (SBP 70–100 mmHg) &amp; restrictive use of fluids&lt;br&gt;FAST exam to evaluate for intra-abd hemorrhage → + FAST + persistent hypotension = OR</td>
</tr>
</tbody>
</table>
**Disability**

Rapid neurologic assessment; AVPU (Alert, responds to Verbal stimuli, responds to Painful stimuli, Unresponsive), GCS

**Exposure/environmental**

Remove clothes, avoid hypothermia (massive transfusions/environmental exposures) can lead to coagulopathies (warmed blankets/IVF)

---

**Glasgow Coma Scale**

<table>
<thead>
<tr>
<th>Eye opening</th>
</tr>
</thead>
<tbody>
<tr>
<td>4—Open eyes spontaneously</td>
</tr>
<tr>
<td>3—Open eyes to command</td>
</tr>
<tr>
<td>2—Open eyes to pain</td>
</tr>
<tr>
<td>1—No eye opening</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BEST motor response</th>
</tr>
</thead>
<tbody>
<tr>
<td>6—Obeys commands</td>
</tr>
<tr>
<td>5—Localizes pain</td>
</tr>
<tr>
<td>4—Withdraws to pain</td>
</tr>
<tr>
<td>3—Decorticate posturing (abnl flexion)</td>
</tr>
<tr>
<td>2—Decerebrate posturing (abnl extension)</td>
</tr>
<tr>
<td>1—None (flaccid)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Verbal response</th>
</tr>
</thead>
<tbody>
<tr>
<td>5—Oriented, fluent speech</td>
</tr>
<tr>
<td>4—Confused conversation</td>
</tr>
<tr>
<td>3—Inappropriate words</td>
</tr>
<tr>
<td>2—Incomprehensible words</td>
</tr>
<tr>
<td>1—No speech</td>
</tr>
</tbody>
</table>

---

**HEAD TRAUMA**

**Background**

- Leading cause of traumatic D in pts <25
- 80% mild (GCS 14–15), 10% mod (GCS 9–13), 10% severe (GCS
<9) injuries
- CPP = MAP – ICP, poor outcome if CPP <70 mmHg, CPP constant when MAP b/w 50 & 160
- 1° brain injury: Mechanical, irreversible damage caused by mechanical cell damage
- 2° brain injury: Alteration in cerebral blood flow → cerebral ischemia, membrane disruption, cerebral edema, free radical generation

Approach
- Careful hx: Associated sx (photophobia, vomiting, visual Δ, ocular pain), focal neurologic sx
- Assess for head or neck trauma, medications, substance abuse
- Check fingerstick blood sugar to r/o hypoglycemia as cause for AMS
- Warning signs for neuroimaging: severe HA, vomiting, worsening over days, aggravated by exertion or Valsalva, neck stiffness, AMS, abnl neuro exam, peri- or retro-orbital pain

Skull Fractures

History
- Direct blow to the head, pt c/o pain

Findings
- Skull depression
- Basilar skull fx: Periorbital ecchymosis (raccoon eyes), retroauricular hematoma (Battle sign), otorrhea & rhinorrhea (CSF leak), 7th nerve palsy, hemotympanum

Evaluation
- Noncontrast head CT. CBC, Chem, coags, type & screen, tox screen; plain films not indicated
- CTA to eval for vascular injury if basilar skull fx present

Treatment & Disposition
- Airway management; management guided by underlying brain injury
- Linear skull fx: If no other IC injury may be observed 4–6 h & D/C
- Depressed skull fx: Admit to NSGY, surgical elevation if depressed skull fx > thickness of skull, update tetanus, give ppx abx & consider anticonvulsants
- Basilar skull fx: Admit to NSGY
**Pearl**
- GCS more indicative of underlying brain injury or hemorrhage

**Scalp Laceration**

**History**
- Direct blow to the head, direct bleeding from scalp

**Findings**
- Often blood has clotted upon ED arrival; has potential for large blood loss
- Blood loss may not be evident in ED, eval for blood loss in field

**Evaluation**
- Noncontrast head CT if indicated. CBC, Chem, coags, type & screen, tox screen if significant blood loss
- Thoroughly evaluate & explore skull for depressions & large lacerations

**Treatment**
- Hemostasis & irrigation: Wounds often contaminated despite rich blood supply, direct venous drainage into the venous sinuses can cause significant CNS infections
- Staples can be used if galea not involved
- Interrupted or vertical mattress sutures w/ 3-0 nylon or Prolene
- Galea must be repaired w/ absorbable sutures if lacerated; continued bleeding → subgaleal hematoma that often becomes infected

**Disposition**
- If no other injuries, can d/c. Otherwise admission & observation.

**Pearl**
- Abx not indicated for properly managed head wound unless gross contamination

---

**Head Injury Classifications**

<table>
<thead>
<tr>
<th></th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>GCS</td>
<td>14–15</td>
<td>9–13</td>
<td>&lt;9</td>
</tr>
<tr>
<td>Hx</td>
<td>Transient LOC, amnestic to event</td>
<td>LOC, amnestic to event</td>
<td>Pt unable to provide hx</td>
</tr>
<tr>
<td>Sxs</td>
<td>Mild HA, nausea</td>
<td>Confused or somnolent, often unable to follow commands</td>
<td>Obtunded, cannot follow simple commands</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------------------</td>
<td>--------------------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Head CT</td>
<td>Only if indicated (head CT rules); usually neg</td>
<td>All pts</td>
<td>All pts</td>
</tr>
<tr>
<td>Eval</td>
<td>Evaluate C-spine, no other testing needed</td>
<td>CBC, glucose, Chem, tox, coags, UA, hCG</td>
<td>CBC, glucose, Chem, tox, coags, UA, hCG</td>
</tr>
<tr>
<td>Tx</td>
<td>Observation w/ neuro checks, d/c w/ careful return instructions</td>
<td>24-h admission even if head CT neg, repeat CT if ↓ GCS, AMS</td>
<td>Intubation, NSGY eval, IVF, tight BP control (SBP &gt;90), treat ↑ ICP (mannitol, hypertonic NS, sz tx)</td>
</tr>
</tbody>
</table>

### Canadian Head CT Imaging Rule; Must Have Initial GCS 13–15

**Indications for CT Scan**
- GCS <15 at 2 h postinjury
- Suspected open or depressed skull fx
- Age >64
- Retrograde amnesia to event at >30 min
- Any sign of basilar skull fx
- 2 or more episodes of vomiting
- Dangerous mechanism

### Postconcussive Syndrome

**History**
- Closed head injury, ± LOC (brief); HA, memory problems, dizziness, etc. may last 6 wk

**Findings**
- nl neurologic exam, wide spectrum of mild neuro complaints

**Evaluation**
- Noncontrast CT shows no bleed but clinically insignificant SAH may have occurred

**Treatment**
Symptomatic HA control

Disposition
- D/c w/ careful head injury instructions
- Progressive return to full activity only after complete resolution of concussive sxs

Pearls
- Thought to be secondary to stretching of white matter fibers at time of injury
- 2nd head injury more dangerous than 1st

Intracerebral/Intraparenchymal Hemorrhage

History
- Depends on size & location of bleed

Findings
- Pts commonly c/o HA, N/V

Evaluation
- Noncontrast head CT; CBC, Chem, coags, type & screen

Treatment
- Airway management
- Emergent neurosurgical eval although most pts are managed nonoperatively; ICP monitor if significant bleed present
- Mannitol for ↑ ICP, anticonvulsant medication to all pts
- Reverse coagulopathy emergently w/ appropriate agent (Vit K vs. FFP vs. PCC vs. factor conc) depending on underlying cause of coagulopathy

Disposition
- Follow

Pearl
- Frontal lobe hematoma may cause disinhibition & personality Δ

Subarachnoid Hemorrhage (SAH)

History
- Pt c/o “worst HA of life”; acute onset & rapid progression, meningismus, vomiting, photophobia; can often pinpoint exact moment of onset
Spontaneous (ruptured cerebral aneurysm \(~75\%), AVM \(~10\%\)) or traumatic

**Findings**
- HA, N/V, sz, syncope, acute distress
- Acute AMS is indicative of large bleed, usually requires emergent intervention

**Evaluation**
- Noncontrast CT scan of head, ancillary studies (CBC, BMP, coags, T&S)
- Head CT 95–99% sens for acute SAH (w/i 6–24 h); perform LP if CT neg
- If concern for ruptured cerebral aneurysm, should also obtain CT angiogram
- Large # RBC in CSF highly suggestive of SAH
- RBCs are hemolyzed in CSF, may not be present in large numbers after 12 h or may not be present at all after 2 wk
- Xanthochromia highly suggestive of bleed b/w 12 h & 2 wk (yellow discoloration due to RBC breakdown)
- Check fingerstick blood sugar to R/O hypoglycemia as cause for AMS

**Treatment**
- Airway management if comatose or not protecting airway, neurosurgical consultatation
- ICP & BP monitoring if bleed is significant; a-line, elevate head of bed to 30°
- SPB b/w 90 & 140 mmHg, HR b/w 50 & 90 bpm, nicardipine or labetalol prn
- Mannitol for significant bleed w/ increased ICP
- Nimodipine to decrease vasospasm 60 mg PO q4h \(\times 21\) d
- Sz prophylaxis (phenytoin, Keppra)

**Disposition**
- To neurologic ICU

**Pearls**
- Outcome directly related to amount of intracranial blood
- 30–50% have “sentinel HA” days to weeks prior to SAH
### Clinical Findings of SAH

<table>
<thead>
<tr>
<th>Findings</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA</td>
<td>95–100%</td>
</tr>
<tr>
<td>Meningismus</td>
<td>Frequent</td>
</tr>
<tr>
<td>Transient LOC/syncope</td>
<td>50%</td>
</tr>
<tr>
<td>Retinal subhyaloid hemorrhage</td>
<td>6–30%</td>
</tr>
</tbody>
</table>

### Hunt–Hess Scale for SAH

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
<th>Percent Survival (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.</td>
<td>Asymptomatic or mild HA</td>
<td>70</td>
</tr>
<tr>
<td>II.</td>
<td>Mod-to-severe HA, nuchal rigidity, no neuro deficits or other CN palsy</td>
<td>60</td>
</tr>
<tr>
<td>III.</td>
<td>Confusion, drowsiness, mild focal signs</td>
<td>50</td>
</tr>
<tr>
<td>IV.</td>
<td>Stupor or hemiparesis</td>
<td>40</td>
</tr>
<tr>
<td>V.</td>
<td>Coma, moribund appearance, posturing</td>
<td>10</td>
</tr>
</tbody>
</table>

### Subdural Hematoma (SDH)

**History**
- Often caused by acceleration/deceleration tearing injury of bridging veins
- Can be acute (<48 h), subacute (2 d–3 wk) or chronic (>3 wk)

**Findings**
- Varied. Range from HA w/ nausea to comatose & flaccid

**Evaluation**
- Noncontrast head CT shows crescent-shaped mass. Check CBC, Chem, Coags, type & screen

**Treatment**
- Airway management, emergent neurosurgical eval
- If e/o ↑ ICP or midline shift, mannitol & anticonvulsant
- Reverse coagulopathy emergently w/ appropriate agent (Vit K, PCC, FFP, factor conc.)
Disposition
- Follow

Pearls
- More common than epidural hematoma
- Comatose & flaccid pts w/ SDH have an extremely poor prognosis, should discuss w/ family

**Epidural Hematoma**

**History**
- Brief LOC followed by “lucid interval,” then rapidly progressive deterioration
- Head injury usually in area of temporal bone, causes damage to middle meningeal artery

**Findings**
- Ipsilateral pupil deviation, occasionally contralateral hemiparesis, N/V, sz, hyperreflexia, + Babinski

**Evaluation**
- Noncontrast CT often shows lenticular biconcave mass, possible fx of temporal bone
- CBC, Chem, coag panel, type & screen

**Treatment**
- Airway management, emergent neurosurgical consultation
- Mannitol & anticonvulsant
- Reverse coagulopathy emergently w/ appropriate agent (Vit K, PCC, FFP, factor conc.)

**Disposition**
- Follow

**Pearl**
- Bleeding b/w the dura mater & skull

### Indications for Sz Prophylaxis

<table>
<thead>
<tr>
<th>Indications for Sz Prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depressed skull fractures</td>
</tr>
<tr>
<td>Paralyzed &amp; intubated, severe head injury</td>
</tr>
<tr>
<td>Sz at the time of injury or during ED presentation</td>
</tr>
</tbody>
</table>
Penetrating brain injury

<table>
<thead>
<tr>
<th>GCS ≤8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute SDH, EDH, or ICH</td>
</tr>
<tr>
<td>Hx of szs prior to injury</td>
</tr>
</tbody>
</table>

**Diffuse Axonal Injury (DAI)**

**History**
- Result of tremendous shearing forces seen in high-speed MVCs

**Findings**
- Pts often present in coma; document best neuro response: May have prognostic value

**Evaluation**
- Noncontrast CT often nl, must r/o bleed
- CBC, Chem, coag panel, type & screen, tox; look for other etiology for coma
- MRI (nonemergent) will show Δ & can guide prognosis

**Treatment**
- Airway management
- Emergent neurosurgical consultation for ICP monitor to avoid 2° injury from edema
- Mannitol & anticonvulsants

**Disposition**
- Follow

**Pearl**
- Prognosis determined by clinical course & difficult to predict

---

**MAXILLOFACIAL INJURY**

**Definition**
- Injuries to the soft tissue or bones of the face (50% caused by MVCs)

**Approach**
Inspection
- Deformities, enophthalmos (orbital blowout fracture), jaw malocclusion, dentition step-offs, nasal septal/auricular hematomas, rhinorrhea (CSF leak), trigeminal/facial nerve deficits, abnl EOM, diplopia, gross visual acuity

Palpation
- Facial prominences for tenderness/bony defects/crepitation/false motion, FB

Radiology
- Panoramic x-ray for mandibular/dental fractures, maxillofacial CT scan for most injuries, CTA in injuries at high risk for vascular trauma

Soft Tissue Injury
Definition
- Injury to the soft tissue of the face

History
- MVC/bites/assault

Evaluation
- CT only if bony injury/FB suspected

Treatment
- Irrigate/eval for FB/1° closure w/ in 24 h, abx (cefazolin, Ampicillin/Sulbactam, amoxicillin/clavulanate) for contaminated wounds (eg, bites), plastic surgery repair for nerve damage/extensive repair

Disposition
- Home

Septal/Auricular Hematomas
Definition
- Hematoma of nasal septum/ear

History
- Direct trauma to the nose (a/w nasal bone fractures)/ear (classically in wrestlers)
Physical Findings
- Swelling/purple discoloration

Treatment
- Septal: Apply topical anesthetic, incise/evacuate w/ elliptical incision, pack bilateral nares, abx (amoxicillin/clavulanate) (failure to drain → cartilage necrosis → saddle nose deformity)
- Auricular: Anesthetize area (lidocaine 1%) or auricular block, needle aspiration (chronic hematomas) or incise along skin folds, evacuate, apply compression dressing (failure to drain/compress → cauliflower ear/infection)

Disposition
- Home, f/u in 24 h

Nasal Fractures
Definition
- Fractures of the nasal bone

History
- Direct trauma to the nose

Physical Findings
- Swelling/deformity note: Patency of nares & appearance of septum

Evaluation
- CT only if significant deformity/persistent epistaxis/rhinorrhea

Disposition
- Isolated nasal fractures → Most home w/ plastic/ENT f/u in 5–7 d for reduction, consider reduction in ED if displaced, (pediatric pts → 3 d, ↑ risk for growth dysplasia)

Pearl
- Septal hematoma requires immediate I&D to prevent necrosis

Zygomatic Fracture
Definition
- Fractures of the zygomatic arch or fracture at the zygomatico-temporal suture/
  zygomatico-frontal suture/infraorbital foramen (tripod fracture)
History
- Direct trauma to face

Physical Findings
- Shallow depression over temporal region, trismus, edema, diplopia/vertical dystopia/infraorbital nerve anesthesia (tripod fracture)

Evaluation
- Maxillofacial CT

Treatment
- ENT/OMFS/Plastics consult

Disposition
- Home, ENT/OMFS/plastics f/u for delayed ORIF, sinus precautions

Mandibular Fractures

Definition
- Fracture of the mandible (>50% multiple fracture sites)

History
- Direct trauma to mandible (assaults usually = body/angle fractures, MVC usually = symphysis/condylar fractures)

Physical Findings
- Malocclusion, trismus, associated dental & lingual injury

Evaluation
- Panorex (isolated mandibular fractures): Can miss condylar fracture, maxillofacial CT (preferred): Condylar fractures/additional facial trauma

Treatment
- OMFS or plastic surgery consult: Temporary immobilization (wiring of jaw) or delayed ORIF, abx (PCN, clindamycin) if gingival bleeding

Disposition
- Home

Pearls
- Pts D/C w/ temporary wiring must be D/C w/ wire cutters
- Tongue blade test has high sens for mandibular fx
**Maxillary Fractures**

**Definition**
- Fracture of the maxilla, rare in isolation, a/w significant mechanism, greatest risk of airway compromise, traditionally classified by Le Fort system

**History**
- Significant mechanism trauma to the face (high-speed MVC)

**Physical Findings**
- Midface swelling/mobility, malocclusion of mandible, CSF rhinorrhea

**Evaluation**
- Maxillofacial CT
- CTA in Le Fort II & III should be strongly considered

**Treatment**
- Airway management (eval for difficult airway, Le Fort II/III highest risk), hemorrhage control (nasal packing/nasal Foley/elevation of head), abx (ceftriaxone) for CSF communication, ENT/OMFS consult

**Disposition**
- Admit

<table>
<thead>
<tr>
<th>Le Fort</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Involves only maxilla at level of nasal fossa; Free-floating jaw</td>
</tr>
<tr>
<td>II</td>
<td>Involves maxilla, nasal bones, &amp; medial aspects of the orbits &amp; is described as pyramidal Dysfxn</td>
</tr>
<tr>
<td>III</td>
<td>Involves the maxilla, zygoma, nasal bones, &amp; ethmoids. Extends through the maxillary sinuses &amp; infraorbital rims bilaterally across the bridge of the nose. Is described as craniofacial Dysfxn</td>
</tr>
</tbody>
</table>

**EYE INJURY**

**Definition**
- Injury to eye caused by trauma
Approach
- Assess visual acuity (use lid retractors if needed) & extraocular muscles (EOM), remove contact lenses

Orbital Fracture
Definition
- Fracture to the wall of the orbit (floor/medial wall most common)

History
- Blunt trauma to eye by object larger than the orbital rim

Physical Findings
- Periorbital swelling/crepitance, tenderness/irregularities to bony orbit, vertical diplopia/limited range of motion (ROM) w/ upward gaze (inferior rectus/inferior oblique entrapment), diplopia/limited ROM w/ lateral gaze (medius rectus entrapment), hypoesthesia of lower lid/cheek (infraorbital nerve entrapment), enophthalmos, ptosis

Evaluation
- Orbital CT (opacification of maxillary sinus = orbital floor fracture)

Treatment
- Abx (cover sinus flora), ophthalmology consult (rarely require surgery unless diplopia/entrapment) if any EOM entrapment or visual acuity Δ, “sinus precautions” (no nose blowing/sneezing, no sucking on straws/smoking)

Disposition
- Home

Pearls
- Orbital floor fractures are rare but a/w CNS trauma/infection
- Pts are at ↑ risk zygomatic tripod fractures/Le Fort II & III fractures

Globe Rupture
Definition
- Full-thickness defect in the cornea/sclera

History
- Blunt (most common at muscle insertion sites/corneoscleral junction) or penetrating (more common) trauma, decreased vision, pain
Physical Findings
- ↓ visual acuity, teardrop-shaped pupil, hyphema, + Seidel test (bright stream of aqueous humor after fluorescein) for corneal perforations, intraocular content extrusion, flattening of anterior chamber, oculocardiac reflex can cause bradycardia

Evaluation
- Orbital/head CT (for FB/intracranial injury), US—but must be careful to not apply pressure

Treatment
- Ophthalmology consult (for surgical repair), tetanus, abx (fluoroquinolones, vanc/gent), avoid pressure on eye/topical agents/Valsalva (antiemetics), protective shield

Disposition
- Admit

Chemical Burns
Definition
- Burns to sclera/conjunctiva/cornea/lid caused by alkali (oven cleaner, dish soap, detergents, cement, bleach) or acid (less severe)

History
- Chemical exposure, severe pain, FB sensation, photophobia

Physical Findings
- ↓ visual acuity, conjunctival injection, corneal edema, lens opacification, limbal blanching

Evaluation
- pH testing of effluent in fornixes

Treatment
- Topical anesthetics, irrigation (>2 L NS), use Morgan lens/manual retraction to keep eye open, check pH every 30 min until pH 7.3–7.7 & 10 min later, ↑ IOP treat like glaucoma, cycloplegics (cyclopentolate, tropicamide) if ciliary spasm, antibiotic ointment, ophthalmology consult for corneal haziness/perforation/conjunctival blanching

Disposition
- Admit for increased IOP/intractable pain, minor burns: f/u in 24 h

**Pearls**
- Hydrofluoric acid exposure: Administer 1% calcium gluconate drops during irrigation
- If no pH paper available can use urine dipstick, for nl pH compare to unaffected eye

**Retrobulbar Hematoma**

**Definition**
- Bleeding in the space surrounding the globe

**History**
- Blunt trauma, recent eye surgery, pain, vomiting, ↓ visual acuity

**Physical Findings**
- Afferent papillary defect, restricted EOM, ↑ IOP, proptosis, periorbital ecchymosis, subconjunctival hemorrhage

**Evaluation**
- Orbital CT

**Treatment**
- Immediate ophthalmology consult, treat ↑ IOP (timolol, acetazolamide), decompress w/ lateral canthotomy

**Disposition**
- Admit

**Retinal Detachment**

**Definition**
- Detachment of the retina

**History**
- Floaters/flashling lights, “mosca volante”—solitary large floater, ↑ IOP, visual loss (macula involvement)

**Physical Findings**
- Visual field deficit (curtain being pulled down), dilated retinal exam: Retinal tears/detachment

**Evaluation**
- β-scan u/s w/ undulating, hyperechoic membrane
**Hyphema**

**Definition**
- Accumulation of blood in the anterior chamber caused by rupture iris root vessel (trauma) or sickle cell/DM/anticoagulation

**History**
- Blunt or penetrating trauma to the globe, dull eye pain, photophobia

**Physical Findings**
- Microhyphemas: Visualized w/ slit lamp, larger hyphemas:
  - Visualized w/ tangential pen light, total hyphema (high association w/ globe rupture): ↑ IOP

**Evaluation**
- INR if on Coumadin
- If any FH of hemoglobinopathy pt should be screened

**Treatment**
- Immediate ophthalmology consult for >10%/↑ IOP, treat ↑ IOP (timolol, acetazolamide), metal eye shield, cycloplegics (cyclopentolate, tropicamide) if ciliary spasm
- HOB >45% (upright allows blood to settle in anterior chamber/avoid retinal staining)
- Topical anesthesia if no globe rupture, PO/IV analgesia
- Topical steroids may help prevent rebleeding & synechiae

**Disposition**
- Admit for >50%, ↑ IOP, coagulopathy or sick cell
- Urgent ophthalmology f/u

**Pearls**
- Sickle cell: Avoid acetazolamide/pilocarpine/hyperosmotic, ↑ risk of rapid ↑ IOP → optic nerve injury
- Avoid ASA/NSAIDs 2/2 ↑ rebleed risk
10% rebleed (usually more severe) in 2–5 d

**Vitreous Hemorrhage**

**Definition**
- Blood in the vitreous humor

**History**
- Blunt trauma, floaters, blurry vision, vision loss, sickle cell/DM

**Physical Findings**
- Loss of light reflex, poorly visualized fundus

**Evaluation**
- β-scan u/s: For associated retinal detachment
- Consider noncontrast CTH if a/w trauma

**Treatment**
- Immediate ophthalmology consult, HOB >45%, bed rest

**Disposition**
- Admit if retinal tear/unknown cause

**Pearl**
- Avoid ASA/NSAIDs b/c ↑ risk rebleed

**Subconjunctival Hemorrhage**

**Definition**
- Hemorrhage b/w the conjunctiva & sclera caused by trauma, Valsalva (coughing/straining/vomiting), HTN, coagulopathy

**History**
- Painless red eye

**Physical Findings**
- Blood b/w the conjunctiva & sclera

**Treatment**
- BP control, avoid Valsalva, avoid ASA/NSAIDs, artificial tears for comfort

**Disposition**
- Home, ophthalmology f/u in 1 wk

**Pearls**
Resolution in 2 wk
• Blood chemosis (large/circumferential) ↑ risk globe rupture

NECK TRAUMA

Definition
• Injuries soft tissue & structures of the neck

Approach
• Evaluate 3 main categories: vascular, pharyngoesophageal, laryngotracheal (do not place NGT if esophageal/laryngeal injury suspected)

Inspection
• Violation of platysma (↑ incidence of underlying structure injury, may indicate need for surgical exploration) (Trauma 1979;19:391), pulsatile/expanding hematomas

Penetrating Trauma Zones
• Anterior triangle: Bordered by anterior SCM, midline, mandible. Posterior: Posterior to SCM, anterior to trapezius, superior to clavicle, most significant structures are anterior
• Zone I: Below cricoid cartilage (highest mortality), Zone II: B/w cricoid & angle of mandible, Zone III: Above angle of mandible

<table>
<thead>
<tr>
<th>Injury</th>
<th>Imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular</td>
<td>Unstable → OR for exploration/angiography</td>
</tr>
<tr>
<td></td>
<td>Zone I &amp; III → CTA/angiography (high incidence of vascular injury)</td>
</tr>
<tr>
<td></td>
<td>Zone II → CTA or exploration in OR</td>
</tr>
<tr>
<td>Pharyngoesophageal</td>
<td>CTA, Gastrografin/barium swallow study, endoscopy</td>
</tr>
<tr>
<td>Laryngotracheal</td>
<td>Unstable → bronchoscopy in OR</td>
</tr>
<tr>
<td></td>
<td>Stable → CT scan (sens for detecting glottic/cartilaginous injury)</td>
</tr>
</tbody>
</table>

Penetrating Neck Trauma
Definition
• Injury to the neck from GSW, stabbings, projectile objects
Physical Findings
- Laryngotracheal injuries may have stridor, respiratory distress, hemoptysis, SQ air, dysphonia
- Esophageal injuries may have dysphagia, hematemesis, SQ air
- Vascular injuries may have neuro deficits, expanding/pulsatile hematoma/bleeding, bruit/thrill, hypotension

Evaluation
- CXR/(ptx/htx), lateral neck x-ray in trauma bay, CT, CTA
- Trauma labs: CBC, BMP, type & cross, PTT/PT, ABG

Treatment
- Airway management (may be difficult airway), surgical consultation if platysma violation, abx (if ↑ risk contamination from aerodigestive perforation)
- Treat as trauma resuscitation (ABCs, transfusion, etc.)

Disposition
- Admit if surgical intervention/observation needed

Pearl
- Arrest due to penetrating neck trauma is indication for ED thoracotomy

Strangulation

Definition
- Neck trauma due to strangulation (3500 D/y)

History
- Strangulation, voice Δ, attempt to obtain “height of drop” from EMS

Physical Findings
- Dysphonia/dyspnea (indicators serious injury), petechial hemorrhages (Tardieu spots), ligature/finger marks, neuro deficits/coma

Treatment
- Airway management (may be difficult airway), surgical consultation (if needed), consider CTA, abx (if ↑ risk contamination from aerodigestive perforation)
Disposition
- Admit if needed

Pearls
- ↑ incidence of ARDS & long-term neuropsychiatric sequelae (selective vulnerability of hippocampus to anoxic injury)
- Self-inflicted hanging rarely a/w C-spine injury, see Hangman fracture (Chapter 18)

CERVICAL SPINE TRAUMA

Definition
- Injury to the bony/ligamentous structure of the cervical spine (C2 24%, C6 20%, C7 19%)

Approach
- Maintain C-spine immobilization until cleared clinically w/o imaging (see table) or radiographically

Palpation
- Midline cervical tenderness, step-offs, neurologic deficits

Radiology
- Plain c-spine x-rays: 52% sens (limited use), C-spine CT: 98% sens → persistent midline tenderness/obtunded → Flex/ex films: 94% sens for ligamentous injury if adequate ROM (30° flexion/extension), MRI: 98% sens for ligamentous injury (J Trauma 58(5):902; 53(3):426)

<table>
<thead>
<tr>
<th>Cervical Spine Clearance</th>
<th>NEXUS Low-risk Criteria</th>
<th>Canadian Cervical Spine Rule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 16</td>
<td>No posterior midline tenderness</td>
<td></td>
</tr>
<tr>
<td>GCS 15</td>
<td>No focal neurologic deficits</td>
<td></td>
</tr>
<tr>
<td>nl VS (RR 10–14, SBP &gt; 90 mmHg)</td>
<td>nl alertness</td>
<td></td>
</tr>
<tr>
<td>Injury w/i 48 h</td>
<td>No intoxication</td>
<td></td>
</tr>
<tr>
<td>Blunt trauma</td>
<td>No painful distracting injury (long bone fracture, visceral injury, large laceration, degloving, burns, injury causing functional impairment)</td>
<td></td>
</tr>
<tr>
<td>No paralysis/paresthesia</td>
<td>Not evaluated previously for same injury</td>
<td></td>
</tr>
<tr>
<td>Not pregnant</td>
<td>Not pregnant</td>
<td></td>
</tr>
</tbody>
</table>
Not high risk (<65 y/o, dangerous mechanism: MVC rollover/ejection/>62 mph, fall from ≥3 ft, bicycle accident)
Presence of ≥1 low risk finding (simple rear-end MVC, sitting position in ED, ambulatory after trauma, delayed onset neck pain, no midline tenderness)
Able to rotate neck 45% L & R

| 99.6% sens, 12.9% spec for significant C-spine injury | 99.4% sens, 45.1 spec for significant C-spine injury |

*(NEJM 2000;342:94; 2003;349:2510)*

### C1 Burst Fracture (Jefferson Fracture)

**Definition**
- Unstable burst fracture of atlas (C1) causing widening of lateral masses (33% a/w C2 fracture)

**History**
- Axial load

**Physical Findings**
- C1 tenderness, neurologic deficit rare (wide canal at C1)

**Evaluation**
- CT/CTA, MRI for ligamentous injury

**Treatment**
- C-spine immobilization, spine consult for operative management

**Disposition**
- Admit

### C2 Hangman Fracture

**Definition**
- Unstable fracture of bilateral C2 pedicles (↑ risk of C2 anterior subluxation/C2–C3 disk rupture → high mortality)

**History**
- Hyperextension
- Named due to judicial hangings in which knot is in front of pt & “height of drop” is at least as long as victim
Physical Findings
- C2 tenderness, high-impact trauma, neurologic deficits

Evaluation
- CT/CTA, MRI for ligamentous injury

Treatment
- C-spine immobilization, spine consult for operative management

Disposition
- Admit

Odontoid Fracture (C2 Dens)

Definition
- Fracture through the dens w/ variable stability (see table)

History
- Flexion injury

Physical Findings
- C2 tenderness

Evaluation
- CT scan, MRI for ligamentous injury

Treatment
- C-spine immobilization, spine consult

Disposition
- Likely admit

<table>
<thead>
<tr>
<th>Dens Fracture Classification</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type I</td>
<td>Avulsion fracture through upper part of odontoid process</td>
</tr>
<tr>
<td></td>
<td>Stable &amp; does not require surgical intervention</td>
</tr>
<tr>
<td>Type II</td>
<td>Fracture at the junction of the odontoid process w/ the vertebral body</td>
</tr>
<tr>
<td></td>
<td>Potentially unstable fracture</td>
</tr>
<tr>
<td></td>
<td>Nondisplaced: Halo often used to treat</td>
</tr>
<tr>
<td></td>
<td>Displaced/angulated: Surgery often performed</td>
</tr>
<tr>
<td>Type III</td>
<td>Fracture at base of odontoid that extends down into body of atlas</td>
</tr>
<tr>
<td></td>
<td>Immobilize w/ halo, does not usually require surgical intervention</td>
</tr>
</tbody>
</table>
Tear Drop Fracture

Definition
- Unstable avulsion of cervical vertebral body at insertion of anterior ligament in extension injury (C2 common) or posterior in flexion injury (C5–C6)

History
- Flexion (MVC, diving in pool) or extension (elderly fall on chin)

Physical Findings
- C-spine tenderness, anterior cord syndrome (flexion), central cord syndrome (extension)

Evaluation
- CT/CTA, MRI for ligamentous injury

Treatment
- C-spine immobilization, spine consult

Disposition
- Admit

Clay Shoveler Fracture

Definition
- Stable avulsion fracture of spinous process (most common in low C-spine, >C6)

History
- Forceful flexion (as when clay sticks to a shovel when trying to throw it)

Physical Findings
- C-spine tenderness, no neurologic deficits

Evaluation
- CT scan

Treatment
- C-spine immobilization, spine consult

Disposition
- D/c
Subluxation/Ligamentous Injury

Definition
- Unstable rupture of ligaments w/o bony injury, anterior slipping of vertebrae one over the other

History
- Flexion

Physical Findings
- C-spine tenderness, no neurologic deficits

Evaluation
- CT/CTA scan, MRI

Treatment
- C-spine immobilization, spine consult

Disposition
- May require admission

---

THORACIC/LUMBAR/SACRAL SPINE TRAUMA

Definition
- Injury to the bony/ligamentous structure TLS spine

Approach
- Maintain logroll precautions
- Palpation: Spinal tenderness, step-offs, neurologic deficits

Anterior Wedge/Compression Fracture

Definition
- Stable compression fracture of the vertebral body (wedge → only anterosuperior vertebral body endplate). May be unstable if >50% height loss of vertebral body

History
- Flexion

Physical Findings
- Focal tenderness, no neurologic deficits

**Evaluation**
- CT scan

**Treatment**
- Spine consult

**Disposition**
- D/c if pain controlled

**Burst Fracture**

**Definition**
- Stable compression fracture of anterior & posterior vertebral body
  (may be complicated by retropulsed bony fragments → cord injury)

**History**
- Axial load/vertical compression

**Physical Findings**
- Focal tenderness, ± neurologic deficit

**Evaluation**
- CT scan

**Treatment**
- Spine consult, bracing/orthosis

**Disposition**
- Likely admit

**Chance Fracture**

**Definition**
- Often stable fracture through the vertebra, can also include
  body/pedicles/laminae

**History**
- Back pain after head-on MVC when wearing only a lap belt from
  flexion injury

**Physical Findings**
- Focal tenderness, rare neurologic deficit

**Evaluation**
Sacral Fracture

Definition
- Fractures of the sacrum (may be a/w pelvic fractures in above S4)

History
- Buttock/perirectal/posterior thigh pain after direct trauma to sacrum (fall or force from behind)

Physical Findings
- Focal tenderness, neurologic deficits (above S4), careful eval for cauda equina

Evaluation
- CT scan

Treatment
- Spine consult

Disposition
- Admit
- D/c if isolated & stable

Anterior Cord Syndrome

Definition
- Injury to the anterior cord from blunt or ischemic injury

History
- Flexion/axial load (major trauma), minor trauma (arthritis/spinal stenosis/OA/spinal cord pathology)

Physical Findings
- Bilateral loss of motor/pain/temperature sensation, dorsal column intact (proprioception/vibratory sense) (See Sensory & Motor deficit tables)

Evaluation
Central Cord Syndrome
Definition
- Trauma to central cord → injury of corticospinal motor tracts of UE > tracts of LE (buckling of ligamentum flavum)

History
- Hyperextension of neck, hx of elderly, arthritis, OA, spinal stenosis

Physical Findings
- Loss of motor fn in UE >LE, variable sensory loss (See Sensory & Motor deficit tables), loss of pain & temperature if nontraumatic

Evaluation
- MRI

Brown–Sequard Syndrome (Lateral Cord Syndrome)
Definition
- Hemicord transection from penetrating trauma

History
- Penetrating trauma

Physical Findings
- Ipsilateral motor/propríoception/vibration loss, contralateral pain/temperature sensation loss, deficits occur 2 levels below lesion

Evaluation
- MRI

Treatment
- MRI

Spine consult
- Admit
Spinal Shock

Definition
• Loss of vascular tone caused by cord trauma lasting 24–48 h, rarely can last several weeks

History
• Spinal cord trauma

Physical Findings
• Hypotension, bradycardia, flaccid paralysis, hyporeflexia

Treatment
• Phenylephrine (Neosynephrine peripheral alpha agonist) for BP support

Disposition
• Admit

Pearls
• There is NO evidence to support the administration of steroids in
spinal trauma

- SCIWORA (spinal cord injury w/o radiologic abnl): In pediatric pts, if focal tenderness/neurologic deficits → treat as cord injury regardless of imaging

---

THORACIC TRAUMA

Definition

- Injuries to the thorax & its structures caused by penetrating or blunt trauma (25% all trauma Ds; immediate: heart/great vessel injury, early: Airway obstruction/tamponade/tension PTX, Late: PNA/PE)

Approach

- Evaluate anatomical categories although many injuries do not occur in isolation: Cardiac/vascular, pulmonary, skeletal, esophageal, diaphragmatic

Inspection

- External trauma: Open wounds (do not probe wounds: Clot dislodgement → hemorrhage), exit/entrance wounds, flail segments (may require external fixation or PPV), seat belt marks, impaled objects (stabilization → removal in OR)

Palpation

- Crepitance (PTX), unequal pulses (vascular trauma, mediastinal hematoma), wounds below nipple line/tip of scapula ↑ risk abd trauma (25% have both intra-abd + thoracic trauma) (J Trauma 1998;45:87)

Radiology

- See table

Thoracotomy

- Blunt Traumatic Arrest
  - CPR >10 min, do not perform
  - CPR <10 min or profound refractory shock
- Penetrating Trauma Arrest
  - CPR >15 min, do not perform
• CPR <15 min or profound refractory shock or CPR <5 min penetrating neck or extremity trauma
  • Do not transport pt only if pulseless & no electrical cardiac activity in field
  • Survival rate in pt w/ arrest from blunt trauma 1.6%, survival rate for arrest from penetrating trauma w/ some signs of life is 31.1% (J Trauma Acute Care Surg 2012;73(6):1359)

<table>
<thead>
<tr>
<th>Thoracic Trauma</th>
<th>General Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blunt trauma</td>
<td>If e/o thoracic trauma exists: CXR, chest CT</td>
</tr>
<tr>
<td>Penetrating trauma—traverses mediastinum</td>
<td>Agonal: Thoracotomy</td>
</tr>
<tr>
<td></td>
<td>Unstable: Place bilateral chest tubes</td>
</tr>
<tr>
<td></td>
<td>Stable: CXR, chest CTA, esophagoscopy, bronchoscopy</td>
</tr>
<tr>
<td>Penetrating trauma—does not traverse mediastinum</td>
<td>CXR &amp;/or chest CT for intrathoracic or extrathoracic injury</td>
</tr>
</tbody>
</table>

**Traumatic Aortic Rupture**

**Definition**

› Traumatic rupture of the aorta (descending aorta → fixed to thorax) caused by deceleration injury (fall from height, high-speed MVC, T-boned MVC)

**History**

› Retrosternal/intrascapular pain (80% die immediately)

**Physical Findings**

› Exam has poor sens for detecting injury, must have high index of suspicion w/ high mechanism
› Hypotension, asymmetric pulses/BP

**Evaluation**

› CXR (>8 cm widening of mediastinum, esophageal/trachea deviation, loss of aortic knob/aortopulmonary window, L apical cap, fractures of 1st rib/2nd rib/sternum, widening of paravertebral strip), CTA, TEE

**Treatment**
BP control (labetalol/esmolol/nitroprusside): Allow permissive hypotension (SBP 70–90), surgical consult

Disposition
- Admit

Pearl
- 90% who survive have contained hematoma near ligamentum arteriosum
- nl CXR does not rule out aortic injury

Pneumothorax

Definition
- Air in the plural space (simple: w/o shift/communicating w/ outside air, tension: Injury acts as one-way valve/increased intrapleural pressures, open: wall deficit/collapse on inspiration/expansion on expiration/ineffective ventilation)

History
- Blunt (simple) or penetrating (tension/open) trauma

Physical Findings
- Decreased BS, hyperresonance, tension: Tracheal deviation/neck vein distension/hypotension, open: Chest wound w/ “sucking”

Evaluation
- US, CXR (treat tension PTX prior to imaging), chest CT

Treatment
- 100% O₂
- Tension: Needle decompression (large-bore needle/IV catheter → 2nd intercostal space, midclavicular line), chest tube to 4th–5th intercostal space mid/anterior axillary line
- Open: Sterile occlusive dressing to taped down on 3 sides → allows efflux/not influx of air, chest tube
- Simple: <10% → serial CXR, mod/large → chest tube directed anteriorly/serial CXR
- Occult: No tx other than O₂
- PPx abx indicated in tube thoracostomy in setting of trauma (World J Surg 2006;30:1843)
Disposition
- Admit

Pearl
- Chest tube must be placed if mechanical ventilation required

Hemothorax
Definition
- Blood in the plural space, most common from lung lacerations

History
- Blunt/penetrating trauma

Physical Findings
- Pain, decreased BS, dullness to percussion

Evaluation
- CXR: Costophrenic angle blunting (upright)/diffuse haziness (supine), US, chest CT

Treatment
- Large-bore chest tube directed inferiorly, surgical consult → OR if >1.5 L bloody output initially (>20 mL/kg)/>200 cc/h (>3 mL/kg/h) or if unstable (↑ likelihood of injury to intercostal/internal mammary/hilar vessels)
- PPx abx indicated in tube thoracostomy in setting of trauma

Pearl
- ~300 cc needed to see hemothorax on CXR

Disposition
- Admit

Flail Chest
Definition
- Fracture >3 or more ribs in 2 or more places → discontinuous segment of chest wall → paradoxical movement w/ respiration (5% of thoracic trauma)

History
- Blunt trauma, SOB

Physical Findings
Respiratory distress, tenderness, crepitus, paradoxical movement of chest wall

**Evaluation**
- CXR

**Treatment**
- External stabilization (pillow), CPAP (1st line if poor oxygenation/ventilation in awake/cooperative pt → lower mortality/PNA rates vs. intubation) ([EMJ](https://www.journals.co.uk/EMJ) 22(5):325), ± chest tube placement, pain control (rib block catheter/epidural is best), intubate only if necessary (obtunded, airway obstruction, respiratory distress)

**Disposition**
- Admit

**Pearl**
- 35–50% mortality → related to underlying injuries & cx (pulmonary contusions, PNA)

**Pulmonary Contusion**

**Definition**
- Injury to lung parenchyma → hemorrhage/edema → V/Q mismatch

**History**
- Blunt trauma, SOB

**Physical Findings**
- Respiratory distress, tenderness, tachypnea, tachycardia, hemoptysis, hypoxia ↑ 1–2 d/resolve 7 d

**Evaluation**
- CXR: May be nl initially, bilateral alveolar infiltrates

**Treatment**
- Restrict IVF goal euvolemia, intubate if needed

**Disposition**
- Admit

**Cardiac Tamponade**

**Definition**
- Hemopericardium → constriction of the heart → decreased CO,
most commonly due to penetrating injury (rarely blunt trauma)

**History**
- Penetrating trauma

**Physical Findings**
- Beck triad (hypotension/JVD/muffled heart sounds), tachycardia, pulsus paradoxus

**Evaluation**
- Bedside/formal US: Pericardial effusion/diastolic collapse of RA/RV, ECG: Low voltage/electrical alternans, CXR: Usually unremarkable

**Treatment**
- Aggressive IVF (preload dependent)
- Hypotension + pericardial effusion → OR/pericardiocentesis (blood usually clotted, if fresh may be in RV)
- Arrest → thoracotomy

**Disposition**
- Admit

**Pearl**
- JVD is rare in trauma pts given hypovolemia

**Cardiac Contusion**

**Definition**
- Contusion of the myocardium/coronary vessels/valves/septum

**History**
- Blunt trauma

**Physical Findings**
- Tachycardia, hypotension

**Evaluation**
**ECG:** New BBB, dysrhythmias (rare after 1st 24 h), ST Δ/conduction abnl/RV Dysfxn, ± cardiac enzymes (poor sens, levels not predictive of outcome)

**Treatment**
- IV fluid resuscitation (RV damage → preload dependence), see table
Disposition
- Admit to Tele

Pearl
- New ECG Δ consider 1° cardiac event → trauma

<table>
<thead>
<tr>
<th>Cardiac Contusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic, no ECG Δ, no dysrhythmias</td>
</tr>
<tr>
<td>Can be D/C home</td>
</tr>
<tr>
<td>ECG Δ or dysrhythmia in HD stable pt</td>
</tr>
<tr>
<td>24 h of cardiac monitoring</td>
</tr>
<tr>
<td>ECG Δ or dysrhythmia in HD unstable pt</td>
</tr>
<tr>
<td>Echo ± cardiology consult</td>
</tr>
<tr>
<td>Life-threatening dysrhythmias</td>
</tr>
<tr>
<td>ACLS guidelines</td>
</tr>
</tbody>
</table>

**Esophageal Injury**

**Definition**
- Injury to the esophagus most commonly from penetrating trauma (possible w/ significant epigastric blunt trauma)

**History**
- Penetrating trauma

**Physical Findings**
- Respiratory distress, neck/chest crepitus, hematemesis
- Often will have severe other injuries in blunt trauma

**Evaluation**
- CXR: Mediastinal/deep cervical air, neck films: Esophageal + laryngeal injury → air column in the esophagus, flexible esophagoscopy + esophagram (90% sens), CT

**Treatment**
- Surgical consult for operative management, broad-spectrum abx

**Disposition**
- Admit

**Tracheobronchial Tear**

**Definition**
- Tear to trachea/bronchus, most commonly due to penetrating trauma
History
- Penetrating trauma or severe deceleration injury, often die at scene

Physical Findings
- Crepitance, large persistent air leak or recurrent ptx after chest tube placement (if cervical injury may not have air leak)

Evaluation
- CXR: PTX/pneumomediastinum/“fallen lung sign,” chest CT, bronchoscopy (gold standard, may miss injuries >2 cm above carina)

Treatment
- Fiberoptic intubation (in major bronchial lesions → consider double lumen ETT), chest tube placement (may require >1 chest tube)

Disposition
- Admit

Pearl
- May p/w difficulty passing ETT/difficulty w/ ventilation after ETT intubation

ABDOMINAL TRAUMA

Definition
- Trauma to the abdomen & its structures

Approach

Evaluate 4 Main Areas
- Anterior abdomen: nipple line → inguinal ligaments/pubic symphysis → anterior axillary line, Flank: B/w anterior & posterior axillary lines from 6th rib → iliac crest, Back: Inf scapular tips → iliac crest, gluteal region: Iliac crest → gluteal fold

Inspection
- Entrance/exit wounds (check b/w buttock/thigh/axilla/neck), seat belt sign (↑ risk mesenteric tear/avulsion, bowel perforation, aorta/iliac thrombosis, chance fracture of L1/L2), do not remove objects, cover
eviscerated organs in saline soaked gauze

**Palpation**
- Peritoneal signs (operative management), rectal exam (high-riding prostate/blood/tone)

**Labs**
- CBC (Hct may be nl initially in setting of hemorrhage), ABG, lactate, LFTs, lipase, UA

**Radiology**
- FAST (90–100% sens for hemoperitoneum, not spec), CXR (abd free air), pelvic x-ray (loss of psoas shadow → retroperitoneal injury, location of bullets), CT (definitive test, low sens for early pancreatic/diaphragmatic/bowel injury)

**Diagnostic Peritoneal Lavage (DPL)**
- Rarely used given FAST/CT scans, positive study → >10 cc gross blood or enteric contents, blunt trauma >100000 RBCs, penetrating trauma >5000–10000 RBC

**Liver Laceration**

**Definition**
- Laceration to liver (most commonly injured organ)

**History**
- Blunt or penetrating trauma

**Physical Findings**
- ± RUQ tenderness

**Evaluation**
- LFTs, HCT, FAST, CT scan: Grading of laceration (I–VI)

**Treatment**
- Surgical consultation for operative vs. conservative management (HD stable, serial exams/HCT)

**Disposition**
- Admit ICU vs. floor

<table>
<thead>
<tr>
<th>Approach to Abd Trauma</th>
<th>Most Common</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Abd Trauma</th>
<th>Examples</th>
<th>Injuries</th>
<th>General Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blunt trauma</td>
<td>Motor vehicle crash, falls, assaults</td>
<td>Spleen, liver, intestine, kidney</td>
<td>Unstable + distention → OR Unstable → FAST Stable → CT (IV contrast only), FAST, or serial abd exams</td>
</tr>
<tr>
<td>Penetrating trauma—</td>
<td>GSW, SW</td>
<td>Small bowel, colon, liver, &amp; vascular structures (GSW); liver, small bowel, diaphragm</td>
<td>GSW to anterior abdomen → OR Unstable w/ non-GSW trauma → OR Stable w/ non-GSW trauma → local wound exploration, CT</td>
</tr>
<tr>
<td>anterior abdomen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penetrating trauma—</td>
<td>GSW, SW</td>
<td></td>
<td>Unstable → OR. Stable GSW → triple contrast (IV, PO, PR) Stable non-GSWs → local wound exploration, CT, serial exams</td>
</tr>
<tr>
<td>flank &amp; back</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
(1) 1° objective is to identify need for surgical exploration.
(2) Peritoneal irritation often seen w/ hollow viscus injury, but not w/ hemoperitoneum.
(3) If fascia penetration is found, f/u w/ DPL, CT, or ex lap. If not pt can be D/C after wound care.
(4) Intra-abd organ injury occurs in 20% of non-GSW flank injuries & 5–10% of non-GSW back injuries.

**Splenic Laceration**

**Definition**
- Laceration to spleen (most commonly injured organ in blunt trauma)

**History**
- Blunt or penetrating trauma, L shoulder pain (Kehr sign)/chest/flank/upper quadrant pain

**Physical Findings**
LUQ pain

**Evaluation**
- FAST, CT scan: Grading of laceration (I–V)

**Treatment**
- Surgical consultation for operative vs. conservative management (HD stable, serial exams/HCT), IR for embolization

**Disposition**
- Admit ICU vs. floor

### Splenic Laceration Grading

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade I</td>
<td>Subcapsular hematoma &lt;10% surface area, capsular tear &lt;1 cm depth</td>
</tr>
<tr>
<td>Grade II</td>
<td>Subcapsular hematoma 10–50%, intraparenchymal hematoma &lt;5 cm diameter, parenchymal laceration 1–3 cm not involving vessels</td>
</tr>
<tr>
<td>Grade III</td>
<td>Subcapsular hematoma &gt;50% or expanding, ruptured subcapsular/intraparenchymal hematoma, intraparenchymal hematoma &gt;5 cm, splenic laceration &gt;3 cm/involving trabecular vessels</td>
</tr>
<tr>
<td>Grade IV</td>
<td>Laceration of segmental or hilar vessels → devascularization of &gt;25%</td>
</tr>
<tr>
<td>Grade V</td>
<td>Shattered spleen, hilar vascular injury → complete devascularization</td>
</tr>
</tbody>
</table>

### Small Bowel Injury

**Definition**
- Injury to small bowel (GSW > SW > blunt trauma)

**History**
- Blunt or penetrating trauma, classically handlebar injury

**Physical Findings**
- Seat belt sign (MVC), peritoneal signs (may be delayed)

**Evaluation**
- Unstable → FAST/DPL, Stable → CT scan (low sens, fluid collection/bowel-wall thickening/stranding/free air) CXR (rarely shows free air), Lumbar XR (Chance fracture)

**Treatment**
Colorectal Injury

Definition
- Injury to colon or rectum (transverse colon most common)

History
- Penetrating trauma (GSW)

Physical Findings
- Hypoactive bowels, peritoneal signs, gross rectal blood

Evaluation
- Triple contrast CT scan (Gastrografin, barium is irritating), KUB (air lining psoas), f/u sigmoidoscopy

Treatment
- Surgical consultation for operative management (perforation or devascularization), abx (ampicillin/ciprofloxacin/metronidazole)

Disposition
- Admit

Duodenal Injury

Definition
- Injury to duodenum (80% a/w other injury)

History
- Penetrating trauma, N/V (obstructing hematoma)

Physical Findings
- Epigastric tenderness, heme positive stool, bloody NGT aspirate

Evaluation
- Upright CXR (free air), CT scan (duodenal wall hematoma), Upper GI (“coiled spring” area)

Treatment
- Surgical consultation for operative management (perforation or
devascularization), abx (ampicillin/ciprofloxacin/metronidazole), NGT placement

Disposition
- Admit

Pearls
- 2nd portion most commonly injured (contains bile/pancreatic duct openings)
- Mortality 40% if dx delayed 24 h

Gastric Injury

Definition
- Injury to stomach, uncommon

History
- Penetrating trauma

Physical Findings
- Epigastric tenderness, heme positive stool, bloody NGT aspirate

Evaluation
- Upright CXR (free air)

Treatment
- Surgical consultation for operative management, abx (ampicillin/ciprofloxacin/metronidazole)

Disposition
- Admit

Pancreatic Injury

Definition
- Injury to pancreas (75% penetrating trauma)

History
- Penetrating trauma, direct epigastric trauma (steering wheel, bicycle handles)

Physical Findings
- Minimal epigastric tenderness (retroperitoneal structure)

Evaluation
CT scan (low sens early), lipase (may be nl), ERCP for ductal injury

**Treatment**
- Surgical consultation

**Disposition**
- Admit

**Pearl**
- A/w other injuries 90% of the time

**Vascular Trauma**

**Definition**
- Injury to abd vasculature (10% of SW, 25% of GSW)

**History**
- Penetrating trauma

**Physical Findings**
- Distension, expanding hematoma, Grey–Turner sign (flank ecchymosis)/Cullen sign (periumbilical ecchymosis) → retroperitoneal hemorrhage

**Evaluation**
- FAST, CT scan (if stable), wound exploration

**Treatment**
- Surgical consultation, unstable → OR

**Disposition**
- Admit

**Pearl**
- Avoid LE venous access

**Diaphragmatic Tear**

**Definition**
- Tear to diaphragm from blunt trauma, ↑ lateral impact (large, L-sided 2–3× more likely than R, posterolaterally located) or penetrating trauma (small but enlarge w/ time)

**History**
- Penetrating/blunt trauma, delayed presentation; pain, ± obstruction
Physical Findings
- BS over chest

Evaluation
- CXR (50% sens): Hemothorax/PTX (penetrating), abnl diaphragmatic shadow (blunt), US, CT scan, careful NGT placement (may be seen in hemithorax)

Treatment
- Respiratory distress → NGT placement for decompression, surgery consult for operative repair. CXR may be misinterpreted as hemothorax, avoid chest tube placement

Disposition
- Admit

Pearl
- Intrapericardial diaphragmatic rupture/bowel herniation → tamponade

GENITOURINARY TRAUMA

Definition
- Trauma to the structures of the genitourinary tract, uncommon to be life-threat unless significant renal/vascular injury

Approach

Inspection
- Blood at meatus (urethra trauma), blood in vagina, perineal lacerations (do not probe → hemorrhage), scrotal ecchymosis/lacerations, flank bruising

Palpation
- Rectal exam (high-riding prostate/boggy → membranous urethral injury, blood → rectal laceration), testicular disruption

Labs
- UA (microscopic hematuria → no eval, gross blood → serious GU trauma)
**Radiology**

- **RUG:** Males w/ blood at meatus before Foley placement (to prevent full urethral tear/false passage), inject 50 cc contrast into urethra → pelvic x-ray for extravasation
- **Cystogram:** Instill 400–500 cc contrast into bladder via Foley → AP film or CT scan → repeat image after contrast is washed out (posterior bladder tears)
- **IV pyelogram:** Rarely indicated
- **CT scan (IV contrast):** Complete eval of kidneys

**Renal Laceration**

**Definition**

- Laceration to kidney (major: Extend to medulla/collecting system, minor: No involvement of collecting system/medulla, no extraversion of urine, pedicle: injury to renal vasculature)

**History**

- Penetrating trauma

**Physical Findings**

- Flank wound, gross hematuria, ± hypotension

**Evaluation**

- CBC, UA, other trauma labs as needed, CT scan: Eval extent of injury

**Treatment**

- Surgery consult, minor lacerations may be nonoperative

**Disposition**

- Admit

**Renal Contusion**

**Definition**

- Contusion to kidney

**History**

- Blunt trauma

**Physical Findings**

- Flank ecchymosis
Evaluation
- UA (if neg → no further testing), CT scan

Treatment
- Surgery consult, subcapsular hematoma → 24 h observation/serial HCT/serial UA/bed rest, microscopic hematuria → avoid strenuous exercise/repeat UA in 2 d + until clear

Disposition
- Admit: Major/subcapsular hematoma
- Home: Microscopic hematuria

Renal Pedicle/Vascular Injury
Definition
- Injury to renal pedicle or vasculature

History
- High-velocity deceleration, penetrating trauma

Physical Findings
- Flank ecchymosis, hypotension

Evaluation
- UA, CBC, Coags, BMP, CT scan: Nonenhancing kidney/± perirenal hematoma

Treatment
- Surgery consult for operative management → repair (20% salvage rate in pedicle lacerations) vs. nephrectomy

Disposition
- Admit

Renal Pelvis Rupture
Definition
- Rupture of the renal pelvis

History
- High-velocity deceleration, penetrating trauma

Physical Findings
- Flank ecchymosis, hypotension
Evaluation
› UA, CBC, Coags, BMP, CT scan: Extravasation of urine in perirenal space

Treatment
› Urology consult for operative repair

Disposition
› Admit

Pearl
› ↑ risk of infection in delayed repair

Ureteral Injuries
Definition
› Injury to ureter (very rare), majority are iatrogenic from gyn/uro procedures

History
› Hyperextension, penetrating trauma, forced flexion of L-spine → rupture below UPJ, delayed necrosis from microvascular injury after GSW (rare)

Evaluation
› UA, HCT, CT scan: Extravasation of urine, IVP (limited sens)

Treatment
› Urology consult for operative ureteroureterostomy

Disposition
› Admit

Intraperitoneal Bladder Rupture
Definition
› Laceration at dome of bladder w/ intraperitoneal communication

History
› MVC, blunt trauma (burst injury)

Physical Findings
› Lower abd tenderness, ↓ UOP, hematuria

Evaluation
UA, HCT, CT cystogram/cystogram: Extravasation of urine

Treatment
› Urology consult for urgent operative repair

Disposition
› Admit

Extraperitoneal Bladder Rupture

Definition
› Rupture of the bladder w/ extraperitoneal spillage

History
› MVC, blunt trauma

Physical Findings
› Lower abd tenderness, ↓ UOP, hematuria

Evaluation
› UA, HCT, CT cystogram/cystogram w/ washout: Extravasation of urine

Treatment
› Urology consult (usually nonoperative unless extends to bladder neck), Foley 10–14 d

Disposition
› Admit

Male Urethral Injuries

Definition
› Injury to posterior (prostatomembranous) urethra (a/w pelvic fractures, esp bilateral or both ipsilateral pubic rami fx & posterior disruption injuries) & anterior (bulbous/ penile) urethra (a/w direct trauma to penis/penile fracture/saddle injuries/falls/GSW)

History
› Blunt or penetrating trauma

Physical Findings
› Blood at meatus, gross hematuria, inability to void

Evaluation
Female Urethral Injuries

Definition
- Injury to female urethra associated most commonly with pelvic fractures (rarely saddle injuries, falls, GSW, instrumentation)

History
- Blunt or penetrating trauma, much less common than in males

Physical Findings
- Vaginal bleeding, inability to place Foley, labial edema

Evaluation
- RUG not useful, passage of Foley precludes complete tear

Treatment
- Suprapubic bladder decompression if needed, urology consult for surgical repair

Disposition
- Admit

Testicular Contusion/Rupture

Definition
- Blunt trauma to the testicle leading to contusion or rupture (disruption of tunica albuginea)

History
- Blunt trauma, pain, swelling

Physical Findings
- Ecchymosis, edema, tenderness, inability to palpate testicle due to dislocation

Evaluation
Testicular US (mod sens/spec for rupture)

Treatment
- Urology consult for surgical repair/clot evacuation (early intervention → ↓ morbidity)

Disposition
- Admit

Penile Fracture
Definition
- Blunt injury to the erect penis when penis is forcefully bent leading to rupture of the tunica albuginea/rupture of corpora cavernosa

History
- “Cracking sound” usually during sexual activity → severe pain

Physical Findings
- Swelling, discoloration (vascular engorgement), ecchymosis, blood at meatus (10–20% a/w urethral injury)

Evaluation
- RUG for urethral injury (concomitant injury in 15–20%)

Treatment
- Urology consult for surgical urethral repair/clot evacuation

Disposition
- Admit

Penile Amputation/Laceration
Definition
- Complete or partial amputation/laceration of the penis

History
- Penetrating trauma, zipper injury

Evaluation
- RUG or testicular US if associated injuries suspected

Treatment
- Amputation: Urology consult (best results in reimplanted in 18 h)
- Simple laceration: Repair w/ absorbable suture
Zipper injury: Remove zipper w/ mineral oil/wire cutters at zipper median bar to break apart

Disposition
- D/C unless reimplantation required

Female Genital Injuries
Definition
- Injury to ovary, uterus, fallopian tube, vagina (difficult to Dx usually found when evaluating for other injury), a/w pelvic fractures

History
- Blunt or penetrating trauma, vaginal bleeding

Physical Findings
- Blood in vaginal vault, lower abd tenderness

Evaluation
- CT scan, pelvic US (in gravid pt, ↑ risk)

Treatment
- Open vaginal lacerations open → abx (ampicillin, gentamicin, Flagyl) GYN consult
- Simple vaginal lacerations: Repair w/ absorbable suture

Disposition
- Admit if needed

HIP/PELVIC TRAUMA

Definition
- Trauma to hip or pelvis

Approach

Pelvis Anatomy
- Sacrum, coccyx, & R/L innominate bones (ileum, ischium, pubis) fuse at acetabulum

Inspection
- Perineal edema/lacerations/ecchymosis, deformities (length
discrepancy, internal/external rotation)

**Palpation**

- Rectal exam (blood, high-riding prostate, tone), pulses, pelvic stability (limit manipulation if unstable → clot dislodgement), neurologic exam (strength, sensation, DTRs), in females pelvic exam

**Radiology**

- AP pelvis (can miss sacral fractures/SI joint disruptions → inlet/outlet views), CT scan (superior for acetabular fractures/associated injuries), hip x-ray

**Pelvic Fractures**

**Definition**

- Fractures of the pelvis usually caused by significant mechanism (↑ association w/ other injuries)

**History**

- Blunt trauma, lateral/AP compression, vertical shear (fall)

**Physical Findings**

- External contusion/abrasion/ecchymosis, caution w/ manual compression/distraction of pelvis (may dislodge clot → hemorrhage), evaluate for open pelvic fx as these have 40–50% mortality, hypotension (42–50% mortality), blood at meatus, perineal trauma, neurologic abnl (cauda equina syndrome, plexopathies, radiculopathies)

**Evaluation**

- FAST, AP pelvis, CT scan, evaluate carefully for intra-abd trauma as >15% w/ pelvic fx will have intra-abd injury

**Treatment**

- Unstable: Temporizing measures (wrapped sheet/external binders/external clamps), immediate orthopedic & trauma surgery consult (reduction/external fixation & pelvic packing), IR for hemorrhage control
- Stable: Orthopedic consult

**Disposition**
Admit

**Pearls**
- Type A (inferior pubic rami/avulsion) & type B2 (bucket handle) → most common
- Type B3 (open book) & C (70% have major associated injuries) → most life-threatening

<table>
<thead>
<tr>
<th>Pelvic Fracture Classification (Tile Classification System)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td>Type A: Stable pelvic ring fracture</td>
</tr>
<tr>
<td>A1: Avulsion of innominate bone → sudden muscle contraction, iliac wing (Duverney) fracture → direct lateral to medical trauma</td>
</tr>
<tr>
<td>A2: Stable or minimally displaced fracture of pelvic ring (ramus/ischium) → elderly fall</td>
</tr>
<tr>
<td>A3: Transverse fracture of sacrum/coccyx → fall in sitting position</td>
</tr>
<tr>
<td>Type B: Partially stable pelvic ring injuries (rotationally unstable/vertically stable)</td>
</tr>
<tr>
<td>B1: Unilateral open book (disruption symphysis pubis + SI joint hinge rotation) → AP compression</td>
</tr>
<tr>
<td>B2: Bucket handle fractures → lateral compression</td>
</tr>
<tr>
<td>B3: Bilateral open book fracture → severe AP compression</td>
</tr>
<tr>
<td>Type C: Unstable pelvic ring fractures</td>
</tr>
<tr>
<td>Distracting vertical sacral fractures/other vertical shear fractures → vertical shear injuries</td>
</tr>
</tbody>
</table>

**Vascular Pelvic Injuries**

**Definition**
- Injury to vascular structures of pelvis a/w pelvic fractures (most commonly AP trauma or vertical shear)

**History**
- Blunt trauma, lateral/AP compression, vertical shear (fall)

**Physical Findings**
- Unstable pelvis, hypotension resistant to resuscitation

**Evaluation**
- FAST, AP pelvis, CT scan (if stable), pelvic angiography, consider DPA if FAST neg but HD unstable

**Treatment**
- Stabilization of pelvis, orthopedic & trauma surgery consult (external fixation & pelvic packing to control hemorrhage), IR embolization for continued hypotension (less effective for venous bleed → high collateralization)

**Disposition**
- Admit

**Acetabular Fractures**

**Definition**
- Fractures to the acetabulum (MVC → knee striking dashboard or lateral intrusion), fall in elderly

**History**
- Blunt trauma, pain w/ movement of hip

**Physical Findings**
- Pain w/ movement of hip/compression of sole of foot or greater trochanter

**Evaluation**
- AP pelvis, lateral hip films (± Judet views), CT scan (if plain films unrevealing)
- 3 types (although some fit in multiple categories
  - Wall: Anterior, posterior, posterior wall/column, transverse/posterior wall
  - Column: Anterior, posterior, both, posterior wall/column, anterior/transverse
  - Transverse: Transverse, T, transverse/posterior wall, anterior column/transverse

**Treatment**
- Orthopedic consult for operative management

**Disposition**
- Admit

**Hip Fractures**

**Definition**
- Fractures of the hip (femoral head/neck/trochanter)

**History**
• Elderly → fall from standing, young → significant mechanism trauma (MVC)

**Physical Findings**
• External rotation, shortening of leg

**Evaluation**
• AP pelvis, lateral hip films, CT (if unable to bear weight + neg plain films)

**Treatment**
• Orthopedic consult for operative management (femoral neck fractures → ↑ risk avascular necrosis of femoral head, surgical repair in <6 h)

**Disposition**
• Admit

**Pearl**
• Hip fracture in elderly → 25% 1-y mortality

<table>
<thead>
<tr>
<th>Hip Fractures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type</strong></td>
</tr>
</tbody>
</table>
| Intracapsular | Femoral head: Rare in isolation, a/w posterior dislocations  
Femoral neck: ↑ risk avascular necrosis of femoral head, most common in elderly women |
| Extracapsular | Intertrochanteric: Markedly externally rotated/shortened, elderly fall  
Subtrochanteric: ↑ risk bleeding into thigh, elderly fall/MVC |

**Hip Dislocations**

**Definition**
• Dislocation of femoral head from acetabulum (90% posterior)

**History**
• Elderly fall w/ hx of hip total hip replacement, MVC (knee hitting dashboard, a/w other injuries), athlete running & lands w/ hip flexed/internally rotated & adducted

**Physical Findings**
• Flexed/adducted/internally rotated hip (posterior)
Evaluation
- AP pelvis, lateral hip films

Treatment
- Orthopedic consult if fracture or prosthetic hip, reduction under conscious sedation (in <6 h, ↑ risk avascular necrosis of femoral head)

Disposition
- Admit if needed

EXTREMITY INJURY

Definition
- Injuries to the extremities (vascular/bony/soft tissue/nerve)

Approach

History
- Last tetanus (booster if >5 y), hand dominance, time of injury, mechanism (crush/penetrating), neurologic deficit (loss of sensation/motor), environmental exposures (burn/cold), preinjury functional status

Inspection
- Color (discoloration/ecchymosis/perfusion), soft tissue defects (control hemorrhage during 1° survey), deformities (angulations/shortening), swelling

Palpation
- Pulses, all joints/bones (tenderness), FB, crepitance, strength, sensation, DTRs, range all joints, joint effusions

Radiology
- Plain films guided by PE

Consults
- Orthopedic &/or vascular for open fractures/amputations/vascular injuries/compartment syndrome, hand surgery for significant hand injuries
Extremity Vascular Injury

Definition
- Injury to the vasculature of the extremities

History
- Blunt trauma (fracture/dislocation → tearing of vessels) or penetrating trauma

Physical Findings
- Obvious vascular compromise → pulseless/pallor/pain/paresthesia/cold, indicators of vascular injury → swelling/pain/↓ cap refill/mottled skin/↓ pulses

Evaluation
- Plain films (blunt trauma), CTA, or angiography (if stable), Ankle/Brachial index or Ankle/Ankle index: Abnl if <0.9

Treatment
- Vascular surgery consult for immediate surgical repair (↓ salvage rate if >6 h)

Disposition
- Admit if needed

Extremity Orthopedic Injuries

Definition
- Bony fractures or joint dislocations of the extremities

History
- Blunt trauma or penetrating

Physical Findings
- Deformities, pain, swelling, crepitance, neurologic deficits, diminished pulses

Evaluation
- Plain films, image joint above & below for significant fracture, CT in certain injuries (tibial plateau)

Treatment
- Open fractures: Immediate orthopedic consult for operative washout/fixation (<6 h), abx (cefazolin 1–2 g)
- Closed UE fractures + intact neuro exam: Splint, outpt f/u (see table)
- Closed LE fractures + intact neuro exam: Splint, outpt f/u if able to use crutches (see table)
- Dislocations: ED reduction, pt f/u

**Disposition**
- Admit if needed

---

### Principles of Immobilization & Referral

<table>
<thead>
<tr>
<th>Fracture Sites</th>
<th>Splint/Immobilization Technique</th>
<th>Referral Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Femoral fractures</td>
<td>Temporary traction splints</td>
<td>Emergent ED consult</td>
</tr>
<tr>
<td>Knee injuries (w/ no e/o dislocation &amp; no neurovascular compromise)</td>
<td>Knee immobilizer/long leg cast w/ leg flexed 10°</td>
<td>Orthopedic f/u w/i 1 wk</td>
</tr>
<tr>
<td>Tibia fractures (not tibial plateau)</td>
<td>Lower leg posterior splint</td>
<td>Orthopedic f/u in 1–2 d</td>
</tr>
<tr>
<td>Ankle fractures</td>
<td>Lower leg posterior U-splint</td>
<td>If fracture fragments well aligned, orthopedic f/u in 1 wk. If angulation or distraction, needs next-day f/u</td>
</tr>
<tr>
<td>Hand fractures</td>
<td>Thumb &amp; index finger—radial gutter splint Middle, ring, &amp; little fingers —ulnar gutter splint</td>
<td>If fracture fragments well aligned &amp; fracture is closed, f/u w/ hand surgeon w/i 1 wk</td>
</tr>
<tr>
<td>Wrist fractures</td>
<td>Wrist splint/immobilizer unless scaphoid fracture then thumb spica cast</td>
<td>Orthopedic f/u in 7–10 d unless scaphoid displacement—then f/u in 1–2 d</td>
</tr>
<tr>
<td>Distal radius/ulna fractures</td>
<td>Short arm cast</td>
<td>Orthopedic f/u in 1–2 d unless closed reduction results in good anatomic alignment—then f/u in 7–10 d</td>
</tr>
<tr>
<td>Humerus fractures</td>
<td>Sling, coaptation splint rarely used</td>
<td>Orthopedic f/u in 7–10 d, sooner if articular surface or tuberosity</td>
</tr>
<tr>
<td>Shoulder dislocations</td>
<td>Sling, early ROM to prevent frozen shoulder</td>
<td>Orthopedic f/u in 7–10 d</td>
</tr>
</tbody>
</table>

**Pearls**
5th MCP fractures or “Boxer fractures” have a high rate of infection secondary to breaks in skin from opponent’s tooth. Always r/o FB w/ plain radiographs & f/u in 1–2 d in ED or in hand clinic
Scaphoid tenderness w/o radiologic e/o fracture requires splinting & orthopedic f/u & repeated x-rays w/i 7 d
ED, emergency department; MCP, metacarpal

**Extremity Soft Tissue Injury**

**Definition**
- Injury to the soft tissue of the extremities

**History**
- Blunt trauma or penetrating (polytrauma, industrial accidents)

**Physical Findings**
- Soft tissue defects, FBs

**Evaluation**
- Plain films for FB/underlying fractures, US, CPK (if extensive injury)

**Treatment**
- Irrigate, explore for FB (↑ risk wound infection → poor cosmetic outcome), plastic surgery consult (extensive injuries), hand consult for palmar injuries as exploration w/ potential for iatrogenic injury, abx (grossly contaminated wounds)

**Disposition**
- Admit if extensive, e/o rhabdomyolysis/compartment syndrome

**Extremity Nerve Injury**

**Definition**
- Injury to the nerves of the extremities (a/w fractures/dislocations/lacerations/vascular ischemia/compartment syndrome)

**History**
- Blunt trauma or penetrating

**Physical Findings**
- See table

**Evaluation**
Plain films for fracture/dislocation

**Treatment**
- Reduce fracture/dislocation (↓ pressure on nerve), fasciotomy (compartment syndrome), orthopedic/plastic surgery consult

**Disposition**
- Admit if needed

<table>
<thead>
<tr>
<th>Nerve</th>
<th>Motor</th>
<th>Sensation</th>
<th>Injury</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ulnar</td>
<td>Index finger abduction</td>
<td>Tip of little finger</td>
<td>Elbow injury</td>
</tr>
<tr>
<td>Median (distal)</td>
<td>Thenar opposition</td>
<td>Tip of index finger</td>
<td>Wrist dislocation</td>
</tr>
<tr>
<td>Median (anterior interosseous)</td>
<td>Index tip flexion</td>
<td></td>
<td>Supracondylar fx of humerus in children</td>
</tr>
<tr>
<td>Musculocutaneous</td>
<td>Elbow flexion</td>
<td>Lateral forearm</td>
<td>Anterior shoulder dislocation</td>
</tr>
<tr>
<td>Radial</td>
<td>Thumb, finger MCP extension</td>
<td>1st dorsal web space</td>
<td>Distal humeral shaft, anterior shoulder dislocation</td>
</tr>
<tr>
<td>Axillary</td>
<td>Deltoid</td>
<td>Lateral shoulder</td>
<td>Proximal humerus fx, anterior shoulder dislocation</td>
</tr>
<tr>
<td>Femoral</td>
<td>Knee extension</td>
<td>Anterior knee</td>
<td>Pubic rami fx</td>
</tr>
<tr>
<td>Obturator</td>
<td>Hip adduction</td>
<td>Medial thigh</td>
<td>Obturator ring fx</td>
</tr>
<tr>
<td>Posterior tibial</td>
<td>Toe dorsiflexion</td>
<td>Sole of foot</td>
<td>Knee dislocation</td>
</tr>
<tr>
<td>Superficial peroneal</td>
<td>Ankle eversion</td>
<td>Lateral dorsum of foot</td>
<td>Fibular neck fx, knee dislocation</td>
</tr>
<tr>
<td>Deep peroneal</td>
<td>Ankle/toe dorsiflexion</td>
<td>Dorsal 1st to 2nd web space of foot</td>
<td>Fibular neck fx, compartment syndrome</td>
</tr>
<tr>
<td>Sciatic</td>
<td>Plantar &amp; dorsiflexion</td>
<td>Foot</td>
<td>Posterior hip dislocation</td>
</tr>
<tr>
<td>Superior gluteal</td>
<td>Hip abduction</td>
<td></td>
<td>Acetabular fx</td>
</tr>
<tr>
<td>Inferior gluteal</td>
<td>Gluteus maximus hip</td>
<td></td>
<td>Acetabular fx</td>
</tr>
</tbody>
</table>
**Compartment Syndrome**

**Definition**
- A condition in which perfusion pressures < tissue pressures in closed space (fascial compartments) → ↓ circulation/tissue fxn (↑ risk injuries: Tibial/forearm fractures, crush injuries, burns, immobilized injuries in tight dressing/cast)

**History**
- Blunt trauma or penetrating, pain > than expected/worse w/ passive muscle stretching

**Physical Findings**
- Tenderness, tense swelling, classically: Pain, pallor, paresthesias, paralysis, pulselessness (late finding). Pain w/ passive stretching is early sign but not always reliable

**Evaluation**
- Compartment pressures (measure w/ Stryker or 18 G IV + arterial line transducer) >30 mmHg or <20–30 mmHg difference b/w DBP & compartment pressure (if hypotensive necrosis occurs at ↓ pressures), CK

**Treatment**
- Remove restrictive dressings/casts, elevate extremity, correct BP, surgery consult for fasciotomy (do not delay fasciotomy for surgical availability)

**Disposition**
- Admit

**Crush Syndrome/Rhabdomyolysis**

**Definition**
- Crush injury → release in cellular contents of muscle cells → CK levels >5000 U/L

**History**
- Crush injury

**Physical Findings**
- May have minimal external injury, dark brown/orange urine
Evaluation
- CK levels >5000 U/L, ↑ Cr (15–47% a/w ARF), ↑ potassium, UA (+ myoglobin), observe closely for reperfusion syndrome, esp if in field

Treatment
- IV fluids for UOP >1 mL/g/h, traditionally alkalization of urine (sodium bicarbonate, 1 amp/1 L NS → urine pH >7 → prevents tubular precipitation of myoglobin) → no difference than NS in prevention of renal failure, treat hyperkalemia (J Trauma 2004;56:1191)

Disposition
- Admit

Partial/Complete Amputation

Definition
- Amputation of extremity

History
- Blunt or penetrating trauma (polytrauma, industrial accident)

Physical Findings
- Document motor/neurologic/vascular fxn in remaining limb

Evaluation
- Plain films of stump + amputated fragment, ± angiography (if not going directly to OR)

Treatment
- Limit mobility, hemostasis w/ direct pressure, immediate surgery consult for replantation, abx (cefazolin 1–2 g IV), pack stump w/ sterile NS soaked gauze, wrap amputated part in cold NS soaked gauze/place on ice (do not place in direct contact w/ ice or NS)

Disposition
- Admit

Pearl
- Replantation depends on age, vocation, injury severity
Approach

History
- Time of event (>12 h → irrigate/heal by secondary intention or delayed 1° closure, face/significant soft tissue defect → 1° closure in <24 h), location (suture selection/time until removal), mechanism (↑ risk FB/contamination), tetanus (booster if >5 y)

Inspection
- FB, wound approximation

Palpation
- Pulses, strength, sensation distal to injury

Laceration

Definition
- Cut or tear to skin & soft tissues

History
- Penetrating or blunt trauma

Physical Findings
- Skin defect, ↓ pulses/sensation/motor (neurovascular injury)

Evaluation
- Plain films only if FB/fracture suspected

Treatment
- Hemostasis: Direct pressure, lidocaine w/ epinephrine if needed (avoid in digits, nose, ears, penis), hemostatic agents (eg, thrombin, Surgicel), proximal tourniquet
- Analgesia: Use regional blocks when possible (↓ wound distortion/amount of analgesic needed)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Trade Name</th>
<th>Class</th>
<th>Concentrations (%)</th>
<th>Maximum Safe Dose</th>
<th>Onset</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lidocaine w/epinephrine</td>
<td>Xylocaine</td>
<td>Amide</td>
<td>0.5–2</td>
<td>4.5 mg/kg 7 mg/kg</td>
<td>-5 min</td>
<td>1–2 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2–4 h</td>
</tr>
<tr>
<td>Bupivacaine w/epinephrine</td>
<td>Marcaine</td>
<td>Amide</td>
<td>0.125–0.25</td>
<td>2 mg/kg 3 mg/kg</td>
<td>-5 min</td>
<td>4–8 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8–16 h</td>
</tr>
</tbody>
</table>
- Irrigation: >500 cc NS (no benefit over tap water) \( (\text{Ann Emerg Med 1999;34:356}) \), 8 psi of pressure (18 g IV catheter or Zerowet splash shield in 30–60 cc syringe), caution on delicate tissues (eye lids)
- Exploration (through a full ROM): FB, tendons (including in position of injury), fascial planes
- Repair:

<table>
<thead>
<tr>
<th>Suture Choice</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body Part</strong></td>
</tr>
<tr>
<td>Scalp</td>
</tr>
<tr>
<td>Face</td>
</tr>
<tr>
<td>Chest</td>
</tr>
<tr>
<td>Back</td>
</tr>
<tr>
<td>Forearm</td>
</tr>
<tr>
<td>Finger/hand</td>
</tr>
<tr>
<td>LE</td>
</tr>
</tbody>
</table>

- Abx: Not routinely required (must be given for certain bites)

**Disposition**

- Home

**Pearls**

- Scarring: Take up to 1 y to fully develop, apply sunscreen/keep covered even on cloudy days, apply Vit E
- Hand flexor tendon lacerations: Emergent 1° repair by hand surgeon, splint (wrist 30° flexion, MP joint 70° flexion, DIP/PIP 10° flexion)
- Hand extensor tendon lacerations: Zone IV & VI repair 1° in ED, splint, hand surgery f/u

**Foreign Body**

**Definition**
Retained FB in wound (most common hand/foot) → ↑ risk delayed infection/ granuloma/formation/local compression of structures/embolization/allergic rxns (reactive FBs: Wood, organic matter, clothing, skin fragments)

History
- Know FB, ↑ risk wounds: Stepping on glass/punching windows/MVC w/ glass exposure/
  fall on gravel/pain at IVD site/persistent wound infections/failure to heal (41% wounds caused by glass)

Physical Findings
- Visible/palpable FB

Evaluation
- Explore wound (adequate anesthesia/hemostasis/probe w/ instrument), plain films for radiopaque FBs (glass, metal, bone, teeth, graphite, gravel), US (use 100 cc bag of NS or other transducing material for superficial FB location)

Treatment
- Not all FB require removal (deep, small, inert, asymptomatic, away from vital structures), removal (significant pain, functional impairment, reactive, contamination, near vital structures, cosmetic concerns): May require wound extension, irrigation, fine tip forceps

Disposition
- D/C

Fingertip Wounds

Definition
- Amputations/laceration/crush to fingertip (skin/volar pulp/distal phalanx/nail/nail bed)

History
- Cutting/crushing injury

Physical Findings
- Amputation, nail bed lacerations, subungual hematoma

Evaluation
Finger plain film (FB, fracture)

**Treatment**
- Amputation: Distal to DIP joint → wound care/secondary intention (may need to trim back bone/should always be covered by soft tissue)/abx, significant bone/soft tissue loss → emergent hand surgery consult
- Subungual hematoma: Large → nail trephination, small → no intervention
- Nail bed laceration: 1° repair → remove nail, repair w/ 6-0 absorbable suture, replace nail into nail fold (suture or secure w/ tape) to splint nail bed/maintain nail fold (nail growth → 70–160 d)

**Disposition**
- D/C

### ABUSE

**Approach**

**History**
- Delays in seeking care, hx inconsistent w/ injury, multiple past injuries, injuries in various stages of healing

**Team Approach**
- Social work, child protective services, trained sexual assault nurses, pt advocate

**Documentation**
- Record factual events/injuries, avoid judgments, informed consent for forensic collection/release of information, mandatory reporting for child/elder abuse

**Child Abuse**

**History**
- Story inconsistent w/ injuries/child’s developmental age, inconsistent stories by caretakers

**Physical Findings**
- Child neglect: Flattening/alopecia of occiput (supine for long periods
of time), decreased SC tissue/prominent ribs/loose skin over buttocks (FTT)

- Child abuse: Bruises/fracture varying stages, bruises in areas not prone to trauma (lower back, buttock, thighs, cheeks, ear pinna), geometric-shaped bruising (belts, cords), scald burns w/o splash marks or in “dip” pattern, multiple deep contact burns, unexplained extremity swelling (long bone spiral fracture, metaphyseal chip fractures, femur fractures in <3 y), posterior rib fractures, MS Δ (shaken baby), suspicious oral/facial trauma (torn frenulum, dental trauma present in 50% of abuse)
- Child sexual assault: Penile/vaginal d/c (STDs), UTI, genital/rectal trauma (inner thigh bruising, rectal tears, loss rectal tone), often no physical findings if delay in presentation

Evaluation

- Skeletal series (children <5), head CT (suspected intracranial injury), dilated eye exam (retinal detachment/hemorrhage → shaken baby), CBC, Coags, LFTs, tox screen, growth measurements, vaginal/rectal/oral swabs

Treatment

- Social work/child protective services, treat injuries as appropriate

Disposition

- D/C per child protective services

Pearls

- 2–3% children (physical abuse associated low SES)
- ↑ risk in children w/ mental/physical disabilities/chronic medical problems
- Consider Munchausen syndrome by proxy in cases w/ extensive/neg prior w/u
- Most important to suspect abuse & allow trained specialists to opine if abuse occurred

Sexual Assault

History

- Time, date, number/description of assailants, threats made, weapons used, type of assault, drugs used, LOC, post assault activity (Δ of clothing, urination, showering, tampon use), last time of
voluntary intercourse

**Physical Findings**
- Document: Appearance of clothes, scratches, bruising, lacerations (can use toluidine dye to identify vaginal lacerations), d/c

**Evaluation**
- Imaging as needed, have pt advocate present, pregnancy test, ± STD testing, full rape kit if <72 h (modify as appropriate), vaginal/rectal secretions for acid phosphatase/glycoprotein p30, tox screen
- Many areas will have SANE services available & pt may need transfer for SANE exam, must medically clear pt 1st

**Treatment**
- Pregnancy prophylaxis (levonorgestrel 0.75 q12h × 2 doses), STD prophylaxis (gonorrhea: Ceftriaxone 125 mg IM × 1, Chlamydia: Azithromycin 1 g PO × 1, Hep B: 1st of 2 vaccines, HIV), antiemetics

**Disposition**
- D/C w/ f/u counseling

**Pearl**
- 1/5 women is sexually assaulted in lifetime, only 7% reported

**Intimate-partner Violence**

**History**
- Story inconsistent w/ injuries, frequent ED visits, vague medical complaints, chronic pain (>abd pain), overbearing/controlling partner, injury during pregnancy

**Physical Findings**
- Injuries face/head/neck/areas covered by clothes (most common)

**Evaluation**
- Imaging as needed

**Treatment**
- Photographs as appropriate, determine safety of home/immediate risk (escalating violence, treats, firearms), devise safety plan (avoid sedative/arguments in small rooms/access to firearms, teach children to call 911), social work consult
Disposition
- D/C to shelter if unsafe home

Pearls
- ↑ risk during pregnancy/attempts to leave partner
- Universal screening for all pts should be done in the ED

Elder Abuse

History
- Delayed presentation, hx of med noncompliance/missed appointments, often lives w/ abuser, have dementia, are dependent on abuser for ADLs, RFs for abusive caretaker: Mental illness, substance abuse, hx of family violence/financial stress/stress of being caretaker

Physical Findings
- Poor hygiene, malnutrition, decubitus ulcers, “urine rash,” unexplained injuries to face/head/torso/back/buttocks/limb contractures (restraints)/bilateral upper extremities (grabbing)

Evaluation
- Imaging as needed, CBC, BMP, CK (rhabdomyolysis)

Treatment
- Photographs as appropriate, arrange for support services to relieve stress on caretaker (VNA, meals-on-wheels), arrange for home safety eval

Disposition
- Admit if unsafe to go home

Pearls
- May be as high as 5–10% in elderly
- Decreased reporting for fear of institutionalization
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/P</td>
<td>assessment and plan</td>
</tr>
<tr>
<td>a/w</td>
<td>Associated with</td>
</tr>
<tr>
<td>AAA</td>
<td>Abdominal aortic aneurysm</td>
</tr>
<tr>
<td>βB</td>
<td>Beta-blocker</td>
</tr>
<tr>
<td>ABC</td>
<td>Airway, berthing, circulation</td>
</tr>
<tr>
<td>ABG</td>
<td>Arterial blood gas</td>
</tr>
<tr>
<td>ABI</td>
<td>Ankle-brachial index</td>
</tr>
<tr>
<td>abnl</td>
<td>Abnormal</td>
</tr>
<tr>
<td>abnlty</td>
<td>Abnormality</td>
</tr>
<tr>
<td>abx</td>
<td>Antibiotics</td>
</tr>
<tr>
<td>AC</td>
<td>Acromioclavicular</td>
</tr>
<tr>
<td>ACE-I/ACEI</td>
<td>Angiotensin-converting enzyme inhibitor</td>
</tr>
<tr>
<td>ACS</td>
<td>Acute coronary syndrome</td>
</tr>
<tr>
<td>ADH</td>
<td>Antidiuretic hormone</td>
</tr>
<tr>
<td>ADHD</td>
<td>Attention-deficit hyperactivity disorder</td>
</tr>
<tr>
<td>AED</td>
<td>Antiepileptic drug</td>
</tr>
<tr>
<td>AF</td>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>AFL</td>
<td>Atrial flutter</td>
</tr>
<tr>
<td>AG</td>
<td>Aminoglycoside</td>
</tr>
<tr>
<td>AGE</td>
<td>Arterial gas embolism</td>
</tr>
<tr>
<td>AI</td>
<td>Aortic insufficiency</td>
</tr>
<tr>
<td>AIDS</td>
<td>Acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>AIVR</td>
<td>Accelerated idioventricular rhythm</td>
</tr>
<tr>
<td>AKD</td>
<td>Acute kidney disease</td>
</tr>
<tr>
<td>AKI</td>
<td>acute kidney injury</td>
</tr>
<tr>
<td>ALI</td>
<td>Acute lung injury</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine transaminase</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>ALTE</td>
<td>Apparent life-threatening event</td>
</tr>
<tr>
<td>AMS</td>
<td>Acute mountain sickness</td>
</tr>
<tr>
<td>ANC</td>
<td>Absolute neutrophil count</td>
</tr>
<tr>
<td>APAP</td>
<td>Acetaminophen</td>
</tr>
<tr>
<td>ARB</td>
<td>Angiotensin receptor blocker</td>
</tr>
<tr>
<td>ARDS</td>
<td>Acute respiratory distress syndrome</td>
</tr>
<tr>
<td>ARF</td>
<td>Acute renal failure</td>
</tr>
<tr>
<td>AS</td>
<td>Aortic stenosis</td>
</tr>
<tr>
<td>ASA</td>
<td>acetylsalicylic acid (aspirin)</td>
</tr>
<tr>
<td>ASD</td>
<td>Atrial septal defect</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>AT</td>
<td>Atrial tachycardia</td>
</tr>
<tr>
<td>ATN</td>
<td>Acute tubular necrosis</td>
</tr>
<tr>
<td>AVA</td>
<td>Aortic valve area</td>
</tr>
<tr>
<td>AVM</td>
<td>Arteriovenous malformation</td>
</tr>
<tr>
<td>AVN</td>
<td>Atrioventricular node</td>
</tr>
<tr>
<td>AVNRT</td>
<td>AV node re-entrant tachycardia</td>
</tr>
<tr>
<td>AVR</td>
<td>Aortic valve replacement</td>
</tr>
<tr>
<td>AVRT</td>
<td>AV reciprocating tachycardia</td>
</tr>
<tr>
<td>b/c</td>
<td>Because</td>
</tr>
<tr>
<td>b/w</td>
<td>Between</td>
</tr>
<tr>
<td>BAL</td>
<td>Blood alcohol level</td>
</tr>
<tr>
<td>BBB</td>
<td>Bundle branch block</td>
</tr>
<tr>
<td>BiPAP</td>
<td>Bilevel positive airway pressure</td>
</tr>
<tr>
<td>BMP</td>
<td>Basic metabolic panel</td>
</tr>
<tr>
<td>BMS</td>
<td>Bare metal stent</td>
</tr>
<tr>
<td>BNP</td>
<td>brain natriuretic peptide</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>BPH</td>
<td>Benign prostatic hyperplasia</td>
</tr>
<tr>
<td>BPPV</td>
<td>Benign paroxysmal positional vertigo</td>
</tr>
<tr>
<td>BSUS</td>
<td>bedside ultrasound</td>
</tr>
<tr>
<td>BVM</td>
<td>Bag-valve mask</td>
</tr>
<tr>
<td>BZD</td>
<td>Benzodiazepines</td>
</tr>
<tr>
<td>c/o</td>
<td>Complaint of</td>
</tr>
</tbody>
</table>
c/w Compared with
CABG Coronary artery bypass graft
CAD Coronary artery disease
CAP Community-acquired pneumonia
CBC Complete blood count
CBD Common bile duct
CCB Calcium channel blocker
CCU Coronary care unit
CHF Congestive heart failure
CKD Chronic kidney disease
Cl Contraindication
CMP Cardiomyopathy
CMV Cytomegalovirus
CN Cranial nerve
CNS Central nervous system
CO Carbon monoxide, cardiac output
CO₂ Carbon dioxide
COPD Chronic obstructive pulmonary disease
CP Chest pain
CPAP Continuous positive airway pressure
CPK Creatine phosphokinase
CPP Cerebral perfusion pressure
CPR Cardiopulmonary resuscitation
Cr Creatinine
CRAO Central retinal artery occlusion
CRP C-reactive protein
CRVO Central retinal vein occlusion
CSF Cerebrospinal fluid
CT Computed tomography
CTA Computed tomography angiography
CTH Chronic tension headache
cTn Cardiac troponin
CTV Computed tomography venography
CTX ceftriaxone
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMS</td>
<td>Emergency medical services</td>
</tr>
<tr>
<td>EOM</td>
<td>Extraocular muscles</td>
</tr>
<tr>
<td>EP</td>
<td>Electrophysiologist</td>
</tr>
<tr>
<td>ERCP</td>
<td>Endoscopic retrograde cholangiopancreatography</td>
</tr>
<tr>
<td>ESBL</td>
<td>extended spectrum beta-lactamase</td>
</tr>
<tr>
<td>esp</td>
<td>Especially</td>
</tr>
<tr>
<td>ESR</td>
<td>Erythrocyte sedimentation rate</td>
</tr>
<tr>
<td>EtOH</td>
<td>Ethanol</td>
</tr>
<tr>
<td>ETT</td>
<td>Endotracheal tube</td>
</tr>
<tr>
<td>eval</td>
<td>Evaluation</td>
</tr>
<tr>
<td>f/b</td>
<td>followed by</td>
</tr>
<tr>
<td>f/u</td>
<td>Follow-up</td>
</tr>
<tr>
<td>FAST</td>
<td>Focused assessment with sonography for trauma</td>
</tr>
<tr>
<td>FB</td>
<td>Foreign body</td>
</tr>
<tr>
<td>FFP</td>
<td>Fresh frozen plasma</td>
</tr>
<tr>
<td>FH</td>
<td>Family history</td>
</tr>
<tr>
<td>FHH</td>
<td>Familial hypocalciuric hypercalcemia</td>
</tr>
<tr>
<td>FSG</td>
<td>Fingerstick glucose</td>
</tr>
<tr>
<td>FTT</td>
<td>Failure to thrive</td>
</tr>
<tr>
<td>FUO</td>
<td>Fever of unknown origin</td>
</tr>
<tr>
<td>G6PD</td>
<td>Glucose-6-phosphate dehydrogenase</td>
</tr>
<tr>
<td>GC</td>
<td>Gonococcal</td>
</tr>
<tr>
<td>GCS</td>
<td>Glasgow coma scale</td>
</tr>
<tr>
<td>GERD</td>
<td>Gastroesophageal reflux</td>
</tr>
<tr>
<td>GI</td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td>GIB</td>
<td>Gastrointestinal bleeding</td>
</tr>
<tr>
<td>GNR</td>
<td>gram-negative rods</td>
</tr>
<tr>
<td>GP</td>
<td>glycoprotein</td>
</tr>
<tr>
<td>GSW</td>
<td>Gunshot wound</td>
</tr>
<tr>
<td>GVHD</td>
<td>Graft versus host disease</td>
</tr>
<tr>
<td>h</td>
<td>Hour(s)</td>
</tr>
<tr>
<td>H&amp;P</td>
<td>history and physical</td>
</tr>
<tr>
<td>HA</td>
<td>Headache</td>
</tr>
<tr>
<td>HACE</td>
<td>High altitude cerebral edema</td>
</tr>
</tbody>
</table>
HAPE     High altitude pulmonary edema
HCAP     Health-care associated pneumonia
Hct      Hematocrit
HD       Hemodialysis, hemodynamically
HEENT    head, eyes, ears, nose, and throat
HELPP    Hemolysis, Elevated Liver enzymes, and Low Platelets
HHS      Hyperosmolar hyperglycemic state
HI       Homicidal ideation
HIDA     Hydroxy iminodiacetic acid
HIT      Heparin-induced thrombocytopenia
HIV      human immunodeficiency virus
HK       Hypokinesia
HL       Hyperlipidemia
HLD      Hyperlipidemia
HOB      Head of bed
HR       Heart rate
HRUS     High-resolution ultrasound
HSCT     hematopoietic stem cell transplantation
HSP      Henoch–Schönlein purpura
HSV      Herpes simplex virus
HTN      Hypertension
HUS      Hemolytic uremic syndrome
hx       History
I&D      Incision and drainage
IABP     Intra-aortic balloon pump
IBD      Inflammatory bowel disease
ICH      Intracranial hemorrhage
ICP      Intracranial pressure
ICU      intensive care unit
IFA      Immunofluorescence antibody
ILD      Interstitial lung disease
inpt     inpatient
INR      International normalized ratio
IO       Intraosseous
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>IOP</td>
<td>Intraocular pressure</td>
</tr>
<tr>
<td>IPH</td>
<td>Intraparenchymal hemorrhage</td>
</tr>
<tr>
<td>IR</td>
<td>Interventional radiology</td>
</tr>
<tr>
<td>ITP</td>
<td>Immune thrombocytopenic purpura</td>
</tr>
<tr>
<td>IVDA</td>
<td>Intravenous drug abuse</td>
</tr>
<tr>
<td>IVDU</td>
<td>Intravenous drug use</td>
</tr>
<tr>
<td>IVIG</td>
<td>Intravenous immunoglobulin</td>
</tr>
<tr>
<td>IVP</td>
<td>Intravenous pyelogram</td>
</tr>
<tr>
<td>JVD</td>
<td>Jugular venous distension</td>
</tr>
<tr>
<td>JVP</td>
<td>Jugular venous pressure</td>
</tr>
<tr>
<td>KUB</td>
<td>Kidney ureter bladder</td>
</tr>
<tr>
<td>L</td>
<td>Left</td>
</tr>
<tr>
<td>LAD</td>
<td>Lymphadenopathy, Left-axis deviation</td>
</tr>
<tr>
<td>LAE</td>
<td>Left atrial enlargement</td>
</tr>
<tr>
<td>LAFB</td>
<td>Left anterior fascicular block</td>
</tr>
<tr>
<td>LBBB</td>
<td>Left bundle branch block</td>
</tr>
<tr>
<td>LBP</td>
<td>Lower back pain</td>
</tr>
<tr>
<td>LDH</td>
<td>Lactate dehydrogenase</td>
</tr>
<tr>
<td>LE</td>
<td>Lower extremity</td>
</tr>
<tr>
<td>LFT</td>
<td>Liver function test</td>
</tr>
<tr>
<td>LGIB</td>
<td>Lower gastrointestinal bleeding</td>
</tr>
<tr>
<td>LLL</td>
<td>Left lower lobe</td>
</tr>
<tr>
<td>LLQ</td>
<td>Left lower quadrant</td>
</tr>
<tr>
<td>LMN</td>
<td>Lower motor neuron</td>
</tr>
<tr>
<td>LMP</td>
<td>Last menstrual period</td>
</tr>
<tr>
<td>LOC</td>
<td>Loss of consciousness</td>
</tr>
<tr>
<td>LP</td>
<td>Lumbar puncture</td>
</tr>
<tr>
<td>LPFB</td>
<td>Left posterior fascicular block</td>
</tr>
<tr>
<td>LV</td>
<td>Left ventricle</td>
</tr>
<tr>
<td>LVAD</td>
<td>Left ventricular assist device</td>
</tr>
<tr>
<td>LVH</td>
<td>Left ventricular hypertrophy</td>
</tr>
<tr>
<td>MAHA</td>
<td>Microangiopathic hemolytic anemia</td>
</tr>
<tr>
<td>MAP</td>
<td>Mean arterial pressure</td>
</tr>
<tr>
<td>MAT</td>
<td>Multifocal atrial tachycardia</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>MCP</td>
<td>Metacarpophalangeal</td>
</tr>
<tr>
<td>MDR</td>
<td>Multiple drug resistance</td>
</tr>
<tr>
<td>MDRO</td>
<td>multi-drug resistant organism</td>
</tr>
<tr>
<td>MDS</td>
<td>myelodysplastic syndrome</td>
</tr>
<tr>
<td>MH</td>
<td>Malignant hyperthermia</td>
</tr>
<tr>
<td>MI</td>
<td>Myocardial infarction</td>
</tr>
<tr>
<td>min</td>
<td>Minute(s)</td>
</tr>
<tr>
<td>MM</td>
<td>Mucous membrane</td>
</tr>
<tr>
<td>mo</td>
<td>Month(s)</td>
</tr>
<tr>
<td>mod</td>
<td>Moderate</td>
</tr>
<tr>
<td>MR</td>
<td>Mitral regurgitation</td>
</tr>
<tr>
<td>MRA</td>
<td>Magnetic resonance angiography</td>
</tr>
<tr>
<td>MRCP</td>
<td>mental retardation/cerebral palsy</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>MRSA</td>
<td>Methicillin-resistant <em>Staphylococcus aureus</em></td>
</tr>
<tr>
<td>MRV</td>
<td>Magnetic resonance venography</td>
</tr>
<tr>
<td>MS</td>
<td>Mitral stenosis</td>
</tr>
<tr>
<td>MSK</td>
<td>musculoskeletal</td>
</tr>
<tr>
<td>MV</td>
<td>Mitral valve</td>
</tr>
<tr>
<td>MVC</td>
<td>Motor vehicle collision</td>
</tr>
<tr>
<td>MVP</td>
<td>Mitral valve prolapsed</td>
</tr>
<tr>
<td>N/V</td>
<td>Nausea/vomiting</td>
</tr>
<tr>
<td>NAPQI</td>
<td>N-acetyl-p-benzoquinone imine</td>
</tr>
<tr>
<td>NCHCT</td>
<td>non-contrast head computed tomography</td>
</tr>
<tr>
<td>NEC</td>
<td>Necrotizing enterocolitis</td>
</tr>
<tr>
<td>neg</td>
<td>Negative</td>
</tr>
<tr>
<td>NGT</td>
<td>nasogastric tube</td>
</tr>
<tr>
<td>NHL</td>
<td>non-Hodgkin’s lymphoma</td>
</tr>
<tr>
<td>NIF</td>
<td>Negative inspiratory force</td>
</tr>
<tr>
<td>NIPPV</td>
<td>non-invasive positive-pressure ventilation</td>
</tr>
<tr>
<td>NIV</td>
<td>Noninvasive ventilation</td>
</tr>
<tr>
<td>nl</td>
<td>Normal</td>
</tr>
<tr>
<td>NMS</td>
<td>Neuroleptic malignant syndrome</td>
</tr>
<tr>
<td>NPJT</td>
<td>Nonparoxysmal junctional tachycardia</td>
</tr>
</tbody>
</table>
NPO  Nil per OS
NPV  Negative predictive value
NRB  Nonrebreather
NSAID  Nonsteroidal anti-inflammatory drug
NSTEMI  Non-ST-elevation MI
NSTV  Nonsustained ventricular tachycardia
NTG  Nitroglycerin
o/w  Otherwise
O₂  Oxygen
OA  Osteoarthritis
OCP  Oral contraceptive pill
OE  Otitis externa
OM  Otitis media
OMFS  Oral and maxillofacial surgery
OR  Operating room
ORIF  Open reduction and internal fixation
OSA  Obstructive sleep apnea
OTC  Over-the-counter
otw  otherwise
outpt(s)  Outpatient(s)
p/w  Presents with
PAN  Polyarteritis nodosa
PCI  Percutaneous coronary intervention
PCKD  Polycystic kidney disease
PCN  Penicillin
PCOS  Polycystic ovary syndrome
PCP  Pneumocystis jirovecii pneumonia, primary care physician
PCR  Polymerase chain reaction
PDA  Patent ductus arteriosus
PE  Pulmonary embolism
PEEP  Positive end-expiratory pressure
PEFR  Peak expiratory flow rate
PGE₁  Prostaglandin E₁
PHT  Pulmonary hypertension
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PID</td>
<td>Pelvic inflammatory disease</td>
</tr>
<tr>
<td>PIP</td>
<td>Proximal interphalangeal joint</td>
</tr>
<tr>
<td>pl</td>
<td>Pleural</td>
</tr>
<tr>
<td>PLT</td>
<td>Platelet</td>
</tr>
<tr>
<td>PM</td>
<td>Pacemaker</td>
</tr>
<tr>
<td>PMH</td>
<td>Past medical history</td>
</tr>
<tr>
<td>PMR</td>
<td>Polymyalgia rheumatica</td>
</tr>
<tr>
<td>PMV</td>
<td>Percutaneous mitral valvuloplasty</td>
</tr>
<tr>
<td>PNA</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>PND</td>
<td>Paroxysmal nocturnal dyspnea</td>
</tr>
<tr>
<td>PostTP</td>
<td>Posttest probability</td>
</tr>
<tr>
<td>PPM</td>
<td>Permanent pacemaker</td>
</tr>
<tr>
<td>PPV</td>
<td>Positive predictive value, positive pressure ventilation</td>
</tr>
<tr>
<td>PQRST</td>
<td>Palliation, quality, radiation, severity, timing</td>
</tr>
<tr>
<td>PRBC</td>
<td>Packed red blood cell</td>
</tr>
<tr>
<td>PreTP</td>
<td>Pretest probability</td>
</tr>
<tr>
<td>PRWP</td>
<td>Poor R-wave progression</td>
</tr>
<tr>
<td>PS</td>
<td>Pulmonary stenosis</td>
</tr>
<tr>
<td>PT</td>
<td>Prothrombin time, Posterior tibialis</td>
</tr>
<tr>
<td>pt(s)</td>
<td>Patient(s)</td>
</tr>
<tr>
<td>PTX</td>
<td>Pneumothorax</td>
</tr>
<tr>
<td>PUD</td>
<td>Peptic ulcer disease</td>
</tr>
<tr>
<td>PVD</td>
<td>Peripheral vascular disease</td>
</tr>
<tr>
<td>Qw</td>
<td>Q wave</td>
</tr>
<tr>
<td>R</td>
<td>Right</td>
</tr>
<tr>
<td>r/o</td>
<td>Rule out</td>
</tr>
<tr>
<td>RAD</td>
<td>Right axis deviation</td>
</tr>
<tr>
<td>RAE</td>
<td>Right atrial enlargement</td>
</tr>
<tr>
<td>RBBB</td>
<td>Right bundle branch block</td>
</tr>
<tr>
<td>RF</td>
<td>Risk factor</td>
</tr>
<tr>
<td>RLQ</td>
<td>Right lower quadrant</td>
</tr>
<tr>
<td>RMSF</td>
<td>Rocky Mountain spotted fever</td>
</tr>
<tr>
<td>ROM</td>
<td>Range of motion</td>
</tr>
<tr>
<td>ROS</td>
<td>Review of systems</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>ROSC</td>
<td>Return of spontaneous circulation</td>
</tr>
<tr>
<td>RPR</td>
<td>Rapid plasma reagin</td>
</tr>
<tr>
<td>RR</td>
<td>Respiratory rate</td>
</tr>
<tr>
<td>RSI</td>
<td>Rapid sequence intubation</td>
</tr>
<tr>
<td>RSV</td>
<td>Respiratory syncytial virus</td>
</tr>
<tr>
<td>RTA</td>
<td>Renal tubular acidosis</td>
</tr>
<tr>
<td>RUG</td>
<td>Retrograde urethrogram</td>
</tr>
<tr>
<td>RUQ</td>
<td>Right upper quadrant</td>
</tr>
<tr>
<td>RV</td>
<td>Right ventricle</td>
</tr>
<tr>
<td>RVH</td>
<td>Right ventricular hypertrophy</td>
</tr>
<tr>
<td>RVOT</td>
<td>Right ventricular outflow tract</td>
</tr>
<tr>
<td>rxn</td>
<td>Reaction</td>
</tr>
<tr>
<td>SAH</td>
<td>Subarachnoid hemorrhage</td>
</tr>
<tr>
<td>SBE</td>
<td>Subacute bacterial endocarditis</td>
</tr>
<tr>
<td>SBO</td>
<td>Small bowel obstruction</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic blood pressure</td>
</tr>
<tr>
<td>SCD</td>
<td>Sickle cell disease</td>
</tr>
<tr>
<td>SCFE</td>
<td>Slipped capital femoral epiphysis</td>
</tr>
<tr>
<td>SCM</td>
<td>Sternocleidomastoid</td>
</tr>
<tr>
<td>SDH</td>
<td>Subdural hemorrhage</td>
</tr>
<tr>
<td>sec</td>
<td>Second(s)</td>
</tr>
<tr>
<td>sens</td>
<td>Sensitive, Sensitivity</td>
</tr>
<tr>
<td>SFV</td>
<td>Superficial femoral vein</td>
</tr>
<tr>
<td>SI</td>
<td>Suicidal ideation</td>
</tr>
<tr>
<td>SIRS</td>
<td>Systemic inflammatory response syndrome</td>
</tr>
<tr>
<td>SJS</td>
<td>Stevens–Johnson syndrome</td>
</tr>
<tr>
<td>SLE</td>
<td>Systemic Lupus Erythematosus</td>
</tr>
<tr>
<td>SMA</td>
<td>Superior mesenteric artery</td>
</tr>
<tr>
<td>SOB</td>
<td>Shortness of breath</td>
</tr>
<tr>
<td>spec</td>
<td>Specific, Specificity</td>
</tr>
<tr>
<td>SS</td>
<td>Serotonin syndrome</td>
</tr>
<tr>
<td>SSRI</td>
<td>Selective serotonin reuptake inhibitor</td>
</tr>
<tr>
<td>SSSS</td>
<td>Staphylococcal scalded skin</td>
</tr>
<tr>
<td>ST</td>
<td>Sinus tachycardia</td>
</tr>
<tr>
<td>Acronym</td>
<td>Full Form</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>ST-T</td>
<td>ST-segment-T wave</td>
</tr>
<tr>
<td>STD</td>
<td>Sexually transmitted disease</td>
</tr>
<tr>
<td>STEMI</td>
<td>ST-segment elevation MI</td>
</tr>
<tr>
<td>SVC</td>
<td>superior vena cava</td>
</tr>
<tr>
<td>SVT</td>
<td>Supraventricular tachycardia</td>
</tr>
<tr>
<td>sxS</td>
<td>Symptoms</td>
</tr>
<tr>
<td>sz</td>
<td>Seizure</td>
</tr>
<tr>
<td>T+S</td>
<td>type and screen</td>
</tr>
<tr>
<td>TAH</td>
<td>total abdominal hysterectomy</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>TBI</td>
<td>Traumatic brain injury</td>
</tr>
<tr>
<td>TBW</td>
<td>Total body weight</td>
</tr>
<tr>
<td>TCA</td>
<td>Tricyclic antidepressants</td>
</tr>
<tr>
<td>TCP</td>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td>TEE</td>
<td>Transesophageal echocardiogram</td>
</tr>
<tr>
<td>Tele</td>
<td>Telemetry</td>
</tr>
<tr>
<td>TEN</td>
<td>Toxic epidermal necrolysis</td>
</tr>
<tr>
<td>TIA</td>
<td>Transient ischemic attack</td>
</tr>
<tr>
<td>TM</td>
<td>Tympanic membrane</td>
</tr>
<tr>
<td>TMJ</td>
<td>Temporomandibular joint</td>
</tr>
<tr>
<td>TOA</td>
<td>Tubo-ovarian abscess</td>
</tr>
<tr>
<td>tox</td>
<td>toxicity</td>
</tr>
<tr>
<td>TRACO</td>
<td>transfusion-associated circulatory overload</td>
</tr>
<tr>
<td>TRALI</td>
<td>transfusion-associated lung injury</td>
</tr>
<tr>
<td>TSH</td>
<td>thyroid stimulating hormone</td>
</tr>
<tr>
<td>TSS</td>
<td>Toxic shock syndrome</td>
</tr>
<tr>
<td>TTE</td>
<td>Transthoracic echocardiogram</td>
</tr>
<tr>
<td>TTP</td>
<td>Thrombotic thrombocytopenic purpura</td>
</tr>
<tr>
<td>TWI</td>
<td>T-wave inversion</td>
</tr>
<tr>
<td>tx</td>
<td>Treatment</td>
</tr>
<tr>
<td>TXA</td>
<td>tranexamic acid</td>
</tr>
<tr>
<td>u/s</td>
<td>Ultrasound</td>
</tr>
<tr>
<td>UA</td>
<td>Urine analysis, Unstable angina</td>
</tr>
<tr>
<td>UAG</td>
<td>Urinary anion gap</td>
</tr>
</tbody>
</table>
### Drugs Dosages Used in PALS

<table>
<thead>
<tr>
<th>Medication</th>
<th>Route</th>
<th>nl Dose</th>
<th>Incremental Dose</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenosine</td>
<td>Rapid IV push</td>
<td>0.1 mg/kg (up to 6 mg)</td>
<td>0.2 mg/kg</td>
<td>12 mg</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Rapid IV/IO</td>
<td>5 mg/kg</td>
<td></td>
<td>15 mg/kg/d</td>
</tr>
<tr>
<td>Atropine</td>
<td>IV/IO/ET</td>
<td>0.02 mg/kg</td>
<td>0.04 mg/kg</td>
<td>0.5 mg single dose</td>
</tr>
<tr>
<td>Calcium chloride</td>
<td>IV/IO</td>
<td>20 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dobutamine</td>
<td>IV/IO</td>
<td>2–20 μg/kg/min</td>
<td></td>
<td>Titrate to effect</td>
</tr>
<tr>
<td>Epinephrine PEA, bradycardia</td>
<td>IV/IO: 0.01 mg/kg (1:10000) ET: 0.1 mg/kg (1:1000)</td>
<td>q3–5min during CPR</td>
<td>0.1 mL/kg</td>
<td></td>
</tr>
<tr>
<td>Glucose</td>
<td>IV/IO</td>
<td>0.5–1 g/kg</td>
<td></td>
<td>2–4 mL/kg 25%</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>IV/IO/ET</td>
<td>1 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mg sulfate</td>
<td>IV/IO</td>
<td>25–50 μg/kg</td>
<td></td>
<td>2 g</td>
</tr>
<tr>
<td>Naloxone</td>
<td></td>
<td>If &lt;5 yr or &lt;20 mg: 0.1 mg/kg</td>
<td></td>
<td>Titrate to effect</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If &gt;5 yr or &gt;20 kg: 2 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cardioversion in PALS

<table>
<thead>
<tr>
<th>Reason</th>
<th>nl Dose</th>
<th>Incremental Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tachycardia</td>
<td>0.5–1 J/kg</td>
<td>2 J/kg if ineffective</td>
</tr>
<tr>
<td>VF/pulseless VT</td>
<td>2–4 J/kg</td>
<td>4 J/kg if ineffective w/i 30–60 sec after med</td>
</tr>
</tbody>
</table>

MECHANICAL VENTILATION

(NEJM 2001;344:1986)
**Approach**

- Choose invasive ventilation vs. NIV → choose type of NIV or invasive mode → adjust settings
- In the ED, NIV is used to avoid intubation, esp in acute COPD/RAD or CHF/pulm edema

<table>
<thead>
<tr>
<th>Indications for Ventilation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of Ventilation</strong></td>
</tr>
<tr>
<td>Noninvasive</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Invasive</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Noninvasive Ventilation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPAP</strong></td>
</tr>
<tr>
<td>Opens atelectatic alveoli, can improve respiratory mechanics &amp; hemodynamics</td>
</tr>
<tr>
<td>In ACPE → ↓ intubation, mortality</td>
</tr>
<tr>
<td>Relative CIs: Aspiration risk, vomiting, UGIB/epistaxis, agitation or lethargy precluding compliance, hemodynamic instability</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Invasive Ventilation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Invasive Ventilation Modes</strong></td>
</tr>
<tr>
<td>Assist control</td>
</tr>
<tr>
<td><strong>Invasive Ventilation Modes</strong></td>
</tr>
<tr>
<td>Synchronized intermittent mandatory ventilation</td>
</tr>
<tr>
<td>Volume targeted</td>
</tr>
</tbody>
</table>
### Pressure targeted
Set inspiratory pressure for assisted breaths
Useful for pts at risk for barotrauma

### Other Ventilator Settings

<table>
<thead>
<tr>
<th>Standard initial settings</th>
<th>Assist control ventilation, TV 4–8 mL/kg, RR 12–14, FiO$_2$ 100%, PEEP 5 cm H$_2$O, Wean FiO$_2$ as quickly as tolerated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other modes</td>
<td>See above</td>
</tr>
<tr>
<td>PEEP</td>
<td>Positive pressure present during exhalation → maintains patent alveoli → ↓ shunting &amp; ↑ oxygenation (cardiac effects dictate CO &amp; oxygenation); 5 cm H$_2$O = “physiologic” PEEP</td>
</tr>
<tr>
<td></td>
<td>Preload: Decreased via ↑ intrathoracic pressure → ↓ venous return</td>
</tr>
<tr>
<td></td>
<td>Afterload: Decreased via ↓ transmural cardiac pressure</td>
</tr>
<tr>
<td>Auto-PEEP</td>
<td>Presence of flow at end expiration due to “breath stacking”: ↓ time for exhalation → incomplete expiration → lungs “trap” air → leading to potential compromise of respiratory mechanics &amp; hemodynamics (↓ preload)</td>
</tr>
<tr>
<td>Inspiratory flow rate</td>
<td>↑ Flow rate → ↓ inspiratory time → ↑ expiratory time (ie, ↓ I:E ratio) → improves ventilation &amp; minimizes auto-PEEP in obstructive dz (asthma, COPD)</td>
</tr>
<tr>
<td>Pplat</td>
<td>Plateau pressure, measured at end expiration; determined by respiratory system compliance</td>
</tr>
<tr>
<td></td>
<td>↑ Pplat w/ obesity, pulmonary edema, ARDS → auto-PEEP, asynchronous breathing</td>
</tr>
<tr>
<td>PIP</td>
<td>Peak pressure measured during inspiration affected by airway resistance plus lung/chest wall compliance</td>
</tr>
<tr>
<td></td>
<td>If ↑ PIP &amp; nl Pplat → cause = airway resistance (bronchospasm, secretions, etc.)</td>
</tr>
</tbody>
</table>

### Making Changes to the Ventilator

| Improve oxygenation       | ↑ PEEP, ↑ FiO$_2$ |
| Improve ventilation       | ↑ TV, ↑ RR |
| Reduce auto-PEEP          | ↓ RR, ↑ expiratory time, ↑ insp flow rate |
| Permissive hypercapnia    | Low TV (4–6 mL/kg) to reduce baro/volutrauma in ALI/ARDS |

### ANALGESIA & CONSCIOUS SEDATION
### Opioids

<table>
<thead>
<tr>
<th>Medication</th>
<th>nl Dose</th>
<th>Incremental Dose</th>
<th>Onset of Action</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>0.1 mg/kg</td>
<td>½ nl dose</td>
<td>5–10 min</td>
<td>3–4 h</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>0.5–2 mg</td>
<td>½ nl dose</td>
<td>3–5 min</td>
<td>2–4 h</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>0.5–1 μg/kg</td>
<td>25 μg</td>
<td>1–2 min</td>
<td>10 min–1 h</td>
</tr>
</tbody>
</table>

### Benzodiazepines

<table>
<thead>
<tr>
<th>Medication</th>
<th>nl Dose</th>
<th>Incremental Dose</th>
<th>Onset of Action</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diazepam</td>
<td>5–10 mg</td>
<td>2.5 mg</td>
<td>1–5 min</td>
<td>30 min–2 h</td>
</tr>
<tr>
<td>Midazolam</td>
<td>1–5 mg</td>
<td>0.5–1 mg</td>
<td>1–2 min</td>
<td>15–60 min</td>
</tr>
</tbody>
</table>

### Conscious Sedation Medications

<table>
<thead>
<tr>
<th>Medication</th>
<th>nl Dose</th>
<th>Incremental Dose</th>
<th>Onset of Action</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketamine*</td>
<td>1–2 mg/kg IV or 2–4 mg/kg IM</td>
<td>1 mg/kg</td>
<td>1–2 min</td>
<td>10–30 min</td>
</tr>
<tr>
<td>Chloral hydrate**</td>
<td>50–75 mg/kg prn</td>
<td>25–75 mg/kg</td>
<td>20–30 min</td>
<td>2–6 h</td>
</tr>
<tr>
<td>Propofol</td>
<td>1–3 mg/kg</td>
<td>0.5–5 mg/kg</td>
<td>&lt;1 min</td>
<td>8–10 min</td>
</tr>
<tr>
<td>Etomidate</td>
<td>0.2–0.5 mg/kg</td>
<td>0.05 mg/kg</td>
<td>&lt;1 min</td>
<td>5–8 min</td>
</tr>
<tr>
<td>Nitrous oxide</td>
<td>30–50%</td>
<td>Constant</td>
<td>1–2 min</td>
<td>5 min</td>
</tr>
</tbody>
</table>

*Consider administration w/ glycopyrrolate (0.01 mg/kg) or atropine (0.01 mg/kg) as an antisialogogue

**Pediatric only, rarely used

### Reversal Agents

<table>
<thead>
<tr>
<th>Medication</th>
<th>nl Dose</th>
<th>Incremental Dose</th>
<th>Onset of Action</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naloxone (opioids)</td>
<td>0.4–2 mg</td>
<td>0.04 mg</td>
<td>1–2 min</td>
<td>30 min–1 h</td>
</tr>
<tr>
<td>Flumazenil (benzo)</td>
<td>1 mg</td>
<td>0.2 mg</td>
<td>1–2 min</td>
<td>30 min–1.5 h</td>
</tr>
<tr>
<td>Drug</td>
<td>Class</td>
<td>Dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------</td>
<td>---------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pressors, Inotropes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenylephrine</td>
<td>α&lt;sub&gt;1&lt;/sub&gt;</td>
<td>50–200 μg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>α&lt;sub&gt;1&lt;/sub&gt; &gt; β&lt;sub&gt;1&lt;/sub&gt;</td>
<td>0.05–0.5 μg/kg/min, max ~5 μg/kg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasopressin</td>
<td>V&lt;sub&gt;1&lt;/sub&gt;</td>
<td>0.04 U/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dopamine</td>
<td>Dβ, Dα, βD</td>
<td>0.5–2 μg/kg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2–10 μg/kg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;10 μg/kg/min, max 50 μg/kg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dobutamine</td>
<td>β&lt;sub&gt;1&lt;/sub&gt; &gt; β&lt;sub&gt;2&lt;/sub&gt;</td>
<td>2–20 μg/kg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epinephrine</td>
<td>α&lt;sub&gt;1&lt;/sub&gt;, α&lt;sub&gt;2&lt;/sub&gt;, β&lt;sub&gt;1&lt;/sub&gt;, β&lt;sub&gt;2&lt;/sub&gt;</td>
<td>0.05–0.5 μg/kg/min, max ~5 μg/kg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vasodilators</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitroglycerin</td>
<td>NO</td>
<td>5–1000 μg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitroprusside</td>
<td>NO</td>
<td>0.1–10 μg/kg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enalaprilat</td>
<td>ACEI</td>
<td>0.625–2.5 mg over 5 min then 0.625–5 mg q6h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydralazine</td>
<td>Vasodilator</td>
<td>5–20 mg q20–30min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labetalol</td>
<td>α&lt;sub&gt;1&lt;/sub&gt;, β&lt;sub&gt;1&lt;/sub&gt;, β&lt;sub&gt;2&lt;/sub&gt; blockers</td>
<td>20 mg over 2 min then 20–80 mg q10min or 10–120 mg/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicardipine</td>
<td>NO</td>
<td>2.5–15 mg/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antiarrhythmics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Class III</td>
<td>150 mg over 10 min, then 1 mg/min × 6 h, then 0.5 mg/min × 18 h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lidocaine</td>
<td>Class IB (Na channel)</td>
<td>1–1.5 mg/kg (100 mg) then 1–4 mg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procainamide</td>
<td>Class IA (Na channel)</td>
<td>17 mg/kg (1 g) over 60 min, then 1–4 mg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ibutilide</td>
<td>Class III (K channel)</td>
<td>1 mg over 10 min, may repeat × 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Propranolol</td>
<td>βB</td>
<td>0.5–1 mg q5min then 1–10 mg/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Class</td>
<td>Dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esmolol</td>
<td>β₁ blocker</td>
<td>β₁ blocker &gt; β₂ blocker 500 μg/kg (20–40 mg) over 1 min, then 25–300 μg/kg/min (2–20 mg/min)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td>CCB</td>
<td>2.5–5 mg over 1–2 min repeat 5–10 mg in 15–30 min prn, 5–20 mg/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diltiazem</td>
<td>CCB</td>
<td>0.25 mg/kg (20 mg) over 2 min, reload 0.35 mg/kg (25 mg) × 1 prn, then 5–15 mg/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenosine</td>
<td>Purinergic</td>
<td>6 mg rapid push, if no response 12 mg rapid push, repeat × 1 prn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine</td>
<td>Opioid</td>
<td>1–unlimited mg/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etomidate</td>
<td>Anesthetic</td>
<td>0.2–0.5 mg (100–300 mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Propofol</td>
<td>Anesthetic</td>
<td>1–3 mg/kg (50–200 mg) then 0.3–5 mg/kg/h (20–400 mg/h)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diazepam</td>
<td>Benzo</td>
<td>1–5 mg q1–2h then q6 prn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Midazolam</td>
<td>Benzo</td>
<td>0.5–2 mg q5min prn or 0.5–4 mg then 1–10 mg/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketamine</td>
<td>Anesthetic</td>
<td>1–2 mg/kg (60–150 mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haloperidol</td>
<td>Antipsychotic</td>
<td>2–5 mg q20–30min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Succinylcholine</td>
<td>Depolarizing</td>
<td>0.6–1.1 mg/kg (70–100 mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancuronium</td>
<td>nACh</td>
<td>0.08 mg/kg (2–4 mg) q30–90min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rocuronium</td>
<td>nACh</td>
<td>0.6 mg/kg (60–100 mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vecuronium</td>
<td>nACh</td>
<td>0.08 mg/kg (5–10 mg) over 1–3 min, then 0.5–0.1 mg/kg/h (2–8 mg/h)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cisatracurium</td>
<td>nACh</td>
<td>5–10 μg/kg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td></td>
<td>0.1 U/kg/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucagon</td>
<td></td>
<td>5–10 mg then 1–5 mg/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Octreotide</td>
<td>Somatostatin analog</td>
<td>50 μg then 50 μg/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Antiepileptic</td>
<td>20 mg/kg (1–1.5 g) over 20–30 min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fosphenytoin</td>
<td>Antiepileptic</td>
<td>20 mg/kg (1–1.5 g) over 10 min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medication</td>
<td>Type</td>
<td>Dosage or Protocol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>Barbiturate</td>
<td>20 mg/kg (1–1.5 g) over 20 min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiopental</td>
<td>Barbiturate</td>
<td>3–5 mg/kg (200–400 mg) over 2 min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mannitol</td>
<td>Osmotic</td>
<td>1.5–2 g/kg over 30–60 min, repeat q6–12h to keep oSm 310–320</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naloxone</td>
<td>Opioid antagonist</td>
<td>0.4–2 mg q2–3min to total 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flumazenil</td>
<td>Benzo antagonist</td>
<td>0.2 mg over 30 sec then 0.3 mg over 30 sec, may repeat 0.5 mg over 30 sec to max 3 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fentanyl</td>
<td>Opioid</td>
<td>50–100 μg then 50–unlimited μg/h</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**EQUATIONS**

**Metabolic**

**Anion Gap:** \( \text{Na} – (\text{Cl} + \text{Bicarb}) \)

**Delta/Delta** = \( \frac{(\text{actual anion gap} – \text{normal gap})}{(\text{normal} \ \text{HCO}_3^– – \text{actual} \ \text{HCO}_3^–)} \)

**Total body water (TBW)** = \( \text{weight (kg)} \times 0.6 \) (use 0.5 if female/elderly, 0.6 for infants)

**Corrected Na** = \( \text{measured Na} + [2.4 \times (\text{measured glucose} – 100)] \)

**Calculated osmoles** = \( (2 \times \text{Na}) + (\text{glucose}/18) + (\text{BUN}/2.8) + (\text{EtOH}/4.6) \)

**Osmolal gap** = \( \text{measured osmoles} – \text{calculated osmoles (mL)} \)

**Estimated Cr clearance** = \( \frac{[140 – \text{age (y)}] \times \text{wt (kg)}}{\text{Serum Cr (mg/dL)} \times 72} \times (0.85 \text{ in women}) \)

**Pediatric fluid maintenance (4-2-1 Rule):**

\( (4 \text{ cc/kg for 1st 10 kg}) + (2 \text{ cc/kg for 2nd 10 kg}) + (1 \text{ cc/kg for remainder kg}) \)

**Hyponatremia:**

\[
\Delta [\text{Na}]\text{literate infusate} = \frac{[\text{Na}]\text{infusate} \times [\text{Na}]\text{serum}}{\text{TBW} + 1}
\]

\[
\text{Rate of infusion (mL/h)} = \frac{1000 \times [\text{TBW} \times (\text{desired Na} – \text{serum Na})]}{[\text{Na (mmol/L)}]\text{infusate} \times \text{time (h)}}
\]
Hyponatremia:

$$\text{Free water deficit} = \text{total body water} \times [(140/\text{serum Na}) - 1]$$

$$\Delta [\text{Na}] \text{/liter infusate} = \frac{([\text{Na}] \text{infusate} + [\text{K}] \text{infusate}) - [\text{Na}] \text{serum}}{\text{TBW} + 1}$$

$$\text{Total infusion (L)} = \frac{\text{Desired} \ [\text{Na} \ (\text{mEq/L})] - \text{Serum} \ [\text{Na} \ (\text{mEq/L})]}{\Delta [\text{Na}] \text{/liter infusate}}$$

Rate of infusion (mL/h) = total infusion (mL)/24 h

**CARDIOPULMONARY**

A-a gradient = PAO$_2$ – PaO$_2$ (nl ≈ 4 + (age/4))

Stroke volume = cardiac output/heart rate

Mean arterial pressure = $\frac{[SBP + (DBP \times 2)]}{3}$ (nl 70–100 mmHg)

**PROCEDURES**

<table>
<thead>
<tr>
<th>Type</th>
<th>Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory</td>
<td>Airway management (Ch. 17), mechanical ventilation (see above), thoracentesis, tube thoracostomy</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Cardiac pacing, pericardiocentesis, ED thoracotomy</td>
</tr>
<tr>
<td>Vascular</td>
<td>Arterial puncture/catheterization, peripheral IV, central venous catheterization &amp; CVP monitoring, venous cutdown, IO placement</td>
</tr>
<tr>
<td>Anesthesia</td>
<td>Conscious sedation, nerve blocks</td>
</tr>
<tr>
<td>Skin &amp; soft tissue</td>
<td>Wound closure, FB removal, I&amp;D</td>
</tr>
<tr>
<td>GI</td>
<td>Nasogastric intubation, balloon tamponade of esophageal varices, paracentesis, anorectal procedures</td>
</tr>
<tr>
<td>Orthopedic</td>
<td>Fracture/dislocation reductions, splinting, arthrocentesis, compartment pressure measurement</td>
</tr>
</tbody>
</table>
GU | Bladder catheterization (urethral, suprapubic)
OB | Emergency delivery
Neuro | LP, Dix–Hallpike/Epley maneuver
Ophtho | Eye irrigation, FB removal, lateral canthotomy
ENT | Peritonsillar abscess drainage, ear canal & nasal FB removal, drainage of auricular hematoma
Dental | Dental nerve blocks, abscess drainage, mandibular reduction

ARterial Puncture and Catheterization

Purpose
- Puncture to obtain ABG; catheterization for continuous real-time BP monitoring or need for repeat arterial blood sampling

Equipment
- Puncture: Local anesthetic, 3-mL syringe, 22-gauge needle (or insulin syringe)
- Catheterization: Arm board, tape, angiocath (size depends on artery cannulated), guidewire, pressure tubing, pressure transducer, suture, needle driver, sterile dressing

Positioning
- Ideally placed in the radial, femoral, or DP artery; brachial & axillary are also useable but they are terminal (no collateral supply) so worse prognosis if thrombosis occurs. Document Allen’s test before & after catheterization of radial artery.

Procedure
- Sterilize area, use sterile gloves, but generally drape & gown are not required
- Puncture: Palpate artery w/ nondominant hand, insert needle distal to palpated artery at a 30° angle to skin, advance until flash in syringe or angiocath, remove 1–2 mL blood, remove air bubbles, & send immediately to lab on ice. US w/ sterile cover may help.
- Catheterization: Immobilize wrist in slight dorsiflexion using tape/arm board, insert needle as above until flash is observed, then advance
another 2–3 mm, remove needle & leave catheter, pull back slowly until arterial blood flow is observed, pass guidewire into artery, advance catheter to hub along the guidewire, remove wire, check flow, attach to pressure tubing, suture in place, apply sterile dressing

Complications

- Hematoma, AV fistula, pseudoaneurysm, bleeding, PAIN. Rarely: Catheter infection, thrombosis or stenosis of artery, hand/limb ischemia.

Central Venous Catheterization

Purpose

- Rapid volume resuscitation, emergency venous access, administration of spec medicines (ie, pressors, high concentration electrolytes), central venous pressure monitoring
- Sometimes used when peripheral access is not obtainable, but 1st consider external jugular, basilic, or cephalic vein catheterization, or IO access

Choice of Site

- Each site has advantages & disadvantages. Overall, no compelling evidence that one site is uniformly superior to others, or definite difference in infection risk. CDC recommends weighing risk/benefits for each pt, but avoiding femoral when possible (“Guidelines for the Prevention of Intravascular Catheter-related Infections”, 2011, CDC: www.cdc.gov).

<table>
<thead>
<tr>
<th>Site</th>
<th>Pros</th>
<th>Cons</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Internal jugular</td>
<td>Bleeding easily controlled</td>
<td>Can be more time consuming w/ U/S</td>
<td>U/S guidance is now the standard of care for IJ</td>
</tr>
<tr>
<td></td>
<td>Low mechanical cx rate when used w/ U/S</td>
<td>Intermediate risk of infection</td>
<td></td>
</tr>
<tr>
<td>Infraclavicular subclavian</td>
<td>Fast, considered ↓ infection rate</td>
<td>↑ Risk of PTX ↓ Bleeding control</td>
<td>± U/S guided</td>
</tr>
<tr>
<td>Supraclavicular</td>
<td>Practical for cardiac</td>
<td>↑ Risk of PTX</td>
<td>± U/S guided</td>
</tr>
<tr>
<td>subclavian arrest</td>
<td>↓ Bleeding control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Femoral Fast, practical during arrest</td>
<td>Thought to have ↑ risk of infection ± U/S guided</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Equipment**

- Chlorhexidine, cap, mask, sterile drape/gloves/gown, catheter device kit (includes 1% lidocaine w/ 10-mL syringe & 25-gauge needle, catheterization needle/syringe, guidewire, scalpel, dilator, catheter, needle driver, scissors, suture, sterile dressing)

**Positioning**

- Supine pt, Trendelenburg position for IJ; can do subclavians upright (eg, in CHF)
- Internal jugular: Bedside U/S guidance recommended if available
  - Locate the IJ vein (compressible) & carotid artery (pulsatile, noncompressible) using a sterile U/S probe w/i the triangle created by the clavicle & the sternal & clavicular heads of the sternocleidomastoid muscle
  - Advance the needle toward the IJ vein & away from the carotid artery w/ needle at 30° angle to skin while observing the needle penetrate the vein on U/S towards ipsilateral nipple
  - Confirm venous cannulation via U/S once the wire is in place
- Infraclavicular: Insert needle 2 cm inferior & 2 cm lateral to the angle of the clavicle (located along the middle third), point toward spot just superior to the suprasternal notch & advance just posterior to the clavicle
- Supraclavicular: Insert needle at the junction of the middle & medial thirds of the clavicle, just posterior to the clavicle, point toward the contralateral nipple
- Femoral: Palpate femoral artery, then advance needle at 45° angle to skin toward the head just medial to the palpable artery

**Procedure**

- Rate of CVL-associated infection ↓ w/ use of observer & checklist (*NEJM* 2006;355:2725)
- Sterile technique. Attach catheterization needle to syringe, advance while aspirating.
- Remove syringe once vein is entered & check for free return of
nonpulsatile blood
- Place the curved end of the guidewire into the needle & advance, check that the wire passes easily, & advance to estimated location of SVC
- Remove the needle while keeping the wire in position
- Make a 1-cm incision through the dermis where the wire meets the skin
- Advance the dilator over the wire several centimeters, then remove the dilator
- Advance catheter over wire, advance to the estimated location of the SVC, remove wire
- Suture in place, cover w/ sterile dressing, obtain CXR to r/o PTX (for all but femoral lines)

**Complications**
- Arterial puncture (if needle/wire puncture & compressible, apply prolonged pressure). If a major artery was *dilated*, leave in place & consult IR & vascular surgery.
- PTX: Always r/o w/ XR. Always stat XR if SOB during line placement.
- Bloodstream infection, air embolus, nerve injury (phrenic, brachial plexus, femoral)

**Pearls**
- A triple-lumen CVC has a slower infusion rate than most PIVs, consider percutaneous introducer if large-volume resuscitation needed

---

**INCISION AND DRAINAGE**

**Purpose**
- Definitive tx of a soft-tissue abscess

**Equipment**
- Consider bedside U/S prior to procedure to confirm fluid collection. Hemostat, scissors, forceps, scalpel, packing gauze, 1–2% lidocaine w/ 10-mL syringe & 25-gauge needle.
Procedure
- Anesthetize skin over the most fluctuant area. Make a single, linear incision w/ scalpel over the entire length of the abscess cavity
- Dissect wound using a hemostat & probe into all corners of the cavity to break up loculations & evaluate for an FB, then irrigate wound
- Place enough packing gauze to prevent wound closure but do not pack tightly

INTRAOSSEOUS CATHETERIZATION

Purpose
- Rapid temporary vascular access. Increasing use in adults & nonemergent cases.

Equipment
- IO needle w/ stylet & syringe, EZ-IO drill if available, gauze

Positioning
- Anteromedial aspect of the proximal tibia, 1–3 cm distal to the tibial tuberosity
- Secondary options include distal femur or proximal humerus

Procedure
- Sterile technique. Advance IO needle/stylet perpendicular to the bone w/ firm pressure & a twisting motion until the cortex is penetrated, remove stylet, attach syringe & aspirate to correct positioning of the needle. Secure in place w/ gauze pads.

Complications
- Infection, bleeding, fracture, retained FB, pain

LUMBAR PUNCTURE

Purpose
- Dx of meningitis (in the absence of elevated ICP), SAH, idiopathic intracranial HTN, other infectious, inflammatory, neoplastic processes
Equipment
- Careful neurologic exam beforehand (avoid in any pt w/ focal neurologic findings), sterile technique, 20–22-gauge spinal or Whitacre needle, LP tray (w/ collecting tubes, lidocaine 1%, manometer/stopcock, 25-gauge needle, 10-cc syringe, sterile drapes)
- Consider U/S in obese pts to identify nonpalpable landmarks
- Consider CTH prior to procedure if concern for mass effect/elevated ICP

Positioning
- Lateral decubitus w/ shoulders/hips perpendicular to the bed (preferable & necessary to measure opening pressure) or sitting up on the edge of the bed
- Have the pt maximally flex neck, hips, & knees, & arch back, into a fetal position
- L4 spinous process is found at the intersection of a line b/w the spine & the iliac crests; enter through the interspace above or below this location

Procedure
- Anesthetize locally w/ lidocaine 1% using 25-gauge needle, then advance needle while aspirating → inject lidocaine into the interspinous ligament
- Advance spinal needle toward the umbilicus w/ bevel pointed toward the pt’s side (left or right) until a “pop” or sudden decrease in resistance is felt → remove the stylet
- Once clear fluid is obtained, attach the manometer & record opening pressure
- If fluid is not found, replace the stylet, pull back the needle to the level of SQ tissue, confirm that you are in midline, & reangle your needle slightly
- Obtain at least 1 cc in each collecting tube (more if extensive studies are necessary)
- Replace stylet, remove needle, place sterile dressing over wound
- Tests: Send for cell count (tubes #1, 4), protein/glucose (#2 or #3), gram stain & culture (#2 or #3)
Complications

- HA (5–40%), localized infection, epidural hematoma (rare), herniation (in cases of elevated ICP)

---

**Nasogastric Intubation**

**Purpose**

- Aspiration of stomach contents in pts at risk for recurrent vomiting (eg, GI obstruction), stomach decompression during trauma or after intubation

**Equipment**

- 16- or 18-gauge NG tube, lubricant, 60-cc syringe, cup of water w/ straw, towel, tape, stethoscope, topical anesthetic jelly, nasal vasoconstrictor

**Positioning**

- Sitting up, chin down

**Procedure**

- Place towel over chest, estimate distance to stomach (from xiphoid to earlobe to stomach)
- Lubricate tube, spray patent nare w/ vasoconstrictor, apply anesthetic jelly, wait a few minutes
- Advance tube posteriorly along the floor of the nose until it enters the oropharynx, then have pt continuously sip water through straw while the tube is advanced into esophagus; once in the esophagus, quickly advance the tube to the desired distance
- Confirm placement by insufflating the NG tube w/ air using 60-cc syringe & listening over stomach for gush of air, & aspiration of GI contents. Obtain upright CXR if any concern.
- Secure tube using tape attached to the nose & wrapped around the tube from each side; tape should also be used to attach a 2nd segment of the NG tube to the gown

**Complications**

- Vomiting during placement, tracheal intubation, small risk of intracranial penetration (contraindicated in facial fractures), bleeding,
esophageal rupture (hx of esophageal stricture/alkali injury), pain

**Paracentesis**

**Purpose**
- Diagnostic: Removal of peritoneal fluid in a pt w/ ascites to (a) diagnose the cause of new ascites; (b) assess for spontaneous bacterial peritonitis
- Therapeutic: Relieve sxs in pts w/ tense ascites (eg, hypoxia from mass effect)

**Equipment**
- Use bedside U/S prior to procedure to confirm ascites & identify large pocket
- Sterile technique
- 25-gauge needle, 1% lidocaine. For diagnostic tap, only need 20–22-gauge needle & large syringe to aspirate fluid. For therapeutic tap, use paracentesis kit w/ 18-gauge needle, catheter sheath, & vacuum-sealed collection bottles.

**Positioning**
- Supine; identify entry site: Usually 4–5 cm cephalad & medial to anterior superior iliac spine, lateral to the rectus muscle sheath, being careful to avoid any visible veins

**Procedure**
- Check for severe coagulopathy prior to procedure
- Perform w/ real-time bedside U/S if possible
- Anesthetize locally w/ lidocaine 1% using 25-gauge needle
- Z-tract: Pull the skin 2 cm caudad before advancing the larger-bore needle, then place the needle perpendicular to the skin, advance needle slowly while occasionally aspirating, until ascitic fluid is aspirated, then release skin
- It may be necessary to make a 0.5 cm stab incision at the dermis to allow passage of the needle/catheter
- After aspirating fluid, advance catheter 1–2 cm & remove needle → connect catheter to stopcock, & collect fluid into sterile containers
- Fluid: Send for cell count, albumin, culture. Consider total protein,
glucose, LDH, amylase, gram stain

Complications
- Hypotension (can have severe fluid shifts in large-volume tap), ascitic fluid leakage, abdominal wall hematoma, infection, hemoperitoneum, viscera perforation

**Pericardiocentesis**

**Purpose**
- Emergent tx of pericardial effusion/tamponade in a pt w/ cardiac arrest (often PEA) or periarrrest; hemorrhagic tamponade is best treated w/ thoracotomy

**Equipment**
- 16- or 18-gauge spinal needle attached to a 30- or 60-cc syringe

**Positioning**
- Supine pt, angle needle 30°–45° to the skin, insert b/w xiphoid process & left costal margin, aim needle toward left shoulder (parasternal technique: 90° angle above 5th/6th rib L sternal border)

**Procedure**
- Sterile technique. Bedside U/S guidance recommended if available. Advance needle slowly while aspirating until fluid is removed (presence of blood suggests ventricular puncture)

**Complications**
- “Dry tap,” PTX, myocardial laceration, coronary vessel laceration, hemopericardium, ventricular penetration, visceral injury

**Thoracentesis**

**Purpose**
- Diagnostic eval (new/unclear etiology) or therapeutic tx of pl effusion

**Equipment**
- 20- or 22-gauge needle w/ catheter or thoracentesis kit
**Positioning**
- Pt sitting upright, needle angled 90° to skin, insert in intercostal space above rib (no lower than 8th intercostal space) in midscapular line

**Procedure**
- Sterile technique. Bedside U/S guidance is recommended for locating height of effusion & distance of lung from the parietal pleura.
- Anesthetize locally w/ lidocaine 1% using 25-gauge needle, then advance needle while aspirating → inject lidocaine → advance while aspirating further, until pl fluid is aspirated
- Remove needle, make a small 0.5 cm incision at the insertion site, then insert 20- or 22-gauge needle w/ catheter → advance while aspirating
- After aspirating fluid, advance catheter & remove needle
- Connect catheter to stopcock, & collect fluid into sterile containers
- Goal: Diagnostic (50–100 mL), therapeutic (relief of dyspnea, up to 1500 mL)
- Fluid: Send for LDH, protein, glucose, cell count, amylase, cytology, gram stain, culture
- Obtain postprocedure CXR

**Complications**
- PTX, bleeding (caution if PLT <50000 or >1.5 × nl PT/PTT), cough, infection, hemothorax, diaphragmatic penetration

---

**Tube Thoracostomy**

**Purpose**
- Drainage of air (PTX), blood (hemothorax), or fluid (pl effusion, empyema) in the pl space that threatens cardiac or pulmonary function

**Equipment**
- #10 scalpel, Kelly clamp, #0 or 1 suture, scissors chest tube (28F minimum, larger for hemothorax; may consider pigtail catheter for small PTX)
Positioning
- Supine pt, shoulder abducted (raised overhead), enter at midaxillary line @ 4th–5th intercostal space (nipple line), lateral to pectoralis major

Procedure
- Sterile technique
- Create wheal using lidocaine 1% w/ epinephrine (1:100000) & a 25- or 27-gauge needle, then advance needle while aspirating, & infiltrate broadly through muscle, periosteum & parietal pleura, staying above the rib; ± intercostal nerve block (at level, above, & below)
- Make 3–4 cm incision parallel & just over rib, through skin & fat overlying the rib
- Perform blunt dissection w/a Kelly or scissors down to the rib & just above it
- Apply firm pressure w/ the Kelly closed to pop through the parietal pleura
- Look/listen for rush of fluid or air. Leave Kelly in place & spread to open the pleura further.
- Insert finger into the chest wall (Kelly still in place) to verify that it is the pl space (feel lung, ensure no abdominal organs)
- Keep finger in place, remove Kelly, pass the tube over finger while gently spinning the tube
- Typically, direct tube superiorly & posteriorly (can go anteriorly if certain there is only air)
- Rotate the tube 360° to ↓ kinking & ensure all the tube holes are in the pl space
- Attach to water seal or suction. Never clamp a chest tube
- Confirm placement: Condensation w/ respiration, bubbles in water seal w/ coughing, CXR
- Suture in place, place petroleum gauze over wound, cover w/ dry gauze & tape in place

Complications
- Infection, intercostal vessel/nerve laceration, lung laceration, intra-abdominal entry, solid organ tube placement, subcutaneous placement
INDEX

A

- Abdominal aortic aneurysm, 3-4
- Abdominal pain, 3-1, 14-1
  - diffuse pain
    - abdominal aortic aneurysm, 3-4
    - large bowel obstruction, 3-5–3-6
    - mesenteric ischemia, 3-6
    - perforated viscous, 3-6
    - small bowel obstruction, 3-5
    - perforated viscous, 3-6
    - spontaneous bacterial peritonitis, 3-7
    - volvulus, 35
  - epigastric pain
    - pancreatitis, 3-2–3-3
  - Hirschsprung disease, 14-3–14-4
  - incarcerated/strangulated hernia, 14-2–14-3
  - inflammatory bowel disease, 3-7–3-8
  - intussusception, 14-2
  - lower quadrant/pelvic pain
    - appendicitis, 3-3, 14-1–14-2
    - diverticulitis, 3-4
    - hernia, 3-4
    - pelvic inflammatory disease, 7-6
  - malrotation with midgut volvulus, 14-2
  - Meckel diverticulum, 14-3
  - necrotizing enterocolitis, 14-3
  - right upper quadrant pain, 3-1
- cholangitis, 3-2
- cholecystitis, 3-2
- choledocholithiasis, 3-1–3-2
- cholelithiasis, 3-1
- Abdominal trauma, 18-20–18-23
  - colorectal injury, 18-22
  - diaphragmatic tear, 18-23–18-24
  - duodenal injury, 18-22–18-23
  - gastric injury, 18-23
  - liver laceration, 18-21
  - pancreatic injury, 18-23
  - small bowel injury, 18-22
  - splenic laceration, 18-21–18-22
  - vascular trauma, 18-23
- Abnormal bleeding
  - anticoagulation reversal, 11-10
  - disseminated intravascular coagulation, 11-8
  - hemolytic-uremic syndrome, 11-7–11-8
  - hemophilia A/B, 11-9
  - heparin-induced thrombocytopenia, 11-7
  - immune thrombocytopenia, 11-6–11-7
  - thrombotic thrombocytopenic purpura, 11-7–11-8
  - transfusions, 11-9–11-10
  - von Willebrand disease, 11-8
- ABO and Rh incompatibility, 14-7
- Abruptio placentae, 7-2
- Abscess, 4-2–4-6
  - headache, 5-2
  - intracranial, 4-5–4-6
  - perirectal, 4-4–4-5
  - soft tissue
    - Bartholin gland cyst, 4-4
• cutaneous abscess, 4-2–4-3
• paronychia, 4-3
• pilonidal cyst, 4-3–4-4

Abuse
• child, 18-36
• elder, 18-37
• intimate-partner violence, 18-36–18-37
• sexual assault, 18-36

Accessory pathway, 1-47

Acclimatization, 10-12

Acetabular fractures, 18-29

Acetaminophen (APAP) poisoning, 16-10–16-11

Acetazolamide
• for high-altitude illness, 10-12
• for idiopathic intracranial hypertension, 5-5

Achilles tendonitis, 12-5

Acid/alkaline ingestions, 16-15

Acid–base disorders
• low anion gap, 9-2
• metabolic acidosis, 9-1
• metabolic alkalosis, 9-2
• osmolar gap causes, 9-2
• respiratory acidosis, 9-2
• respiratory alkalosis, 9-2

Acrocyanosis, 14-4

Acromioclavicular syndrome, 12-5

Activated charcoal, 16-1

Activated protein C, 1-38

Acute bronchitis, 2-2

Acute coronary syndrome, 1-4
• chronic angina, 1-4
• disposition, 1-7
• evaluation
  • cardiac biomarkers, 1-6
  • chest x-ray, 1-7
  • ECG, 1-6
  • risk-stratification testing, 1-7
  • transthoracic echo, 1-7
• history, 1-5
• myocardial infarction, 1-5
• NSTEMI, 1-10–1-12
• physical exam, 1-6
• STEMI, 1-8–1-10
• treatment, 1-7
• unstable angina, 1-10–1-12
• Acute extremity arterial occlusion, 12-1
• Acute febrile neutrophilic dermatosis, 8-15
• Acute kidney injury (AKI), 6-10
• Acute lumbosacral strain, 12-3
• Acute necrotizing ulcerative gingivitis, 13-10–13-11
• Acute pericarditis. See Pericarditis
• Acute respiratory distress syndrome (ARDS), 2-6
• Adenovirus, 14-15
• Adrenal insufficiency, 9-16–9-17
• Adrenal replacement, 9-14
• AICD, 1-48
  • malfunction, 1-49–1-50
• Airway emergencies, upper, 14-23
• Airway management
  • airway algorithms, 17-1
  • cricothyrotomy, 17-2–17-3
  • in neck trauma, 18-10–18-11
• Albumin, for spontaneous bacterial peritonitis, 3-7
• Albuterol
• for asthma, 2-4, 14-22
• for chronic obstructive pulmonary disease, 2-5
• for hyperkalemia, 9-7
• Alcohol ingestions
  • ethanol, 16-6
  • ethylene glycol, 16-7
  • isopropyl alcohol, 16-7
  • methanol, 16-6–16-7
• Alcohol withdrawal, 16-7–16-8
• Alfuzosin, for urolithiasis, 6-9
• Alteplase
  • for STEMI, 1-9
• Alveolar osteitis, 13-11
• Amiodarone
  • for atrial fibrillation/atrial flutter, 1-45, 1-46
  • for ventricular tachycardia, 1-48
• Amoxicillin
  • for acute sinusitis, 5-4
  • for Lyme disease, 4-6
• Amoxicillin–clavulanate, for acute sinusitis, 13-5
• Amputation, complete18-33
• Amyotrophic lateral sclerosis (ALS), 5-20
• Analgesia
  • benzodiazepines, 16-8
  • conscious sedation medications, 19-7
  • opiates, 19-6
  • reversal agents, 19-7
  • in STEMI, 1-8
  • in UA/NSTEMI, 1-11
• Analgesic overdose
  • acetaminophen poisoning, 16-10–16-11
  • salicylate poisoning, 16-12
Anaphylaxis, 11-1–11-2
Angina pectoris, 1-4
  • Canadian Cardiovascular Society (CCS) grading of, 1-4
Angioedema, 11-1–11-2
Angiography
  • in UA/NSTEMI, 1-12
Angiotensin-converting enzyme inhibitor (ACEI), for hypertension, 1-33, 1-34
Angiotensin receptor blocker (ARB), for hypertension, 1-33, 1-34
Angle-closure glaucoma, acute, 13-6–13-8
Anion gap acidosis, 9-1
Ankle-brachial indices (ABIs), measurement of, 12-2
Ankle fractures, 18-31
Anterior cord syndrome, 18-15
Anterior uveitis/iritis, 13-7
Anterior wedge fracture, 18-14
Anthrax, 4-22
Anticholinergic ingestion, 16-2–16-3
Anticoagulation
  • in atrial fibrillation/atrial flutter, 1-46
  • in deep vein thrombosis, 1-19
  • in pulmonary embolism, 1-21
Anticonvulsants, for primary seizures, 14-11–14-12
Antidromic AVRT, 1-47
Antiemetics
  • for cholelithiasis, 3-1
  • for hyperemesis gravidarum, 7-3–7-4
  • for Mallory–Weiss tear, 3-10
  • for nausea and vomiting, 3-8–8-9
  • for testicular torsion, 6-12
Antihistamines
  • for atopic dermatitis, 8-16
Antiretrovirals, for HIV exposure, 10-6

Antithrombotic treatment
- in STEMI, 1-8, 1-9
- in UA/NSTEMI, 1-11

Aortic dissection, 1-24–1-26
- approach, 1-24
- classification, 1-24
- definition, 1-24
- disposition, 1-26
- evaluation, 1-25
- history & physical exam, 1-25
- prognosis, 1-24
- risk factors, 1-24
- sensitivity of components of history, 1-25
- treatment, 1-26

Aortic Dissection Detection (ADD) risk score, 1-26

Aortic regurgitation, 1-24

Aortic stenosis, 1-23

Aortoenteric fistula, 3-10

Apixaban
- in deep vein thrombosis, 1-19
- in pulmonary embolism, 1-21

Apparent life-threatening event (ALTE), 14-18–14-19

Appendicitis, 3-3

Arterial gas embolism (AGE), 10-10

Arterial puncture and catheterization, 19-9–19-10

ASA
- in myocardial infarction, 1-7
- in UA/NSTEMI, 1-11

Asthma, 14-21–14-22

Asymptomatic bacteriuria, 6-1

Atopic dermatitis, 8-16
Atrial fibrillation, 1-43–1-47
Atrial flutter, 1-43–1-47
Auricular hematomas, 18-6
AV node block, 1-41
  • differential, 1-41
  • treatment, 1-41

B
  • Babesiosis, 4-18
  • *Bacillus Anthracis*, 4-22
  • Bacitracin, 10-7
  • Back pain, lower, 12-2–12-3
    • infectious
      • spinal epidural abscess, 12-4
    • neoplastic
      • bony metastasis, 12-4
    • neurologic
      • cauda equina syndrome, 12-3
      • herniated disc, 12-4
      • lumbar spinal stenosis, 12-3–12-4
    • trauma
      • acute lumbosacral strain, 12-3
      • vertebral compression fracture, 12-3
  • Baclofen, for multiple sclerosis, 5-21
  • Bacterial prostatitis, 6-6
  • Bacterial tracheitis, 14-24–14-25
  • Bactrim
    • for cutaneous abscess, 4-2–4-3
    • for cutaneous/subcutaneous cellulitis, 4-6
    • for plague, 4-21
  • Balloon angioplasty, 1-14
  • Barium/air/water enema, 14-2
Bartholin gland cyst/abscess, 4-4
Beck’s triad, 1-28
Bell’s palsy, 5-13
Benzathine penicillin, 13-3
Beta blockers (BB)
  • in atrial fibrillation/atrial flutter, 1-45
  • in hypertension, 1-33
  • overdose, 16-12–16-13
  • in STEMI, 1-8
  • in UA/NSTEMI, 1-11
β-lactams, 6-2
Bicarbonate, for hyperkalemia, 9-7
Biliary colic, 3-1
Bioterrorism, 4-21–4-23
  • anthrax, 4-22
  • botulism, 4-23
  • plague, 4-22–4-23
  • small pox, 4-23
Bisphosphonates, for hypercalcemia, 9-9
Bites and stings, 10-2
  • human & animal bites, 10-2–10-3
  • hymenoptera, 10-5
  • jellyfish stings, 10-5
  • scorpion bites, 10-4
  • snake bites, 10-3–10-4
  • spider bites, 10-4–10-5
Bivalirudin
  • in STEMI, 1-9
  • in UA/NSTEMI, 1-11
Black widow bite, 10-4–10-5
Bladder rupture
  • extraperitoneal, 18-26
• intraperitoneal, 18-25–18-26
• Blood products, 1-38
• Blue bloater, 2-5
• Bony metastasis, 12-4
• *Borrelia burgdorferi*, 4-16
• Botulism, 4-23, 10-19–10-20
• Bradyarrhythmias, 1-14
• Bradycardia, 1-39–1-40
• Breast-feeding jaundice, 14-7
• Breast milk jaundice, 14-7
• Breath-holding spell, 14-4
• Bronchiolitis, 14-21–14-22
• Bronchitis, acute, 2-2
• Bronchopulmonary dysplasia, 14-22–14-23
• Brown recluse bite, 10-4
• Brown-Sequard syndrome, 18-16
• Brugada syndrome, 1-48
• Burns, 10-7–10-8
  • clinical findings by degree, 10-7
  • Parkland formula, 10-7
  • transfer to burn unit, criteria for, 10-7
• Bursitis, 12-7
• Burst fracture, 18-14

C

• Calcium channel blocker (CCB)
  • for atrial fibrillation/atrial flutter, 1-45
  • for hypertension, 1-33
  • overdose, 16-13–16-14
• Calcium chloride
  • for hyperkalemia, 9-7
  • for hypokalemia, 9-8
• Calcium gluconate
  • for hyperkalemia, 9-7
  • for hypermagnesemia, 9-10
  • for hypokalemia, 9-8
• Cardiac contusion, 18-19
• Cardiac biomarkers, 1-6
• Cardiac catheterization, 1-14
• Cardiac tamponade, 1-28–1-29
  • definition, 1-28
  • disposition, 1-29
  • evaluation, 1-28
  • history & physical exam, 1-28
  • pulsus paradoxus test, 1-28
  • treatment, 1-29
• Cardiogenic shock, 1-14, 1-37
• Catheter-associated asymptomatic bacteriuria (CA-ASB), 6-4
• Cauda equina syndrome, 12-3
• Caustic ingestions, 16-14–16-15
• Caustic injury, eye, 13-6
• C1 burst fracture, 18-12
• Central cord syndrome, 18-15–18-16
• Central retinal artery occlusion, 13-8–13-9
• Central retinal vein occlusion, 13-9
• Cerumen impaction, 13-2
• Cervical spine trauma, 18-12–18-14
  • C1 burst fracture, 18-12
  • cervical spine clearance, 18-12
  • C2 Hangman fracture, 18-12–18-13
  • clay Shoveler fracture, 18-13–18-14
  • odontoid fracture, 18-13
  • subluxation/ligamentous injury, 18-14
  • tear drop fracture, 18-13
CHADS2 score, 1-46
Chance fracture, 18-15
C2 Hangman fracture, 18-12–18-13
Charcot’s triad, 3-2
Chemical burns, 18-9
Chest pain. See also Myocardial infarction (MI)
  • approach in, 1-1
  • causes of, 1-1
    • Chikungunya, 4-21
Chickenpox, 8-6
Child abuse, 18-36
Chloral hydrate, for conscious sedation, 19-7
Chloramphenicol
  • for plague, 4-23
  • for rocky mountain spotted fever, 4-17
Cholangitis, 3-2
Cholecystitis, 3-2
Choledocholithiasis, 3-1–3-2
Cholelithiasis, 3-1
Chlorthalidone, for hypertension, 1-33
Chronic obstructive pulmonary disease (COPD), 2-5
Cirrhosis, 3-16
Cisatracurium, 19-8
CK-MB (cardiac enzymes), 1-6
Claudication, 12-1
Clay Shoveler fracture, 18-13–18-14
Clopidogrel
  • for ischemic stroke, 5-17–5-18
  • in STEMI, 1-8, 1-9
  • for transient ischemic attack, 5-17
  • in UA/NSTEMI, 1-11
Clostridium difficile, 3-14
- *Clostridium perfringens*, 3-14
- Clotted AV graft/fistula, 6-16
- Cluster headache, 5-3
- Cocaine-induced angina, 1-16
- Colchicine
  - for gout, 12-6
  - for pericarditis, 1-28
- Colonic angiodysplasia, 3-11
- Colorectal cancer, 3-11
- Colorectal injury, 18-22
- Compartment syndrome, 12-2, 18-32–18-33
- Compression fracture, 18-14
- C1 burst fracture, 18-12
- Conjunctivitis, 13-7
- Constipation, 3-14–3-15
  - rectal foreign body, 3-15
  - simple, 3-14
- Constrictive pericarditis, 1-23
- Contact dermatitis, 8-16
- Corneal abrasion, 13-7
- Corneal ulcer/keratitis, 13-6
- Coronary computed tomographic angiography, 1-13
- Cough
  - acute bronchitis, 2-2
  - pneumonia, 2-1–2-2
- Cricothyrotomy, 17-2–17-3
- Crohn’s disease (CD), 3-7
- Croup, 13-3–13-4
- Croup Severity Score, 13-3
- Crush syndrome, 18-33
- Crying and colic, 14-18
- C-spine immobilization, 1-39
CURB-65 score, 2-2
Cutaneous abscess, 4-2
Cutaneous candidiasis, 8-10
Cutaneous cellulitis, 4-6
Cyanosis, 14-4
Cystitis, acute, 6-2–6-3

D
Dantrolene
  • for malignant hyperthermia, 10-17
  • for neuroleptic malignant syndrome, 10-17
Dapsone, 10-4
Daptomycin, for cutaneous/subcutaneous cellulitis, 4-6
D-dimer assays, 1-17
Decompensated heart failure, 1-21
  • acute, 1-21–1-23
  • approach, 1-22
  • disposition, 1-23
  • evaluation, 1-22
  • history & physical exam, 1-22
  • manifestations of, 1-21
  • precipitants of, 1-21
  • treatment, 1-23
Decompression sickness (DCS), 10-9–10-10
Deep vein thrombosis (DVT), 1-16–1-19
  • complications, 1-19
  • evaluation, 1-17, 1-18
  • history & physical exam, 1-16–1-17
  • lower-extremity, 1-16
  • treatment, 1-19
  • upper-extremity, 1-16
  • Well’s criteria for, 1-17
Dehydration, 10-1–10-2
  • degrees of, 10-1
  • resuscitation fluids in, composition of, 10-2
  • types of, 10-1
Delirium, 5-1
Dementia, 5-2
Demerol, for analgesia & conscious sedation, 19-6
Dengue fever, 4-19–4-20
Dental caries, 13-10
Dental fractures, 13-10
De Quervain tenosynovitis, 12-6
Dermatitis
  • atopic, 8-16
  • contact, 8-16
  • nummular, 8-16
  • seborrheic, 8-16
  • xerotic, 8-16
Dermatologic emergencies
  • erythema multiforme, 8-14
  • Stephens-Johnson syndrome, 8-11
  • toxic epidermal necrolysis, 8-11–8-12
Desmopressin (DDAVP), 11-8
Dexamethasone
  • for croup, 13-3
  • for group A Streptococcus pharyngitis, 13-3
  • for high-altitude illness, 10-2
Diabetic ketoacidosis (DKA), 9-11–9-13, 14-25
Diagnostic peritoneal lavage (DPL), 18-21
Dialysis disequilibrium syndrome, 6-16
Diaphragmatic tear, 18-23–18-24
Diarrhea, 3-12–3-14
  • acute, 3-12
• chronic, 3-12
• infectious, 3-13
• irritable bowel syndrome, 3-14
  • Diazepam
    • for analgesia & conscious sedation, 19-6
    • for peripheral vertigo, 5-12
    • for preeclampsia/eclampsia, 7-3
    • for primary seizures, 14-12
    • for psychiatric patient, 15-1
    • for status epilepticus, 5-10
  • Dicloxacillin
    • for erysipelas, 4-7
    • for periorbital/preseptal cellulitis, 4-9–4-10
  • Difficulty swallowing, 3-11–3-12
  • Diffuse axonal injury (DAI), 18-5
  • Digoxin
    • for atrial fibrillation/atrial flutter, 1-45
  • Dilated CMP, 1-23
  • Dilaudid, for analgesia & conscious sedation, 19-6
  • Diltiazem, 19-7
    • for atrial fibrillation/atrial flutter, 1-45
  • Diphenhydramine, for peripheral vertigo, 5-3
  • Direct current cardioversion, 1-45
  • Disseminated intravascular coagulation (DIC), 11-8
  • Distal radius/ulna fractures, 18-31
  • Diuresis
    • for decompensated heart failure, 1-23
  • Diuretics
    • for hyperkalemia, 9-7
    • for hypermagnesemia, 9-10
  • Diverticulitis, 3-4
  • Diverticulosis bleeding, 3-11
• Dobutamine, 1-36, 19-5
  • for cardiogenic shock, 1-37
  • for pediatric advanced life support, 19-5
• Dofetilide
  • for atrial fibrillation/atrial flutter, 1-46
• Dog bite, 10-2–10-3
• Dopamine, 1-36
  • for AV node block, 1-41
  • for cardiogenic shock, 1-37
  • for sepsis, 1-38
• Dopamine antagonists, for neuroleptic malignant syndrome, 10-17
• Doxazosin, for urolithiasis, 6-9
• Doxycycline
  • for anthrax, 4-22
  • for bacterial prostatitis, 6-6
  • for Bell’s palsy, 5-13
  • for cat bite, 10-2
  • for ehrlichiosis, 4-7
  • for gonococcal septic arthritis, 12-8
  • for Lyme disease, 4-6
  • for pelvic inflammatory disease, 7-6
  • for plague, 4-21
  • for rocky mountain spotted fever, 4-17
  • for sexually transmitted infection, 7-5
  • for tubo-ovarian abscess, 7-6
• Dressler’s syndrome, 1-15
• Drowning, 10-19
• Drug-eluting stent, 1-14
• Drugs of abuse, 16-8
  • benzodiazepines, 16-8
  • cocaine, 16-9–16-10
  • gamma-hydroxybutyrate, 16-8–16-9
• lysergic acid diethylamide, 16-10
• methamphetamine, 16-10
• methylenedioxymethamphetamine, 16-10

Dry socket. See Alveolar osteitis

Duke Treadmill Score, in exercise stress testing, 1-13
Duodenal injury, 18-22–18-23

Dysbarism
• decompression sickness, 10-9–10-10
• middle ear barotrauma, 10-10

Dysphagia, 3-11

Dyspnea, 2-3
• acute respiratory distress syndrome, 2-6
• approach to patient in, 2-3
• asthma, 2-4–2-5
• chronic obstructive pulmonary disease, 2-5
• definition, 2-3
• foreign body, 2-6
• upper airway obstruction, 2-6

Dysrhythmia, 1-39. See also Bradycardia

Dysuria, 6-1

E

Ear pain, 13-1-13-2
• malignant (necrotizing) otitis externa, 13-1
• mastoiditis, 13-2
• otitis externa, 13-1
• otitis media, 13-1–13-2

Eastern equine encephalitis, 4-20–4-21
 Echo imaging, 1-13

Eclampsia, 7-3

Ecstasy, 16-10

Ectopic pregnancy, 7-2
- Ehrlichiosis, 4-17–4-18
- Elapidae or coral snake, 10-3–10-4
- Elder abuse, 18-37
- Electrical injury, 10-11
- Electrocardiography, 1-1
- atrial abnormality and ventricular hypertrophy, 1-4
- axis, determination of, 1-2
- calibration and standardization, 1-1
- conduction delays, 1-3
- heart rate, determination of, 1-1
- normal/abnormal intervals, 1-3
- rhythm, determination of, 1-1
- Electrocardiography (continued)
- ST elevation, causes & morphologies of, 1-4
- waveforms and segments, 1-2
- Electrolyte repletion, for diabetic ketoacidosis, 14-25
- Electrolytes, abnormal, 9-3
- hypercalcemia, 9-8–9-9
- hyperkalemia, 9-7–9-8
- hypermagnesemia, 9-10
- hypernatremia, 9-4–9-5
- hypocalcemia, 9-8
- hypoglycemia, 9-10–9-11
- hypokalemia, 9-5–9-6
- hypomagnesemia, 9-9–9-10
- hyponatremia, 9-3–9-4
- Emergencies in dialysis patients, 6-15–6-6
- Emergency delivery, 7-4–7-5
- Emergent dialysis, 6-12
- Enalaprilat, 19-7
- Encephalitis, 5-8
- Endocarditis, 4-1–4-2
Enoxaparin
• in STEMI, 1-8
• in UA/NSTEMI, 1-11

Entamoeba histolytica, 3-14
Enterohemorrhagic Escherichia coli, 3-14
Enterotoxic Escherichia coli, 3-13
Epididymitis, 6-6–6-7
Epidural hematoma, 18-5
Epiglottitis, 13-4, 14-24
Epilepsy, 14-12–14-13
Epinephrine, 1-36
• in sepsis, 1-38
Epistaxis, 13-5
Epley maneuver, 5-11
Equations, 19-8–19-9
Ertapenem, for cholangitis, 3-2
Erysipelas, 4-7, 14-28
Erythema infectiosum, 8-4–8-5
Erythema nodosum, 8-14
Escape rhythm, 1-40
Esmolol, 19-7
• for atrial fibrillation/atrial flutter, 1-45
• for hypertension, 1-34
Esophageal food impaction, 3-11–3-12
Esophageal injury, 18-20
Etomidate, 19-7
Euvolemic hypernatremia, 9-5
Euvolemic hyponatremia, 9-4
Exanthema subitum. See Roseola infantum
Exercise treadmill testing, 1-12–1-13
Extraperitoneal bladder rupture, 18-26
Extremity injury, 18-30
• compartment syndrome, 18-32–18-33
• crush syndrome/rhabdomyolysis, 18-33
• nerve injury, 18-32
• orthopedic injuries, 18-30–18-31
• partial/complete amputation, 18-33
• soft tissue injury, 18-31–18-32
• vascular injury, 18-30
• Eye injury, 18-8–18-10
  • chemical burns, 18-9
  • globe rupture, 18-8
  • hyphema, 18-9–18-10
  • orbital fracture, 18-8
  • retinal detachment, 18-9
  • retrobulbar hematoma, 18-9
  • subconjunctival hemorrhage, 18-10
  • vitreous hemorrhage, 18-10
• Eye pain/redness, 13-6–13-8

F
• Facial barotrauma, 10-10
• Facial droop, 5-12–5-13
• Famciclovir, for herpes genitalis, 8-6
• Febrile seizures, 14-13–14-14
• Female pelvic pain, 7-5
  • ovarian cyst, 7-5
  • ovarian torsion, 7-5
• Femoral fractures, 18-31
• Fentanyl, 19-6
  • for analgesia & conscious sedation, 19-6
• Fever, 4-1
  • differential, 4-1
  • endocarditis, 4-1–4-2
- pediatric, 14-4–14-5
  - Fibrinolysis, in STEMI, 1-8, 1-9
  - Fifth Disease. See Erythema infectiosum
  - Fingertip wounds, 18-35
  - First Disease. See Measles
  - Flail chest, 18-18
  - Flank pain, 6-7–6-8
    - urolithiasis, 6-8–6-9
  - Flecainide
    - for atrial fibrillation/atrial flutter, 1-45
  - Fluconazole, for sexually transmitted infection, 7-6
  - Fluid and electrolyte abnormalities, pediatric, 14-26–14-28
  - Flumazenil, 19-7, 19-8
  - Fluoroquinolone
    - for acute sinusitis, 5-4
    - for appendicitis, 3-3
    - for bacterial prostatitis, 6-6
    - for complicated urinary tract infection, 6-3–6-4
  - Fluoroquinolones, 6-2
  - Folate/thiamine, 16-7
  - Fomepizole, 16-7
  - Fondaparinux
    - in deep vein thrombosis, 1-19
    - in STEMI, 1-8
    - in UA/NSTEMI, 1-11
  - Foreign body, 2-6, 3-15
    - in wound, 18-35
  - Fosfomycin
    - for acute cystitis, 6-2–6-3
    - for recurrent urinary tract infection, 6-4–6-5
  - Fractional excretion of sodium (FeNa), 9-3
  - Frostbite, 10-14
Frozen shoulder, 12-5
Furosemide
• for hypercalcemia, 9-9
• for hyperkalemia, 9-7

G
• Gamma-hydroxybutyrate (GHB), 16-8–16-9
• Gastric injury, 18-23
• Gastritis, 3-9–3-10
• Gastroenteritis, 3-8–3-9, 14-15–14-16
• Gastroesophageal reflux disease, 14-15
• Gastrointestinal bleed, 3-9
  • lower, 3-11
    • colonic angiodysplasia, 3-11
    • colorectal cancer, 3-11
    • diverticulosis bleeding, 3-11
    • hemorrhoids, 3-17
  • upper, 3-9
    • aortoenteric fistula, 3-10
    • Glasgow–Blatchford score, 3-9
    • Mallory–Weiss tear, 3-10
    • peptic ulcer disease or gastritis, 3-9
    • variceal bleeds, 3-10
• Genital injuries, female, 18-27
• Genitourinary trauma, 18-24
  • extraperitoneal bladder rupture, 18-26
  • female genital injuries, 18-27
  • female urethral injuries, 18-26
  • intraperitoneal bladder rupture, 18-25–18-26
  • male urethral injuries, 18-26
  • penile amputation/laceration, 18-27
  • penile fracture, 18-27
renal contusion, 18-24–18-25
renal laceration, 18-24
renal pelvis rupture, 18-25
testicular contusion/rupture, 18-26–18-27
ureteral injuries, 18-25
Gentamicin
for cutaneous/subcutaneous cellulitis, 4-6
for Ludwig angina, 4-10
for pediatric meningitis, 14-17
for pelvic inflammatory disease/tubo-ovarian abscess, 7-6
for plague, 4-21
for pneumonia, 14-21
German Measles. See Rubella
Giant cell arteritis. See Temporal arteritis
Giardia lamblia, 3-14
GI Decontamination, 16-1
Glasgow–Blatchford score, 3-9
Glasgow Coma Scale, 18-1
Globe rupture, 18-8
Glucagon, 14-26
Glucose, for pediatric advanced life support, 19-5
Gonococcal septic arthritis, 12-8
Gout, 12-6–12-7
GP IIb/IIIa inh
in UA/NSTEMI, 1-11
Group A Streptococcus pharyngitis, 13-3
Guillain–Barré syndrome, 5-20

H
Hand-foot-and-mouth disease, 14-28
Hand fractures, 18-31
HAS-BLED score, 1-46–1-47
Headache
- acute sinusitis, 5-4
- cluster, 5-3
- dural leak/post-LP, 5-5–5-6
- migraine, 5-3
- pseudotumor cerebri, 5-5
- temporal arteritis, 5-5
- tension, 5-3
- trigeminal neuralgia, 5-4

Head trauma
- canadian head CT imaging rule, 18-3
- diffuse axonal injury, 18-5
- epidural hematoma, 18-5
- head injury classifications, 18-3
- intracerebral/intraparenchymal hemorrhage, 18-3–18-4
- postconcussive syndrome, 18-3
- scalp laceration, 18-2
- skull fractures, 18-2
- subarachnoid hemorrhage, 18-4
- subdural hematoma, 18-4–18-5

Hearing loss
- cerumen impaction/foreign body, 13-2
- ruptured tympanic membrane, 13-2–13-3

Heart failure, 1-21. See also Decompensated heart failure
- structural causes of, 1-23

HEART score, for chest pain patients, 1-7
- Heat cramps, 10-15
- Heat edema, 10-15
- Heat exhaustion, 10-16
- Heat rash, 10-15
- Heat stroke, 10-16–10-17
- Heat syncope, 10-15–10-16
Heliox, for asthma, 14-22
Hematuria, 6-9–6-10
Hemolytic disease, 14-7–14-8
Hemolytic-uremic syndrome (HUS), 11-7–11-8
Hemophilia A/B, 11-9
Hemoptysis, 2-6–2-7
Hemorrhoids, 3-17
Hemothorax, 18-18
Henoch–Schönlein purpura, 14-29–14-30
Heparin-induced thrombocytopenia (HIT), 11-7
Hep B immune globulin (HBIG), 10-6
Hernia, 3-4
Herniated disc, 12-4
Herpes genitalis, 8-5–8-6
Herpes gingivostomatitis, 8-5
Herpes labialis, 8-5
Herpes simplex 1 and 2 (HHV-1 and HHV-2), 8-5–8-6
Herpes zoster, 8-7
High-altitude illness, 10-12
Hip dislocations, 18-30
Hip fractures, 18-29
Hip/pelvic trauma, 18-28–18-30
• acetabular fractures, 18-29
• hip dislocations, 18-30
• hip fractures, 18-29
• pelvic fractures, 18-28
• vascular pelvic injuries, 18-29
Hirschsprung disease, 14-3–14-4
HIV/AIDS
• antiretroviral drugs reactions, 4-13
• complications of, 4-12
• opportunistic infection prophylaxis, 4-12
• organ involvement of, 4-13
  ‣ Hydralazine, for hypertension, 1-34
  ‣ Hydrochlorothiazide (HCTZ), for hypertension, 1-33
  ‣ Hydrocortisone
    • for adrenal insufficiency, 9-16–9-17
    • for hypercalcemia, 9-9
    • for sepsis, 1-38
  ‣ Hypercalcemia, 9-8–9-9
  ‣ Hyperemesis gravidarum, 7-3
  ‣ Hyperglycemic emergencies
    • diabetic ketoacidosis, 9-12–9-13
    • hyperosmolar hyperglycemic state, 9-12–9-13
  ‣ Hypermagnesemia, 9-10
  ‣ Hypernatremia, 9-4–9-5
  ‣ Hyperosmolar hyperglycemic state (HHS), 9-12–9-13
  ‣ Hypertension (HTN), 1-33–1-34
    • definition, 1-33
    • differential for, 1-33
    • evaluation, 1-33
    • urgency, 1-33
    • treatment, 1-33–1-34
    • emergency, 1-33, 1-34
  ‣ Hypertensive crisis. See Hypertension urgency
  ‣ Hypertensive headache, 5-4
  ‣ Hyperthermia
    • external heat emergencies
      • heat cramps, 10-15
      • heat edema, 10-15
      • heat exhaustion, 10-16
      • heat rash, 10-15
      • heat stroke, 10-16–10-17
      • heat syncope, 10-15–10-16
- internal heat emergencies
  - malignant hyperthermia, 10-17
  - neuroleptic malignant syndrome, 10-17
  - serotonin syndrome, 10-17–10-18

Hyperthyroidism, 9-14–9-16

Hypertrophic CMP, 1-23

Hypervolemic hypernatremia, 9-5

Hypervolemic hyponatremia, 9-4

Hyphema, 13-7, 18-9–18-10

Hypocalcemia, 9-8

Hypoglycemia, 14-26

Hypoglycemics, 16-16–16-17

Hypokalemia, 9-5–9-6

Hypomagnesemia, 9-9–9-10

Hyponatremia, 9-3–9-4

Hypotension
  - definition, 1-34
  - differential for, 1-35
  - evaluation, 1-35
  - and shock, 1-34–1-36
  - treatment, 1-35–1-36

Hypovolemic shock, 1-36–1-37

Hypothermia
  - classifications of, 10-13
  - frostbite, 10-14

Hypothyroidism, 9-13–9-14

Hypovolemic hypernatremia, 9-5

Hypovolemic hyponatremia, 9-4

Ibutilide
  - for atrial fibrillation/atrial flutter, 1-46
ICU medications, 19-7–19-8
Idiopathic intracranial hypertension, 5-5
Immune thrombocytopenia, 11-6–11-7
Impetigo, 8-8–8-9, 14-28–14-29
Infarct expansion, 1-15
Infectious diarrhea, 3-13–3-14
Infectious mononucleosis, 4-11–4-12
Infectious tenosynovitis, 12-6
Inflammatory bowel disease, 3-7–3-8
Inner ear barotrauma, 10-10
Inotropes
  • for decompensated heart failure, 1-23
Insulin, 19-8
  • for diabetic ketoacidosis, 14-25
  • for hyperkalemia, 9-7
Intertrigo, 8-10
Intimate-partner violence, 18-36–18-37
Intoxicated patient, approach to, 16-1–16-2
Intracerebral/intraparenchymal hemorrhage, 18-3–18-4
Intracranial abscess, 4-5–4-6
Intraosseous catheterization, 19-11
Intubation
  • for asthma, 14-22
  • indications for, 17-1
Intussusception, 14-2
Invasive ventilation, chronic obstructive pulmonary disease, 2-5
Iodine, for thyroid storm, 9-16
Ipratropium bromide
  • for asthma, 14-22
  • for chronic obstructive pulmonary disease, 2-5
Ipratropium, for asthma, 2-4
Irritable bowel syndrome, 3-14
Ischemic stroke, 5-15–5-19
Ivermectin, for scabies, 4-16
IVC filter, 1-21
IV hydration, for diabetic ketoacidosis, 14-25

J
Jaundice, 3-15–3-17, 14-6
  • ABO and Rh incompatibility, 14-7
  • acute liver failure, 3-16–3-17
  • breast-feeding jaundice, 14-7
  • breast milk jaundice, 14-7
  • cirrhosis, 3-16
  • conjugated hyperbilirubinemia, 14-8
  • hemolytic disease, 14-7
  • physiologic jaundice, 14-6–14-7
  • unconjugated hyperbilirubinemia in children, 14-6
Jefferson fracture, 18-12
Jellyfish stings, 10-5
Joint pain
  • bursitis, 12-7
  • etiology, 25
  • gout, 12-6
  • infectious
    • gonococcal septic arthritis, 12-8
    • septic arthritis, 12-7–12-8
  • pseudogout, 12-6–12-7
  • tenosynovitis, 12-6

K
Kanavel signs, 12-6
Kawasaki disease, 14-29
Kayexalate, for hyperkalemia, 9-7
Keflex, for cutaneous/subcutaneous cellulitis, 4-6
Knee injuries, 18-31
Koplik spots, 8-4

L

Labetalol
  • for hypertensive headache, 5-4
  • for preeclampsia/eclampsia, 7-3
Large bowel obstruction, 3-5–3-6
Laryngotracheobronchitis, 14-23–14-24. See Croup
Lateral cord syndrome. See Brown-Sequard syndrome
Lateral epicondylitis, 12-5
Le Fort classification, 18-8
Left ventricular aneurysm, 1-15
Left ventricular thrombus, 1-15
Legg–Calvé–Perthes disease, 14-10
Leg pain and swelling, 12-1-12-2
  • peripheral vascular disease
    • acute extremity arterial occlusion, 12-1
    • ankle-brachial indices (ABIs), measurement of, 12-2
    • claudication, 12-1
  • trauma
    • compartment syndrome, 12-2
Lemierre syndrome, 13-4
Leukocytoclastic vasculitis, 8-14–8-15
Levofloxacin
  • for cutaneous/subcutaneous cellulitis, 4-6
  • for epididymitis/orchitis, 6-6–6-7
  • for perirectal abscesses, 4-4–4-5
  • for plague, 4-21
  • for sexually transmitted infection, 7-5–7-6
  • for spontaneous bacterial peritonitis, 3-7
Levothyroxine
- for hypothermia, 10-14
- for hypothyroidism, 9-13–9-14

Lid disorders, 13-8

Lidocaine
- for ventricular tachycardia, 1-48

Lightning injury, 10-18–10-19

Limp, 14-8–14-9
- infectious
  - septic arthritis of hip, 14-9
  - toxic (transient) synovitis, 14-9–14-10
- musculoskeletal
  - Legg–Calvé–Perthes disease, 14-10
  - Osgood–Schlatter disease, 14-11
  - slipped capital femoral epiphysis, 14-10

Lindane, for scabies, 4-16

Linezolid
- for cutaneous abscess, 4-2
- for cutaneous/subcutaneous cellulitis, 4-6

Lithium toxicity, 16-5

Liver failure, acute, 3-16

Liver laceration, 18-21

LMWH
- in deep vein thrombosis, 1-19
- in pulmonary embolism, 1-21

Log-roll precautions, 1-39

Lorazepam
- for primary seizures, 14-12
- for status epilepticus, 5-10

Lou Gehrig’s disease. See Amyotrophic lateral sclerosis

Lower back pain. See Back pain, lower

LRINEC score, 4-8
Lumbar nerve root compression, 12-4
Lumbar puncture, 19-11–19-12
Lumbar spinal stenosis, 12-3–12-4
LV systolic dysfunction, 1-14
Lyme disease, 4-16
Lysergic acid diethylamide (LSD), 16-10

M
Macrolide, for pneumonia, 14-21
Magnesium
  • for hypertension, 1-34
  • for ventricular tachycardia, 1-48
Malaria, 4-18
Malignant hyperthermia (MH), 10-17
Malignant (necrotizing) otitis externa, 13-1
Mallory–Weiss tear, 3-10
Malrotation with midgut volvulus, 14-2
Mandibular fractures, 18-7
Mannitol, 10-16, 18-4
Mastoiditis, 13-2
Maxillary fractures, 18-7–18-8
Maxillofacial injury
  • mandibular fractures, 18-7
  • maxillary fractures, 18-7
  • nasal fractures, 18-6–18-7
  • septal/auricular hematomas, 18-6
  • soft tissue injury, 18-6
  • zygomatic fracture, 18-7
Measles, 8-3–8-4
Mechanical ventilation, 19-5
  • acute respiratory distress syndrome, 2-6
  • indications for, 19-5
• invasive ventilation, 19-5–19-6
• making changes to ventilator, 19-6
• noninvasive ventilation, 19-5
• ventilator settings, 19-6
  • Meckel diverticulum, 14-3
  • Medial epicondylitis, 12-5
  • Meningitis, 5-6–5-7
  • Mental status, altered
• delirium, 5-2
• dementia, 5-2
• Mesenteric ischemia, 3-6
• Metabolic acidosis, 9-1
• Metabolic alkalosis, 9-2
• Metal stent, 1-14
• Metamucil, 3-14
• Methamphetamine, 16-10
• Methemoglobinemia, 16-16
• Methimazole, for thyroid storm, 9-15
• Methotrexate, for miscarriage, 7-1
• Methylene dioxyamphetamine (MDMA), 16-10
• Methylxanthine derivatives, 5-6
• Metoprolol
  • for atrial fibrillation/atrial flutter, 1-45
  • for hypertension, 1-34
• Metronidazole
  • for appendicitis, 3-3
  • for cholangitis, 3-2
  • for intracranial abscess, 4-5
  • for Ludwig angina, 4-10
  • for perirectal abscesses, 4-4–4-5
  • for sexually transmitted infection, 7-5–7-6
• Midazolam
• for analgesia & conscious sedation, 19-6–19-7
• for primary seizures, 14-12
  ‣ Middle ear barotrauma, 10-10
  ‣ Migraine, 5-3
  ‣ Milrinone, 1-36
  ‣ Miscarriage, 7-1
  ‣ Mitral regurgitation, 1-24
  ‣ Mitral stenosis, 1-24
  ‣ Modified Duke criteria, for endocarditis, 4-1–4-2
  ‣ Molluscum contagiosum, 8-8
  ‣ Morphine
    • in STEMI, 1-8
    • in UA/NSTEMI, 1-11
• Mosquito-borne diseases
  • chikungunya, 4-21
  • dengue fever, 4-19–40-20
  • malaria, 4-18–4-19
  • yellow fever, 4-19
  • eastern equine encephalitis, 4-20–4-21
  • west nile disease, 4-20
  • zika virus disease, 4-21
• Multiple sclerosis (MS), 5-21
• Myasthenia gravis, 5-19–5-20
• Myocardial infarction (MI), 1-5
  • classification, 1-5
  • differential, 1-5
  • ECG findings, 1-6
  • post-MI complications, 1-14–1-15
  • Sgarbossa criteria, 1-6
  • symptoms, 1-5
  • universal definition, 1-5
• Myocarditis, 1-29
Myxedema coma, 9-13–9-14

Nafcillin
- for cutaneous/subcutaneous cellulitis, 4-6
- for mastoiditis, 13-2
- for necrotizing soft tissue infections, 4-8
- for staphylococcus scalded skin syndrome, 4-4
- for toxic shock syndrome, 4-8

Nail bed laceration, 18-35
Nasal fractures, 18-6–18-7
Nasal vasoconstrictor drops/spray, 10-10
Nasogastric intubation, 19-12
Nausea and vomiting
- gastroenteritis, 3-8–3-9, 14-15–14-16
- gastroesophageal reflux disease, 14-15
- hyperemesis gravidarum, 7-3
- pyloric stenosis, 14-14
Neck trauma, 18-10–18-11
- penetrating, 18-11
- strangulation, 18-11
Necrotizing enterocolitis (NEC), 14-3
Neonatal complaints
- apparent life-threatening event, 14-18–14-19
- constipation, 14-17–14-18
- crying and colic, 14-18
- poor feeding, 14-17
- SIDS, 14-19
Nephrolithiasis, 6-8–6-9
Neurogenic shock, 1-39
Neuroleptic malignant syndrome (NMS), 10-17, 16-4
Neuromuscular syndromes
• amyotrophic lateral sclerosis, 5-20
• Guillain–Barré syndrome, 5-20
• multiple sclerosis, 5-21
• myasthenia gravis, 5-19–5-20
• transverse myelitis, 5-21–5-22
› Neutropenic fever, 11-2–11-3
› Nicardipine, 19-7
› Nifedipine
› for high-altitude illness, 10-12
› for urolithiasis, 6-9
› NIH Stroke Scale, 5-16
› Nimodipine, for subarachnoid hemorrhage 18-4
› Nitrates
› in decompensated heart failure, 1-23
› in STEMI, 1-8
› in UA/NSTEMI, 1-11
› Nitrofurantoin
› for asymptomatic bacteriuria in pregnancy, 6-2
› for recurrent urinary tract infection, 6-4–6-5
› Nitroglycerin (NTG)
› for hypertension, 1-34
› Nitrogen narcosis, 10-10
› Nitroprusside
› for hypertension, 1-34
› Norepinephrine, 1-36
› in sepsis, 1-38
› Norwalk virus, 14-15
› Novocaine, 18-34
› NSAIDs
› for pericarditis, 1-28
› NSTEMI. See Unstable angina (UA)/NSTEMI
› Nuclear SPECT imaging, 1-13
O
- Occupational exposure, 10-6
- Odontoid fracture, 18-13
- Odynophagia, 3-12
- Olanzapine, for psychiatric patient, 15-2
- Oncologic emergencies
  - hyperviscosity syndrome, 11-4–11-5
  - neutropenic enterocolitis, 11-4
  - neutropenic fever, 11-2
  - superior vena cava syndrome, 11-4
  - tumor lysis syndrome, 11-3–11-4
- Ondansetron, 14-15
- Opiate analgesics, for cholelithiasis, 3-1
- Optic neuritis, 13-9
- Orbital cellulitis, 4-10
- Orbital fracture, 18-8
- Orchitis, 6-6–6-7
- Organophosphates overdose, 16-18
- Orthodromic AVRT, 1-47
- Orthopedic injuries, extremity, 18-30–18-31
- Osgood–Schlatter disease, 14-11
- Osmolar gap, 9-2
- Otitis externa, 13-1
- Otitis media, 13-1–13-2
- Ovarian cyst, 7-5
- Ovarian torsion, 7-5

P
- Pacemaker malfunction, 1-48–1-49
- Palpitations, 1-42–1-48
- Pancreatic injury, 18-23
- Pancreatitis, 3-2–3-3
- Pancuronium, 19-4
- Papillary muscle rupture, 1-15
- Paracentesis, 19-12–19-13
- Paraphimosis, 6-13–6-14
- Paronychia, 4-3
- Patellar tendonitis, 12-5
- PDE-5 inhibitors, 10-12
- Pediatric advanced life support (PALS), 19-5
- Pediatric exanthems
  - erysipelas, 14-28
  - hand-foot-and-mouth disease, 14-28
  - Henoch–Schönlein purpura, 14-29–14-30
  - impetigo, 14-28–14-29
  - Kawasaki disease, 14-29
  - serum sickness, 14-29
  - viral exanthem, 14-28
- Pediatric fever, 14-4–14-6
- Pediatric meningitis, 14-17
- Pediatric seizure
  - cerebral palsy, 14-13
  - epilepsy, 14-12–14-13
  - febrile seizures, 14-13–14-14
  - primary, 14-12
  - types, 14-13
- Pelvic fractures, 18-28
- Pelvic inflammatory disease, 7-6
- Pelvic pain, female
  - ovarian cyst, 7-5
  - ovarian torsion, 7-5
- Penicillin G, for erysipelas, 14-28
- Penile amputation/laceration, 18-27
- Penile fracture, 18-27
• Peptic ulcer disease (PUD), 3-9
• Percutaneous coronary intervention (PCI), 1-14
  • post-PCI complications, 1-14
  • in STEMI, 1-9, 1-10
  • types of, 1-14
• Perforated viscus, 3-6
• Pericardiocentesis, 1-28, 19-13
• Pericarditis, 1-15, 1-27–1-28
  • definition, 1-27
  • disposition, 1-28
  • ECG changes in, stages of, 1-27
  • evaluation, 1-27–1-28
  • history & physical exam, 1-27
  • treatment, 1-28
• Peripheral vascular disease, 12-1
• Perirectal abscess, 4-4–4-5
• Peritonitis, 6-16
• Permethrin, for scabies, 4-16
• Pertussis, 13-4
• Phenoxybenzamine
  • for hypertension, 1-34
• Phentolamine
  • for hypertension, 1-34
• Phenylephrine, 1-36, 6-14
• Phenytoin
  • for primary seizures, 14-12
  • for seizures, 5-9
  • for status epilepticus, 5-10
• Phimosis, 6-13–6-14
• Phlegmasia alba dolens, 1-19
• Phlegmasia cerulea dolens, 1-19
• Photosensitive reaction, 8-15
Physiologic jaundice, 14-6–14-7
Physostigmine, 16-3
Pilonidal cyst, 4-3–4-4
Pink puffer, 2-5
Pit viper envenomation, 10-3
Pityriasis rosea, 8-7
Placenta previa, 7-2
Plague, 4-22–4-23
Pneumomediastinum, 10-10
Pneumonia, 2-1–2-1, 14-21
  • pneumonia severity index, 2-2
  • treatment, 2-1
Pneumothorax, 18-17–18-18
PORT score, 2-2
Positive pressure ventilation
  • for decompensated heart failure, 1-23
Postcoital bleeding, 7-3
Postconcussive syndrome, 18-3
Postinfarction ischemia, 1-15
Potassium replacement, 9-6
pPCI, in STEMI, 1-9, 1-10
Prasugrel
  • in STEMI, 1-9
Prednisone
  • for Bell’s palsy, 5-13
  • for chronic obstructive pulmonary disease, 2-5
  • for cluster, 5-3
  • for idiopathic intracranial hypertension, 5-5
  • for pericarditis, 1-28
  • for temporal arteritis, 5-5
Preeclampsia, 7-3
Priapism, 6-14–6-15
• definition of, 6-14
• treatment, 6-14
• types, 6-14
  ‣ Prickly heat. See Heat rash
  ‣ Primary survey, 18-1
  ‣ Prinzmetal’s (variant) angina, 1-15
  ‣ Procainamide
    • for atrial fibrillation/atrial flutter, 1-45
  ‣ Procedures, 19-9–19-14
    • arterial puncture and catheterization, 19-9–19-10
    • central venous catheterization, 19-10–19-11
    • incision and drainage, 19-11
    • intraosseous catheterization, 19-11
    • lumbar puncture, 19-11–19-12
    • nasogastric intubation, 19-12
    • paracentesis, 19-12–19-13
    • pericardiocentesis, 19-13
    • thoracentesis, 19-13
    • tube thoracostomy, 19-14
  ‣ Propafenone
    • for atrial fibrillation/atrial flutter, 1-45
  ‣ Propranolol
    • for atrial fibrillation/atrial flutter, 1-45
  ‣ Pseudogout, 12-6–12-7
  ‣ Pseudotumor cerebri, 5-5
  ‣ Pulmonary contusion, 18-19
  ‣ Pulmonary embolism (PE), 1-19–1-21
    • disposition, 1-21
    • evaluation, 1-20–1-21
    • history & physical exam, 1-19
    • PERC criteria for, 1-19
• revised & simplified Geneva score for, 1-20
• treatment, 1-21
• Well’s criteria for, 1-20
  - Pulsus paradoxus test, 1-28
  - Pyloric stenosis, 14-14

R
  - Rabies, 4-13–4-14
  - Ramsay Hunt syndrome, 8-7
  - Ranitidine, 14-15
  - Rasburicase, 11-4
  - Raxibacumab injection, 4-22
  - Rectal pain, 3-17
  - Renal contusion, 18-24
  - Renal laceration, 18-24
  - Renal pelvis rupture, 18-25
  - Renal replacement therapy, 1-38
  - Respiratory acidosis, 9-2
  - Respiratory alkalosis, 9-2
  - Respiratory complaints
    - asthma, 14-21–14-22
    - bacterial tracheitis, 14-24–14-25
    - bronchiolitis, 14-22
    - bronchopulmonary dysplasia, 14-22–14-23
    - epiglottitis, 14-24
    - foreign body/upper airway obstruction, 14-23–14-24
    - pneumonia, 14-21
    - upper airway emergencies, 14-23
  - Restrictive CMP, 1-23
  - Retained products of conception, 7-2
  - Reteplase
    - for STEMI, 1-9
Retinal detachment, 13-9
Retrobulbar hematoma, 18-9
Reversal agents, 19-7
Rhabdomyolysis, 18-33
Rh immunoglobulin, 7-2
*Rickettsia Rickettsii*, 4-17
Risk stratification testing, 1-12–1-14
Rivaroxaban
• in deep vein thrombosis, 1-19
• in pulmonary embolism, 1-21
Rocky mountain spotted fever, 4-17
Roseola infantum, 8-5
Rotator cuff injury, 12-5
Rotavirus, 14-15
Rubella, 8-4

S
Sacral fracture, 18-15
Salicylate poisoning, 16-12
SA node block, 1-40
Scabies, 4-15–4-16
Scalp laceration, 18-2
Scarlatina. See Scarlet fever
Scarlet fever, 8-8
Scleral penetration, 13-6
Scorpion bites, 10-4
Seborrheic dermatitis, 8-16
Second disease. See Scarlet fever
Seizure, pediatric, 14-11–14-14
Seizures
• primary, 5-9
• status epilepticus, 5-10
- types of, 5-9
- Selective serotonin reuptake inhibitors (SSRI), 16-3–16-4
- Sepsis, 1-37–1-39
- diagnostic criteria for, 1-38
- postabortion, 7-2
- treatment, 1-38
- Septal hematoma, 18-7
- Septic arthritis, 12-7–12-8
- Septic shock, 1-37–1-39
- Serotonin reuptake inhibitors (SRIs), 16-3
- Serotonin syndrome (SS), 10-17–10-18, 16-3–16-4
- Serum sickness, 14-29
- Severe inflammatory response syndrome (SIRS), 1-37
- Severe sepsis, 1-37
- Sexual assault, 18-36
- Sexually transmitted infection, 7-5–7-6
- Shigella, 3-13, 14-16
- Shingles. See Herpes zoster
- Shock
  - cardiogenic, 1-37
  - definition, 1-34
  - hypotension and, 1-34–1-36
  - hypovolemic, 1-36–1-37
  - neurogenic, 1-39
  - RUSH (Rapid Ultrasound in Shock) protocol, 1-35
  - septic, 1-37–1-39
- Shortness of breath. See Dyspnea
- Shoulder dislocations, 18-31
- SIADH, 9-4
- Sickle cell disease, 11-5
- Sick sinus syndrome, 1-40
- Sinus bradycardia, 1-40
Sinusitis, acute, 5-4
Sinus node dysfunction, 1-40
Sixth Disease. See Roseola infantum
Skin hydration, 8-16
Skull fractures, 18-2
Slipped capital femoral epiphysis (SCFE), 14-10
Small bowel injury, 18-22
Small bowel obstruction, 3-5
Small pox, 4-23
Snake bites, 10-3–10-4
  - crotalinae/pit vipers, 10-3–10-4
  - elapidae/coral snake, 10-3–10-4
Sodium bicarbonate, 16-5
  - for TCA overdose, 16-5
Sodium polystyrene sulfonate (Kayexalate), 16-5
Soft tissue infections
  - dermatologic
    - cellulitis, 4-6–4-7
    - erysipelas, 4-7
    - necrotizing fasciitis, 4-8–4-9
    - staphylococcus scalded skin syndrome, 4-7
    - subcutaneous cellulitis, 4-6
    - toxic shock syndrome, 4-8
  - genitourinary
    - Fournier gangrene, 4-9
  - ophthalmologic
    - orbital cellulitis, 4-10
    - periorbital cellulitis, 4-9–4-10
    - preseptal cellulitis, 4-9–4-10
    - otolaryngologic, Ludwig angina, 4-10
Sore throat, 13-3
  - croup, 13-3–13-4
• epiglottitis, 13-4
• group A Streptococcus pharyngitis, 13-3
• Lemierre syndrome, 13-4
• pertussis, 13-4
• Spider bites
  • black widow, 10-4–10-5
  • brown recluse, 10-4
• Spinal epidural abscess, 12-4
• Spinal shock, 18-16
• Spine trauma, 18-14
  • anterior cord syndrome, 18-15
  • anterior wedge/compression fracture, 18-14
  • Brown-Sequard syndrome, 18-16
  • burst fracture, 18-14
  • central cord syndrome, 18-15–18-16
  • chance fracture, 18-15
  • sacral fracture, 18-15
  • spinal shock, 18-16
• Splenic laceration, 18-21–18-22
• Spontaneous bacterial peritonitis, 3-7
  • Staphylococcus aureus, 3-13
• Status epilepticus, 5-9
• STEMI, 1-8–1-10
  • definition, 1-8
  • ECG criteria, 1-8
  • fibrinolysis in, 1-8
  • pPCI in, 1-9
  • treatment, 1-8
• Stenosing flexor tenosynovitis, 12-6
• Stent
  • drug-eluting, 1-14
  • metal, 1-14
- **stenosis**, 1-14
- **thrombosis**, 1-14

**Steroids**
- for adrenal insufficiency, 9-16–9-17
- for asthma, 2-4
- for chronic obstructive pulmonary disease, 2-5
- for croup, 14-23
- for gout, 12-6
- for immune thrombocytopenia, 11-6–11-7
- for pericarditis, 1-28
- for thyroid storm, 9-14
- for toxic shock syndrome, 4-8
- for transverse myelitis, 5-21–5-22
- for urticaria, 8-12
- Strangulated hernia, 14-2–14-3
- Strangulation, 18-11
- Streptomycin, for plague, 4-23

**Stroke**
- ABCD2 score, 5-17
- NIH Stroke Scale, 5-16
- patterns, 5-18
- thrombolysis in, 5-19
- transient ischemic attack, 5-17
- Subarachnoid hemorrhage (SAH)
  - clinical findings of, 18-4
  - Hunt–Hess scale of, 18-4
- Subconjunctival hemorrhage, 18-10
- Subdural hematoma (SDH), 18-4–18-5
- Subluxation/ligamentous injury, 18-14
- Sumatriptan, headache, 5-3
- Supplemental oxygen, 1-38
- in STEMI, 1-8
- in UA/NSTEMI, 1-11
  - Surgical thrombectomy, 1-21
  - Supraventricular tachycardia (SVT), 1-42–1-43
    - definition, 1-42
    - diagnosis, 1-42
    - pathophysiology, 1-42
    - treatment, 1-43
  - Sweet's syndrome, 8-15
  - Swimmer's ear. See Otitis externa
  - Syncope, 1-29–1-33
    - Boston syncope criteria, 1-32–1-33
    - causes of, 1-29–1-31
    - definition, 1-29
    - disposition, 1-31
    - ECG findings in, 1-31
    - evaluation, 1-31
    - history & physical exam, 1-31
    - OESIL score, 1-32
    - pre-syncope/near-syncope, 1-29
    - San Francisco syncope rule, 1-32

T
  - Tachyarrhythmias, 1-14
  - Tachy–Brady syndrome, 1-40
  - Tachycardia, 1-39, 1-42–1-48
  - Tamsulosin, for urolithiasis, 6-9
  - Tear drop fracture, 18-13
  - Temporal arteritis, 5-5, 13-9
  - Tenecteplas
    - for STEMI, 1-9
  - Tenosynovitis, 12-6
  - Tension headache, 5-3
Terazosin, for urolithiasis, 6-9
Terbutaline, for asthma, 14-22
Testicular contusion/rupture, 18-26–18-27
Testicular torsion, 6-12–6-13
Tetanus prophylaxis, 10-7
Tetracycline
  • for cutaneous abscess, 4-4
  • for cellulitis, 4-6–4-7
Tetralogy of fallot, 14-20
Third disease. See Rubella
Thoracentesis, 19-13
Thoracic aortic aneurysm, 1-26–1-27
  • complications rate, 1-26
  • disposition, 1-27
  • evaluation, 1-27
  • history & physical exam, 1-27
  • treatment, 1-27
  • urgent cardiac surgical consultation, 1-27
Thoracic aortic pseudoaneurysm, 1-26
Thoracic trauma, 18-16–18-20
  • cardiac contusion, 18-19
  • cardiac tamponade, 18-19
  • esophageal injury, 18-20
  • flail chest, 18-18
  • hemothorax, 18-18
  • pneumothorax, 18-17–18-18
  • pulmonary contusion, 18-19
  • tracheobronchial tear, 18-20
  • traumatic aortic rupture, 18-17
Thrombotic thrombocytopenic purpura (TTP), 11-7–11-8
Thyroid emergencies, 9-13–9-15
  • hyperthyroidism, 9-14–9-16
hypothesisim, 9-13-9-14
myxedema coma, 9-13-9-14
thyroid storm, 9-14-9-16
thyrotoxicosis, 9-14-9-16
Thyroid replacement, 9-14
Thyroid storm, 9-14-9-16
Thyrotoxicosis, 9-14-9-16
Tibia fractures, 18-31
Ticagrelor
in STEMI, 1-9
in UA/NSTEMI, 1-11
Ticarcillin/clavulanate, for cholangitis, 3-2
Ticlopidine, for ischemic stroke, 5-18
Toothache
acute necrotizing ulcerative gingivitis, 13-10-13-11
alveolar osteitis, 13-11
dental caries, 13-10
dental fractures, 13-10
periapical abscess, 13-10
tooth subluxation and avulsion, 13-10
Tooth subluxation and avulsion, 13-10
Torsion of appendix, 6-12
Toxic epidermal necrolysis (TEN), 8-11-8-12
Toxic shock syndrome (TSS), 4-8
Toxic (transient) synovitis, 14-9-14-10
Tracheobronchial tear, 18-20
Transcutaneous pacing, 1-41
Transfusion
cryoprecipitate, 11-10
fresh frozen plasma, 11-9-11-10
overview, 11-9
packed red blood cell, 11-9
• platelet, 11-9
  › Transient ischemic attack, 5-17
  › Transthoracic echo, 1-7
  › Transverse myelitis, 5-21–5-22
  › Trauma
    • for acute lumbosacral strain, 12-3
    • for vertebral compression fracture, 12-3
  › Traumatic aortic rupture, 18-17
  › Trench mouth. See Acute necrotizing ulcerative gingivitis
  › Tricyclic antidepressants (TCA), 16-5
  › Trochanteric bursitis, 12-5
  › Troponin I assays, 1-6
  › Tube thoracostomy, 19-14
  › Tumor lysis syndrome, 11-3–11-4
  › Tympanic membrane, rupture of, 13-2–13-3

U
  › UFH
    • in deep vein thrombosis, 1-19
    • in pulmonary embolism, 1-21
    • in STEMI, 1-8, 1-9
    • in UA/NSTEMI, 1-11
  › Ulcerative colitis (UC), 3-7–3-8
  › Unasyn
    • for Fournier gangrene, 4-9
    • for human bite, 10-2
    • for Ludwig angina, 4-10
    • for orbital cellulitis, 4-10
    • for periorbital/preseptal cellulitis, 4-9–4-10
  › Unstable angina (UA)/NSTEMI, 1-10–1-12
    • angiography selection & timing in, 1-12
    • definition, 1-10
- disposition, 1-12
- early invasive vs. conservative approach, 1-12
- GRACE risk score, 1-10
- medical therapies, 1-11
- TIMI risk score, 1-11
- Upper airway obstruction, 14-23–14-24
- Ureteral injuries, 18-25
- Ureterolithiasis, 6-8–6-9
- Urethral injuries
  - female, 18-26
  - male, 18-26
- Urethritis, 6-5–6-6
- Urinary anion gap, 9-1
- Urinary tract infections (UTIs), 6-1–6-7
  - asymptomatic bacteriuria, 6-2
  - catheter-associated, 6-4
  - classification, 6-1
  - complicated, 6-3–6-4
  - male urogenital tract infections
    - acute bacterial prostatitis, 6-6
    - epididymitis, 6-6–6-7
    - orchitis, 6-6–6-7
    - recurrent, 6-4–6-5
    - uncomplicated, 6-2–6-3
    - uncomplicated pyelonephritis, 6-3
    - urethritis, 6-5–6-6
- Urolithiasis, 6-8–6-9

V
- Vaginal bleeding, 7-1–7-3
  - abruptio placentae, 7-2
  - ectopic pregnancy, 7-2
- miscarriage, 7-1
- placenta previa, 7-2
- postabortion sepsis, 7-2–7-3
- postcoital bleeding, 7-3
- retained products of conception, 7-2
- Vaginal discharge, 7-5–7-6
- Valacyclovir, for herpes genitalis, 8-6
- Valvular heart disease, 1-23–1-24
- Vancomycin
  - for cutaneous abscess, 4-2–4-3
  - for cutaneous/subcutaneous cellulitis, 4-6
- for Fournier gangrene, 4-9
- for intracranial abscess, 4-5
- for Ludwig angina, 4-10
- for orbital cellulitis, 4-10
- for pediatric meningitis, 14-17
- for septic arthritis, 12-7–12-8
- for spontaneous bacterial peritonitis, 3-7
- for toxic shock syndrome, 4-8
- Variceal bleeds, 3-10
- Varicella, 8-6
- Variola, 4-23
- Vascular access hemorrhage, 6-16
- Vascular injury, extremity, 18-30
- Vascular pelvic injuries, 18-29
- Vascular trauma, 18-23
- Vasopressin, 1-36
  - in sepsis, 1-38
- Vasopressors
  - in neurogenic shock, 1-39
  - in sepsis, 1-38
- Vector-borne infections, 4-16
- mosquito-borne diseases
  - chikungunya, 4-21
  - dengue fever, 4-19–4-20
  - eastern equine encephalitis, 4-20–4-21
  - malaria, 4-18–4-19
  - West Nile disease, 4-20
  - yellow fever, 4-9
  - zika virus disease, 4-21
- tick-borne diseases
  - anaplasmosis, 4-17–4-18
  - babesiosis, 4-18
  - ehrlichiosis, 4-17–4-18
  - Lyme disease, 4-16
  - rocky mountain spotted fever, 4-17
- Vecuronium, 19-8
- Ventricular tachycardia, 1-47–1-48
- Ventricular wall rupture, 1-15
- Venous sinus thrombosis, 5-4–5-5
- Verapamil, 19-7
  - for atrial fibrillation/atrial flutter, 1-45
- Vertebral compression fracture, 12-3
- Vertigo, 5-11–5-1
- Vibrio parahaemolyticus, 3-14
- Viral exanthem
  - erythema infectiosum, 8-4–8-5
  - herpes simplex 1 and 2, 8-5–8-6
  - herpes zoster, 8-7
  - pityriasis rosea, 8-7
  - molluscum contagiosum, 8-8
  - rubella, 8-4
  - varicella, 8-6
- Viral hepatitis, 3-15–3-16
Viral infections, 4-11
- HIV/AIDS, 4-12–4-13
- infectious mononucleosis, 4-11–4-12
Vision change and vision loss, 13-8–13-9
- central retinal artery occlusion, 13-8–13-9
- central retinal vein occlusion, 13-9
- optic neuritis, 13-9
- retinal detachment, 13-9
- temporal arteritis, 5-5
Vitreous hemorrhage, 18-10
Volvulus, 3-5–3-6
Von Willebrand disease (vWD), 11-8

W
- Warfarin
  - in deep vein thrombosis, 1-19
  - in pulmonary embolism, 1-21
- Wasp, 10-5
- Westley Score, 13-3
- West Nile disease, 4-20
- Whole bowel irrigation, 16-1
- Whooping cough. See Pertussis
- Wolff–Parkinson–White, 1-47
- Wound management, 18-33–18-35
  - fingertip wounds, 18-35
  - foreign body, 18-35
  - laceration, 18-34
- Wrist fractures, 18-31

X
- Xylocaine, 18-34
Y
  ‣ Yellow fever, 4-19
  ‣ *Yersinia Pestis*, 4-22–4-23

Z
  ‣ Zika virus disease, 4-21
  ‣ Zinc supplementation, 14-15
  ‣ Ziprasidone, for psychiatric patient, 15-2
  ‣ Zosyn, for Fournier gangrene, 4-9
  ‣ Zygomatic fracture, 18-7